### 10335724
Serial	10	16		|O
measurements	17	29		|O
of	30	32		|O
antineutrophil	33	47		|O
cytoplasmic	48	59		|O
autoantibodies	60	74		|O
in	75	77		|O
patients	78	86		|O
with	87	91		|O
systemic	92	100		|O
vasculitis	101	111		|O
.	111	112		|O
PURPOSE	114	121		|O
:	121	122		|O
To	123	125		|O
assess	126	132		|O
the	133	136		|O
value	137	142		|O
of	143	145		|O
serial	146	152		|O
determinations	153	167		|O
of	168	170		|O
antineutrophil	171	185		|O
cytoplasmic	186	197		|O
autoantibodies	198	212		|O
(	213	214		|O
ANCA	214	218		|O
)	218	219		|O
for	220	223		|O
monitoring	224	234		|O
disease	235	242		|O
activity	243	251		|O
in	252	254		|O
patients	255	263		|O
with	264	268		|O
systemic	269	277		|O
vasculitis	278	288		|O
.	288	289		|O
PATIENTS	290	298		|O
AND	299	302		|O
METHODS	303	310		|O
:	310	311		|O
Forty	312	317		|O
-	317	318		|O
three	318	323		|O
patients	324	332		|O
with	333	337		|O
histologically	338	352		|O
proven	353	359		|O
vasculitis	360	370		|O
(	371	372		|O
21	372	374		|O
with	375	379		|O
Wegener	380	387		|O
's	387	389		|O
granulomatosis	390	404		|O
,	404	405		|O
17	406	408		|O
with	409	413		|O
microscopic	414	425		|O
polyangiitis	426	438		|O
,	438	439		|O
and	440	443		|O
5	444	445		|O
with	446	450		|O
renal	451	456		|O
-	456	457		|O
limited	457	464		|O
vasculitis	465	475		|O
)	475	476		|O
were	477	481		|O
studied	482	489		|O
for	490	493		|O
a	494	495		|O
median	496	502		|O
follow	503	509		|O
-	509	510		|O
up	510	512		|O
of	513	515		|O
22	516	518		|O
months	519	525		|O
.	525	526		|O
Disease	527	534		|O
activity	535	543		|O
was	544	547		|O
prospectively	548	561		|O
assessed	562	570		|O
and	571	574		|O
quantified	575	585		|O
by	586	588		|O
the	589	592		|O
Birmingham	593	603		|O
Vasculitis	604	614		|O
Activity	615	623		|O
Score	624	629		|O
.	629	630		|O
A	631	632		|O
total	633	638		|O
of	639	641		|O
347	642	645		|O
sera	646	650		|O
were	651	655		|O
analyzed	656	664		|O
for	665	668		|O
ANCA	669	673		|O
determination	674	687		|O
.	687	688		|O
RESULTS	689	696		|O
:	696	697		|O
Relapses	698	706		|O
occurred	707	715		|O
in	716	718		|O
23	719	721		|O
(	722	723		|O
54%	723	726		|O
)	726	727		|O
of	728	730		|O
43	731	733		|O
patients	734	742		|O
.	742	743		|O
Diagnostic	744	754		|O
category	755	763		|O
(	764	765		|O
Wegener	765	772		|O
's	772	774		|O
granulomatosis	775	789		|O
vs	790	792		|O
micropolyangiitis	793	810		|O
and	811	814		|O
renal	815	820		|O
-	820	821		|O
limited	821	828		|O
vasculitis	829	839		|O
)	839	840		|O
,	840	841		|O
severity	842	850		|O
of	851	853		|O
initial	854	861		|O
symptoms	862	870		|O
(	871	872		|O
mean	872	876		|O
vasculitis	877	887		|O
activity	888	896		|O
score	897	902		|O
,	902	903		|O
mean	904	908		|O
number	909	915		|O
of	916	918		|O
organs	919	925		|O
involved	926	934		|O
)	934	935		|O
,	935	936		|O
and	937	940		|O
ANCA	941	945		|O
pattern	946	953		|O
[	954	955		|O
cytoplasmic	955	966		|O
-	966	967		|O
ANCA	967	971		|O
(	972	973		|O
c	973	974		|O
-	974	975		|O
ANCA	975	979		|O
)	979	980		|O
vs	981	983		|O
perinuclear	984	995		|O
-	995	996		|O
ANCA	996	1000		|O
(	1001	1002		|O
p	1002	1003		|O
-	1003	1004		|O
ANCA	1004	1008		|O
)	1008	1009		|O
]	1009	1010		|O
did	1011	1014		|O
not	1015	1018		|O
significantly	1019	1032		|O
differ	1033	1039		|O
between	1040	1047		|O
relapsers	1048	1057		|O
and	1058	1061		|O
nonrelapsers	1062	1074		|O
.	1074	1075		|O
Lung	1076	1080		|O
involvement	1081	1092		|O
was	1093	1096		|O
more	1097	1101		|O
frequent	1102	1110		|O
at	1111	1113		|O
onset	1114	1119		|O
among	1120	1125		|O
relapsers	1126	1135		|O
[	1136	1137		|O
16	1137	1139		|O
of	1140	1142		|O
23	1143	1145		|O
(	1146	1147		|O
)	1150	1151		|O
vs	1152	1154		|O
6	1155	1156		|O
of	1157	1159		|O
(	1163	1164		|O
)	1167	1168		|O
;	1168	1169		|O
P	1170	1171		|O
=	1172	1173		|O
0.02	1174	1178		|O
]	1178	1179		|O
.	1179	1180		|O
Relapses	1181	1189		|O
were	1190	1194		|O
slightly	1195	1203		|O
,	1203	1204		|O
but	1205	1208		|O
not	1209	1212		|O
significantly	1213	1226		|O
,	1226	1227		|O
more	1228	1232		|O
frequent	1233	1241		|O
in	1242	1244		|O
patients	1245	1253		|O
with	1254	1258		|O
Wegener	1259	1266		|O
's	1266	1268		|O
granulomatosis	1269	1283		|O
or	1284	1286		|O
a	1287	1288		|O
c	1289	1290		|O
-	1290	1291		|O
ANCA	1291	1295		|O
pattern	1296	1303		|O
.	1303	1304		|O
The	1305	1308		|O
percentage	1309	1319		|O
of	1320	1322		|O
relapsers	1323	1332		|O
was	1333	1336		|O
greater	1337	1344		|O
in	1345	1347		|O
patients	1348	1356		|O
with	1357	1361		|O
persistently	1362	1374		|O
positive	1375	1383		|O
ANCA	1384	1388		|O
than	1389	1393		|O
in	1394	1396		|O
patients	1397	1405		|O
with	1406	1410		|O
negative	1411	1419		|O
or	1420	1422		|O
decreasing	1423	1433		|O
ANCA	1434	1438		|O
titers	1439	1445		|O
(	1446	1447		|O
86%	1447	1450		|O
vs	1451	1453		|O
,	1457	1458		|O
P	1459	1460		|O
=	1461	1462		|O
0.0001	1463	1469		|O
)	1469	1470		|O
.	1470	1471		|O
However	1472	1479		|O
,	1479	1480		|O
the	1481	1484		|O
predictive	1485	1495		|O
value	1496	1501		|O
of	1502	1504		|O
an	1505	1507		|O
increase	1508	1516		|O
in	1517	1519		|O
ANCA	1520	1524		|O
titers	1525	1531		|O
for	1532	1535		|O
the	1536	1539		|O
occurrence	1540	1550		|O
of	1551	1553		|O
a	1554	1555		|O
subsequent	1556	1566		|O
relapse	1567	1574		|O
was	1575	1578		|O
only	1579	1583		|O
28%	1584	1587		|O
(	1588	1589		|O
4	1589	1590		|O
of	1591	1593		|O
14	1594	1596		|O
)	1596	1597		|O
for	1598	1601		|O
c	1602	1603		|O
-	1603	1604		|O
ANCA	1604	1608		|O
,	1608	1609		|O
12%	1610	1613		|O
(	1614	1615		|O
2	1615	1616		|O
of	1617	1619		|O
17	1620	1622		|O
)	1622	1623		|O
for	1624	1627		|O
anti	1628	1632		|O
-	1632	1633		|O
proteinase	1633	1643		|O
3	1644	1645		|O
-	1645	1646		|O
ANCA	1646	1650		|O
,	1650	1651		|O
and	1652	1655		|O
43%	1656	1659		|O
(	1660	1661		|O
6	1661	1662		|O
of	1663	1665		|O
14	1666	1668		|O
)	1668	1669		|O
for	1670	1673		|O
anti	1674	1678		|O
-	1678	1679		|O
myeloperoxidase	1679	1694		|O
-	1694	1695		|O
ANCA	1695	1699		|O
.	1699	1700		|O
An	1701	1703		|O
increase	1704	1712		|O
in	1713	1715		|O
ANCA	1716	1720		|O
occurred	1721	1729		|O
before	1730	1736		|O
or	1737	1739		|O
during	1740	1746		|O
relapse	1747	1754		|O
in	1755	1757		|O
33%	1758	1761		|O
(	1762	1763		|O
of	1766	1768		|O
)	1771	1772		|O
of	1773	1775		|O
cases	1776	1781		|O
for	1782	1785		|O
c	1786	1787		|O
-	1787	1788		|O
ANCA	1788	1792		|O
/	1792	1793		|O
anti	1793	1797		|O
-	1797	1798		|O
proteinase	1798	1808		|O
3	1809	1810		|O
antibodies	1811	1821		|O
,	1821	1822		|O
and	1823	1826		|O
73%	1827	1830		|O
(	1831	1832		|O
11	1832	1834		|O
of	1835	1837		|O
15	1838	1840		|O
)	1840	1841		|O
of	1842	1844		|O
cases	1845	1850		|O
for	1851	1854		|O
anti	1855	1859		|O
-	1859	1860		|O
myeloperoxidase	1860	1875		|O
antibodies	1876	1886		|O
.	1886	1887		|O
CONCLUSION	1888	1898		|O
:	1898	1899		|O
The	1900	1903		|O
persistence	1904	1915		|O
of	1916	1918		|O
ANCA	1919	1923		|O
positivity	1924	1934		|O
is	1935	1937		|O
strongly	1938	1946		|O
associated	1947	1957		|O
with	1958	1962		|O
relapses	1963	1971		|O
.	1971	1972		|O
However	1973	1980		|O
,	1980	1981		|O
an	1982	1984		|O
increase	1985	1993		|O
in	1994	1996		|O
ANCA	1997	2001		|O
titers	2002	2008		|O
has	2009	2012		|O
a	2013	2014		|O
poor	2015	2019		|O
value	2020	2025		|O
for	2026	2029		|O
the	2030	2033		|O
early	2034	2039		|O
prediction	2040	2050		|O
of	2051	2053		|O
a	2054	2055		|O
subsequent	2056	2066		|O
relapse	2067	2074		|O
and	2075	2078		|O
should	2079	2085		|O
not	2086	2089		|O
be	2090	2092		|O
used	2093	2097		|O
as	2098	2100		|O
a	2101	2102		|O
sole	2103	2107		|O
parameter	2108	2117		|O
for	2118	2121		|O
therapeutic	2122	2133		|O
intervention	2134	2146		|O
.	2146	2147		|O
In	2148	2150		|O
addition	2151	2159		|O
,	2159	2160		|O
our	2161	2164		|O
results	2165	2172		|O
suggest	2173	2180		|O
that	2181	2185		|O
serial	2186	2192		|O
anti	2193	2197		|O
-	2197	2198		|O
myeloperoxidase	2198	2213		|O
determination	2214	2227		|O
may	2228	2231		|O
be	2232	2234		|O
useful	2235	2241		|O
as	2242	2244		|O
a	2245	2246		|O
prognostic	2247	2257		|O
marker	2258	2264		|O
in	2265	2267		|O
patients	2268	2276		|O
who	2277	2280		|O
are	2281	2284		|O
p	2285	2286		|O
-	2286	2287		|O
ANCA	2287	2291		|O
positive	2292	2300		|O
.	2300	2301		|O

### 9719587
The	0	3		|O
synthesis	4	13		|O
of	14	16		|O
a	17	18		|O
range	19	24		|O
of	25	27		|O
3	28	29	3-hydroxy-4(1H)-pyridinones	|B-IUPAC
-	29	30		|I-IUPAC
hydroxy	30	37		|I-IUPAC
-	37	38		|I-IUPAC
4	38	39		|I-IUPAC
(	39	40		|I-IUPAC
1H	40	42		|I-IUPAC
)	42	43		|I-IUPAC
-	43	44		|I-IUPAC
pyridinones	44	55		|I-IUPAC
with	56	60		|O
potential	61	70		|O
for	71	74		|O
the	75	78		|O
chelation	79	88		|O
of	89	91		|O
iron	92	96	iron(III)	|B-TRIVIAL
(	96	97		|I-TRIVIAL
III	97	100		|I-TRIVIAL
)	100	101		|I-TRIVIAL
is	102	104		|O
described	105	114		|O
.	114	115		|O
The	116	119		|O
pKa	120	123		|O
values	124	130		|O
of	131	133		|O
respective	134	144		|O
ligands	145	152		|O
and	153	156		|O
the	157	160		|O
stability	161	170		|O
constants	171	180		|O
of	181	183		|O
their	184	189		|O
iron	190	194	iron(III)	|B-TRIVIAL
(	194	195		|I-TRIVIAL
III	195	198		|I-TRIVIAL
)	198	199		|I-TRIVIAL
complexes	200	209	complexes	|B-MODIFIER
are	210	213		|O
presented	214	223		|O
.	223	224		|O
The	225	228		|O
distribution	229	241		|O
coefficient	242	253		|O
values	254	260		|O
of	261	263		|O
a	264	265		|O
range	266	271		|O
of	272	274		|O
48	275	277		|O
hydroxypyridinones	277	295	 hydroxypyridinones	|B-FAMILY
and	297	300		|O
their	301	306		|O
corresponding	307	320		|O
iron	321	325	iron(III)	|B-TRIVIAL
(	325	326		|I-TRIVIAL
III	326	329		|I-TRIVIAL
)	329	330		|I-TRIVIAL
complexes	331	340	complexes	|B-MODIFIER
between	341	348		|O
1	349	350	1-octanol	|B-TRIVIAL
-	350	351		|I-TRIVIAL
octanol	351	358		|I-TRIVIAL
and	359	362		|O
MOPS	363	367		|O
buffer	368	374		|O
(	375	376		|O
pH	376	378		|O
7.4	379	382		|O
)	382	383		|O
are	384	387		|O
reported	388	396		|O
.	396	397		|O
The	398	401		|O
range	402	407		|O
of	408	410		|O
log	411	414		|O
Dcomplex	415	423		|O
values	424	430		|O
covers	431	437		|O
7	438	439		|O
orders	440	446		|O
of	447	449		|O
magnitude	450	459		|O
.	459	460		|O
The	461	464		|O
results	465	472		|O
suggest	473	480		|O
the	481	484		|O
existence	485	494		|O
of	495	497		|O
a	498	499		|O
biphasic	500	508		|O
relationship	509	521		|O
between	522	529		|O
the	530	533		|O
distribution	534	546		|O
coefficient	547	558		|O
values	559	565		|O
of	566	568		|O
the	569	572		|O
chelator	573	581		|O
and	582	585		|O
the	586	589		|O
corresponding	590	603		|O
iron	603	607	 iron(III)	|B-TRIVIAL
(	608	609		|I-TRIVIAL
III	609	612		|I-TRIVIAL
)	612	613		|I-TRIVIAL
complexes	614	623	complexes	|B-MODIFIER
.	623	624		|O
For	625	628		|O
ligands	629	636		|O
with	637	641		|O
a	642	643		|O
log	644	647		|O
Dligand	648	655		|O
=	656	657		|O
-	658	659		|O
1	659	660		|O
,	660	661		|O
a	662	663		|O
linear	664	670		|O
relationship	671	683		|O
exists	684	690		|O
with	691	695		|O
a	696	697		|O
value	698	703		|O
of	704	706		|O
the	707	710		|O
slope	711	716		|O
2.53	717	721		|O
,	721	722		|O
whereas	723	730		|O
with	731	735		|O
ligands	736	743		|O
with	744	748		|O
a	749	750		|O
log	751	754		|O
Dligand	755	762		|O
&	763	764		|O
lt	764	766		|O
;	766	767		|O
-	768	769		|O
1	769	770		|O
,	770	771		|O
a	772	773		|O
linear	774	780		|O
relationship	781	793		|O
exists	794	800		|O
with	801	805		|O
a	806	807		|O
slope	808	813		|O
of	814	816		|O
0.49	817	821		|O
.	821	822		|O
The	823	826		|O
reduced	827	834		|O
slope	835	840		|O
for	841	844		|O
the	845	848		|O
more	849	853		|O
hydrophilic	854	865		|O
molecules	866	875		|O
of	876	878		|O
the	879	882		|O
series	883	889		|O
offers	890	896		|O
some	897	901		|O
advantage	902	911		|O
for	912	915		|O
this	916	920		|O
type	921	925		|O
of	926	928		|O
hydroxypyridinone	929	946	hydroxypyridinone	|B-FAMILY
as	947	949		|O
the	950	953		|O
distribution	954	966		|O
coefficients	967	979		|O
for	980	983		|O
such	984	988		|O
complexes	989	998		|O
do	999	1001		|O
not	1002	1005		|O
change	1006	1012		|O
so	1013	1015		|O
rapidly	1016	1023		|O
with	1024	1028		|O
increasing	1029	1039		|O
ligand	1040	1046		|O
hydrophilicity	1047	1061		|O
.	1061	1062		|O
The	1063	1066		|O
ability	1067	1074		|O
of	1075	1077		|O
selected	1078	1086		|O
3	1087	1088	3-hydroxypyridinones	|B-IUPAC
-	1088	1089		|I-IUPAC
hydroxypyridinones	1089	1107		|I-IUPAC
to	1108	1110		|O
facilitate	1111	1121		|O
the	1122	1125		|O
excretion	1126	1135		|O
of	1136	1138		|O
iron	1139	1143		|O
in	1144	1146		|O
bile	1147	1151		|O
was	1152	1155		|O
investigated	1156	1168		|O
in	1169	1171		|O
non	1172	1175		|O
-	1175	1176		|O
iron	1176	1180		|O
-	1180	1181		|O
overloaded	1181	1191		|O
,	1191	1192		|O
bile	1193	1197		|O
duct	1198	1202		|O
-	1202	1203		|O
cannulated	1203	1213		|O
rats	1214	1218		|O
and	1219	1222		|O
in	1223	1225		|O
a	1226	1227		|O
[	1228	1229	[59Fe]ferritin	|B-IUPAC
59Fe	1229	1233		|I-IUPAC
]	1233	1234		|I-IUPAC
ferritin	1234	1242		|I-IUPAC
-	1242	1243		|O
loaded	1243	1249		|O
rat	1250	1253		|O
model	1254	1259		|O
.	1259	1260		|O
Both	1261	1265		|O
systems	1266	1273		|O
compare	1274	1281		|O
the	1282	1285		|O
ability	1286	1293		|O
of	1294	1296		|O
chelators	1297	1306		|O
to	1307	1309		|O
remove	1310	1316		|O
iron	1317	1321		|O
from	1322	1326		|O
the	1327	1330		|O
liver	1331	1336		|O
,	1336	1337		|O
the	1338	1341		|O
prime	1342	1347		|O
target	1348	1354		|O
organ	1355	1360		|O
in	1361	1363		|O
thalassemia	1364	1375		|O
.	1375	1376		|O
The	1377	1380		|O
N	1381	1382	N-(hydroxyalkyl)-3-hydroxypyridin-4-ones	|B-IUPAC
-	1382	1383		|I-IUPAC
(	1383	1384		|I-IUPAC
hydroxyalkyl	1384	1396		|I-IUPAC
)	1396	1397		|I-IUPAC
-	1397	1398		|I-IUPAC
3	1398	1399		|I-IUPAC
-	1399	1400		|I-IUPAC
hydroxypyridin	1400	1414		|I-IUPAC
-	1414	1415		|I-IUPAC
4	1415	1416		|I-IUPAC
-	1416	1417		|I-IUPAC
ones	1417	1421		|I-IUPAC
are	1422	1425		|O
demonstrated	1426	1438		|O
to	1439	1441		|O
be	1442	1444		|O
orally	1445	1451		|O
active	1452	1458		|O
under	1459	1464		|O
the	1465	1468		|O
in	1469	1471		|O
vivo	1472	1476		|O
conditions	1477	1487		|O
adopted	1488	1495		|O
.	1495	1496		|O
Thus	1497	1501		|O
both	1502	1506		|O
1	1507	1508	1-(hydroxyalkyl)-	|B-PARTIUPAC
-	1508	1509		|I-PARTIUPAC
(	1509	1510		|I-PARTIUPAC
hydroxyalkyl	1510	1522		|I-PARTIUPAC
)	1522	1523		|I-PARTIUPAC
-	1523	1524		|I-PARTIUPAC
and	1525	1528		|O
1	1529	1530	1-(carboxyalkyl)pyridinones	|B-IUPAC
-	1530	1531		|I-IUPAC
(	1531	1532		|I-IUPAC
carboxyalkyl	1532	1544		|I-IUPAC
)	1544	1545		|I-IUPAC
pyridinones	1545	1556		|I-IUPAC
are	1557	1560		|O
able	1561	1565		|O
to	1566	1568		|O
remove	1569	1575		|O
iron	1576	1580	iron	|B-TRIVIAL
from	1581	1585		|O
the	1586	1589		|O
liver	1590	1595		|O
.	1595	1596		|O
Although	1597	1605		|O
1	1606	1607	1-(carboxyalkyl)hydroxypyridinones	|B-IUPAC
-	1607	1608		|I-IUPAC
(	1608	1609		|I-IUPAC
carboxyalkyl	1609	1621		|I-IUPAC
)	1621	1622		|I-IUPAC
hydroxypyridinones	1622	1640		|I-IUPAC
are	1641	1644		|O
active	1645	1651		|O
,	1651	1652		|O
they	1653	1657		|O
do	1658	1660		|O
not	1661	1664		|O
demonstrate	1665	1676		|O
any	1677	1680		|O
clear	1681	1686		|O
advantage	1687	1696		|O
over	1697	1701		|O
Deferiprone	1702	1713	Deferiprone	|B-TRIVIAL
(	1714	1715		|O
1,2	1715	1718	1,2-dimethyl-3-hydroxypyridin-4-one	|B-IUPAC
-	1718	1719		|I-IUPAC
dimethyl	1719	1727		|I-IUPAC
-	1727	1728		|I-IUPAC
3	1728	1729		|I-IUPAC
-	1729	1730		|I-IUPAC
hydroxypyridin	1730	1744		|I-IUPAC
-	1744	1745		|I-IUPAC
4	1745	1746		|I-IUPAC
-	1746	1747		|I-IUPAC
one	1747	1750		|I-IUPAC
)	1750	1751		|O
.	1751	1752		|O
Indeed	1753	1759		|O
1	1760	1761	1-(hydroxyalkyl)hydroxypyridinones	|B-IUPAC
-	1761	1762		|I-IUPAC
(	1762	1763		|I-IUPAC
hydroxyalkyl	1763	1775		|I-IUPAC
)	1775	1776		|I-IUPAC
hydroxypyridinones	1776	1794		|I-IUPAC
which	1795	1800		|O
are	1801	1804		|O
known	1805	1810		|O
to	1811	1813		|O
be	1814	1816		|O
rapidly	1817	1824		|O
converted	1825	1834		|O
to	1835	1837		|O
1	1838	1839	1-(carboxyalkyl)hydroxypyridinones	|B-IUPAC
-	1839	1840		|I-IUPAC
(	1840	1841		|I-IUPAC
carboxyalkyl	1841	1853		|I-IUPAC
)	1853	1854		|I-IUPAC
hydroxypyridinones	1854	1872		|I-IUPAC
are	1873	1876		|O
also	1877	1881		|O
marginally	1882	1892		|O
superior	1893	1901		|O
to	1902	1904		|O
Deferiprone	1905	1916	Deferiprone	|B-TRIVIAL
.	1916	1917		|O
In	1918	1920		|O
contrast	1921	1929		|O
,	1929	1930		|O
2	1931	1932	2-ethyl-1-(2'-hydroxyethyl)-3-hydroxypyridin-4-one	|B-IUPAC
-	1932	1933		|I-IUPAC
ethyl	1933	1938		|I-IUPAC
-	1938	1939		|I-IUPAC
1	1939	1940		|I-IUPAC
-	1940	1941		|I-IUPAC
(	1941	1942		|I-IUPAC
2'	1942	1944		|I-IUPAC
-	1944	1945		|I-IUPAC
hydroxyethyl	1945	1957		|I-IUPAC
)	1957	1958		|I-IUPAC
-	1958	1959		|I-IUPAC
3	1959	1960		|I-IUPAC
-	1960	1961		|I-IUPAC
hydroxypyridin	1961	1975		|I-IUPAC
-	1975	1976		|I-IUPAC
4	1976	1977		|I-IUPAC
-	1977	1978		|I-IUPAC
one	1978	1981		|I-IUPAC
,	1981	1982		|O
which	1983	1988		|O
is	1989	1991		|O
not	1992	1995		|O
metabolized	1996	2007		|O
to	2008	2010		|O
the	2011	2014		|O
corresponding	2015	2028		|O
(	2029	2030	(carboxyalkyl)hydroxypyridinone	|B-TRIVIAL
carboxyalkyl	2030	2042		|I-TRIVIAL
)	2042	2043		|I-TRIVIAL
hydroxypyridinone	2043	2060		|I-TRIVIAL
,	2060	2061		|O
was	2062	2065		|O
found	2066	2071		|O
to	2072	2074		|O
be	2075	2077		|O
superior	2078	2086		|O
to	2087	2089		|O
Deferiprone	2090	2101	Deferiprone	|B-TRIVIAL
and	2102	2105		|O
therefore	2106	2115		|O
deserves	2116	2124		|O
further	2125	2132		|O
consideration	2133	2146		|O
as	2147	2149		|O
an	2150	2152		|O
orally	2153	2159		|O
active	2160	2166		|O
iron	2167	2171		|O
chelator	2172	2180		|O
with	2181	2185		|O
potential	2186	2195		|O
for	2196	2199		|O
the	2200	2203		|O
treatment	2204	2213		|O
of	2214	2216		|O
iron	2217	2221	iron	|B-TRIVIAL
overload	2221	2229		|O
associated	2231	2241		|O
with	2242	2246		|O
transfusion	2247	2258		|O
-	2258	2259		|O
dependent	2259	2268		|O
thalassemia	2269	2280		|O
.	2280	2281		|O

### 3625710
A	0	1		|O
series	2	8		|O
of	9	11		|O
analogues	12	21		|O
of	22	24		|O
the	25	28		|O
analgesic	29	38		|O
dipeptide	39	48		|O
derivative	49	59		|O
H	60	61	H-Lys-Trp(NPS)-OMe	|O
-	61	62		|O
Lys	62	65		|O
-	65	66		|O
Trp	66	69		|O
(	69	70		|O
NPS	70	73		|O
)	73	74		|O
-	74	75		|O
OMe	75	78		|O
has	79	82		|O
been	83	87		|O
designed	88	96		|O
to	97	99		|O
determine	100	109		|O
the	110	113		|O
influence	114	123		|O
of	124	126		|O
the	127	130		|O
(	131	132	(2-nitrophenyl)sulfenyl	|B-PARTIUPAC
2	132	133		|I-PARTIUPAC
-	133	134		|I-PARTIUPAC
nitrophenyl	134	145		|I-PARTIUPAC
)	145	146		|I-PARTIUPAC
sulfenyl	146	154		|I-PARTIUPAC
(	155	156		|O
NPS	156	159	NPS	|B-ABBREVIATION
)	159	160		|O
moiety	161	167	moiety	|B-MODIFIER
on	168	170		|O
the	171	174		|O
activity	175	183		|O
.	183	184		|O
The	185	188		|O
syntheses	189	198		|O
and	199	202		|O
antinociceptive	203	218		|O
effects	219	226		|O
of	227	229		|O
these	230	235		|O
analogues	236	245		|O
of	246	248		|O
general	249	256		|O
formula	257	264		|O
H	264	265	 H-Lys-Trp(R)-OMe	|O
-	266	267		|O
Lys	267	270		|O
-	270	271		|O
Trp	271	274		|O
(	274	275		|O
R	275	276		|O
)	276	277		|O
-	277	278		|O
OMe	278	281		|O
[	282	283		|O
R	283	284		|O
=	285	286		|O
phenylsulfenyl	287	301	phenylsulfenyl	|B-PARTIUPAC
(	302	303		|O
PS	303	305	PS	|B-ABBREVIATION
)	305	306		|O
(	307	308		|O
9	308	309		|O
)	309	310		|O
;	310	311		|O
R	312	313		|O
=	314	315		|O
(	316	317		|O
2	317	318	2-carbomethyoxyphenyl)sulfenyl	|B-PARTIUPAC
-	318	319		|I-PARTIUPAC
carbomethyoxyphenyl	319	338		|I-PARTIUPAC
)	338	339		|I-PARTIUPAC
sulfenyl	339	347		|I-PARTIUPAC
(	348	349		|O
CmPS	349	353	CmPS	|B-ABBREVIATION
)	353	354		|O
(	355	356		|O
)	358	359		|O
;	359	360		|O
R	361	362		|O
=	363	364		|O
(	365	366		|O
4	366	367	4-nitrophenyl)sulfenyl	|B-PARTIUPAC
-	367	368		|I-PARTIUPAC
nitrophenyl	368	379		|I-PARTIUPAC
)	379	380		|I-PARTIUPAC
sulfenyl	380	388		|I-PARTIUPAC
(	389	390		|O
pNPS	390	394	pNPS	|B-ABBREVIATION
)	394	395		|O
(	396	397		|O
11	397	399		|O
)	399	400		|O
;	400	401		|O
R	402	403		|O
=	404	405		|O
(	406	407		|O
2,4	407	410	2,4-dinitrophenyl)sulfenyl	|B-PARTIUPAC
-	410	411		|I-PARTIUPAC
dinitrophenyl	411	424		|I-PARTIUPAC
)	424	425		|I-PARTIUPAC
sulfenyl	425	433		|I-PARTIUPAC
(	434	435		|O
DNPS	435	439	DNPS	|B-ABBREVIATION
)	439	440		|O
(	441	442		|O
12	442	444		|O
)	444	445		|O
;	445	446		|O
R	447	448		|O
=	449	450		|O
[	451	452	[2-(acetylamino)-2-carbomethoxyethyl]sulfenyl	|B-PARTIUPAC
2	452	453		|I-PARTIUPAC
-	453	454		|I-PARTIUPAC
(	454	455		|I-PARTIUPAC
acetylamino	455	466		|I-PARTIUPAC
)	466	467		|I-PARTIUPAC
-	467	468		|I-PARTIUPAC
2	468	469		|I-PARTIUPAC
-	469	470		|I-PARTIUPAC
carbomethoxyethyl	470	487		|I-PARTIUPAC
]	487	488		|I-PARTIUPAC
sulfenyl	488	496		|I-PARTIUPAC
(	497	498		|O
AacCmES	498	505	AacCmES	|B-ABBREVIATION
)	505	506		|O
(	507	508		|O
13	508	510		|O
)	510	511		|O
;	511	512		|O
R	513	514		|O
=	515	516		|O
[	517	518	[2-(acetylamino)phenyl]sulfenyl	|B-PARTIUPAC
2	518	519		|I-PARTIUPAC
-	519	520		|I-PARTIUPAC
(	520	521		|I-PARTIUPAC
acetylamino	521	532		|I-PARTIUPAC
)	532	533		|I-PARTIUPAC
phenyl	533	539		|I-PARTIUPAC
]	539	540		|I-PARTIUPAC
sulfenyl	540	548		|I-PARTIUPAC
(	549	550		|O
AacPS	550	555	AacPS	|B-ABBREVIATION
)	555	556		|O
(	557	558		|O
17	558	560		|O
)	560	561		|O
;	561	562		|O
R	563	564		|O
=	565	566		|O
tert	567	571	tert-butylsulfenyl	|B-PARTIUPAC
-	571	572		|I-PARTIUPAC
butylsulfenyl	572	585		|I-PARTIUPAC
(	586	587		|O
t	587	588	t-BuS	|B-ABBREVIATION
-	588	589		|I-ABBREVIATION
BuS	589	592		|I-ABBREVIATION
)	592	593		|O
(	594	595		|O
23	595	597		|O
)	597	598		|O
;	598	599		|O
R	600	601		|O
=	602	603		|O
(	604	605	(2-carbomethoxyethyl)sulfenyl	|B-PARTIUPAC
2	605	606		|I-PARTIUPAC
-	606	607		|I-PARTIUPAC
carbomethoxyethyl	607	624		|I-PARTIUPAC
)	624	625		|I-PARTIUPAC
sulfenyl	625	633		|I-PARTIUPAC
(	634	635		|O
CmES	635	639	CmES	|B-ABBREVIATION
)	639	640		|O
(	641	642		|O
24	642	644		|O
)	644	645		|O
]	645	646		|O
are	647	650		|O
described	651	660		|O
.	660	661		|O
Reaction	662	670		|O
of	671	673		|O
Z	674	675	Z-Lys(Z)-Trp-OMe	|O
-	675	676		|O
Lys	676	679		|O
(	679	680		|O
Z	680	681		|O
)	681	682		|O
-	682	683		|O
Trp	683	686		|O
-	686	687		|O
OMe	687	690		|O
(	691	692		|O
3	692	693		|O
)	693	694		|O
with	695	699		|O
PS	700	702	PS	|B-ABBREVIATION
-	702	703		|O
,	703	704		|O
CmPS	705	709	CmPS	|B-ABBREVIATION
-	709	710		|O
,	710	711		|O
pNPS	712	716	pNPS	|B-ABBREVIATION
-	716	717		|O
,	717	718		|O
DNPS	719	723	DNPS	|B-ABBREVIATION
-	723	724		|O
,	724	725		|O
and	726	729		|O
AacCmES	730	737	AacCmES-Cl	|B-ABBREVIATION
-	737	738		|I-ABBREVIATION
Cl	738	740		|I-ABBREVIATION
afforded	741	749		|O
the	750	753		|O
corresponding	754	767		|O
2	768	769	2-(sulfenyl)tryptophan	|B-IUPAC
-	769	770		|I-IUPAC
(	770	771		|I-IUPAC
sulfenyl	771	779		|I-IUPAC
)	779	780		|I-IUPAC
tryptophan	780	790		|I-IUPAC
derivatives	791	802	derivatives	|B-MODIFIER
,	802	803		|O
which	804	809		|O
on	810	812		|O
treatment	813	822		|O
with	823	827		|O
boron	828	833	boron-tris(trifluoroacetate)	|B-IUPAC
-	833	834		|I-IUPAC
tris	834	838		|I-IUPAC
(	838	839		|I-IUPAC
trifluoroacetate	839	855		|I-IUPAC
)	855	856		|I-IUPAC
/	856	857		|O
trifluoroacetic	857	872	trifluoroacetic acid	|B-IUPAC
acid	873	877		|I-IUPAC
or	878	880		|O
trimethylsilyl	881	895	trimethylsilyl iodide	|B-IUPAC
iodide	896	902		|I-IUPAC
in	903	905		|O
acetonitrile	906	918	acetonitrile	|B-TRIVIAL
(	919	920		|O
Me3SiI	920	926	Me3SiI	|B-SUM
/	926	927		|O
CH3CN	927	932	CH3CN	|B-SUM
)	932	933		|O
provided	934	942		|O
9-13	943	947		|O
,	947	948		|O
respectively	949	961		|O
.	961	962		|O
Sulfenylation	963	976		|O
of	977	979		|O
3	980	981		|O
with	982	986		|O
NPS	987	990	NPS-Cl	|B-ABBREVIATION
-	990	991		|I-ABBREVIATION
Cl	991	993		|I-ABBREVIATION
gave	994	998		|O
Z	999	1000	Z-Lys(Z)-Trp(NPS)-OMe	|O
-	1000	1001		|O
Lys	1001	1004		|O
(	1004	1005		|O
Z	1005	1006		|O
)	1006	1007		|O
-	1007	1008		|O
Trp	1008	1011		|O
(	1011	1012		|O
NPS	1012	1015		|O
)	1015	1016		|O
-	1016	1017		|O
OMe	1017	1020		|O
,	1020	1021		|O
which	1022	1027		|O
,	1027	1028		|O
on	1029	1031		|O
catalytic	1032	1041		|O
hydrogenation	1042	1055		|O
of	1056	1058		|O
the	1059	1062		|O
nitro	1063	1068		|O
group	1069	1074		|O
using	1075	1080		|O
Pd	1085	1087		|O
/	1087	1088		|O
C	1088	1089		|O
followed	1090	1098		|O
by	1099	1101		|O
acetylation	1102	1113		|O
of	1114	1116		|O
the	1117	1120		|O
resulting	1121	1130		|O
amino	1131	1136		|O
function	1137	1145		|O
and	1146	1149		|O
removal	1150	1157		|O
of	1158	1160		|O
the	1161	1164		|O
protecting	1165	1175		|O
Z	1176	1177		|O
groups	1178	1184		|O
,	1184	1185		|O
gave	1186	1190		|O
17	1191	1193		|O
.	1193	1194		|O
Condensation	1195	1207		|O
of	1208	1210		|O
2	1211	1212	2-(tert-butylsulfenyl)-	|B-PARTIUPAC
-	1212	1213		|I-PARTIUPAC
(	1213	1214		|I-PARTIUPAC
tert	1214	1218		|I-PARTIUPAC
-	1218	1219		|I-PARTIUPAC
butylsulfenyl	1219	1232		|I-PARTIUPAC
)	1232	1233		|I-PARTIUPAC
-	1233	1234		|I-PARTIUPAC
and	1235	1238		|O
2	1239	1240	2-[(2-carbomethoxyethyl)sulfenyl]tryptophan methyl ester	|B-IUPAC
-	1240	1241		|I-IUPAC
[	1241	1242		|I-IUPAC
(	1242	1243		|I-IUPAC
2	1243	1244		|I-IUPAC
-	1244	1245		|I-IUPAC
carbomethoxyethyl	1245	1262		|I-IUPAC
)	1262	1263		|I-IUPAC
sulfenyl	1263	1271		|I-IUPAC
]	1271	1272		|I-IUPAC
tryptophan	1272	1282		|I-IUPAC
methyl	1283	1289		|I-IUPAC
ester	1290	1295		|I-IUPAC
,	1295	1296		|O
obtained	1297	1305		|O
by	1306	1308		|O
reaction	1309	1317		|O
of	1318	1320		|O
methyl	1321	1327	methyl 3a-hydroxy-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indole-2-carboxyla te	|B-IUPAC
3a	1328	1330		|I-IUPAC
-	1330	1331		|I-IUPAC
hydroxy	1331	1338		|I-IUPAC
-	1338	1339		|I-IUPAC
1,2,3,3	1339	1346		|I-IUPAC
a	1346	1347		|I-IUPAC
,	1347	1348		|I-IUPAC
8,8	1348	1351		|I-IUPAC
a	1351	1352		|I-IUPAC
-	1352	1353		|I-IUPAC
hexahydropyrrolo	1353	1369		|I-IUPAC
[	1369	1370		|I-IUPAC
2,3	1370	1373		|I-IUPAC
-	1373	1374		|I-IUPAC
b	1374	1375		|I-IUPAC
]	1375	1376		|I-IUPAC
indole	1376	1382		|I-IUPAC
-	1382	1383		|I-IUPAC
2	1383	1384		|I-IUPAC
-	1384	1385		|I-IUPAC
carboxyla	1385	1394		|I-IUPAC
te	1395	1397		|I-IUPAC
with	1398	1402		|O
the	1403	1406		|O
corresponding	1407	1420		|O
thiol	1421	1426		|O
,	1426	1427		|O
with	1428	1432		|O
Z	1433	1434	Z-Lys(Z)-OSu afforded Z-Lys(Z)-Trp(t-BuS)-OMe	|O
-	1434	1435		|O
Lys	1435	1438		|O
(	1438	1439		|O
Z	1439	1440		|O
)	1440	1441		|O
-	1441	1442		|O
OSu	1442	1445		|O
afforded	1446	1454		|O
Z	1455	1456		|O
-	1456	1457		|O
Lys	1457	1460		|O
(	1460	1461		|O
Z	1461	1462		|O
)	1462	1463		|O
-	1463	1464		|O
Trp	1464	1467		|O
(	1467	1468		|O
t	1468	1469		|O
-	1469	1470		|O
BuS	1470	1473		|O
)	1473	1474		|O
-	1474	1475		|O
OMe	1475	1478		|O
and	1479	1482		|O
Z	1483	1484	Z-Lys(Z)-Trp(CmES)-OMe	|O
-	1484	1485		|O
Lys	1485	1488		|O
(	1488	1489		|O
Z	1489	1490		|O
)	1490	1491		|O
-	1491	1492		|O
Trp	1492	1495		|O
(	1495	1496		|O
CmES	1496	1500		|O
)	1500	1501		|O
-	1501	1502		|O
OMe	1502	1505		|O
,	1505	1506		|O
which	1507	1512		|O
on	1513	1515		|O
treatment	1516	1525		|O
with	1526	1530		|O
Me3SiI	1531	1537	Me3SiI	|B-SUM
/	1537	1538		|O
CH3CN	1538	1543	CH3CN	|B-SUM
provided	1544	1552		|O
23	1553	1555		|O
and	1556	1559		|O
24	1560	1562		|O
,	1562	1563		|O
respectively	1564	1576		|O
.	1576	1577		|O
Intracerebroventricular	1578	1601		|O
administration	1602	1616		|O
of	1617	1619		|O
elicited	1623	1631		|O
a	1632	1633		|O
naloxone	1634	1642	naloxone	|B-TRIVIAL
-	1642	1643		|O
reversible	1643	1653		|O
antinociceptive	1654	1669		|O
effect	1670	1676		|O
in	1677	1679		|O
mice	1680	1684		|O
similar	1685	1692		|O
to	1693	1695		|O
that	1696	1700		|O
of	1701	1703		|O
H	1704	1705	H-Lys-Trp(NPS)-OMe	|O
-	1705	1706		|O
Lys	1706	1709		|O
-	1709	1710		|O
Trp	1710	1713		|O
(	1713	1714		|O
NPS	1714	1717		|O
)	1717	1718		|O
-	1718	1719		|O
OMe	1719	1722		|O
.	1722	1723		|O
No	1724	1726		|O
analgesia	1727	1736		|O
was	1737	1740		|O
however	1741	1748		|O
found	1749	1754		|O
with	1755	1759		|O
the	1760	1763		|O
phenylsulfenyl	1764	1778	phenylsulfenyl	|B-PARTIUPAC
or	1779	1781		|O
acyclic	1782	1789	acyclic sulfenyl substituted dipeptides	|B-IUPAC
sulfenyl	1790	1798		|I-IUPAC
substituted	1799	1810		|I-IUPAC
dipeptides	1811	1821		|I-IUPAC
9	1822	1823		|O
,	1823	1824		|O
11	1825	1827		|O
,	1827	1828		|O
and	1829	1832		|O
17	1833	1835		|O
or	1836	1838		|O
13	1839	1841		|O
,	1841	1842		|O
23	1843	1845		|O
,	1845	1846		|O
and	1847	1850		|O
24	1851	1853		|O
.	1853	1854		|O
The	1855	1858		|O
Trp	1859	1862	Trp(DNPS)	|B-ABBREVIATION
(	1862	1863		|I-ABBREVIATION
DNPS	1863	1867		|I-ABBREVIATION
)	1867	1868		|I-ABBREVIATION
-	1868	1869		|O
containing	1869	1879		|O
analogue	1880	1888		|O
was	1889	1892		|O
neurotoxic	1893	1903		|O
.	1903	1904		|O
Structure	1905	1914		|O
-	1914	1915		|O
activity	1915	1923		|O
studies	1924	1931		|O
indicate	1932	1940		|O
that	1941	1945		|O
the	1946	1949		|O
role	1950	1954		|O
of	1955	1957		|O
the	1958	1961		|O
NPS	1962	1965	NPS	|B-ABBREVIATION
and	1966	1969		|O
CmPS	1970	1974	CmPS	|B-ABBREVIATION
moieties	1975	1983	moieties	|B-MODIFIER
could	1983	1988		|O
be	1990	1992		|O
related	1993	2000		|O
to	2001	2003		|O
the	2004	2007		|O
adoption	2008	2016		|O
of	2017	2019		|O
a	2020	2021		|O
preferential	2022	2034		|O
active	2035	2041		|O
conformation	2042	2054		|O
.	2054	2055		|O

### 2153828
A	0	1		|O
series	2	8		|O
of	9	11		|O
substituted	12	23		|O
1,4	24	27	1,4-dihydronaphthoquinones	|B-IUPAC
-	27	28		|I-IUPAC
dihydronaphthoquinones	28	50		|I-IUPAC
,	50	51		|O
hydroindoloquinones	52	71	hydroindoloquinones	|B-TRIVIAL
,	71	72		|O
benzofuran	73	83	benzofuran-4,7-dihydroquinones	|B-IUPAC
-	83	84		|I-IUPAC
4,7	84	87		|I-IUPAC
-	87	88		|I-IUPAC
dihydroquinones	88	103		|I-IUPAC
,	103	104		|O
and	105	108		|O
benzothiophene	109	123	benzothiophene-4,7-dihydroquinones	|B-IUPAC
-	123	124		|I-IUPAC
4,7	124	127		|I-IUPAC
-	127	128		|I-IUPAC
dihydroquinones	128	143		|I-IUPAC
were	144	148		|O
synthesized	149	160		|O
and	161	164		|O
evaluated	165	174		|O
for	175	178		|O
inhibitory	179	189		|O
activity	190	198		|O
against	199	206		|O
5	207	208		|O
-	208	209		|O
lipoxygenase	209	221		|O
.	221	222		|O
These	223	228		|O
compounds	229	238		|O
were	239	243		|O
found	244	249		|O
to	250	252		|O
be	253	255		|O
active	256	262		|O
in	263	265		|O
vitro	266	271		|O
for	272	275		|O
LTC4	276	280		|O
/	280	281		|O
D4	281	283		|O
inhibition	284	294		|O
with	295	299		|O
the	300	303		|O
potencies	304	313		|O
(	314	315		|O
IC50	315	319		|O
's	319	321		|O
)	321	322		|O
ranging	323	330		|O
from	331	335		|O
0.2	336	339		|O
to	340	342		|O
85	343	345		|O
microM	346	352		|O
.	352	353		|O
Active	354	360		|O
1,4	361	364	1,4-dihydronaphthoquinone acetates	|B-IUPAC
-	364	365		|I-IUPAC
dihydronaphthoquinone	365	386		|I-IUPAC
acetates	387	395		|I-IUPAC
(	396	397		|O
IC50	397	401		|O
less	402	406		|O
than	407	411		|O
microM	415	421		|O
)	421	422		|O
were	423	427		|O
evaluated	428	437		|O
in	438	440		|O
an	441	443		|O
ex	444	446		|O
vivo	447	451		|O
LTB4	452	456		|O
inhibition	457	467		|O
assay	468	473		|O
.	473	474		|O
The	475	478		|O
acetates	479	487	acetates	|B-FAMILY
of	488	490		|O
1,4	491	494	1,4-dihydronaphthoquinones	|B-IUPAC
-	494	495		|I-IUPAC
dihydronaphthoquinones	495	517		|I-IUPAC
containing	518	528		|O
the	529	532		|O
alkyl	533	538	alkyl	|B-PARTIUPAC
substituent	539	550	substituent(s)	|B-MODIFIER
(	550	551		|I-MODIFIER
s	551	552		|I-MODIFIER
)	552	553		|I-MODIFIER
(	554	555		|O
2	555	556	2-n-butyl	|B-PARTIUPAC
-	556	557		|I-PARTIUPAC
n	557	558		|I-PARTIUPAC
-	558	559		|I-PARTIUPAC
butyl	559	564		|I-PARTIUPAC
,	564	565		|O
11	566	568		|O
,	568	569		|O
and	570	573		|O
2,3	574	577	2,3-diethyl	|B-PARTIUPAC
-	577	578		|I-PARTIUPAC
diethyl	578	585		|I-PARTIUPAC
,	585	586		|O
15	587	589		|O
)	589	590		|O
exhibited	591	600		|O
the	601	604		|O
best	605	609		|O
activity	610	618		|O
in	619	621		|O
LTC4	622	626		|O
/	626	627		|O
D4	627	629		|O
inhibition	630	640		|O
(	641	642		|O
IC50	642	646		|O
=	647	648		|O
0.2-0.4	649	656		|O
microM	657	663		|O
,	663	664		|O
in	665	667		|O
vitro	668	673		|O
)	673	674		|O
as	675	677		|O
well	678	682		|O
as	683	685		|O
in	686	688		|O
LTB4	689	693		|O
inhibition	694	704		|O
(	705	706		|O
inhibition	713	723		|O
)	723	724		|O
.	724	725		|O

### 8817480
The	9	12		|O
regulation	13	23		|O
of	24	26		|O
total	27	32		|O
creatine	33	41	creatine	|B-TRIVIAL
content	42	49		|O
in	50	52		|O
a	53	54		|O
myoblast	55	63		|O
cell	64	68		|O
line	69	73		|O
.	73	74		|O
Total	76	81		|O
cellular	82	90		|O
creatine	91	99	creatine	|B-TRIVIAL
content	100	107		|O
is	108	110		|O
an	111	113		|O
important	114	123		|O
bioenergetic	124	136		|O
parameter	137	146		|O
in	147	149		|O
skeletal	150	158		|O
muscle	159	165		|O
.	165	166		|O
To	167	169		|O
understand	170	180		|O
its	181	184		|O
regulation	185	195		|O
we	196	198		|O
investigated	199	211		|O
creatine	212	220	creatine	|B-TRIVIAL
transport	221	230		|O
and	231	234		|O
accumulation	235	247		|O
in	248	250		|O
the	251	254		|O
G8	255	257		|O
cultured	258	266		|O
skeletal	267	275		|O
myoblast	276	284		|O
line	285	289		|O
.	289	290		|O
Like	291	295		|O
other	296	301		|O
cell	302	306		|O
types	307	312		|O
,	312	313		|O
these	314	319		|O
contain	320	327		|O
a	328	329		|O
creatine	330	338		|O
transporter	339	350		|O
,	350	351		|O
whose	352	357		|O
activity	358	366		|O
,	366	367		|O
measured	368	376		|O
using	377	382		|O
a	383	384		|O
radiolabelling	385	399		|O
technique	400	409		|O
,	409	410		|O
was	411	414		|O
saturable	415	424		|O
(	425	426		|O
Km	426	428		|O
=	429	430		|O
+	435	436		|O
/	436	437		|O
-	437	438		|O
25	439	441		|O
microM	442	448		|O
)	448	449		|O
and	450	453		|O
largely	454	461		|O
dependent	462	471		|O
on	472	474		|O
extracellular	475	488		|O
[	489	490		|O
Na+	490	493		|O
]	493	494		|O
.	494	495		|O
To	496	498		|O
study	499	504		|O
sustained	505	514		|O
influences	515	525		|O
on	526	528		|O
steady	529	535		|O
state	536	541		|O
creatine	542	550	creatine	|B-TRIVIAL
concentration	551	564		|O
we	565	567		|O
measured	568	576		|O
total	577	582		|O
cellular	583	591		|O
creatine	592	600	creatine	|B-TRIVIAL
content	601	608		|O
using	609	614		|O
a	615	616		|O
fluorimetric	617	629		|O
method	630	636		|O
in	637	639		|O
48	640	642		|O
h	643	644		|O
incubations	645	656		|O
.	656	657		|O
We	658	660		|O
found	661	666		|O
that	667	671		|O
the	672	675		|O
total	676	681		|O
cellular	682	690		|O
creatine	691	699	creatine	|B-TRIVIAL
content	700	707		|O
was	708	711		|O
relatively	712	722		|O
independent	723	734		|O
of	735	737		|O
extracellular	738	751		|O
creatine	752	760	creatine	|B-TRIVIAL
concentration	761	774		|O
,	774	775		|O
consistent	776	786		|O
with	787	791		|O
high	792	796		|O
affinity	797	805		|O
sodium	806	812	sodium	|B-TRIVIAL
-	812	813		|O
dependent	813	822		|O
uptake	823	829		|O
balanced	830	838		|O
by	839	841		|O
slow	842	846		|O
passive	847	854		|O
efflux	855	861		|O
.	861	862		|O
Accordingly	863	874		|O
,	874	875		|O
in	876	878		|O
creatine	879	887	creatine	|B-TRIVIAL
-	887	888		|O
free	888	892		|O
incubations	893	904		|O
net	905	908		|O
creatine	909	917	creatine	|B-TRIVIAL
efflux	918	924		|O
was	925	928		|O
slow	929	933		|O
(	934	935		|O
5	935	936		|O
+	937	938		|O
/	938	939		|O
-	939	940		|O
1%	941	943		|O
of	944	946		|O
basal	947	952		|O
creatine	953	961	creatine	|B-TRIVIAL
content	962	969		|O
per	970	973		|O
day	974	977		|O
over	978	982		|O
6	983	984		|O
days	985	989		|O
)	989	990		|O
,	990	991		|O
while	992	997		|O
creatine	998	1006	creatine	|B-TRIVIAL
content	1007	1014		|O
in	1015	1017		|O
48	1018	1020		|O
h	1021	1022		|O
incubations	1023	1034		|O
was	1035	1038		|O
reduced	1039	1046		|O
by	1047	1049		|O
28	1050	1052		|O
+	1053	1054		|O
/	1054	1055		|O
-	1055	1056		|O
13%	1057	1060		|O
of	1061	1063		|O
control	1064	1071		|O
by	1072	1074		|O
the	1075	1078		|O
Na+	1079	1082		|O
,	1082	1083		|O
K	1084	1085		|O
(	1085	1086		|O
+	1086	1087		|O
)	1087	1088		|O
-	1088	1089		|O
ATPase	1089	1095		|O
inhibitor	1096	1105		|O
ouabain	1106	1113	ouabain	|B-TRIVIAL
.	1113	1114		|O
Creatine	1115	1123	Creatine	|B-TRIVIAL
accumulation	1124	1136		|O
after	1137	1142		|O
48	1143	1145		|O
h	1146	1147		|O
was	1148	1151		|O
stimulated	1152	1162		|O
by	1163	1165		|O
treatment	1166	1175		|O
with	1176	1180		|O
the	1181	1184		|O
mixed	1185	1190		|O
alpha	1191	1196		|O
-	1196	1197		|O
and	1198	1201		|O
beta	1202	1206		|O
-	1206	1207		|O
adrenergic	1207	1217		|O
agonist	1218	1225		|O
noradrenaline	1226	1239	noradrenaline	|B-TRIVIAL
,	1239	1240		|O
the	1241	1244		|O
beta	1245	1249		|O
-	1249	1250		|O
adrenergic	1250	1260		|O
agonist	1261	1268		|O
isoproterenol	1269	1282	isoproterenol	|B-TRIVIAL
,	1282	1283		|O
the	1284	1287		|O
beta	1288	1292		|O
2	1293	1294		|O
-	1294	1295		|O
agonist	1295	1302		|O
clenbuterol	1303	1314	clenbuterol	|B-TRIVIAL
and	1315	1318		|O
the	1319	1322		|O
cAMP	1323	1327	cAMP	|B-TRIVIAL
analogue	1328	1336	analogue	|B-MODIFIER
N6	1337	1339	N6,2'-O-dibutyryladenosine 3',5'-cyclic monophosphate	|B-IUPAC
,	1339	1340		|I-IUPAC
2'	1340	1342		|I-IUPAC
-	1342	1343		|I-IUPAC
O	1343	1344		|I-IUPAC
-	1344	1345		|I-IUPAC
dibutyryladenosine	1345	1363		|I-IUPAC
3'	1364	1366		|I-IUPAC
,	1366	1367		|I-IUPAC
5'	1367	1369		|I-IUPAC
-	1369	1370		|I-IUPAC
cyclic	1370	1376		|I-IUPAC
monophosphate	1377	1390		|I-IUPAC
,	1390	1391		|O
but	1392	1395		|O
was	1396	1399		|O
unaffected	1400	1410		|O
by	1411	1413		|O
the	1414	1417		|O
alpha	1418	1423		|O
1	1424	1425		|O
adrenergic	1426	1436		|O
agonist	1437	1444		|O
methoxamine	1445	1456	methoxamine	|B-TRIVIAL
.	1456	1457		|O
The	1458	1461		|O
noradrenaline	1462	1475	noradrenaline	|B-TRIVIAL
enhancement	1476	1487		|O
of	1488	1490		|O
creatine	1491	1499	creatine	|B-TRIVIAL
accumulation	1500	1512		|O
at	1513	1515		|O
48	1516	1518		|O
h	1519	1520		|O
was	1521	1524		|O
inhibited	1525	1534		|O
by	1535	1537		|O
the	1538	1541		|O
mixed	1542	1547		|O
alpha	1548	1553		|O
-	1553	1554		|O
and	1555	1558		|O
beta	1559	1563		|O
-	1563	1564		|O
antagonist	1564	1574		|O
labetalol	1575	1584	labetalol	|B-TRIVIAL
and	1585	1588		|O
by	1589	1591		|O
the	1592	1595		|O
beta	1596	1600		|O
-	1600	1601		|O
antagonist	1601	1611		|O
propranolol	1612	1623	propranolol	|B-TRIVIAL
,	1623	1624		|O
but	1625	1628		|O
was	1629	1632		|O
unaffected	1633	1643		|O
by	1644	1646		|O
the	1647	1650		|O
alpha	1651	1656		|O
2	1657	1658		|O
antagonist	1659	1669		|O
phentolamine	1670	1682	phentolamine	|B-TRIVIAL
;	1682	1683		|O
greater	1684	1691		|O
inhibition	1692	1702		|O
was	1703	1706		|O
caused	1707	1713		|O
by	1714	1716		|O
the	1717	1720		|O
beta	1721	1725		|O
2	1726	1727		|O
antagonist	1728	1738		|O
butoxamine	1739	1749	butoxamine	|B-TRIVIAL
than	1750	1754		|O
the	1755	1758		|O
beta	1759	1763		|O
1	1764	1765		|O
antagonist	1766	1776		|O
atenolol	1777	1785	atenolol	|B-TRIVIAL
.	1785	1786		|O
Creatine	1787	1795	Creatine	|B-TRIVIAL
accumulation	1796	1808		|O
at	1809	1811		|O
48	1812	1814		|O
h	1815	1816		|O
was	1817	1820		|O
increased	1821	1830		|O
to	1831	1833		|O
+	1838	1839		|O
/	1839	1840		|O
-	1840	1841		|O
6%	1842	1844		|O
of	1845	1847		|O
control	1848	1855		|O
by	1856	1858		|O
insulin	1859	1866		|O
and	1867	1870		|O
by	1871	1873		|O
+	1878	1879		|O
/	1879	1880		|O
-	1880	1881		|O
13%	1882	1885		|O
by	1886	1888		|O
IGF	1889	1892		|O
-	1892	1893		|O
I	1893	1894		|O
(	1895	1896		|O
both	1896	1900		|O
at	1901	1903		|O
3	1904	1905		|O
nM	1906	1908		|O
)	1908	1909		|O
.	1909	1910		|O
Creatine	1911	1919	Creatine	|B-TRIVIAL
accumulation	1920	1932		|O
at	1933	1935		|O
48	1936	1938		|O
h	1939	1940		|O
was	1941	1944		|O
also	1945	1949		|O
increased	1950	1959		|O
to	1960	1962		|O
+	1967	1968		|O
/	1968	1969		|O
-	1969	1970		|O
of	1975	1977		|O
control	1978	1985		|O
by	1986	1988		|O
3,3	1989	1992	3,3',5-triiodothyronine	|B-IUPAC
'	1992	1993		|I-IUPAC
,	1993	1994		|I-IUPAC
5	1994	1995		|I-IUPAC
-	1995	1996		|I-IUPAC
triiodothyronine	1996	2012		|I-IUPAC
(	2013	2014		|O
at	2014	2016		|O
microM	2020	2026		|O
)	2026	2027		|O
and	2028	2031		|O
to	2032	2034		|O
+	2039	2040		|O
/	2040	2041		|O
-	2041	2042		|O
35%	2043	2046		|O
of	2047	2049		|O
control	2050	2057		|O
by	2058	2060		|O
amylin	2061	2067	amylin	|B-TRIVIAL
(	2068	2069		|O
nM	2072	2074		|O
)	2074	2075		|O
.	2075	2076		|O
As	2077	2079		|O
3,3	2080	2083	3,3', 5-triiodothyronine	|B-IUPAC
'	2083	2084		|I-IUPAC
,	2084	2085		|I-IUPAC
5	2086	2087		|I-IUPAC
-	2087	2088		|I-IUPAC
triiodothyronine	2088	2104		|I-IUPAC
,	2104	2105		|O
amylin	2106	2112	amylin	|B-TRIVIAL
and	2113	2116		|O
isoproterenol	2117	2130	isoproterenol	|B-TRIVIAL
all	2131	2134		|O
stimulate	2135	2144		|O
the	2145	2148		|O
Na+	2149	2152		|O
,	2152	2153		|O
K	2154	2155		|O
(	2155	2156		|O
+	2156	2157		|O
)	2157	2158		|O
-	2158	2159		|O
ATPase	2159	2165		|O
,	2165	2166		|O
we	2167	2169		|O
suggest	2170	2177		|O
that	2178	2182		|O
they	2183	2187		|O
stimulate	2188	2197		|O
Na	2198	2200	Na(+)	|B-SUM
(	2200	2201		|I-SUM
+	2201	2202		|I-SUM
)	2202	2203		|I-SUM
-	2203	2204		|O
creatine	2204	2212	creatine	|B-TRIVIAL
cotransport	2213	2224		|O
indirectly	2225	2235		|O
by	2236	2238		|O
increasing	2239	2249		|O
the	2250	2253		|O
transmembrane	2254	2267		|O
[	2268	2269		|O
Na+	2269	2272	Na+	|B-SUM
]	2272	2273		|O
concentration	2274	2287		|O
gradient	2288	2296		|O
and	2297	2300		|O
membrane	2301	2309		|O
potential	2310	2319		|O
.	2319	2320		|O

### 12742193
12742193	0	8		|O
Attenuation	10	21		|O
of	22	24		|O
cerebral	25	33		|O
vasospasm	34	43		|O
in	44	46		|O
rabbits	47	54		|O
using	55	60		|O
clonidine	61	70	clonidine hydrochloride	|B-IUPAC
hydrochloride	71	84		|I-IUPAC
,	84	85		|O
a	86	87		|O
central	88	95		|O
adrenergic	96	106		|O
agonist	107	114		|O
.	114	115		|O
The	117	120		|O
aim	121	124		|O
of	125	127		|O
this	128	132		|O
study	133	138		|O
was	139	142		|O
to	143	145		|O
assess	146	152		|O
,	152	153		|O
firstly	154	161		|O
,	161	162		|O
if	163	165		|O
exclusion	166	175		|O
of	176	178		|O
central	179	186		|O
noradrenergic	187	200		|O
areas	201	206		|O
in	207	209		|O
the	210	213		|O
hypothalamus	214	226		|O
and	227	230		|O
brain	231	236		|O
stem	237	241		|O
with	242	246		|O
the	247	250		|O
central	251	258		|O
sympathetic	259	270		|O
blocker	271	278		|O
clonidine	279	288	clonidine hydrochloride	|B-IUPAC
hydrochloride	289	302		|I-IUPAC
could	303	308		|O
prevent	309	316		|O
the	317	320		|O
development	321	332		|O
of	333	335		|O
chronic	336	343		|O
vasospasm	344	353		|O
following	354	363		|O
experimental	364	376		|O
subarachnoid	377	389		|O
haemorrhage	390	401		|O
in	402	404		|O
rabbits	405	412		|O
and	413	416		|O
,	416	417		|O
secondly	418	426		|O
,	426	427		|O
if	428	430		|O
,	430	431		|O
parallel	432	440		|O
with	441	445		|O
the	446	449		|O
effect	450	456		|O
on	457	459		|O
cerebral	460	468		|O
arteries	469	477		|O
,	477	478		|O
changes	479	486		|O
in	487	489		|O
dopamine	490	498		|O
beta	499	503		|O
-	503	504		|O
hydroxylase	504	515		|O
concentration	516	529		|O
in	530	532		|O
the	533	536		|O
hypothalamus	537	549		|O
and	550	553		|O
brain	554	559		|O
stem	560	564		|O
could	565	570		|O
also	571	575		|O
be	576	578		|O
detected	579	587		|O
.	587	588		|O
Experimental	588	600		|O
subarachnoid	601	613		|O
haemorrhage	614	625		|O
,	625	626		|O
in	627	629		|O
concentrations	630	644		|O
of	645	647		|O
1	648	649		|O
ml	650	652		|O
of	653	655		|O
autologous	656	666		|O
arterial	667	675		|O
blood	676	681		|O
/	681	682		|O
1	682	683		|O
kg	684	686		|O
of	687	689		|O
body	690	694		|O
weight	695	701		|O
was	702	705		|O
carried	706	713		|O
out	714	717		|O
on	718	720		|O
18	721	723		|O
New	724	727		|O
Zealand	728	735		|O
rabbits	736	743		|O
.	743	744		|O
Histological	745	757		|O
specimens	758	767		|O
were	768	772		|O
obtained	773	781		|O
by	782	784		|O
the	785	788		|O
method	789	795		|O
of	796	798		|O
perfusion	799	808		|O
fixation	809	817		|O
after	818	823		|O
the	824	827		|O
rabbits	828	835		|O
were	836	840		|O
sacrificed	841	851		|O
on	852	854		|O
day	855	858		|O
8	859	860		|O
after	861	866		|O
subarachnoid	867	879		|O
haemorrhage	880	891		|O
.	891	892		|O
The	893	896		|O
spastic	897	904		|O
effect	905	911		|O
of	912	914		|O
experimentally	915	929		|O
induced	930	937		|O
subarachnoid	938	950		|O
haemorrhage	951	962		|O
was	963	966		|O
determined	967	977		|O
by	978	980		|O
assessing	981	990		|O
the	991	994		|O
intensity	995	1004		|O
of	1005	1007		|O
corrugation	1008	1019		|O
of	1020	1022		|O
the	1023	1026		|O
intima	1027	1033		|O
of	1034	1036		|O
the	1037	1040		|O
rabbit	1041	1047		|O
basilar	1048	1055		|O
artery	1056	1062		|O
by	1063	1065		|O
the	1066	1069		|O
previously	1070	1080		|O
developed	1081	1090		|O
method	1091	1097		|O
of	1098	1100		|O
corrugation	1101	1112		|O
coefficient	1113	1124		|O
and	1125	1128		|O
computer	1129	1137		|O
image	1138	1143		|O
analysis	1144	1152		|O
.	1152	1153		|O
The	1154	1157		|O
concentration	1158	1171		|O
and	1172	1175		|O
localization	1176	1188		|O
of	1189	1191		|O
dopamine	1192	1200		|O
beta	1201	1205		|O
-	1205	1206		|O
hydroxylase	1206	1217		|O
in	1218	1220		|O
noradrenaline	1221	1234	noradrenaline	|B-TRIVIAL
-	1234	1235		|O
containing	1235	1245		|O
neurons	1246	1253		|O
was	1254	1257		|O
immunohistochemically	1258	1279		|O
assessed	1280	1288		|O
(	1289	1290		|O
semiquantitatively	1290	1308		|O
as	1309	1311		|O
0	1312	1313		|O
,	1313	1314		|O
1	1315	1316		|O
and	1317	1320		|O
2	1321	1322		|O
)	1322	1323		|O
with	1324	1328		|O
anti	1329	1333		|O
-	1333	1334		|O
dopamine	1334	1342		|O
beta	1343	1347		|O
-	1347	1348		|O
hydroxylase	1348	1359		|O
,	1359	1360		|O
at	1361	1363		|O
precisely	1364	1373		|O
defined	1374	1381		|O
sites	1382	1387		|O
of	1388	1390		|O
the	1391	1394		|O
hypothalamus	1395	1407		|O
and	1408	1411		|O
brain	1412	1417		|O
stem	1418	1422		|O
of	1423	1425		|O
the	1426	1429		|O
same	1430	1434		|O
rabbit	1435	1441		|O
.	1441	1442		|O
The	1442	1445		|O
results	1446	1453		|O
revealed	1454	1462		|O
less	1463	1467		|O
corrugated	1468	1478		|O
and	1479	1482		|O
smoother	1483	1491		|O
intima	1492	1498		|O
in	1499	1501		|O
the	1502	1505		|O
basilar	1506	1513		|O
artery	1514	1520		|O
and	1521	1524		|O
significantly	1525	1538		|O
lower	1539	1544		|O
dopamine	1545	1553		|O
beta	1554	1558		|O
-	1558	1559		|O
hydroxylase	1559	1570		|O
concentration	1571	1584		|O
in	1585	1587		|O
the	1588	1591		|O
control	1592	1599		|O
group	1600	1605		|O
of	1606	1608		|O
rabbits	1609	1616		|O
with	1617	1621		|O
sham	1622	1626		|O
subarachnoid	1627	1639		|O
haemorrhage	1640	1651		|O
and	1652	1655		|O
without	1656	1663		|O
any	1664	1667		|O
additional	1668	1678		|O
interventions	1679	1692		|O
(	1693	1694		|O
mean	1694	1698		|O
corrugation	1699	1710		|O
coefficient	1711	1722		|O
=	1722	1723		|O
1.123	1723	1728		|O
+	1728	1729		|O
/	1729	1730		|O
-	1730	1731		|O
0.024	1731	1736		|O
,	1736	1737		|O
P	1738	1739		|O
=	1739	1740		|O
0.35	1740	1744		|O
x	1745	1746		|O
(	1749	1750		|O
-	1750	1751		|O
3	1751	1752		|O
)	1752	1753		|O
;	1753	1754		|O
mean	1755	1759		|O
dopamine	1760	1768		|O
beta	1769	1773		|O
-	1773	1774		|O
hydroxylase	1774	1785		|O
=	1785	1786		|O
0.350	1786	1791		|O
+	1791	1792		|O
/	1792	1793		|O
-	1793	1794		|O
0.071	1794	1799		|O
,	1799	1800		|O
P	1801	1802		|O
=	1802	1803		|O
0.22	1803	1807		|O
x	1808	1809		|O
(	1812	1813		|O
-	1813	1814		|O
3	1814	1815		|O
)	1815	1816		|O
)	1816	1817		|O
,	1817	1818		|O
and	1819	1822		|O
smoother	1823	1831		|O
intima	1832	1838		|O
in	1839	1841		|O
the	1842	1845		|O
basilar	1846	1853		|O
artery	1854	1860		|O
with	1861	1865		|O
significantly	1866	1879		|O
lower	1880	1885		|O
concentration	1886	1899		|O
of	1900	1902		|O
dopamine	1903	1911		|O
beta	1912	1916		|O
-	1916	1917		|O
hydroxylase	1917	1928		|O
in	1929	1931		|O
the	1932	1935		|O
clonidine	1936	1945	clonidine	|B-TRIVIAL
group	1946	1951	group	|B-MODIFIER
(	1952	1953		|O
rabbits	1953	1960		|O
with	1961	1965		|O
subarachnoid	1966	1978		|O
haemorrhage	1979	1990		|O
and	1991	1994		|O
central	1995	2002		|O
alpha	2003	2008		|O
(	2008	2009		|O
2	2009	2010		|O
)	2010	2011		|O
-	2011	2012		|O
blocker	2012	2019		|O
clonidine	2020	2029	clonidine hydrochloride	|B-IUPAC
hydrochloride	2030	2043		|I-IUPAC
at	2044	2046		|O
a	2047	2048		|O
daily	2049	2054		|O
dose	2055	2059		|O
of	2060	2062		|O
0.03	2063	2067		|O
mg	2068	2070		|O
/	2070	2071		|O
kg	2071	2073		|O
of	2074	2076		|O
body	2077	2081		|O
weight	2082	2088		|O
for	2089	2092		|O
8	2093	2094		|O
days	2095	2099		|O
;	2099	2100		|O
mean	2101	2105		|O
corrugation	2106	2117		|O
coefficient	2118	2129		|O
=	2129	2130		|O
1.177	2130	2135		|O
+	2135	2136		|O
/	2136	2137		|O
-	2137	2138		|O
0.058	2138	2143		|O
,	2143	2144		|O
P	2145	2146		|O
=	2146	2147		|O
1.7	2147	2150		|O
x	2151	2152		|O
(	2155	2156		|O
-	2156	2157		|O
3	2157	2158		|O
)	2158	2159		|O
;	2159	2160		|O
mean	2161	2165		|O
dopamine	2166	2174	dopamine	|B-TRIVIAL
beta	2175	2179		|O
-	2179	2180		|O
hydroxylase	2180	2191		|O
=	2191	2192		|O
0.583	2192	2197		|O
+	2197	2198		|O
/	2198	2199		|O
-	2199	2200		|O
0.175	2200	2205		|O
,	2205	2206		|O
P	2207	2208		|O
=	2208	2209		|O
1.1	2209	2212		|O
x	2213	2214		|O
(	2217	2218		|O
-	2218	2219		|O
3	2219	2220		|O
)	2220	2221		|O
)	2221	2222		|O
.	2222	2223		|O
In	2224	2226		|O
comparison	2227	2237		|O
,	2237	2238		|O
the	2239	2242		|O
haemorrhage	2243	2254		|O
only	2255	2259		|O
group	2260	2265		|O
(	2266	2267		|O
rabbits	2267	2274		|O
with	2275	2279		|O
subarachnoid	2280	2292		|O
haemorrhage	2293	2304		|O
and	2305	2308		|O
without	2309	2316		|O
medication	2317	2327		|O
;	2327	2328		|O
mean	2329	2333		|O
corrugation	2334	2345		|O
coefficient	2346	2357		|O
=	2357	2358		|O
1.370	2358	2363		|O
+	2363	2364		|O
/	2364	2365		|O
-	2365	2366		|O
0.101	2366	2371		|O
;	2371	2372		|O
mean	2373	2377		|O
dopamine	2378	2386		|O
beta	2387	2391		|O
-	2391	2392		|O
hydroxylase	2392	2403		|O
=	2403	2404		|O
1.214	2404	2409		|O
+	2409	2410		|O
/	2410	2411		|O
-	2411	2412		|O
0.313	2412	2417		|O
)	2417	2418		|O
displayed	2419	2428		|O
intensive	2429	2438		|O
corrugation	2439	2450		|O
of	2451	2453		|O
the	2454	2457		|O
intima	2458	2464		|O
of	2465	2467		|O
the	2468	2471		|O
basilar	2472	2479		|O
artery	2480	2486		|O
and	2487	2490		|O
a	2491	2492		|O
significantly	2493	2506		|O
more	2507	2511		|O
intensive	2512	2521		|O
accumulation	2522	2534		|O
of	2535	2537		|O
dopamine	2538	2546		|O
beta	2547	2551		|O
-	2551	2552		|O
hydroxylase	2552	2563		|O
than	2564	2568		|O
did	2569	2572		|O
the	2573	2576		|O
control	2577	2584		|O
group	2585	2590		|O
and	2591	2594		|O
the	2595	2598		|O
clonidine	2599	2608		|O
group	2609	2614		|O
.	2614	2615		|O
The	2615	2618		|O
results	2619	2626		|O
of	2627	2629		|O
this	2630	2634		|O
study	2635	2640		|O
demonstrated	2641	2653		|O
that	2654	2658		|O
the	2659	2662		|O
central	2663	2670		|O
alpha	2671	2676		|O
(	2676	2677		|O
2	2677	2678		|O
)	2678	2679		|O
-	2679	2680		|O
blocker	2680	2687		|O
clonidine	2688	2697	clonidine hydrochloride	|B-IUPAC
hydrochloride	2698	2711		|I-IUPAC
effectively	2711	2722		|O
prevents	2724	2732		|O
vasospasm	2733	2742		|O
,	2742	2743		|O
and	2744	2747		|O
diminishes	2748	2758		|O
the	2759	2762		|O
concentration	2763	2776		|O
of	2777	2779		|O
cerebral	2780	2788		|O
dopamine	2789	2797		|O
beta	2798	2802		|O
-	2802	2803		|O
hydroxylase	2803	2814		|O
in	2815	2817		|O
the	2818	2821		|O
hypothalamus	2822	2834		|O
and	2835	2838		|O
brain	2839	2844		|O
stem	2845	2849		|O
after	2850	2855		|O
experimental	2856	2868		|O
subarachnoid	2869	2881		|O
haemorrhage	2882	2893		|O
in	2894	2896		|O
rabbits	2897	2904		|O
.	2904	2905		|O

### 16682228
16682228	0	8		|O
Heterologous	10	22		|O
expression	23	33		|O
of	34	36		|O
lipoprotein	37	48		|O
-	48	49		|O
associated	49	59		|O
phospholipase	60	73		|O
A2	74	76		|O
in	77	79		|O
different	80	89		|O
expression	90	100		|O
systems	101	108		|O
.	108	109		|O
Lipoprotein	111	122		|O
-	122	123		|O
associated	123	133		|O
phospholipase	134	147		|O
A	148	149		|O
(	149	150		|O
2	150	151		|O
)	151	152		|O
(	153	154		|O
Lp	154	156		|O
-	156	157		|O
PLA	157	160		|O
(	160	161		|O
2	161	162		|O
)	162	163		|O
)	163	164		|O
is	165	167		|O
a	168	169		|O
key	170	173		|O
enzyme	174	180		|O
involved	181	189		|O
in	190	192		|O
atherosclerosis	193	208		|O
,	208	209		|O
and	210	213		|O
has	214	217		|O
been	218	222		|O
considered	223	233		|O
as	234	236		|O
a	237	238		|O
new	239	242		|O
target	243	249		|O
for	250	253		|O
drug	254	258		|O
discovery	259	268		|O
.	268	269		|O
The	270	273		|O
major	274	279		|O
difficulty	280	290		|O
for	291	294		|O
high	295	299		|O
-	299	300		|O
throughput	300	310		|O
screening	311	320		|O
of	321	323		|O
Lp	324	326		|O
-	326	327		|O
PLA	327	330		|O
(	330	331		|O
2	331	332		|O
)	332	333		|O
inhibitors	334	344		|O
and	345	348		|O
for	349	352		|O
functional	353	363		|O
studies	364	371		|O
was	372	375		|O
their	376	381		|O
fast	382	386		|O
and	387	390		|O
efficient	391	400		|O
production	401	411		|O
.	411	412		|O
Purification	413	425		|O
of	426	428		|O
native	429	435		|O
Lp	436	438		|O
-	438	439		|O
PLA	439	442		|O
(	442	443		|O
2	443	444		|O
)	444	445		|O
from	446	450		|O
human	451	456		|O
plasma	457	463		|O
was	464	467		|O
complicated	468	479		|O
and	480	483		|O
produced	484	492		|O
a	493	494		|O
very	495	499		|O
low	500	503		|O
yield	504	509		|O
.	509	510		|O
We	511	513		|O
herein	514	520		|O
examined	521	529		|O
the	530	533		|O
feasibility	534	545		|O
of	546	548		|O
expressing	549	559		|O
and	560	563		|O
purifying	564	573		|O
recombinant	574	585		|O
Lp	586	588		|O
-	588	589		|O
PLA	589	592		|O
(	592	593		|O
2	593	594		|O
)	594	595		|O
in	596	598		|O
different	599	608		|O
heterologous	609	621		|O
expression	622	632		|O
systems	633	640		|O
.	640	641		|O
The	642	645		|O
fusion	646	652		|O
Lp	653	655		|O
-	655	656		|O
PLA	656	659		|O
(	659	660		|O
2	660	661		|O
)	661	662		|O
was	663	666		|O
expressed	667	676		|O
at	677	679		|O
high	680	684		|O
levels	685	691		|O
and	692	695		|O
exhibited	696	705		|O
strong	706	712		|O
enzyme	713	719		|O
activity	720	728		|O
in	729	731		|O
insect	732	738		|O
cell	739	743		|O
-	743	744		|O
baculovirus	744	755		|O
expression	756	766		|O
system	767	773		|O
.	773	774		|O
The	775	778		|O
functional	779	789		|O
enzyme	790	796		|O
could	797	802		|O
also	803	807		|O
be	808	810		|O
produced	811	819		|O
in	820	822		|O
Pichia	823	829		|O
pastoris	830	838		|O
.	838	839		|O
The	840	843		|O
inclusion	844	853		|O
of	854	856		|O
a	857	858		|O
Kozak	859	864		|O
sequence	865	873		|O
increased	874	883		|O
greatly	884	891		|O
the	892	895		|O
expression	896	906		|O
level	907	912		|O
of	913	915		|O
recombinant	916	927		|O
Lp	928	930		|O
-	930	931		|O
PLA	931	934		|O
(	934	935		|O
2	935	936		|O
)	936	937		|O
in	938	940		|O
insect	941	947		|O
cells	948	953		|O
,	953	954		|O
but	955	958		|O
had	959	962		|O
little	963	969		|O
effect	970	976		|O
on	977	979		|O
the	980	983		|O
expression	984	994		|O
of	995	997		|O
recombinant	998	1009		|O
Lp	1010	1012		|O
-	1012	1013		|O
PLA	1013	1016		|O
(	1016	1017		|O
2	1017	1018		|O
)	1018	1019		|O
in	1020	1022		|O
P	1023	1024		|O
.	1024	1025		|O
pastoris	1026	1034		|O
and	1035	1038		|O
Escherichia	1039	1050		|O
coli	1051	1055		|O
.	1055	1056		|O
P	1057	1058		|O
.	1058	1059		|O
pastoris	1060	1068		|O
-	1068	1069		|O
produced	1069	1077		|O
Lp	1078	1080		|O
-	1080	1081		|O
PLA	1081	1084		|O
(	1084	1085		|O
2	1085	1086		|O
)	1086	1087		|O
could	1088	1093		|O
be	1094	1096		|O
purified	1097	1105		|O
rapidly	1106	1113		|O
and	1114	1117		|O
conveniently	1118	1130		|O
through	1131	1138		|O
a	1139	1140		|O
one	1141	1144		|O
-	1144	1145		|O
step	1145	1149		|O
procedure	1150	1159		|O
,	1159	1160		|O
while	1161	1166		|O
baculovirus	1167	1178		|O
-	1178	1179		|O
produced	1179	1187		|O
Lp	1188	1190		|O
-	1190	1191		|O
PLA	1191	1194		|O
(	1194	1195		|O
2	1195	1196		|O
)	1196	1197		|O
could	1198	1203		|O
be	1204	1206		|O
efficiently	1207	1218		|O
purified	1219	1227		|O
through	1228	1235		|O
a	1236	1237		|O
two	1238	1241		|O
-	1241	1242		|O
step	1242	1246		|O
procedure	1247	1256		|O
.	1256	1257		|O
This	1258	1262		|O
ability	1263	1270		|O
to	1271	1273		|O
readily	1274	1281		|O
produce	1282	1289		|O
recombinant	1290	1301		|O
Lp	1302	1304		|O
-	1304	1305		|O
PLA	1305	1308		|O
(	1308	1309		|O
2	1309	1310		|O
)	1310	1311		|O
could	1312	1317		|O
provide	1318	1325		|O
a	1326	1327		|O
screening	1328	1337		|O
model	1338	1343		|O
for	1344	1347		|O
Lp	1348	1350		|O
-	1350	1351		|O
PLA	1351	1354		|O
(	1354	1355		|O
2	1355	1356		|O
)	1356	1357		|O
inhibitors	1358	1368		|O
and	1369	1372		|O
will	1373	1377		|O
facilitate	1378	1388		|O
further	1389	1396		|O
studies	1397	1404		|O
on	1405	1407		|O
this	1408	1412		|O
enzyme	1413	1419		|O
.	1419	1420		|O

### 10639285
A	0	1		|O
series	2	8		|O
of	9	11		|O
2	12	13	2-(diethylamino)thieno1,3?xazin-4-ones	|B-IUPAC
-	13	14		|I-IUPAC
(	14	15		|I-IUPAC
diethylamino	15	27		|I-IUPAC
)	27	28		|I-IUPAC
thieno1	28	35		|I-IUPAC
,	35	36		|I-IUPAC
3	36	37		|I-IUPAC
?	37	38		|I-IUPAC
xazin	38	43		|I-IUPAC
-	43	44		|I-IUPAC
4	44	45		|I-IUPAC
-	45	46		|I-IUPAC
ones	46	50		|I-IUPAC
was	51	54		|O
synthesized	55	66		|O
and	67	70		|O
evaluated	71	80		|O
in	81	83		|O
vitro	84	89		|O
for	90	93		|O
inhibitory	94	104		|O
activity	105	113		|O
toward	114	120		|O
human	121	126		|O
leukocyte	127	136		|O
elastase	137	145		|O
(	146	147		|O
HLE	147	150		|O
)	150	151		|O
.	151	152		|O
The	153	156		|O
Gewald	157	163		|O
thiophene	164	173	thiophene	|B-TRIVIAL
synthesis	174	183		|O
was	184	187		|O
utilized	188	196		|O
to	197	199		|O
obtain	200	206		|O
several	207	214		|O
ethyl	215	220	ethyl 2-aminothiophene-3-carboxylates	|B-IUPAC
2	221	222		|I-IUPAC
-	222	223		|I-IUPAC
aminothiophene	223	237		|I-IUPAC
-	237	238		|I-IUPAC
3	238	239		|I-IUPAC
-	239	240		|I-IUPAC
carboxylates	240	252		|I-IUPAC
.	252	253		|O
These	254	259		|O
precursors	260	270		|O
were	271	275		|O
subjected	276	285		|O
to	286	288		|O
a	289	290		|O
five	291	295		|O
-	295	296		|O
step	296	300		|O
route	301	306		|O
to	307	309		|O
obtain	310	316		|O
thieno2	317	324	thieno2,3-d1,3?xazin-4-ones	|B-IUPAC
,	324	325		|I-IUPAC
3	325	326		|I-IUPAC
-	326	327		|I-IUPAC
d1	327	329		|I-IUPAC
,	329	330		|I-IUPAC
3	330	331		|I-IUPAC
?	331	332		|I-IUPAC
xazin	332	337		|I-IUPAC
-	337	338		|I-IUPAC
4	338	339		|I-IUPAC
-	339	340		|I-IUPAC
ones	340	344		|I-IUPAC
bearing	345	352		|O
various	353	360		|O
substituents	361	373		|O
at	374	376		|O
positions	377	386		|O
5	387	388		|O
and	389	392		|O
6	393	394		|O
.	394	395		|O
Both	396	400		|O
thieno2	401	408	thieno2,3-d	|B-PARTIUPAC
,	408	409		|I-PARTIUPAC
3	409	410		|I-PARTIUPAC
-	410	411		|I-PARTIUPAC
d	411	412		|I-PARTIUPAC
and	413	416		|O
thieno3	417	424	thieno3,2-d	|B-PARTIUPAC
,	424	425		|I-PARTIUPAC
2	425	426		|I-PARTIUPAC
-	426	427		|I-PARTIUPAC
d	427	428		|I-PARTIUPAC
fused	429	434		|O
oxazin	435	441	oxazin-4-ones	|B-IUPAC
-	441	442		|I-IUPAC
4	442	443		|I-IUPAC
-	443	444		|I-IUPAC
ones	444	448		|I-IUPAC
possess	449	456		|O
extraordinary	457	470		|O
chemical	471	479		|O
stability	480	489		|O
,	489	490		|O
which	491	496		|O
was	497	500		|O
expressed	501	510		|O
as	511	513		|O
rate	514	518		|O
constants	519	528		|O
of	529	531		|O
the	532	535		|O
alkaline	536	544		|O
hydrolysis	545	555		|O
.	555	556		|O
The	557	560		|O
kinetic	561	568		|O
parameters	569	579		|O
of	580	582		|O
the	583	586		|O
HLE	587	590		|O
inhibition	591	601		|O
were	602	606		|O
determined	607	617		|O
.	617	618		|O
The	619	622		|O
most	623	627		|O
potent	628	634		|O
compound	635	643		|O
,	643	644		|O
2	645	646	2-(diethylamino)-4H-1benzothieno2,3-d1,3?xazin-4-one	|B-IUPAC
-	646	647		|I-IUPAC
(	647	648		|I-IUPAC
diethylamino	648	660		|I-IUPAC
)	660	661		|I-IUPAC
-	661	662		|I-IUPAC
4H	662	664		|I-IUPAC
-	664	665		|I-IUPAC
1benzothieno2	665	678		|I-IUPAC
,	678	679		|I-IUPAC
3	679	680		|I-IUPAC
-	680	681		|I-IUPAC
d1	681	683		|I-IUPAC
,	683	684		|I-IUPAC
3	684	685		|I-IUPAC
?	685	686		|I-IUPAC
xazin	686	691		|I-IUPAC
-	691	692		|I-IUPAC
4	692	693		|I-IUPAC
-	693	694		|I-IUPAC
one	694	697		|I-IUPAC
,	697	698		|O
exhibited	699	708		|O
a	709	710		|O
K	711	712		|O
(	712	713		|O
i	713	714		|O
)	714	715		|O
value	716	721		|O
of	722	724		|O
5.8	725	728		|O
nM	729	731		|O
.	731	732		|O
2	733	734	2-(Diethylamino)thieno1, 3?xazin-4-ones	|B-IUPAC
-	734	735		|I-IUPAC
(	735	736		|I-IUPAC
Diethylamino	736	748		|I-IUPAC
)	748	749		|I-IUPAC
thieno1	749	756		|I-IUPAC
,	756	757		|I-IUPAC
3	758	759		|I-IUPAC
?	759	760		|I-IUPAC
xazin	760	765		|I-IUPAC
-	765	766		|I-IUPAC
4	766	767		|I-IUPAC
-	767	768		|I-IUPAC
ones	768	772		|I-IUPAC
act	773	776		|O
as	777	779		|O
acyl	780	784		|O
-	784	785		|O
enzyme	785	791		|O
inhibitors	792	802		|O
of	803	805		|O
HLE	806	809		|O
,	809	810		|O
similar	811	818		|O
to	819	821		|O
the	822	825		|O
inhibition	826	836		|O
of	837	839		|O
serine	840	846		|O
proteases	847	856		|O
by	857	859		|O
4H	860	862	4H-3,1-benzoxazin-4-ones	|B-IUPAC
-	862	863		|I-IUPAC
3,1	863	866		|I-IUPAC
-	866	867		|I-IUPAC
benzoxazin	867	877		|I-IUPAC
-	877	878		|I-IUPAC
4	878	879		|I-IUPAC
-	879	880		|I-IUPAC
ones	880	884		|I-IUPAC
.	884	885		|O
The	886	889		|O
isosteric	890	899		|O
benzene	900	907	benzene-thiophene	|B-IUPAC
-	907	908		|I-IUPAC
thiophene	908	917		|I-IUPAC
replacement	917	928		|O
accounts	930	938		|O
for	939	942		|O
an	943	945		|O
enhanced	946	954		|O
stability	955	964		|O
of	965	967		|O
the	968	971		|O
acyl	972	976		|O
-	976	977		|O
enzyme	977	983		|O
intermediates	984	997		|O
.	997	998		|O

### 17371003
Structure	0	9		|O
-	9	10		|O
activity	10	18		|O
relationships	19	32		|O
have	33	37		|O
been	38	42		|O
investigated	43	55		|O
for	56	59		|O
inhibition	60	70		|O
of	71	73		|O
DNA	74	77		|O
-	77	78		|O
dependent	78	87		|O
protein	88	95		|O
kinase	96	102		|O
(	103	104		|O
DNA	104	107		|O
-	107	108		|O
PK	108	110		|O
)	110	111		|O
and	112	115		|O
ATM	116	119		|O
kinase	120	126		|O
by	127	129		|O
a	130	131		|O
series	132	138		|O
of	139	141		|O
pyran	142	147	pyran-2-ones	|B-FAMILY
-	147	148		|I-FAMILY
2	148	149		|I-FAMILY
-	149	150		|I-FAMILY
ones	150	154		|I-FAMILY
,	154	155		|O
pyran	156	161	pyran-4-ones	|B-FAMILY
-	161	162		|I-FAMILY
4	162	163		|I-FAMILY
-	163	164		|I-FAMILY
ones	164	168		|I-FAMILY
,	168	169		|O
thiopyran	170	179	thiopyran-4-ones	|B-FAMILY
-	179	180		|I-FAMILY
4	180	181		|I-FAMILY
-	181	182		|I-FAMILY
ones	182	186		|I-FAMILY
,	186	187		|O
and	188	191		|O
pyridin	192	199	pyridin-4-ones	|B-FAMILY
-	199	200		|I-FAMILY
4	200	201		|I-FAMILY
-	201	202		|I-FAMILY
ones	202	206		|I-FAMILY
.	206	207		|O
A	208	209		|O
wide	210	214		|O
range	215	220		|O
of	221	223		|O
IC50	224	228		|O
values	229	235		|O
were	236	240		|O
observed	241	249		|O
for	250	253		|O
pyranones	254	263	pyranones	|B-FAMILY
and	264	267		|O
thiopyranones	268	281	thiopyranones	|B-FAMILY
substituted	282	293		|O
at	294	296		|O
the	297	300		|O
6	301	302		|O
-	302	303		|O
position	303	311		|O
,	311	312		|O
with	313	317		|O
the	318	321		|O
3	322	323		|O
-	323	324		|O
and	325	328		|O
5	329	330		|O
-	330	331		|O
positions	331	340		|O
proving	341	348		|O
intolerant	349	359		|O
to	360	362		|O
substitution	363	375		|O
.	375	376		|O
Related	377	384		|O
pyran	385	390	pyran-2-ones	|B-FAMILY
-	390	391		|I-FAMILY
2	391	392		|I-FAMILY
-	392	393		|I-FAMILY
ones	393	397		|I-FAMILY
,	397	398		|O
pyran	399	404	pyran-4-ones	|B-FAMILY
-	404	405		|I-FAMILY
4	405	406		|I-FAMILY
-	406	407		|I-FAMILY
ones	407	411		|I-FAMILY
,	411	412		|O
and	413	416		|O
thiopyran	417	426	thiopyran-4-ones	|B-FAMILY
-	426	427		|I-FAMILY
4	427	428		|I-FAMILY
-	428	429		|I-FAMILY
ones	429	433		|I-FAMILY
showed	434	440		|O
similar	441	448		|O
IC50	449	453		|O
values	454	460		|O
against	461	468		|O
DNA	469	472		|O
-	472	473		|O
PK	473	475		|O
,	475	476		|O
whereas	477	484		|O
the	485	488		|O
pyridin	489	496	pyridin-4-one	|B-FAMILY
-	496	497		|I-FAMILY
4	497	498		|I-FAMILY
-	498	499		|I-FAMILY
one	499	502		|I-FAMILY
system	503	509		|O
proved	510	516		|O
,	516	517		|O
in	518	520		|O
general	521	528		|O
,	528	529		|O
ineffective	530	541		|O
at	542	544		|O
inhibiting	545	555		|O
DNA	556	559		|O
-	559	560		|O
PK	560	562		|O
.	562	563		|O
Extended	564	572		|O
libraries	573	582		|O
exploring	583	592		|O
the	593	596		|O
6	597	598		|O
-	598	599		|O
position	599	607		|O
of	608	610		|O
2	611	612	2-morpholino-pyran-4-ones	|B-IUPAC
-	612	613		|I-IUPAC
morpholino	613	623		|I-IUPAC
-	623	624		|I-IUPAC
pyran	624	629		|I-IUPAC
-	629	630		|I-IUPAC
4	630	631		|I-IUPAC
-	631	632		|I-IUPAC
ones	632	636		|I-IUPAC
and	637	640		|O
2	641	642	2-morpholino-thiopyrano-4-ones	|B-IUPAC
-	642	643		|I-IUPAC
morpholino	643	653		|I-IUPAC
-	653	654		|I-IUPAC
thiopyrano	654	664		|I-IUPAC
-	664	665		|I-IUPAC
4	665	666		|I-IUPAC
-	666	667		|I-IUPAC
ones	667	671		|I-IUPAC
identified	672	682		|O
the	683	686		|O
first	687	692		|O
highly	693	699		|O
potent	700	706		|O
and	707	710		|O
selective	711	720		|O
ATM	721	724		|O
inhibitor	725	734		|O
2	735	736	2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one	|B-IUPAC
-	736	737		|I-IUPAC
morpholin	737	746		|I-IUPAC
-	746	747		|I-IUPAC
4	747	748		|I-IUPAC
-	748	749		|I-IUPAC
yl	749	751		|I-IUPAC
-	751	752		|I-IUPAC
6	752	753		|I-IUPAC
-	753	754		|I-IUPAC
thianthren	754	764		|I-IUPAC
-	764	765		|I-IUPAC
1	765	766		|I-IUPAC
-	766	767		|I-IUPAC
yl	767	769		|I-IUPAC
-	769	770		|I-IUPAC
pyran	770	775		|I-IUPAC
-	775	776		|I-IUPAC
4	776	777		|I-IUPAC
-	777	778		|I-IUPAC
one	778	781		|I-IUPAC
(	782	783		|O
151C	783	787		|O
;	787	788		|O
ATM	789	792		|O
;	792	793		|O
IC50	794	798		|O
=	799	800		|O
13	801	803		|O
nM	804	806		|O
)	806	807		|O
and	808	811		|O
revealed	812	820		|O
constrained	821	832		|O
SARs	833	837		|O
for	838	841		|O
ATM	842	845		|O
inhibition	846	856		|O
compared	857	865		|O
with	866	870		|O
DNA	871	874		|O
-	874	875		|O
PK	875	877		|O
.	877	878		|O
One	879	882		|O
of	883	885		|O
the	886	889		|O
most	890	894		|O
potent	895	901		|O
DNA	902	905		|O
-	905	906		|O
PK	906	908		|O
inhibitors	909	919		|O
identified	920	930		|O
,	930	931		|O
2	932	933	2-(4-methoxyphenyl)-6-(morpholin-4-yl)pyran-4-one	|B-IUPAC
-	933	934		|I-IUPAC
(	934	935		|I-IUPAC
4	935	936		|I-IUPAC
-	936	937		|I-IUPAC
methoxyphenyl	937	950		|I-IUPAC
)	950	951		|I-IUPAC
-	951	952		|I-IUPAC
6	952	953		|I-IUPAC
-	953	954		|I-IUPAC
(	954	955		|I-IUPAC
morpholin	955	964		|I-IUPAC
-	964	965		|I-IUPAC
4	965	966		|I-IUPAC
-	966	967		|I-IUPAC
yl	967	969		|I-IUPAC
)	969	970		|I-IUPAC
pyran	970	975		|I-IUPAC
-	975	976		|I-IUPAC
4	976	977		|I-IUPAC
-	977	978		|I-IUPAC
one	978	981		|I-IUPAC
(	982	983		|O
16	983	985		|O
;	985	986		|O
DNA	987	990		|O
-	990	991		|O
PK	991	993		|O
;	993	994		|O
IC50	995	999		|O
=	1000	1001		|O
nM	1006	1008		|O
)	1008	1009		|O
effectively	1010	1021		|O
sensitized	1022	1032		|O
HeLa	1033	1037		|O
cells	1038	1043		|O
to	1044	1046		|O
the	1047	1050		|O
topoisomerase	1051	1064		|O
II	1065	1067		|O
inhibitor	1068	1077		|O
etoposide	1078	1087	etoposide	|B-TRIVIAL
in	1087	1089		|O
vitro	1091	1096		|O
.	1096	1097		|O

### 6780324
Differential	9	21		|O
effects	22	29		|O
of	30	32		|O
luteinizing	33	44		|O
hormone	45	52		|O
-	52	53		|O
releasing	53	62		|O
hormone	63	70		|O
on	71	73		|O
follicle	74	82		|O
-	82	83		|O
stimulating	83	94		|O
hormone	95	102		|O
-	102	103		|O
dependent	103	112		|O
responses	113	122		|O
in	123	125		|O
rat	126	129		|O
granulosa	130	139		|O
cells	140	145		|O
and	146	149		|O
Sertoli	150	157		|O
cells	158	163		|O
in	164	166		|O
vitro	167	172		|O
.	172	173		|O
The	175	178		|O
abilities	179	188		|O
of	189	191		|O
LHRH	192	196		|O
and	197	200		|O
a	201	202		|O
potent	203	209		|O
LHRH	210	214		|O
agonist	215	222		|O
(	223	224		|O
[	224	225	[D-Ser-(But),6, des-Gly-NH210]LHRH ethylamide	|O
D	225	226		|O
-	226	227		|O
Ser	227	230		|O
-	230	231		|O
(	231	232		|O
But	232	235		|O
)	235	236		|O
,	236	237		|O
6	237	238		|O
,	238	239		|O
des	240	243		|O
-	243	244		|O
Gly	244	247		|O
-	247	248		|O
NH210	248	253		|O
]	253	254		|O
LHRH	254	258		|O
ethylamide	259	269		|O
)	269	270		|O
inhibit	271	278		|O
FSH	279	282		|O
responses	283	292		|O
by	293	295		|O
rat	296	299		|O
granulosa	300	309		|O
cells	310	315		|O
and	316	319		|O
Sertoli	320	327		|O
cells	328	333		|O
in	334	336		|O
vitro	337	342		|O
have	343	347		|O
been	348	352		|O
compared	353	361		|O
.	361	362		|O
Granulosa	363	372		|O
cells	373	378		|O
isolated	379	387		|O
from	388	392		|O
22	393	395		|O
-	395	396		|O
or	397	399		|O
25	400	402		|O
-	402	403		|O
day	403	406		|O
-	406	407		|O
old	407	410		|O
diethylstilbestrol	411	429	diethylstilbestrol	|B-TRIVIAL
-	429	430		|O
primed	430	436		|O
rats	437	441		|O
and	442	445		|O
cultured	446	454		|O
under	455	460		|O
defined	461	468		|O
conditions	469	479		|O
for	480	483		|O
48	484	486		|O
h	487	488		|O
with	489	493		|O
NIH	494	497	NIH-FSH-S13	|B-TRIVIALVAR
-	497	498		|I-TRIVIALVAR
FSH	498	501		|I-TRIVIALVAR
-	501	502		|I-TRIVIALVAR
S13	502	505		|I-TRIVIALVAR
(	506	507		|O
ng	511	513		|O
/	513	514		|O
ml	514	516		|O
)	516	517		|O
or	518	520		|O
cholera	521	528	cholera toxin	|B-TRIVIAL
toxin	529	534		|I-TRIVIAL
(	535	536		|O
0.1	536	539		|O
microgram	540	549		|O
/	549	550		|O
ml	550	552		|O
)	552	553		|O
showed	554	560		|O
increased	561	570		|O
aromatase	571	580		|O
activity	581	589		|O
,	589	590		|O
as	591	593		|O
determined	594	604		|O
by	605	607		|O
the	608	611		|O
release	612	619		|O
of	620	622		|O
3H2O	623	627		|O
from	628	632		|O
[	633	634	[1 beta-3H]testosterone	|B-IUPAC
1	634	635		|I-IUPAC
beta	636	640		|I-IUPAC
-	640	641		|I-IUPAC
3H	641	643		|I-IUPAC
]	643	644		|I-IUPAC
testosterone	644	656		|I-IUPAC
.	656	657		|O
LHRH	658	662		|O
(	663	664		|O
(	666	667		|O
-	667	668		|O
7	668	669		|O
)	669	670		|O
M	671	672		|O
)	672	673		|O
or	674	676		|O
th	677	679		|O
agonist	680	687		|O
(	688	689		|O
(	691	692		|O
-	692	693		|O
8	693	694		|O
)	694	695		|O
M	696	697		|O
)	697	698		|O
added	699	704		|O
simultaneously	705	719		|O
with	720	724		|O
FSH	725	728		|O
or	729	731		|O
cholera	732	739	cholera toxin	|B-TRIVIAL
toxin	740	745		|I-TRIVIAL
inhibited	746	755		|O
the	756	759		|O
effects	760	767		|O
on	768	770		|O
the	771	774		|O
release	775	782		|O
of	783	785		|O
3H2O	786	790	3H2O	|B-SUM
without	791	798		|O
influencing	799	810		|O
the	811	814		|O
protein	815	822		|O
content	823	830		|O
of	831	833		|O
the	834	837		|O
cell	838	842		|O
cultures	843	851		|O
.	851	852		|O
A	853	854		|O
smaller	855	862		|O
stimulation	863	874		|O
of	875	877		|O
3H2O	878	882	3H2O	|B-SUM
production	883	893		|O
occurred	894	902		|O
with	903	907		|O
(	908	909	(Bu)2cAMP	|B-IUPAC
Bu	909	911		|I-IUPAC
)	911	912		|I-IUPAC
2cAMP	912	917		|I-IUPAC
(	918	919		|O
1.0	919	922		|O
mM	923	925		|O
)	925	926		|O
plus	927	931		|O
3	932	933	3-isobutyl-l-methylxanthine	|B-IUPAC
-	933	934		|I-IUPAC
isobutyl	934	942		|I-IUPAC
-	942	943		|I-IUPAC
l	943	944		|I-IUPAC
-	944	945		|I-IUPAC
methylxanthine	945	959		|I-IUPAC
(	960	961		|O
0.1	961	964		|O
mM	965	967		|O
)	967	968		|O
,	968	969		|O
and	970	973		|O
this	974	978		|O
was	979	982		|O
partially	983	992		|O
suppressed	993	1003		|O
in	1004	1006		|O
the	1007	1010		|O
presence	1011	1019		|O
of	1020	1022		|O
LHRH	1023	1027		|O
or	1028	1030		|O
the	1031	1034		|O
agonist	1035	1042		|O
.	1042	1043		|O
Parallel	1044	1052		|O
studies	1053	1060		|O
with	1061	1065		|O
Sertoli	1066	1073		|O
cells	1074	1079		|O
from	1080	1084		|O
15	1085	1087		|O
-	1087	1088		|O
or	1089	1091		|O
-	1094	1095		|O
day	1095	1098		|O
-	1098	1099		|O
old	1099	1102		|O
rats	1103	1107		|O
demonstrated	1108	1120		|O
that	1121	1125		|O
culture	1126	1133		|O
under	1134	1139		|O
appropriate	1140	1151		|O
conditions	1152	1162		|O
with	1163	1167		|O
FSH	1168	1171		|O
,	1171	1172		|O
cholera	1173	1180	cholera toxin	|B-TRIVIAL
toxin	1181	1186		|I-TRIVIAL
,	1186	1187		|O
or	1188	1190		|O
(	1191	1192	(Bu)2cAMP	|B-IUPAC
Bu	1192	1194		|I-IUPAC
)	1194	1195		|I-IUPAC
2cAMP	1195	1200		|I-IUPAC
(	1201	1202		|O
0.5	1202	1205		|O
mM	1206	1208		|O
)	1208	1209		|O
for	1210	1213		|O
24	1214	1216		|O
h	1217	1218		|O
caused	1219	1225		|O
an	1226	1228		|O
increase	1229	1237		|O
in	1238	1240		|O
cellular	1241	1249		|O
aromatase	1250	1259		|O
activity	1260	1268		|O
and	1269	1272		|O
enhanced	1273	1281		|O
secretion	1282	1291		|O
into	1292	1296		|O
the	1297	1300		|O
medium	1301	1307		|O
of	1308	1310		|O
plasminogen	1311	1322		|O
activator	1323	1332		|O
.	1332	1333		|O
However	1334	1341		|O
,	1341	1342		|O
no	1343	1345		|O
inhibition	1346	1356		|O
by	1357	1359		|O
LHRH	1360	1364		|O
(	1365	1366		|O
(	1368	1369		|O
-	1369	1370		|O
7	1370	1371		|O
)	1371	1372		|O
or	1373	1375		|O
(	1378	1379		|O
-	1379	1380		|O
9	1380	1381		|O
)	1381	1382		|O
M	1383	1384		|O
)	1384	1385		|O
or	1386	1388		|O
the	1389	1392		|O
agonist	1393	1400		|O
(	1401	1402		|O
(	1404	1405		|O
-	1405	1406		|O
6	1406	1407		|O
)	1407	1408		|O
or	1409	1411		|O
(	1414	1415		|O
-	1415	1416		|O
8	1416	1417		|O
)	1417	1418		|O
M	1419	1420		|O
)	1420	1421		|O
occurred	1422	1430		|O
when	1431	1435		|O
the	1436	1439		|O
peptides	1440	1448		|O
were	1449	1453		|O
added	1454	1459		|O
either	1460	1466		|O
simultaneously	1467	1481		|O
or	1482	1484		|O
24	1485	1487		|O
h	1488	1489		|O
before	1490	1496		|O
the	1497	1500		|O
stimulatory	1501	1512		|O
agent	1513	1518		|O
.	1518	1519		|O
Similarly	1520	1529		|O
,	1529	1530		|O
Sertoli	1531	1538		|O
cells	1539	1544		|O
from	1545	1549		|O
11	1550	1552		|O
-	1552	1553		|O
day	1553	1556		|O
-	1556	1557		|O
old	1557	1560		|O
rats	1561	1565		|O
treated	1566	1573		|O
daily	1574	1579		|O
with	1580	1584		|O
LHRH	1585	1589		|O
agonist	1590	1597		|O
for	1598	1601		|O
5	1602	1603		|O
days	1604	1608		|O
in	1609	1611		|O
culture	1612	1619		|O
,	1619	1620		|O
showed	1621	1627		|O
no	1628	1630		|O
inhibition	1631	1641		|O
of	1642	1644		|O
aromatase	1645	1654		|O
activity	1655	1663		|O
after	1664	1669		|O
a	1670	1671		|O
4	1672	1673		|O
-	1673	1674		|O
h	1674	1675		|O
stimulation	1676	1687		|O
with	1688	1692		|O
FSH	1693	1696		|O
or	1697	1699		|O
(	1700	1701	(Bu)2cAMP	|B-IUPAC
Bu	1701	1703		|I-IUPAC
)	1703	1704		|I-IUPAC
2cAMP	1704	1709		|I-IUPAC
.	1709	1710		|O
FSH	1711	1714		|O
dose	1715	1719		|O
-	1719	1720		|O
response	1720	1728		|O
curves	1729	1735		|O
(	1736	1737		|O
0-300	1737	1742		|O
ng	1743	1745		|O
/	1745	1746		|O
ml	1746	1748		|O
)	1748	1749		|O
for	1750	1753		|O
aromatase	1754	1763		|O
activity	1764	1772		|O
were	1773	1777		|O
shown	1778	1783		|O
to	1784	1786		|O
be	1787	1789		|O
similar	1790	1797		|O
after	1798	1803		|O
5	1804	1805		|O
days	1806	1810		|O
of	1811	1813		|O
culture	1814	1821		|O
with	1822	1826		|O
or	1827	1829		|O
without	1830	1837		|O
(	1840	1841		|O
-	1841	1842		|O
8	1842	1843		|O
)	1843	1844		|O
M	1845	1846		|O
LHRH	1847	1851		|O
agonist	1852	1859		|O
,	1859	1860		|O
indicating	1861	1871		|O
that	1872	1876		|O
the	1877	1880		|O
LHRH	1881	1885		|O
did	1886	1889		|O
not	1890	1893		|O
cause	1894	1899		|O
a	1900	1901		|O
shift	1902	1907		|O
in	1908	1910		|O
the	1911	1914		|O
sensitivity	1915	1926		|O
to	1927	1929		|O
FSH	1930	1933		|O
.	1933	1934		|O
The	1935	1938		|O
lack	1939	1943		|O
of	1944	1946		|O
inhibition	1947	1957		|O
was	1958	1961		|O
seen	1962	1966		|O
in	1967	1969		|O
Sertoli	1970	1977		|O
cell	1978	1982		|O
cultures	1983	1991		|O
maintained	1992	2002		|O
at	2003	2005		|O
37	2006	2008		|O
or	2009	2011		|O
32	2012	2014		|O
C	2015	2016		|O
.	2016	2017		|O
The	2018	2021		|O
enzyme	2022	2028		|O
digestion	2029	2038		|O
method	2039	2045		|O
used	2046	2050		|O
to	2051	2053		|O
isolated	2054	2062		|O
Sertoli	2063	2070		|O
cells	2071	2076		|O
was	2077	2080		|O
not	2081	2084		|O
responsible	2085	2096		|O
for	2097	2100		|O
the	2101	2104		|O
lack	2105	2109		|O
of	2110	2112		|O
effects	2113	2120		|O
of	2121	2123		|O
LHRH	2124	2128		|O
,	2128	2129		|O
since	2130	2135		|O
cell	2136	2140		|O
cultures	2141	2149		|O
prepared	2150	2158		|O
without	2159	2166		|O
the	2167	2170		|O
aid	2171	2174		|O
of	2175	2177		|O
proteolytic	2178	2189		|O
enzymes	2190	2197		|O
showed	2198	2204		|O
similar	2205	2212		|O
FSH	2213	2216		|O
stimulation	2217	2228		|O
of	2229	2231		|O
aromatase	2232	2241		|O
activity	2242	2250		|O
in	2251	2253		|O
the	2254	2257		|O
presence	2258	2266		|O
or	2267	2269		|O
absence	2270	2277		|O
of	2278	2280		|O
(	2283	2284		|O
-	2284	2285		|O
8	2285	2286		|O
)	2286	2287		|O
M	2288	2289		|O
agonist	2290	2297		|O
.	2297	2298		|O
Further	2299	2306		|O
,	2306	2307		|O
there	2308	2313		|O
was	2314	2317		|O
no	2318	2320		|O
evidence	2321	2329		|O
of	2330	2332		|O
degradation	2333	2344		|O
of	2345	2347		|O
the	2348	2351		|O
LHRH	2352	2356		|O
agonist	2357	2364		|O
when	2365	2369		|O
incubated	2370	2379		|O
with	2380	2384		|O
Sertoli	2385	2392		|O
cell	2393	2397		|O
cultures	2398	2406		|O
.	2406	2407		|O
From	2408	2412		|O
these	2413	2418		|O
studies	2419	2426		|O
,	2426	2427		|O
we	2428	2430		|O
conclude	2431	2439		|O
that	2440	2444		|O
1	2445	2446		|O
)	2446	2447		|O
granulosa	2448	2457		|O
cells	2458	2463		|O
and	2464	2467		|O
Sertoli	2468	2475		|O
cells	2476	2481		|O
from	2482	2486		|O
immature	2487	2495		|O
rats	2496	2500		|O
differ	2501	2507		|O
in	2508	2510		|O
their	2511	2516		|O
responses	2517	2526		|O
to	2527	2529		|O
LHRH	2530	2534		|O
,	2534	2535		|O
and	2536	2539		|O
2	2540	2541		|O
)	2541	2542		|O
the	2543	2546		|O
immature	2547	2555		|O
Sertoli	2556	2563		|O
cell	2564	2568		|O
is	2569	2571		|O
an	2572	2574		|O
unlikely	2575	2583		|O
target	2584	2590		|O
for	2591	2594		|O
a	2595	2596		|O
direct	2597	2603		|O
inhibiting	2604	2614		|O
influence	2615	2624		|O
of	2625	2627		|O
LHRH	2628	2632		|O
on	2633	2635		|O
spermatogenesis	2636	2651		|O
.	2651	2652		|O

### 12672235
We	0	2		|O
have	3	7		|O
previously	8	18		|O
described	19	28		|O
(	29	30	(RS)-2-amino-3-(3-hydroxy-7,8-dihydro-6H-cyclohepta[d]isoxazol-4-yl)propionic acid	|B-IUPAC
RS	30	32		|I-IUPAC
)	32	33		|I-IUPAC
-	33	34		|I-IUPAC
2	34	35		|I-IUPAC
-	35	36		|I-IUPAC
amino	36	41		|I-IUPAC
-	41	42		|I-IUPAC
3	42	43		|I-IUPAC
-	43	44		|I-IUPAC
(	44	45		|I-IUPAC
3	45	46		|I-IUPAC
-	46	47		|I-IUPAC
hydroxy	47	54		|I-IUPAC
-	54	55		|I-IUPAC
7,8	55	58		|I-IUPAC
-	58	59		|I-IUPAC
dihydro	59	66		|I-IUPAC
-	66	67		|I-IUPAC
6H	67	69		|I-IUPAC
-	69	70		|I-IUPAC
cyclohepta	70	80		|I-IUPAC
[	80	81		|I-IUPAC
d	81	82		|I-IUPAC
]	82	83		|I-IUPAC
isoxazol	83	91		|I-IUPAC
-	91	92		|I-IUPAC
4	92	93		|I-IUPAC
-	93	94		|I-IUPAC
yl	94	96		|I-IUPAC
)	96	97		|I-IUPAC
propionic	97	106		|I-IUPAC
acid	107	111		|I-IUPAC
(	112	113		|O
4	113	114	4-AHCP	|B-ABBREVIATION
-	114	115		|I-ABBREVIATION
AHCP	115	119		|I-ABBREVIATION
)	119	120		|O
as	121	123		|O
a	124	125		|O
highly	126	132		|O
effective	133	142		|O
agonist	143	150		|O
at	151	153		|O
non	154	157		|O
-	157	158		|O
N	158	159		|O
-	159	160		|O
methyl	160	166		|O
-	166	167		|O
d	167	168		|O
-	168	169		|O
aspartate	169	178		|O
(	179	180		|O
non	180	183		|O
-	183	184		|O
NMDA	184	188		|O
)	188	189		|O
glutamate	190	199		|O
(	200	201		|O
Glu	201	204		|O
)	204	205		|O
receptors	206	215		|O
in	216	218		|O
vivo	219	223		|O
,	223	224		|O
which	225	230		|O
is	231	233		|O
more	234	238		|O
potent	239	245		|O
than	246	250		|O
(	251	252	(RS)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic acid	|B-IUPAC
RS	252	254		|I-IUPAC
)	254	255		|I-IUPAC
-	255	256		|I-IUPAC
2	256	257		|I-IUPAC
-	257	258		|I-IUPAC
amino	258	263		|I-IUPAC
-	263	264		|I-IUPAC
3	264	265		|I-IUPAC
-	265	266		|I-IUPAC
(	266	267		|I-IUPAC
3	267	268		|I-IUPAC
-	268	269		|I-IUPAC
hydroxy	269	276		|I-IUPAC
-	276	277		|I-IUPAC
5	277	278		|I-IUPAC
-	278	279		|I-IUPAC
methylisoxazol	279	293		|I-IUPAC
-	293	294		|I-IUPAC
4	294	295		|I-IUPAC
-	295	296		|I-IUPAC
yl	296	298		|I-IUPAC
)	298	299		|I-IUPAC
propionic	299	308		|I-IUPAC
acid	309	313		|I-IUPAC
(	314	315		|O
AMPA	315	319	AMPA	|B-ABBREVIATION
)	319	320		|O
but	321	324		|O
inactive	325	333		|O
at	334	336		|O
NMDA	337	341		|O
receptors	342	351		|O
.	351	352		|O
However	353	360		|O
,	360	361		|O
4	362	363	4-AHCP	|B-ABBREVIATION
-	363	364		|I-ABBREVIATION
AHCP	364	368		|I-ABBREVIATION
was	369	372		|O
found	373	378		|O
to	379	381		|O
be	382	384		|O
much	385	389		|O
weaker	390	396		|O
than	397	401		|O
AMPA	402	406	AMPA	|B-ABBREVIATION
as	407	409		|O
an	410	412		|O
inhibitor	413	422		|O
of	423	425		|O
[	426	427	[(3)H]AMPA	|B-IUPAC
(	427	428		|I-IUPAC
3	428	429		|I-IUPAC
)	429	430		|I-IUPAC
H	430	431		|I-IUPAC
]	431	432		|I-IUPAC
AMPA	432	436		|I-IUPAC
binding	437	444		|O
and	445	448		|O
to	449	451		|O
have	452	456		|O
limited	457	464		|O
effect	465	471		|O
in	472	474		|O
a	475	476		|O
[	477	478	[(3)H]kainic acid	|B-IUPAC
(	478	479		|I-IUPAC
3	479	480		|I-IUPAC
)	480	481		|I-IUPAC
H	481	482		|I-IUPAC
]	482	483		|I-IUPAC
kainic	483	489		|I-IUPAC
acid	490	494		|I-IUPAC
binding	495	502		|O
assay	503	508		|O
using	509	514		|O
rat	515	518		|O
cortical	519	527		|O
membranes	528	537		|O
.	537	538		|O
To	539	541		|O
shed	542	546		|O
light	547	552		|O
on	553	555		|O
the	556	559		|O
mechanism	560	569		|O
(	569	570		|O
s	570	571		|O
)	571	572		|O
underlying	573	583		|O
this	584	588		|O
quite	589	594		|O
enigmatic	595	604		|O
pharmacological	605	620		|O
profile	621	628		|O
of	629	631		|O
4	632	633	4-AHCP	|B-ABBREVIATION
-	633	634		|I-ABBREVIATION
AHCP	634	638		|I-ABBREVIATION
,	638	639		|O
we	640	642		|O
have	643	647		|O
now	648	651		|O
developed	652	661		|O
a	662	663		|O
synthesis	664	673		|O
of	674	676		|O
(	677	678	(S)-4-AHCP	|B-ABBREVIATION
S	678	679		|I-ABBREVIATION
)	679	680		|I-ABBREVIATION
-	680	681		|I-ABBREVIATION
4	681	682		|I-ABBREVIATION
-	682	683		|I-ABBREVIATION
AHCP	683	687		|I-ABBREVIATION
(	688	689		|O
6	689	690		|O
)	690	691		|O
and	692	695		|O
(	696	697	(R)-4-AHCP	|B-ABBREVIATION
R	697	698		|I-ABBREVIATION
)	698	699		|I-ABBREVIATION
-	699	700		|I-ABBREVIATION
4	700	701		|I-ABBREVIATION
-	701	702		|I-ABBREVIATION
AHCP	702	706		|I-ABBREVIATION
(	707	708		|O
7	708	709		|O
)	709	710		|O
.	710	711		|O
At	712	714		|O
cloned	715	721		|O
metabotropic	722	734		|O
Glu	735	738		|O
receptors	739	748		|O
mGluR1alpha	749	760		|O
(	761	762		|O
group	762	767		|O
I	768	769		|O
)	769	770		|O
,	770	771		|O
mGluR2	772	778		|O
(	779	780		|O
group	780	785		|O
II	786	788		|O
)	788	789		|O
,	789	790		|O
and	791	794		|O
mGluR4a	795	802		|O
(	803	804		|O
group	804	809		|O
III	810	813		|O
)	813	814		|O
,	814	815		|O
neither	816	823		|O
6	824	825		|O
nor	826	829		|O
7	830	831		|O
showed	832	838		|O
significant	839	850		|O
agonist	851	858		|O
or	859	861		|O
antagonist	862	872		|O
effects	873	880		|O
.	880	881		|O
The	882	885		|O
stereoisomer	886	898		|O
6	899	900		|O
,	900	901		|O
but	902	905		|O
not	906	909		|O
7	910	911		|O
,	911	912		|O
activated	913	922		|O
cloned	923	929		|O
AMPA	930	934		|O
receptor	935	943		|O
subunits	944	952		|O
GluR1o	953	959		|O
,	959	960		|O
GluR3o	961	967		|O
,	967	968		|O
and	969	972		|O
GluR4o	973	979		|O
with	980	984		|O
EC	985	987		|O
(	987	988		|O
)	990	991		|O
values	992	998		|O
in	999	1001		|O
the	1002	1005		|O
range	1006	1011		|O
4.5-15	1012	1018		|O
microM	1019	1025		|O
and	1026	1029		|O
the	1030	1033		|O
coexpressed	1034	1045		|O
kainate	1046	1053	kainate	|B-TRIVIAL
-	1053	1054		|O
preferring	1054	1064		|O
subunits	1065	1073		|O
GluR6	1074	1079		|O
+	1080	1081		|O
KA2	1082	1085		|O
(	1086	1087		|O
EC	1087	1089		|O
(	1089	1090		|O
)	1092	1093		|O
=	1094	1095		|O
6.4	1096	1099		|O
microM	1100	1106		|O
)	1106	1107		|O
.	1107	1108		|O
Compound	1109	1117		|O
6	1118	1119		|O
,	1119	1120		|O
but	1121	1124		|O
not	1125	1128		|O
7	1129	1130		|O
,	1130	1131		|O
proved	1132	1138		|O
to	1139	1141		|O
be	1142	1144		|O
a	1145	1146		|O
very	1147	1151		|O
potent	1152	1158		|O
agonist	1159	1166		|O
(	1167	1168		|O
EC	1168	1170		|O
(	1170	1171		|O
)	1173	1174		|O
=	1175	1176		|O
0.13	1177	1181		|O
microM	1182	1188		|O
)	1188	1189		|O
at	1190	1192		|O
the	1193	1196		|O
kainate	1197	1204	kainate	|B-TRIVIAL
-	1204	1205		|O
preferring	1205	1215		|O
GluR5	1216	1221		|O
subunit	1222	1229		|O
,	1229	1230		|O
equipotent	1231	1241		|O
with	1242	1246		|O
(	1247	1248	(S)-2-amino-3-(5-tert-butyl-3-hydroxyisothiazol-4-yl)propionic acid	|B-IUPAC
S	1248	1249		|I-IUPAC
)	1249	1250		|I-IUPAC
-	1250	1251		|I-IUPAC
2	1251	1252		|I-IUPAC
-	1252	1253		|I-IUPAC
amino	1253	1258		|I-IUPAC
-	1258	1259		|I-IUPAC
3	1259	1260		|I-IUPAC
-	1260	1261		|I-IUPAC
(	1261	1262		|I-IUPAC
5	1262	1263		|I-IUPAC
-	1263	1264		|I-IUPAC
tert	1264	1268		|I-IUPAC
-	1268	1269		|I-IUPAC
butyl	1269	1274		|I-IUPAC
-	1274	1275		|I-IUPAC
3	1275	1276		|I-IUPAC
-	1276	1277		|I-IUPAC
hydroxyisothiazol	1277	1294		|I-IUPAC
-	1294	1295		|I-IUPAC
4	1295	1296		|I-IUPAC
-	1296	1297		|I-IUPAC
yl	1297	1299		|I-IUPAC
)	1299	1300		|I-IUPAC
propionic	1300	1309		|I-IUPAC
acid	1310	1314		|I-IUPAC
[	1315	1316		|O
(	1316	1317	(S)-Thio-ATPA	|B-ABBREVIATION
S	1317	1318		|I-ABBREVIATION
)	1318	1319		|I-ABBREVIATION
-	1319	1320		|I-ABBREVIATION
Thio	1320	1324		|I-ABBREVIATION
-	1324	1325		|I-ABBREVIATION
ATPA	1325	1329		|I-ABBREVIATION
,	1329	1330		|O
4	1331	1332		|O
]	1332	1333		|O
and	1334	1337		|O
almost	1338	1344		|O
4	1345	1346		|O
times	1347	1352		|O
more	1353	1357		|O
potent	1358	1364		|O
than	1365	1369		|O
(	1370	1371	(S)-2-amino-3-(5-tert-butyl-3-hydroxyisoxazol-4-yl)propionic acid	|B-IUPAC
S	1371	1372		|I-IUPAC
)	1372	1373		|I-IUPAC
-	1373	1374		|I-IUPAC
2	1374	1375		|I-IUPAC
-	1375	1376		|I-IUPAC
amino	1376	1381		|I-IUPAC
-	1381	1382		|I-IUPAC
3	1382	1383		|I-IUPAC
-	1383	1384		|I-IUPAC
(	1384	1385		|I-IUPAC
5	1385	1386		|I-IUPAC
-	1386	1387		|I-IUPAC
tert	1387	1391		|I-IUPAC
-	1391	1392		|I-IUPAC
butyl	1392	1397		|I-IUPAC
-	1397	1398		|I-IUPAC
3	1398	1399		|I-IUPAC
-	1399	1400		|I-IUPAC
hydroxyisoxazol	1400	1415		|I-IUPAC
-	1415	1416		|I-IUPAC
4	1416	1417		|I-IUPAC
-	1417	1418		|I-IUPAC
yl	1418	1420		|I-IUPAC
)	1420	1421		|I-IUPAC
propionic	1421	1430		|I-IUPAC
acid	1431	1435		|I-IUPAC
[	1436	1437		|O
(	1437	1438	(S)-ATPA	|B-ABBREVIATION
S	1438	1439		|I-ABBREVIATION
)	1439	1440		|I-ABBREVIATION
-	1440	1441		|I-ABBREVIATION
ATPA	1441	1445		|I-ABBREVIATION
,	1445	1446		|O
3	1447	1448		|O
]	1448	1449		|O
.	1449	1450		|O
Compound	1451	1459		|O
6	1460	1461		|O
thus	1462	1466		|O
represents	1467	1477		|O
a	1478	1479		|O
new	1480	1483		|O
structural	1484	1494		|O
class	1495	1500		|O
of	1501	1503		|O
GluR5	1504	1509		|O
agonists	1510	1518		|O
.	1518	1519		|O
Molecular	1520	1529		|O
modeling	1530	1538		|O
and	1539	1542		|O
docking	1543	1550		|O
to	1551	1553		|O
a	1554	1555		|O
crystal	1556	1563		|O
structure	1564	1573		|O
of	1574	1576		|O
the	1577	1580		|O
extracellular	1581	1594		|O
binding	1595	1602		|O
domain	1603	1609		|O
of	1610	1612		|O
the	1613	1616		|O
AMPA	1617	1621	AMPA	|B-ABBREVIATION
subunit	1621	1628		|O
GluR2	1630	1635		|O
has	1636	1639		|O
enabled	1640	1647		|O
identification	1648	1662		|O
of	1663	1665		|O
the	1666	1669		|O
probable	1670	1678		|O
active	1679	1685		|O
conformation	1686	1698		|O
and	1699	1702		|O
binding	1703	1710		|O
mode	1711	1715		|O
of	1716	1718		|O
6	1719	1720		|O
.	1720	1721		|O
We	1722	1724		|O
are	1725	1728		|O
able	1729	1733		|O
to	1734	1736		|O
rationalize	1737	1748		|O
the	1749	1752		|O
observed	1753	1761		|O
selectivities	1762	1775		|O
by	1776	1778		|O
comparing	1779	1788		|O
the	1789	1792		|O
docking	1793	1800		|O
of	1801	1803		|O
4	1804	1805		|O
and	1806	1809		|O
6	1810	1811		|O
to	1812	1814		|O
subtype	1815	1822		|O
constructs	1823	1833		|O
,	1833	1834		|O
i.e.	1835	1839		|O
,	1839	1840		|O
a	1841	1842		|O
crystal	1843	1850		|O
structure	1851	1860		|O
of	1861	1863		|O
the	1864	1867		|O
extracellular	1868	1881		|O
binding	1882	1889		|O
domain	1890	1896		|O
of	1897	1899		|O
GluR2	1900	1905		|O
and	1906	1909		|O
a	1910	1911		|O
homology	1912	1920		|O
model	1921	1926		|O
of	1927	1929		|O
GluR5	1930	1935		|O
.	1935	1936		|O

### 7205876
The	0	3		|O
synthesis	4	13		|O
of	14	16		|O
aminoaceto	17	27	aminoaceto-2',6'-xylidides	|B-IUPAC
-	27	28		|I-IUPAC
2'	28	30		|I-IUPAC
,	30	31		|I-IUPAC
6'	31	33		|I-IUPAC
-	33	34		|I-IUPAC
xylidides	34	43		|I-IUPAC
substituted	44	55	substituted	|B-MODIFIER
on	56	58		|O
the	59	62		|O
amide	63	68	amide	|B-FAMILY
nitrogen	69	77	nitrogen	|B-TRIVIAL
with	78	82		|O
2	83	84	2-(diethylamino)ethyl	|B-PARTIUPAC
-	84	85		|I-PARTIUPAC
(	85	86		|I-PARTIUPAC
diethylamino	86	98		|I-PARTIUPAC
)	98	99		|I-PARTIUPAC
ethyl	99	104		|I-PARTIUPAC
,	104	105		|O
2	106	107	2-aminoethyl	|B-PARTIUPAC
-	107	108		|I-PARTIUPAC
aminoethyl	108	118		|I-PARTIUPAC
,	118	119		|O
2	120	121	2-hydroxyethyl	|B-PARTIUPAC
-	121	122		|I-PARTIUPAC
hydroxyethyl	122	134		|I-PARTIUPAC
,	134	135		|O
and	136	139		|O
2	140	141	2-ethoxyethyl	|B-PARTIUPAC
-	141	142		|I-PARTIUPAC
ethoxyethyl	142	153		|I-PARTIUPAC
groups	154	160	groups	|B-MODIFIER
is	161	163		|O
described	164	173		|O
.	173	174		|O
The	175	178		|O
2	179	180	2-aminoethyl	|B-PARTIUPAC
-	180	181		|I-PARTIUPAC
aminoethyl	181	191		|I-PARTIUPAC
derivatives	192	203	derivatives	|B-MODIFIER
were	204	208		|O
prepared	209	217		|O
by	218	220		|O
treatment	221	230		|O
of	231	233		|O
N	234	235	N-(2-phthalimidoethyl)-2',6'-xylidine	|B-IUPAC
-	235	236		|I-IUPAC
(	236	237		|I-IUPAC
2	237	238		|I-IUPAC
-	238	239		|I-IUPAC
phthalimidoethyl	239	255		|I-IUPAC
)	255	256		|I-IUPAC
-	256	257		|I-IUPAC
2'	257	259		|I-IUPAC
,	259	260		|I-IUPAC
6'	260	262		|I-IUPAC
-	262	263		|I-IUPAC
xylidine	263	271		|I-IUPAC
with	272	276		|O
chloroacetyl	277	289	chloroacetyl chloride	|B-IUPAC
chloride	290	298		|I-IUPAC
,	298	299		|O
followed	300	308		|O
by	309	311		|O
treatment	312	321		|O
with	322	326		|O
either	327	333		|O
potassium	334	343	potassium phthalmide	|B-IUPAC
phthalmide	344	354		|I-IUPAC
or	355	357		|O
diethylamine	358	370	diethylamine	|B-TRIVIAL
.	370	371		|O
Hydrazinolysis	372	386		|O
of	387	389		|O
the	390	393		|O
phthalimides	394	406	phthalimides	|B-FAMILY
liberated	407	416		|O
the	417	420		|O
free	421	425		|O
amines	426	432	amines	|B-FAMILY
.	432	433		|O
The	434	437		|O
remaining	438	447		|O
target	448	454		|O
compounds	455	464		|O
were	465	469		|O
produced	470	478		|O
by	479	481		|O
alkylation	482	492		|O
of	493	495		|O
lidocaine	496	505	lidocaine	|B-TRIVIAL
or	506	508		|O
of	509	511		|O
2	512	513	2-phthalimidoaceto-2',6'-xylidide	|B-IUPAC
-	513	514		|I-IUPAC
phthalimidoaceto	514	530		|I-IUPAC
-	530	531		|I-IUPAC
2'	531	533		|I-IUPAC
,	533	534		|I-IUPAC
6'	534	536		|I-IUPAC
-	536	537		|I-IUPAC
xylidide	537	545		|I-IUPAC
with	546	550		|O
the	551	554		|O
appropriate	555	566		|O
halide	567	573	halide	|B-PARTIUPAC
and	574	577		|O
sodium	578	584	sodium hydride	|B-IUPAC
hydride	585	592		|I-IUPAC
,	592	593		|O
followed	594	602		|O
by	603	605		|O
hydrazinolysis	606	620		|O
where	621	626		|O
necessary	627	636		|O
.	636	637		|O
All	638	641		|O
target	642	648		|O
compounds	649	658		|O
were	659	663		|O
evaluated	664	673		|O
for	674	677		|O
antiarrhythmic	678	692		|O
efficacy	693	701		|O
against	702	709		|O
chloroform	710	720	chloroform	|B-TRIVIAL
-	720	721		|O
induced	721	728		|O
ventricular	729	740		|O
tachycardia	741	752		|O
,	752	753		|O
as	754	756		|O
well	757	761		|O
as	762	764		|O
for	765	768		|O
acute	769	774		|O
CNS	775	778		|O
toxicity	779	787		|O
in	788	790		|O
mice	791	795		|O
.	795	796		|O
Most	797	801		|O
of	802	804		|O
the	805	808		|O
target	809	815		|O
compounds	816	825		|O
were	826	830		|O
more	831	835		|O
potent	836	842		|O
than	843	847		|O
the	848	851		|O
corresponding	852	865		|O
secondary	866	875		|O
amides	876	882		|O
and	883	886		|O
had	887	890		|O
improved	891	899		|O
therapeutic	900	911		|O
margins	912	919		|O
toward	920	926		|O
CNS	927	930		|O
toxicity	931	939		|O
.	939	940		|O
The	941	944		|O
diamines	945	953		|O
N	954	955	N-(2-aminoethyl)-2-aminoaceto-2',6'-xylidide	|B-IUPAC
-	955	956		|I-IUPAC
(	956	957		|I-IUPAC
2	957	958		|I-IUPAC
-	958	959		|I-IUPAC
aminoethyl	959	969		|I-IUPAC
)	969	970		|I-IUPAC
-	970	971		|I-IUPAC
2	971	972		|I-IUPAC
-	972	973		|I-IUPAC
aminoaceto	973	983		|I-IUPAC
-	983	984		|I-IUPAC
2'	984	986		|I-IUPAC
,	986	987		|I-IUPAC
6'	987	989		|I-IUPAC
-	989	990		|I-IUPAC
xylidide	990	998		|I-IUPAC
(	999	1000		|O
13	1000	1002		|O
)	1002	1003		|O
and	1004	1007		|O
N	1008	1009	N-(2-aminoethyl)--2-(diethylamino)aceto-2',6'-xylidide	|B-IUPAC
-	1009	1010		|I-IUPAC
(	1010	1011		|I-IUPAC
2	1011	1012		|I-IUPAC
-	1012	1013		|I-IUPAC
aminoethyl	1013	1023		|I-IUPAC
)	1023	1024		|I-IUPAC
-	1024	1025		|I-IUPAC
-	1025	1026		|I-IUPAC
2	1026	1027		|I-IUPAC
-	1027	1028		|I-IUPAC
(	1028	1029		|I-IUPAC
diethylamino	1029	1041		|I-IUPAC
)	1041	1042		|I-IUPAC
aceto	1042	1047		|I-IUPAC
-	1047	1048		|I-IUPAC
2'	1048	1050		|I-IUPAC
,	1050	1051		|I-IUPAC
6'	1051	1053		|I-IUPAC
-	1053	1054		|I-IUPAC
xylidide	1054	1062		|I-IUPAC
(	1062	1063		|O
29	1064	1066		|O
)	1066	1067		|O
are	1068	1071		|O
especially	1072	1082		|O
promising	1083	1092		|O
in	1093	1095		|O
this	1096	1100		|O
respect	1101	1108		|O
.	1108	1109		|O
Several	1110	1117		|O
compounds	1118	1127		|O
were	1128	1132		|O
tested	1133	1139		|O
as	1140	1142		|O
spinal	1143	1149		|O
anesthetics	1150	1161		|O
.	1161	1162		|O

### 2104934
Some	0	4		|O
novel	5	10		|O
6	11	12	6-fluoro-7-substituted-1,4-dihydro-4-oxoquinoline-3-carboxylic acids	|B-IUPAC
-	12	13		|I-IUPAC
fluoro	13	19		|I-IUPAC
-	19	20		|I-IUPAC
7	20	21		|I-IUPAC
-	21	22		|I-IUPAC
substituted	22	33		|I-IUPAC
-	33	34		|I-IUPAC
1,4	34	37		|I-IUPAC
-	37	38		|I-IUPAC
dihydro	38	45		|I-IUPAC
-	45	46		|I-IUPAC
4	46	47		|I-IUPAC
-	47	48		|I-IUPAC
oxoquinoline	48	60		|I-IUPAC
-	60	61		|I-IUPAC
3	61	62		|I-IUPAC
-	62	63		|I-IUPAC
carboxylic	63	73		|I-IUPAC
acids	74	79		|I-IUPAC
have	80	84		|O
been	85	89		|O
prepared	90	98		|O
.	98	99		|O
At	100	102		|O
the	103	106		|O
N	107	108		|O
-	108	109		|O
1	109	110		|O
position	111	119		|O
"	120	121		|O
standard	121	129		|O
"	129	130		|O
substitution	131	143		|O
was	144	147		|O
employed	148	156		|O
with	157	161		|O
the	162	165		|O
ethyl	166	171	ethyl	|B-PARTIUPAC
,	171	172		|O
cyclopropyl	173	184	cyclopropyl	|B-PARTIUPAC
,	184	185		|O
and	186	189		|O
p	190	191	p-fluorophenyl	|B-PARTIUPAC
-	191	192		|I-PARTIUPAC
fluorophenyl	192	204		|I-PARTIUPAC
groups	205	211	groups	|B-MODIFIER
being	212	217		|O
used	218	222		|O
.	222	223		|O
At	224	226		|O
C	227	228		|O
-	228	229		|O
7	229	230		|O
the	231	234		|O
introduction	235	247		|O
of	248	250		|O
some	251	255		|O
novel	256	261		|O
piperazines	262	273	piperazines	|B-FAMILY
was	274	277		|O
made	278	282		|O
.	282	283		|O
Most	284	288		|O
notably	289	296		|O
,	296	297		|O
2	298	299	2-(fluoromethyl)piperazine	|B-IUPAC
-	299	300		|I-IUPAC
(	300	301		|I-IUPAC
fluoromethyl	301	313		|I-IUPAC
)	313	314		|I-IUPAC
piperazine	314	324		|I-IUPAC
(	325	326		|O
)	328	329		|O
and	330	333		|O
hexahydro	334	343	hexahydro-6-fluoro-1H-1,4-diazepine	|B-IUPAC
-	343	344		|I-IUPAC
6	344	345		|I-IUPAC
-	345	346		|I-IUPAC
fluoro	346	352		|I-IUPAC
-	352	353		|I-IUPAC
1H	353	355		|I-IUPAC
-	355	356		|I-IUPAC
1,4	356	359		|I-IUPAC
-	359	360		|I-IUPAC
diazepine	360	369		|I-IUPAC
(	370	371		|O
16	371	373		|O
,	373	374		|O
fluorohomopiperazine	375	395	fluorohomopiperazine	|B-TRIVIAL
)	395	396		|O
at	397	399		|O
the	400	403		|O
quinolone	404	413	quinolone	|B-TRIVIAL
C	414	415		|O
-	415	416		|O
7	416	417		|O
position	418	426		|O
produced	427	435		|O
products	436	444		|O
with	445	449		|O
similar	450	457		|O
in	458	460		|O
vitro	461	466		|O
antibacterial	467	480		|O
activity	481	489		|O
as	490	492		|O
the	493	496		|O
ciprofloxacin	497	510	ciprofloxacin	|B-TRIVIAL
reference	511	520		|O
.	520	521		|O
The	522	525		|O
in	526	528		|O
vivo	529	533		|O
efficacy	534	542		|O
of	543	545		|O
1	546	547	1-cyclopropyl-6-fluoro-7-[3-(fluoromethyl)piperazinyl]-1,4-dihydro-4- oxoquinoline-3-carboxylic acid	|B-IUPAC
-	547	548		|I-IUPAC
cyclopropyl	548	559		|I-IUPAC
-	559	560		|I-IUPAC
6	560	561		|I-IUPAC
-	561	562		|I-IUPAC
fluoro	562	568		|I-IUPAC
-	568	569		|I-IUPAC
7	569	570		|I-IUPAC
-	570	571		|I-IUPAC
[	571	572		|I-IUPAC
3	572	573		|I-IUPAC
-	573	574		|I-IUPAC
(	574	575		|I-IUPAC
fluoromethyl	575	587		|I-IUPAC
)	587	588		|I-IUPAC
piperazinyl	588	599		|I-IUPAC
]	599	600		|I-IUPAC
-	600	601		|I-IUPAC
1,4	601	604		|I-IUPAC
-	604	605		|I-IUPAC
dihydro	605	612		|I-IUPAC
-	612	613		|I-IUPAC
4	613	614		|I-IUPAC
-	614	615		|I-IUPAC
oxoquinoline	616	628		|I-IUPAC
-	628	629		|I-IUPAC
3	629	630		|I-IUPAC
-	630	631		|I-IUPAC
carboxylic	631	641		|I-IUPAC
acid	642	646		|I-IUPAC
(	647	648		|O
)	650	651		|O
was	652	655		|O
excellent	656	665		|O
with	666	670		|O
better	671	677		|O
oral	678	682		|O
absorption	683	693		|O
than	694	698		|O
ciprofloxacin	699	712	ciprofloxacin	|B-TRIVIAL
(	712	713		|O
2	714	715		|O
)	715	716		|O
.	716	717		|O

### 2329575
The	0	3		|O
thermal	4	11		|O
Fischer	12	19		|O
indolization	20	32		|O
of	33	35		|O
hydrazones	36	46	hydrazones	|B-FAMILY
resulting	47	56		|O
from	57	61		|O
4	62	63	4-hydrazino-5-methyl-1H-pyridin-2-one	|B-IUPAC
-	63	64		|I-IUPAC
hydrazino	64	73		|I-IUPAC
-	73	74		|I-IUPAC
5	74	75		|I-IUPAC
-	75	76		|I-IUPAC
methyl	76	82		|I-IUPAC
-	82	83		|I-IUPAC
1H	83	85		|I-IUPAC
-	85	86		|I-IUPAC
pyridin	86	93		|I-IUPAC
-	93	94		|I-IUPAC
2	94	95		|I-IUPAC
-	95	96		|I-IUPAC
one	96	99		|I-IUPAC
and	100	103		|O
various	104	111		|O
beta	112	116	beta-	|B-PARTIUPAC
-	116	117		|I-PARTIUPAC
and	118	121		|O
alpha	122	127	alpha-tetralones	|B-IUPAC
-	127	128		|I-IUPAC
tetralones	128	138		|I-IUPAC
led	139	142		|O
to	143	145		|O
4	146	147	4-methyl-6,7-dihydro-2H,5H-pyrido[4,3- b]benzo[e]indol-1-ones	|B-IUPAC
-	147	148		|I-IUPAC
methyl	148	154		|I-IUPAC
-	154	155		|I-IUPAC
6,7	155	158		|I-IUPAC
-	158	159		|I-IUPAC
dihydro	159	166		|I-IUPAC
-	166	167		|I-IUPAC
2H	167	169		|I-IUPAC
,	169	170		|I-IUPAC
5H	170	172		|I-IUPAC
-	172	173		|I-IUPAC
pyrido	173	179		|I-IUPAC
[	179	180		|I-IUPAC
4,3	180	183		|I-IUPAC
-	183	184		|I-IUPAC
b	185	186		|I-IUPAC
]	186	187		|I-IUPAC
benzo	187	192		|I-IUPAC
[	192	193		|I-IUPAC
e	193	194		|I-IUPAC
]	194	195		|I-IUPAC
indol	195	200		|I-IUPAC
-	200	201		|I-IUPAC
1	201	202		|I-IUPAC
-	202	203		|I-IUPAC
ones	203	207		|I-IUPAC
and	208	211		|O
4	212	213	4-methyl-11-dihydro-2H,5H-pyrido[4,3- b]benzo[g]indol-1-ones	|B-IUPAC
-	213	214		|I-IUPAC
methyl	214	220		|I-IUPAC
-	220	221		|I-IUPAC
11	221	223		|I-IUPAC
-	223	224		|I-IUPAC
dihydro	224	231		|I-IUPAC
-	231	232		|I-IUPAC
2H	232	234		|I-IUPAC
,	234	235		|I-IUPAC
5H	235	237		|I-IUPAC
-	237	238		|I-IUPAC
pyrido	238	244		|I-IUPAC
[	244	245		|I-IUPAC
4,3	245	248		|I-IUPAC
-	248	249		|I-IUPAC
b	250	251		|I-IUPAC
]	251	252		|I-IUPAC
benzo	252	257		|I-IUPAC
[	257	258		|I-IUPAC
g	258	259		|I-IUPAC
]	259	260		|I-IUPAC
indol	260	265		|I-IUPAC
-	265	266		|I-IUPAC
1	266	267		|I-IUPAC
-	267	268		|I-IUPAC
ones	268	272		|I-IUPAC
,	272	273		|O
respectively	274	286		|O
.	286	287		|O
After	288	293		|O
aromatization	294	307		|O
,	307	308		|O
these	309	314		|O
compounds	315	324		|O
were	325	329		|O
transformed	330	341		|O
by	342	344		|O
phosphorus	345	355	phosphorus oxychloride	|B-IUPAC
oxychloride	356	367		|I-IUPAC
,	367	368		|O
giving	369	375		|O
1	376	377	1-chloro-4-methyl-5H-pyrido[4,3- b]benzo[e]-	|B-PARTIUPAC
-	377	378		|I-PARTIUPAC
chloro	378	384		|I-PARTIUPAC
-	384	385		|I-PARTIUPAC
4	385	386		|I-PARTIUPAC
-	386	387		|I-PARTIUPAC
methyl	387	393		|I-PARTIUPAC
-	393	394		|I-PARTIUPAC
5H	394	396		|I-PARTIUPAC
-	396	397		|I-PARTIUPAC
pyrido	397	403		|I-PARTIUPAC
[	403	404		|I-PARTIUPAC
4,3	404	407		|I-PARTIUPAC
-	407	408		|I-PARTIUPAC
b	409	410		|I-PARTIUPAC
]	410	411		|I-PARTIUPAC
benzo	411	416		|I-PARTIUPAC
[	416	417		|I-PARTIUPAC
e	417	418		|I-PARTIUPAC
]	418	419		|I-PARTIUPAC
-	419	420		|I-PARTIUPAC
and	421	424		|O
-	425	426	-benzo[g]indoles	|B-PARTIUPAC
benzo	426	431		|I-PARTIUPAC
[	431	432		|I-PARTIUPAC
g	432	433		|I-PARTIUPAC
]	433	434		|I-PARTIUPAC
indoles	434	441		|I-PARTIUPAC
which	442	447		|O
were	448	452		|O
substituted	453	464		|O
by	465	467		|O
[	468	469	[(dialkylamino)alkyl]amines	|B-IUPAC
(	469	470		|I-IUPAC
dialkylamino	470	482		|I-IUPAC
)	482	483		|I-IUPAC
alkyl	483	488		|I-IUPAC
]	488	489		|I-IUPAC
amines	489	495		|I-IUPAC
.	495	496		|O
The	497	500		|O
resulting	501	510		|O
1	511	512	1-[[(dialkylamino)alkyl]amino]-4-methyl-5H-pyrido- [4,3-b]benzo[e]-	|B-PARTIUPAC
-	512	513		|I-PARTIUPAC
[	513	514		|I-PARTIUPAC
[	514	515		|I-PARTIUPAC
(	515	516		|I-PARTIUPAC
dialkylamino	516	528		|I-PARTIUPAC
)	528	529		|I-PARTIUPAC
alkyl	529	534		|I-PARTIUPAC
]	534	535		|I-PARTIUPAC
amino	535	540		|I-PARTIUPAC
]	540	541		|I-PARTIUPAC
-	541	542		|I-PARTIUPAC
4	542	543		|I-PARTIUPAC
-	543	544		|I-PARTIUPAC
methyl	544	550		|I-PARTIUPAC
-	550	551		|I-PARTIUPAC
5H	551	553		|I-PARTIUPAC
-	553	554		|I-PARTIUPAC
pyrido	554	560		|I-PARTIUPAC
-	560	561		|I-PARTIUPAC
[	562	563		|I-PARTIUPAC
4,3	563	566		|I-PARTIUPAC
-	566	567		|I-PARTIUPAC
b	567	568		|I-PARTIUPAC
]	568	569		|I-PARTIUPAC
benzo	569	574		|I-PARTIUPAC
[	574	575		|I-PARTIUPAC
e	575	576		|I-PARTIUPAC
]	576	577		|I-PARTIUPAC
-	577	578		|I-PARTIUPAC
and	579	582		|O
-	583	584	-benzo[g]indoles	|B-PARTIUPAC
benzo	584	589		|I-PARTIUPAC
[	589	590		|I-PARTIUPAC
g	590	591		|I-PARTIUPAC
]	591	592		|I-PARTIUPAC
indoles	592	599		|I-PARTIUPAC
,	599	600		|O
as	601	603		|O
well	604	608		|O
as	609	611		|O
hydroxy	611	618	 hydroxy	|B-PARTIUPAC
derivatives	620	631	derivatives	|B-MODIFIER
obtained	632	640		|O
by	641	643		|O
demethylation	644	657		|O
of	658	660		|O
methoxylated	661	673		|O
compounds	674	683		|O
with	684	688		|O
hydrobromic	689	700	hydrobromic acid	|B-IUPAC
acid	701	705		|I-IUPAC
,	705	706		|O
were	707	711		|O
tested	712	718		|O
for	719	722		|O
antitumor	723	732		|O
activity	733	741		|O
in	742	744		|O
vitro	745	750		|O
(	751	752		|O
leukemic	752	760		|O
and	761	764		|O
solid	765	770		|O
tumor	771	776		|O
cells	777	782		|O
)	782	783		|O
and	784	787		|O
in	788	790		|O
vivo	791	795		|O
on	796	798		|O
various	799	806		|O
experimental	807	819		|O
tumor	820	825		|O
models	826	832		|O
using	833	838		|O
the	839	842		|O
standard	843	851		|O
NCI	852	855		|O
protocols	856	865		|O
.	865	866		|O
1	867	868	1-[[3-(Dialkylamino)propyl]-amino]-4-methyl-9-hydroxy-5H-pyrido[4,3- b]benzo[e]indoles	|B-IUPAC
-	868	869		|I-IUPAC
[	869	870		|I-IUPAC
[	870	871		|I-IUPAC
3	871	872		|I-IUPAC
-	872	873		|I-IUPAC
(	873	874		|I-IUPAC
Dialkylamino	874	886		|I-IUPAC
)	886	887		|I-IUPAC
propyl	887	893		|I-IUPAC
]	893	894		|I-IUPAC
-	894	895		|I-IUPAC
amino	895	900		|I-IUPAC
]	900	901		|I-IUPAC
-	901	902		|I-IUPAC
4	902	903		|I-IUPAC
-	903	904		|I-IUPAC
methyl	904	910		|I-IUPAC
-	910	911		|I-IUPAC
9	911	912		|I-IUPAC
-	912	913		|I-IUPAC
hydroxy	913	920		|I-IUPAC
-	920	921		|I-IUPAC
5H	921	923		|I-IUPAC
-	923	924		|I-IUPAC
pyrido	924	930		|I-IUPAC
[	930	931		|I-IUPAC
4,3	931	934		|I-IUPAC
-	934	935		|I-IUPAC
b	936	937		|I-IUPAC
]	937	938		|I-IUPAC
benzo	938	943		|I-IUPAC
[	943	944		|I-IUPAC
e	944	945		|I-IUPAC
]	945	946		|I-IUPAC
indoles	946	953		|I-IUPAC
appeared	953	961		|O
as	963	965		|O
a	966	967		|O
promising	968	977		|O
new	978	981		|O
class	982	987		|O
of	988	990		|O
antineoplastic	991	1005		|O
agents	1006	1012		|O
.	1012	1013		|O

### 596853
596853	0	6		|O
[	8	9		|O
Synthesis	9	18		|O
and	19	22		|O
properties	23	33		|O
of	34	36		|O
carminomycinone	37	52	carminomycinone	|B-TRIVIAL
derivatives	53	64	derivatives	|B-MODIFIER
]	64	65		|O
The	67	70		|O
possibility	71	82		|O
of	83	85		|O
chemical	86	94		|O
modification	95	107		|O
of	108	110		|O
carminomycinone	111	126	carminomycinone-aglycone	|B-TRIVIAL
-	126	127		|I-TRIVIAL
aglycone	127	135		|I-TRIVIAL
(	136	137		|O
II	137	139		|O
)	139	140		|O
of	141	143		|O
carminomicin	144	156	carminomicin	|B-TRIVIAL
,	156	157		|O
a	158	159		|O
side	160	164		|O
product	165	172		|O
in	173	175		|O
the	176	179		|O
antibiotic	180	190		|O
production	191	201		|O
was	202	205		|O
studied	206	213		|O
.	213	214		|O
The	215	218		|O
methyl	219	225	methyl	|B-PARTIUPAC
group	226	231	group	|B-MODIFIER
C	232	233	C-14	|B-SUM
-	233	234		|I-SUM
14	234	236		|I-SUM
was	237	240		|O
functionilized	241	255		|O
by	256	258		|O
introducing	259	270		|O
the	271	274		|O
bromine	275	282	bromine	|B-TRIVIAL
atom	283	287	atom	|B-MODIFIER
and	288	291		|O
performing	292	302		|O
a	303	304		|O
number	305	311		|O
of	312	314		|O
exchange	315	323		|O
reactions	324	333		|O
with	334	338		|O
the	339	342		|O
bromine	343	350	bromine	|B-TRIVIAL
atom	351	355	atom	|B-MODIFIER
.	355	356		|O
It	357	359		|O
was	360	363		|O
found	364	369		|O
that	370	374		|O
under	375	380		|O
definite	381	389		|O
conditions	390	400		|O
(	401	402		|O
1	402	403		|O
.	403	404		|O
1	405	406		|O
equiv	407	412		|O
.	412	413		|O
Br2	414	417	Br2	|B-SUM
in	417	419		|O
dioxane	420	427	dioxane	|B-TRIVIAL
,	427	428		|O
degrees	432	439		|O
,	439	440		|O
24	441	443		|O
hours	444	449		|O
)	449	450		|O
carminomycinone	451	466	carminomycinone	|B-TRIVIAL
(	467	468		|O
II	468	470		|O
)	470	471		|O
was	472	475		|O
subjected	476	485		|O
to	486	488		|O
selective	489	498		|O
bromination	499	510		|O
into	511	515		|O
the	516	519		|O
side	520	524		|O
acetyl	525	531	acetyl	|B-TRIVIAL
group	532	537	group	|B-MODIFIER
with	538	542		|O
formation	543	552		|O
of	553	555		|O
14	556	558	14-bromcarminomycinone	|B-IUPAC
-	558	559		|I-IUPAC
bromcarminomycinone	559	578		|I-IUPAC
(	579	580		|O
III	580	583		|O
)	583	584		|O
.	584	585		|O
On	586	588		|O
interaction	589	600		|O
with	601	605		|O
anhydrous	606	615		|O
potassium	616	625	potassium acetate 14-bromcarminomycinone	|B-IUPAC
acetate	626	633		|I-IUPAC
14	634	636		|I-IUPAC
-	636	637		|I-IUPAC
bromcarminomycinone	637	656		|I-IUPAC
(	657	658		|O
III	658	661		|O
)	661	662		|O
yield	663	668		|O
14	669	671	14-acetoxycarminomycinone	|B-IUPAC
-	671	672		|I-IUPAC
acetoxycarminomycinone	672	694		|I-IUPAC
(	695	696		|O
IV	696	698		|O
)	698	699		|O
.	699	700		|O
In	701	703		|O
its	704	707		|O
turn	708	712		|O
the	713	716		|O
latter	717	723		|O
compound	724	732		|O
(	733	734		|O
IV	734	736		|O
)	736	737		|O
easily	738	744		|O
hydrolized	745	755		|O
to	756	758		|O
14	759	761	14-oxycarminomycinone	|B-IUPAC
-	761	762		|I-IUPAC
oxycarminomycinone	762	780		|I-IUPAC
(	781	782		|O
V	782	783		|O
)	783	784		|O
in	785	787		|O
treatment	788	797		|O
with	798	802		|O
aqueous	803	810		|O
alkali	811	817		|O
or	818	820		|O
acid	821	825		|O
.	825	826		|O
14	827	829	14-oxycarminomycinone	|B-IUPAC
-	829	830		|I-IUPAC
oxycarminomycinone	830	848		|I-IUPAC
(	849	850		|O
V	850	851		|O
)	851	852		|O
was	853	856		|O
also	857	861		|O
prepared	862	870		|O
with	871	875		|O
a	876	877		|O
high	878	882		|O
yield	883	888		|O
(	889	890		|O
per	893	896		|O
cent	897	901		|O
)	901	902		|O
by	903	905		|O
direct	906	912		|O
alkaline	913	921		|O
hydrolysis	922	932		|O
of	933	935		|O
14	936	938	14-bromcarminomycinone	|B-IUPAC
-	938	939		|I-IUPAC
bromcarminomycinone	939	958		|I-IUPAC
(	959	960		|O
III	960	963		|O
)	963	964		|O
in	965	967		|O
treatment	968	977		|O
with	978	982		|O
0.1	983	986		|O
N	986	987		|O
solution	988	996		|O
of	997	999		|O
sodium	1000	1006	sodium carbonate	|B-IUPAC
carbonate	1007	1016		|I-IUPAC
in	1017	1019		|O
a	1020	1021		|O
mixture	1022	1029		|O
of	1030	1032		|O
dioxane	1033	1040	dioxane	|B-TRIVIAL
and	1041	1044		|O
water	1045	1050		|O
.	1050	1051		|O
The	1052	1055		|O
structure	1056	1065		|O
of	1066	1068		|O
14	1069	1071		|O
-	1071	1072		|O
substituted	1072	1083		|O
derivatives	1084	1095	derivatives	|B-MODIFIER
of	1096	1098		|O
carminomycinone	1099	1114	carminomycinone	|B-TRIVIAL
was	1115	1118		|O
proved	1119	1125		|O
by	1126	1128		|O
analytical	1129	1139		|O
and	1140	1143		|O
spectral	1144	1152		|O
data	1153	1157		|O
and	1158	1161		|O
confirmed	1162	1171		|O
by	1172	1174		|O
their	1175	1180		|O
transformation	1181	1195		|O
.	1195	1196		|O
Thus	1197	1201		|O
,	1201	1202		|O
according	1203	1212		|O
to	1213	1215		|O
the	1216	1219		|O
data	1220	1224		|O
of	1225	1227		|O
mass	1228	1232		|O
-	1232	1233		|O
spectrometry	1233	1245		|O
14	1246	1248	14-oxycarminomycinone	|B-IUPAC
-	1248	1249		|I-IUPAC
oxycarminomycinone	1249	1267		|I-IUPAC
(	1268	1269		|O
V	1269	1270		|O
)	1270	1271		|O
had	1272	1275		|O
a	1276	1277		|O
molecular	1278	1287		|O
weight	1288	1294		|O
of	1295	1297		|O
c	1302	1303		|O
.	1303	1304		|O
u	1305	1306		|O
.	1306	1307		|O
In	1308	1310		|O
treatment	1311	1320		|O
with	1321	1325		|O
an	1326	1328		|O
excess	1329	1335		|O
of	1336	1338		|O
acetic	1339	1345	acetic anhydride	|B-IUPAC
anhydride	1346	1355		|I-IUPAC
in	1356	1358		|O
pyridine	1359	1367	pyridine	|B-TRIVIAL
it	1368	1370		|O
formed	1371	1377		|O
a	1378	1379		|O
hexa	1380	1384	hexa-acetyl	|B-IUPAC
-	1384	1385		|I-IUPAC
acetyl	1385	1391		|I-IUPAC
derivative	1392	1402	derivative	|B-MODIFIER
,	1402	1403		|O
i.e.	1404	1408		|O
4	1409	1410	4, 6, 7, 9, 11, 14-hexa-acetyl-14-oxycarminomycinone	|B-IUPAC
,	1410	1411		|I-IUPAC
6	1412	1413		|I-IUPAC
,	1413	1414		|I-IUPAC
7	1415	1416		|I-IUPAC
,	1416	1417		|I-IUPAC
9	1418	1419		|I-IUPAC
,	1419	1420		|I-IUPAC
11	1421	1423		|I-IUPAC
,	1423	1424		|I-IUPAC
14	1425	1427		|I-IUPAC
-	1427	1428		|I-IUPAC
hexa	1428	1432		|I-IUPAC
-	1432	1433		|I-IUPAC
acetyl	1433	1439		|I-IUPAC
-	1439	1440		|I-IUPAC
14	1440	1442		|I-IUPAC
-	1442	1443		|I-IUPAC
oxycarminomycinone	1443	1461		|I-IUPAC
(	1462	1463		|O
VI	1463	1465		|O
)	1465	1466		|O
.	1466	1467		|O
The	1468	1471		|O
aglycones	1472	1481	aglycones	|B-FAMILY
(	1482	1483		|O
III	1483	1486		|O
-	1486	1487		|O
V	1487	1488		|O
)	1488	1489		|O
prepared	1490	1498		|O
by	1499	1501		|O
us	1502	1504		|O
may	1505	1508		|O
serve	1509	1514		|O
a	1515	1516		|O
starting	1517	1525		|O
material	1526	1534		|O
in	1535	1537		|O
chemical	1538	1546		|O
synthesis	1547	1556		|O
,	1556	1557		|O
as	1558	1560		|O
well	1561	1565		|O
as	1566	1568		|O
biosynthesis	1569	1581		|O
of	1582	1584		|O
semi	1585	1589		|O
-	1589	1590		|O
synthetic	1590	1599		|O
preparations	1600	1612		|O
of	1613	1615		|O
the	1616	1619		|O
carminomycin	1620	1632	carminomycin	|B-TRIVIAL
series	1633	1639	series	|B-MODIFIER
.	1639	1640		|O

### 7040662
Adenosine	0	9		|O
5'	10	12		|O
-	12	13		|O
triphosphate	13	25		|O
(	26	27		|O
ATP	27	30	ATP	|B-ABBREVIATION
)	30	31		|O
derivatives	32	43	derivatives	|B-MODIFIER
of	44	46		|O
the	47	50		|O
types	51	56		|O
N6	57	59	N6-R-ATP	|B-ABBREVIATION
-	59	60		|I-ABBREVIATION
R	60	61		|I-ABBREVIATION
-	61	62		|I-ABBREVIATION
ATP	62	65		|I-ABBREVIATION
[	66	67		|O
R	67	68		|O
=	69	70		|O
(	71	72	(CH2)nNHCOCH2I	|B-SUM
CH2	72	75		|I-SUM
)	75	76		|I-SUM
nNHCOCH2I	76	85		|I-SUM
,	85	86		|O
(	87	88	(CH2)nNHCO-(CH2)mNHCOCH2I	|B-SUM
CH2	88	91		|I-SUM
)	91	92		|I-SUM
nNHCO	92	97		|I-SUM
-	97	98		|I-SUM
(	98	99		|I-SUM
CH2	99	102		|I-SUM
)	102	103		|I-SUM
mNHCOCH2I	103	112		|I-SUM
,	112	113		|O
or	114	116		|O
(	117	118	(CH2)nCON(Me)(CH2)mN(Me)CO(CH2)nNHCOCH2I	|B-SUM
CH2	118	121		|I-SUM
)	121	122		|I-SUM
nCON	122	126		|I-SUM
(	126	127		|I-SUM
Me	127	129		|I-SUM
)	129	130		|I-SUM
(	130	131		|I-SUM
CH2	131	134		|I-SUM
)	134	135		|I-SUM
mN	135	137		|I-SUM
(	137	138		|I-SUM
Me	138	140		|I-SUM
)	140	141		|I-SUM
CO	141	143		|I-SUM
(	143	144		|I-SUM
CH2	144	147		|I-SUM
)	147	148		|I-SUM
nNHCOCH2I	148	157		|I-SUM
]	157	158		|O
,	158	159		|O
N6	160	162	N6-Me-N6-R-ATP	|B-ABBREVIATION
-	162	163		|I-ABBREVIATION
Me	163	165		|I-ABBREVIATION
-	165	166		|I-ABBREVIATION
N6	166	168		|I-ABBREVIATION
-	168	169		|I-ABBREVIATION
R	169	170		|I-ABBREVIATION
-	170	171		|I-ABBREVIATION
ATP	171	174		|I-ABBREVIATION
[	175	176		|O
R	176	177		|O
=	178	179		|O
(	180	181	(CH2)nN-(Me)CO(CH2)mNHCOCH2I	|B-SUM
CH2	181	184		|I-SUM
)	184	185		|I-SUM
nN	185	187		|I-SUM
-	187	188		|I-SUM
(	188	189		|I-SUM
Me	189	191		|I-SUM
)	191	192		|I-SUM
CO	192	194		|I-SUM
(	194	195		|I-SUM
CH2	195	198		|I-SUM
)	198	199		|I-SUM
mNHCOCH2I	199	208		|I-SUM
]	208	209		|O
,	209	210		|O
and	211	214		|O
8	215	216	8-R-ATP	|B-ABBREVIATION
-	216	217		|I-ABBREVIATION
R	217	218		|I-ABBREVIATION
-	218	219		|I-ABBREVIATION
ATP	219	222		|I-ABBREVIATION
[	223	224		|O
R	224	225		|O
=	226	227		|O
NM	228	230	NM(CH2)nNHCOCH2I	|B-SUM
(	230	231		|I-SUM
CH2	231	234		|I-SUM
)	234	235		|I-SUM
nNHCOCH2I	235	244		|I-SUM
]	244	245		|O
with	246	250		|O
5	251	252		|O
-	252	253		|O
-	253	254		|O
19	254	256		|O
spacer	257	263		|O
atoms	264	269		|O
between	270	277		|O
N6	278	280		|O
or	281	283		|O
C	284	285		|O
-	285	286		|O
8	286	287		|O
and	288	291		|O
iodine	292	298	iodine	|B-TRIVIAL
have	299	303		|O
been	304	308		|O
evaluated	309	318		|O
as	319	321		|O
potential	322	331		|O
exo	332	335		|O
-	335	336		|O
ATP	336	339	ATP	|B-ABBREVIATION
-	339	340		|O
site	340	344		|O
-	344	345		|O
directed	345	353		|O
reagents	354	362		|O
for	363	366		|O
phosphokinases	367	381		|O
.	381	382		|O
Substrate	383	392		|O
and	393	396		|O
inhibitor	397	406		|O
properties	407	417		|O
indicated	418	427		|O
that	428	432		|O
the	433	436		|O
compounds	437	446		|O
possessed	447	456		|O
affinity	457	465		|O
for	466	469		|O
the	470	473		|O
ATP	474	477	ATP	|B-ABBREVIATION
sites	478	483		|O
of	484	486		|O
the	487	490		|O
muscle	491	497		|O
(	498	499		|O
M	499	500		|O
)	500	501		|O
,	501	502		|O
kidney	503	509		|O
(	510	511		|O
K	511	512		|O
)	512	513		|O
,	513	514		|O
and	515	518		|O
liver	519	524		|O
(	525	526		|O
L	526	527		|O
)	527	528		|O
isozymes	529	537		|O
of	538	540		|O
rat	541	544		|O
pyruvate	545	553		|O
kinase	554	560		|O
(	561	562		|O
PK	562	564		|O
)	564	565		|O
,	565	566		|O
of	567	569		|O
E	570	571		|O
.	571	572		|O
coli	573	577		|O
thymidine	578	587		|O
kinase	588	594		|O
(	595	596		|O
TK	596	598		|O
)	598	599		|O
,	599	600		|O
and	601	604		|O
of	605	607		|O
yeast	608	613		|O
hexokinase	614	624		|O
(	625	626		|O
HK	626	628		|O
)	628	629		|O
and	630	633		|O
rat	634	637		|O
KH	638	640		|O
I	641	642		|O
,	642	643		|O
II	644	646		|O
,	646	647		|O
and	648	651		|O
III	652	655		|O
isozymes	656	664		|O
.	664	665		|O
Tests	666	671		|O
for	672	675		|O
time	676	680		|O
-	680	681		|O
dependent	681	690		|O
loss	691	695		|O
of	696	698		|O
enzyme	699	705		|O
activity	706	714		|O
(	715	716		|O
inactivation	716	728		|O
)	728	729		|O
were	730	734		|O
performed	735	744		|O
under	745	750		|O
conditions	751	761		|O
in	762	764		|O
which	765	770		|O
a	771	772		|O
large	773	778		|O
proportion	779	789		|O
of	790	792		|O
each	793	797		|O
phosphokinase	798	811		|O
was	812	815		|O
present	816	823		|O
as	824	826		|O
an	827	829		|O
enzyme	830	836		|O
-	836	837		|O
inhibitor	837	846		|O
complex	847	854		|O
.	854	855		|O
No	856	858		|O
ATP	859	862	ATP	|B-ABBREVIATION
-	862	863		|O
site	863	867		|O
-	867	868		|O
directed	868	876		|O
inactivations	877	890		|O
resulted	891	899		|O
when	900	904		|O
the	905	908		|O
M	909	910		|O
,	910	911		|O
L	912	913		|O
,	913	914		|O
or	915	917		|O
K	918	919		|O
isozymes	920	928		|O
of	929	931		|O
PK	932	934		|O
were	935	939		|O
exposed	940	947		|O
for	948	951		|O
8	952	953		|O
h	954	955		|O
,	955	956		|O
22	957	959		|O
degrees	960	967		|O
C	968	969		|O
,	969	970		|O
to	971	973		|O
5	974	975		|O
mM	976	978		|O
levels	979	985		|O
of	986	988		|O
18	989	991		|O
ATP	992	995	ATP	|B-ABBREVIATION
derivatives	996	1007	derivatives	|B-MODIFIER
or	1008	1010		|O
6	1011	1012		|O
analogous	1013	1022		|O
ADP	1023	1026	ADP	|B-ABBREVIATION
derivatives	1027	1038	derivatives	|B-MODIFIER
or	1039	1041		|O
when	1042	1046		|O
yeast	1047	1052		|O
HK	1053	1055		|O
or	1056	1058		|O
rat	1059	1062		|O
KH	1063	1065		|O
I	1066	1067		|O
,	1067	1068		|O
II	1069	1071		|O
,	1071	1072		|O
or	1073	1075		|O
III	1076	1079		|O
was	1080	1083		|O
exposed	1084	1091		|O
for	1092	1095		|O
6	1096	1097		|O
h	1098	1099		|O
,	1099	1100		|O
22	1101	1103		|O
degrees	1104	1111		|O
C	1112	1113		|O
,	1113	1114		|O
to	1115	1117		|O
5	1118	1119		|O
mM	1120	1122		|O
levels	1123	1129		|O
of	1130	1132		|O
28	1133	1135		|O
ATP	1136	1139	ATP	|B-ABBREVIATION
derivatives	1140	1151	derivatives	|B-MODIFIER
.	1151	1152		|O
Escherichia	1153	1164		|O
coli	1165	1169		|O
TK	1170	1172		|O
was	1173	1176		|O
inactivated	1177	1188		|O
by	1189	1191		|O
6	1192	1193		|O
of	1194	1196		|O
25	1197	1199		|O
ATP	1200	1203		|O
derivatives	1204	1215		|O
tested	1216	1222		|O
at	1223	1225		|O
mM	1229	1231		|O
,	1231	1232		|O
6	1233	1234		|O
h	1235	1236		|O
,	1236	1237		|O
0	1238	1239		|O
degrees	1240	1247		|O
C	1248	1249		|O
;	1249	1250		|O
inactivation	1251	1263		|O
was	1264	1267		|O
slowed	1268	1274		|O
by	1275	1277		|O
MgATP	1278	1283	MgATP	|B-ABBREVIATION
in	1284	1286		|O
the	1287	1290		|O
case	1291	1295		|O
of	1296	1298		|O
N6	1299	1301	N6-CH3-N6-R-ATP	|B-ABBREVIATION
-	1301	1302		|I-ABBREVIATION
CH3	1302	1305		|I-ABBREVIATION
-	1305	1306		|I-ABBREVIATION
N6	1306	1308		|I-ABBREVIATION
-	1308	1309		|I-ABBREVIATION
R	1309	1310		|I-ABBREVIATION
-	1310	1311		|I-ABBREVIATION
ATP	1311	1314		|I-ABBREVIATION
[	1315	1316		|O
R	1316	1317		|O
=	1318	1319		|O
(	1320	1321	(CH2)4N(CH3)CO(CH2)5NHCOCH2I	|B-SUM
CH2	1321	1324		|I-SUM
)	1324	1325		|I-SUM
4N	1325	1327		|I-SUM
(	1327	1328		|I-SUM
CH3	1328	1331		|I-SUM
)	1331	1332		|I-SUM
CO	1332	1334		|I-SUM
(	1334	1335		|I-SUM
CH2	1335	1338		|I-SUM
)	1338	1339		|I-SUM
5NHCOCH2I	1339	1348		|I-SUM
]	1348	1349		|O
.	1349	1350		|O
Only	1351	1355		|O
1%	1356	1358		|O
of	1359	1361		|O
298	1362	1365		|O
enzyme	1366	1372		|O
-	1372	1373		|O
inhibitor	1373	1382		|O
combinations	1383	1395		|O
exhibited	1396	1405		|O
ATP	1406	1409	ATP	|B-ABBREVIATION
-	1409	1410		|O
site	1410	1414		|O
-	1414	1415		|O
directed	1415	1423		|O
inactivation	1424	1436		|O
,	1436	1437		|O
signifying	1438	1448		|O
that	1449	1453		|O
few	1454	1457		|O
suitably	1458	1466		|O
positioned	1467	1477		|O
and	1478	1481		|O
sufficiently	1482	1494		|O
reactive	1495	1503		|O
nucleophilic	1504	1516		|O
groups	1517	1523		|O
were	1524	1528		|O
present	1529	1536		|O
near	1537	1541		|O
the	1542	1545		|O
enzymic	1546	1553		|O
ATP	1554	1557	ATP	|B-ABBREVIATION
sites	1557	1562		|O
.	1563	1564		|O
Studies	1565	1572		|O
have	1573	1577		|O
now	1578	1581		|O
shown	1582	1587		|O
that	1588	1592		|O
exo	1593	1596		|O
-	1596	1597		|O
active	1597	1603		|O
-	1603	1604		|O
site	1604	1608		|O
-	1608	1609		|O
directed	1609	1617		|O
reagents	1618	1626		|O
can	1627	1630		|O
act	1631	1634		|O
as	1635	1637		|O
isozyme	1638	1645		|O
-	1645	1646		|O
or	1647	1649		|O
species	1650	1657		|O
-	1657	1658		|O
selective	1658	1667		|O
enzyme	1668	1674		|O
inhibitors	1675	1685		|O
.	1685	1686		|O
The	1687	1690		|O
present	1691	1698		|O
survey	1699	1705		|O
indicates	1706	1715		|O
that	1716	1720		|O
in	1721	1723		|O
many	1724	1728		|O
cases	1729	1734		|O
such	1735	1739		|O
reagents	1740	1748		|O
may	1749	1752		|O
be	1753	1755		|O
difficult	1756	1765		|O
of	1766	1768		|O
access	1769	1775		|O
when	1776	1780		|O
data	1781	1785		|O
are	1786	1789		|O
not	1790	1793		|O
available	1794	1803		|O
regarding	1804	1813		|O
structural	1814	1824		|O
or	1825	1827		|O
physicochemical	1828	1843		|O
features	1844	1852		|O
of	1853	1855		|O
the	1856	1859		|O
target	1860	1866		|O
enzyme	1867	1873		|O
adjacent	1874	1882		|O
to	1883	1885		|O
its	1886	1889		|O
catalytic	1890	1899		|O
site	1900	1904		|O
.	1904	1905		|O

### 2944474
2944474	0	7		|O
Effect	9	15		|O
of	16	18		|O
recombinant	19	30		|O
human	31	36		|O
fibroblast	37	47		|O
interferon	48	58		|O
and	59	62		|O
mezerein	63	71	mezerein	|B-TRIVIAL
on	72	74		|O
growth	75	81		|O
,	81	82		|O
differentiation	83	98		|O
,	98	99		|O
immune	100	106		|O
interferon	107	117		|O
binding	118	125		|O
and	126	129		|O
tumor	130	135		|O
associated	136	146		|O
antigen	147	154		|O
expression	155	165		|O
in	166	168		|O
human	169	174		|O
melanoma	175	183		|O
cells	184	189		|O
.	189	190		|O
The	192	195		|O
combination	196	207		|O
of	208	210		|O
recombinant	211	222		|O
human	223	228		|O
fibroblast	229	239		|O
interferon	240	250		|O
(	251	252		|O
INF	252	255		|O
-	255	256		|O
delta	256	261		|O
)	261	262		|O
and	263	266		|O
the	267	270		|O
antileukemic	271	283		|O
compound	284	292		|O
mezerein	293	301	mezerein	|B-TRIVIAL
(	302	303		|O
MEZ	303	306	MEZ	|B-ABBREVIATION
)	306	307		|O
results	308	315		|O
in	316	318		|O
a	319	320		|O
synergistic	321	332		|O
suppression	333	344		|O
in	345	347		|O
the	348	351		|O
growth	352	358		|O
of	359	361		|O
human	362	367		|O
melanoma	368	376		|O
cells	377	382		|O
and	383	386		|O
a	387	388		|O
concomitant	389	400		|O
increase	401	409		|O
in	410	412		|O
melanin	413	420	melanin	|B-TRIVIAL
synthesis	421	430		|O
.	430	431		|O
In	432	434		|O
the	435	438		|O
present	439	446		|O
study	447	452		|O
we	453	455		|O
have	456	460		|O
further	461	468		|O
analyzed	469	477		|O
this	478	482		|O
synergistic	483	494		|O
interaction	495	506		|O
and	507	510		|O
have	511	515		|O
also	516	520		|O
evaluated	521	530		|O
the	531	534		|O
effect	535	541		|O
of	542	544		|O
IFN	545	548		|O
-	548	549		|O
delta	549	554		|O
and	555	558		|O
MEZ	559	562	MEZ	|B-ABBREVIATION
,	562	563		|O
alone	564	569		|O
and	570	573		|O
in	574	576		|O
combination	577	588		|O
,	588	589		|O
on	590	592		|O
recombinant	593	604		|O
human	605	610		|O
gamma	611	616		|O
interferon	617	627		|O
(	628	629		|O
IFN	629	632		|O
-	632	633		|O
gamma	633	638		|O
)	638	639		|O
binding	640	647		|O
and	648	651		|O
Class	652	657		|O
I	658	659		|O
HLA	660	663		|O
and	664	667		|O
melanoma	668	676		|O
associated	677	687		|O
antigen	688	695		|O
(	696	697		|O
MAA	697	700		|O
)	700	701		|O
expression	702	712		|O
in	713	715		|O
the	716	719		|O
HO	720	722		|O
-	722	723		|O
1	723	724		|O
human	725	730		|O
melanoma	731	739		|O
cell	740	744		|O
line	745	749		|O
.	749	750		|O
Single	751	757		|O
cell	758	762		|O
clones	763	769		|O
isolated	770	778		|O
from	779	783		|O
the	784	787		|O
HO	788	790		|O
-	790	791		|O
1	791	792		|O
cell	793	797		|O
line	798	802		|O
varied	803	809		|O
in	810	812		|O
their	813	818		|O
sensitivity	819	830		|O
to	831	833		|O
the	834	837		|O
antiproliferative	838	855		|O
effects	856	863		|O
of	864	866		|O
IFN	867	870		|O
-	870	871		|O
delta	871	876		|O
and	877	880		|O
MEZ	881	884	MEZ	|B-ABBREVIATION
.	884	885		|O
With	886	890		|O
all	891	894		|O
twelve	895	901		|O
clones	902	908		|O
,	908	909		|O
however	910	917		|O
,	917	918		|O
the	919	922		|O
combination	923	934		|O
of	935	937		|O
IFN	938	941		|O
-	941	942		|O
delta	942	947		|O
plus	948	952		|O
MEZ	953	956	MEZ	|B-ABBREVIATION
was	957	960		|O
more	961	965		|O
growth	966	972		|O
inhibitory	973	983		|O
than	984	988		|O
either	989	995		|O
agent	996	1001		|O
used	1002	1006		|O
alone	1007	1012		|O
,	1012	1013		|O
even	1014	1018		|O
in	1019	1021		|O
HO	1022	1024		|O
-	1024	1025		|O
1	1025	1026		|O
subclones	1027	1036		|O
displaying	1037	1047		|O
relative	1048	1056		|O
resistance	1057	1067		|O
to	1068	1070		|O
IFN	1071	1074		|O
-	1074	1075		|O
delta	1075	1080		|O
.	1080	1081		|O
By	1082	1084		|O
continuous	1085	1095		|O
growth	1096	1102		|O
in	1103	1105		|O
gradually	1106	1115		|O
increasing	1116	1126		|O
concentrations	1127	1141		|O
of	1142	1144		|O
IFN	1145	1148		|O
-	1148	1149		|O
delta	1149	1154		|O
,	1154	1155		|O
a	1156	1157		|O
variant	1158	1165		|O
population	1166	1176		|O
of	1177	1179		|O
HO	1180	1182		|O
-	1182	1183		|O
1	1183	1184		|O
cells	1185	1190		|O
,	1190	1191		|O
HO	1192	1194		|O
-	1194	1195		|O
1	1195	1196		|O
delta	1197	1202		|O
R	1203	1204		|O
-	1204	1205		|O
D	1205	1206		|O
,	1206	1207		|O
was	1208	1211		|O
generated	1212	1221		|O
which	1222	1227		|O
was	1228	1231		|O
more	1232	1236		|O
resistant	1237	1246		|O
to	1247	1249		|O
the	1250	1253		|O
antigrowth	1254	1264		|O
effects	1265	1272		|O
of	1273	1275		|O
IFN	1276	1279		|O
-	1279	1280		|O
delta	1280	1285		|O
than	1286	1290		|O
the	1291	1294		|O
original	1295	1303		|O
HO	1304	1306		|O
-	1306	1307		|O
1	1307	1308		|O
parental	1309	1317		|O
cell	1318	1322		|O
line	1323	1327		|O
.	1327	1328		|O
In	1329	1331		|O
the	1332	1335		|O
IFN	1336	1339		|O
delta	1340	1345		|O
R	1346	1347		|O
-	1347	1348		|O
D	1348	1349		|O
cell	1350	1354		|O
line	1355	1359		|O
the	1360	1363		|O
combination	1364	1375		|O
of	1376	1378		|O
IFN	1379	1382		|O
-	1382	1383		|O
delta	1383	1388		|O
plus	1389	1393		|O
MEZ	1394	1397	MEZ	|B-ABBREVIATION
synergistically	1398	1413		|O
suppressed	1414	1424		|O
growth	1425	1431		|O
.	1431	1432		|O
Exposure	1433	1441		|O
of	1442	1444		|O
HO	1445	1447		|O
-	1447	1448		|O
1	1448	1449		|O
cells	1450	1455		|O
to	1456	1458		|O
units	1464	1469		|O
/	1469	1470		|O
ml	1470	1472		|O
IFN	1473	1476		|O
-	1476	1477		|O
delta	1477	1482		|O
or	1483	1485		|O
ng	1489	1491		|O
/	1491	1492		|O
ml	1492	1494		|O
MEZ	1495	1498	MEZ	|B-ABBREVIATION
for	1499	1502		|O
96	1503	1505		|O
hr	1506	1508		|O
resulted	1509	1517		|O
in	1518	1520		|O
no	1521	1523		|O
change	1524	1530		|O
or	1531	1533		|O
an	1534	1536		|O
increase	1537	1545		|O
in	1546	1548		|O
the	1549	1552		|O
binding	1553	1560		|O
of	1561	1563		|O
labelled	1564	1572		|O
IFN	1573	1576		|O
-	1576	1577		|O
gamma	1577	1582		|O
to	1583	1585		|O
surface	1586	1593		|O
receptors	1594	1603		|O
,	1603	1604		|O
whereas	1605	1612		|O
the	1613	1616		|O
combination	1617	1628		|O
of	1629	1631		|O
IFN	1632	1635		|O
-	1635	1636		|O
delta	1636	1641		|O
plus	1642	1646		|O
MEZ	1647	1650	MEZ	|B-ABBREVIATION
increased	1651	1660		|O
IFN	1661	1664		|O
-	1664	1665		|O
gamma	1665	1670		|O
binding	1671	1678		|O
2	1679	1680		|O
-	1680	1681		|O
to	1681	1683		|O
-	1683	1684		|O
4	1684	1685		|O
-	1685	1686		|O
fold	1686	1690		|O
in	1691	1693		|O
HO	1694	1696		|O
-	1696	1697		|O
1	1697	1698		|O
cells	1699	1704		|O
.	1704	1705		|O
This	1706	1710		|O
increase	1711	1719		|O
was	1720	1723		|O
the	1724	1727		|O
result	1728	1734		|O
of	1735	1737		|O
an	1738	1740		|O
increase	1741	1749		|O
in	1750	1752		|O
the	1753	1756		|O
number	1757	1763		|O
of	1764	1766		|O
receptors	1767	1776		|O
on	1777	1779		|O
treated	1780	1787		|O
cells	1788	1793		|O
coupled	1794	1801		|O
with	1802	1806		|O
a	1807	1808		|O
protection	1809	1819		|O
against	1820	1827		|O
a	1828	1829		|O
decrease	1830	1838		|O
in	1839	1841		|O
receptors	1842	1851		|O
observed	1852	1860		|O
for	1861	1864		|O
confluent	1865	1874		|O
untreated	1875	1884		|O
cells	1885	1890		|O
.	1890	1891		|O
Changes	1892	1899		|O
in	1900	1902		|O
IFN	1903	1906		|O
-	1906	1907		|O
gamma	1907	1912		|O
binding	1913	1920		|O
resulting	1921	1930		|O
from	1931	1935		|O
treatment	1936	1945		|O
with	1946	1950		|O
IFN	1951	1954		|O
-	1954	1955		|O
delta	1955	1960		|O
plus	1961	1965		|O
MEZ	1966	1969	MEZ	|B-ABBREVIATION
were	1970	1974		|O
not	1975	1978		|O
associated	1979	1989		|O
with	1990	1994		|O
alterations	1995	2006		|O
in	2007	2009		|O
the	2010	2013		|O
binding	2014	2021		|O
affinity	2022	2030		|O
of	2031	2033		|O
INF	2034	2037		|O
-	2037	2038		|O
gamma	2038	2043		|O
to	2044	2046		|O
its	2047	2050		|O
receptor	2051	2059		|O
.	2059	2060		|O
Changes	2061	2068		|O
were	2069	2073		|O
also	2074	2078		|O
observed	2079	2087		|O
in	2088	2090		|O
the	2091	2094		|O
expression	2095	2105		|O
of	2106	2108		|O
HLA	2109	2112		|O
Class	2113	2118		|O
I	2119	2120		|O
antigens	2121	2129		|O
and	2130	2133		|O
MAAs	2134	2138		|O
following	2139	2148		|O
treatment	2149	2158		|O
of	2159	2161		|O
HO	2162	2164		|O
-	2164	2165		|O
1	2165	2166		|O
cells	2167	2172		|O
with	2173	2177		|O
IFN	2178	2181		|O
-	2181	2182		|O
delta	2182	2187		|O
,	2187	2188		|O
MEZ	2189	2192	MEZ	|B-ABBREVIATION
or	2193	2195		|O
IFN	2196	2199		|O
-	2199	2200		|O
delta	2200	2205		|O
plus	2206	2210		|O
MEZ	2211	2214	MEZ	|B-ABBREVIATION
.	2214	2215		|O
IFN	2216	2219		|O
-	2219	2220		|O
delta	2220	2225		|O
and	2226	2229		|O
MEZ	2230	2233	MEZ	|B-ABBREVIATION
increased	2233	2242		|O
the	2244	2247		|O
expression	2248	2258		|O
of	2259	2261		|O
HLA	2262	2265		|O
Class	2266	2271		|O
I	2272	2273		|O
antigens	2274	2282		|O
a	2283	2284		|O
96	2285	2287		|O
kd	2288	2290		|O
MAA	2291	2294		|O
defined	2295	2302		|O
by	2303	2305		|O
MoAb	2306	2310		|O
CL203	2311	2316		|O
,	2316	2317		|O
a	2318	2319		|O
kd	2324	2326		|O
MAA	2327	2330		|O
defined	2331	2338		|O
by	2339	2341		|O
MoAb	2342	2346		|O
376.96	2347	2353		|O
and	2354	2357		|O
a	2358	2359		|O
115	2360	2363		|O
kd	2364	2366		|O
MAA	2367	2370		|O
defined	2371	2378		|O
by	2379	2381		|O
MoAb	2382	2386		|O
345.134	2387	2394		|O
but	2395	2398		|O
decreased	2399	2408		|O
the	2409	2412		|O
expression	2413	2423		|O
of	2424	2426		|O
a	2427	2428		|O
high	2429	2433		|O
molecular	2434	2443		|O
weight	2444	2450		|O
-	2450	2451		|O
melanoma	2451	2459		|O
associated	2460	2470		|O
antigen	2471	2478		|O
(	2479	2480		|O
HMW	2480	2483		|O
-	2483	2484		|O
MAA	2484	2487		|O
)	2487	2488		|O
defined	2489	2496		|O
by	2497	2499		|O
MoAb	2500	2504		|O
325.28	2505	2511		|O
S	2511	2512		|O
.	2512	2513		|O
(	2513	2514		|O
ABSTRACT	2514	2522		|O
TRUNCATED	2523	2532		|O
AT	2533	2535		|O
WORDS	2540	2545		|O
)	2545	2546		|O

### 16033265
Degarelix	0	9		|O
(	10	11		|O
FE200486	11	19	FE200486	|B-TRIVIALVAR
,	19	20		|O
Ac	21	23	Ac-d-2Nal(1)-d-4Cpa(2)-d-3Pal(3)-Ser(4)-4Aph(l-Hor)(5)-d-4Aph(Cbm)(6)-Leu(7)-ILys(8)-Pro(9)-d-Ala(10)-NH(2)	|O
-	23	24		|O
d	24	25		|O
-	25	26		|O
2Nal	26	30		|O
(	30	31		|O
1	31	32		|O
)	32	33		|O
-	33	34		|O
d	34	35		|O
-	35	36		|O
4Cpa	36	40		|O
(	40	41		|O
2	41	42		|O
)	42	43		|O
-	43	44		|O
d	44	45		|O
-	45	46		|O
3Pal	46	50		|O
(	50	51		|O
3	51	52		|O
)	52	53		|O
-	53	54		|O
Ser	54	57		|O
(	57	58		|O
4	58	59		|O
)	59	60		|O
-	60	61		|O
4Aph	61	65		|O
(	65	66		|O
l	66	67		|O
-	67	68		|O
Hor	68	71		|O
)	71	72		|O
(	72	73		|O
5	73	74		|O
)	74	75		|O
-	75	76		|O
d	76	77		|O
-	77	78		|O
4Aph	78	82		|O
(	82	83		|O
Cbm	83	86		|O
)	86	87		|O
(	87	88		|O
6	88	89		|O
)	89	90		|O
-	90	91		|O
Leu	91	94		|O
(	94	95		|O
7	95	96		|O
)	96	97		|O
-	97	98		|O
ILys	98	102		|O
(	102	103		|O
8	103	104		|O
)	104	105		|O
-	105	106		|O
Pro	106	109		|O
(	109	110		|O
9	110	111		|O
)	111	112		|O
-	112	113		|O
d	113	114		|O
-	114	115		|O
Ala	115	118		|O
(	118	119		|O
)	121	122		|O
-	122	123		|O
NH	123	125		|O
(	125	126		|O
2	126	127		|O
)	127	128		|O
)	128	129		|O
is	130	132		|O
a	133	134		|O
potent	135	141		|O
and	142	145		|O
very	146	150		|O
long	151	155		|O
acting	156	162		|O
antagonist	163	173		|O
of	174	176		|O
gonadotropin	177	189		|O
-	189	190		|O
releasing	190	199		|O
hormone	200	207		|O
(	208	209		|O
GnRH	209	213		|O
)	213	214		|O
after	215	220		|O
subcutaneous	221	233		|O
administration	234	248		|O
in	249	251		|O
mammals	252	259		|O
including	260	269		|O
humans	270	276		|O
.	276	277		|O
Analogues	278	287		|O
of	288	290		|O
degarelix	291	300	degarelix	|B-TRIVIAL
were	301	305		|O
synthesized	306	317		|O
,	317	318		|O
characterized	319	332		|O
,	332	333		|O
and	334	337		|O
screened	338	346		|O
for	347	350		|O
the	351	354		|O
antagonism	355	365		|O
of	366	368		|O
GnRH	369	373		|O
-	373	374		|O
induced	374	381		|O
response	382	390		|O
in	391	393		|O
a	394	395		|O
reporter	396	404		|O
gene	405	409		|O
assay	410	415		|O
in	416	418		|O
HEK	419	422		|O
-	422	423		|O
293	423	426		|O
cells	427	432		|O
expressing	433	443		|O
the	444	447		|O
human	448	453		|O
GnRH	454	458		|O
receptor	459	467		|O
.	467	468		|O
The	469	472		|O
duration	473	481		|O
of	482	484		|O
action	485	491		|O
was	492	495		|O
also	496	500		|O
determined	501	511		|O
in	512	514		|O
the	515	518		|O
castrated	519	528		|O
male	529	533		|O
rat	534	537		|O
assay	538	543		|O
to	544	546		|O
measure	547	554		|O
the	555	558		|O
extent	559	565		|O
(	566	567		|O
efficacy	567	575		|O
and	576	579		|O
duration	580	588		|O
of	589	591		|O
action	592	598		|O
)	598	599		|O
of	600	602		|O
inhibition	603	613		|O
of	614	616		|O
luteinizing	617	628		|O
hormone	629	636		|O
(	637	638		|O
LH	638	640		|O
)	640	641		|O
release	642	649		|O
.	649	650		|O
Structurally	651	663		|O
,	663	664		|O
this	665	669		|O
series	670	676		|O
of	677	679		|O
analogues	680	689		|O
has	690	693		|O
novel	694	699		|O
substitutions	700	713		|O
at	714	716		|O
positions	717	726		|O
3	727	728		|O
,	728	729		|O
7	730	731		|O
,	731	732		|O
and	733	736		|O
8	737	738		|O
and	739	742		|O
N	743	744		|O
(	744	745		|O
alpha	745	750		|O
)	750	751		|O
-	751	752		|O
methylation	752	763		|O
at	764	766		|O
positions	767	776		|O
6	777	778		|O
,	778	779		|O
7	780	781		|O
,	781	782		|O
and	783	786		|O
8	787	788		|O
in	789	791		|O
the	792	795		|O
structure	796	805		|O
of	806	808		|O
degarelix	809	818	degarelix	|B-TRIVIAL
.	818	819		|O
These	820	825		|O
substitutions	826	839		|O
were	840	844		|O
designed	845	853		|O
to	854	856		|O
probe	857	862		|O
the	863	866		|O
spatial	867	874		|O
limitations	875	886		|O
of	887	889		|O
the	890	893		|O
receptor	894	902		|O
's	902	904		|O
cavity	905	911		|O
and	912	915		|O
to	916	918		|O
map	919	922		|O
the	923	926		|O
steric	927	933		|O
and	934	937		|O
ionic	938	943		|O
boundaries	944	954		|O
.	954	955		|O
Some	956	960		|O
functional	961	971		|O
groups	972	978		|O
were	979	983		|O
introduced	984	994		|O
that	995	999		|O
were	1000	1004		|O
hypothesized	1005	1017		|O
to	1018	1020		|O
influence	1021	1030		|O
the	1031	1034		|O
phamacokinetic	1035	1049		|O
properties	1050	1060		|O
of	1061	1063		|O
the	1064	1067		|O
analogues	1068	1077		|O
such	1078	1082		|O
as	1083	1085		|O
bioavailability	1086	1101		|O
,	1101	1102		|O
solubility	1103	1113		|O
,	1113	1114		|O
intra	1115	1120		|O
-	1120	1121		|O
or	1122	1124		|O
intermolecular	1125	1139		|O
hydrogen	1140	1148		|O
bond	1149	1153		|O
forming	1154	1161		|O
capacity	1162	1170		|O
,	1170	1171		|O
and	1172	1175		|O
ability	1176	1183		|O
to	1184	1186		|O
bind	1187	1191		|O
carrier	1192	1199		|O
proteins	1200	1208		|O
.	1208	1209		|O
Substitutions	1210	1223		|O
at	1224	1226		|O
positions	1227	1236		|O
3	1237	1238		|O
(	1239	1240		|O
[	1240	1241	[N(beta)-(2-pyridyl-methyl)d-Dap(3)]degarelix	|B-IUPAC
N	1241	1242		|I-IUPAC
(	1242	1243		|I-IUPAC
beta	1243	1247		|I-IUPAC
)	1247	1248		|I-IUPAC
-	1248	1249		|I-IUPAC
(	1249	1250		|I-IUPAC
2	1250	1251		|I-IUPAC
-	1251	1252		|I-IUPAC
pyridyl	1252	1259		|I-IUPAC
-	1259	1260		|I-IUPAC
methyl	1260	1266		|I-IUPAC
)	1266	1267		|I-IUPAC
d	1267	1268		|I-IUPAC
-	1268	1269		|I-IUPAC
Dap	1269	1272		|I-IUPAC
(	1272	1273		|I-IUPAC
3	1273	1274		|I-IUPAC
)	1274	1275		|I-IUPAC
]	1275	1276		|I-IUPAC
degarelix	1276	1285		|I-IUPAC
,	1285	1286		|O
IC	1287	1289		|O
(	1289	1290		|O
)	1292	1293		|O
=	1294	1295		|O
2.71	1296	1300		|O
nM	1301	1303		|O
)	1303	1304		|O
(	1305	1306		|O
5	1306	1307		|O
)	1307	1308		|O
,	1308	1309		|O
7	1310	1311		|O
(	1312	1313		|O
[	1313	1314	[Pra(7)]degarelix	|B-TRIVIAL
Pra	1314	1317		|I-TRIVIAL
(	1317	1318		|I-TRIVIAL
7	1318	1319		|I-TRIVIAL
)	1319	1320		|I-TRIVIAL
]	1320	1321		|I-TRIVIAL
degarelix	1321	1330		|I-TRIVIAL
,	1330	1331		|O
IC	1332	1334		|O
(	1334	1335		|O
)	1337	1338		|O
=	1339	1340		|O
2.11	1341	1345		|O
nM	1346	1348		|O
)	1348	1349		|O
(	1350	1351		|O
16	1351	1353		|O
)	1353	1354		|O
,	1354	1355		|O
and	1356	1359		|O
8	1360	1361		|O
(	1362	1363		|O
[	1363	1364	[N(delta)-(IGly)Orn(8)]degarelix	|B-IUPAC
N	1364	1365		|I-IUPAC
(	1365	1366		|I-IUPAC
delta	1366	1371		|I-IUPAC
)	1371	1372		|I-IUPAC
-	1372	1373		|I-IUPAC
(	1373	1374		|I-IUPAC
IGly	1374	1378		|I-IUPAC
)	1378	1379		|I-IUPAC
Orn	1379	1382		|I-IUPAC
(	1382	1383		|I-IUPAC
8	1383	1384		|I-IUPAC
)	1384	1385		|I-IUPAC
]	1385	1386		|I-IUPAC
degarelix	1386	1395		|I-IUPAC
,	1395	1396		|O
IC	1397	1399		|O
(	1399	1400		|O
)	1402	1403		|O
=	1404	1405		|O
1.38	1406	1410		|O
nM	1411	1413		|O
)	1413	1414		|O
(	1415	1416		|O
)	1418	1419		|O
and	1420	1423		|O
N	1424	1425		|O
-	1425	1426		|O
methylation	1426	1437		|O
(	1438	1439		|O
[	1439	1440	[N(alpha)-methyl-Leu(7)]degarelix	|B-IUPAC
N	1440	1441		|I-IUPAC
(	1441	1442		|I-IUPAC
alpha	1442	1447		|I-IUPAC
)	1447	1448		|I-IUPAC
-	1448	1449		|I-IUPAC
methyl	1449	1455		|I-IUPAC
-	1455	1456		|I-IUPAC
Leu	1456	1459		|I-IUPAC
(	1459	1460		|I-IUPAC
7	1460	1461		|I-IUPAC
)	1461	1462		|I-IUPAC
]	1462	1463		|I-IUPAC
degarelix	1463	1472		|I-IUPAC
,	1472	1473		|O
IC	1474	1476		|O
(	1476	1477		|O
)	1479	1480		|O
=	1481	1482		|O
1.47	1483	1487		|O
nM	1488	1490		|O
)	1490	1491		|O
(	1492	1493		|O
32	1493	1495		|O
)	1495	1496		|O
yielded	1497	1504		|O
analogues	1505	1514		|O
that	1515	1519		|O
were	1520	1524		|O
equipotent	1525	1535		|O
to	1536	1538		|O
degarelix	1539	1548	degarelix	|B-TRIVIAL
(	1549	1550		|O
2	1550	1551		|O
)	1551	1552		|O
in	1553	1555		|O
vitro	1556	1561		|O
(	1562	1563		|O
IC	1563	1565		|O
(	1565	1566		|O
)	1568	1569		|O
=	1570	1571		|O
1.64	1572	1576		|O
nM	1577	1579		|O
)	1579	1580		|O
but	1581	1584		|O
shorter	1585	1592		|O
acting	1593	1599		|O
in	1600	1602		|O
vivo	1603	1607		|O
.	1607	1608		|O
Out	1609	1612		|O
of	1613	1615		|O
the	1616	1619		|O
33	1620	1622		|O
novel	1623	1628		|O
analogues	1629	1638		|O
tested	1639	1645		|O
for	1646	1649		|O
the	1650	1653		|O
duration	1654	1662		|O
of	1663	1665		|O
action	1666	1672		|O
in	1673	1675		|O
this	1676	1680		|O
series	1681	1687		|O
,	1687	1688		|O
two	1689	1692		|O
analogues	1693	1702		|O
(	1703	1704		|O
[	1704	1705	[N(epsilon)-cyclohexyl-Lys(8)]degarelix	|B-IUPAC
N	1705	1706		|I-IUPAC
(	1706	1707		|I-IUPAC
epsilon	1707	1714		|I-IUPAC
)	1714	1715		|I-IUPAC
-	1715	1716		|I-IUPAC
cyclohexyl	1716	1726		|I-IUPAC
-	1726	1727		|I-IUPAC
Lys	1727	1730		|I-IUPAC
(	1730	1731		|I-IUPAC
8	1731	1732		|I-IUPAC
)	1732	1733		|I-IUPAC
]	1733	1734		|I-IUPAC
degarelix	1734	1743		|I-IUPAC
,	1743	1744		|O
IC	1745	1747		|O
(	1747	1748		|O
)	1750	1751		|O
=	1752	1753		|O
1.50	1754	1758		|O
nM	1759	1761		|O
)	1761	1762		|O
(	1763	1764		|O
23	1764	1766		|O
)	1766	1767		|O
and	1768	1771		|O
(	1772	1773		|O
[	1773	1774	[N(beta)-(IbetaAla)Dap(8)]degarelix	|B-IUPAC
N	1774	1775		|I-IUPAC
(	1775	1776		|I-IUPAC
beta	1776	1780		|I-IUPAC
)	1780	1781		|I-IUPAC
-	1781	1782		|I-IUPAC
(	1782	1783		|I-IUPAC
IbetaAla	1783	1791		|I-IUPAC
)	1791	1792		|I-IUPAC
Dap	1792	1795		|I-IUPAC
(	1795	1796		|I-IUPAC
8	1796	1797		|I-IUPAC
)	1797	1798		|I-IUPAC
]	1798	1799		|I-IUPAC
degarelix	1799	1808		|I-IUPAC
,	1808	1809		|O
IC	1810	1812		|O
(	1812	1813		|O
)	1815	1816		|O
=	1817	1818		|O
1.98	1819	1823		|O
nM	1824	1826		|O
)	1826	1827		|O
(	1828	1829		|O
26	1829	1831		|O
)	1831	1832		|O
had	1833	1836		|O
antagonist	1837	1847		|O
potencies	1848	1857		|O
and	1858	1861		|O
duration	1862	1870		|O
of	1871	1873		|O
action	1874	1880		|O
similar	1881	1888		|O
to	1889	1891		|O
that	1892	1896		|O
of	1897	1899		|O
azaline	1900	1907	azaline B	|B-TRIVIAL
B	1908	1909		|I-TRIVIAL
{	1910	1911		|O
inhibited	1911	1920		|O
LH	1921	1923		|O
(	1924	1925		|O
&	1925	1926		|O
gt	1926	1928		|O
;	1928	1929		|O
)	1932	1933		|O
release	1934	1941		|O
for	1942	1945		|O
&	1946	1947		|O
gt	1947	1949		|O
;	1949	1950		|O
72	1950	1952		|O
h	1953	1954		|O
after	1955	1960		|O
sc	1961	1963		|O
injection	1964	1973		|O
to	1974	1976		|O
castrated	1977	1986		|O
male	1987	1991		|O
rats	1992	1996		|O
at	1997	1999		|O
a	2000	2001		|O
standard	2002	2010		|O
dose	2011	2015		|O
of	2016	2018		|O
mug	2022	2025		|O
/	2025	2026		|O
rat	2026	2029		|O
in	2030	2032		|O
5%	2033	2035		|O
mannitol	2036	2044		|O
}	2044	2045		|O
.	2045	2046		|O
Under	2047	2052		|O
similar	2053	2060		|O
conditions	2061	2071		|O
analogues	2072	2081		|O
(	2082	2083		|O
[	2083	2084	[N(gamma)-(IGly)Dab(8)]degarelix	|B-IUPAC
N	2084	2085		|I-IUPAC
(	2085	2086		|I-IUPAC
gamma	2086	2091		|I-IUPAC
)	2091	2092		|I-IUPAC
-	2092	2093		|I-IUPAC
(	2093	2094		|I-IUPAC
IGly	2094	2098		|I-IUPAC
)	2098	2099		|I-IUPAC
Dab	2099	2102		|I-IUPAC
(	2102	2103		|I-IUPAC
8	2103	2104		|I-IUPAC
)	2104	2105		|I-IUPAC
]	2105	2106		|I-IUPAC
degarelix	2106	2115		|I-IUPAC
,	2115	2116		|O
IC	2117	2119		|O
(	2119	2120		|O
)	2122	2123		|O
=	2124	2125		|O
1.56	2126	2130		|O
nM	2131	2133		|O
)	2133	2134		|O
(	2135	2136		|O
21	2136	2138		|O
)	2138	2139		|O
and	2140	2143		|O
(	2144	2145		|O
[	2145	2146	[IOrn(8)]degarelix	|B-IUPAC
IOrn	2146	2150		|I-IUPAC
(	2150	2151		|I-IUPAC
8	2151	2152		|I-IUPAC
)	2152	2153		|I-IUPAC
]	2153	2154		|I-IUPAC
degarelix	2154	2163		|I-IUPAC
,	2163	2164		|O
IC	2165	2167		|O
(	2167	2168		|O
)	2170	2171		|O
=	2172	2173		|O
1.72	2174	2178		|O
nM	2179	2181		|O
)	2181	2182		|O
(	2183	2184		|O
18	2184	2186		|O
)	2186	2187		|O
had	2188	2191		|O
a	2192	2193		|O
longer	2194	2200		|O
duration	2201	2209		|O
of	2210	2212		|O
action	2213	2219		|O
{	2220	2221		|O
inhibited	2221	2230		|O
LH	2231	2233		|O
(	2234	2235		|O
&	2235	2236		|O
gt	2236	2238		|O
;	2238	2239		|O
96	2239	2241		|O
h	2242	2243		|O
)	2243	2244		|O
release	2245	2252		|O
}	2252	2253		|O
than	2254	2258		|O
azaline	2259	2266	azaline B	|B-TRIVIAL
B	2267	2268		|I-TRIVIAL
;	2268	2269		|O
however	2270	2277		|O
they	2278	2282		|O
were	2283	2287		|O
shorter	2288	2295		|O
acting	2296	2302		|O
than	2303	2307		|O
degarelix	2308	2317	degarelix	|B-TRIVIAL
.	2317	2318		|O
Hydrophilicity	2319	2333		|O
of	2334	2336		|O
these	2337	2342		|O
analogues	2343	2352		|O
,	2352	2353		|O
a	2354	2355		|O
potential	2356	2365		|O
measure	2366	2373		|O
of	2374	2376		|O
their	2377	2382		|O
ability	2383	2390		|O
to	2391	2393		|O
be	2394	2396		|O
formulated	2397	2407		|O
for	2408	2411		|O
sustained	2412	2421		|O
release	2422	2429		|O
,	2429	2430		|O
was	2431	2434		|O
determined	2435	2445		|O
using	2446	2451		|O
RP	2452	2454		|O
-	2454	2455		|O
HPLC	2455	2459		|O
at	2460	2462		|O
neutral	2463	2470		|O
pH	2471	2473		|O
yielding	2474	2482		|O
analogues	2483	2492		|O
with	2493	2497		|O
shorter	2498	2505		|O
as	2506	2508		|O
well	2509	2513		|O
as	2514	2516		|O
longer	2517	2523		|O
retention	2524	2533		|O
times	2534	2539		|O
.	2539	2540		|O
No	2541	2543		|O
correlation	2544	2555		|O
was	2556	2559		|O
found	2560	2565		|O
between	2566	2573		|O
retention	2574	2583		|O
times	2584	2589		|O
and	2590	2593		|O
antagonist	2594	2604		|O
potency	2605	2612		|O
or	2613	2615		|O
duration	2616	2624		|O
of	2625	2627		|O
action	2628	2634		|O
.	2634	2635		|O

### 16329601
[	10	11		|O
Method	11	17		|O
of	18	20		|O
determination	21	34		|O
of	35	37		|O
biogenic	38	46		|O
amines	47	53	amines	|B-FAMILY
in	54	56		|O
wines	57	62		|O
by	63	65		|O
high	66	70		|O
-	70	71		|O
performance	71	82		|O
liquid	83	89		|O
chromatography	90	104		|O
with	105	109		|O
fluorescence	110	122		|O
detector	123	131		|O
and	132	135		|O
ultraviolet	136	147		|O
detector	148	156		|O
]	156	157		|O
OBJECTIVE	159	168		|O
:	168	169		|O
A	170	171		|O
pre	172	175		|O
-	175	176		|O
column	176	182		|O
derivation	183	193		|O
reversed	194	202		|O
-	202	203		|O
phase	203	208		|O
high	209	213		|O
-	213	214		|O
performance	214	225		|O
liquid	226	232		|O
chromatography	233	247		|O
method	248	254		|O
was	255	258		|O
developed	259	268		|O
for	269	272		|O
the	273	276		|O
determination	277	290		|O
of	291	293		|O
biogenic	294	302		|O
amines	303	309		|O
(	310	311		|O
tryptamine	311	321	tryptamine	|B-TRIVIAL
,	321	322		|O
phenylethyamine	323	338	phenylethyamine	|B-TRIVIAL
,	338	339		|O
putrescine	340	350	putrescine	|B-TRIVIAL
,	350	351		|O
cadaverine	352	362	cadaverine	|B-TRIVIAL
,	362	363		|O
histamine	364	373	histamine	|B-TRIVIAL
,	373	374		|O
tyramine	375	383	tyramine	|B-TRIVIAL
,	383	384		|O
spermidine	385	395	spermidine	|B-TRIVIAL
,	395	396		|O
and	397	400		|O
spermine	401	409	spermine	|B-TRIVIAL
)	409	410		|O
in	411	413		|O
wines	414	419		|O
with	420	424		|O
fluorescecse	425	437		|O
detector	438	446		|O
(	447	448		|O
FLD	448	451		|O
)	451	452		|O
and	453	456		|O
ultraviolet	457	468		|O
detector	469	477		|O
(	478	479		|O
UVD	479	482		|O
)	482	483		|O
.	483	484		|O
METHODS	485	492		|O
:	492	493		|O
Liqiud	494	500		|O
-	500	501		|O
liqiud	501	507		|O
extraction	508	518		|O
(	519	520		|O
LLE	520	523		|O
)	523	524		|O
was	525	528		|O
used	529	533		|O
to	534	536		|O
clean	537	542		|O
up	543	545		|O
wine	546	550		|O
samples	551	558		|O
with	559	563		|O
chloroform	564	574	chloroform	|B-TRIVIAL
/	574	575		|O
butanol	575	582	butanol	|B-TRIVIAL
prior	583	588		|O
to	589	591		|O
derivatization	592	606		|O
with	607	611		|O
dansyl	612	618	dansyl chloride	|B-IUPAC
chloride	619	627		|I-IUPAC
,	627	628		|O
biogenic	629	637		|O
amines	638	644		|O
were	645	649		|O
separated	650	659		|O
using	660	665		|O
gradient	666	674		|O
elution	675	682		|O
.	682	683		|O
Mobile	684	690		|O
phase	691	696		|O
A	697	698		|O
was	699	702		|O
methanol	703	711		|O
and	712	715		|O
mobile	716	722		|O
phase	723	728		|O
B	729	730		|O
was	731	734		|O
water	735	740		|O
with	741	745		|O
the	746	749		|O
flow	750	754		|O
rate	755	759		|O
1.5	760	763		|O
ml	764	766		|O
/	766	767		|O
min	767	770		|O
.	770	771		|O
The	772	775		|O
column	776	782		|O
used	783	787		|O
was	788	791		|O
a	792	793		|O
CAPCELL	794	801		|O
PAK	802	805		|O
C18	806	809		|O
MG	810	812		|O
(	813	814		|O
4.6	814	817		|O
mm	818	820		|O
I	821	822		|O
.	822	823		|O
D	823	824		|O
.	824	825		|O
x	826	827		|O
mm	832	834		|O
,	834	835		|O
5	836	837		|O
microm	838	844		|O
)	844	845		|O
and	846	849		|O
gradient	850	858		|O
elution	859	866		|O
at	867	869		|O
constant	870	878		|O
column	879	885		|O
tempereture	886	897		|O
with	898	902		|O
degrees	906	913		|O
C	914	915		|O
under	916	921		|O
fluorescence	922	934		|O
detector	935	943		|O
with	944	948		|O
Ex	949	951		|O
and	958	961		|O
Em	962	964		|O
,	970	971		|O
The	972	975		|O
method	976	982		|O
and	983	986		|O
ultraviolet	987	998		|O
detector	999	1007		|O
with	1008	1012		|O
254nm	1013	1018		|O
.	1018	1019		|O
1,7	1020	1023	1,7-Diaminoheptane	|B-IUPAC
-	1023	1024		|I-IUPAC
Diaminoheptane	1024	1038		|I-IUPAC
was	1039	1042		|O
used	1043	1047		|O
as	1048	1050		|O
the	1051	1054		|O
internal	1055	1063		|O
standard	1064	1072		|O
(	1073	1074		|O
IS	1074	1076		|O
)	1076	1077		|O
.	1077	1078		|O
RESULTS	1079	1086		|O
:	1086	1087		|O
was	1088	1091		|O
linear	1092	1098		|O
for	1099	1102		|O
the	1103	1106		|O
amines	1107	1113		|O
studied	1114	1121		|O
at	1122	1124		|O
concentration	1125	1138		|O
ranging	1139	1146		|O
from	1147	1151		|O
0.05	1152	1156		|O
to	1157	1159		|O
25	1160	1162		|O
mg	1163	1165		|O
/	1165	1166		|O
L	1166	1167		|O
,	1167	1168		|O
except	1169	1175		|O
for	1176	1179		|O
spermidine	1180	1190	spermidine	|B-TRIVIAL
and	1191	1194		|O
spermine	1195	1203	spermine	|B-TRIVIAL
,	1203	1204		|O
which	1205	1210		|O
ranging	1211	1218		|O
from	1219	1223		|O
0.05	1224	1228		|O
to	1229	1231		|O
15	1232	1234		|O
mg	1235	1237		|O
/	1237	1238		|O
L	1238	1239		|O
.	1239	1240		|O
The	1241	1244		|O
average	1245	1252		|O
recoveries	1253	1263		|O
ranged	1264	1270		|O
from	1271	1275		|O
79.2%	1276	1281		|O
to	1282	1284		|O
127.5%	1285	1291		|O
for	1292	1295		|O
all	1296	1299		|O
amines	1300	1306		|O
,	1306	1307		|O
The	1308	1311		|O
RSDs	1312	1316		|O
were	1317	1321		|O
less	1322	1326		|O
than	1327	1331		|O
.	1335	1336		|O
With	1337	1341		|O
this	1342	1346		|O
method	1347	1353		|O
,	1353	1354		|O
5	1355	1356		|O
wine	1357	1361		|O
samples	1362	1369		|O
were	1370	1374		|O
determined	1375	1385		|O
,	1385	1386		|O
the	1387	1390		|O
results	1391	1398		|O
were	1399	1403		|O
favorable	1404	1413		|O
.	1413	1414		|O
CONCLUTION	1415	1425		|O
:	1425	1426		|O
method	1427	1433		|O
can	1434	1437		|O
be	1438	1440		|O
applied	1441	1448		|O
for	1449	1452		|O
determination	1453	1466		|O
of	1467	1469		|O
biogenic	1470	1478		|O
amines	1479	1485		|O
in	1486	1488		|O
wines	1489	1494		|O
.	1494	1495		|O

### 3656362
The	0	3		|O
isomeric	4	12		|O
4	13	14	4-(3-chloro-4-hydroxyphenyl)-	|B-PARTIUPAC
-	14	15		|I-PARTIUPAC
(	15	16		|I-PARTIUPAC
3	16	17		|I-PARTIUPAC
-	17	18		|I-PARTIUPAC
chloro	18	24		|I-PARTIUPAC
-	24	25		|I-PARTIUPAC
4	25	26		|I-PARTIUPAC
-	26	27		|I-PARTIUPAC
hydroxyphenyl	27	40		|I-PARTIUPAC
)	40	41		|I-PARTIUPAC
-	41	42		|I-PARTIUPAC
and	43	46		|O
4	47	48	4-(4-chloro-3-hydroxyphenyl)-1,2,3,4-tetrahydroisoquinolines	|B-IUPAC
-	48	49		|I-IUPAC
(	49	50		|I-IUPAC
4	50	51		|I-IUPAC
-	51	52		|I-IUPAC
chloro	52	58		|I-IUPAC
-	58	59		|I-IUPAC
3	59	60		|I-IUPAC
-	60	61		|I-IUPAC
hydroxyphenyl	61	74		|I-IUPAC
)	74	75		|I-IUPAC
-	75	76		|I-IUPAC
1,2,3,4	76	83		|I-IUPAC
-	83	84		|I-IUPAC
tetrahydroisoquinolines	84	107		|I-IUPAC
,	107	108		|O
the	109	112		|O
N	113	114	N-methyl	|B-PARTIUPAC
-	114	115		|I-PARTIUPAC
methyl	115	121		|I-PARTIUPAC
derivative	122	132	derivative	|B-MODIFIER
of	133	135		|O
the	136	139		|O
4	140	141	4-(4-chloro-3-hydroxyphenyl)	|B-IUPAC
-	141	142		|I-IUPAC
(	142	143		|I-IUPAC
4	143	144		|I-IUPAC
-	144	145		|I-IUPAC
chloro	145	151		|I-IUPAC
-	151	152		|I-IUPAC
3	152	153		|I-IUPAC
-	153	154		|I-IUPAC
hydroxyphenyl	154	167		|I-IUPAC
)	167	168		|I-IUPAC
isomer	169	175	isomer	|B-MODIFIER
,	175	176		|O
and	177	180		|O
4	181	182	4-(3-hydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline	|B-IUPAC
-	182	183		|I-IUPAC
(	183	184		|I-IUPAC
3	184	185		|I-IUPAC
-	185	186		|I-IUPAC
hydroxyphenyl	186	199		|I-IUPAC
)	199	200		|I-IUPAC
-	200	201		|I-IUPAC
1,2,3,4	201	208		|I-IUPAC
-	208	209		|I-IUPAC
tetrahydroisoquinoline	209	231		|I-IUPAC
were	232	236		|O
synthesized	237	248		|O
and	249	252		|O
evaluated	253	262		|O
for	263	266		|O
dopamine	267	275		|O
D	276	277		|O
-	277	278		|O
1	278	279		|O
antagonist	280	290		|O
activity	291	299		|O
.	299	300		|O
The	301	304		|O
4	305	306	4-(3-chloro-4-hydroxyphenyl)	|B-IUPAC
-	306	307		|I-IUPAC
(	307	308		|I-IUPAC
3	308	309		|I-IUPAC
-	309	310		|I-IUPAC
chloro	310	316		|I-IUPAC
-	316	317		|I-IUPAC
4	317	318		|I-IUPAC
-	318	319		|I-IUPAC
hydroxyphenyl	319	332		|I-IUPAC
)	332	333		|I-IUPAC
and	334	337		|O
the	338	341		|O
4	342	343	4-(3-hydroxyphenyl)	|B-IUPAC
-	343	344		|I-IUPAC
(	344	345		|I-IUPAC
3	345	346		|I-IUPAC
-	346	347		|I-IUPAC
hydroxyphenyl	347	360		|I-IUPAC
)	360	361		|I-IUPAC
isomer	362	368	isomer	|B-MODIFIER
possessed	369	378		|O
similar	379	386		|O
potencies	387	396		|O
as	397	399		|O
D	400	401		|O
-	401	402		|O
1	402	403		|O
antagonists	404	415		|O
.	415	416		|O
Introduction	417	429		|O
of	430	432		|O
the	433	436		|O
N	437	438	N-methyl	|B-PARTIUPAC
-	438	439		|I-PARTIUPAC
methyl	439	445		|I-PARTIUPAC
group	446	451	group	|B-MODIFIER
enhanced	452	460		|O
potency	461	468		|O
about	469	474		|O
twofold	475	482		|O
.	482	483		|O
The	484	487		|O
"	488	489		|O
pharmacophore	489	502		|O
"	502	503		|O
for	504	507		|O
selective	508	517		|O
dopamine	518	526		|O
D	527	528		|O
-	528	529		|O
1	529	530		|O
antagonist	531	541		|O
activity	542	550		|O
appears	551	558		|O
to	559	561		|O
be	562	564		|O
a	565	566		|O
tertiary	567	575		|O
2	576	577	2-(3-hydroxyphenyl)-2-phenethylamine	|B-IUPAC
-	577	578		|I-IUPAC
(	578	579		|I-IUPAC
3	579	580		|I-IUPAC
-	580	581		|I-IUPAC
hydroxyphenyl	581	594		|I-IUPAC
)	594	595		|I-IUPAC
-	595	596		|I-IUPAC
2	596	597		|I-IUPAC
-	597	598		|I-IUPAC
phenethylamine	598	612		|I-IUPAC
.	612	613		|O

### 14998335
In	0	2		|O
a	3	4		|O
continuing	5	15		|O
effort	16	22		|O
to	23	25		|O
design	26	32		|O
small	33	38		|O
-	38	39		|O
molecule	39	47		|O
inhibitors	48	58		|O
of	59	61		|O
dihydrofolate	62	75		|O
reductase	76	85		|O
(	86	87		|O
DHFR	87	91		|O
)	91	92		|O
that	93	97		|O
combine	98	105		|O
the	106	109		|O
enzyme	110	116		|O
-	116	117		|O
binding	117	124		|O
selectivity	125	136		|O
of	137	139		|O
2,4	140	143	2,4-diamino-5-(3',4',5'-trimethoxybenzyl)pyrimidine	|B-IUPAC
-	143	144		|I-IUPAC
diamino	144	151		|I-IUPAC
-	151	152		|I-IUPAC
5	152	153		|I-IUPAC
-	153	154		|I-IUPAC
(	154	155		|I-IUPAC
3'	155	157		|I-IUPAC
,	157	158		|I-IUPAC
4'	158	160		|I-IUPAC
,	160	161		|I-IUPAC
5'	161	163		|I-IUPAC
-	163	164		|I-IUPAC
trimethoxybenzyl	164	180		|I-IUPAC
)	180	181		|I-IUPAC
pyrimidine	181	191		|I-IUPAC
(	192	193		|O
trimethoprim	193	205	trimethoprim	|B-TRIVIAL
,	205	206		|O
TMP	207	210	TMP	|B-ABBREVIATION
)	210	211		|O
with	212	216		|O
the	217	220		|O
potency	221	228		|O
of	229	231		|O
2,4	232	235	2,4-diamino-5-methyl-6-(2',5'-dimethoxybenzyl)pyrido[2,3-d]pyrimidine	|B-IUPAC
-	235	236		|I-IUPAC
diamino	236	243		|I-IUPAC
-	243	244		|I-IUPAC
5	244	245		|I-IUPAC
-	245	246		|I-IUPAC
methyl	246	252		|I-IUPAC
-	252	253		|I-IUPAC
6	253	254		|I-IUPAC
-	254	255		|I-IUPAC
(	255	256		|I-IUPAC
2'	256	258		|I-IUPAC
,	258	259		|I-IUPAC
5'	259	261		|I-IUPAC
-	261	262		|I-IUPAC
dimethoxybenzyl	262	277		|I-IUPAC
)	277	278		|I-IUPAC
pyrido	278	284		|I-IUPAC
[	284	285		|I-IUPAC
2,3	285	288		|I-IUPAC
-	288	289		|I-IUPAC
d	289	290		|I-IUPAC
]	290	291		|I-IUPAC
pyrimidine	291	301		|I-IUPAC
(	302	303		|O
piritrexim	303	313	piritrexim	|B-TRIVIAL
,	313	314		|O
PTX	315	318	PTX	|B-ABBREVIATION
)	318	319		|O
,	319	320		|O
seven	321	326		|O
previously	327	337		|O
undescribed	338	349		|O
2,4	350	353	2,4-diamino-5-[2'-methoxy-5'-(substituted benzyl)]pyrimidines	|B-IUPAC
-	353	354		|I-IUPAC
diamino	354	361		|I-IUPAC
-	361	362		|I-IUPAC
5	362	363		|I-IUPAC
-	363	364		|I-IUPAC
[	364	365		|I-IUPAC
2'	365	367		|I-IUPAC
-	367	368		|I-IUPAC
methoxy	368	375		|I-IUPAC
-	375	376		|I-IUPAC
5'	376	378		|I-IUPAC
-	378	379		|I-IUPAC
(	379	380		|I-IUPAC
substituted	380	391		|I-IUPAC
benzyl	392	398		|I-IUPAC
)	398	399		|I-IUPAC
]	399	400		|I-IUPAC
pyrimidines	400	411		|I-IUPAC
were	412	416		|O
synthesized	417	428		|O
in	429	431		|O
which	432	437		|O
the	438	441		|O
substituent	442	453		|O
at	454	456		|O
the	457	460		|O
5'	461	463		|O
-	463	464		|O
position	464	472		|O
was	473	476		|O
a	477	478		|O
carboxyphenyl	479	492	carboxyphenyl	|B-PARTIUPAC
group	493	498	group	|B-MODIFIER
linked	499	505		|O
to	506	508		|O
the	509	512		|O
benzyl	513	519	benzyl	|B-PARTIUPAC
moiety	520	526	moiety	|B-MODIFIER
by	527	529		|O
a	530	531		|O
bridge	532	538		|O
of	539	541		|O
two	542	545		|O
or	546	548		|O
four	549	553		|O
atoms	554	559		|O
in	560	562		|O
length	563	569		|O
.	569	570		|O
The	571	574		|O
new	575	578		|O
analogues	579	588		|O
were	589	593		|O
all	594	597		|O
obtained	598	606		|O
from	607	611		|O
2,4	612	615	2,4-diamino-5-(5'-iodo-2'-methoxybenzyl)pyrimidine	|B-IUPAC
-	615	616		|I-IUPAC
diamino	616	623		|I-IUPAC
-	623	624		|I-IUPAC
5	624	625		|I-IUPAC
-	625	626		|I-IUPAC
(	626	627		|I-IUPAC
5'	627	629		|I-IUPAC
-	629	630		|I-IUPAC
iodo	630	634		|I-IUPAC
-	634	635		|I-IUPAC
2'	635	637		|I-IUPAC
-	637	638		|I-IUPAC
methoxybenzyl	638	651		|I-IUPAC
)	651	652		|I-IUPAC
pyrimidine	652	662		|I-IUPAC
via	663	666		|O
a	667	668		|O
Sonogashira	669	680		|O
reaction	681	689		|O
,	689	690		|O
followed	691	699		|O
,	699	700		|O
where	701	706		|O
appropriate	707	718		|O
,	718	719		|O
by	720	722		|O
catalytic	723	732		|O
hydrogenation	733	746		|O
.	746	747		|O
The	748	751		|O
new	752	755		|O
analogues	756	765		|O
were	766	770		|O
tested	771	777		|O
as	778	780		|O
inhibitors	781	791		|O
of	792	794		|O
DHFR	795	799		|O
from	800	804		|O
Pneumocystis	805	817		|O
carinii	818	825		|O
(	826	827		|O
Pc	827	829		|O
)	829	830		|O
,	830	831		|O
Toxoplasma	832	842		|O
gondii	843	849		|O
(	850	851		|O
Tg	851	853		|O
)	853	854		|O
,	854	855		|O
and	856	859		|O
Mycobacterium	860	873		|O
avium	874	879		|O
(	880	881		|O
Ma	881	883		|O
)	883	884		|O
,	884	885		|O
three	886	891		|O
life	892	896		|O
-	896	897		|O
threatening	897	908		|O
pathogens	909	918		|O
often	919	924		|O
found	925	930		|O
in	931	933		|O
AIDS	934	938		|O
patients	939	947		|O
and	948	951		|O
individuals	952	963		|O
whose	964	969		|O
immune	970	976		|O
system	977	983		|O
is	984	986		|O
impaired	987	995		|O
as	996	998		|O
a	999	1000		|O
result	1001	1007		|O
of	1008	1010		|O
treatment	1011	1020		|O
with	1021	1025		|O
immunosuppressive	1026	1043		|O
chemotherapy	1044	1056		|O
or	1057	1059		|O
radiation	1060	1069		|O
.	1069	1070		|O
The	1071	1074		|O
selectivity	1075	1086		|O
index	1087	1092		|O
(	1093	1094		|O
SI	1094	1096		|O
)	1096	1097		|O
of	1098	1100		|O
each	1101	1105		|O
compound	1106	1114		|O
was	1115	1118		|O
obtained	1119	1127		|O
by	1128	1130		|O
dividing	1131	1139		|O
its	1140	1143		|O
inhibitory	1148	1158		|O
concentration	1159	1172		|O
(	1173	1174		|O
IC	1174	1176		|O
(	1176	1177		|O
)	1179	1180		|O
)	1180	1181		|O
against	1182	1189		|O
Pc	1190	1192		|O
,	1192	1193		|O
Tg	1194	1196		|O
,	1196	1197		|O
or	1198	1200		|O
Ma	1201	1203		|O
DHFR	1204	1208		|O
by	1209	1211		|O
its	1212	1215		|O
IC	1216	1218		|O
(	1218	1219		|O
)	1221	1222		|O
against	1223	1230		|O
rat	1231	1234		|O
DHFR	1235	1239		|O
.	1239	1240		|O
2,4	1241	1244	2,4-Diamino-[2'-methoxy-5'-(3-carboxyphenyl)ethynylbenzyl]pyrimidine	|B-IUPAC
-	1244	1245		|I-IUPAC
Diamino	1245	1252		|I-IUPAC
-	1252	1253		|I-IUPAC
[	1253	1254		|I-IUPAC
2'	1254	1256		|I-IUPAC
-	1256	1257		|I-IUPAC
methoxy	1257	1264		|I-IUPAC
-	1264	1265		|I-IUPAC
5'	1265	1267		|I-IUPAC
-	1267	1268		|I-IUPAC
(	1268	1269		|I-IUPAC
3	1269	1270		|I-IUPAC
-	1270	1271		|I-IUPAC
carboxyphenyl	1271	1284		|I-IUPAC
)	1284	1285		|I-IUPAC
ethynylbenzyl	1285	1298		|I-IUPAC
]	1298	1299		|I-IUPAC
pyrimidine	1299	1309		|I-IUPAC
(	1310	1311		|O
28	1311	1313		|O
)	1313	1314		|O
,	1314	1315		|O
with	1316	1320		|O
an	1321	1323		|O
IC	1324	1326		|O
(	1326	1327		|O
)	1329	1330		|O
of	1331	1333		|O
23	1334	1336		|O
nM	1337	1339		|O
and	1340	1343		|O
an	1344	1346		|O
SI	1347	1349		|O
of	1350	1352		|O
28	1353	1355		|O
in	1356	1358		|O
the	1359	1362		|O
Pc	1363	1365		|O
DHFR	1366	1370		|O
assay	1371	1376		|O
,	1376	1377		|O
had	1378	1381		|O
about	1382	1387		|O
the	1388	1391		|O
same	1392	1396		|O
potency	1397	1404		|O
as	1405	1407		|O
PTX	1408	1411	PTX	|B-ABBREVIATION
and	1412	1415		|O
was	1416	1419		|O
times	1424	1429		|O
more	1430	1434		|O
potent	1435	1441		|O
than	1442	1446		|O
TMP	1447	1450	TMP	|B-ABBREVIATION
.	1450	1451		|O
As	1452	1454		|O
an	1455	1457		|O
inhibitor	1458	1467		|O
of	1468	1470		|O
Tg	1471	1473		|O
DHFR	1474	1478		|O
,	1478	1479		|O
28	1480	1482		|O
had	1483	1486		|O
an	1487	1489		|O
IC	1490	1492		|O
(	1492	1493		|O
)	1495	1496		|O
of	1497	1499		|O
5.5	1500	1503		|O
nM	1504	1506		|O
(	1507	1508		|O
-	1511	1512		|O
fold	1512	1516		|O
lower	1517	1522		|O
than	1523	1527		|O
that	1528	1532		|O
of	1533	1535		|O
TMP	1536	1539	TMP	|B-ABBREVIATION
and	1540	1543		|O
similar	1544	1551		|O
to	1552	1554		|O
that	1555	1559		|O
of	1560	1562		|O
PTX	1563	1566	PTX	|B-ABBREVIATION
)	1566	1567		|O
and	1568	1571		|O
an	1572	1574		|O
SI	1575	1577		|O
value	1578	1583		|O
of	1584	1586		|O
(	1591	1592		|O
2	1592	1593		|O
-	1593	1594		|O
fold	1594	1598		|O
better	1599	1605		|O
than	1606	1610		|O
TMP	1611	1614	TMP	|B-ABBREVIATION
and	1615	1618		|O
vastly	1619	1625		|O
superior	1626	1634		|O
to	1635	1637		|O
PTX	1638	1641	PTX	|B-ABBREVIATION
)	1641	1642		|O
.	1642	1643		|O
Against	1644	1651		|O
Ma	1652	1654		|O
DHFR	1655	1659		|O
,	1659	1660		|O
28	1661	1663		|O
had	1664	1667		|O
IC	1668	1670		|O
(	1670	1671		|O
)	1673	1674		|O
and	1675	1678		|O
SI	1679	1681		|O
values	1682	1688		|O
of	1689	1691		|O
1.5	1692	1695		|O
nM	1696	1698		|O
and	1699	1702		|O
,	1706	1707		|O
respectively	1708	1720		|O
,	1720	1721		|O
compared	1722	1730		|O
with	1731	1735		|O
nM	1740	1742		|O
and	1743	1746		|O
for	1751	1754		|O
TMP	1755	1758	TMP	|B-ABBREVIATION
.	1758	1759		|O
Although	1760	1768		|O
it	1769	1771		|O
had	1772	1775		|O
2.5	1776	1779		|O
-	1779	1780		|O
fold	1780	1784		|O
lower	1785	1790		|O
potency	1791	1798		|O
than	1799	1803		|O
28	1804	1806		|O
against	1807	1814		|O
Ma	1815	1817		|O
DHFR	1818	1822		|O
(	1823	1824		|O
IC	1824	1826		|O
(	1826	1827		|O
)	1829	1830		|O
=	1831	1832		|O
3.7	1833	1836		|O
nM	1837	1839		|O
)	1839	1840		|O
and	1841	1844		|O
was	1845	1848		|O
substantially	1849	1862		|O
weaker	1863	1869		|O
against	1870	1877		|O
Pc	1878	1880		|O
and	1881	1884		|O
Tg	1885	1887		|O
DHFR	1888	1892		|O
,	1892	1893		|O
2,4	1894	1897	2,4-diamino-[2'-methoxy-5'-(4-carboxyphenyl)ethynylbenzyl]pyrimidine	|B-IUPAC
-	1897	1898		|I-IUPAC
diamino	1898	1905		|I-IUPAC
-	1905	1906		|I-IUPAC
[	1906	1907		|I-IUPAC
2'	1907	1909		|I-IUPAC
-	1909	1910		|I-IUPAC
methoxy	1910	1917		|I-IUPAC
-	1917	1918		|I-IUPAC
5'	1918	1920		|I-IUPAC
-	1920	1921		|I-IUPAC
(	1921	1922		|I-IUPAC
4	1922	1923		|I-IUPAC
-	1923	1924		|I-IUPAC
carboxyphenyl	1924	1937		|I-IUPAC
)	1937	1938		|I-IUPAC
ethynylbenzyl	1938	1951		|I-IUPAC
]	1951	1952		|I-IUPAC
pyrimidine	1952	1962		|I-IUPAC
(	1963	1964		|O
29	1964	1966		|O
)	1966	1967		|O
,	1967	1968		|O
with	1969	1973		|O
the	1974	1977		|O
carboxy	1978	1985	carboxy	|B-TRIVIAL
group	1986	1991	group	|B-MODIFIER
at	1992	1994		|O
the	1995	1998		|O
para	1999	2003		|O
rather	2004	2010		|O
than	2011	2015		|O
the	2016	2019		|O
meta	2020	2024		|O
position	2025	2033		|O
,	2033	2034		|O
displayed	2035	2044		|O
-	2049	2050		|O
fold	2050	2054		|O
selectivity	2055	2066		|O
against	2067	2074		|O
the	2075	2078		|O
Ma	2079	2081		|O
enzyme	2082	2088		|O
and	2089	2092		|O
was	2093	2096		|O
the	2097	2100		|O
most	2101	2105		|O
selective	2106	2115		|O
2,4	2116	2119	2,4-diamino-5-(5'-substituted benzyl)pyrimidine	|B-IUPAC
-	2119	2120		|I-IUPAC
diamino	2120	2127		|I-IUPAC
-	2127	2128		|I-IUPAC
5	2128	2129		|I-IUPAC
-	2129	2130		|I-IUPAC
(	2130	2131		|I-IUPAC
5'	2131	2133		|I-IUPAC
-	2133	2134		|I-IUPAC
substituted	2134	2145		|I-IUPAC
benzyl	2146	2152		|I-IUPAC
)	2152	2153		|I-IUPAC
pyrimidine	2153	2163		|I-IUPAC
inhibitor	2163	2172		|O
of	2174	2176		|O
this	2177	2181		|O
enzyme	2182	2188		|O
we	2189	2191		|O
have	2192	2196		|O
encountered	2197	2208		|O
to	2209	2211		|O
date	2212	2216		|O
.	2216	2217		|O
Additional	2218	2228		|O
bioassay	2229	2237		|O
data	2238	2242		|O
for	2243	2246		|O
these	2247	2252		|O
compounds	2253	2262		|O
are	2263	2266		|O
also	2267	2271		|O
reported	2272	2280		|O
.	2280	2281		|O

### 9120816
Parenteral	9	19		|O
hydroxypropyl	20	33	hydroxypropyl cyclodextrins	|B-IUPAC
cyclodextrins	34	47		|I-IUPAC
:	47	48		|O
intravenous	49	60		|O
and	61	64		|O
intracerebral	65	78		|O
administration	79	93		|O
of	94	96		|O
lipophiles	97	107		|O
.	107	108		|O
Hydroxypropyl	110	123	Hydroxypropyl cyclodextrins	|B-IUPAC
cyclodextrins	124	137		|I-IUPAC
are	138	141		|O
nontoxic	142	150		|O
carbohydrate	151	163	carbohydrate	|B-FAMILY
derivatives	164	175	derivatives	|B-MODIFIER
of	176	178		|O
moderate	179	187		|O
molecular	188	197		|O
weight	198	204		|O
(	205	206		|O
Da	216	218		|O
)	218	219		|O
which	220	225		|O
form	226	230		|O
water	231	236		|O
-	236	237		|O
soluble	237	244		|O
complexes	245	254		|O
with	255	259		|O
many	260	264		|O
lipophiles	265	275		|O
.	275	276		|O
The	277	280		|O
fate	281	285		|O
of	286	288		|O
hydroxypropyl	289	302	hydroxypropyl beta-cyclodextrin	|B-IUPAC
beta	303	307		|I-IUPAC
-	307	308		|I-IUPAC
cyclodextrin	308	320		|I-IUPAC
alone	321	326		|O
and	327	330		|O
in	331	333		|O
complex	334	341		|O
with	342	346		|O
testosterone	347	359	testosterone	|B-TRIVIAL
or	360	362		|O
cholesterol	363	374	cholesterol	|B-TRIVIAL
injected	375	383		|O
intravenously	384	397		|O
or	398	400		|O
intracerebrally	401	416		|O
into	417	421		|O
rats	422	426		|O
was	427	430		|O
followed	431	439		|O
.	439	440		|O
More	441	445		|O
than	446	450		|O
of	455	457		|O
intravenously	458	471		|O
administered	472	484		|O
hydroxypropyl	485	498	hydroxypropyl beta-cyclodextrin	|B-IUPAC
beta	499	503		|I-IUPAC
-	503	504		|I-IUPAC
cyclodextrin	504	516		|I-IUPAC
was	517	520		|O
cleared	521	528		|O
into	529	533		|O
urine	534	539		|O
in	540	542		|O
4	543	544		|O
h	545	546		|O
,	546	547		|O
as	548	550		|O
previously	551	561		|O
described	562	571		|O
(	572	573		|O
Monbaliu	573	581		|O
,	581	582		|O
J	583	584		|O
.	584	585		|O
;	585	586		|O
Van	587	590		|O
Beijsterveld	591	603		|O
,	603	604		|O
L	605	606		|O
.	606	607		|O
;	607	608		|O
Meuldermans	609	620		|O
,	620	621		|O
W	622	623		|O
.	623	624		|O
;	624	625		|O
Szathmary	626	635		|O
,	635	636		|O
S	637	638		|O
.	638	639		|O
;	639	640		|O
Haykants	641	649		|O
,	649	650		|O
J	651	652		|O
.	652	653		|O
Abstracts	654	663		|O
,	663	664		|O
5th	665	668		|O
International	669	682		|O
Symposium	683	692		|O
on	693	695		|O
Cyclodextrins	696	709	Cyclodextrins	|B-TRIVIAL
,	709	710		|O
Paris	711	716		|O
,	716	717		|O
;	722	723		|O
Abstract	724	732		|O
65	733	735		|O
)	735	736		|O
.	736	737		|O
After	738	743		|O
the	744	747		|O
injection	748	757		|O
of	758	760		|O
steroids	761	769		|O
in	770	772		|O
complex	773	780		|O
with	781	785		|O
hydroxypropyl	786	799	hydroxypropyl beta-cyclodextrin	|B-IUPAC
beta	800	804		|I-IUPAC
-	804	805		|I-IUPAC
cyclodextrin	805	817		|I-IUPAC
into	818	822		|O
the	823	826		|O
tail	827	831		|O
vein	832	836		|O
of	837	839		|O
rats	840	844		|O
,	844	845		|O
the	846	849		|O
steroid	850	857		|O
component	858	867		|O
was	868	871		|O
released	872	880		|O
from	881	885		|O
the	886	889		|O
complex	890	897		|O
,	897	898		|O
before	899	905		|O
it	906	908		|O
reached	909	916		|O
the	917	920		|O
kidneys	921	928		|O
;	928	929		|O
the	930	933		|O
release	934	941		|O
occurred	942	950		|O
mainly	951	957		|O
into	958	962		|O
the	963	966		|O
proteins	967	975		|O
and	976	979		|O
lipoproteins	980	992		|O
of	993	995		|O
serum	996	1001		|O
.	1001	1002		|O
Hydroxypropyl	1003	1016	Hydroxypropyl beta-cyclodextrins	|B-IUPAC
beta	1017	1021		|I-IUPAC
-	1021	1022		|I-IUPAC
cyclodextrins	1022	1035		|I-IUPAC
injected	1036	1044		|O
alone	1045	1050		|O
into	1051	1055		|O
the	1056	1059		|O
brain	1060	1065		|O
were	1066	1070		|O
cleared	1071	1078		|O
within	1079	1085		|O
less	1086	1090		|O
than	1091	1095		|O
24	1096	1098		|O
h	1099	1100		|O
,	1100	1101		|O
presumably	1102	1112		|O
via	1113	1116		|O
the	1117	1120		|O
flow	1121	1125		|O
of	1126	1128		|O
interstitial	1129	1141		|O
and	1142	1145		|O
cerebrospinal	1146	1159		|O
fluids	1160	1166		|O
,	1166	1167		|O
and	1168	1171		|O
eventually	1172	1182		|O
were	1183	1187		|O
excreted	1188	1196		|O
in	1197	1199		|O
urine	1200	1205		|O
.	1205	1206		|O
Testosterone	1207	1219	Testosterone	|B-TRIVIAL
,	1219	1220		|O
incorporated	1221	1233		|O
in	1234	1236		|O
a	1237	1238		|O
hydroxypropyl	1239	1252	hydroxypropyl beta-cyclodextrin	|B-IUPAC
beta	1253	1257		|I-IUPAC
-	1257	1258		|I-IUPAC
cyclodextrin	1258	1270		|I-IUPAC
complex	1271	1278	complex	|B-MODIFIER
,	1278	1279		|O
after	1280	1285		|O
intracerebral	1286	1299		|O
injection	1300	1309		|O
was	1310	1313		|O
cleared	1314	1321		|O
from	1322	1326		|O
the	1327	1330		|O
brain	1331	1336		|O
even	1337	1341		|O
more	1342	1346		|O
rapidly	1347	1354		|O
than	1355	1359		|O
hydroxypropyl	1360	1373	hydroxypropyl beta-cyclodextrin	|B-IUPAC
beta	1374	1378		|I-IUPAC
-	1378	1379		|I-IUPAC
cyclodextrin	1379	1391		|I-IUPAC
,	1391	1392		|O
presumably	1393	1403		|O
by	1404	1406		|O
crossing	1407	1415		|O
the	1416	1419		|O
blood	1420	1425		|O
-	1425	1426		|O
brain	1426	1431		|O
barrier	1432	1439		|O
and	1440	1443		|O
later	1444	1449		|O
removal	1450	1457		|O
to	1458	1460		|O
the	1461	1464		|O
liver	1465	1470		|O
by	1471	1473		|O
the	1474	1477		|O
specific	1478	1486		|O
carrier	1487	1494		|O
proteins	1495	1503		|O
in	1504	1506		|O
serum	1507	1512		|O
.	1512	1513		|O
Complexed	1514	1523		|O
cholesterol	1524	1535	cholesterol	|B-TRIVIAL
,	1535	1536		|O
in	1537	1539		|O
a	1540	1541		|O
similar	1542	1549		|O
experiment	1550	1560		|O
,	1560	1561		|O
was	1562	1565		|O
largely	1566	1573		|O
retained	1574	1582		|O
in	1583	1585		|O
the	1586	1589		|O
brain	1590	1595		|O
and	1596	1599		|O
its	1600	1603		|O
distribution	1604	1616		|O
there	1617	1622		|O
was	1623	1626		|O
uneven	1627	1633		|O
and	1634	1637		|O
remained	1638	1646		|O
that	1647	1651		|O
way	1652	1655		|O
for	1656	1659		|O
at	1660	1662		|O
least	1663	1668		|O
3	1669	1670		|O
days	1671	1675		|O
.	1675	1676		|O
It	1677	1679		|O
is	1680	1682		|O
clear	1683	1688		|O
that	1689	1693		|O
lipophilic	1694	1704		|O
agents	1705	1711		|O
,	1711	1712		|O
after	1713	1718		|O
their	1719	1724		|O
incorporation	1725	1738		|O
into	1739	1743		|O
hydroxypropyl	1744	1757	hydroxypropyl beta-cyclodextrin	|B-IUPAC
beta	1758	1762		|I-IUPAC
-	1762	1763		|I-IUPAC
cyclodextrin	1763	1775		|I-IUPAC
complexes	1776	1785	complexes	|B-MODIFIER
and	1786	1789		|O
subsequent	1790	1800		|O
in	1801	1803		|O
vivo	1804	1808		|O
administration	1809	1823		|O
,	1823	1824		|O
are	1825	1828		|O
rapidly	1829	1836		|O
released	1837	1845		|O
and	1846	1849		|O
exchanged	1850	1859		|O
into	1860	1864		|O
the	1865	1868		|O
plasma	1869	1875		|O
.	1875	1876		|O
In	1877	1879		|O
absence	1880	1887		|O
of	1888	1890		|O
plasma	1891	1897		|O
they	1898	1902		|O
enter	1903	1908		|O
tissues	1909	1916		|O
surrounding	1917	1928		|O
the	1929	1932		|O
injection	1933	1942		|O
site	1943	1947		|O
and	1948	1951		|O
thus	1952	1956		|O
are	1957	1960		|O
also	1961	1965		|O
promptly	1966	1974		|O
transferred	1975	1986		|O
into	1987	1991		|O
the	1992	1995		|O
organism	1996	2004		|O
's	2004	2006		|O
lipid	2007	2012	lipid	|B-FAMILY
systems	2013	2020		|O
.	2020	2021		|O
The	2022	2025		|O
manner	2026	2032		|O
in	2033	2035		|O
which	2036	2041		|O
different	2042	2051		|O
lipophilic	2052	2062		|O
agents	2063	2069		|O
are	2070	2073		|O
transported	2074	2085		|O
in	2086	2088		|O
vivo	2089	2093		|O
appears	2094	2101		|O
not	2102	2105		|O
to	2106	2108		|O
be	2109	2111		|O
greatly	2112	2119		|O
affected	2120	2128		|O
by	2129	2131		|O
their	2132	2137		|O
previous	2138	2146		|O
complexation	2147	2159		|O
;	2159	2160		|O
rather	2161	2167		|O
hydroxypropyl	2168	2181	hydroxypropyl cyclodextrins	|B-IUPAC
cyclodextrins	2182	2195		|I-IUPAC
just	2195	2199		|O
enable	2201	2207		|O
their	2208	2213		|O
entry	2214	2219		|O
in	2220	2222		|O
a	2223	2224		|O
larger	2225	2231		|O
amount	2232	2238		|O
and	2239	2242		|O
in	2243	2245		|O
an	2246	2248		|O
exchangeable	2249	2261		|O
,	2261	2262		|O
nonaggregated	2263	2276		|O
form	2277	2281		|O
.	2281	2282		|O

### 6264792
6264792	0	7		|O
Inhibition	9	19		|O
of	20	22		|O
renin	23	28		|O
secretion	29	38		|O
by	39	41		|O
intrarenal	42	52		|O
alpha	53	58		|O
-	58	59		|O
adrenoceptor	59	71		|O
blockade	72	80		|O
.	80	81		|O
This	83	87		|O
study	88	93		|O
was	94	97		|O
designed	98	106		|O
to	107	109		|O
determine	110	119		|O
whether	120	127		|O
renal	128	133		|O
alpha	134	139		|O
-	139	140		|O
adrenoceptors	140	153		|O
can	154	157		|O
mediate	158	165		|O
tonic	166	171		|O
neural	172	178		|O
stimulation	179	190		|O
of	191	193		|O
renin	194	199		|O
secretion	200	209		|O
.	209	210		|O
The	211	214		|O
effect	215	221		|O
of	222	224		|O
alpha	225	230		|O
-	230	231		|O
adrenoceptor	231	243		|O
blockade	244	252		|O
by	253	255		|O
phenoxybenzamine	256	272	phenoxybenzamine	|B-TRIVIAL
(	273	274		|O
POB	274	277	POB	|B-ABBREVIATION
)	277	278		|O
or	279	281		|O
prazosin	282	290	prazosin	|B-TRIVIAL
on	291	293		|O
renin	294	299		|O
secretion	300	309		|O
rate	310	314		|O
(	315	316		|O
RSR	316	319		|O
)	319	320		|O
was	321	324		|O
studied	325	332		|O
in	333	335		|O
pentobarbital	336	349	pentobarbital	|B-TRIVIAL
-	349	350		|O
anesthetized	350	362		|O
dogs	363	367		|O
in	368	370		|O
which	371	376		|O
renal	377	382		|O
perfusion	383	392		|O
pressure	393	401		|O
was	402	405		|O
held	406	410		|O
constant	411	419		|O
with	420	424		|O
an	425	427		|O
adjustable	428	438		|O
aortic	439	445		|O
clamp	446	451		|O
.	451	452		|O
POB	453	456	POB	|B-ABBREVIATION
alone	457	462		|O
(	463	464		|O
micrograms	468	478		|O
.	478	479		|O
kg	479	481		|O
-	481	482		|O
1	482	483		|O
.	483	484		|O
min	484	487		|O
-	487	488		|O
1	488	489		|O
iv	490	492		|O
)	492	493		|O
did	494	497		|O
not	498	501		|O
change	502	508		|O
arterial	509	517		|O
plasma	518	524		|O
renin	525	530		|O
activity	531	539		|O
(	540	541		|O
PRA	541	544		|O
)	544	545		|O
.	545	546		|O
However	547	554		|O
,	554	555		|O
when	556	560		|O
beta	561	565		|O
-	565	566		|O
adrenoceptors	566	579		|O
were	580	584		|O
blocked	585	592		|O
by	593	595		|O
intravenous	596	607		|O
propranolol	608	619	propranolol	|B-TRIVIAL
,	619	620		|O
intravenous	621	632		|O
POB	633	636	POB	|B-ABBREVIATION
infusion	637	645		|O
(	646	647		|O
micrograms	651	661		|O
.	661	662		|O
kg	662	664		|O
-	664	665		|O
1	665	666		|O
.	666	667		|O
min	667	670		|O
-	670	671		|O
1	671	672		|O
)	672	673		|O
decreased	674	683		|O
PRA	684	687		|O
and	688	691		|O
RSR	692	695		|O
to	696	698		|O
48	699	701		|O
+	702	703		|O
/	703	704		|O
-	704	705		|O
8	706	707		|O
and	708	711		|O
21	712	714		|O
+	715	716		|O
/	716	717		|O
-	717	718		|O
9%	719	721		|O
of	722	724		|O
previous	725	733		|O
levels	734	740		|O
within	741	747		|O
min	751	754		|O
.	754	755		|O
This	756	760		|O
effect	761	767		|O
was	768	771		|O
abolished	772	781		|O
by	782	784		|O
acute	785	790		|O
bilateral	791	800		|O
renal	801	806		|O
denervation	807	818		|O
.	818	819		|O
Direct	820	826		|O
intrarenal	827	837		|O
POB	838	841	POB	|B-ABBREVIATION
infusion	842	850		|O
(	851	852		|O
or	855	857		|O
3.3	858	861		|O
micrograms	862	872		|O
.	872	873		|O
kg	873	875		|O
-	875	876		|O
1	876	877		|O
.	877	878		|O
min	878	881		|O
-	881	882		|O
1	882	883		|O
)	883	884		|O
decreased	885	894		|O
RSR	895	898		|O
,	898	899		|O
whereas	900	907		|O
intravenous	908	919		|O
POB	920	923	POB	|B-ABBREVIATION
(	924	925		|O
3.3	925	928		|O
micrograms	929	939		|O
.	939	940		|O
kg	940	942		|O
-	942	943		|O
1	943	944		|O
.	944	945		|O
min	945	948		|O
-	948	949		|O
1	949	950		|O
)	950	951		|O
had	952	955		|O
no	956	958		|O
effect	959	965		|O
on	966	968		|O
either	969	975		|O
RSR	976	979		|O
or	980	982		|O
PRA	983	986		|O
in	987	989		|O
propranolol	990	1001	propranolol	|B-TRIVIAL
-	1001	1002		|O
pretreated	1002	1012		|O
dogs	1013	1017		|O
.	1017	1018		|O
Prazosin	1019	1027	Prazosin	|B-TRIVIAL
(	1028	1029		|O
1	1029	1030		|O
microgram	1031	1040		|O
.	1040	1041		|O
kg	1041	1043		|O
-	1043	1044		|O
1	1044	1045		|O
.	1045	1046		|O
min	1046	1049		|O
-	1049	1050		|O
1	1050	1051		|O
iv	1052	1054		|O
)	1054	1055		|O
also	1056	1060		|O
significantly	1061	1074		|O
decreased	1075	1084		|O
PRA	1085	1088		|O
.	1088	1089		|O
These	1090	1095		|O
data	1096	1100		|O
indicate	1101	1109		|O
that	1110	1114		|O
when	1115	1119		|O
beta	1120	1124		|O
-	1124	1125		|O
adrenoceptors	1125	1138		|O
are	1139	1142		|O
blocked	1143	1150		|O
by	1151	1153		|O
propranolol	1154	1165	propranolol	|B-TRIVIAL
,	1165	1166		|O
tonic	1167	1172		|O
neural	1173	1179		|O
stimulation	1180	1191		|O
of	1192	1194		|O
renin	1195	1200		|O
secretion	1201	1210		|O
is	1211	1213		|O
mediated	1214	1222		|O
by	1223	1225		|O
renal	1226	1231		|O
alpha	1232	1237		|O
-	1237	1238		|O
adrenoceptors	1238	1251		|O
.	1251	1252		|O

### 5808825
Metabolism	9	19		|O
of	20	22		|O
D	23	24	D-	|B-IUPAC
-	24	25		|I-IUPAC
and	26	29		|O
L	30	31	L-glyceraldehyde	|B-IUPAC
-	31	32		|I-IUPAC
glyceraldehyde	32	46		|I-IUPAC
in	47	49		|O
adipose	50	57		|O
tissue	58	64		|O
:	64	65		|O
a	66	67		|O
stereochemical	68	82		|O
probe	83	88		|O
for	89	92		|O
glycerokinase	93	106		|O
activity	107	115		|O
.	115	116		|O
Distributions	118	131		|O
of	132	134		|O
(	135	136	(14)C	|B-SUM
14	136	138		|I-SUM
)	138	139		|I-SUM
C	139	140		|I-SUM
have	141	145		|O
been	146	150		|O
determined	151	161		|O
in	162	164		|O
free	165	169		|O
glycerol	170	178	glycerol	|B-TRIVIAL
,	178	179		|O
in	180	182		|O
glycerol	183	191	glycerol	|B-TRIVIAL
from	192	196		|O
triglycerides	197	210	triglycerides	|B-FAMILY
,	210	211		|O
in	212	214		|O
glucose	215	222	glucose	|B-TRIVIAL
from	223	227		|O
glycogen	228	236	glycogen	|B-TRIVIAL
,	236	237		|O
and	238	241		|O
in	242	244		|O
lactate	245	252		|O
after	253	258		|O
incubation	259	269		|O
of	270	272		|O
d	273	274	d-glyceraldehyde-3-(14)C	|B-IUPAC
-	274	275		|I-IUPAC
glyceraldehyde	275	289		|I-IUPAC
-	289	290		|I-IUPAC
3	290	291		|I-IUPAC
-	291	292		|I-IUPAC
(	292	293		|I-IUPAC
14	293	295		|I-IUPAC
)	295	296		|I-IUPAC
C	296	297		|I-IUPAC
and	298	301		|O
l	301	302	 l-glyceraldehyde-3-(14)C	|B-IUPAC
-	303	304		|I-IUPAC
glyceraldehyde	304	318		|I-IUPAC
-	318	319		|I-IUPAC
3	319	320		|I-IUPAC
-	320	321		|I-IUPAC
(	321	322		|I-IUPAC
14	322	324		|I-IUPAC
)	324	325		|I-IUPAC
C	325	326		|I-IUPAC
with	327	331		|O
rat	332	335		|O
adipose	336	343		|O
tissue	344	350		|O
.	350	351		|O
The	352	355		|O
distributions	356	369		|O
are	370	373		|O
interpreted	374	385		|O
in	386	388		|O
terms	389	394		|O
of	395	397		|O
presently	398	407		|O
accepted	408	416		|O
possible	417	425		|O
reactions	426	435		|O
for	436	439		|O
the	440	443		|O
initial	444	451		|O
metabolism	452	462		|O
of	463	465		|O
glyceraldehyde	466	480	glyceraldehyde	|B-TRIVIAL
.	480	481		|O
Formation	482	491		|O
of	492	494		|O
glycerol	495	503	glycerol-1-(14)C	|B-IUPAC
-	503	504		|I-IUPAC
1	504	505		|I-IUPAC
-	505	506		|I-IUPAC
(	506	507		|I-IUPAC
14	507	509		|I-IUPAC
)	509	510		|I-IUPAC
C	510	511		|I-IUPAC
from	512	516		|O
d	516	517	 d-glyceraldehyde-3-(14)C	|B-IUPAC
-	518	519		|I-IUPAC
glyceraldehyde	519	533		|I-IUPAC
-	533	534		|I-IUPAC
3	534	535		|I-IUPAC
-	535	536		|I-IUPAC
(	536	537		|I-IUPAC
14	537	539		|I-IUPAC
)	539	540		|I-IUPAC
C	540	541		|I-IUPAC
indicates	542	551		|O
that	552	556		|O
in	557	559		|O
adipose	560	567		|O
tissue	568	574		|O
glyceraldehyde	575	589	glyceraldehyde	|B-TRIVIAL
is	590	592		|O
reduced	593	600		|O
to	601	603		|O
glycerol	604	612	glycerol	|B-TRIVIAL
.	612	613		|O
Incorporation	614	627		|O
of	628	630		|O
(	631	632	(14)C	|B-SUM
14	632	634		|I-SUM
)	634	635		|I-SUM
C	635	636		|I-SUM
from	637	641		|O
d	642	643	d-glyceraldehyde-3-(14)C	|B-IUPAC
-	643	644		|I-IUPAC
glyceraldehyde	644	658		|I-IUPAC
-	658	659		|I-IUPAC
3	659	660		|I-IUPAC
-	660	661		|I-IUPAC
(	661	662		|I-IUPAC
14	662	664		|I-IUPAC
)	664	665		|I-IUPAC
C	665	666		|I-IUPAC
into	667	671		|O
carbon	672	678	carbon	|B-TRIVIAL
3	679	680		|O
of	681	683		|O
the	684	687		|O
glycerol	688	696	glycerol	|B-TRIVIAL
of	697	699		|O
triglyceride	700	712	triglyceride	|B-FAMILY
indicates	713	722		|O
that	723	727		|O
d	727	728	 d-glyceraldehyde	|B-IUPAC
-	729	730		|I-IUPAC
glyceraldehyde	730	744		|I-IUPAC
is	745	747		|O
either	748	754		|O
phosphorylated	755	769		|O
or	770	772		|O
oxidized	773	781		|O
to	782	784		|O
d	785	786	d-glyceric acid	|B-IUPAC
-	786	787		|I-IUPAC
glyceric	787	795		|I-IUPAC
acid	796	800		|I-IUPAC
,	800	801		|O
or	802	804		|O
both	805	809		|O
,	809	810		|O
in	811	813		|O
its	814	817		|O
initial	818	825		|O
metabolism	826	836		|O
.	836	837		|O
Incorporation	838	851		|O
of	852	854		|O
(	855	856	(14)C	|B-SUM
14	856	858		|I-SUM
)	858	859		|I-SUM
C	859	860		|I-SUM
from	861	865		|O
l	865	866	 l-glyceraldehyde-3-(14)C	|B-IUPAC
-	867	868		|I-IUPAC
glyceraldehyde	868	882		|I-IUPAC
-	882	883		|I-IUPAC
3	883	884		|I-IUPAC
-	884	885		|I-IUPAC
(	885	886		|I-IUPAC
14	886	888		|I-IUPAC
)	888	889		|I-IUPAC
C	889	890		|I-IUPAC
into	891	895		|O
carbon	896	902	carbon	|B-TRIVIAL
3	903	904		|O
of	905	907		|O
glycerol	908	916	glycerol	|B-TRIVIAL
indicates	917	926		|O
that	927	931		|O
l	932	933	l-glyceraldehyde	|B-IUPAC
-	933	934		|I-IUPAC
glyceraldehyde	934	948		|I-IUPAC
is	949	951		|O
reduced	952	959		|O
to	960	962		|O
glycerol	963	971	glycerol	|B-TRIVIAL
,	971	972		|O
which	973	978		|O
is	979	981		|O
phosphorylated	982	996		|O
and	997	1000		|O
(	1001	1002		|O
or	1002	1004		|O
)	1004	1005		|O
converted	1006	1015		|O
to	1016	1018		|O
d	1019	1020	d-glyceric acid	|B-IUPAC
-	1020	1021		|I-IUPAC
glyceric	1021	1029		|I-IUPAC
acid	1030	1034		|I-IUPAC
via	1035	1038		|O
l	1039	1040	l-glyceric acid	|B-IUPAC
-	1040	1041		|I-IUPAC
glyceric	1041	1049		|I-IUPAC
acid	1050	1054		|I-IUPAC
.	1054	1055		|O
Some	1056	1060		|O
(	1061	1062	(14)C	|B-SUM
14	1062	1064		|I-SUM
)	1064	1065		|I-SUM
C	1065	1066		|I-SUM
from	1067	1071		|O
l	1072	1073	l-glyceraldehyde-3-(14)C	|B-IUPAC
-	1073	1074		|I-IUPAC
glyceraldehyde	1074	1088		|I-IUPAC
-	1088	1089		|I-IUPAC
3	1089	1090		|I-IUPAC
-	1090	1091		|I-IUPAC
(	1091	1092		|I-IUPAC
14	1092	1094		|I-IUPAC
)	1094	1095		|I-IUPAC
C	1095	1096		|I-IUPAC
is	1097	1099		|O
incorporated	1100	1112		|O
into	1113	1117		|O
carbon	1118	1124	carbon	|B-TRIVIAL
1	1125	1126		|O
of	1127	1129		|O
glycerol	1130	1138	glycerol	|B-TRIVIAL
of	1139	1141		|O
triglycerides	1142	1155	triglycerides	|B-FAMILY
and	1156	1159		|O
carbon	1160	1166	carbon	|B-TRIVIAL
4	1167	1168		|O
of	1169	1171		|O
glycogen	1172	1180	glycogen	|B-TRIVIAL
;	1180	1181		|O
the	1182	1185		|O
explanation	1186	1197		|O
for	1198	1201		|O
this	1202	1206		|O
incorporation	1207	1220		|O
is	1221	1223		|O
uncertain	1224	1233		|O
.	1233	1234		|O

### 12553880
Attenuation	10	21		|O
of	22	24		|O
glucocorticoid	25	39	glucocorticoid	|B-FAMILY
functions	40	49		|O
in	50	52		|O
an	53	55		|O
Anx	56	59		|O
-	59	60		|O
A1	60	62		|O
-	62	63		|O
/	63	64		|O
-	64	65		|O
cell	66	70		|O
line	71	75		|O
.	75	76		|O
The	78	81		|O
Ca	82	84		|O
(	84	85		|O
2+	85	87		|O
)	87	88		|O
-	88	89		|O
and	90	93		|O
phospholipid	94	106		|O
-	106	107		|O
binding	107	114		|O
protein	115	122		|O
Anx	123	126		|O
-	126	127		|O
A1	127	129		|O
(	130	131		|O
annexin	131	138		|O
1	139	140		|O
;	140	141		|O
lipocortin	142	152		|O
1	153	154		|O
)	154	155		|O
has	156	159		|O
been	160	164		|O
described	165	174		|O
both	175	179		|O
as	180	182		|O
an	183	185		|O
inhibitor	186	195		|O
of	196	198		|O
phospholipase	199	212		|O
A	213	214		|O
(	214	215		|O
2	215	216		|O
)	216	217		|O
(	218	219		|O
PLA	219	222		|O
(	222	223		|O
2	223	224		|O
)	224	225		|O
)	225	226		|O
activity	227	235		|O
and	236	239		|O
as	240	242		|O
a	243	244		|O
mediator	245	253		|O
of	254	256		|O
glucocorticoid	257	271	glucocorticoid	|B-FAMILY
-	271	272		|O
regulated	272	281		|O
cell	282	286		|O
growth	287	293		|O
and	294	297		|O
eicosanoid	298	308	eicosanoid	|B-TRIVIAL
generation	309	319		|O
.	319	320		|O
Here	321	325		|O
we	326	328		|O
show	329	333		|O
that	334	338		|O
,	338	339		|O
when	340	344		|O
compared	345	353		|O
with	354	358		|O
Anx	359	362		|O
-	362	363		|O
A1	363	365		|O
(	365	366		|O
+	366	367		|O
/	367	368		|O
+	368	369		|O
)	369	370		|O
cells	371	376		|O
,	376	377		|O
lung	378	382		|O
fibroblast	383	393		|O
cell	394	398		|O
lines	399	404		|O
derived	405	412		|O
from	413	417		|O
the	418	421		|O
Anx	422	425		|O
-	425	426		|O
A1	426	428		|O
(	428	429		|O
-	429	430		|O
/	430	431		|O
-	431	432		|O
)	432	433		|O
mouse	434	439		|O
exhibit	440	447		|O
an	448	450		|O
altered	451	458		|O
morphology	459	469		|O
characterized	470	483		|O
by	484	486		|O
a	487	488		|O
spindle	489	496		|O
-	496	497		|O
shaped	497	503		|O
appearance	504	514		|O
and	515	518		|O
an	519	521		|O
accumulation	522	534		|O
of	535	537		|O
intracellular	538	551		|O
organelles	552	562		|O
.	562	563		|O
Unlike	564	570		|O
their	571	576		|O
wild	577	581		|O
-	581	582		|O
type	582	586		|O
counterparts	587	599		|O
,	599	600		|O
Anx	601	604		|O
-	604	605		|O
A1	605	607		|O
(	607	608		|O
-	608	609		|O
/	609	610		|O
-	610	611		|O
)	611	612		|O
cells	613	618		|O
also	619	623		|O
overexpress	624	635		|O
cyclo	636	641		|O
-	641	642		|O
oxygenase	642	651		|O
2	652	653		|O
(	654	655		|O
COX	655	658		|O
2	659	660		|O
)	660	661		|O
,	661	662		|O
cytosolic	663	672		|O
PLA	673	676		|O
(	676	677		|O
2	677	678		|O
)	678	679		|O
and	680	683		|O
secretory	684	693		|O
PLA	694	697		|O
(	697	698		|O
2	698	699		|O
)	699	700		|O
and	701	704		|O
in	705	707		|O
response	708	716		|O
to	717	719		|O
fetal	720	725		|O
calf	726	730		|O
serum	731	736		|O
,	736	737		|O
exhibit	738	745		|O
an	746	748		|O
exaggerated	749	760		|O
release	761	768		|O
of	769	771		|O
eicosanoids	772	783	eicosanoids	|B-TRIVIAL
,	783	784		|O
which	785	790		|O
is	791	793		|O
insensitive	794	805		|O
to	806	808		|O
dexamethasone	809	822	dexamethasone	|B-TRIVIAL
(	823	824		|O
(	826	827		|O
-	827	828		|O
8	828	829		|O
)	829	830		|O
-	830	831		|O
(	834	835		|O
-	835	836		|O
6	836	837		|O
)	837	838		|O
M	839	840		|O
)	840	841		|O
inhibition	842	852		|O
.	852	853		|O
Proliferation	854	867		|O
and	868	871		|O
serum	872	877		|O
-	877	878		|O
induced	878	885		|O
progression	886	897		|O
of	898	900		|O
Anx	901	904		|O
-	904	905		|O
A1	905	907		|O
(	907	908		|O
+	908	909		|O
/	909	910		|O
+	910	911		|O
)	911	912		|O
cells	913	918		|O
from	919	923		|O
G	924	925		|O
(	925	926		|O
0	926	927		|O
)	927	928		|O
/	928	929		|O
G	929	930		|O
(	930	931		|O
1	931	932		|O
)	932	933		|O
into	934	938		|O
S	939	940		|O
phase	941	946		|O
,	946	947		|O
and	948	951		|O
the	952	955		|O
associated	956	966		|O
expression	967	977		|O
of	978	980		|O
extracellular	981	994		|O
signal	995	1001		|O
-	1001	1002		|O
regulated	1002	1011		|O
kinase	1012	1018		|O
2	1019	1020		|O
(	1021	1022		|O
ERK2	1022	1026		|O
)	1026	1027		|O
,	1027	1028		|O
cyclin	1029	1035		|O
-	1035	1036		|O
dependent	1036	1045		|O
kinase	1046	1052		|O
4	1053	1054		|O
(	1055	1056		|O
cdk4	1056	1060		|O
)	1060	1061		|O
and	1062	1065		|O
COX	1066	1069		|O
2	1070	1071		|O
,	1071	1072		|O
is	1073	1075		|O
strongly	1076	1084		|O
inhibited	1085	1094		|O
by	1095	1097		|O
dexamethasone	1098	1111		|O
,	1111	1112		|O
whereas	1113	1120		|O
Anx	1121	1124		|O
-	1124	1125		|O
A1	1125	1127		|O
(	1127	1128		|O
-	1128	1129		|O
/	1129	1130		|O
-	1130	1131		|O
)	1131	1132		|O
cells	1133	1138		|O
are	1139	1142		|O
refractory	1143	1153		|O
to	1154	1156		|O
the	1157	1160		|O
drug	1161	1165		|O
.	1165	1166		|O
Loss	1167	1171		|O
of	1172	1174		|O
the	1175	1178		|O
response	1179	1187		|O
to	1188	1190		|O
dexamethasone	1191	1204	dexamethasone	|B-TRIVIAL
in	1205	1207		|O
Anx	1208	1211		|O
-	1211	1212		|O
A1	1212	1214		|O
(	1214	1215		|O
-	1215	1216		|O
/	1216	1217		|O
-	1217	1218		|O
)	1218	1219		|O
cells	1220	1225		|O
occurs	1226	1232		|O
against	1233	1240		|O
a	1241	1242		|O
background	1243	1253		|O
of	1254	1256		|O
no	1257	1259		|O
apparent	1260	1268		|O
change	1269	1275		|O
in	1276	1278		|O
glucocorticoid	1279	1293		|O
receptor	1294	1302		|O
expression	1303	1313		|O
or	1314	1316		|O
sensitivity	1317	1328		|O
to	1329	1331		|O
non	1332	1335		|O
-	1335	1336		|O
steroidal	1336	1345		|O
anti	1346	1350		|O
-	1350	1351		|O
inflammatory	1351	1363		|O
drugs	1364	1369		|O
.	1369	1370		|O
Taken	1371	1376		|O
together	1377	1385		|O
,	1385	1386		|O
these	1387	1392		|O
observations	1393	1405		|O
suggest	1406	1413		|O
strongly	1414	1422		|O
that	1423	1427		|O
Anx	1428	1431		|O
-	1431	1432		|O
A1	1432	1434		|O
functions	1435	1444		|O
as	1445	1447		|O
an	1448	1450		|O
inhibitor	1451	1460		|O
of	1461	1463		|O
signal	1464	1470		|O
-	1470	1471		|O
transduction	1471	1483		|O
pathways	1484	1492		|O
that	1493	1497		|O
lead	1498	1502		|O
to	1503	1505		|O
cell	1506	1510		|O
proliferation	1511	1524		|O
and	1525	1528		|O
may	1529	1532		|O
help	1533	1537		|O
to	1538	1540		|O
explain	1541	1548		|O
how	1549	1552		|O
glucocorticoids	1553	1568	glucocorticoids	|B-FAMILY
regulate	1568	1576		|O
these	1578	1583		|O
processes	1584	1593		|O
.	1593	1594		|O

### 14591846
14591846	0	8		|O
Cognitive	10	19		|O
assessment	20	30		|O
of	31	33		|O
geriatric	34	43		|O
schizophrenic	44	57		|O
patients	58	66		|O
with	67	71		|O
severe	72	78		|O
impairment	79	89		|O
.	89	90		|O
There	92	97		|O
is	98	100		|O
evidence	101	109		|O
that	110	114		|O
some	115	119		|O
elderly	120	127		|O
patients	128	136		|O
with	137	141		|O
chronic	142	149		|O
schizophrenia	150	163		|O
experience	164	174		|O
marked	175	181		|O
impairments	182	193		|O
in	194	196		|O
cognitive	197	206		|O
functioning	207	218		|O
.	218	219		|O
Assessment	220	230		|O
of	231	233		|O
these	234	239		|O
patients	240	248		|O
may	249	252		|O
be	253	255		|O
difficult	256	265		|O
with	266	270		|O
traditional	271	282		|O
neuropsychological	283	301		|O
measures	302	310		|O
.	310	311		|O
The	312	315		|O
purpose	316	323		|O
of	324	326		|O
the	327	330		|O
present	331	338		|O
study	339	344		|O
was	345	348		|O
to	349	351		|O
determine	352	361		|O
if	362	364		|O
cognitive	365	374		|O
functioning	375	386		|O
could	387	392		|O
be	393	395		|O
validly	396	403		|O
assessed	404	412		|O
with	413	417		|O
the	418	421		|O
Alzheimer	422	431		|O
's	431	433		|O
Disease	434	441		|O
Assessment	442	452		|O
Scale	453	458		|O
-	458	459		|O
Late	459	463		|O
Version	464	471		|O
Cognitive	472	481		|O
factor	482	488		|O
score	489	494		|O
(	495	496		|O
ADAS	496	500		|O
-	500	501		|O
L	501	502		|O
Cog	503	506		|O
)	506	507		|O
in	508	510		|O
patients	511	519		|O
whose	520	525		|O
scores	526	532		|O
on	533	535		|O
the	536	539		|O
Mini	540	544		|O
-	544	545		|O
Mental	545	551		|O
State	552	557		|O
Examination	558	569		|O
(	570	571		|O
MMSE	571	575		|O
)	575	576		|O
reflect	577	584		|O
profound	585	593		|O
cognitive	594	603		|O
impairment	604	614		|O
.	614	615		|O
Patients	616	624		|O
with	625	629		|O
MMSE	630	634		|O
scores	635	641		|O
from	642	646		|O
0	647	648		|O
to	649	651		|O
were	655	659		|O
selected	660	668		|O
from	669	673		|O
a	674	675		|O
larger	676	682		|O
database	683	691		|O
.	691	692		|O
Neuropsychological	693	711		|O
instruments	712	723		|O
designed	724	732		|O
for	733	736		|O
the	737	740		|O
assessment	741	751		|O
of	752	754		|O
mild	755	759		|O
to	760	762		|O
moderate	763	771		|O
dementia	772	780		|O
were	781	785		|O
found	786	791		|O
to	792	794		|O
be	795	797		|O
inadequate	798	808		|O
in	809	811		|O
this	812	816		|O
profoundly	817	827		|O
impaired	828	836		|O
population	837	847		|O
,	847	848		|O
due	849	852		|O
to	853	855		|O
floor	856	861		|O
effects	862	869		|O
.	869	870		|O
In	871	873		|O
contrast	874	882		|O
,	882	883		|O
there	884	889		|O
was	890	893		|O
a	894	895		|O
significant	896	907		|O
relationship	908	920		|O
between	921	928		|O
ADAS	929	933		|O
-	933	934		|O
L	934	935		|O
scores	936	942		|O
and	943	946		|O
several	947	954		|O
criterion	955	964		|O
measures	965	973		|O
,	973	974		|O
including	975	984		|O
the	985	988		|O
MMSE	989	993		|O
(	994	995		|O
R	995	996		|O
=	996	997		|O
-	997	998		|O
.71	998	1001		|O
,	1001	1002		|O
P	1003	1004		|O
<	1004	1005		|O
.001	1005	1009		|O
)	1009	1010		|O
,	1010	1011		|O
the	1012	1015		|O
Social	1016	1022		|O
Adaptive	1023	1031		|O
Functions	1032	1041		|O
Evaluation	1042	1052		|O
(	1053	1054		|O
SAFE	1054	1058		|O
)	1058	1059		|O
social	1060	1066		|O
functions	1067	1076		|O
scale	1077	1082		|O
(	1083	1084		|O
R	1084	1085		|O
=	1085	1086		|O
.47	1086	1089		|O
,	1089	1090		|O
P	1091	1092		|O
<	1092	1093		|O
.001	1093	1097		|O
)	1097	1098		|O
,	1098	1099		|O
and	1100	1103		|O
the	1104	1107		|O
negative	1108	1116		|O
symptom	1117	1124		|O
total	1125	1130		|O
score	1131	1136		|O
of	1137	1139		|O
the	1140	1143		|O
Positive	1144	1152		|O
and	1153	1156		|O
Negative	1157	1165		|O
Syndrome	1166	1174		|O
Scale	1175	1180		|O
(	1181	1182		|O
PANSS	1182	1187		|O
)	1187	1188		|O
(	1189	1190		|O
R	1190	1191		|O
=	1191	1192		|O
.412	1192	1196		|O
,	1196	1197		|O
P	1198	1199		|O
<	1199	1200		|O
.001	1200	1204		|O
)	1204	1205		|O
.	1205	1206		|O
The	1207	1210		|O
MMSE	1211	1215		|O
was	1216	1219		|O
somewhat	1220	1228		|O
less	1229	1233		|O
strongly	1234	1242		|O
correlated	1243	1253		|O
with	1254	1258		|O
both	1259	1263		|O
social	1264	1270		|O
functions	1271	1280		|O
(	1281	1282		|O
R	1282	1283		|O
=	1283	1284		|O
-	1284	1285		|O
.401	1285	1289		|O
,	1289	1290		|O
P	1291	1292		|O
<	1292	1293		|O
.001	1293	1297		|O
)	1297	1298		|O
and	1299	1302		|O
the	1303	1306		|O
negative	1307	1315		|O
symptom	1316	1323		|O
total	1324	1329		|O
score	1330	1335		|O
of	1336	1338		|O
the	1339	1342		|O
PANSS	1343	1348		|O
(	1349	1350		|O
R	1350	1351		|O
=	1351	1352		|O
-	1352	1353		|O
.366	1353	1357		|O
,	1357	1358		|O
P	1359	1360		|O
<	1360	1361		|O
.001	1361	1365		|O
)	1365	1366		|O
.	1366	1367		|O
These	1368	1373		|O
results	1374	1381		|O
suggest	1382	1389		|O
that	1390	1394		|O
cognition	1395	1404		|O
can	1405	1408		|O
be	1409	1411		|O
reliably	1412	1420		|O
and	1421	1424		|O
validly	1425	1432		|O
assessed	1433	1441		|O
with	1442	1446		|O
instruments	1447	1458		|O
such	1459	1463		|O
as	1464	1466		|O
the	1467	1470		|O
ADAS	1471	1475		|O
-	1475	1476		|O
L	1476	1477		|O
that	1478	1482		|O
are	1483	1486		|O
designed	1487	1495		|O
for	1496	1499		|O
the	1500	1503		|O
assessment	1504	1514		|O
of	1515	1517		|O
severely	1518	1526		|O
impaired	1527	1535		|O
patients	1536	1544		|O
.	1544	1545		|O

### 721701
Evidence	9	17		|O
for	18	21		|O
messenger	22	31		|O
ribonucleic	32	43		|O
acid	44	48		|O
of	49	51		|O
an	52	54		|O
ammonium	55	63		|O
-	63	64		|O
inducible	64	73		|O
glutamate	74	83		|O
dehydrogenase	84	97		|O
and	98	101		|O
synthesis	102	111		|O
,	111	112		|O
covalent	113	121		|O
modification	122	134		|O
,	134	135		|O
and	136	139		|O
degradation	140	151		|O
of	152	154		|O
enzyme	155	161		|O
subunits	162	170		|O
in	171	173		|O
uninduced	174	183		|O
Chlorella	184	193		|O
sorokiniana	194	205		|O
cells	206	211		|O
.	211	212		|O
The	214	217		|O
cells	218	223		|O
of	224	226		|O
Chlorella	227	236		|O
sorokiniana	237	248		|O
cultured	249	257		|O
in	258	260		|O
nitrate	261	268	nitrate	|B-TRIVIAL
medium	269	275		|O
contain	276	283		|O
no	284	286		|O
detectable	287	297		|O
catalytic	298	307		|O
activity	308	316		|O
of	317	319		|O
an	320	322		|O
ammonium	323	331		|O
-	331	332		|O
inducible	332	341		|O
nicotinamide	342	354		|O
adenine	355	362		|O
dinucleotide	363	375		|O
phosphate	376	385		|O
-	385	386		|O
specific	386	394		|O
glutamate	395	404		|O
dehydrogenase	405	418		|O
(	419	420		|O
NADP	420	424		|O
-	424	425		|O
GDH	425	428		|O
)	428	429		|O
.	429	430		|O
However	431	438		|O
,	438	439		|O
several	440	447		|O
lines	448	453		|O
of	454	456		|O
experimental	457	469		|O
evidence	470	478		|O
indicated	479	488		|O
that	489	493		|O
the	494	497		|O
NADP	498	502		|O
-	502	503		|O
GDH	503	506		|O
messenger	507	516		|O
ribonucleic	517	528		|O
acid	529	533		|O
was	534	537		|O
present	538	545		|O
at	546	548		|O
high	549	553		|O
levels	554	560		|O
and	561	564		|O
was	565	568		|O
being	569	574		|O
translated	575	585		|O
in	586	588		|O
uninduced	589	598		|O
cells	599	604		|O
.	604	605		|O
First	606	611		|O
,	611	612		|O
binding	613	620		|O
studies	621	628		|O
with	629	633		|O
125I	634	638		|O
-	638	639		|O
labeled	639	646		|O
anti	647	651		|O
-	651	652		|O
NADP	652	656		|O
-	656	657		|O
GDH	657	660		|O
immunoglobulin	661	675		|O
G	676	677		|O
and	678	681		|O
total	682	687		|O
polysomes	688	697		|O
isolated	698	706		|O
from	707	711		|O
uninduced	712	721		|O
and	722	725		|O
induced	726	733		|O
cells	734	739		|O
showed	740	746		|O
that	747	751		|O
NADP	752	756		|O
-	756	757		|O
GDH	757	760		|O
subunits	761	769		|O
were	770	774		|O
being	775	780		|O
synthesized	781	792		|O
on	793	795		|O
polysomes	796	805		|O
from	806	810		|O
both	811	815		|O
types	816	821		|O
of	822	824		|O
cells	825	830		|O
.	830	831		|O
Second	832	838		|O
,	838	839		|O
when	840	844		|O
polyadenylic	845	857	polyadenylic acid	|B-IUPAC
acid	858	862		|I-IUPAC
-	862	863		|O
containing	863	873		|O
ribonucleic	874	885		|O
acid	886	890		|O
was	891	894		|O
extracted	895	904		|O
from	905	909		|O
polysomes	910	919		|O
from	920	924		|O
uninduced	925	934		|O
and	935	938		|O
induced	939	946		|O
cells	947	952		|O
and	953	956		|O
placed	957	963		|O
into	964	968		|O
a	969	970		|O
messenger	971	980		|O
ribonucleic	981	992		|O
acid	993	997		|O
-	997	998		|O
dependent	998	1007		|O
in	1008	1010		|O
vitro	1011	1016		|O
translation	1017	1028		|O
system	1029	1035		|O
,	1035	1036		|O
NADP	1037	1041		|O
-	1041	1042		|O
GDH	1042	1045		|O
subunits	1046	1054		|O
were	1055	1059		|O
synthesized	1060	1071		|O
from	1072	1076		|O
the	1077	1080		|O
ribonucleic	1081	1092		|O
acid	1093	1097		|O
from	1098	1102		|O
both	1103	1107		|O
sources	1108	1115		|O
.	1115	1116		|O
Third	1117	1122		|O
,	1122	1123		|O
when	1124	1128		|O
ammonia	1129	1136	ammonia	|B-FAMILY
was	1137	1140		|O
added	1141	1146		|O
to	1147	1149		|O
uninduced	1150	1159		|O
cells	1160	1165		|O
,	1165	1166		|O
NADP	1167	1171		|O
-	1171	1172		|O
GDH	1172	1175		|O
antigen	1176	1183		|O
accumulated	1184	1195		|O
without	1196	1203		|O
an	1204	1206		|O
apparent	1207	1215		|O
induction	1216	1225		|O
lag	1226	1229		|O
.	1229	1230		|O
Fourth	1231	1237		|O
,	1237	1238		|O
by	1239	1241		|O
use	1242	1245		|O
of	1246	1248		|O
a	1249	1250		|O
specific	1251	1259		|O
immunoprecipitation	1260	1279		|O
procedure	1280	1289		|O
coupled	1290	1297		|O
to	1298	1300		|O
pulse	1301	1306		|O
-	1306	1307		|O
chase	1307	1312		|O
studies	1313	1320		|O
with	1321	1325		|O
[	1326	1327	[35S]sulfate	|B-IUPAC
35S	1327	1330		|I-IUPAC
]	1330	1331		|I-IUPAC
sulfate	1331	1338		|I-IUPAC
,	1338	1339		|O
it	1340	1342		|O
was	1343	1346		|O
shown	1347	1352		|O
that	1353	1357		|O
the	1358	1361		|O
NADP	1362	1366		|O
-	1366	1367		|O
GDH	1367	1370		|O
subunits	1371	1379		|O
are	1380	1383		|O
rapidly	1384	1391		|O
synthesized	1392	1403		|O
,	1403	1404		|O
covalently	1405	1415		|O
modified	1416	1424		|O
,	1424	1425		|O
and	1426	1429		|O
then	1430	1434		|O
degraded	1435	1443		|O
in	1444	1446		|O
uninduced	1447	1456		|O
cells	1457	1462		|O
.	1462	1463		|O

### 1350435
Nucleotide	9	19	Nucleotide	|B-FAMILY
regulation	20	30		|O
of	31	33		|O
heat	34	38		|O
-	38	39		|O
stable	39	45		|O
enterotoxin	46	57		|O
receptor	58	66		|O
binding	67	74		|O
and	75	78		|O
of	79	81		|O
guanylate	82	91		|O
cyclase	92	99		|O
activation	100	110		|O
.	110	111		|O
Certain	113	120		|O
nucleotides	121	132	nucleotides	|B-FAMILY
were	133	137		|O
found	138	143		|O
to	144	146		|O
regulate	147	155		|O
the	156	159		|O
binding	160	167		|O
of	168	170		|O
the	171	174		|O
Escherichia	175	186		|O
coli	187	191		|O
heat	192	196		|O
-	196	197		|O
stable	197	203		|O
enterotoxin	204	215		|O
(	216	217		|O
STa	217	220		|O
)	220	221		|O
to	222	224		|O
its	225	228		|O
receptor	229	237		|O
in	238	240		|O
pig	241	244		|O
intestinal	245	255		|O
brush	256	261		|O
border	262	268		|O
membranes	269	278		|O
.	278	279		|O
ATP	280	283	ATP	|B-ABBREVIATION
and	284	287		|O
adenine	288	295	adenine	|B-TRIVIAL
nucleotide	296	306	nucleotide	|B-FAMILY
analogues	307	316	analogues	|B-MODIFIER
inhibited	317	326		|O
125I	327	331		|O
-	331	332		|O
STa	332	335		|O
binding	336	343		|O
,	343	344		|O
while	345	350		|O
guanine	351	358	guanine	|B-TRIVIAL
nucleotide	359	369	nucleotide	|B-FAMILY
analogues	370	379	analogues	|B-MODIFIER
stimulated	380	390		|O
binding	391	398		|O
,	398	399		|O
with	400	404		|O
maximal	405	412		|O
effects	413	420		|O
at	421	423		|O
0.5-1.0	424	431		|O
mM	432	434		|O
.	434	435		|O
The	436	439		|O
strongest	440	449		|O
inhibitors	450	460		|O
were	461	465		|O
adenosine	466	475	adenosine 5'-[beta gamma-imido]triphosphate	|B-IUPAC
5'	476	478		|I-IUPAC
-	478	479		|I-IUPAC
[	479	480		|I-IUPAC
beta	480	484		|I-IUPAC
gamma	485	490		|I-IUPAC
-	490	491		|I-IUPAC
imido	491	496		|I-IUPAC
]	496	497		|I-IUPAC
triphosphate	497	509		|I-IUPAC
(	510	511		|O
App	511	514	App[NH]p	|B-ABBREVIATION
[	514	515		|I-ABBREVIATION
NH	515	517		|I-ABBREVIATION
]	517	518		|I-ABBREVIATION
p	518	519		|I-ABBREVIATION
)	519	520		|O
(	521	522		|O
36%	522	525		|O
)	525	526		|O
and	527	530		|O
adenosine	531	540	adenosine 5'-[beta-thio]diphosphate	|B-IUPAC
5'	541	543		|I-IUPAC
-	543	544		|I-IUPAC
[	544	545		|I-IUPAC
beta	545	549		|I-IUPAC
-	549	550		|I-IUPAC
thio	550	554		|I-IUPAC
]	554	555		|I-IUPAC
diphosphate	555	566		|I-IUPAC
(	567	568		|O
ADP	568	571	ADP[S]	|B-ABBREVIATION
[	571	572		|I-ABBREVIATION
S	572	573		|I-ABBREVIATION
]	573	574		|I-ABBREVIATION
)	574	575		|O
(	576	577		|O
41%	577	580		|O
)	580	581		|O
.	581	582		|O
Inhibition	583	593		|O
did	594	597		|O
not	598	601		|O
require	602	609		|O
Mg2+	610	614	Mg2+	|B-SUM
,	614	615		|O
and	616	619		|O
was	620	623		|O
blocked	624	631		|O
by	632	634		|O
p	635	636	p-chloromercuribenzenesulphonate	|B-IUPAC
-	636	637		|I-IUPAC
chloromercuribenzenesulphonate	637	667		|I-IUPAC
(	668	669		|O
PCMBS	669	674	PCMBS	|B-ABBREVIATION
)	674	675		|O
.	675	676		|O
Stimulation	677	688		|O
of	689	691		|O
binding	692	699		|O
required	700	708		|O
Mg2+	709	713	Mg2+	|B-SUM
,	713	714		|O
was	715	718		|O
not	719	722		|O
prevented	723	732		|O
by	733	735		|O
PCMBS	736	741	PCMBS	|B-ABBREVIATION
and	742	745		|O
was	746	749		|O
maximal	750	757		|O
with	758	762		|O
GDP	763	766	GDP[S]	|B-ABBREVIATION
[	766	767		|I-ABBREVIATION
S	767	768		|I-ABBREVIATION
]	768	769		|I-ABBREVIATION
(	770	771		|O
41%	771	774		|O
)	774	775		|O
.	775	776		|O
While	777	782		|O
App	783	786	App[NH]p	|B-ABBREVIATION
[	786	787		|I-ABBREVIATION
NH	787	789		|I-ABBREVIATION
]	789	790		|I-ABBREVIATION
p	790	791		|I-ABBREVIATION
and	792	795		|O
MgGDP	796	801	MgGDP[S]	|B-ABBREVIATION
[	801	802		|I-ABBREVIATION
S	802	803		|I-ABBREVIATION
]	803	804		|I-ABBREVIATION
appeared	805	813		|O
to	814	816		|O
be	817	819		|O
acting	820	826		|O
at	827	829		|O
different	830	839		|O
sites	840	845		|O
,	845	846		|O
they	847	851		|O
also	852	856		|O
interfered	857	867		|O
with	868	872		|O
each	873	877		|O
other	878	883		|O
.	883	884		|O
These	885	890		|O
nucleotides	891	902	nucleotides	|B-FAMILY
exerted	903	910		|O
only	911	915		|O
inhibitory	916	926		|O
effects	927	934		|O
on	935	937		|O
STa	938	941		|O
-	941	942		|O
stimulated	942	952		|O
guanylate	953	962		|O
cyclase	963	970		|O
activity	971	979		|O
,	979	980		|O
in	981	983		|O
contrast	984	992		|O
with	993	997		|O
the	998	1001		|O
stimulatory	1002	1013		|O
effects	1014	1021		|O
of	1022	1024		|O
adenine	1025	1032	adenine	|B-TRIVIAL
nucleotides	1033	1044		|O
on	1045	1047		|O
atrial	1048	1054		|O
natriuretic	1055	1066		|O
peptide	1067	1074		|O
(	1075	1076		|O
ANP	1076	1079		|O
)	1079	1080		|O
-	1080	1081		|O
stimulated	1081	1091		|O
guanylate	1092	1101		|O
cyclase	1102	1109		|O
.	1109	1110		|O
Inhibition	1111	1121		|O
by	1122	1124		|O
low	1125	1128		|O
concentrations	1129	1143		|O
of	1144	1146		|O
MgApp	1146	1151	 MgApp[NH]p	|B-ABBREVIATION
[	1152	1153		|I-ABBREVIATION
NH	1153	1155		|I-ABBREVIATION
]	1155	1156		|I-ABBREVIATION
p	1156	1157		|I-ABBREVIATION
and	1158	1161		|O
MgATP	1162	1167	MgATP	|B-ABBREVIATION
was	1168	1171		|O
weaker	1172	1178		|O
above	1179	1184		|O
0.1	1185	1188		|O
mM	1189	1191		|O
,	1191	1192		|O
while	1193	1198		|O
MgGDP	1199	1204	MgGDP[S]	|B-ABBREVIATION
[	1204	1205		|I-ABBREVIATION
S	1205	1206		|I-ABBREVIATION
]	1206	1207		|I-ABBREVIATION
and	1208	1211		|O
magnesium	1212	1221	magnesium guanosine 5'-[gamma-thio]triphosphate	|B-IUPAC
guanosine	1222	1231		|I-IUPAC
5'	1232	1234		|I-IUPAC
-	1234	1235		|I-IUPAC
[	1235	1236		|I-IUPAC
gamma	1236	1241		|I-IUPAC
-	1241	1242		|I-IUPAC
thio	1242	1246		|I-IUPAC
]	1246	1247		|I-IUPAC
triphosphate	1247	1259		|I-IUPAC
(	1260	1261		|O
MgGTP	1261	1266	MgGTP[S]	|B-ABBREVIATION
[	1266	1267		|I-ABBREVIATION
S	1267	1268		|I-ABBREVIATION
]	1268	1269		|I-ABBREVIATION
)	1269	1270		|O
inhibited	1271	1280		|O
in	1281	1283		|O
a	1284	1285		|O
single	1286	1292		|O
phase	1293	1298		|O
.	1298	1299		|O
Inhibition	1300	1310		|O
by	1311	1313		|O
MgApp	1314	1319	MgApp[NH]p	|B-ABBREVIATION
[	1319	1320		|I-ABBREVIATION
NH	1320	1322		|I-ABBREVIATION
]	1322	1323		|I-ABBREVIATION
p	1323	1324		|I-ABBREVIATION
,	1324	1325		|O
at	1326	1328		|O
all	1329	1332		|O
concentrations	1333	1347		|O
,	1347	1348		|O
was	1349	1352		|O
competitive	1353	1364		|O
with	1365	1369		|O
the	1370	1373		|O
substrate	1374	1383		|O
(	1384	1385		|O
MgGTP	1385	1390	MgGTP	|B-ABBREVIATION
)	1390	1391		|O
,	1391	1392		|O
as	1393	1395		|O
was	1396	1399		|O
that	1400	1404		|O
by	1405	1407		|O
MgGDP	1408	1413	MgGDP[S]	|B-ABBREVIATION
[	1413	1414		|I-ABBREVIATION
S	1414	1415		|I-ABBREVIATION
]	1415	1416		|I-ABBREVIATION
and	1417	1420		|O
MgGTP	1421	1426	MgGTP[S]	|B-ABBREVIATION
[	1426	1427		|I-ABBREVIATION
S	1427	1428		|I-ABBREVIATION
]	1428	1429		|I-ABBREVIATION
.	1429	1430		|O
Whereas	1431	1438		|O
membrane	1439	1447		|O
guanylate	1448	1457		|O
cyclases	1458	1466		|O
usually	1467	1474		|O
show	1475	1479		|O
positively	1480	1490		|O
co	1491	1493		|O
-	1493	1494		|O
operative	1494	1503		|O
kinetics	1504	1512		|O
with	1513	1517		|O
respect	1518	1525		|O
to	1526	1528		|O
the	1529	1532		|O
substrate	1533	1542		|O
,	1542	1543		|O
STa	1544	1547		|O
-	1547	1548		|O
stimulated	1548	1558		|O
activity	1559	1567		|O
exhibited	1568	1577		|O
Michaelis	1578	1587		|O
-	1587	1588		|O
Menten	1588	1594		|O
kinetics	1595	1603		|O
with	1604	1608		|O
respect	1609	1616		|O
to	1617	1619		|O
MgGTP	1620	1625	MgGTP	|B-ABBREVIATION
.	1625	1626		|O
This	1627	1631		|O
changed	1632	1639		|O
to	1640	1642		|O
positive	1643	1651		|O
co	1652	1654		|O
-	1654	1655		|O
operativity	1655	1666		|O
when	1667	1671		|O
Lubrol	1672	1678	Lubrol PX	|B-TRIVIAL
PX	1679	1681		|I-TRIVIAL
was	1682	1685		|O
the	1686	1689		|O
activator	1690	1699		|O
,	1699	1700		|O
or	1701	1703		|O
when	1704	1708		|O
the	1709	1712		|O
substrate	1713	1722		|O
was	1723	1726		|O
MnGTP	1727	1732	MnGTP	|B-ABBREVIATION
.	1732	1733		|O
These	1734	1739		|O
results	1740	1747		|O
suggest	1748	1755		|O
the	1756	1759		|O
presence	1760	1768		|O
of	1769	1771		|O
both	1772	1776		|O
a	1777	1778		|O
regulatory	1779	1789		|O
and	1790	1793		|O
a	1794	1795		|O
catalytic	1796	1805		|O
nucleotide	1806	1816		|O
-	1816	1817		|O
binding	1817	1824		|O
site	1825	1829		|O
,	1829	1830		|O
which	1831	1836		|O
do	1837	1839		|O
not	1840	1843		|O
interact	1844	1852		|O
co	1853	1855		|O
-	1855	1856		|O
operatively	1856	1867		|O
with	1868	1872		|O
STa	1873	1876		|O
activation	1877	1887		|O
.	1887	1888		|O

### 6292417
The	0	3		|O
syntheses	4	13		|O
of	14	16		|O
(	17	18	(3RS,4RS)-4-hydroxypiperidine-3-carboxylic acid	|B-IUPAC
3RS	18	21		|I-IUPAC
,	21	22		|I-IUPAC
4RS	22	25		|I-IUPAC
)	25	26		|I-IUPAC
-	26	27		|I-IUPAC
4	27	28		|I-IUPAC
-	28	29		|I-IUPAC
hydroxypiperidine	29	46		|I-IUPAC
-	46	47		|I-IUPAC
3	47	48		|I-IUPAC
-	48	49		|I-IUPAC
carboxylic	49	59		|I-IUPAC
acid	60	64		|I-IUPAC
(	65	66		|O
4	66	67		|O
)	67	68		|O
,	68	69		|O
(	70	71	(3RS,5SR)-5-hydroxypiperidine-3-carboxylic acid	|B-IUPAC
3RS	71	74		|I-IUPAC
,	74	75		|I-IUPAC
5SR	75	78		|I-IUPAC
)	78	79		|I-IUPAC
-	79	80		|I-IUPAC
5	80	81		|I-IUPAC
-	81	82		|I-IUPAC
hydroxypiperidine	82	99		|I-IUPAC
-	99	100		|I-IUPAC
3	100	101		|I-IUPAC
-	101	102		|I-IUPAC
carboxylic	102	112		|I-IUPAC
acid	113	117		|I-IUPAC
(	118	119		|O
)	121	122		|O
,	122	123		|O
(	124	125	(3RS,4SR)-4-acetamidopiperidine-3-carboxylic acid	|B-IUPAC
3RS	125	128		|I-IUPAC
,	128	129		|I-IUPAC
4SR	129	132		|I-IUPAC
)	132	133		|I-IUPAC
-	133	134		|I-IUPAC
4	134	135		|I-IUPAC
-	135	136		|I-IUPAC
acetamidopiperidine	136	155		|I-IUPAC
-	155	156		|I-IUPAC
3	156	157		|I-IUPAC
-	157	158		|I-IUPAC
carboxylic	158	168		|I-IUPAC
acid	169	173		|I-IUPAC
(	174	175		|O
)	177	178		|O
,	178	179		|O
and	180	183		|O
(	184	185	(3RS,5SR)-5-acetamidopiperidine-3-carboxylic acid	|B-IUPAC
3RS	185	188		|I-IUPAC
,	188	189		|I-IUPAC
5SR	189	192		|I-IUPAC
)	192	193		|I-IUPAC
-	193	194		|I-IUPAC
5	194	195		|I-IUPAC
-	195	196		|I-IUPAC
acetamidopiperidine	196	215		|I-IUPAC
-	215	216		|I-IUPAC
3	216	217		|I-IUPAC
-	217	218		|I-IUPAC
carboxylic	218	228		|I-IUPAC
acid	229	233		|I-IUPAC
(	234	235		|O
18	235	237		|O
)	237	238		|O
,	238	239		|O
related	240	247		|O
to	248	250		|O
the	251	254		|O
specific	255	263		|O
gamma	264	269	gamma-aminobutyric acid	|B-IUPAC
-	269	270		|I-IUPAC
aminobutyric	270	282		|I-IUPAC
acid	283	287		|I-IUPAC
(	288	289		|O
GABA	289	293	GABA	|B-ABBREVIATION
)	293	294		|O
uptake	295	301		|O
inhibitors	302	312		|O
(	313	314	(RS)-piperidine-3-carboxylic acid	|B-IUPAC
RS	314	316		|I-IUPAC
)	316	317		|I-IUPAC
-	317	318		|I-IUPAC
piperidine	318	328		|I-IUPAC
-	328	329		|I-IUPAC
3	329	330		|I-IUPAC
-	330	331		|I-IUPAC
carboxylic	331	341		|I-IUPAC
acid	342	346		|I-IUPAC
(	347	348		|O
nipecotic	348	357	nipecotic acid	|B-IUPAC
acid	358	362		|I-IUPAC
)	362	363		|O
and	364	367		|O
(	368	369	(3RS,4SR)-4-hydroxypiperidine-3-carboxylic acid	|B-IUPAC
3RS	369	372		|I-IUPAC
,	372	373		|I-IUPAC
4SR	373	376		|I-IUPAC
)	376	377		|I-IUPAC
-	377	378		|I-IUPAC
4	378	379		|I-IUPAC
-	379	380		|I-IUPAC
hydroxypiperidine	380	397		|I-IUPAC
-	397	398		|I-IUPAC
3	398	399		|I-IUPAC
-	399	400		|I-IUPAC
carboxylic	400	410		|I-IUPAC
acid	411	415		|I-IUPAC
(	416	417		|O
21	417	419		|O
)	419	420		|O
,	420	421		|O
are	422	425		|O
described	426	435		|O
.	435	436		|O
Furthermore	437	448		|O
,	448	449		|O
(	450	451	(3RS,4SR)-3-hydroxypiperidine-4-carboxylic acid	|B-IUPAC
3RS	451	454		|I-IUPAC
,	454	455		|I-IUPAC
4SR	455	458		|I-IUPAC
)	458	459		|I-IUPAC
-	459	460		|I-IUPAC
3	460	461		|I-IUPAC
-	461	462		|I-IUPAC
hydroxypiperidine	462	479		|I-IUPAC
-	479	480		|I-IUPAC
4	480	481		|I-IUPAC
-	481	482		|I-IUPAC
carboxylic	482	492		|I-IUPAC
acid	493	497		|I-IUPAC
(	498	499		|O
14	499	501		|O
)	501	502		|O
,	502	503		|O
related	504	511		|O
to	512	514		|O
the	515	518		|O
specific	519	527		|O
GABA	528	532	GABA	|B-ABBREVIATION
agonist	533	540		|O
piperidine	541	551	piperidine-4-carboxylic acid	|B-IUPAC
-	551	552		|I-IUPAC
4	552	553		|I-IUPAC
-	553	554		|I-IUPAC
carboxylic	554	564		|I-IUPAC
acid	565	569		|I-IUPAC
(	570	571		|O
isonipecotic	571	583	isonipecotic acid	|B-IUPAC
acid	584	588		|I-IUPAC
)	588	589		|O
,	589	590		|O
has	591	594		|O
been	595	599		|O
synthesized	600	611		|O
.	611	612		|O
The	613	616		|O
structures	617	627		|O
of	628	630		|O
4	631	632		|O
,	632	633		|O
,	636	637		|O
14	638	640		|O
,	640	641		|O
18	642	644		|O
,	644	645		|O
and	646	649		|O
have	653	657		|O
been	658	662		|O
established	663	674		|O
by	675	677		|O
-	681	682		|O
MHz	682	685		|O
1H	686	688		|O
NMR	689	692		|O
spectroscopic	693	706		|O
analyses	707	715		|O
.	715	716		|O
The	717	720		|O
affinity	721	729		|O
of	730	732		|O
the	733	736		|O
compounds	737	746		|O
for	747	750		|O
the	751	754		|O
GABA	755	759		|O
receptors	760	769		|O
and	770	773		|O
for	774	777		|O
the	778	781		|O
neuronal	782	790		|O
(	791	792		|O
synaptosomal	792	804		|O
)	804	805		|O
GABA	806	810	GABA	|B-ABBREVIATION
uptake	811	817		|O
system	818	824		|O
in	825	827		|O
vitro	828	833		|O
has	834	837		|O
been	838	842		|O
measured	843	851		|O
.	851	852		|O
Compound	853	861		|O
14	862	864		|O
interacts	865	874		|O
selectively	875	886		|O
with	887	891		|O
the	892	895		|O
GABA	896	900		|O
receptors	901	910		|O
but	911	914		|O
less	915	919		|O
effectively	920	931		|O
than	932	936		|O
isonipecotic	937	949	isonipecotic acid	|B-IUPAC
acid	950	954		|I-IUPAC
and	955	958		|O
the	959	962		|O
cis	963	966		|O
-	966	967		|O
isomer	967	973		|O
22	974	976		|O
.	976	977		|O
Compounds	978	987		|O
4	988	989		|O
,	989	990		|O
18	991	993		|O
,	993	994		|O
and	995	998		|O
are	1002	1005		|O
inhibitors	1006	1016		|O
of	1017	1019		|O
the	1020	1023		|O
GABA	1024	1028	GABA	|B-ABBREVIATION
uptake	1029	1035		|O
system	1036	1042		|O
,	1042	1043		|O
although	1044	1052		|O
much	1053	1057		|O
weaker	1058	1064		|O
than	1065	1069		|O
nipecotic	1070	1079	nipecotic acid	|B-IUPAC
acid	1080	1084		|I-IUPAC
and	1085	1088		|O
(	1089	1090	(3RS,4SR)-4-hydroxypiperidine-3-carboxylic acid	|B-IUPAC
3RS	1090	1093		|I-IUPAC
,	1093	1094		|I-IUPAC
4SR	1094	1097		|I-IUPAC
)	1097	1098		|I-IUPAC
-	1098	1099		|I-IUPAC
4	1099	1100		|I-IUPAC
-	1100	1101		|I-IUPAC
hydroxypiperidine	1101	1118		|I-IUPAC
-	1118	1119		|I-IUPAC
3	1119	1120		|I-IUPAC
-	1120	1121		|I-IUPAC
carboxylic	1121	1131		|I-IUPAC
acid	1132	1136		|I-IUPAC
(	1136	1137		|O
21	1138	1140		|O
)	1140	1141		|O
.	1141	1142		|O
Compound	1143	1151		|O
is	1155	1157		|O
inactive	1158	1166		|O
in	1167	1169		|O
both	1170	1174		|O
test	1175	1179		|O
systems	1180	1187		|O
.	1187	1188		|O

### 16946562
16946562	0	8		|O
Novel	10	15		|O
genetic	16	23		|O
variations	24	34		|O
and	35	38		|O
haplotypes	39	49		|O
of	50	52		|O
hepatocyte	53	63		|O
nuclear	64	71		|O
factor	72	78		|O
4alpha	79	85		|O
(	86	87		|O
HNF4A	87	92		|O
)	92	93		|O
found	94	99		|O
in	100	102		|O
Japanese	103	111		|O
type	112	116		|O
II	117	119		|O
diabetic	120	128		|O
patients	129	137		|O
.	137	138		|O
Thirty	140	146		|O
-	146	147		|O
nine	147	151		|O
single	152	158		|O
nucleotide	159	169		|O
variations	170	180		|O
,	180	181		|O
including	182	191		|O
16	192	194		|O
novel	195	200		|O
ones	201	205		|O
,	205	206		|O
were	207	211		|O
found	212	217		|O
in	218	220		|O
the	221	224		|O
5'	225	227		|O
promoter	228	236		|O
region	237	243		|O
,	243	244		|O
all	245	248		|O
of	249	251		|O
the	252	255		|O
exons	256	261		|O
and	262	265		|O
their	266	271		|O
surrounding	272	283		|O
introns	284	291		|O
of	292	294		|O
HNF4A	295	300		|O
in	301	303		|O
74	304	306		|O
Japanese	307	315		|O
type	316	320		|O
II	321	323		|O
diabetic	324	332		|O
patients	333	341		|O
.	341	342		|O
The	343	346		|O
following	347	356		|O
novel	357	362		|O
variations	363	373		|O
were	374	378		|O
identified	379	389		|O
(	390	391		|O
based	391	396		|O
on	397	399		|O
the	400	403		|O
amino	404	409		|O
acid	410	414		|O
numbering	415	424		|O
of	425	427		|O
splicing	428	436		|O
variant	437	444		|O
2	445	446		|O
)	446	447		|O
:	447	448		|O
-	449	450		|O
>	454	455		|O
C	455	456		|O
in	457	459		|O
the	460	463		|O
5'	464	466		|O
promoter	467	475		|O
region	476	482		|O
;	482	483		|O
1154C	484	489		|O
>	489	490		|O
T	490	491		|O
(	492	493		|O
A385V	493	498		|O
)	498	499		|O
and	500	503		|O
1193T	504	509		|O
>	509	510		|O
C	510	511		|O
(	512	513		|O
M398T	513	518		|O
)	518	519		|O
in	520	522		|O
the	523	526		|O
coding	527	533		|O
exons	534	539		|O
;	539	540		|O
>	546	547		|O
A	547	548		|O
,	548	549		|O
1852G	550	555		|O
>	555	556		|O
T	556	557		|O
,	557	558		|O
>	564	565		|O
T	565	566		|O
,	566	567		|O
>	573	574		|O
A	574	575		|O
,	575	576		|O
and	577	580		|O
2362	581	585		|O
_2380	585	590		|O
delAAGAATGGTGTGGGAGAGG	590	612		|O
in	613	615		|O
the	616	619		|O
3'	620	622		|O
-	622	623		|O
untranslated	623	635		|O
region	636	642		|O
,	642	643		|O
and	644	647		|O
IVS1+	648	653		|O
231G	653	657		|O
>	657	658		|O
A	658	659		|O
,	659	660		|O
IVS2	661	665		|O
-	665	666		|O
83C	666	669		|O
>	669	670		|O
T	670	671		|O
,	671	672		|O
IVS3+	673	678		|O
>	681	682		|O
T	682	683		|O
,	683	684		|O
IVS3	685	689		|O
-	689	690		|O
54delC	690	696		|O
,	696	697		|O
IVS5+	698	703		|O
173	703	706		|O
_176	706	710		|O
delTTAG	710	717		|O
,	717	718		|O
IVS5	719	723		|O
-	723	724		|O
181	724	727		|O
_	727	728		|O
-	728	729		|O
,	737	738		|O
IVS8	739	743		|O
-	743	744		|O
>	748	749		|O
G	749	750		|O
,	750	751		|O
and	752	755		|O
IVS9	756	760		|O
-	760	761		|O
151A	761	765		|O
>	765	766		|O
C	766	767		|O
in	768	770		|O
the	771	774		|O
introns	775	782		|O
.	782	783		|O
The	784	787		|O
allele	788	794		|O
frequencies	795	806		|O
were	807	811		|O
0.311	812	817		|O
for	818	821		|O
2362	822	826		|O
_2380	826	831		|O
delAAGAATGGTGTGGGAGAGG	831	853		|O
,	853	854		|O
0.054	855	860		|O
for	861	864		|O
>	870	871		|O
A	871	872		|O
,	872	873		|O
0.047	874	879		|O
for	880	883		|O
1852G	884	889		|O
>	889	890		|O
T	890	891		|O
,	891	892		|O
0.020	893	898		|O
for	899	902		|O
IVS1+	903	908		|O
231G	908	912		|O
>	912	913		|O
A	913	914		|O
,	914	915		|O
0.014	916	921		|O
for	922	925		|O
IVS9	926	930		|O
-	930	931		|O
151A	931	935		|O
>	935	936		|O
C	936	937		|O
,	937	938		|O
and	939	942		|O
0.007	943	948		|O
for	949	952		|O
the	953	956		|O
other	957	962		|O
11	963	965		|O
variations	966	976		|O
.	976	977		|O
In	978	980		|O
addition	981	989		|O
,	989	990		|O
one	991	994		|O
known	995	1000		|O
nonsynonymous	1001	1014		|O
single	1015	1021		|O
nucleotide	1022	1032		|O
polymorphism	1033	1045		|O
,	1045	1046		|O
416C	1047	1051		|O
>	1051	1052		|O
T	1052	1053		|O
(	1054	1055		|O
T139I	1055	1060		|O
)	1060	1061		|O
,	1061	1062		|O
was	1063	1066		|O
detected	1067	1075		|O
at	1076	1078		|O
a	1079	1080		|O
0.007	1081	1086		|O
frequency	1087	1096		|O
.	1096	1097		|O
Based	1098	1103		|O
on	1104	1106		|O
the	1107	1110		|O
linkage	1111	1118		|O
disequilibrium	1119	1133		|O
profiles	1134	1142		|O
,	1142	1143		|O
the	1144	1147		|O
region	1148	1154		|O
analyzed	1155	1163		|O
was	1164	1167		|O
divided	1168	1175		|O
into	1176	1180		|O
three	1181	1186		|O
blocks	1187	1193		|O
.	1193	1194		|O
Haplotype	1195	1204		|O
analysis	1205	1213		|O
determined	1214	1224		|O
/	1224	1225		|O
inferred	1225	1233		|O
,	1236	1237		|O
16	1238	1240		|O
,	1240	1241		|O
and	1242	1245		|O
12	1246	1248		|O
haplotypes	1249	1259		|O
for	1260	1263		|O
block	1264	1269		|O
1	1270	1271		|O
,	1271	1272		|O
2	1273	1274		|O
,	1274	1275		|O
and	1276	1279		|O
3	1280	1281		|O
,	1281	1282		|O
respectively	1283	1295		|O
.	1295	1296		|O
Our	1297	1300		|O
results	1301	1308		|O
on	1309	1311		|O
HNF4A	1312	1317		|O
variations	1318	1328		|O
and	1329	1332		|O
haplotypes	1333	1343		|O
would	1344	1349		|O
be	1350	1352		|O
useful	1353	1359		|O
for	1360	1363		|O
pharmacogenetic	1364	1379		|O
studies	1380	1387		|O
in	1388	1390		|O
Japanese	1391	1399		|O
.	1399	1400		|O

### 15620433
Predictive	10	20		|O
clinical	21	29		|O
parameters	30	40		|O
for	41	44		|O
therapeutic	45	56		|O
efficacy	57	65		|O
of	66	68		|O
rosiglitazone	69	82	rosiglitazone	|B-TRIVIAL
in	83	85		|O
Korean	86	92		|O
type	93	97		|O
2	98	99		|O
diabetes	100	108		|O
mellitus	109	117		|O
.	117	118		|O
This	120	124		|O
study	125	130		|O
evaluated	131	140		|O
the	141	144		|O
efficacy	145	153		|O
of	154	156		|O
rosiglitazone	157	170	rosiglitazone	|B-TRIVIAL
in	171	173		|O
non	174	177		|O
-	177	178		|O
obese	178	183		|O
and	184	187		|O
obese	188	193		|O
Korean	194	200		|O
type	201	205		|O
2	206	207		|O
diabetic	208	216		|O
patients	217	225		|O
of	226	228		|O
long	229	233		|O
duration	234	242		|O
.	242	243		|O
A	244	245		|O
total	246	251		|O
of	252	254		|O
125	255	258		|O
patients	259	267		|O
(	268	269		|O
M	269	270		|O
:	270	271		|O
F	271	272		|O
=	272	273		|O
44	273	275		|O
:	275	276		|O
81	276	278		|O
,	278	279		|O
mean	280	284		|O
age	285	288		|O
:	288	289		|O
58.4	290	294		|O
+	294	295		|O
/	295	296		|O
-	296	297		|O
9.1	297	300		|O
years	301	306		|O
,	306	307		|O
BMI	308	311		|O
:	311	312		|O
24.2	313	317		|O
+	317	318		|O
/	318	319		|O
-	319	320		|O
2.7	320	323		|O
kg	324	326		|O
/	326	327		|O
m2	327	329		|O
,	329	330		|O
duration	331	339		|O
of	340	342		|O
diabetes	343	351		|O
:	351	352		|O
11.0	353	357		|O
+	357	358		|O
/	358	359		|O
-	359	360		|O
6.4	360	363		|O
years	364	369		|O
)	369	370		|O
were	371	375		|O
randomly	376	384		|O
allocated	385	394		|O
to	395	397		|O
12	398	400		|O
weeks	401	406		|O
of	407	409		|O
rosiglitazone	410	423	rosiglitazone	|B-TRIVIAL
treatment	424	433		|O
(	434	435		|O
4	435	436		|O
mg	437	439		|O
per	440	443		|O
day	444	447		|O
)	447	448		|O
or	449	451		|O
a	452	453		|O
control	454	461		|O
group	462	467		|O
.	467	468		|O
Responders	469	479		|O
were	480	484		|O
defined	485	492		|O
as	493	495		|O
patients	496	504		|O
who	505	508		|O
experienced	509	520		|O
fasting	521	528		|O
plasma	529	535		|O
glucose	536	543	glucose	|B-TRIVIAL
(	544	545		|O
FPG	545	548		|O
)	548	549		|O
reduction	550	559		|O
of	560	562		|O
>	563	564		|O
or	568	570		|O
HbA1c	571	576		|O
reduction	577	586		|O
of	587	589		|O
>	590	591		|O
1	591	592		|O
(	593	594		|O
%	594	595		|O
)	595	596		|O
.	596	597		|O
Rosiglitazone	598	611	Rosiglitazone	|B-TRIVIAL
significantly	612	625		|O
improved	626	634		|O
glycemic	635	643		|O
control	644	651		|O
by	652	654		|O
reducing	655	663		|O
FPG	664	667		|O
and	668	671		|O
HbA1c	672	677		|O
(	678	679		|O
-	679	680		|O
3.4	680	683		|O
mmol	684	688		|O
/	688	689		|O
l	689	690		|O
and	691	694		|O
-	695	696		|O
1.1%	696	700		|O
,	700	701		|O
P	702	703		|O
<	703	704		|O
0.001	704	709		|O
,	709	710		|O
respectively	711	723		|O
)	723	724		|O
.	724	725		|O
It	726	728		|O
also	729	733		|O
significantly	734	747		|O
increased	748	757		|O
HOMA	758	762		|O
(	762	763		|O
beta	763	767		|O
-	767	768		|O
cell	768	772		|O
function	773	781		|O
)	781	782		|O
(	783	784		|O
+	784	785		|O
9.7	785	788		|O
,	788	789		|O
P	790	791		|O
<	791	792		|O
0.01	792	796		|O
)	796	797		|O
and	798	801		|O
QUICKI	802	808		|O
(	809	810		|O
+	810	811		|O
0.029	811	816		|O
,	816	817		|O
P	818	819		|O
<	819	820		|O
0.001	820	825		|O
)	825	826		|O
,	826	827		|O
and	828	831		|O
decreased	832	841		|O
HOMA	842	846		|O
(	846	847		|O
IR	847	849		|O
)	849	850		|O
(	851	852		|O
-	852	853		|O
1.73	853	857		|O
,	857	858		|O
P	859	860		|O
<	860	861		|O
0.001	861	866		|O
)	866	867		|O
.	867	868		|O
Females	869	876		|O
and	877	880		|O
those	881	886		|O
with	887	891		|O
higher	892	898		|O
waist	899	904		|O
-	904	905		|O
hip	905	908		|O
ratio	909	914		|O
made	915	919		|O
up	920	922		|O
a	923	924		|O
greater	925	932		|O
portion	933	940		|O
of	941	943		|O
rosiglitazone	944	957		|O
-	957	958		|O
responders	958	968		|O
.	968	969		|O
Responders	970	980		|O
(	981	982		|O
45	982	984		|O
patients	985	993		|O
,	993	994		|O
75%	995	998		|O
)	998	999		|O
also	1000	1004		|O
showed	1005	1011		|O
significantly	1012	1025		|O
higher	1026	1032		|O
FPG	1033	1036		|O
,	1036	1037		|O
HbA1c	1038	1043		|O
,	1043	1044		|O
systolic	1045	1053		|O
blood	1054	1059		|O
pressures	1060	1069		|O
,	1069	1070		|O
fasting	1071	1078		|O
insulin	1079	1086		|O
levels	1087	1093		|O
and	1094	1097		|O
HOMA	1098	1102		|O
(	1102	1103		|O
IR	1103	1105		|O
)	1105	1106		|O
,	1106	1107		|O
and	1108	1111		|O
lower	1112	1117		|O
QUICKI	1118	1124		|O
than	1125	1129		|O
nonresponders	1130	1143		|O
.	1143	1144		|O
Among	1145	1150		|O
these	1151	1156		|O
parameters	1157	1167		|O
of	1168	1170		|O
responders	1171	1181		|O
,	1181	1182		|O
waist	1183	1188		|O
-	1188	1189		|O
hip	1189	1192		|O
ratio	1193	1198		|O
of	1199	1201		|O
non	1202	1205		|O
-	1205	1206		|O
obese	1206	1211		|O
subgroup	1212	1220		|O
,	1220	1221		|O
initial	1222	1229		|O
glycemic	1230	1238		|O
control	1239	1246		|O
of	1247	1249		|O
obese	1250	1255		|O
subgroup	1256	1264		|O
,	1264	1265		|O
and	1266	1269		|O
systolic	1270	1278		|O
blood	1279	1284		|O
pressure	1285	1293		|O
of	1294	1296		|O
both	1297	1301		|O
subgroups	1302	1311		|O
lost	1312	1316		|O
their	1317	1322		|O
significance	1323	1335		|O
after	1336	1341		|O
subdivision	1342	1353		|O
analysis	1354	1362		|O
.	1362	1363		|O
However	1364	1371		|O
,	1371	1372		|O
the	1373	1376		|O
baseline	1377	1385		|O
HOMA	1386	1390		|O
(	1390	1391		|O
IR	1391	1393		|O
)	1393	1394		|O
and	1395	1398		|O
QUICKI	1399	1405		|O
were	1406	1410		|O
significantly	1411	1424		|O
correlated	1425	1435		|O
with	1436	1440		|O
the	1441	1444		|O
response	1445	1453		|O
rate	1454	1458		|O
to	1459	1461		|O
rosiglitazone	1462	1475	rosiglitazone	|B-TRIVIAL
.	1475	1476		|O
Moreover	1477	1485		|O
,	1485	1486		|O
in	1487	1489		|O
multiple	1490	1498		|O
logistic	1499	1507		|O
regression	1508	1518		|O
analysis	1519	1527		|O
,	1527	1528		|O
HOMA	1529	1533		|O
(	1533	1534		|O
IR	1534	1536		|O
)	1536	1537		|O
and	1538	1541		|O
QUICKI	1542	1548		|O
retained	1549	1557		|O
their	1558	1563		|O
significance	1564	1576		|O
as	1577	1579		|O
the	1580	1583		|O
independent	1584	1595		|O
predictors	1596	1606		|O
.	1606	1607		|O
Even	1608	1612		|O
in	1613	1615		|O
Korean	1616	1622		|O
type	1623	1627		|O
2	1628	1629		|O
diabetic	1630	1638		|O
patients	1639	1647		|O
of	1648	1650		|O
long	1651	1655		|O
duration	1656	1664		|O
but	1665	1668		|O
with	1669	1673		|O
relatively	1674	1684		|O
preserved	1685	1694		|O
beta	1695	1699		|O
-	1699	1700		|O
cell	1700	1704		|O
function	1705	1713		|O
,	1713	1714		|O
rosiglitazone	1715	1728		|O
improved	1729	1737		|O
glycemic	1738	1746		|O
control	1747	1754		|O
,	1754	1755		|O
insulin	1756	1763		|O
sensitivity	1764	1775		|O
,	1775	1776		|O
and	1777	1780		|O
beta	1781	1785		|O
-	1785	1786		|O
cell	1786	1790		|O
function	1791	1799		|O
.	1799	1800		|O
In	1801	1803		|O
this	1804	1808		|O
ethnic	1809	1815		|O
group	1816	1821		|O
,	1821	1822		|O
female	1823	1829		|O
gender	1830	1836		|O
,	1836	1837		|O
central	1838	1845		|O
obesity	1846	1853		|O
,	1853	1854		|O
and	1855	1858		|O
especially	1859	1869		|O
severe	1870	1876		|O
insulin	1877	1884		|O
resistance	1885	1895		|O
were	1896	1900		|O
identified	1901	1911		|O
as	1912	1914		|O
predictive	1915	1925		|O
clinical	1926	1934		|O
parameters	1935	1945		|O
of	1946	1948		|O
rosiglitazone	1949	1962	rosiglitazone	|B-TRIVIAL
-	1962	1963		|O
responders	1963	1973		|O
.	1973	1974		|O

### 2231607
The	0	3		|O
synthesis	4	13		|O
of	14	16		|O
2'	17	19	2'-fluoro-10-propargyl-5,8-dideazafolic acid	|B-IUPAC
-	19	20		|I-IUPAC
fluoro	20	26		|I-IUPAC
-	26	27		|I-IUPAC
-	29	30		|I-IUPAC
propargyl	30	39		|I-IUPAC
-	39	40		|I-IUPAC
5,8	40	43		|I-IUPAC
-	43	44		|I-IUPAC
dideazafolic	44	56		|I-IUPAC
acid	57	61		|I-IUPAC
and	62	65		|O
its	66	69		|O
2	70	71	2-desamino	|B-PARTIUPAC
-	71	72		|I-PARTIUPAC
desamino	72	80		|I-PARTIUPAC
,	80	81		|O
2	82	83	2-desamino-2-hydroxymethyl	|B-PARTIUPAC
-	83	84		|I-PARTIUPAC
desamino	84	92		|I-PARTIUPAC
-	92	93		|I-PARTIUPAC
2	93	94		|I-PARTIUPAC
-	94	95		|I-PARTIUPAC
hydroxymethyl	95	108		|I-PARTIUPAC
,	108	109		|O
and	110	113		|O
2	114	115	2-desamino-2-methoxy	|B-PARTIUPAC
-	115	116		|I-PARTIUPAC
desamino	116	124		|I-PARTIUPAC
-	124	125		|I-PARTIUPAC
2	125	126		|I-PARTIUPAC
-	126	127		|I-PARTIUPAC
methoxy	127	134		|I-PARTIUPAC
analogues	135	144	analogues	|B-MODIFIER
is	145	147		|O
described	148	157		|O
.	157	158		|O
In	159	161		|O
general	162	169		|O
the	170	173		|O
synthetic	174	183		|O
route	184	189		|O
involved	190	198		|O
the	199	202		|O
coupling	203	211		|O
of	212	214		|O
diethyl	215	222	diethyl N-[2-fluoro-4-(prop-2-ynylamino)benzoyl]-L-glutamate	|B-IUPAC
N	223	224		|I-IUPAC
-	224	225		|I-IUPAC
[	225	226		|I-IUPAC
2	226	227		|I-IUPAC
-	227	228		|I-IUPAC
fluoro	228	234		|I-IUPAC
-	234	235		|I-IUPAC
4	235	236		|I-IUPAC
-	236	237		|I-IUPAC
(	237	238		|I-IUPAC
prop	238	242		|I-IUPAC
-	242	243		|I-IUPAC
2	243	244		|I-IUPAC
-	244	245		|I-IUPAC
ynylamino	245	254		|I-IUPAC
)	254	255		|I-IUPAC
benzoyl	255	262		|I-IUPAC
]	262	263		|I-IUPAC
-	263	264		|I-IUPAC
L	264	265		|I-IUPAC
-	265	266		|I-IUPAC
glutamate	266	275		|I-IUPAC
with	276	280		|O
the	281	284		|O
appropriate	285	296		|O
6	297	298	6-(bromomethyl)quinazoline	|B-IUPAC
-	298	299		|I-IUPAC
(	299	300		|I-IUPAC
bromomethyl	300	311		|I-IUPAC
)	311	312		|I-IUPAC
quinazoline	312	323		|I-IUPAC
followed	324	332		|O
by	333	335		|O
deprotection	336	348		|O
with	349	353		|O
mild	354	358		|O
alkali	359	365		|O
.	365	366		|O
These	367	372		|O
four	373	377		|O
compounds	378	387		|O
together	388	396		|O
with	397	401		|O
the	402	405		|O
2	406	407	2-desamino-2-methyl	|B-PARTIUPAC
-	407	408		|I-PARTIUPAC
desamino	408	416		|I-PARTIUPAC
-	416	417		|I-PARTIUPAC
2	417	418		|I-PARTIUPAC
-	418	419		|I-PARTIUPAC
methyl	419	425		|I-PARTIUPAC
analogue	426	434	analogue	|B-MODIFIER
were	435	439		|O
tested	440	446		|O
for	447	450		|O
their	451	456		|O
activity	457	465		|O
against	466	473		|O
L1210	474	479		|O
thymidylate	480	491		|O
synthase	492	500		|O
(	501	502		|O
TS	502	504		|O
)	504	505		|O
.	505	506		|O
They	507	511		|O
were	512	516		|O
also	517	521		|O
examined	522	530		|O
for	531	534		|O
their	535	540		|O
inhibition	541	551		|O
of	552	554		|O
the	555	558		|O
growth	559	565		|O
of	566	568		|O
the	569	572		|O
L1210	573	578		|O
cell	579	583		|O
line	584	588		|O
and	589	592		|O
of	593	595		|O
two	596	599		|O
mutant	600	606		|O
L1210	607	612		|O
cell	613	617		|O
lines	618	623		|O
,	623	624		|O
the	625	628		|O
L1210	629	634		|O
:	634	635		|O
R7A	635	638		|O
that	639	643		|O
overproduces	644	656		|O
dihydrofolate	657	670		|O
reductase	671	680		|O
(	681	682		|O
DHFR	682	686		|O
)	686	687		|O
and	688	691		|O
the	692	695		|O
L1210	696	701		|O
:	701	702		|O
1565	702	706		|O
that	707	711		|O
has	712	715		|O
impaired	716	724		|O
uptake	725	731		|O
of	732	734		|O
reduced	735	742		|O
folates	743	750		|O
.	750	751		|O
Compared	752	760		|O
with	761	765		|O
their	766	771		|O
non	772	775		|O
-	775	776		|O
fluorinated	776	787		|O
parent	788	794		|O
compounds	795	804		|O
,	804	805		|O
the	806	809		|O
2'	810	812	2'-fluoro	|B-PARTIUPAC
-	812	813		|I-PARTIUPAC
fluoro	813	819		|I-PARTIUPAC
analogues	820	829	analogues	|B-MODIFIER
were	829	833		|O
all	835	838		|O
approximately	839	852		|O
2	853	854		|O
-	854	855		|O
fold	855	859		|O
more	860	864		|O
potent	865	871		|O
as	872	874		|O
TS	875	877		|O
inhibitors	878	888		|O
.	888	889		|O
Similarly	890	899		|O
,	899	900		|O
they	901	905		|O
also	906	910		|O
showed	911	917		|O
improved	918	926		|O
inhibition	927	937		|O
of	938	940		|O
L1210	941	946		|O
cell	947	951		|O
growth	952	958		|O
(	959	960		|O
1.5-5	960	965		|O
-	965	966		|O
fold	966	970		|O
)	970	971		|O
,	971	972		|O
and	973	976		|O
this	977	981		|O
activity	982	990		|O
was	991	994		|O
prevented	995	1004		|O
by	1005	1007		|O
co	1008	1010		|O
-	1010	1011		|O
incubation	1011	1021		|O
with	1022	1026		|O
thymidine	1027	1036		|O
.	1036	1037		|O
All	1038	1041		|O
had	1042	1045		|O
retained	1046	1054		|O
or	1055	1057		|O
improved	1058	1066		|O
activity	1067	1075		|O
against	1076	1083		|O
both	1084	1088		|O
the	1089	1092		|O
L1210	1093	1098		|O
:	1098	1099		|O
R7A	1099	1102		|O
and	1103	1106		|O
L1210	1107	1112		|O
:	1112	1113		|O
1565	1113	1117		|O
cell	1118	1122		|O
lines	1123	1128		|O
.	1128	1129		|O

### 11985471
A	0	1		|O
novel	2	7		|O
class	8	13		|O
of	14	16		|O
5	17	18	5-substituted acyclic pyrimidine nucleosides	|B-IUPAC
-	18	19		|I-IUPAC
substituted	19	30		|I-IUPAC
acyclic	31	38		|I-IUPAC
pyrimidine	39	49		|I-IUPAC
nucleosides	50	61		|I-IUPAC
,	61	62		|O
1	63	64	1-[(2-hydroxyethoxy)methyl]-5-(1-azidovinyl)uracil	|B-IUPAC
-	64	65		|I-IUPAC
[	65	66		|I-IUPAC
(	66	67		|I-IUPAC
2	67	68		|I-IUPAC
-	68	69		|I-IUPAC
hydroxyethoxy	69	82		|I-IUPAC
)	82	83		|I-IUPAC
methyl	83	89		|I-IUPAC
]	89	90		|I-IUPAC
-	90	91		|I-IUPAC
5	91	92		|I-IUPAC
-	92	93		|I-IUPAC
(	93	94		|I-IUPAC
1	94	95		|I-IUPAC
-	95	96		|I-IUPAC
azidovinyl	96	106		|I-IUPAC
)	106	107		|I-IUPAC
uracil	107	113		|I-IUPAC
(	114	115		|O
9a	115	117		|O
)	117	118		|O
,	118	119		|O
1	120	121	1-[(2-hydroxy-1-(hydroxymethyl)ethoxy)methyl]-5-(1-azidovinyl)uracil	|B-IUPAC
-	121	122		|I-IUPAC
[	122	123		|I-IUPAC
(	123	124		|I-IUPAC
2	124	125		|I-IUPAC
-	125	126		|I-IUPAC
hydroxy	126	133		|I-IUPAC
-	133	134		|I-IUPAC
1	134	135		|I-IUPAC
-	135	136		|I-IUPAC
(	136	137		|I-IUPAC
hydroxymethyl	137	150		|I-IUPAC
)	150	151		|I-IUPAC
ethoxy	151	157		|I-IUPAC
)	157	158		|I-IUPAC
methyl	158	164		|I-IUPAC
]	164	165		|I-IUPAC
-	165	166		|I-IUPAC
5	166	167		|I-IUPAC
-	167	168		|I-IUPAC
(	168	169		|I-IUPAC
1	169	170		|I-IUPAC
-	170	171		|I-IUPAC
azidovinyl	171	181		|I-IUPAC
)	181	182		|I-IUPAC
uracil	182	188		|I-IUPAC
(	189	190		|O
9b	190	192		|O
)	192	193		|O
,	193	194		|O
and	195	198		|O
1	199	200	1-[4-hydroxy-3-(hydroxymethyl)-1-butyl]-5-(1-azidovinyl)uracil	|B-IUPAC
-	200	201		|I-IUPAC
[	201	202		|I-IUPAC
4	202	203		|I-IUPAC
-	203	204		|I-IUPAC
hydroxy	204	211		|I-IUPAC
-	211	212		|I-IUPAC
3	212	213		|I-IUPAC
-	213	214		|I-IUPAC
(	214	215		|I-IUPAC
hydroxymethyl	215	228		|I-IUPAC
)	228	229		|I-IUPAC
-	229	230		|I-IUPAC
1	230	231		|I-IUPAC
-	231	232		|I-IUPAC
butyl	232	237		|I-IUPAC
]	237	238		|I-IUPAC
-	238	239		|I-IUPAC
5	239	240		|I-IUPAC
-	240	241		|I-IUPAC
(	241	242		|I-IUPAC
1	242	243		|I-IUPAC
-	243	244		|I-IUPAC
azidovinyl	244	254		|I-IUPAC
)	254	255		|I-IUPAC
uracil	255	261		|I-IUPAC
(	262	263		|O
9c	263	265		|O
)	265	266		|O
,	266	267		|O
were	268	272		|O
synthesized	273	284		|O
by	285	287		|O
regiospecific	288	301		|O
addition	302	310		|O
of	311	313		|O
bromine	314	321	bromine azide	|B-IUPAC
azide	322	327		|I-IUPAC
to	328	330		|O
the	331	334		|O
5	335	336	5-vinyl	|B-PARTIUPAC
-	336	337		|I-PARTIUPAC
vinyl	337	342		|I-PARTIUPAC
substituent	343	354	substituent	|B-MODIFIER
of	355	357		|O
the	358	361		|O
respective	362	372		|O
5	373	374	5-vinyluracils	|B-IUPAC
-	374	375		|I-IUPAC
vinyluracils	375	387		|I-IUPAC
(	388	389		|O
2a	389	391		|O
-	391	392		|O
c	392	393		|O
)	393	394		|O
followed	395	403		|O
by	404	406		|O
treatment	407	416		|O
of	417	419		|O
the	420	423		|O
obtained	424	432		|O
5	433	434	5-(1-azido-2-bromoethyl)	|B-IUPAC
-	434	435		|I-IUPAC
(	435	436		|I-IUPAC
1	436	437		|I-IUPAC
-	437	438		|I-IUPAC
azido	438	443		|I-IUPAC
-	443	444		|I-IUPAC
2	444	445		|I-IUPAC
-	445	446		|I-IUPAC
bromoethyl	446	456		|I-IUPAC
)	456	457		|I-IUPAC
compounds	458	467	compounds	|B-MODIFIER
(	468	469		|O
3a	469	471		|O
-	471	472		|O
c	472	473		|O
)	473	474		|O
with	475	479		|O
t	480	481	t-BuOK	|B-TRIVIAL
-	481	482		|I-TRIVIAL
BuOK	482	486		|I-TRIVIAL
,	486	487		|O
to	488	490		|O
affect	491	497		|O
the	498	501		|O
base	502	506		|O
-	506	507		|O
catalyzed	507	516		|O
elimination	517	528		|O
of	529	531		|O
HBr	532	535	HBr	|B-SUM
.	535	536		|O
Thermal	537	544		|O
decomposition	545	558		|O
of	559	561		|O
9b	562	564		|O
and	565	568		|O
9c	569	571		|O
at	572	574		|O
degrees	579	586		|O
C	587	588		|O
in	589	591		|O
dioxane	592	599	dioxane	|B-TRIVIAL
yielded	600	607		|O
corresponding	608	621		|O
5	622	623	5-[2-(1-azirinyl)]uracil	|B-IUPAC
-	623	624		|I-IUPAC
[	624	625		|I-IUPAC
2	625	626		|I-IUPAC
-	626	627		|I-IUPAC
(	627	628		|I-IUPAC
1	628	629		|I-IUPAC
-	629	630		|I-IUPAC
azirinyl	630	638		|I-IUPAC
)	638	639		|I-IUPAC
]	639	640		|I-IUPAC
uracil	640	646		|I-IUPAC
analogues	647	656	analogues	|B-MODIFIER
(	657	658		|O
,	661	662		|O
c	662	663		|O
)	663	664		|O
.	664	665		|O
The	666	669		|O
5	670	671	5-(1-azidovinyl)uracil	|B-IUPAC
-	671	672		|I-IUPAC
(	672	673		|I-IUPAC
1	673	674		|I-IUPAC
-	674	675		|I-IUPAC
azidovinyl	675	685		|I-IUPAC
)	685	686		|I-IUPAC
uracil	686	692		|I-IUPAC
derivatives	693	704	derivatives	|B-MODIFIER
9a	705	707		|O
-	707	708		|O
c	708	709		|O
were	710	714		|O
found	715	720		|O
to	721	723		|O
exhibit	724	731		|O
potent	732	738		|O
and	739	742		|O
selective	743	752		|O
in	753	755		|O
vitro	756	761		|O
anti	762	766		|O
-	766	767		|O
HBV	767	770		|O
activity	771	779		|O
against	780	787		|O
duck	788	792		|O
hepatitis	793	802		|O
B	803	804		|O
virus	805	810		|O
(	811	812		|O
DHBV	812	816		|O
)	816	817		|O
infected	818	826		|O
primary	827	834		|O
duck	835	839		|O
hepatocytes	840	851		|O
at	852	854		|O
low	855	858		|O
concentrations	859	873		|O
(	874	875		|O
EC	875	877		|O
(	877	878		|O
)	880	881		|O
=	882	883		|O
0.01-0.1	884	892		|O
microg	893	899		|O
/	899	900		|O
mL	900	902		|O
range	903	908		|O
)	908	909		|O
.	909	910		|O
The	911	914		|O
most	915	919		|O
active	920	926		|O
anti	927	931		|O
-	931	932		|O
DHBV	932	936		|O
agent	937	942		|O
(	943	944		|O
9c	944	946		|O
)	946	947		|O
,	947	948		|O
possessing	949	959		|O
a	960	961		|O
[	962	963	[4-hydroxy-3-(hydroxymethyl)-1-butyl]	|B-PARTIUPAC
4	963	964		|I-PARTIUPAC
-	964	965		|I-PARTIUPAC
hydroxy	965	972		|I-PARTIUPAC
-	972	973		|I-PARTIUPAC
3	973	974		|I-PARTIUPAC
-	974	975		|I-PARTIUPAC
(	975	976		|I-PARTIUPAC
hydroxymethyl	976	989		|I-PARTIUPAC
)	989	990		|I-PARTIUPAC
-	990	991		|I-PARTIUPAC
1	991	992		|I-PARTIUPAC
-	992	993		|I-PARTIUPAC
butyl	993	998		|I-PARTIUPAC
]	998	999		|I-PARTIUPAC
substituent	1000	1011	substituent	|B-MODIFIER
at	1012	1014		|O
N	1015	1016		|O
-	1016	1017		|O
1	1017	1018		|O
,	1018	1019		|O
exhibited	1020	1029		|O
an	1030	1032		|O
activity	1033	1041		|O
(	1042	1043		|O
EC	1043	1045		|O
(	1045	1046		|O
)	1048	1049		|O
of	1050	1052		|O
0.01-0.05	1053	1062		|O
microg	1063	1069		|O
/	1069	1070		|O
mL	1070	1072		|O
)	1072	1073		|O
comparable	1074	1084		|O
to	1085	1087		|O
that	1088	1092		|O
of	1093	1095		|O
reference	1096	1105		|O
compound	1106	1114		|O
(	1115	1116	(-)-beta-L-2',3'-dideoxy-3'-thiacytidine	|B-IUPAC
-	1116	1117		|I-IUPAC
)	1117	1118		|I-IUPAC
-	1118	1119		|I-IUPAC
beta	1119	1123		|I-IUPAC
-	1123	1124		|I-IUPAC
L	1124	1125		|I-IUPAC
-	1125	1126		|I-IUPAC
2'	1126	1128		|I-IUPAC
,	1128	1129		|I-IUPAC
3'	1129	1131		|I-IUPAC
-	1131	1132		|I-IUPAC
dideoxy	1132	1139		|I-IUPAC
-	1139	1140		|I-IUPAC
3'	1140	1142		|I-IUPAC
-	1142	1143		|I-IUPAC
thiacytidine	1143	1155		|I-IUPAC
(	1156	1157		|O
3	1157	1158		|O
-	1158	1159		|O
TC	1159	1161		|O
)	1161	1162		|O
(	1163	1164		|O
EC	1164	1166		|O
(	1166	1167		|O
)	1169	1170		|O
=	1171	1172		|O
0.01-0.05	1173	1182		|O
microg	1183	1189		|O
/	1189	1190		|O
mL	1190	1192		|O
)	1192	1193		|O
.	1193	1194		|O
In	1195	1197		|O
contrast	1198	1206		|O
,	1206	1207		|O
related	1208	1215		|O
5	1216	1217	5-[2-(1-azirinyl)]uracil	|B-IUPAC
-	1217	1218		|I-IUPAC
[	1218	1219		|I-IUPAC
2	1219	1220		|I-IUPAC
-	1220	1221		|I-IUPAC
(	1221	1222		|I-IUPAC
1	1222	1223		|I-IUPAC
-	1223	1224		|I-IUPAC
azirinyl	1224	1232		|I-IUPAC
)	1232	1233		|I-IUPAC
]	1233	1234		|I-IUPAC
uracil	1234	1240		|I-IUPAC
analogues	1241	1250	analogues	|B-MODIFIER
(	1251	1252		|O
,	1255	1256		|O
c	1256	1257		|O
)	1257	1258		|O
were	1259	1263		|O
devoid	1264	1270		|O
of	1271	1273		|O
anti	1274	1278		|O
-	1278	1279		|O
DHBV	1279	1283		|O
activity	1284	1292		|O
,	1292	1293		|O
indicating	1294	1304		|O
that	1305	1309		|O
an	1310	1312		|O
acyclic	1313	1320		|O
side	1321	1325		|O
chain	1326	1331		|O
at	1332	1334		|O
C	1335	1336		|O
-	1336	1337		|O
5	1337	1338		|O
position	1339	1347		|O
of	1348	1350		|O
the	1351	1354		|O
pyrimidine	1355	1365	pyrimidine	|B-FAMILY
ring	1366	1370		|O
is	1371	1373		|O
essential	1374	1383		|O
for	1384	1387		|O
anti	1388	1392		|O
-	1392	1393		|O
HBV	1393	1396		|O
activity	1397	1405		|O
.	1405	1406		|O
The	1407	1410		|O
pyrimidine	1411	1421	pyrimidine	|B-FAMILY
nucleosides	1422	1433	nucleosides	|B-MODIFIER
(	1433	1434		|O
9a	1435	1437		|O
-	1437	1438		|O
c	1438	1439		|O
,	1439	1440		|O
,	1444	1445		|O
c	1445	1446		|O
)	1446	1447		|O
exhibited	1448	1457		|O
no	1458	1460		|O
cytotoxic	1461	1470		|O
activity	1471	1479		|O
against	1480	1487		|O
a	1488	1489		|O
panel	1490	1495		|O
of	1496	1498		|O
human	1502	1507		|O
cancer	1508	1514		|O
cell	1515	1519		|O
lines	1520	1525		|O
.	1525	1526		|O
All	1527	1530		|O
of	1531	1533		|O
the	1534	1537		|O
compounds	1538	1547		|O
investigated	1548	1560		|O
did	1561	1564		|O
not	1565	1568		|O
show	1569	1573		|O
any	1574	1577		|O
detectable	1578	1588		|O
toxicity	1589	1597		|O
to	1598	1600		|O
several	1601	1608		|O
stationary	1609	1619		|O
and	1620	1623		|O
proliferating	1624	1637		|O
host	1638	1642		|O
cell	1643	1647		|O
lines	1648	1653		|O
or	1654	1656		|O
to	1657	1659		|O
mitogen	1660	1667		|O
stimulated	1668	1678		|O
proliferating	1679	1692		|O
human	1693	1698		|O
T	1699	1700		|O
lymphocytes	1701	1712		|O
,	1712	1713		|O
up	1714	1716		|O
to	1717	1719		|O
the	1720	1723		|O
highest	1724	1731		|O
concentration	1732	1745		|O
tested	1746	1752		|O
.	1752	1753		|O

### 10813108
Antiestrogens	10	23		|O
reduce	24	30		|O
plasma	31	37		|O
levels	38	44		|O
of	45	47		|O
endothelin	48	58		|O
-	58	59		|O
1	59	60		|O
without	61	68		|O
affecting	69	78		|O
nitrate	79	86	nitrate	|B-IUPAC
levels	87	93		|O
in	94	96		|O
breast	97	103		|O
cancer	104	110		|O
patients	111	119		|O
.	119	120		|O
Tamoxifen	122	131	Tamoxifen	|B-TRIVIAL
protects	132	140		|O
against	141	148		|O
myocardial	149	159		|O
infarction	160	170		|O
through	171	178		|O
mechanisms	179	189		|O
that	190	194		|O
are	195	198		|O
poorly	199	205		|O
understood	206	216		|O
.	216	217		|O
We	218	220		|O
studied	221	228		|O
the	229	232		|O
effects	233	240		|O
of	241	243		|O
tamoxifen	244	253	tamoxifen	|B-TRIVIAL
and	254	257		|O
another	258	265		|O
antiestrogen	266	278		|O
,	278	279		|O
toremifene	280	290	toremifene	|B-TRIVIAL
,	290	291		|O
on	292	294		|O
the	295	298		|O
production	299	309		|O
of	310	312		|O
vasoconstrictive	313	329		|O
endothelin	330	340		|O
-	340	341		|O
1	341	342		|O
and	343	346		|O
of	347	349		|O
vasodilatory	350	362		|O
nitric	363	369	nitric oxide	|B-IUPAC
oxide	370	375		|I-IUPAC
in	376	378		|O
44	379	381		|O
postmenopausal	382	396		|O
patients	397	405		|O
with	406	410		|O
breast	411	417		|O
cancer	418	424		|O
.	424	425		|O
These	426	431		|O
started	432	439		|O
treatment	440	449		|O
,	449	450		|O
in	451	453		|O
randomized	454	464		|O
order	465	470		|O
,	470	471		|O
with	472	476		|O
either	477	483		|O
tamoxifen	484	493	tamoxifen	|B-TRIVIAL
(	494	495		|O
mg	498	500		|O
/	500	501		|O
day	501	504		|O
;	504	505		|O
n	506	507		|O
=	508	509		|O
25	510	512		|O
)	512	513		|O
or	514	516		|O
toremifene	517	527		|O
(	528	529		|O
mg	532	534		|O
/	534	535		|O
day	535	538		|O
;	538	539		|O
n	540	541		|O
=	542	543		|O
19	544	546		|O
)	546	547		|O
.	547	548		|O
Plasma	549	555		|O
samples	556	563		|O
collected	564	573		|O
before	574	580		|O
treatment	581	590		|O
and	591	594		|O
after	595	600		|O
6	601	602		|O
and	603	606		|O
12	607	609		|O
months	610	616		|O
of	617	619		|O
both	620	624		|O
regimens	625	633		|O
were	634	638		|O
assayed	639	646		|O
for	647	650		|O
endothelin	651	661		|O
-	661	662		|O
1	662	663		|O
with	664	668		|O
a	669	670		|O
specific	671	679		|O
radioimmunoassay	680	696		|O
and	697	700		|O
for	701	704		|O
nitrite	705	712	nitrite	|B-TRIVIAL
/	712	713		|O
nitrate	713	720	nitrate	|B-TRIVIAL
with	721	725		|O
a	726	727		|O
method	728	734		|O
based	735	740		|O
on	741	743		|O
the	744	747		|O
Griess	748	754		|O
reaction	755	763		|O
.	763	764		|O
The	765	768		|O
antiestrogen	769	781		|O
group	782	787		|O
as	788	790		|O
a	791	792		|O
whole	793	798		|O
showed	799	805		|O
a	806	807		|O
fall	808	812		|O
in	813	815		|O
endothelin	816	826		|O
-	826	827		|O
1	827	828		|O
at	829	831		|O
6	832	833		|O
months	834	840		|O
(	841	842		|O
5.9	842	845		|O
+	846	847		|O
/	847	848		|O
-	848	849		|O
3.3%	850	854		|O
;	854	855		|O
p	856	857		|O
=	858	859		|O
0.06	860	864		|O
)	864	865		|O
(	866	867		|O
mean	867	871		|O
+	872	873		|O
/	873	874		|O
-	874	875		|O
SE	876	878		|O
)	878	879		|O
and	880	883		|O
at	884	886		|O
12	887	889		|O
months	890	896		|O
(	897	898		|O
7.1	898	901		|O
+	902	903		|O
/	903	904		|O
-	904	905		|O
5.5%	906	910		|O
;	910	911		|O
p	912	913		|O
=	914	915		|O
0.03	916	920		|O
)	920	921		|O
.	921	922		|O
This	923	927		|O
fall	928	932		|O
was	933	936		|O
solely	937	943		|O
due	944	947		|O
to	948	950		|O
toremifene	951	961	toremifene	|B-TRIVIAL
,	961	962		|O
the	963	966		|O
use	967	970		|O
of	971	973		|O
which	974	979		|O
was	980	983		|O
associated	984	994		|O
with	995	999		|O
falls	1000	1005		|O
in	1006	1008		|O
endothelin	1009	1019		|O
-	1019	1020		|O
1	1020	1021		|O
at	1022	1024		|O
6	1025	1026		|O
months	1027	1033		|O
(	1034	1035		|O
12.9	1035	1039		|O
+	1040	1041		|O
/	1041	1042		|O
-	1042	1043		|O
4.7%	1044	1048		|O
;	1048	1049		|O
p	1050	1051		|O
=	1052	1053		|O
0.01	1054	1058		|O
)	1058	1059		|O
and	1060	1063		|O
12	1064	1066		|O
months	1067	1073		|O
(	1074	1075		|O
9.2	1075	1078		|O
+	1079	1080		|O
/	1080	1081		|O
-	1081	1082		|O
6.2%	1083	1087		|O
;	1087	1088		|O
p	1089	1090		|O
=	1091	1092		|O
0.06	1093	1097		|O
)	1097	1098		|O
.	1098	1099		|O
The	1100	1103		|O
antiestrogen	1104	1116		|O
regimen	1117	1124		|O
failed	1125	1131		|O
to	1132	1134		|O
affect	1135	1141		|O
plasma	1142	1148		|O
nitric	1149	1155	nitric oxide	|B-IUPAC
oxide	1156	1161		|I-IUPAC
significantly	1162	1175		|O
but	1176	1179		|O
nevertheless	1180	1192		|O
the	1193	1196		|O
ratio	1197	1202		|O
between	1203	1210		|O
nitric	1211	1217	nitric oxide	|B-IUPAC
oxide	1218	1223		|I-IUPAC
and	1224	1227		|O
endothelin	1228	1238		|O
-	1238	1239		|O
1	1239	1240		|O
rose	1241	1245		|O
by	1246	1248		|O
31.6	1249	1253		|O
+	1254	1255		|O
/	1255	1256		|O
-	1256	1257		|O
13.3%	1258	1263		|O
at	1264	1266		|O
6	1267	1268		|O
months	1269	1275		|O
and	1276	1279		|O
by	1280	1282		|O
35.6	1283	1287		|O
+	1288	1289		|O
/	1289	1290		|O
-	1290	1291		|O
15.3%	1292	1297		|O
at	1298	1300		|O
12	1301	1303		|O
months	1304	1310		|O
in	1311	1313		|O
the	1314	1317		|O
antiestrogen	1318	1330		|O
users	1331	1336		|O
,	1336	1337		|O
an	1338	1340		|O
effect	1341	1347		|O
similar	1348	1355		|O
in	1356	1358		|O
the	1359	1362		|O
tamoxifen	1363	1372	tamoxifen	|B-TRIVIAL
and	1373	1376		|O
toremifene	1377	1387	toremifene	|B-TRIVIAL
groups	1388	1394		|O
.	1394	1395		|O
We	1396	1398		|O
conclude	1399	1407		|O
that	1408	1412		|O
antiestrogens	1413	1426		|O
may	1427	1430		|O
protect	1431	1438		|O
against	1439	1446		|O
myocardial	1447	1457		|O
infarction	1458	1468		|O
by	1469	1471		|O
preventing	1472	1482		|O
the	1483	1486		|O
release	1487	1494		|O
of	1495	1497		|O
endothelin	1498	1508		|O
-	1508	1509		|O
1	1509	1510		|O
and	1511	1514		|O
by	1515	1517		|O
shifting	1518	1526		|O
the	1527	1530		|O
balance	1531	1538		|O
between	1539	1546		|O
nitric	1547	1553	nitric oxide	|B-IUPAC
oxide	1554	1559		|I-IUPAC
and	1560	1563		|O
endothelin	1564	1574		|O
-	1574	1575		|O
1	1575	1576		|O
to	1577	1579		|O
the	1580	1583		|O
dominance	1584	1593		|O
of	1594	1596		|O
the	1597	1600		|O
former	1601	1607		|O
.	1607	1608		|O
Our	1609	1612		|O
data	1613	1617		|O
predict	1618	1625		|O
that	1626	1630		|O
toremifene	1631	1641	toremifene	|B-TRIVIAL
and	1642	1645		|O
tamoxifen	1646	1655	tamoxifen	|B-TRIVIAL
at	1655	1657		|O
the	1659	1662		|O
doses	1663	1668		|O
studied	1669	1676		|O
here	1677	1681		|O
will	1682	1686		|O
provide	1687	1694		|O
similar	1695	1702		|O
cardiovascular	1703	1717		|O
protection	1718	1728		|O
.	1728	1729		|O

### 2299637
A	0	1		|O
series	2	8		|O
of	9	11		|O
new	12	15		|O
5	16	17	5-(1-hydroxy-2-iodoethyl)-2'-deoxyuridine	|B-IUPAC
-	17	18		|I-IUPAC
(	18	19		|I-IUPAC
1	19	20		|I-IUPAC
-	20	21		|I-IUPAC
hydroxy	21	28		|I-IUPAC
-	28	29		|I-IUPAC
2	29	30		|I-IUPAC
-	30	31		|I-IUPAC
iodoethyl	31	40		|I-IUPAC
)	40	41		|I-IUPAC
-	41	42		|I-IUPAC
2'	42	44		|I-IUPAC
-	44	45		|I-IUPAC
deoxyuridine	45	57		|I-IUPAC
and	58	61		|O
uridine	62	69	uridine	|B-TRIVIAL
compounds	70	79	compounds	|B-MODIFIER
(	80	81		|O
11	81	83		|O
,	83	84		|O
16	85	87		|O
)	87	88		|O
was	89	92		|O
synthesized	93	104		|O
by	105	107		|O
the	108	111		|O
regiospecific	112	125		|O
addition	126	134		|O
of	135	137		|O
HOI	138	141	HOI	|B-SUM
to	142	144		|O
the	145	148		|O
vinyl	149	154	vinyl	|B-TRIVIAL
substituent	155	166	substituent	|B-MODIFIER
of	167	169		|O
5	170	171	5-vinyl-2'-deoxyuridine	|B-IUPAC
-	171	172		|I-IUPAC
vinyl	172	177		|I-IUPAC
-	177	178		|I-IUPAC
2'	178	180		|I-IUPAC
-	180	181		|I-IUPAC
deoxyuridine	181	193		|I-IUPAC
(	194	195		|O
)	198	199		|O
,	199	200		|O
5	201	202	5-vinyl-2'-fluoro-2'-deoxyuridine	|B-IUPAC
-	202	203		|I-IUPAC
vinyl	203	208		|I-IUPAC
-	208	209		|I-IUPAC
2'	209	211		|I-IUPAC
-	211	212		|I-IUPAC
fluoro	212	218		|I-IUPAC
-	218	219		|I-IUPAC
2'	219	221		|I-IUPAC
-	221	222		|I-IUPAC
deoxyuridine	222	234		|I-IUPAC
(	235	236		|O
)	239	240		|O
,	240	241		|O
5	242	243	5-vinyluridine	|B-IUPAC
-	243	244		|I-IUPAC
vinyluridine	244	256		|I-IUPAC
(	257	258		|O
)	261	262		|O
,	262	263		|O
and	264	267		|O
(	268	269	(E)-5-(2-iodovinyl)-2'-deoxyuridine	|B-IUPAC
E	269	270		|I-IUPAC
)	270	271		|I-IUPAC
-	271	272		|I-IUPAC
5	272	273		|I-IUPAC
-	273	274		|I-IUPAC
(	274	275		|I-IUPAC
2	275	276		|I-IUPAC
-	276	277		|I-IUPAC
iodovinyl	277	286		|I-IUPAC
)	286	287		|I-IUPAC
-	287	288		|I-IUPAC
2'	288	290		|I-IUPAC
-	290	291		|I-IUPAC
deoxyuridine	291	303		|I-IUPAC
(	304	305		|O
4b	305	307		|O
)	307	308		|O
.	308	309		|O
Treatment	310	319		|O
of	320	322		|O
the	323	326		|O
iodohydrins	327	338	iodohydrins	|B-FAMILY
11a	339	342		|O
-	342	343		|O
c	343	344		|O
with	345	349		|O
methanolic	350	360	methanolic sulfuric acid	|B-IUPAC
sulfuric	361	369		|I-IUPAC
acid	370	374		|I-IUPAC
afforded	375	383		|O
the	384	387		|O
corresponding	388	401		|O
5	402	403	5-(1-methoxy-2-iodoethyl)	|B-IUPAC
-	403	404		|I-IUPAC
(	404	405		|I-IUPAC
1	405	406		|I-IUPAC
-	406	407		|I-IUPAC
methoxy	407	414		|I-IUPAC
-	414	415		|I-IUPAC
2	415	416		|I-IUPAC
-	416	417		|I-IUPAC
iodoethyl	417	426		|I-IUPAC
)	426	427		|I-IUPAC
derivatives	428	439	derivatives	|B-MODIFIER
(	440	441		|O
12a	441	444		|O
-	444	445		|O
c	445	446		|O
)	446	447		|O
.	447	448		|O
In	449	451		|O
contrast	452	460		|O
,	460	461		|O
reaction	462	470		|O
of	471	473		|O
5	474	475	5-(1-hydroxy-2-iodoethyl)-2'-deoxyuridine	|B-IUPAC
-	475	476		|I-IUPAC
(	476	477		|I-IUPAC
1	477	478		|I-IUPAC
-	478	479		|I-IUPAC
hydroxy	479	486		|I-IUPAC
-	486	487		|I-IUPAC
2	487	488		|I-IUPAC
-	488	489		|I-IUPAC
iodoethyl	489	498		|I-IUPAC
)	498	499		|I-IUPAC
-	499	500		|I-IUPAC
2'	500	502		|I-IUPAC
-	502	503		|I-IUPAC
deoxyuridine	503	515		|I-IUPAC
(	516	517		|O
11a	517	520		|O
)	520	521		|O
with	522	526		|O
sodium	527	533	sodium carbonate	|B-IUPAC
carbonate	534	543		|I-IUPAC
in	544	546		|O
methanol	547	555	methanol	|B-TRIVIAL
afforded	556	564		|O
a	565	566		|O
mixture	567	574		|O
of	575	577		|O
5	578	579	5-(1-hydroxy-2-methoxyethyl)-2'-deoxyuridine	|B-IUPAC
-	579	580		|I-IUPAC
(	580	581		|I-IUPAC
1	581	582		|I-IUPAC
-	582	583		|I-IUPAC
hydroxy	583	590		|I-IUPAC
-	590	591		|I-IUPAC
2	591	592		|I-IUPAC
-	592	593		|I-IUPAC
methoxyethyl	593	605		|I-IUPAC
)	605	606		|I-IUPAC
-	606	607		|I-IUPAC
2'	607	609		|I-IUPAC
-	609	610		|I-IUPAC
deoxyuridine	610	622		|I-IUPAC
(	623	624		|O
13	624	626		|O
)	626	627		|O
and	628	631		|O
2,3	632	635	2,3-dihydro-3-hydroxy-5-(2'-deoxy-beta-D-ribofuranosyl)- furano[2,3-d]pyrimidin-6(5H)-one	|B-IUPAC
-	635	636		|I-IUPAC
dihydro	636	643		|I-IUPAC
-	643	644		|I-IUPAC
3	644	645		|I-IUPAC
-	645	646		|I-IUPAC
hydroxy	646	653		|I-IUPAC
-	653	654		|I-IUPAC
5	654	655		|I-IUPAC
-	655	656		|I-IUPAC
(	656	657		|I-IUPAC
2'	657	659		|I-IUPAC
-	659	660		|I-IUPAC
deoxy	660	665		|I-IUPAC
-	665	666		|I-IUPAC
beta	666	670		|I-IUPAC
-	670	671		|I-IUPAC
D	671	672		|I-IUPAC
-	672	673		|I-IUPAC
ribofuranosyl	673	686		|I-IUPAC
)	686	687		|I-IUPAC
-	687	688		|I-IUPAC
furano	689	695		|I-IUPAC
[	695	696		|I-IUPAC
2,3	696	699		|I-IUPAC
-	699	700		|I-IUPAC
d	700	701		|I-IUPAC
]	701	702		|I-IUPAC
pyrimidin	702	711		|I-IUPAC
-	711	712		|I-IUPAC
6	712	713		|I-IUPAC
(	713	714		|I-IUPAC
5H	714	716		|I-IUPAC
)	716	717		|I-IUPAC
-	717	718		|I-IUPAC
one	718	721		|I-IUPAC
(	722	723		|O
14	723	725		|O
)	725	726		|O
.	726	727		|O
The	728	731		|O
most	732	736		|O
active	737	743		|O
compound	744	752		|O
,	752	753		|O
5	754	755	5-(1-methoxy-2-iodoethyl)-2'-deoxyuridine	|B-IUPAC
-	755	756		|I-IUPAC
(	756	757		|I-IUPAC
1	757	758		|I-IUPAC
-	758	759		|I-IUPAC
methoxy	759	766		|I-IUPAC
-	766	767		|I-IUPAC
2	767	768		|I-IUPAC
-	768	769		|I-IUPAC
iodoethyl	769	778		|I-IUPAC
)	778	779		|I-IUPAC
-	779	780		|I-IUPAC
2'	780	782		|I-IUPAC
-	782	783		|I-IUPAC
deoxyuridine	783	795		|I-IUPAC
(	796	797		|O
12a	797	800		|O
,	800	801		|O
ID50	802	806		|O
=	807	808		|O
0.1	809	812		|O
micrograms	813	823		|O
/	823	824		|O
mL	824	826		|O
)	826	827		|O
,	827	828		|O
which	829	834		|O
exhibited	835	844		|O
antiviral	845	854		|O
activity	855	863		|O
(	864	865		|O
HSV	865	868		|O
-	868	869		|O
1	869	870		|O
)	870	871		|O
-	875	876		|O
fold	876	880		|O
higher	881	887		|O
than	888	892		|O
that	893	897		|O
of	898	900		|O
the	901	904		|O
5	905	906	5-(1-hydroxy-2-iodoethyl)	|B-IUPAC
-	906	907		|I-IUPAC
(	907	908		|I-IUPAC
1	908	909		|I-IUPAC
-	909	910		|I-IUPAC
hydroxy	910	917		|I-IUPAC
-	917	918		|I-IUPAC
2	918	919		|I-IUPAC
-	919	920		|I-IUPAC
iodoethyl	920	929		|I-IUPAC
)	929	930		|I-IUPAC
analogue	931	939	analogue	|B-MODIFIER
(	940	941		|O
11a	941	944		|O
)	944	945		|O
,	945	946		|O
was	947	950		|O
less	951	955		|O
active	956	962		|O
than	963	967		|O
IVDU	968	972	IVDU	|B-ABBREVIATION
or	973	975		|O
acyclovir	976	985	acyclovir	|B-TRIVIAL
(	986	987		|O
ID50	987	991		|O
=	992	993		|O
0.01-0.1	994	1002		|O
micrograms	1003	1013		|O
/	1013	1014		|O
mL	1014	1016		|O
range	1017	1022		|O
)	1022	1023		|O
.	1023	1024		|O
The	1025	1028		|O
C	1029	1030	C-5	|B-PARTIUPAC
-	1030	1031		|I-PARTIUPAC
5	1031	1032		|I-PARTIUPAC
substituent	1033	1044	substituent	|B-MODIFIER
in	1045	1047		|O
the	1048	1051		|O
2'	1052	1054	2'-deoxyuridine	|B-IUPAC
-	1054	1055		|I-IUPAC
deoxyuridine	1055	1067		|I-IUPAC
series	1068	1074	series	|B-MODIFIER
was	1075	1078		|O
a	1079	1080		|O
determinant	1081	1092		|O
of	1093	1095		|O
cytotoxic	1096	1105		|O
activity	1106	1114		|O
,	1114	1115		|O
as	1116	1118		|O
determined	1119	1129		|O
in	1130	1132		|O
the	1133	1136		|O
in	1137	1139		|O
vitro	1140	1145		|O
L1210	1146	1151		|O
screen	1152	1158		|O
,	1158	1159		|O
where	1160	1165		|O
the	1166	1169		|O
relative	1170	1178		|O
activity	1179	1187		|O
order	1188	1193		|O
was	1194	1197		|O
CH	1198	1200	CH(OH)CHI2	|B-SUM
(	1200	1201		|I-SUM
OH	1201	1203		|I-SUM
)	1203	1204		|I-SUM
CHI2	1204	1208		|I-SUM
(	1209	1210		|O
16	1210	1212		|O
)	1212	1213		|O
greater	1214	1221		|O
than	1222	1226		|O
CH	1227	1229	CH(OMe)CH2I	|B-SUM
(	1229	1230		|I-SUM
OMe	1230	1233		|I-SUM
)	1233	1234		|I-SUM
CH2I	1234	1238		|I-SUM
(	1239	1240		|O
12a	1240	1243		|O
)	1243	1244		|O
greater	1245	1252		|O
than	1253	1257		|O
CH	1258	1260	CH(OH)CH2I	|B-SUM
(	1260	1261		|I-SUM
OH	1261	1263		|I-SUM
)	1263	1264		|I-SUM
CH2I	1264	1268		|I-SUM
(	1269	1270		|O
11a	1270	1273		|O
)	1273	1274		|O
congruent	1275	1284		|O
to	1285	1287		|O
CH	1288	1290	CH(OH)CH2OMe	|B-SUM
(	1290	1291		|I-SUM
OH	1291	1293		|I-SUM
)	1293	1294		|I-SUM
CH2OMe	1294	1300		|I-SUM
(	1301	1302		|O
13	1302	1304		|O
)	1304	1305		|O
.	1305	1306		|O
The	1307	1310		|O
2'	1311	1313	2'-	|B-PARTIUPAC
-	1313	1314		|I-PARTIUPAC
substituent	1314	1325		|O
was	1326	1329		|O
also	1330	1334		|O
a	1335	1336		|O
determinant	1337	1348		|O
of	1349	1351		|O
cytotoxic	1352	1361		|O
activity	1362	1370		|O
in	1371	1373		|O
the	1374	1377		|O
5	1378	1379	5-(1-hydroxy-2-iodoethyl)	|B-IUPAC
-	1379	1380		|I-IUPAC
(	1380	1381		|I-IUPAC
1	1381	1382		|I-IUPAC
-	1382	1383		|I-IUPAC
hydroxy	1383	1390		|I-IUPAC
-	1390	1391		|I-IUPAC
2	1391	1392		|I-IUPAC
-	1392	1393		|I-IUPAC
iodoethyl	1393	1402		|I-IUPAC
)	1402	1403		|I-IUPAC
(	1404	1405		|O
11a	1405	1408		|O
-	1408	1409		|O
c	1409	1410		|O
)	1410	1411		|O
and	1412	1415		|O
5	1416	1417	5-(1-methoxy-2-iodoethyl)	|B-IUPAC
-	1417	1418		|I-IUPAC
(	1418	1419		|I-IUPAC
1	1419	1420		|I-IUPAC
-	1420	1421		|I-IUPAC
methoxy	1421	1428		|I-IUPAC
-	1428	1429		|I-IUPAC
2	1429	1430		|I-IUPAC
-	1430	1431		|I-IUPAC
iodoethyl	1431	1440		|I-IUPAC
)	1440	1441		|I-IUPAC
series	1442	1448	series	|B-MODIFIER
of	1449	1451		|O
compounds	1452	1461		|O
,	1461	1462		|O
where	1463	1468		|O
the	1469	1472		|O
relative	1473	1481		|O
activity	1482	1490		|O
profile	1491	1498		|O
was	1499	1502		|O
2'	1503	1505	2'-deoxyuridine	|B-IUPAC
-	1505	1506		|I-IUPAC
deoxyuridine	1506	1518		|I-IUPAC
greater	1519	1526		|O
than	1527	1531		|O
2'	1532	1534	2'-fluoro-2'-deoxyuridine	|B-IUPAC
-	1534	1535		|I-IUPAC
fluoro	1535	1541		|I-IUPAC
-	1541	1542		|I-IUPAC
2'	1542	1544		|I-IUPAC
-	1544	1545		|I-IUPAC
deoxyuridine	1545	1557		|I-IUPAC
greater	1558	1565		|O
than	1566	1570		|O
uridine	1571	1578	uridine	|B-TRIVIAL
(	1579	1580		|O
11a	1580	1583		|O
greater	1584	1591		|O
than	1592	1596		|O
11b	1597	1600		|O
greater	1601	1608		|O
than	1609	1613		|O
or	1614	1616		|O
equal	1617	1622		|O
to	1623	1625		|O
11c	1626	1629		|O
;	1629	1630		|O
12a	1631	1634		|O
greater	1635	1642		|O
than	1643	1647		|O
12b	1648	1651		|O
greater	1652	1659		|O
than	1660	1664		|O
12c	1665	1668		|O
)	1668	1669		|O
.	1669	1670		|O
The	1671	1674		|O
most	1675	1679		|O
active	1680	1686		|O
cytotoxic	1687	1696		|O
agent	1697	1702		|O
(	1703	1704		|O
16	1704	1706		|O
)	1706	1707		|O
,	1707	1708		|O
possessing	1709	1719		|O
a	1720	1721		|O
5	1722	1723	5-(1-hydroxy-2,2-diiodoethyl)	|B-PARTIUPAC
-	1723	1724		|I-PARTIUPAC
(	1724	1725		|I-PARTIUPAC
1	1725	1726		|I-PARTIUPAC
-	1726	1727		|I-PARTIUPAC
hydroxy	1727	1734		|I-PARTIUPAC
-	1734	1735		|I-PARTIUPAC
2,2	1735	1738		|I-PARTIUPAC
-	1738	1739		|I-PARTIUPAC
diiodoethyl	1739	1750		|I-PARTIUPAC
)	1750	1751		|I-PARTIUPAC
substituent	1752	1763	substituent	|B-MODIFIER
(	1764	1765		|O
ED50	1765	1769		|O
=	1770	1771		|O
0.77	1772	1776		|O
micrograms	1777	1787		|O
/	1787	1788		|O
mL	1788	1790		|O
)	1790	1791		|O
,	1791	1792		|O
exhibited	1793	1802		|O
an	1803	1805		|O
activity	1806	1814		|O
approaching	1815	1826		|O
that	1827	1831		|O
of	1832	1834		|O
melphalan	1835	1844	melphalan	|B-TRIVIAL
(	1845	1846		|O
ED50	1846	1850		|O
=	1851	1852		|O
0.15	1853	1857		|O
micrograms	1858	1868		|O
/	1868	1869		|O
mL	1869	1871		|O
)	1871	1872		|O
.	1872	1873		|O
All	1874	1877		|O
compounds	1878	1887		|O
tested	1888	1894		|O
,	1894	1895		|O
except	1896	1902		|O
for	1903	1906		|O
13	1907	1909		|O
and	1910	1913		|O
14	1914	1916		|O
,	1916	1917		|O
exhibited	1918	1927		|O
high	1928	1932		|O
affinity	1933	1941		|O
(	1942	1943		|O
Ki	1943	1945		|O
=	1946	1947		|O
0.035-0.22	1948	1958		|O
mM	1959	1961		|O
range	1962	1967		|O
relative	1968	1976		|O
to	1977	1979		|O
deoxyuridine	1980	1992	deoxyuridine	|B-TRIVIAL
,	1992	1993		|O
Ki	1994	1996		|O
=	1997	1998		|O
0.125	1999	2004		|O
)	2004	2005		|O
for	2006	2009		|O
the	2010	2013		|O
murine	2014	2020		|O
NBMPR	2021	2026		|O
-	2026	2027		|O
sensitive	2027	2036		|O
erythrocyte	2037	2048		|O
nucleoside	2049	2059		|O
transport	2060	2069		|O
system	2070	2076		|O
,	2076	2077		|O
suggesting	2078	2088		|O
that	2089	2093		|O
these	2094	2099		|O
iodohydrins	2100	2111	iodohydrins	|B-FAMILY
are	2111	2114		|O
good	2116	2120		|O
permeants	2121	2130		|O
of	2131	2133		|O
cell	2134	2138		|O
membranes	2139	2148		|O
.	2148	2149		|O

### 3735316
N	0	1		|O
-	1	2		|O
Methylacetazolamide	2	21		|O
was	22	25		|O
shown	26	31		|O
to	32	34		|O
be	35	37		|O
active	38	44		|O
topically	45	54		|O
in	55	57		|O
reducing	58	66		|O
intraocular	67	78		|O
pressure	79	87		|O
(	88	89		|O
IOP	89	92		|O
)	92	93		|O
to	94	96		|O
a	97	98		|O
small	99	104		|O
but	105	108		|O
statistically	109	122		|O
significant	123	134		|O
level	135	140		|O
in	141	143		|O
the	144	147		|O
normotensive	148	160		|O
rabbit	161	167		|O
eye	168	171		|O
.	171	172		|O
In	173	175		|O
vivo	176	180		|O
experiments	181	192		|O
with	193	197		|O
N	198	199	N-methylacetazolamide	|B-IUPAC
-	199	200		|I-IUPAC
methylacetazolamide	200	219		|I-IUPAC
suggest	220	227		|O
that	228	232		|O
ocular	233	239		|O
metabolism	240	250		|O
to	251	253		|O
acetazolamide	254	267	acetazolamide	|B-TRIVIAL
was	268	271		|O
responsible	272	283		|O
for	284	287		|O
the	288	291		|O
observed	292	300		|O
topical	301	308		|O
activity	309	317		|O
.	317	318		|O
Examination	319	330		|O
of	331	333		|O
initial	334	341		|O
rate	342	346		|O
kinetics	347	355		|O
of	356	358		|O
carbonic	359	367		|O
anhydrase	368	377		|O
catalyzed	378	387		|O
p	388	389	p-nitrophenyl acetate	|B-IUPAC
-	389	390		|I-IUPAC
nitrophenyl	390	401		|I-IUPAC
acetate	402	409		|I-IUPAC
hydrolysis	410	420		|O
showed	421	427		|O
that	428	432		|O
N	433	434	N-methylacetazolamide	|B-IUPAC
-	434	435		|I-IUPAC
methylacetazolamide	435	454		|I-IUPAC
was	455	458		|O
a	459	460		|O
competitive	461	472		|O
inhibitor	473	482		|O
,	482	483		|O
in	484	486		|O
contrast	487	495		|O
to	496	498		|O
noncompetitive	499	513		|O
inhibition	514	524		|O
seen	525	529		|O
with	530	534		|O
acetazolamide	535	548	acetazolamide	|B-TRIVIAL
and	549	552		|O
other	553	558		|O
primary	559	566		|O
sulfonamide	567	578	sulfonamide	|B-TRIVIAL
inhibitors	579	589		|O
.	589	590		|O
N	591	592	N-Substituted	|B-PARTIUPAC
-	592	593		|I-PARTIUPAC
Substituted	593	604		|I-PARTIUPAC
and	605	608		|O
unsubstituted	609	622	unsubstituted 4-chlorobenzene-	|B-PARTIUPAC
4	623	624		|I-PARTIUPAC
-	624	625		|I-PARTIUPAC
chlorobenzene	625	638		|I-PARTIUPAC
-	638	639		|I-PARTIUPAC
and	640	643		|O
4	644	645	4-nitrobenzenesulfonamides	|B-IUPAC
-	645	646		|I-IUPAC
nitrobenzenesulfonamides	646	670		|I-IUPAC
were	671	675		|O
also	676	680		|O
synthesized	681	692		|O
,	692	693		|O
and	694	697		|O
their	698	703		|O
biochemical	704	715		|O
characteristics	716	731		|O
and	732	735		|O
in	736	738		|O
vivo	739	743		|O
ability	744	751		|O
to	752	754		|O
lower	755	760		|O
IOP	761	764		|O
when	765	769		|O
applied	770	777		|O
topically	778	787		|O
were	788	792		|O
determined	793	803		|O
.	803	804		|O
The	805	808		|O
primary	809	816		|O
sulfonamides	817	829	sulfonamides	|B-FAMILY
were	830	834		|O
reversible	835	845		|O
noncompetitive	846	860		|O
inhibitors	861	871		|O
of	872	874		|O
carbonic	875	883		|O
anhydrase	884	893		|O
,	893	894		|O
with	895	899		|O
no	900	902		|O
effect	903	909		|O
on	910	912		|O
IOP	913	916		|O
after	917	922		|O
topical	923	930		|O
administration	931	945		|O
.	945	946		|O
4	947	948	4-Nitrobenzene-	|B-PARTIUPAC
-	948	949		|I-PARTIUPAC
Nitrobenzene	949	961		|I-PARTIUPAC
-	961	962		|I-PARTIUPAC
and	963	966		|O
4	967	968	4-chlorobenzenesulfonamides	|B-IUPAC
-	968	969		|I-IUPAC
chlorobenzenesulfonamides	969	994		|I-IUPAC
containing	995	1005		|O
both	1006	1010		|O
N	1011	1012	N-hydroxy	|B-PARTIUPAC
-	1012	1013		|I-PARTIUPAC
hydroxy	1013	1020		|I-PARTIUPAC
and	1021	1024		|O
N	1025	1026	N-methyl	|B-PARTIUPAC
-	1026	1027		|I-PARTIUPAC
methyl	1027	1033		|I-PARTIUPAC
substituents	1034	1046	substituents	|B-MODIFIER
were	1047	1051		|O
model	1052	1057		|O
irreversible	1058	1070		|O
inhibitors	1071	1081		|O
of	1082	1084		|O
carbonic	1085	1093		|O
anhydrase	1094	1103		|O
and	1104	1107		|O
exhibited	1108	1117		|O
a	1118	1119		|O
trend	1120	1125		|O
toward	1126	1132		|O
topical	1133	1140		|O
activity	1141	1149		|O
in	1150	1152		|O
reducing	1153	1161		|O
IOP	1162	1165		|O
in	1166	1168		|O
normotensive	1169	1181		|O
rabbit	1182	1188		|O
eyes	1189	1193		|O
.	1193	1194		|O
Therefore	1195	1204		|O
,	1204	1205		|O
this	1206	1210		|O
paper	1211	1216		|O
describes	1217	1226		|O
the	1227	1230		|O
synthesis	1231	1240		|O
and	1241	1244		|O
characterization	1245	1261		|O
of	1262	1264		|O
two	1265	1268		|O
types	1269	1274		|O
of	1275	1277		|O
carbonic	1278	1286		|O
anhydrase	1287	1296		|O
inhibitors	1297	1307		|O
;	1307	1308		|O
the	1309	1312		|O
N	1313	1314	N-methyl-substituted sulfonamides	|B-IUPAC
-	1314	1315		|I-IUPAC
methyl	1315	1321		|I-IUPAC
-	1321	1322		|I-IUPAC
substituted	1322	1333		|I-IUPAC
sulfonamides	1334	1346		|I-IUPAC
are	1347	1350		|O
reversible	1351	1361		|O
competitive	1362	1373		|O
inhibitors	1374	1384		|O
of	1385	1387		|O
carbonic	1388	1396		|O
anhydrase	1397	1406		|O
,	1406	1407		|O
while	1408	1413		|O
the	1414	1417		|O
N	1418	1419	N-hydroxy-N-methyl-substituted sulfonamides	|B-IUPAC
-	1419	1420		|I-IUPAC
hydroxy	1420	1427		|I-IUPAC
-	1427	1428		|I-IUPAC
N	1428	1429		|I-IUPAC
-	1429	1430		|I-IUPAC
methyl	1430	1436		|I-IUPAC
-	1436	1437		|I-IUPAC
substituted	1437	1448		|I-IUPAC
sulfonamides	1449	1461		|I-IUPAC
are	1461	1464		|O
irreversible	1466	1478		|O
inhibitors	1479	1489		|O
.	1489	1490		|O

### 6827523
Condensation	0	12		|O
of	13	15		|O
14	16	18	14-bromodaunorubicin	|B-IUPAC
-	18	19		|I-IUPAC
bromodaunorubicin	19	36		|I-IUPAC
with	37	41		|O
thiols	42	48	thiols	|B-FAMILY
in	49	51		|O
methanol	52	60	methanol	|B-TRIVIAL
,	60	61		|O
in	62	64		|O
the	65	68		|O
presence	69	77		|O
of	78	80		|O
potassium	81	90	potassium carbonate	|B-TRIVIAL
carbonate	91	100		|I-TRIVIAL
,	100	101		|O
resulted	102	110		|O
in	111	113		|O
the	114	117		|O
formation	118	127		|O
of	128	130		|O
14	131	133	14-thia	|B-PARTIUPAC
-	133	134		|I-PARTIUPAC
thia	134	138		|I-PARTIUPAC
analogues	139	148	analogues	|B-MODIFIER
of	149	151		|O
the	152	155		|O
antitumor	156	165		|O
antibiotic	166	176		|O
adriamycin	177	187	adriamycin	|B-TRIVIAL
.	187	188		|O
However	189	196		|O
,	196	197		|O
similar	198	205		|O
condensation	206	218		|O
of	219	221		|O
N	222	223	N-(trifluoroacetyl)-14-iododaunorubicin	|B-IUPAC
-	223	224		|I-IUPAC
(	224	225		|I-IUPAC
trifluoroacetyl	225	240		|I-IUPAC
)	240	241		|I-IUPAC
-	241	242		|I-IUPAC
14	242	244		|I-IUPAC
-	244	245		|I-IUPAC
iododaunorubicin	245	261		|I-IUPAC
with	262	266		|O
thiols	267	273		|O
invariably	274	284		|O
led	285	288		|O
to	289	291		|O
a	292	293		|O
redox	294	299		|O
reaction	300	308		|O
,	308	309		|O
with	310	314		|O
the	315	318		|O
formation	319	328		|O
of	329	331		|O
N	332	333	N-(trifluoroacetyl)daunorubicin	|B-IUPAC
-	333	334		|I-IUPAC
(	334	335		|I-IUPAC
trifluoroacetyl	335	350		|I-IUPAC
)	350	351		|I-IUPAC
daunorubicin	351	363		|I-IUPAC
and	364	367		|O
disulfides	368	378	disulfides	|B-FAMILY
.	378	379		|O
Accordingly	380	391		|O
,	391	392		|O
N	393	394	N-(trifluoroacetyl)-14-bromodaunorubicin	|B-IUPAC
-	394	395		|I-IUPAC
(	395	396		|I-IUPAC
trifluoroacetyl	396	411		|I-IUPAC
)	411	412		|I-IUPAC
-	412	413		|I-IUPAC
14	413	415		|I-IUPAC
-	415	416		|I-IUPAC
bromodaunorubicin	416	433		|I-IUPAC
was	434	437		|O
used	438	442		|O
for	443	446		|O
reaction	447	455		|O
with	456	460		|O
thiols	461	467	thiols	|B-FAMILY
to	468	470		|O
yield	471	476		|O
thia	477	481		|O
analogues	482	491		|O
of	492	494		|O
the	495	498		|O
clinically	499	509		|O
active	510	516		|O
but	517	520		|O
non	521	524		|O
-	524	525		|O
DNA	525	528		|O
-	528	529		|O
binding	529	536		|O
adriamycin	537	547	adriamycin	|B-TRIVIAL
analogue	548	556	analogue	|B-MODIFIER
N	557	558	N-(trifluoroacetyl)adriamycin 14-valerate	|B-IUPAC
-	558	559		|I-IUPAC
(	559	560		|I-IUPAC
trifluoroacetyl	560	575		|I-IUPAC
)	575	576		|I-IUPAC
adriamycin	576	586		|I-IUPAC
14	587	589		|I-IUPAC
-	589	590		|I-IUPAC
valerate	590	598		|I-IUPAC
(	599	600		|O
AD	600	602		|O
32	603	605		|O
)	605	606		|O
.	606	607		|O
Reaction	608	616		|O
of	617	619		|O
14	620	622	14-bromoadunorubicin	|B-IUPAC
-	622	623		|I-IUPAC
bromoadunorubicin	623	640		|I-IUPAC
with	641	645		|O
alpha	646	651	alpha, omega-alkanedithiols	|B-IUPAC
,	651	652		|I-IUPAC
omega	653	658		|I-IUPAC
-	658	659		|I-IUPAC
alkanedithiols	659	673		|I-IUPAC
gave	674	678		|O
bis	679	682	bis(thiaadriamycin)	|B-TRIVIAL
(	682	683		|I-TRIVIAL
thiaadriamycin	683	697		|I-TRIVIAL
)	697	698		|I-TRIVIAL
analogues	699	708	analogues	|B-MODIFIER
as	709	711		|O
potential	712	721		|O
difunctional	722	734		|O
intercalating	735	748		|O
agents	749	755		|O
.	755	756		|O
The	757	760		|O
aforementioned	761	775		|O
products	776	784		|O
,	784	785		|O
plus	786	790		|O
two	791	794		|O
related	795	802		|O
phenylselena	803	815	phenylselena	|B-TRIVIAL
derivatives	816	827	derivatives	|B-MODIFIER
,	827	828		|O
were	829	833		|O
examined	834	842		|O
for	843	846		|O
in	847	849		|O
vitro	850	855		|O
growth	856	862		|O
inhibition	863	873		|O
,	873	874		|O
in	875	877		|O
vivo	878	882		|O
antitumor	883	892		|O
activity	893	901		|O
,	901	902		|O
and	903	906		|O
,	906	907		|O
where	908	913		|O
appropriate	914	925		|O
,	925	926		|O
DNA	927	930		|O
binding	931	938		|O
.	938	939		|O
A	940	941		|O
number	942	948		|O
of	949	951		|O
agents	952	958		|O
,	958	959		|O
most	960	964		|O
notably	965	972		|O
14	973	975	14-(carbethoxymethyl)-14-thiaadriamycin	|B-IUPAC
-	975	976		|I-IUPAC
(	976	977		|I-IUPAC
carbethoxymethyl	977	993		|I-IUPAC
)	993	994		|I-IUPAC
-	994	995		|I-IUPAC
14	995	997		|I-IUPAC
-	997	998		|I-IUPAC
thiaadriamycin	998	1012		|I-IUPAC
and	1013	1016		|O
N	1017	1018	N-(trifluoroacetyl)-14-phenyl-14-selenaadriamycin	|B-IUPAC
-	1018	1019		|I-IUPAC
(	1019	1020		|I-IUPAC
trifluoroacetyl	1020	1035		|I-IUPAC
)	1035	1036		|I-IUPAC
-	1036	1037		|I-IUPAC
14	1037	1039		|I-IUPAC
-	1039	1040		|I-IUPAC
phenyl	1040	1046		|I-IUPAC
-	1046	1047		|I-IUPAC
14	1047	1049		|I-IUPAC
-	1049	1050		|I-IUPAC
selenaadriamycin	1050	1066		|I-IUPAC
,	1066	1067		|O
were	1068	1072		|O
active	1073	1079		|O
against	1080	1087		|O
murine	1088	1094		|O
L1210	1095	1100		|O
leukemia	1101	1109		|O
in	1110	1112		|O
vivo	1113	1117		|O
.	1117	1118		|O
Several	1119	1126		|O
of	1127	1129		|O
the	1130	1133		|O
amino	1134	1139	amino glycoside unsubstituted 14-thiaadriamycin	|B-IUPAC
glycoside	1140	1149		|I-IUPAC
unsubstituted	1150	1163		|I-IUPAC
14	1164	1166		|I-IUPAC
-	1166	1167		|I-IUPAC
thiaadriamycin	1167	1181		|I-IUPAC
analogues	1182	1191	analogues	|B-MODIFIER
exhibited	1192	1201		|O
DNA	1202	1205		|O
-	1205	1206		|O
binding	1206	1213		|O
properties	1214	1224		|O
equivalent	1225	1235		|O
to	1236	1238		|O
those	1239	1244		|O
of	1245	1247		|O
adriamycin	1248	1258	adriamycin	|B-TRIVIAL
.	1258	1259		|O

### 10783907
Enalapril	10	19	Enalapril	|B-TRIVIAL
in	20	22		|O
subantihypertensive	23	42		|O
dosage	43	49		|O
attenuates	50	60		|O
kidney	61	67		|O
proliferation	68	81		|O
and	82	85		|O
functional	86	96		|O
recovery	97	105		|O
in	106	108		|O
normotensive	109	121		|O
ablation	122	130		|O
nephropathy	131	142		|O
of	143	145		|O
the	146	149		|O
rat	150	153		|O
.	153	154		|O
Most	156	160		|O
studies	161	168		|O
on	169	171		|O
the	172	175		|O
antiproliferative	176	193		|O
action	194	200		|O
of	201	203		|O
angiotensin	204	215		|O
converting	216	226		|O
enzyme	227	233		|O
inhibitors	234	244		|O
(	245	246		|O
ACEI	246	250		|O
)	250	251		|O
were	252	256		|O
performed	257	266		|O
in	267	269		|O
a	270	271		|O
rat	272	275		|O
hypertensive	276	288		|O
remnant	289	296		|O
kidney	297	303		|O
model	304	309		|O
with	310	314		|O
5/6	315	318		|O
kidney	319	325		|O
ablation	326	334		|O
which	335	340		|O
raised	341	347		|O
objections	348	358		|O
about	359	364		|O
the	365	368		|O
antihypertensive	369	385		|O
effect	386	392		|O
of	393	395		|O
ACEI	396	400		|O
and	401	404		|O
the	405	408		|O
influence	409	418		|O
of	419	421		|O
other	422	427		|O
antihypertensive	428	444		|O
drugs	445	450		|O
administered	451	463		|O
to	464	466		|O
remnant	467	474		|O
kidney	475	481		|O
control	482	489		|O
rats	490	494		|O
.	494	495		|O
To	496	498		|O
prevent	499	506		|O
these	507	512		|O
objections	513	523		|O
,	523	524		|O
a	525	526		|O
normotensive	527	539		|O
4/6	540	543		|O
remnant	544	551		|O
kidney	552	558		|O
model	559	564		|O
was	565	568		|O
elaborated	569	579		|O
and	580	583		|O
a	584	585		|O
subantihypertensive	586	605		|O
dosage	606	612		|O
of	613	615		|O
enalapril	616	625	enalapril	|B-TRIVIAL
was	626	629		|O
used	630	634		|O
to	635	637		|O
evaluate	638	646		|O
its	647	650		|O
antiproliferative	651	668		|O
action	669	675		|O
.	675	676		|O
Subtotally	677	687		|O
nephrectomized	688	702		|O
rats	703	707		|O
(	708	709		|O
Nx	709	711		|O
)	711	712		|O
markedly	713	721		|O
increased	722	731		|O
the	732	735		|O
remnant	736	743		|O
kidney	744	750		|O
weight	751	757		|O
during	758	764		|O
a	765	766		|O
4	767	768		|O
-	768	769		|O
week	769	773		|O
period	774	780		|O
and	781	784		|O
this	785	789		|O
rise	790	794		|O
was	795	798		|O
prevented	799	808		|O
by	809	811		|O
the	812	815		|O
treatment	816	825		|O
with	826	830		|O
enalapril	831	840	enalapril	|B-TRIVIAL
(	841	842		|O
NxE	842	845		|O
)	845	846		|O
(	847	848		|O
Nx	848	850		|O
+	851	852		|O
297	852	855		|O
+	855	856		|O
/	856	857		|O
-	857	858		|O
35	858	860		|O
mg	861	863		|O
vs.	864	867		|O
sham	868	872		|O
-	872	873		|O
operated	873	881		|O
+	882	883		|O
145	883	886		|O
+	886	887		|O
/	887	888		|O
-	888	889		|O
32	889	891		|O
mg	892	894		|O
,	894	895		|O
p	896	897		|O
<	897	898		|O
0.001	898	903		|O
;	903	904		|O
NxE	905	908		|O
+	909	910		|O
154	910	913		|O
+	913	914		|O
/	914	915		|O
-	915	916		|O
35	916	918		|O
mg	919	921		|O
vs.	922	925		|O
Nx	926	928		|O
p	929	930		|O
<	930	931		|O
0.001	931	936		|O
)	936	937		|O
.	937	938		|O
While	939	944		|O
collagen	945	953		|O
concentration	954	967		|O
in	968	970		|O
the	971	974		|O
kidney	975	981		|O
cortex	982	988		|O
was	989	992		|O
not	993	996		|O
increased	997	1006		|O
in	1007	1009		|O
sham	1010	1014		|O
-	1014	1015		|O
operated	1015	1023		|O
rats	1024	1028		|O
(	1029	1030		|O
Sham	1030	1034		|O
)	1034	1035		|O
in	1036	1038		|O
comparison	1039	1049		|O
with	1050	1054		|O
the	1055	1058		|O
control	1059	1066		|O
group	1067	1072		|O
(	1073	1074		|O
Ctrl	1074	1078		|O
)	1078	1079		|O
at	1080	1082		|O
the	1083	1086		|O
beginning	1087	1096		|O
of	1097	1099		|O
the	1100	1103		|O
study	1104	1109		|O
,	1109	1110		|O
the	1111	1114		|O
subsequent	1115	1125		|O
increase	1126	1134		|O
was	1135	1138		|O
significant	1139	1150		|O
in	1151	1153		|O
the	1154	1157		|O
Nx	1158	1160		|O
group	1161	1166		|O
and	1167	1170		|O
enalapril	1171	1180	enalapril	|B-TRIVIAL
did	1181	1184		|O
not	1185	1188		|O
attenuate	1189	1198		|O
this	1199	1203		|O
increase	1204	1212		|O
(	1213	1214		|O
Sham	1214	1218		|O
148	1219	1222		|O
+	1222	1223		|O
/	1223	1224		|O
-	1224	1225		|O
5	1225	1226		|O
mg	1227	1229		|O
/	1229	1230		|O
g	1234	1235		|O
w	1236	1237		|O
.	1237	1238		|O
w	1238	1239		|O
.	1239	1240		|O
vs.	1241	1244		|O
Nx	1245	1247		|O
164	1248	1251		|O
+	1251	1252		|O
/	1252	1253		|O
-	1253	1254		|O
2	1254	1255		|O
mg	1256	1258		|O
/	1258	1259		|O
g	1263	1264		|O
w	1265	1266		|O
.	1266	1267		|O
w	1267	1268		|O
.	1268	1269		|O
,	1269	1270		|O
p	1271	1272		|O
<	1272	1273		|O
0.01	1273	1277		|O
;	1277	1278		|O
NxE	1279	1282		|O
161	1283	1286		|O
+	1286	1287		|O
/	1287	1288		|O
-	1288	1289		|O
4	1289	1290		|O
mg	1291	1293		|O
/	1293	1294		|O
g	1298	1299		|O
w	1300	1301		|O
.	1301	1302		|O
w	1302	1303		|O
.	1303	1304		|O
vs.	1305	1308		|O
Sham	1309	1313		|O
p	1314	1315		|O
<	1315	1316		|O
0.05	1316	1320		|O
)	1320	1321		|O
.	1321	1322		|O
The	1323	1326		|O
tubular	1327	1334		|O
protein	1335	1342		|O
/	1342	1343		|O
DNA	1343	1346		|O
ratio	1347	1352		|O
increase	1353	1361		|O
,	1361	1362		|O
which	1363	1368		|O
was	1369	1372		|O
significant	1373	1384		|O
in	1385	1387		|O
the	1388	1391		|O
Nx	1392	1394		|O
group	1395	1400		|O
,	1400	1401		|O
was	1402	1405		|O
inhibited	1406	1415		|O
by	1416	1418		|O
enalapril	1419	1428	enalapril	|B-TRIVIAL
(	1429	1430		|O
Nx	1430	1432		|O
26.2	1433	1437		|O
+	1437	1438		|O
/	1438	1439		|O
-	1439	1440		|O
vs.	1445	1448		|O
NxE	1449	1452		|O
15.3	1453	1457		|O
+	1457	1458		|O
/	1458	1459		|O
-	1459	1460		|O
2.6	1460	1463		|O
,	1463	1464		|O
p	1465	1466		|O
<	1466	1467		|O
0.05	1467	1471		|O
)	1471	1472		|O
.	1472	1473		|O
The	1474	1477		|O
protein	1478	1485		|O
/	1485	1486		|O
DNA	1486	1489		|O
ratio	1490	1495		|O
was	1496	1499		|O
much	1500	1504		|O
lower	1505	1510		|O
in	1511	1513		|O
glomeruli	1514	1523		|O
,	1523	1524		|O
with	1525	1529		|O
no	1530	1532		|O
significant	1533	1544		|O
changes	1545	1552		|O
in	1553	1555		|O
either	1556	1562		|O
the	1563	1566		|O
Nx	1567	1569		|O
or	1570	1572		|O
NxE	1573	1576		|O
groups	1577	1583		|O
.	1583	1584		|O
Serum	1585	1590		|O
urea	1591	1595	urea	|B-TRIVIAL
concentrations	1596	1610		|O
were	1611	1615		|O
slightly	1616	1624		|O
higher	1625	1631		|O
in	1632	1634		|O
the	1635	1638		|O
Nx	1639	1641		|O
group	1642	1647		|O
than	1648	1652		|O
in	1653	1655		|O
the	1656	1659		|O
sham	1660	1664		|O
-	1664	1665		|O
operated	1665	1673		|O
group	1674	1679		|O
,	1679	1680		|O
but	1681	1684		|O
markedly	1685	1693		|O
elevated	1694	1702		|O
in	1703	1705		|O
the	1706	1709		|O
NxE	1710	1713		|O
group	1714	1719		|O
(	1720	1721		|O
Nx	1721	1723		|O
+	1729	1730		|O
/	1730	1731		|O
-	1731	1732		|O
0.76	1732	1736		|O
mmol	1737	1741		|O
/	1741	1742		|O
l	1742	1743		|O
vs.	1744	1747		|O
Sham	1748	1752		|O
6.10	1753	1757		|O
+	1757	1758		|O
/	1758	1759		|O
-	1759	1760		|O
0.33	1760	1764		|O
mmol	1765	1769		|O
/	1769	1770		|O
l	1770	1771		|O
,	1771	1772		|O
p	1773	1774		|O
<	1774	1775		|O
0.001	1775	1780		|O
;	1780	1781		|O
NxE	1782	1785		|O
28.9	1786	1790		|O
+	1790	1791		|O
/	1791	1792		|O
-	1792	1793		|O
2.6	1793	1796		|O
mmol	1797	1801		|O
/	1801	1802		|O
l	1802	1803		|O
vs.	1804	1807		|O
Sham	1808	1812		|O
p	1813	1814		|O
<	1814	1815		|O
0.001	1815	1820		|O
)	1820	1821		|O
.	1821	1822		|O
Creatinine	1823	1833	Creatinine	|B-TRIVIAL
concentrations	1834	1848		|O
in	1849	1851		|O
the	1852	1855		|O
Nx	1856	1858		|O
group	1859	1864		|O
were	1865	1869		|O
increased	1870	1879		|O
in	1880	1882		|O
comparison	1883	1893		|O
with	1894	1898		|O
the	1899	1902		|O
sham	1903	1907		|O
-	1907	1908		|O
operated	1908	1916		|O
group	1917	1922		|O
and	1923	1926		|O
markedly	1927	1935		|O
increased	1936	1945		|O
in	1946	1948		|O
the	1949	1952		|O
NxE	1953	1956		|O
group	1957	1962		|O
(	1963	1964		|O
Nx	1964	1966		|O
63.7	1967	1971		|O
+	1971	1972		|O
/	1972	1973		|O
-	1973	1974		|O
3.56	1974	1978		|O
micromol	1979	1987		|O
/	1987	1988		|O
l	1988	1989		|O
vs.	1990	1993		|O
Sham	1994	1998		|O
37.2	1999	2003		|O
+	2003	2004		|O
/	2004	2005		|O
-	2005	2006		|O
2.84	2006	2010		|O
micromol	2011	2019		|O
/	2019	2020		|O
l	2020	2021		|O
,	2021	2022		|O
p	2023	2024		|O
<	2024	2025		|O
0.001	2025	2030		|O
;	2030	2031		|O
NxE	2032	2035		|O
+	2041	2042		|O
/	2042	2043		|O
-	2043	2044		|O
5.2	2044	2047		|O
micromol	2048	2056		|O
/	2056	2057		|O
l	2057	2058		|O
vs.	2059	2062		|O
Sham	2063	2067		|O
p	2068	2069		|O
<	2069	2070		|O
0.001	2070	2075		|O
)	2075	2076		|O
.	2076	2077		|O
The	2078	2081		|O
clearance	2082	2091		|O
of	2092	2094		|O
creatinine	2095	2105	creatinine	|B-TRIVIAL
was	2106	2109		|O
lower	2110	2115		|O
in	2116	2118		|O
the	2119	2122		|O
Nx	2123	2125		|O
group	2126	2131		|O
than	2132	2136		|O
in	2137	2139		|O
the	2140	2143		|O
sham	2144	2148		|O
-	2148	2149		|O
operated	2149	2157		|O
group	2158	2163		|O
and	2164	2167		|O
was	2168	2171		|O
markedly	2172	2180		|O
reduced	2181	2188		|O
in	2189	2191		|O
the	2192	2195		|O
NxE	2196	2199		|O
group	2200	2205		|O
(	2206	2207		|O
Nx	2207	2209		|O
0.89	2210	2214		|O
+	2214	2215		|O
/	2215	2216		|O
-	2216	2217		|O
0.06	2217	2221		|O
ml	2222	2224		|O
/	2224	2225		|O
min	2225	2228		|O
.	2228	2229		|O
g	2229	2230		|O
kidney	2231	2237		|O
wt	2238	2240		|O
.	2240	2241		|O
vs.	2242	2245		|O
Sham	2246	2250		|O
1.05	2251	2255		|O
+	2255	2256		|O
/	2256	2257		|O
-	2257	2258		|O
0.16	2258	2262		|O
ml	2263	2265		|O
/	2265	2266		|O
min	2266	2269		|O
x	2270	2271		|O
g	2272	2273		|O
kidney	2274	2280		|O
wt	2281	2283		|O
.	2283	2284		|O
,	2284	2285		|O
p	2286	2287		|O
<	2287	2288		|O
0.01	2288	2292		|O
;	2292	2293		|O
NxE	2294	2297		|O
0.58	2298	2302		|O
+	2302	2303		|O
/	2303	2304		|O
-	2304	2305		|O
0.029	2305	2310		|O
ml	2311	2313		|O
/	2313	2314		|O
min	2314	2317		|O
x	2318	2319		|O
g	2320	2321		|O
kidney	2322	2328		|O
wt	2329	2331		|O
.	2331	2332		|O
vs.	2333	2336		|O
Sham	2337	2341		|O
,	2341	2342		|O
p	2343	2344		|O
<	2344	2345		|O
0.001	2345	2350		|O
)	2350	2351		|O
.	2351	2352		|O
Enalapril	2353	2362	Enalapril	|B-TRIVIAL
improved	2363	2371		|O
proteinuria	2372	2383		|O
in	2384	2386		|O
comparison	2387	2397		|O
with	2398	2402		|O
the	2403	2406		|O
Nx	2407	2409		|O
group	2410	2415		|O
(	2416	2417		|O
NxE	2417	2420		|O
5.6	2421	2424		|O
+	2424	2425		|O
/	2425	2426		|O
-	2426	2427		|O
0.6	2427	2430		|O
mg	2431	2433		|O
/	2433	2434		|O
24	2434	2436		|O
h	2437	2438		|O
vs.	2439	2442		|O
Nx	2443	2445		|O
16.1	2446	2450		|O
+	2450	2451		|O
/	2451	2452		|O
-	2452	2453		|O
3.4	2453	2456		|O
mg	2457	2459		|O
/	2459	2460		|O
24	2460	2462		|O
h	2463	2464		|O
,	2464	2465		|O
p	2466	2467		|O
<	2467	2468		|O
0.05	2468	2472		|O
)	2472	2473		|O
.	2473	2474		|O
Thus	2475	2479		|O
remnant	2480	2487		|O
kidney	2488	2494		|O
proliferation	2495	2508		|O
is	2509	2511		|O
substantial	2512	2523		|O
even	2524	2528		|O
in	2529	2531		|O
normotensive	2532	2544		|O
rats	2545	2549		|O
.	2549	2550		|O
It	2551	2553		|O
includes	2554	2562		|O
both	2563	2567		|O
proliferation	2568	2581		|O
and	2582	2585		|O
collagen	2586	2594		|O
accumulation	2595	2607		|O
with	2608	2612		|O
partial	2613	2620		|O
recovery	2621	2629		|O
of	2630	2632		|O
kidney	2633	2639		|O
weight	2640	2646		|O
and	2647	2650		|O
function	2651	2659		|O
,	2659	2660		|O
but	2661	2664		|O
is	2665	2667		|O
accompanied	2668	2679		|O
by	2680	2682		|O
enhanced	2683	2691		|O
proteinuria	2692	2703		|O
.	2703	2704		|O
Enalapril	2705	2714	Enalapril	|B-TRIVIAL
attenuates	2714	2724		|O
the	2726	2729		|O
proliferation	2730	2743		|O
and	2744	2747		|O
decreases	2748	2757		|O
proteinuria	2758	2769		|O
but	2770	2773		|O
prolongs	2774	2782		|O
kidney	2783	2789		|O
function	2790	2798		|O
recovery	2799	2807		|O
.	2807	2808		|O

### 9082041
Replacing	9	18		|O
dietary	19	26		|O
palmitic	27	35	palmitic acid	|B-IUPAC
acid	36	40		|I-IUPAC
with	41	45		|O
elaidic	46	53	elaidic acid	|B-IUPAC
acid	54	58		|I-IUPAC
(	59	60		|O
t	60	61		|O
-	61	62		|O
C18	62	65		|O
:	65	66		|O
1	66	67		|O
delta9	68	74		|O
)	74	75		|O
depresses	76	85		|O
HDL	86	89		|O
and	90	93		|O
increases	94	103		|O
CETP	104	108		|O
activity	109	117		|O
in	118	120		|O
cebus	121	126		|O
monkeys	127	134		|O
.	134	135		|O
The	137	140		|O
question	141	149		|O
whether	150	157		|O
dietary	158	165		|O
trans	166	171		|O
fatty	172	177		|O
acids	178	183		|O
affect	184	190		|O
lipoprotein	191	202		|O
metabolism	203	213		|O
similarly	214	223		|O
to	224	226		|O
specific	227	235		|O
saturated	236	245	saturated fatty acids	|B-FAMILY
fatty	246	251		|I-FAMILY
acids	252	257		|I-FAMILY
was	258	261		|O
investigated	262	274		|O
in	275	277		|O
11	278	280		|O
normolipemic	281	293		|O
cebus	294	299		|O
monkeys	300	307		|O
by	308	310		|O
exchanging	311	321		|O
5%	322	324		|O
dietary	325	332		|O
energy	333	339		|O
(	340	341		|O
%	341	342		|O
en	342	344		|O
)	344	345		|O
between	346	353		|O
elaidic	354	361	elaidic	|B-PARTIUPAC
(	362	363		|O
t	363	364		|O
-	364	365		|O
C18	365	368		|O
:	368	369		|O
1	369	370		|O
delta9	371	377		|O
)	377	378		|O
and	379	382		|O
palmitic	383	391	palmitic acid	|B-IUPAC
acid	392	396		|I-IUPAC
(	397	398		|O
16	398	400		|O
:	400	401		|O
0	401	402		|O
)	402	403		|O
in	404	406		|O
two	407	410		|O
test	411	415		|O
diets	416	421		|O
(	422	423		|O
en	426	428		|O
fat	429	432		|O
+	433	434		|O
mg	439	441		|O
cholesterol	442	453	cholesterol	|B-TRIVIAL
/	453	454		|O
kcal	459	463		|O
diet	464	468		|O
)	468	469		|O
conforming	470	480		|O
to	481	483		|O
the	484	487		|O
American	488	496		|O
Heart	497	502		|O
Association	503	514		|O
(	515	516		|O
AHA	516	519		|O
)	519	520		|O
Step	521	525		|O
1	526	527		|O
guidelines	528	538		|O
.	538	539		|O
These	540	545		|O
were	546	550		|O
compared	551	559		|O
with	560	564		|O
a	565	566		|O
normal	567	573		|O
control	574	581		|O
diet	582	586		|O
rich	587	591		|O
in	592	594		|O
saturated	595	604		|O
fat	605	608		|O
and	609	612		|O
cholesterol	613	624	cholesterol	|B-TRIVIAL
(	625	626		|O
38%	626	629		|O
en	629	631		|O
fat	632	635		|O
+	636	637		|O
mg	642	644		|O
cholesterol	645	656	cholesterol	|B-TRIVIAL
/	656	657		|O
kcal	662	666		|O
diet	667	671		|O
)	671	672		|O
.	672	673		|O
The	674	677		|O
control	678	685		|O
diet	686	690		|O
was	691	694		|O
fed	695	698		|O
initially	699	708		|O
for	709	712		|O
14	713	715		|O
wk	716	718		|O
,	718	719		|O
followed	720	728		|O
by	729	731		|O
each	732	736		|O
of	737	739		|O
the	740	743		|O
the	744	747		|O
two	748	751		|O
test	752	756		|O
diets	757	762		|O
in	763	765		|O
a	766	767		|O
crossover	768	777		|O
design	778	784		|O
.	784	785		|O
Plasma	786	792		|O
lipid	793	798	lipid	|B-FAMILY
concentrations	799	813		|O
were	814	818		|O
determined	819	829		|O
four	830	834		|O
times	835	840		|O
between	841	848		|O
the	849	852		|O
6th	853	856		|O
and	857	860		|O
14th	861	865		|O
wk	866	868		|O
.	868	869		|O
Turnover	870	878		|O
studies	879	886		|O
(	887	888		|O
using	888	893		|O
125I	894	898		|O
-	898	899		|O
HDL	899	902		|O
and	903	906		|O
131I	907	911		|O
-	911	912		|O
LDL	912	915		|O
)	915	916		|O
were	917	921		|O
conducted	922	931		|O
after	932	937		|O
9	938	939		|O
wk	940	942		|O
in	943	945		|O
each	946	950		|O
dietary	951	958		|O
period	959	965		|O
.	965	966		|O
Relative	967	975		|O
to	976	978		|O
the	979	982		|O
control	983	990		|O
diet	991	995		|O
,	995	996		|O
both	997	1001		|O
test	1002	1006		|O
diets	1007	1012		|O
significantly	1013	1026		|O
reduced	1027	1034		|O
plasma	1035	1041		|O
total	1042	1047		|O
cholesterol	1048	1059	cholesterol	|B-TRIVIAL
(	1060	1061		|O
TC	1061	1063		|O
)	1063	1064		|O
,	1064	1065		|O
HDL	1066	1069		|O
cholesterol	1070	1081	cholesterol	|B-TRIVIAL
(	1082	1083		|O
HDL	1083	1086		|O
-	1086	1087		|O
C	1087	1088		|O
)	1088	1089		|O
and	1090	1093		|O
VLDL	1094	1098		|O
plus	1099	1103		|O
LDL	1104	1107		|O
cholesterol	1108	1119	cholesterol	|B-TRIVIAL
(	1120	1121		|O
LDL	1121	1124		|O
-	1124	1125		|O
C	1125	1126		|O
)	1126	1127		|O
concentrations	1128	1142		|O
;	1142	1143		|O
triglyceride	1144	1156	triglyceride	|B-FAMILY
(	1157	1158		|O
TG	1158	1160	TG	|B-ABBREVIATION
)	1160	1161		|O
concentrations	1162	1176		|O
tended	1177	1183		|O
to	1184	1186		|O
be	1187	1189		|O
lower	1190	1195		|O
.	1195	1196		|O
However	1197	1204		|O
,	1204	1205		|O
the	1206	1209		|O
trans	1210	1215		|O
diet	1216	1220		|O
resulted	1221	1229		|O
in	1230	1232		|O
a	1233	1234		|O
significantly	1235	1248		|O
greater	1249	1256		|O
reduction	1257	1266		|O
in	1267	1269		|O
HDL	1270	1273		|O
-	1273	1274		|O
C	1274	1275		|O
than	1276	1280		|O
the	1281	1284		|O
palmitate	1285	1294		|O
diet	1295	1299		|O
(	1300	1301		|O
124	1301	1304		|O
+	1305	1306		|O
/	1306	1307		|O
-	1307	1308		|O
17	1309	1311		|O
,	1311	1312		|O
117	1313	1316		|O
+	1317	1318		|O
/	1318	1319		|O
-	1319	1320		|O
18	1321	1323		|O
and	1324	1327		|O
+	1332	1333		|O
/	1333	1334		|O
-	1334	1335		|O
13	1336	1338		|O
mg	1339	1341		|O
/	1341	1342		|O
dL	1342	1344		|O
for	1345	1348		|O
the	1349	1352		|O
control	1353	1360		|O
,	1360	1361		|O
palmitate	1362	1371		|O
and	1372	1375		|O
trans	1376	1381		|O
diets	1382	1387		|O
,	1387	1388		|O
respectively	1389	1401		|O
)	1401	1402		|O
.	1402	1403		|O
The	1404	1407		|O
palmitate	1408	1417	palmitate	|B-TRIVIAL
diet	1418	1422		|O
significantly	1423	1436		|O
decreased	1437	1446		|O
the	1447	1450		|O
TC	1451	1453		|O
/	1453	1454		|O
HDL	1454	1457		|O
-	1457	1458		|O
C	1458	1459		|O
ratio	1460	1465		|O
by	1466	1468		|O
11%	1469	1472		|O
when	1473	1477		|O
compared	1478	1486		|O
with	1487	1491		|O
the	1492	1495		|O
control	1496	1503		|O
diet	1504	1508		|O
(	1509	1510		|O
1.68	1510	1514		|O
+	1515	1516		|O
/	1516	1517		|O
-	1517	1518		|O
0.17	1519	1523		|O
vs.	1524	1527		|O
1.89	1528	1532		|O
+	1533	1534		|O
/	1534	1535		|O
-	1535	1536		|O
0.30	1537	1541		|O
)	1541	1542		|O
,	1542	1543		|O
whereas	1544	1551		|O
the	1552	1555		|O
trans	1556	1561		|O
diet	1562	1566		|O
had	1567	1570		|O
no	1571	1573		|O
effect	1574	1580		|O
(	1581	1582		|O
1.81	1582	1586		|O
+	1587	1588		|O
/	1588	1589		|O
-	1589	1590		|O
0.20	1591	1595		|O
vs.	1596	1599		|O
1.89	1600	1604		|O
+	1605	1606		|O
/	1606	1607		|O
-	1607	1608		|O
0.30	1609	1613		|O
)	1613	1614		|O
.	1614	1615		|O
Kinetic	1616	1623		|O
studies	1624	1631		|O
revealed	1632	1640		|O
that	1641	1645		|O
,	1645	1646		|O
relative	1647	1655		|O
to	1656	1658		|O
the	1659	1662		|O
control	1663	1670		|O
diet	1671	1675		|O
,	1675	1676		|O
both	1677	1681		|O
test	1682	1686		|O
diets	1687	1692		|O
significantly	1693	1706		|O
lowered	1707	1714		|O
the	1715	1718		|O
LDL	1719	1722		|O
apolipoprotein	1723	1737		|O
B	1738	1739		|O
(	1740	1741		|O
apoB	1741	1745		|O
)	1745	1746		|O
pool	1747	1751		|O
size	1752	1756		|O
,	1756	1757		|O
principally	1758	1769		|O
reflecting	1770	1780		|O
an	1781	1783		|O
increase	1784	1792		|O
in	1793	1795		|O
the	1796	1799		|O
LDL	1800	1803		|O
apoB	1804	1808		|O
fractional	1809	1819		|O
catabolic	1820	1829		|O
rate	1830	1834		|O
(	1835	1836		|O
FCR	1836	1839		|O
)	1839	1840		|O
related	1841	1848		|O
to	1849	1851		|O
the	1852	1855		|O
reduced	1856	1863		|O
cholesterol	1864	1875		|O
intake	1876	1882		|O
.	1882	1883		|O
Between	1884	1891		|O
the	1892	1895		|O
two	1896	1899		|O
test	1900	1904		|O
diets	1905	1910		|O
,	1910	1911		|O
no	1912	1914		|O
significant	1915	1926		|O
differences	1927	1938		|O
in	1939	1941		|O
LDL	1942	1945		|O
kinetic	1946	1953		|O
parameters	1954	1964		|O
were	1965	1969		|O
observed	1970	1978		|O
.	1978	1979		|O
Both	1980	1984		|O
test	1985	1989		|O
diets	1990	1995		|O
significantly	1996	2009		|O
decreased	2010	2019		|O
HDL	2020	2023		|O
apoA1	2024	2029		|O
concentrations	2030	2044		|O
in	2045	2047		|O
comparison	2048	2058		|O
with	2059	2063		|O
the	2064	2067		|O
control	2068	2075		|O
diet	2076	2080		|O
,	2080	2081		|O
which	2082	2087		|O
was	2088	2091		|O
partly	2092	2098		|O
explained	2099	2108		|O
by	2109	2111		|O
an	2112	2114		|O
increase	2115	2123		|O
in	2124	2126		|O
the	2127	2130		|O
fractional	2131	2141		|O
catabolic	2142	2151		|O
rate	2152	2156		|O
of	2157	2159		|O
HDL	2160	2163		|O
.	2163	2164		|O
Of	2165	2167		|O
the	2168	2171		|O
two	2172	2175		|O
test	2176	2180		|O
diets	2181	2186		|O
,	2186	2187		|O
the	2188	2191		|O
trans	2192	2197		|O
diet	2198	2202		|O
was	2203	2206		|O
associated	2207	2217		|O
with	2218	2222		|O
a	2223	2224		|O
9.5%	2225	2229		|O
greater	2230	2237		|O
HDL	2238	2241		|O
FCR	2242	2245		|O
than	2246	2250		|O
the	2251	2254		|O
palmitate	2255	2264	palmitate	|B-TRIVIAL
diet	2265	2269		|O
(	2270	2271		|O
P	2271	2272		|O
<	2273	2274		|O
0.08	2275	2279		|O
)	2279	2280		|O
and	2281	2284		|O
a	2285	2286		|O
significant	2287	2298		|O
increase	2299	2307		|O
in	2308	2310		|O
plasma	2311	2317		|O
cholesteryl	2318	2329		|O
ester	2330	2335		|O
transfer	2336	2344		|O
protein	2345	2352		|O
(	2353	2354		|O
CETP	2354	2358		|O
)	2358	2359		|O
activity	2360	2368		|O
(	2369	2370		|O
%	2370	2371		|O
transfer	2372	2380		|O
114	2381	2384		|O
+	2385	2386		|O
/	2386	2387		|O
-	2387	2388		|O
7	2389	2390		|O
vs.	2391	2394		|O
91	2395	2397		|O
+	2398	2399		|O
/	2399	2400		|O
-	2400	2401		|O
7	2402	2403		|O
;	2403	2404		|O
P	2405	2406		|O
<	2407	2408		|O
0.03	2409	2413		|O
)	2413	2414		|O
.	2414	2415		|O
Thus	2416	2420		|O
,	2420	2421		|O
palmitic	2422	2430	palmitic acid	|B-IUPAC
acid	2431	2435		|I-IUPAC
-	2435	2436		|O
and	2437	2440		|O
elaidic	2441	2448	elaidic acid	|B-IUPAC
acid	2449	2453		|I-IUPAC
-	2453	2454		|O
rich	2454	2458		|O
diets	2459	2464		|O
produced	2465	2473		|O
identical	2474	2483		|O
effects	2484	2491		|O
on	2492	2494		|O
LDL	2495	2498		|O
metabolism	2499	2509		|O
in	2510	2512		|O
normocholesterolemic	2513	2533		|O
cebus	2534	2539		|O
monkeys	2540	2547		|O
fed	2548	2551		|O
diets	2552	2557		|O
with	2558	2562		|O
low	2563	2566		|O
levels	2567	2573		|O
of	2574	2576		|O
cholesterol	2577	2588	cholesterol	|B-TRIVIAL
,	2588	2589		|O
whereas	2590	2597		|O
elaidic	2598	2605	elaidic acid	|B-IUPAC
acid	2606	2610		|I-IUPAC
depressed	2610	2619		|O
HDL	2621	2624		|O
-	2624	2625		|O
C	2625	2626		|O
,	2626	2627		|O
attributable	2628	2640		|O
to	2641	2643		|O
both	2644	2648		|O
increased	2649	2658		|O
CETP	2659	2663		|O
activity	2664	2672		|O
and	2673	2676		|O
HDL	2677	2680		|O
clearance	2681	2690		|O
.	2690	2691		|O

### 10447954
Radiolabeled	0	12		|O
m	13	14	m-iodobenzylguanidine	|B-IUPAC
-	14	15		|I-IUPAC
iodobenzylguanidine	15	34		|I-IUPAC
(	35	36		|O
MIBG	36	40	MIBG	|B-ABBREVIATION
)	40	41		|O
is	42	44		|O
a	45	46		|O
tumor	47	52		|O
-	52	53		|O
seeking	53	60		|O
radioactive	61	72		|O
drug	73	77		|O
used	78	82		|O
in	83	85		|O
the	86	89		|O
diagnosis	90	99		|O
and	100	103		|O
treatment	104	113		|O
of	114	116		|O
pheochromocytomas	117	134		|O
and	135	138		|O
neuroblastomas	139	153		|O
.	153	154		|O
It	155	157		|O
is	158	160		|O
transported	161	172		|O
into	173	177		|O
the	178	181		|O
tumor	182	187		|O
cells	188	193		|O
by	194	196		|O
the	197	200		|O
neuronal	201	209		|O
norepinephrine	210	224	norepinephrine	|B-TRIVIAL
(	225	226		|O
NE	226	228	NE	|B-ABBREVIATION
)	228	229		|O
transporter	230	241		|O
(	242	243		|O
NET	243	246		|O
)	246	247		|O
which	248	253		|O
is	254	256		|O
expressed	257	266		|O
in	267	269		|O
almost	270	276		|O
all	277	280		|O
neuroblastoma	281	294		|O
cells	295	300		|O
.	300	301		|O
Here	302	306		|O
,	306	307		|O
we	308	310		|O
describe	311	319		|O
the	320	323		|O
synthesis	324	333		|O
and	334	337		|O
some	338	342		|O
pharmacological	343	358		|O
properties	359	369		|O
of	370	372		|O
a	373	374		|O
series	375	381		|O
of	382	384		|O
fluorescent	385	396		|O
compounds	397	406		|O
structurally	407	419		|O
related	420	427		|O
to	428	430		|O
the	431	434		|O
NET	435	438		|O
substrate	439	448		|O
,	448	449		|O
MIBG	450	454	MIBG	|B-ABBREVIATION
,	454	455		|O
or	456	458		|O
to	459	461		|O
the	462	465		|O
NET	466	469		|O
inhibitors	470	480		|O
,	480	481		|O
(	482	483	(-)-(2R,3S)-cocaine	|B-IUPAC
-	483	484		|I-IUPAC
)	484	485		|I-IUPAC
-	485	486		|I-IUPAC
(	486	487		|I-IUPAC
2R	487	489		|I-IUPAC
,	489	490		|I-IUPAC
3S	490	492		|I-IUPAC
)	492	493		|I-IUPAC
-	493	494		|I-IUPAC
cocaine	494	501		|I-IUPAC
and	502	505		|O
nisoxetine	506	516	nisoxetine	|B-TRIVIAL
.	516	517		|O
Three	518	523		|O
of	524	526		|O
synthesized	530	541		|O
fluorescent	542	553		|O
compounds	554	563		|O
,	563	564		|O
1	565	566	1-(1-naphthylmethyl)guanidinium sulfate	|B-IUPAC
-	566	567		|I-IUPAC
(	567	568		|I-IUPAC
1	568	569		|I-IUPAC
-	569	570		|I-IUPAC
naphthylmethyl	570	584		|I-IUPAC
)	584	585		|I-IUPAC
guanidinium	585	596		|I-IUPAC
sulfate	597	604		|I-IUPAC
(	605	606		|O
1	606	607		|O
)	607	608		|O
,	608	609		|O
1	610	611	1-[2-(dibenz[b, f]azepin-5-yl)ethyl]guanidinium sulfate	|B-IUPAC
-	611	612		|I-IUPAC
[	612	613		|I-IUPAC
2	613	614		|I-IUPAC
-	614	615		|I-IUPAC
(	615	616		|I-IUPAC
dibenz	616	622		|I-IUPAC
[	622	623		|I-IUPAC
b	623	624		|I-IUPAC
,	624	625		|I-IUPAC
f	626	627		|I-IUPAC
]	627	628		|I-IUPAC
azepin	628	634		|I-IUPAC
-	634	635		|I-IUPAC
5	635	636		|I-IUPAC
-	636	637		|I-IUPAC
yl	637	639		|I-IUPAC
)	639	640		|I-IUPAC
ethyl	640	645		|I-IUPAC
]	645	646		|I-IUPAC
guanidinium	646	657		|I-IUPAC
sulfate	658	665		|I-IUPAC
(	666	667		|O
2	667	668		|O
)	668	669		|O
,	669	670		|O
and	671	674		|O
(	675	676	(2R, 3S)-2beta-ethoxycarbonyl-3beta-tropanyl 5-(dimethylamino)naphthalene-1-sulfonate	|B-IUPAC
2R	676	678		|I-IUPAC
,	678	679		|I-IUPAC
3S	680	682		|I-IUPAC
)	682	683		|I-IUPAC
-	683	684		|I-IUPAC
2beta	684	689		|I-IUPAC
-	689	690		|I-IUPAC
ethoxycarbonyl	690	704		|I-IUPAC
-	704	705		|I-IUPAC
3beta	705	710		|I-IUPAC
-	710	711		|I-IUPAC
tropanyl	711	719		|I-IUPAC
5	720	721		|I-IUPAC
-	721	722		|I-IUPAC
(	722	723		|I-IUPAC
dimethylamino	723	736		|I-IUPAC
)	736	737		|I-IUPAC
naphthalene	737	748		|I-IUPAC
-	748	749		|I-IUPAC
1	749	750		|I-IUPAC
-	750	751		|I-IUPAC
sulfonate	751	760		|I-IUPAC
(	761	762		|O
6	762	763		|O
)	763	764		|O
,	764	765		|O
exhibited	766	775		|O
high	776	780		|O
affinity	781	789		|O
(	790	791		|O
IC	791	793		|O
(	793	794		|O
)	796	797		|O
about	798	803		|O
nM	807	809		|O
)	809	810		|O
for	811	814		|O
the	815	818		|O
NET	819	822		|O
.	822	823		|O
The	824	827		|O
nisoxetine	827	837	 nisoxetine	|B-TRIVIAL
derivatives	839	850	derivatives	|B-MODIFIER
8	851	852		|O
(	853	854		|O
rac	854	857	rac-N-[(3-methylamino-1-phenyl)propyl]-5-(dimethylamino)-1-naphthale nesulfonamide	|B-IUPAC
-	857	858		|I-IUPAC
N	858	859		|I-IUPAC
-	859	860		|I-IUPAC
[	860	861		|I-IUPAC
(	861	862		|I-IUPAC
3	862	863		|I-IUPAC
-	863	864		|I-IUPAC
methylamino	864	875		|I-IUPAC
-	875	876		|I-IUPAC
1	876	877		|I-IUPAC
-	877	878		|I-IUPAC
phenyl	878	884		|I-IUPAC
)	884	885		|I-IUPAC
propyl	885	891		|I-IUPAC
]	891	892		|I-IUPAC
-	892	893		|I-IUPAC
5	893	894		|I-IUPAC
-	894	895		|I-IUPAC
(	895	896		|I-IUPAC
dimethylamino	896	909		|I-IUPAC
)	909	910		|I-IUPAC
-	910	911		|I-IUPAC
1	911	912		|I-IUPAC
-	912	913		|I-IUPAC
naphthale	913	922		|I-IUPAC
nesulfonamide	923	936		|I-IUPAC
)	936	937		|O
and	938	941		|O
9	942	943		|O
(	944	945		|O
rac	945	948	rac-4-[(3-methylamino-1-phenyl)propyl]amino-7-nitro-2,1, 3-benzoxadiazole	|B-IUPAC
-	948	949		|I-IUPAC
4	949	950		|I-IUPAC
-	950	951		|I-IUPAC
[	951	952		|I-IUPAC
(	952	953		|I-IUPAC
3	953	954		|I-IUPAC
-	954	955		|I-IUPAC
methylamino	955	966		|I-IUPAC
-	966	967		|I-IUPAC
1	967	968		|I-IUPAC
-	968	969		|I-IUPAC
phenyl	969	975		|I-IUPAC
)	975	976		|I-IUPAC
propyl	976	982		|I-IUPAC
]	982	983		|I-IUPAC
amino	983	988		|I-IUPAC
-	988	989		|I-IUPAC
7	989	990		|I-IUPAC
-	990	991		|I-IUPAC
nitro	991	996		|I-IUPAC
-	996	997		|I-IUPAC
2,1	997	1000		|I-IUPAC
,	1000	1001		|I-IUPAC
3	1002	1003		|I-IUPAC
-	1003	1004		|I-IUPAC
benzoxadiazole	1004	1018		|I-IUPAC
)	1018	1019		|O
and	1020	1023		|O
especially	1024	1034		|O
the	1035	1038		|O
guanidine	1039	1048	guanidine	|B-TRIVIAL
derivative	1049	1059	derivative	|B-MODIFIER
4	1060	1061		|O
(	1062	1063		|O
1	1063	1064	1-[4-(4-phenyl-1,3-butadienyl)benzyl]guanidinium sulfate	|B-IUPAC
-	1064	1065		|I-IUPAC
[	1065	1066		|I-IUPAC
4	1066	1067		|I-IUPAC
-	1067	1068		|I-IUPAC
(	1068	1069		|I-IUPAC
4	1069	1070		|I-IUPAC
-	1070	1071		|I-IUPAC
phenyl	1071	1077		|I-IUPAC
-	1077	1078		|I-IUPAC
1,3	1078	1081		|I-IUPAC
-	1081	1082		|I-IUPAC
butadienyl	1082	1092		|I-IUPAC
)	1092	1093		|I-IUPAC
benzyl	1093	1099		|I-IUPAC
]	1099	1100		|I-IUPAC
guanidinium	1100	1111		|I-IUPAC
sulfate	1112	1119		|I-IUPAC
)	1119	1120		|O
which	1121	1126		|O
are	1127	1130		|O
characterized	1131	1144		|O
by	1145	1147		|O
intermediate	1148	1160		|O
affinity	1161	1169		|O
for	1170	1173		|O
the	1174	1177		|O
NET	1178	1181		|O
(	1182	1183		|O
IC	1183	1185		|O
(	1185	1186		|O
)	1188	1189		|O
nM	1198	1200		|O
)	1200	1201		|O
caused	1202	1208		|O
significant	1209	1220		|O
and	1221	1224		|O
nisoxetine	1225	1235	nisoxetine	|B-TRIVIAL
-	1235	1236		|O
sensitive	1236	1245		|O
cell	1246	1250		|O
fluorescence	1251	1263		|O
.	1263	1264		|O
At	1265	1267		|O
least	1268	1273		|O
the	1274	1277		|O
guanidine	1278	1287	guanidine	|B-TRIVIAL
derivative	1288	1298	derivative	|B-MODIFIER
4	1298	1299		|O
might	1301	1306		|O
represent	1307	1316		|O
a	1317	1318		|O
potentially	1319	1330		|O
useful	1331	1337		|O
agent	1338	1343		|O
for	1344	1347		|O
imaging	1348	1355		|O
of	1356	1358		|O
neuroblastoma	1359	1372		|O
cells	1373	1378		|O
.	1378	1379		|O

### 11358723
11358723	0	8		|O
Influence	10	19		|O
of	20	22		|O
estrogens	23	32	estrogens	|B-FAMILY
on	33	35		|O
the	36	39		|O
androgen	40	48	androgen	|B-FAMILY
metabolism	49	59		|O
in	60	62		|O
different	63	72		|O
subunits	73	81		|O
of	82	84		|O
human	85	90		|O
hair	91	95		|O
follicles	96	105		|O
.	105	106		|O
The	108	111		|O
molecular	112	121		|O
pathways	122	130		|O
involved	131	139		|O
in	140	142		|O
estrogen	143	151	estrogen	|B-FAMILY
-	151	152		|O
mediated	152	160		|O
induction	161	170		|O
of	171	173		|O
hair	174	178		|O
growth	179	185		|O
in	186	188		|O
androgenetic	189	201		|O
alopecia	202	210		|O
are	211	214		|O
unknown	215	222		|O
.	222	223		|O
Some	224	228		|O
authors	229	236		|O
found	237	242		|O
that	243	247		|O
estradiol	248	257	estradiol	|B-TRIVIAL
(	258	259		|O
E	259	260	E	|B-ABBREVIATION
)	260	261		|O
inhibited	262	271		|O
5alpha	272	278		|O
-	278	279		|O
reductase	279	288		|O
(	289	290		|O
5alpha	290	296		|O
-	296	297		|O
R	297	298		|O
)	298	299		|O
activity	300	308		|O
and	309	312		|O
therefore	313	322		|O
we	323	325		|O
addressed	326	335		|O
the	336	339		|O
question	340	348		|O
whether	349	356		|O
17alpha	357	364	17alpha-	|B-PARTIUPAC
-	364	365		|I-PARTIUPAC
or	366	368		|O
17beta	369	375	17beta-E	|B-IUPAC
-	375	376		|I-IUPAC
E	376	377		|I-IUPAC
are	378	381		|O
able	382	386		|O
to	387	389		|O
modulate	390	398		|O
the	399	402		|O
activity	403	411		|O
of	412	414		|O
5alpha	415	421		|O
-	421	422		|O
R	422	423		|O
,	423	424		|O
3beta	425	430		|O
-	430	431		|O
hydroxysteroid	431	445		|O
dehydrogenase	446	459		|O
(	460	461		|O
3beta	461	466		|O
-	466	467		|O
HSD	467	470		|O
)	470	471		|O
or	472	474		|O
17beta	475	481		|O
-	481	482		|O
hydroxysteroid	482	496		|O
dehydrogenase	497	510		|O
(	511	512		|O
17beta	512	518		|O
-	518	519		|O
HSD	519	522		|O
)	522	523		|O
in	524	526		|O
isolated	527	535		|O
compartments	536	548		|O
of	549	551		|O
human	552	557		|O
hair	558	562		|O
follicles	563	572		|O
.	572	573		|O
For	574	577		|O
this	578	582		|O
purpose	583	590		|O
,	590	591		|O
scalp	592	597		|O
biopsies	598	606		|O
from	607	611		|O
volunteers	612	622		|O
were	623	627		|O
taken	628	633		|O
and	634	637		|O
from	638	642		|O
each	643	647		|O
biopsy	648	654		|O
root	655	659		|O
sheaths	660	667		|O
,	667	668		|O
connective	669	679		|O
tissue	680	686		|O
sheaths	687	694		|O
and	695	698		|O
dermal	699	705		|O
papillae	706	714		|O
(	715	716		|O
DP	716	718		|O
)	718	719		|O
were	720	724		|O
dissected	725	734		|O
and	735	738		|O
incubated	739	748		|O
in	749	751		|O
the	752	755		|O
presence	756	764		|O
of	765	767		|O
3H	768	770	3H-testosterone	|B-IUPAC
-	770	771		|I-IUPAC
testosterone	771	783		|I-IUPAC
(	784	785		|O
T	785	786	T	|B-ABBREVIATION
)	786	787		|O
and	788	791		|O
,	791	792		|O
in	793	795		|O
addition	796	804		|O
,	804	805		|O
either	806	812		|O
17alpha	813	820	17alpha-E	|B-IUPAC
-	820	821		|I-IUPAC
E	821	822		|I-IUPAC
,	822	823		|O
17beta	824	830	17beta-E	|B-IUPAC
-	830	831		|I-IUPAC
E	831	832		|I-IUPAC
,	832	833		|O
progesterone	834	846	progesterone	|B-TRIVIAL
or	847	849		|O
finasteride	849	860	 finasteride	|B-TRIVIAL
for	862	865		|O
up	866	868		|O
to	869	871		|O
48	872	874		|O
hrs	875	878		|O
.	878	879		|O
Thereafter	880	890		|O
high	891	895		|O
-	895	896		|O
performance	896	907		|O
liquid	908	914		|O
chromatography	915	929		|O
analysis	930	938		|O
of	939	941		|O
culture	942	949		|O
supernatants	950	962		|O
was	963	966		|O
performed	967	976		|O
to	977	979		|O
detect	980	986		|O
T	987	988		|O
-	988	989		|O
metabolites	989	1000		|O
.	1000	1001		|O
At	1002	1004		|O
the	1005	1008		|O
tested	1009	1015		|O
concentrations	1016	1030		|O
,	1030	1031		|O
finasteride	1032	1043	finasteride	|B-TRIVIAL
was	1044	1047		|O
found	1048	1053		|O
to	1054	1056		|O
be	1057	1059		|O
a	1060	1061		|O
major	1062	1067		|O
inhibitor	1068	1077		|O
of	1078	1080		|O
dihydrotestosterone	1081	1100	dihydrotestosterone	|B-TRIVIAL
(	1101	1102		|O
DHT	1102	1105	DHT	|B-ABBREVIATION
)	1105	1106		|O
formation	1107	1116		|O
.	1116	1117		|O
Even	1118	1122		|O
1	1123	1124		|O
nM	1125	1127		|O
finasteride	1128	1139	finasteride	|B-TRIVIAL
inhibited	1140	1149		|O
DHT	1150	1153	DHT	|B-ABBREVIATION
synthesis	1154	1163		|O
in	1164	1166		|O
DP	1167	1169		|O
by	1170	1172		|O
86%	1173	1176		|O
and	1177	1180		|O
1	1181	1182		|O
nM	1183	1185		|O
progesterone	1186	1198		|O
by	1199	1201		|O
75%	1202	1205		|O
.	1205	1206		|O
Estrogens	1207	1216	Estrogens	|B-FAMILY
were	1217	1221		|O
less	1222	1226		|O
able	1227	1231		|O
to	1232	1234		|O
inhibit	1235	1242		|O
the	1243	1246		|O
synthesis	1247	1256		|O
of	1257	1259		|O
DHT	1260	1263	DHT	|B-ABBREVIATION
in	1264	1266		|O
DP	1267	1269		|O
(	1270	1271		|O
e.g.	1271	1275		|O
nM	1280	1282		|O
17alpha	1283	1290	17alpha-E	|B-IUPAC
-	1290	1291		|I-IUPAC
E	1291	1292		|I-IUPAC
:	1292	1293		|O
;	1297	1298		|O
nM	1303	1305		|O
17beta	1306	1312	17beta-E	|B-IUPAC
-	1312	1313		|I-IUPAC
E	1313	1314		|I-IUPAC
:	1314	1315		|O
)	1319	1320		|O
.	1320	1321		|O
Whether	1322	1329		|O
E	1330	1331	E	|B-ABBREVIATION
directly	1332	1340		|O
inhibits	1341	1349		|O
5alpha	1350	1356		|O
-	1356	1357		|O
R	1357	1358		|O
in	1359	1361		|O
DP	1362	1364		|O
's	1364	1366		|O
or	1367	1369		|O
whether	1370	1377		|O
the	1378	1381		|O
effect	1382	1388		|O
of	1389	1391		|O
estrogens	1392	1401	estrogens	|B-FAMILY
might	1402	1407		|O
be	1408	1410		|O
explained	1411	1420		|O
by	1421	1423		|O
an	1424	1426		|O
increased	1427	1436		|O
conversion	1437	1447		|O
of	1448	1450		|O
T	1451	1452	T	|B-ABBREVIATION
to	1453	1455		|O
the	1456	1459		|O
weaker	1460	1466		|O
androgens	1467	1476	androgens	|B-FAMILY
such	1477	1481		|O
as	1482	1484		|O
androstendione	1485	1499	androstendione	|B-TRIVIAL
(	1500	1501		|O
via	1501	1504		|O
17beta	1505	1511		|O
-	1511	1512		|O
HSD	1512	1515		|O
)	1515	1516		|O
,	1516	1517		|O
androstenediol	1518	1532	androstenediol	|B-TRIVIAL
(	1533	1534		|O
via	1534	1537		|O
3beta	1538	1543		|O
-	1543	1544		|O
HSD	1544	1547		|O
)	1547	1548		|O
or	1549	1551		|O
17beta	1552	1558	17beta-E	|B-IUPAC
-	1558	1559		|I-IUPAC
E	1559	1560		|I-IUPAC
(	1561	1562		|O
via	1562	1565		|O
aromatase	1566	1575		|O
)	1575	1576		|O
,	1576	1577		|O
thereby	1578	1585		|O
diminishing	1586	1597		|O
the	1598	1601		|O
amount	1602	1608		|O
of	1609	1611		|O
T	1612	1613	T	|B-ABBREVIATION
available	1614	1623		|O
for	1624	1627		|O
the	1628	1631		|O
conversion	1632	1642		|O
to	1643	1645		|O
DHT	1646	1649	DHT	|B-ABBREVIATION
,	1649	1650		|O
remains	1651	1658		|O
to	1659	1661		|O
be	1662	1664		|O
shown	1665	1670		|O
.	1670	1671		|O

### 12890682
Involvement	10	21		|O
of	22	24		|O
phospholipase	25	38		|O
D2	39	41		|O
in	42	44		|O
lysophosphatidate	45	62	lysophosphatidate	|B-TRIVIAL
-	62	63		|O
induced	63	70		|O
transactivation	71	86		|O
of	87	89		|O
platelet	90	98		|O
-	98	99		|O
derived	99	106		|O
growth	107	113		|O
factor	114	120		|O
receptor	121	129		|O
-	129	130		|O
beta	130	134		|O
in	135	137		|O
human	138	143		|O
bronchial	144	153		|O
epithelial	154	164		|O
cells	165	170		|O
.	170	171		|O
Lysophosphatidate	173	190	Lysophosphatidate	|B-TRIVIAL
(	191	192		|O
LPA	192	195	LPA	|B-ABBREVIATION
)	195	196		|O
mediates	197	205		|O
multiple	206	214		|O
cellular	215	223		|O
responses	224	233		|O
via	234	237		|O
heterotrimeric	238	252		|O
G	253	254		|O
protein	255	262		|O
coupled	263	270		|O
LPA	271	274		|O
-	274	275		|O
1	275	276		|O
,	276	277		|O
LPA	278	281		|O
-	281	282		|O
2	282	283		|O
,	283	284		|O
and	285	288		|O
LPA	289	292		|O
-	292	293		|O
3	293	294		|O
receptors	295	304		|O
.	304	305		|O
Many	306	310		|O
G	311	312		|O
protein	313	320		|O
-	320	321		|O
coupled	321	328		|O
receptors	329	338		|O
stimulate	339	348		|O
ERK	349	352		|O
following	353	362		|O
tyrosine	363	371	tyrosine	|B-TRIVIAL
phosphorylation	372	387		|O
of	388	390		|O
growth	391	397		|O
factor	398	404		|O
receptors	405	414		|O
;	414	415		|O
however	416	423		|O
,	423	424		|O
the	425	428		|O
mechanism	429	438		|O
(	438	439		|O
s	439	440		|O
)	440	441		|O
of	442	444		|O
transactivation	445	460		|O
of	461	463		|O
receptor	464	472		|O
tyrosine	473	481		|O
kinases	482	489		|O
are	490	493		|O
not	494	497		|O
well	498	502		|O
defined	503	510		|O
.	510	511		|O
Here	512	516		|O
,	516	517		|O
we	518	520		|O
provide	521	528		|O
evidence	529	537		|O
for	538	541		|O
the	542	545		|O
involvement	546	557		|O
of	558	560		|O
phospholipase	561	574		|O
D	575	576		|O
(	577	578		|O
PLD	578	581		|O
)	581	582		|O
in	583	585		|O
LPA	586	589	LPA	|B-ABBREVIATION
-	589	590		|O
mediated	590	598		|O
transactivation	599	614		|O
of	615	617		|O
platelet	618	626		|O
-	626	627		|O
derived	627	634		|O
growth	635	641		|O
factor	642	648		|O
receptor	649	657		|O
-	657	658		|O
beta	658	662		|O
(	663	664		|O
PDGF	664	668		|O
-	668	669		|O
R	669	670		|O
beta	671	675		|O
)	675	676		|O
.	676	677		|O
In	678	680		|O
primary	681	688		|O
cultures	689	697		|O
of	698	700		|O
human	701	706		|O
bronchial	707	716		|O
epithelial	717	727		|O
cells	728	733		|O
(	734	735		|O
HBEpCs	735	741		|O
)	741	742		|O
,	742	743		|O
LPA	744	747	LPA	|B-ABBREVIATION
stimulated	748	758		|O
tyrosine	759	767	tyrosine	|B-TRIVIAL
phosphorylation	768	783		|O
of	784	786		|O
PDGF	787	791		|O
-	791	792		|O
R	792	793		|O
beta	794	798		|O
and	799	802		|O
threonine	803	812	threonine	|B-TRIVIAL
/	812	813		|O
tyrosine	813	821	tyrosine	|B-TRIVIAL
phosphorylation	822	837		|O
of	838	840		|O
ERK1/2	841	847		|O
.	847	848		|O
The	849	852		|O
LPA	853	856	LPA	|B-ABBREVIATION
-	856	857		|O
mediated	857	865		|O
activation	866	876		|O
of	877	879		|O
ERK	880	883		|O
and	884	887		|O
tyrosine	888	896	tyrosine	|B-TRIVIAL
phosphorylation	897	912		|O
of	913	915		|O
PDGF	916	920		|O
-	920	921		|O
R	921	922		|O
beta	923	927		|O
was	928	931		|O
attenuated	932	942		|O
by	943	945		|O
tyrphostin	946	956	tyrphostin	|B-TRIVIAL
AG	957	959	AG 1296	|B-TRIVIALVAR
1296	960	964		|I-TRIVIALVAR
,	964	965		|O
an	966	968		|O
inhibitor	969	978		|O
of	979	981		|O
PDGF	982	986		|O
-	986	987		|O
R	987	988		|O
kinase	989	995		|O
,	995	996		|O
suggesting	997	1007		|O
transactivation	1008	1023		|O
of	1024	1026		|O
PDGF	1027	1031		|O
-	1031	1032		|O
R	1032	1033		|O
by	1034	1036		|O
LPA	1037	1040	LPA	|B-ABBREVIATION
.	1040	1041		|O
Furthermore	1042	1053		|O
,	1053	1054		|O
LPA	1055	1058	LPA	|B-ABBREVIATION
-	1058	1059		|O
,	1059	1060		|O
but	1061	1064		|O
not	1065	1068		|O
PDGF	1069	1073		|O
beta	1074	1078		|O
-	1078	1079		|O
chain	1079	1084		|O
homodimer	1085	1094		|O
-	1094	1095		|O
induced	1095	1102		|O
tyrosine	1103	1111		|O
phosphorylation	1112	1127		|O
of	1128	1130		|O
PDGF	1131	1135		|O
-	1135	1136		|O
R	1136	1137		|O
beta	1138	1142		|O
was	1143	1146		|O
partially	1147	1156		|O
blocked	1157	1164		|O
by	1165	1167		|O
pertussis	1168	1177		|O
toxin	1178	1183		|O
,	1183	1184		|O
indicating	1185	1195		|O
coupling	1196	1204		|O
of	1205	1207		|O
LPA	1208	1211	LPA	|B-ABBREVIATION
-	1211	1212		|O
R	1212	1213		|O
(	1213	1214		|O
s	1214	1215		|O
)	1215	1216		|O
to	1217	1219		|O
Gi	1220	1222		|O
.	1222	1223		|O
Exposure	1224	1232		|O
of	1233	1235		|O
HBEpCs	1236	1242		|O
to	1243	1245		|O
LPA	1246	1249		|O
activated	1250	1259		|O
PLD	1260	1263		|O
.	1263	1264		|O
Butan	1265	1270	Butan-1-ol	|B-IUPAC
-	1270	1271		|I-IUPAC
1	1271	1272		|I-IUPAC
-	1272	1273		|I-IUPAC
ol	1273	1275		|I-IUPAC
,	1275	1276		|O
which	1277	1282		|O
acts	1283	1287		|O
as	1288	1290		|O
an	1291	1293		|O
acceptor	1294	1302		|O
of	1303	1305		|O
phosphatidate	1306	1319	phosphatidate	|B-TRIVIAL
generated	1320	1329		|O
by	1330	1332		|O
the	1333	1336		|O
PLD	1337	1340		|O
pathway	1341	1348		|O
,	1348	1349		|O
blocked	1350	1357		|O
LPA	1358	1361	LPA	|B-ABBREVIATION
-	1361	1362		|O
mediated	1362	1370		|O
transactivation	1371	1386		|O
of	1387	1389		|O
PDGF	1390	1394		|O
-	1394	1395		|O
R	1395	1396		|O
beta	1397	1401		|O
.	1401	1402		|O
This	1403	1407		|O
effect	1408	1414		|O
was	1415	1418		|O
not	1419	1422		|O
seen	1423	1427		|O
with	1428	1432		|O
butan	1433	1438	butan-3-ol	|B-IUPAC
-	1438	1439		|I-IUPAC
3	1439	1440		|I-IUPAC
-	1440	1441		|I-IUPAC
ol	1441	1443		|I-IUPAC
,	1443	1444		|O
suggesting	1445	1455		|O
PLD	1456	1459		|O
involvement	1460	1471		|O
.	1471	1472		|O
The	1473	1476		|O
role	1477	1481		|O
of	1482	1484		|O
PLD1	1485	1489		|O
and	1490	1493		|O
PLD2	1494	1498		|O
in	1499	1501		|O
the	1502	1505		|O
PDGF	1506	1510		|O
-	1510	1511		|O
R	1511	1512		|O
beta	1513	1517		|O
transactivation	1518	1533		|O
by	1534	1536		|O
LPA	1537	1540	LPA	|B-ABBREVIATION
was	1541	1544		|O
investigated	1545	1557		|O
by	1558	1560		|O
infection	1561	1570		|O
of	1571	1573		|O
cells	1574	1579		|O
with	1580	1584		|O
adenoviral	1585	1595		|O
constructs	1596	1606		|O
of	1607	1609		|O
wild	1610	1614		|O
type	1615	1619		|O
and	1620	1623		|O
catalytically	1624	1637		|O
inactive	1638	1646		|O
mutants	1647	1654		|O
of	1655	1657		|O
PLD	1658	1661		|O
.	1661	1662		|O
LPA	1663	1666	LPA	|B-ABBREVIATION
activated	1667	1676		|O
both	1677	1681		|O
PLD1	1682	1686		|O
and	1687	1690		|O
PLD2	1691	1695		|O
in	1696	1698		|O
HBEpCs	1699	1705		|O
;	1705	1706		|O
however	1707	1714		|O
,	1714	1715		|O
infection	1716	1725		|O
of	1726	1728		|O
cells	1729	1734		|O
with	1735	1739		|O
cDNA	1740	1744		|O
for	1745	1748		|O
wild	1749	1753		|O
type	1754	1758		|O
PLD2	1759	1763		|O
,	1763	1764		|O
but	1765	1768		|O
not	1769	1772		|O
PLD1	1773	1777		|O
,	1777	1778		|O
increased	1779	1788		|O
the	1789	1792		|O
tyrosine	1793	1801		|O
phosphorylation	1802	1817		|O
of	1818	1820		|O
PDGF	1821	1825		|O
-	1825	1826		|O
R	1826	1827		|O
beta	1828	1832		|O
in	1833	1835		|O
response	1836	1844		|O
to	1845	1847		|O
LPA	1848	1851	LPA	|B-ABBREVIATION
.	1851	1852		|O
Also	1853	1857		|O
,	1857	1858		|O
the	1859	1862		|O
LPA	1863	1866	LPA	|B-ABBREVIATION
-	1866	1867		|O
mediated	1867	1875		|O
tyrosine	1876	1884	tyrosine	|B-TRIVIAL
phosphorylation	1885	1900		|O
of	1901	1903		|O
PDGF	1904	1908		|O
-	1908	1909		|O
R	1909	1910		|O
beta	1911	1915		|O
was	1916	1919		|O
attenuated	1920	1930		|O
by	1931	1933		|O
the	1934	1937		|O
catalytically	1938	1951		|O
inactive	1952	1960		|O
mutant	1961	1967		|O
mPLD2	1968	1973		|O
-	1973	1974		|O
K758R	1974	1979		|O
.	1979	1980		|O
Infection	1981	1990		|O
of	1991	1993		|O
HBEpCs	1994	2000		|O
with	2001	2005		|O
adenoviral	2006	2016		|O
constructs	2017	2027		|O
of	2028	2030		|O
wild	2031	2035		|O
type	2036	2040		|O
hPLD1	2041	2046		|O
,	2046	2047		|O
mPLD2	2048	2053		|O
,	2053	2054		|O
and	2055	2058		|O
the	2059	2062		|O
inactive	2063	2071		|O
mutants	2072	2079		|O
of	2080	2082		|O
hPLD1	2083	2088		|O
and	2089	2092		|O
mPLD2	2093	2098		|O
resulted	2099	2107		|O
in	2108	2110		|O
association	2111	2122		|O
of	2123	2125		|O
PLD2	2126	2130		|O
wild	2131	2135		|O
type	2136	2140		|O
and	2141	2144		|O
inactive	2145	2153		|O
mutant	2154	2160		|O
proteins	2161	2169		|O
with	2170	2174		|O
the	2175	2178		|O
PDGF	2179	2183		|O
-	2183	2184		|O
R	2184	2185		|O
beta	2186	2190		|O
compared	2191	2199		|O
with	2200	2204		|O
PLD1	2205	2209		|O
.	2209	2210		|O
These	2211	2216		|O
results	2217	2224		|O
show	2225	2229		|O
for	2230	2233		|O
the	2234	2237		|O
first	2238	2243		|O
time	2244	2248		|O
that	2249	2253		|O
transactivation	2254	2269		|O
of	2270	2272		|O
PDGF	2273	2277		|O
-	2277	2278		|O
R	2278	2279		|O
beta	2280	2284		|O
by	2285	2287		|O
LPA	2288	2291	LPA	|B-ABBREVIATION
in	2291	2293		|O
HBEpCs	2295	2301		|O
is	2302	2304		|O
regulated	2305	2314		|O
by	2315	2317		|O
PLD2	2318	2322		|O
.	2322	2323		|O

### 2229079
Thyrotropin	9	20		|O
modulates	21	30		|O
low	31	34		|O
density	35	42		|O
lipoprotein	43	54		|O
binding	55	62		|O
activity	63	71		|O
in	72	74		|O
FRTL	75	79		|O
-	79	80		|O
5	80	81		|O
thyroid	82	89		|O
cells	90	95		|O
.	95	96		|O
FRTL	98	102		|O
-	102	103		|O
5	103	104		|O
cells	105	110		|O
possess	111	118		|O
high	119	123		|O
affinity	124	132		|O
low	133	136		|O
density	137	144		|O
lipoprotein	145	156		|O
(	157	158		|O
LDL	158	161		|O
)	161	162		|O
receptors	163	172		|O
which	173	178		|O
bind	179	183		|O
,	183	184		|O
internalize	185	196		|O
,	196	197		|O
and	198	201		|O
degrade	202	209		|O
LDL	210	213		|O
.	213	214		|O
When	215	219		|O
FRTL	220	224		|O
-	224	225		|O
5	225	226		|O
cells	227	232		|O
are	233	236		|O
deprived	237	245		|O
of	246	248		|O
thyrotropin	249	260		|O
(	261	262		|O
TSH	262	265		|O
)	265	266		|O
the	267	270		|O
binding	271	278		|O
of	279	281		|O
LDL	282	285		|O
increases	286	295		|O
more	296	300		|O
than	301	305		|O
2	306	307		|O
-	307	308		|O
fold	308	312		|O
.	312	313		|O
Upon	314	318		|O
addition	319	327		|O
of	328	330		|O
TSH	331	334		|O
,	334	335		|O
at	336	338		|O
a	339	340		|O
concentration	341	354		|O
of	355	357		|O
1	358	359		|O
x	360	361		|O
(	364	365		|O
-	365	366		|O
)	368	369		|O
M	370	371		|O
or	372	374		|O
greater	375	382		|O
,	382	383		|O
LDL	384	387		|O
binding	388	395		|O
decreases	396	405		|O
rapidly	406	413		|O
and	414	417		|O
within	418	424		|O
24	425	427		|O
h	428	429		|O
reaches	430	437		|O
the	438	441		|O
level	442	447		|O
which	448	453		|O
is	454	456		|O
typical	457	464		|O
of	465	467		|O
FRTL	468	472		|O
-	472	473		|O
5	473	474		|O
cells	475	480		|O
chronically	481	492		|O
stimulated	493	503		|O
by	504	506		|O
TSH	507	510		|O
.	510	511		|O
The	512	515		|O
data	516	520		|O
available	521	530		|O
suggest	531	538		|O
that	539	543		|O
TSH	544	547		|O
-	547	548		|O
dependent	548	557		|O
down	558	562		|O
-	562	563		|O
regulation	563	573		|O
of	574	576		|O
LDL	577	580		|O
receptor	581	589		|O
activity	590	598		|O
is	599	601		|O
exerted	602	609		|O
through	610	617		|O
a	618	619		|O
reduction	620	629		|O
of	630	632		|O
the	633	636		|O
number	637	643		|O
of	644	646		|O
active	647	653		|O
LDL	654	657		|O
receptors	658	667		|O
,	667	668		|O
with	669	673		|O
no	674	676		|O
change	677	683		|O
in	684	686		|O
affinity	687	695		|O
.	695	696		|O
It	697	699		|O
is	700	702		|O
unlikely	703	711		|O
that	712	716		|O
the	717	720		|O
synthesis	721	730		|O
of	731	733		|O
LDL	734	737		|O
receptors	738	747		|O
is	748	750		|O
impaired	751	759		|O
,	759	760		|O
since	761	766		|O
LDL	767	770		|O
receptor	771	779		|O
messenger	780	789		|O
RNA	790	793		|O
is	794	796		|O
not	797	800		|O
decreased	801	810		|O
by	811	813		|O
TSH	814	817		|O
.	817	818		|O
The	819	822		|O
effect	823	829		|O
of	830	832		|O
the	833	836		|O
hormone	837	844		|O
on	845	847		|O
LDL	848	851		|O
receptor	852	860		|O
activity	861	869		|O
can	870	873		|O
be	874	876		|O
mimicked	877	885		|O
by	886	888		|O
8	889	890	8-Br-cAMP	|B-IUPAC
-	890	891		|I-IUPAC
Br	891	893		|I-IUPAC
-	893	894		|I-IUPAC
cAMP	894	898		|I-IUPAC
and	899	902		|O
is	903	905		|O
completely	906	916		|O
abolished	917	926		|O
by	927	929		|O
the	930	933		|O
protein	934	941		|O
synthesis	942	951		|O
inhibitor	952	961		|O
cycloheximide	962	975	cycloheximide	|B-TRIVIAL
but	976	979		|O
not	980	983		|O
by	984	986		|O
actinomycin	987	998	actinomycin D	|B-TRIVIAL
D	999	1000		|I-TRIVIAL
.	1000	1001		|O
TSH	1002	1005		|O
regulation	1006	1016		|O
of	1017	1019		|O
LDL	1020	1023		|O
receptor	1024	1032		|O
activity	1033	1041		|O
is	1042	1044		|O
lost	1045	1049		|O
in	1050	1052		|O
v	1053	1054		|O
-	1054	1055		|O
ras	1055	1058		|O
Ki	1059	1061		|O
-	1061	1062		|O
transformed	1062	1073		|O
FRTL	1074	1078		|O
-	1078	1079		|O
5	1079	1080		|O
cells	1081	1086		|O
(	1087	1088		|O
Ki	1088	1090		|O
Mol	1091	1094		|O
)	1094	1095		|O
which	1096	1101		|O
also	1102	1106		|O
have	1107	1111		|O
lost	1112	1116		|O
TSH	1117	1120		|O
dependence	1121	1131		|O
for	1132	1135		|O
adenylate	1136	1145		|O
cyclase	1146	1153		|O
activation	1154	1164		|O
and	1165	1168		|O
growth	1169	1175		|O
.	1175	1176		|O
However	1177	1184		|O
,	1184	1185		|O
8	1186	1187	8-Br-cAMP	|B-IUPAC
-	1187	1188		|I-IUPAC
Br	1188	1190		|I-IUPAC
-	1190	1191		|I-IUPAC
cAMP	1191	1195		|I-IUPAC
decreases	1196	1205		|O
LDL	1206	1209		|O
binding	1210	1217		|O
in	1218	1220		|O
Ki	1221	1223		|O
Mol	1224	1227		|O
FRTL	1228	1232		|O
-	1232	1233		|O
5	1233	1234		|O
cells	1235	1240		|O
.	1240	1241		|O
The	1242	1245		|O
reduced	1246	1253		|O
availability	1254	1266		|O
of	1267	1269		|O
LDL	1270	1273		|O
receptor	1274	1282		|O
in	1283	1285		|O
TSH	1286	1289		|O
-	1289	1290		|O
stimulated	1290	1300		|O
FRTL	1301	1305		|O
-	1305	1306		|O
5	1306	1307		|O
cells	1308	1313		|O
may	1314	1317		|O
be	1318	1320		|O
related	1321	1328		|O
to	1329	1331		|O
the	1332	1335		|O
increased	1336	1345		|O
membrane	1346	1354		|O
fluidity	1355	1363		|O
(	1364	1365		|O
Beguinot	1365	1373		|O
,	1373	1374		|O
F	1375	1376		|O
.	1376	1377		|O
,	1377	1378		|O
Beguinot	1379	1387		|O
,	1387	1388		|O
L	1389	1390		|O
.	1390	1391		|O
,	1391	1392		|O
Tramontano	1393	1403		|O
,	1403	1404		|O
D	1405	1406		|O
.	1406	1407		|O
,	1407	1408		|O
Duilio	1409	1415		|O
,	1415	1416		|O
C	1417	1418		|O
.	1418	1419		|O
,	1419	1420		|O
Formisano	1421	1430		|O
,	1430	1431		|O
S	1432	1433		|O
.	1433	1434		|O
,	1434	1435		|O
Bifulco	1436	1443		|O
,	1443	1444		|O
M	1445	1446		|O
.	1446	1447		|O
,	1447	1448		|O
Ambesi	1449	1455		|O
-	1455	1456		|O
Impiombato	1456	1466		|O
,	1466	1467		|O
F	1468	1469		|O
.	1469	1470		|O
S	1471	1472		|O
.	1472	1473		|O
,	1473	1474		|O
and	1475	1478		|O
Aloj	1479	1483		|O
,	1483	1484		|O
S	1485	1486		|O
.	1486	1487		|O
M	1488	1489		|O
.	1489	1490		|O
(	1491	1492		|O
1987	1492	1496		|O
)	1496	1497		|O
J	1498	1499		|O
.	1499	1500		|O
Biol.	1501	1506		|O
Chem.	1507	1512		|O
262	1513	1516		|O
,	1516	1517		|O
1575-1582	1518	1527		|O
)	1527	1528		|O
or	1529	1531		|O
may	1532	1535		|O
reflect	1536	1543		|O
increased	1544	1553		|O
degradation	1554	1565		|O
of	1566	1568		|O
LDL	1569	1572		|O
receptors	1573	1582		|O
.	1582	1583		|O
We	1584	1586		|O
propose	1587	1594		|O
that	1595	1599		|O
a	1600	1601		|O
lower	1602	1607		|O
cholesterol	1608	1619		|O
uptake	1620	1626		|O
is	1627	1629		|O
needed	1630	1636		|O
in	1637	1639		|O
an	1640	1642		|O
actively	1643	1651		|O
proliferating	1652	1665		|O
cell	1666	1670		|O
population	1671	1681		|O
,	1681	1682		|O
to	1683	1685		|O
increase	1686	1694		|O
the	1695	1698		|O
production	1699	1709		|O
of	1710	1712		|O
isoprenoids	1713	1724	isoprenoids	|B-FAMILY
whether	1725	1732		|O
it	1733	1735		|O
be	1736	1738		|O
for	1739	1742		|O
cholesterol	1743	1754	cholesterol	|B-TRIVIAL
biosynthesis	1754	1766		|O
or	1768	1770		|O
for	1771	1774		|O
the	1775	1778		|O
synthesis	1779	1788		|O
of	1789	1791		|O
other	1792	1797		|O
compounds	1798	1807		|O
requiring	1808	1817		|O
isoprenoid	1818	1828		|O
precursors	1829	1839		|O
.	1839	1840		|O

### 8230102
In	0	2		|O
order	3	8		|O
to	9	11		|O
develop	12	19		|O
tracers	20	27		|O
with	28	32		|O
higher	33	39		|O
specific	40	48		|O
activity	49	57		|O
to	58	60		|O
supplant	61	69		|O
the	70	73		|O
currently	74	83		|O
used	84	88		|O
[	89	90	[3H]-8-OH-DPAT	|B-IUPAC
3H	90	92		|I-IUPAC
]	92	93		|I-IUPAC
-	93	94		|I-IUPAC
8	94	95		|I-IUPAC
-	95	96		|I-IUPAC
OH	96	98		|I-IUPAC
-	98	99		|I-IUPAC
DPAT	99	103		|I-IUPAC
[	104	105		|O
8	105	106	8-hydroxy-2-(N,N-di-n-propylamino)tetralin	|B-IUPAC
-	106	107		|I-IUPAC
hydroxy	107	114		|I-IUPAC
-	114	115		|I-IUPAC
2	115	116		|I-IUPAC
-	116	117		|I-IUPAC
(	117	118		|I-IUPAC
N	118	119		|I-IUPAC
,	119	120		|I-IUPAC
N	120	121		|I-IUPAC
-	121	122		|I-IUPAC
di	122	124		|I-IUPAC
-	124	125		|I-IUPAC
n	125	126		|I-IUPAC
-	126	127		|I-IUPAC
propylamino	127	138		|I-IUPAC
)	138	139		|I-IUPAC
tetralin	139	147		|I-IUPAC
]	147	148		|O
for	149	152		|O
in	153	155		|O
vitro	156	161		|O
and	162	165		|O
in	166	168		|O
vivo	169	173		|O
evaluation	174	184		|O
of	185	187		|O
5	188	189		|O
-	189	190		|O
HT1A	190	194		|O
receptors	195	204		|O
,	204	205		|O
a	206	207		|O
new	208	211		|O
radioiodinated	212	226		|O
ligand	227	233		|O
was	234	237		|O
prepared	238	246		|O
.	246	247		|O
(	248	249	(R,S)-trans-8- Hydroxy-2-[N-n-propyl-N-(3'-iodo-2'-propenyl)amino]tetralin	|B-IUPAC
R	249	250		|I-IUPAC
,	250	251		|I-IUPAC
S	251	252		|I-IUPAC
)	252	253		|I-IUPAC
-	253	254		|I-IUPAC
trans	254	259		|I-IUPAC
-	259	260		|I-IUPAC
8	260	261		|I-IUPAC
-	261	262		|I-IUPAC
Hydroxy	263	270		|I-IUPAC
-	270	271		|I-IUPAC
2	271	272		|I-IUPAC
-	272	273		|I-IUPAC
[	273	274		|I-IUPAC
N	274	275		|I-IUPAC
-	275	276		|I-IUPAC
n	276	277		|I-IUPAC
-	277	278		|I-IUPAC
propyl	278	284		|I-IUPAC
-	284	285		|I-IUPAC
N	285	286		|I-IUPAC
-	286	287		|I-IUPAC
(	287	288		|I-IUPAC
3'	288	290		|I-IUPAC
-	290	291		|I-IUPAC
iodo	291	295		|I-IUPAC
-	295	296		|I-IUPAC
2'	296	298		|I-IUPAC
-	298	299		|I-IUPAC
propenyl	299	307		|I-IUPAC
)	307	308		|I-IUPAC
amino	308	313		|I-IUPAC
]	313	314		|I-IUPAC
tetralin	314	322		|I-IUPAC
(	323	324		|O
trans	324	329	trans-8-OH-PIPAT	|B-IUPAC
-	329	330		|I-IUPAC
8	330	331		|I-IUPAC
-	331	332		|I-IUPAC
OH	332	334		|I-IUPAC
-	334	335		|I-IUPAC
PIPAT	335	340		|I-IUPAC
)	340	341		|O
,	341	342		|O
8	343	344		|O
,	344	345		|O
was	346	349		|O
synthesized	350	361		|O
by	362	364		|O
a	365	366		|O
-	369	370		|O
step	370	374		|O
reaction	375	383		|O
.	383	384		|O
Binding	385	392		|O
studies	393	400		|O
with	401	405		|O
rat	406	409		|O
hippocampal	410	421		|O
membrane	422	430		|O
homogenates	431	442		|O
showed	443	449		|O
that	450	454		|O
8	455	456		|O
exhibited	457	466		|O
a	467	468		|O
Ki	469	471		|O
value	472	477		|O
of	478	480		|O
0.92	481	485		|O
nM	486	488		|O
against	489	496		|O
(	497	498	(R,S)-[3H]-8-OH-DPAT	|B-IUPAC
R	498	499		|I-IUPAC
,	499	500		|I-IUPAC
S	500	501		|I-IUPAC
)	501	502		|I-IUPAC
-	502	503		|I-IUPAC
[	503	504		|I-IUPAC
3H	504	506		|I-IUPAC
]	506	507		|I-IUPAC
-	507	508		|I-IUPAC
8	508	509		|I-IUPAC
-	509	510		|I-IUPAC
OH	510	512		|I-IUPAC
-	512	513		|I-IUPAC
DPAT	513	517		|I-IUPAC
.	517	518		|O
Radiolabeled	519	531		|O
[	532	533	[125I]-	|B-PARTIUPAC
125I	533	537		|I-PARTIUPAC
]	537	538		|I-PARTIUPAC
-	538	539		|I-PARTIUPAC
8	539	540		|O
was	541	544		|O
prepared	545	553		|O
from	554	558		|O
the	559	562		|O
corresponding	563	576		|O
tri	577	580	tri-n-butyltin	|B-IUPAC
-	580	581		|I-IUPAC
n	581	582		|I-IUPAC
-	582	583		|I-IUPAC
butyltin	583	591		|I-IUPAC
precursor	592	601		|O
via	602	605		|O
an	606	608		|O
oxidative	609	618		|O
iododestannylation	619	637		|O
reaction	638	646		|O
with	647	651		|O
sodium	652	658		|O
[	659	660	[125I]iodide	|B-IUPAC
125I	660	664		|I-IUPAC
]	664	665		|I-IUPAC
iodide	665	671		|I-IUPAC
.	671	672		|O
Binding	673	680		|O
studies	681	688		|O
in	689	691		|O
the	692	695		|O
hippocampal	696	707		|O
homogenates	708	719		|O
revealed	720	728		|O
that	729	733		|O
[	734	735	[125I]-	|B-PARTIUPAC
125I	735	739		|I-PARTIUPAC
]	739	740		|I-PARTIUPAC
-	740	741		|I-PARTIUPAC
8	741	742		|O
bound	743	748		|O
to	749	751		|O
a	752	753		|O
single	754	760		|O
high	761	765		|O
-	765	766		|O
affinity	766	774		|O
site	775	779		|O
(	780	781		|O
Kd	781	783		|O
=	784	785		|O
0.38	786	790		|O
+	791	792		|O
/	792	793		|O
-	793	794		|O
0.03	795	799		|O
nM	800	802		|O
,	802	803		|O
Bmax	803	807		|O
=	808	809		|O
+	814	815		|O
/	815	816		|O
-	816	817		|O
fmol	821	825		|O
/	825	826		|O
mg	826	828		|O
of	829	831		|O
protein	832	839		|O
)	839	840		|O
.	840	841		|O
Competition	842	853		|O
binding	854	861		|O
experiments	862	873		|O
clearly	874	881		|O
indicated	882	891		|O
that	892	896		|O
the	897	900		|O
new	901	904		|O
ligand	905	911		|O
displayed	912	921		|O
the	922	925		|O
expected	926	934		|O
5	935	936		|O
-	936	937		|O
HT1A	937	941		|O
receptor	942	950		|O
binding	951	958		|O
profile	959	966		|O
.	966	967		|O
The	968	971		|O
rank	972	976		|O
order	977	982		|O
of	983	985		|O
potency	986	993		|O
was	994	997		|O
(	998	999	(R,S)-trans-8-OH-PIPAT	|B-IUPAC
R	999	1000		|I-IUPAC
,	1000	1001		|I-IUPAC
S	1001	1002		|I-IUPAC
)	1002	1003		|I-IUPAC
-	1003	1004		|I-IUPAC
trans	1004	1009		|I-IUPAC
-	1009	1010		|I-IUPAC
8	1010	1011		|I-IUPAC
-	1011	1012		|I-IUPAC
OH	1012	1014		|I-IUPAC
-	1014	1015		|I-IUPAC
PIPAT	1015	1020		|I-IUPAC
&	1021	1022		|O
gt	1022	1024		|O
;	1024	1025		|O
(	1026	1027	(R,S)- 8-OH-DPAT	|B-IUPAC
R	1027	1028		|I-IUPAC
,	1028	1029		|I-IUPAC
S	1029	1030		|I-IUPAC
)	1030	1031		|I-IUPAC
-	1031	1032		|I-IUPAC
8	1033	1034		|I-IUPAC
-	1034	1035		|I-IUPAC
OH	1035	1037		|I-IUPAC
-	1037	1038		|I-IUPAC
DPAT	1038	1042		|I-IUPAC
&	1043	1044		|O
gt	1044	1046		|O
;	1046	1047		|O
WB4101	1048	1054	WB4101	|B-TRIVIAL
&	1055	1056		|O
gt	1056	1058		|O
;	1058	1059		|O
5	1060	1061		|O
-	1061	1062		|O
HT	1062	1064		|O
&	1065	1066		|O
gt	1066	1068		|O
;	1068	1069		|O
(	1070	1071	(R,S)-trans-7-OH-PIPAT	|B-IUPAC
R	1071	1072		|I-IUPAC
,	1072	1073		|I-IUPAC
S	1073	1074		|I-IUPAC
)	1074	1075		|I-IUPAC
-	1075	1076		|I-IUPAC
trans	1076	1081		|I-IUPAC
-	1081	1082		|I-IUPAC
7	1082	1083		|I-IUPAC
-	1083	1084		|I-IUPAC
OH	1084	1086		|I-IUPAC
-	1086	1087		|I-IUPAC
PIPAT	1087	1092		|I-IUPAC
&	1093	1094		|O
gt	1094	1096		|O
;	1096	1097		|O
(	1098	1099	(R,S)-7-OH-DPAT	|B-IUPAC
R	1099	1100		|I-IUPAC
,	1100	1101		|I-IUPAC
S	1101	1102		|I-IUPAC
)	1102	1103		|I-IUPAC
-	1103	1104		|I-IUPAC
7	1104	1105		|I-IUPAC
-	1105	1106		|I-IUPAC
OH	1106	1108		|I-IUPAC
-	1108	1109		|I-IUPAC
DPAT	1109	1113		|I-IUPAC
&	1114	1115		|O
gt	1115	1117		|O
;	1117	1118		|O
(	1119	1120	(R,S)-propranolol	|B-IUPAC
R	1120	1121		|I-IUPAC
,	1121	1122		|I-IUPAC
S	1122	1123		|I-IUPAC
)	1123	1124		|I-IUPAC
-	1124	1125		|I-IUPAC
propranolol	1125	1136		|I-IUPAC
&	1137	1138		|O
gt	1138	1140		|O
;	1140	1141		|O
spiperone	1142	1151	spiperone	|B-TRIVIAL
&	1152	1153		|O
gt	1153	1155		|O
;	1155	1156		|O
&	1156	1157		|O
gt	1157	1159		|O
;	1159	1160		|O
ketanserin	1161	1171	ketanserin	|B-TRIVIAL
&	1172	1173		|O
gt	1173	1175		|O
;	1175	1176		|O
&	1176	1177		|O
gt	1177	1179		|O
;	1179	1180		|O
dopamine	1181	1189	dopamine	|B-TRIVIAL
&	1190	1191		|O
gt	1191	1193		|O
;	1193	1194		|O
atropine	1195	1203	atropine	|B-TRIVIAL
.	1203	1204		|O
This	1205	1209		|O
new	1210	1213		|O
ligand	1214	1220		|O
offers	1221	1227		|O
several	1228	1235		|O
unique	1236	1242		|O
advantages	1243	1253		|O
,	1253	1254		|O
including	1255	1264		|O
high	1265	1269		|O
specific	1270	1278		|O
activity	1279	1287		|O
,	1287	1288		|O
high	1289	1293		|O
binding	1294	1301		|O
affinity	1302	1310		|O
,	1310	1311		|O
and	1312	1315		|O
low	1316	1319		|O
nonspecific	1320	1331		|O
binding	1332	1339		|O
,	1339	1340		|O
all	1341	1344		|O
of	1345	1347		|O
which	1348	1353		|O
make	1354	1358		|O
it	1359	1361		|O
an	1362	1364		|O
excellent	1365	1374		|O
probe	1375	1380		|O
for	1381	1384		|O
the	1385	1388		|O
investigation	1389	1402		|O
and	1403	1406		|O
characterization	1407	1423		|O
of	1424	1426		|O
5	1427	1428		|O
-	1428	1429		|O
HT1A	1429	1433		|O
receptors	1434	1443		|O
.	1443	1444		|O

### 10479279
The	0	3		|O
synthesis	4	13		|O
and	14	17		|O
pharmacological	18	33		|O
profile	34	41		|O
of	42	44		|O
a	45	46		|O
series	47	53		|O
of	54	56		|O
neuroprotective	57	72		|O
adenosine	73	82		|O
agonists	83	91		|O
are	92	95		|O
described	96	105		|O
.	105	106		|O
Novel	107	112		|O
A	113	114		|O
(	114	115		|O
1	115	116		|O
)	116	117		|O
agonists	118	126		|O
with	127	131		|O
potent	132	138		|O
central	139	146		|O
nervous	147	154		|O
system	155	161		|O
effects	162	169		|O
and	170	173		|O
diminished	174	184		|O
influence	185	194		|O
on	195	197		|O
the	198	201		|O
cardiovascular	202	216		|O
system	217	223		|O
are	224	227		|O
reported	228	236		|O
and	237	240		|O
compared	241	249		|O
to	250	252		|O
selected	253	261		|O
reference	262	271		|O
adenosine	272	281		|O
agonists	282	290		|O
.	290	291		|O
The	292	295		|O
novel	296	301		|O
compounds	302	311		|O
featured	312	320		|O
are	321	324		|O
derived	325	332		|O
structurally	333	345		|O
from	346	350		|O
two	351	354		|O
key	355	358		|O
lead	359	363		|O
structures	364	374		|O
:	374	375		|O
2	376	377	2-chloro-N-(1-phenoxy-2-propyl)adenosine	|B-IUPAC
-	377	378		|I-IUPAC
chloro	378	384		|I-IUPAC
-	384	385		|I-IUPAC
N	385	386		|I-IUPAC
-	386	387		|I-IUPAC
(	387	388		|I-IUPAC
1	388	389		|I-IUPAC
-	389	390		|I-IUPAC
phenoxy	390	397		|I-IUPAC
-	397	398		|I-IUPAC
2	398	399		|I-IUPAC
-	399	400		|I-IUPAC
propyl	400	406		|I-IUPAC
)	406	407		|I-IUPAC
adenosine	407	416		|I-IUPAC
(	417	418		|O
NNC	418	421	NNC 21-0041	|B-TRIVIALVAR
21-0041	422	429		|I-TRIVIALVAR
,	429	430		|O
9	431	432		|O
)	432	433		|O
and	434	437		|O
2	438	439	2-chloro-N-(1-piperidinyl)adenosine	|B-IUPAC
-	439	440		|I-IUPAC
chloro	440	446		|I-IUPAC
-	446	447		|I-IUPAC
N	447	448		|I-IUPAC
-	448	449		|I-IUPAC
(	449	450		|I-IUPAC
1	450	451		|I-IUPAC
-	451	452		|I-IUPAC
piperidinyl	452	463		|I-IUPAC
)	463	464		|I-IUPAC
adenosine	464	473		|I-IUPAC
(	474	475		|O
NNC	475	478	NNC 90-1515	|B-TRIVIALVAR
,	486	487		|O
4	488	489		|O
)	489	490		|O
.	490	491		|O
The	492	495		|O
agonists	496	504		|O
are	505	508		|O
characterized	509	522		|O
in	523	525		|O
terms	526	531		|O
of	532	534		|O
their	535	540		|O
in	541	543		|O
vitro	544	549		|O
profiles	550	558		|O
,	558	559		|O
both	560	564		|O
binding	565	572		|O
and	573	576		|O
functional	577	587		|O
,	587	588		|O
and	589	592		|O
in	593	595		|O
vivo	596	600		|O
activity	601	609		|O
in	610	612		|O
relevant	613	621		|O
animal	622	628		|O
models	629	635		|O
.	635	636		|O
Neuroprotective	637	652		|O
properties	653	663		|O
assessed	664	672		|O
after	673	678		|O
postischemic	679	691		|O
dosing	692	698		|O
in	699	701		|O
a	702	703		|O
Mongolian	704	713		|O
gerbil	714	720		|O
severe	721	727		|O
temporary	728	737		|O
forebrain	738	747		|O
ischemia	748	756		|O
paradigm	757	765		|O
,	765	766		|O
using	767	772		|O
hippocampal	773	784		|O
CA1	785	788		|O
damage	789	795		|O
endpoints	796	805		|O
,	805	806		|O
and	807	810		|O
the	811	814		|O
efficacy	815	823		|O
of	824	826		|O
these	827	832		|O
agonists	833	841		|O
in	842	844		|O
an	845	847		|O
A	848	849		|O
(	849	850		|O
1	850	851		|O
)	851	852		|O
functional	853	863		|O
assay	864	869		|O
show	870	874		|O
similarities	875	887		|O
to	888	890		|O
some	891	895		|O
reference	896	905		|O
adenosine	906	915		|O
agonists	916	924		|O
.	924	925		|O
However	926	933		|O
,	933	934		|O
the	935	938		|O
new	939	942		|O
compounds	943	952		|O
we	953	955		|O
describe	956	964		|O
exhibit	965	972		|O
diminished	973	983		|O
cardiovascular	984	998		|O
effects	999	1006		|O
in	1007	1009		|O
both	1010	1014		|O
anesthetized	1015	1027		|O
and	1028	1031		|O
awake	1032	1037		|O
rats	1038	1042		|O
when	1043	1047		|O
compared	1048	1056		|O
to	1057	1059		|O
reference	1060	1069		|O
A	1070	1071		|O
(	1071	1072		|O
1	1072	1073		|O
)	1073	1074		|O
agonists	1075	1083		|O
such	1084	1088		|O
as	1089	1091		|O
(	1092	1093	(R)-phenylisopropyladenosine	|B-IUPAC
R	1093	1094		|I-IUPAC
)	1094	1095		|I-IUPAC
-	1095	1096		|I-IUPAC
phenylisopropyladenosine	1096	1120		|I-IUPAC
(	1121	1122		|O
R	1122	1123	R-PIA	|B-ABBREVIATION
-	1123	1124		|I-ABBREVIATION
PIA	1124	1127		|I-ABBREVIATION
,	1127	1128		|O
5	1129	1130		|O
)	1130	1131		|O
,	1131	1132		|O
N	1133	1134	N-cyclopentyladenosine	|B-IUPAC
-	1134	1135		|I-IUPAC
cyclopentyladenosine	1135	1155		|I-IUPAC
(	1156	1157		|O
CPA	1157	1160	CPA	|B-ABBREVIATION
,	1160	1161		|O
2	1162	1163		|O
)	1163	1164		|O
,	1164	1165		|O
4	1166	1167		|O
,	1167	1168		|O
N	1169	1170	N-[(1S,trans)-2-hydroxycyclopentyl]adenosine	|B-IUPAC
-	1170	1171		|I-IUPAC
[	1171	1172		|I-IUPAC
(	1172	1173		|I-IUPAC
1S	1173	1175		|I-IUPAC
,	1175	1176		|I-IUPAC
trans	1176	1181		|I-IUPAC
)	1181	1182		|I-IUPAC
-	1182	1183		|I-IUPAC
2	1183	1184		|I-IUPAC
-	1184	1185		|I-IUPAC
hydroxycyclopentyl	1185	1203		|I-IUPAC
]	1203	1204		|I-IUPAC
adenosine	1204	1213		|I-IUPAC
(	1214	1215		|O
GR	1215	1217	GR 79236	|B-TRIVIALVAR
79236	1218	1223		|I-TRIVIALVAR
,	1223	1224		|O
26	1225	1227		|O
)	1227	1228		|O
,	1228	1229		|O
N	1230	1231	N-cyclohexyl-2'-O-methyladenosine	|B-IUPAC
-	1231	1232		|I-IUPAC
cyclohexyl	1232	1242		|I-IUPAC
-	1242	1243		|I-IUPAC
2'	1243	1245		|I-IUPAC
-	1245	1246		|I-IUPAC
O	1246	1247		|I-IUPAC
-	1247	1248		|I-IUPAC
methyladenosine	1248	1263		|I-IUPAC
(	1264	1265		|O
SDZ	1265	1268	SDZ WAG 994	|B-TRIVIALVAR
WAG	1269	1272		|I-TRIVIALVAR
994	1273	1276		|I-TRIVIALVAR
,	1276	1277		|O
27	1278	1280		|O
)	1280	1281		|O
,	1281	1282		|O
and	1283	1286		|O
N	1287	1288	N-[(2-methylphenyl)methyl]adenosine	|B-IUPAC
-	1288	1289		|I-IUPAC
[	1289	1290		|I-IUPAC
(	1290	1291		|I-IUPAC
2	1291	1292		|I-IUPAC
-	1292	1293		|I-IUPAC
methylphenyl	1293	1305		|I-IUPAC
)	1305	1306		|I-IUPAC
methyl	1306	1312		|I-IUPAC
]	1312	1313		|I-IUPAC
adenosine	1313	1322		|I-IUPAC
(	1323	1324		|O
Metrifudil	1324	1334	Metrifudil	|B-TRIVIAL
,	1334	1335		|O
28	1336	1338		|O
)	1338	1339		|O
.	1339	1340		|O
In	1341	1343		|O
mouse	1344	1349		|O
permanent	1350	1359		|O
middle	1360	1366		|O
cerebral	1367	1375		|O
artery	1376	1382		|O
occlusion	1383	1392		|O
focal	1393	1398		|O
ischemia	1399	1407		|O
,	1407	1408		|O
2	1409	1410	2-chloro-N-[(R)-[(2-benzothiazolyl)thio]-2-propyl]adenosine	|B-IUPAC
-	1410	1411		|I-IUPAC
chloro	1411	1417		|I-IUPAC
-	1417	1418		|I-IUPAC
N	1418	1419		|I-IUPAC
-	1419	1420		|I-IUPAC
[	1420	1421		|I-IUPAC
(	1421	1422		|I-IUPAC
R	1422	1423		|I-IUPAC
)	1423	1424		|I-IUPAC
-	1424	1425		|I-IUPAC
[	1425	1426		|I-IUPAC
(	1426	1427		|I-IUPAC
2	1427	1428		|I-IUPAC
-	1428	1429		|I-IUPAC
benzothiazolyl	1429	1443		|I-IUPAC
)	1443	1444		|I-IUPAC
thio	1444	1448		|I-IUPAC
]	1448	1449		|I-IUPAC
-	1449	1450		|I-IUPAC
2	1450	1451		|I-IUPAC
-	1451	1452		|I-IUPAC
propyl	1452	1458		|I-IUPAC
]	1458	1459		|I-IUPAC
adenosine	1459	1468		|I-IUPAC
(	1469	1470		|O
NNC	1470	1473	NNC 21-0136	|B-TRIVIALVAR
21-0136	1474	1481		|I-TRIVIALVAR
,	1481	1482		|O
12	1483	1485		|O
)	1485	1486		|O
exhibited	1487	1496		|O
significant	1497	1508		|O
neuroprotection	1509	1524		|O
at	1525	1527		|O
the	1528	1531		|O
remarkably	1532	1542		|O
low	1543	1546		|O
total	1547	1552		|O
intraperitoneal	1553	1568		|O
dose	1569	1573		|O
of	1574	1576		|O
0.1	1577	1580		|O
mg	1581	1583		|O
/	1583	1584		|O
kg	1584	1586		|O
,	1586	1587		|O
a	1588	1589		|O
dose	1590	1594		|O
at	1595	1597		|O
which	1598	1603		|O
no	1604	1606		|O
cardiovascular	1607	1621		|O
effects	1622	1629		|O
are	1630	1633		|O
observed	1634	1642		|O
in	1643	1645		|O
conscious	1646	1655		|O
rats	1656	1660		|O
.	1660	1661		|O
The	1662	1665		|O
novel	1666	1671		|O
agonists	1672	1680		|O
described	1681	1690		|O
inhibit	1691	1698		|O
6	1699	1700	6, 7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate	|B-IUPAC
,	1700	1701		|I-IUPAC
7	1702	1703		|I-IUPAC
-	1703	1704		|I-IUPAC
dimethoxy	1704	1713		|I-IUPAC
-	1713	1714		|I-IUPAC
4	1714	1715		|I-IUPAC
-	1715	1716		|I-IUPAC
ethyl	1716	1721		|I-IUPAC
-	1721	1722		|I-IUPAC
beta	1722	1726		|I-IUPAC
-	1726	1727		|I-IUPAC
carboline	1727	1736		|I-IUPAC
-	1736	1737		|I-IUPAC
3	1737	1738		|I-IUPAC
-	1738	1739		|I-IUPAC
carboxylate	1739	1750		|I-IUPAC
-	1750	1751		|O
induced	1751	1758		|O
seizures	1759	1767		|O
,	1767	1768		|O
and	1769	1772		|O
in	1773	1775		|O
mouse	1776	1781		|O
locomotor	1782	1791		|O
activity	1792	1800		|O
higher	1801	1807		|O
doses	1808	1813		|O
are	1814	1817		|O
required	1818	1826		|O
to	1827	1829		|O
reach	1830	1835		|O
ED	1836	1838		|O
(	1838	1839		|O
)	1841	1842		|O
values	1843	1849		|O
than	1850	1854		|O
for	1855	1858		|O
reference	1859	1868		|O
A	1869	1870		|O
(	1870	1871		|O
1	1871	1872		|O
)	1872	1873		|O
agonists	1874	1882		|O
.	1882	1883		|O
We	1884	1886		|O
conclude	1887	1895		|O
that	1896	1900		|O
two	1901	1904		|O
of	1905	1907		|O
the	1908	1911		|O
novel	1912	1917		|O
adenosine	1918	1927		|O
derivatives	1928	1939		|O
revealed	1940	1948		|O
herein	1949	1955		|O
,	1955	1956		|O
12	1957	1959		|O
and	1960	1963		|O
5'	1964	1966	5'-deoxy-5'-chloro-N-[4-(phenylthio)-1-piperidinyl]adenosine	|B-IUPAC
-	1966	1967		|I-IUPAC
deoxy	1967	1972		|I-IUPAC
-	1972	1973		|I-IUPAC
5'	1973	1975		|I-IUPAC
-	1975	1976		|I-IUPAC
chloro	1976	1982		|I-IUPAC
-	1982	1983		|I-IUPAC
N	1983	1984		|I-IUPAC
-	1984	1985		|I-IUPAC
[	1985	1986		|I-IUPAC
4	1986	1987		|I-IUPAC
-	1987	1988		|I-IUPAC
(	1988	1989		|I-IUPAC
phenylthio	1989	1999		|I-IUPAC
)	1999	2000		|I-IUPAC
-	2000	2001		|I-IUPAC
1	2001	2002		|I-IUPAC
-	2002	2003		|I-IUPAC
piperidinyl	2003	2014		|I-IUPAC
]	2014	2015		|I-IUPAC
adenosine	2015	2024		|I-IUPAC
(	2025	2026		|O
NNC	2026	2029	NNC 21-0147	|B-TRIVIALVAR
21-0147	2030	2037		|I-TRIVIALVAR
,	2037	2038		|O
13	2039	2041		|O
)	2041	2042		|O
,	2042	2043		|O
representatives	2044	2059		|O
of	2060	2062		|O
a	2063	2064		|O
new	2065	2068		|O
series	2069	2075		|O
of	2076	2078		|O
P	2079	2080		|O
(	2080	2081		|O
1	2081	2082		|O
)	2082	2083		|O
ligands	2084	2091		|O
,	2091	2092		|O
reinforce	2093	2102		|O
the	2103	2106		|O
fact	2107	2111		|O
that	2112	2116		|O
novel	2117	2122		|O
selective	2123	2132		|O
adenosine	2133	2142		|O
A	2143	2144		|O
(	2144	2145		|O
1	2145	2146		|O
)	2146	2147		|O
agonists	2148	2156		|O
have	2157	2161		|O
potential	2162	2171		|O
in	2172	2174		|O
the	2175	2178		|O
treatment	2179	2188		|O
of	2189	2191		|O
cerebral	2192	2200		|O
ischemia	2201	2209		|O
in	2210	2212		|O
humans	2213	2219		|O
.	2219	2220		|O

### 1732554
A	0	1		|O
series	2	8		|O
of	9	11		|O
8	12	13	8-(trifluoromethyl)-substituted quinolones	|B-IUPAC
-	13	14		|I-IUPAC
(	14	15		|I-IUPAC
trifluoromethyl	15	30		|I-IUPAC
)	30	31		|I-IUPAC
-	31	32		|I-IUPAC
substituted	32	43		|I-IUPAC
quinolones	44	54		|I-IUPAC
has	55	58		|O
been	59	63		|O
prepared	64	72		|O
and	73	76		|O
evaluated	77	86		|O
for	87	90		|O
in	91	93		|O
vitro	94	99		|O
and	100	103		|O
in	104	106		|O
vivo	107	111		|O
antibacterial	112	125		|O
activity	126	134		|O
,	134	135		|O
and	136	139		|O
phototolerance	140	154		|O
in	155	157		|O
a	158	159		|O
mouse	160	165		|O
phototolerance	166	180		|O
assay	181	186		|O
.	186	187		|O
These	188	193		|O
analogues	194	203		|O
were	204	208		|O
compared	209	217		|O
to	218	220		|O
the	221	224		|O
corresponding	225	238		|O
series	239	245		|O
of	246	248		|O
6,8	249	252	6,8-difluoro-	|B-PARTIUPAC
-	252	253		|I-PARTIUPAC
difluoro	253	261		|I-PARTIUPAC
-	261	262		|I-PARTIUPAC
and	263	266		|O
6	267	268	6-fluoro-8H-quinolones	|B-IUPAC
-	268	269		|I-IUPAC
fluoro	269	275		|I-IUPAC
-	275	276		|I-IUPAC
8H	276	278		|I-IUPAC
-	278	279		|I-IUPAC
quinolones	279	289		|I-IUPAC
(	290	291		|O
ciprofloxacin	291	304	ciprofloxacin	|B-TRIVIAL
type	305	309		|O
)	309	310		|O
.	310	311		|O
Although	312	320		|O
their	321	326		|O
in	327	329		|O
vitro	330	335		|O
antibacterial	336	349		|O
activities	350	360		|O
are	361	364		|O
less	365	369		|O
than	370	374		|O
the	375	378		|O
6,8	379	382	6,8-difluoro	|B-PARTIUPAC
-	382	383		|I-PARTIUPAC
difluoro	383	391		|I-PARTIUPAC
analogues	392	401	analogues	|B-MODIFIER
,	401	402		|O
the	403	406		|O
8	407	408	8-(trifluoromethyl)quinolones	|B-IUPAC
-	408	409		|I-IUPAC
(	409	410		|I-IUPAC
trifluoromethyl	410	425		|I-IUPAC
)	425	426		|I-IUPAC
quinolones	426	436		|I-IUPAC
are	437	440		|O
generally	441	450		|O
equivalent	451	461		|O
to	462	464		|O
their	465	470		|O
8H	471	473	8H	|B-PARTIUPAC
analogues	474	483	analogues	|B-MODIFIER
.	483	484		|O
In	485	487		|O
vivo	488	492		|O
,	492	493		|O
they	494	498		|O
are	499	502		|O
comparable	503	513		|O
to	514	516		|O
the	517	520		|O
6,8	521	524	6,8-difluoro	|B-PARTIUPAC
-	524	525		|I-PARTIUPAC
difluoro	525	533		|I-PARTIUPAC
series	534	540	series	|B-MODIFIER
and	541	544		|O
show	545	549		|O
up	550	552		|O
to	553	555		|O
-	558	559		|O
fold	559	563		|O
improvement	564	575		|O
in	576	578		|O
efficacy	579	587		|O
when	588	592		|O
compared	593	601		|O
to	602	604		|O
their	605	610		|O
ciprofloxacin	611	624	ciprofloxacin	|B-TRIVIAL
counterparts	625	637		|O
vs	638	640		|O
Streptococcus	641	654		|O
pyogenes	655	663		|O
and	664	667		|O
Streptococcus	668	681		|O
pneumonia	682	691		|O
.	691	692		|O
In	693	695		|O
the	696	699		|O
phototolerance	700	714		|O
model	715	720		|O
,	720	721		|O
the	722	725		|O
8	726	727	8-(trifluoromethyl)quinolones	|B-IUPAC
-	727	728		|I-IUPAC
(	728	729		|I-IUPAC
trifluoromethyl	729	744		|I-IUPAC
)	744	745		|I-IUPAC
quinolones	745	755		|I-IUPAC
are	756	759		|O
comparable	760	770		|O
to	771	773		|O
the	774	777		|O
8H	778	780	8H-quinolones	|B-IUPAC
-	780	781		|I-IUPAC
quinolones	781	791		|I-IUPAC
.	791	792		|O
Both	793	797		|O
of	798	800		|O
these	801	806		|O
series	807	813		|O
display	814	821		|O
much	822	826		|O
higher	827	833		|O
no	834	836		|O
effect	837	843		|O
doses	844	849		|O
(	850	851		|O
greater	851	858		|O
tolerance	859	868		|O
)	868	869		|O
than	870	874		|O
the	875	878		|O
corresponding	879	892		|O
6,8	893	896	6,8-difluoroquinolones	|B-IUPAC
-	896	897		|I-IUPAC
difluoroquinolones	897	915		|I-IUPAC
.	915	916		|O

### 3761308
This	0	4		|O
study	5	10		|O
emphasizes	11	21		|O
the	22	25		|O
importance	26	36		|O
of	37	39		|O
the	40	43		|O
metabolic	44	53		|O
conversion	54	64		|O
of	65	67		|O
the	68	71		|O
enantiomers	72	83		|O
of	84	86		|O
3	87	88	3-(3-hydroxyphenyl)-N-n-propylpiperidine	|B-IUPAC
-	88	89		|I-IUPAC
(	89	90		|I-IUPAC
3	90	91		|I-IUPAC
-	91	92		|I-IUPAC
hydroxyphenyl	92	105		|I-IUPAC
)	105	106		|I-IUPAC
-	106	107		|I-IUPAC
N	107	108		|I-IUPAC
-	108	109		|I-IUPAC
n	109	110		|I-IUPAC
-	110	111		|I-IUPAC
propylpiperidine	111	127		|I-IUPAC
(	128	129		|O
3	129	130	3-PPP	|B-ABBREVIATION
-	130	131		|I-ABBREVIATION
PPP	131	134		|I-ABBREVIATION
)	134	135		|O
into	136	140		|O
their	141	146		|O
catechol	147	155	catechol	|B-TRIVIAL
analogues	156	165	analogues	|B-MODIFIER
,	165	166		|O
the	167	170		|O
enantiomers	171	182		|O
of	183	185		|O
3	186	187	3-(3,4-dihydroxyphenyl)-N-n-propylpiperidine	|B-IUPAC
-	187	188		|I-IUPAC
(	188	189		|I-IUPAC
3,4	189	192		|I-IUPAC
-	192	193		|I-IUPAC
dihydroxyphenyl	193	208		|I-IUPAC
)	208	209		|I-IUPAC
-	209	210		|I-IUPAC
N	210	211		|I-IUPAC
-	211	212		|I-IUPAC
n	212	213		|I-IUPAC
-	213	214		|I-IUPAC
propylpiperidine	214	230		|I-IUPAC
.	230	231		|O
These	232	237		|O
isomers	238	245		|O
are	246	249		|O
both	250	254		|O
shown	255	260		|O
to	261	263		|O
be	264	266		|O
excellent	267	276		|O
substrates	277	287		|O
for	288	291		|O
COMT	292	296		|O
,	296	297		|O
with	298	302		|O
a	303	304		|O
slight	305	311		|O
preference	312	322		|O
for	323	326		|O
the	327	330		|O
S	331	332		|O
-	332	333		|O
(	333	334		|O
-	334	335		|O
)	335	336		|O
enantiomer	337	347		|O
.	347	348		|O
Assessment	349	359		|O
of	360	362		|O
the	363	366		|O
dopaminergic	367	379		|O
activity	380	388		|O
of	389	391		|O
these	392	397		|O
catechols	398	407		|O
and	408	411		|O
the	412	415		|O
results	416	423		|O
from	424	428		|O
the	429	432		|O
determination	433	446		|O
of	447	449		|O
brain	450	455		|O
levels	456	462		|O
of	463	465		|O
the	466	469		|O
enantiomers	470	481		|O
of	482	484		|O
3	485	486	3-PPP	|B-ABBREVIATION
-	486	487		|I-ABBREVIATION
PPP	487	490		|I-ABBREVIATION
and	491	494		|O
their	495	500		|O
metabolites	501	512		|O
indicate	513	521		|O
that	522	526		|O
the	527	530		|O
metabolites	531	542		|O
probably	543	551		|O
do	552	554		|O
not	555	558		|O
alter	559	564		|O
the	565	568		|O
pharmacological	569	584		|O
profiles	585	593		|O
established	594	605		|O
for	606	609		|O
(	610	611	(R)-(+)-	|B-PARTIUPAC
R	611	612		|I-PARTIUPAC
)	612	613		|I-PARTIUPAC
-	613	614		|I-PARTIUPAC
(	614	615		|I-PARTIUPAC
+	615	616		|I-PARTIUPAC
)	616	617		|I-PARTIUPAC
-	617	618		|I-PARTIUPAC
and	619	622		|O
(	623	624	(S)-(-)-3-PPP	|B-IUPAC
S	624	625		|I-IUPAC
)	625	626		|I-IUPAC
-	626	627		|I-IUPAC
(	627	628		|I-IUPAC
-	628	629		|I-IUPAC
)	629	630		|I-IUPAC
-	630	631		|I-IUPAC
3	631	632		|I-IUPAC
-	632	633		|I-IUPAC
PPP	633	636		|I-IUPAC
.	636	637		|O
The	638	641		|O
conversion	642	652		|O
of	653	655		|O
the	656	659		|O
monophenols	660	671	monophenols	|B-FAMILY
into	672	676		|O
catecholic	677	687		|O
metabolites	688	699		|O
is	700	702		|O
only	703	707		|O
1-5%	708	712		|O
,	712	713		|O
and	714	717		|O
the	718	721		|O
further	722	729		|O
conversion	730	740		|O
of	741	743		|O
these	744	749		|O
catecholic	750	760		|O
metabolites	761	772		|O
into	773	777		|O
methoxylated	778	790		|O
analogues	791	800		|O
is	801	803		|O
very	804	808		|O
rapid	809	814		|O
.	814	815		|O
However	816	823		|O
,	823	824		|O
the	825	828		|O
very	829	833		|O
interesting	834	845		|O
observation	846	857		|O
was	858	861		|O
made	862	866		|O
that	867	871		|O
,	871	872		|O
when	873	877		|O
inhibiting	878	888		|O
COMT	889	893		|O
by	894	896		|O
means	897	902		|O
of	903	905		|O
tropolone	906	915	tropolone	|B-TRIVIAL
and	916	919		|O
subsequently	920	932		|O
treating	933	941		|O
the	942	945		|O
rats	946	950		|O
with	951	955		|O
high	956	960		|O
doses	961	966		|O
of	967	969		|O
(	970	971	(S)-(-)-3-PPP	|B-IUPAC
S	971	972		|I-IUPAC
)	972	973		|I-IUPAC
-	973	974		|I-IUPAC
(	974	975		|I-IUPAC
-	975	976		|I-IUPAC
)	976	977		|I-IUPAC
-	977	978		|I-IUPAC
3	978	979		|I-IUPAC
-	979	980		|I-IUPAC
PPP	980	983		|I-IUPAC
(	984	985		|O
ip	985	987		|O
)	987	988		|O
,	988	989		|O
postsynaptic	990	1002		|O
dopaminergic	1003	1015		|O
activity	1016	1024		|O
was	1025	1028		|O
elicited	1029	1037		|O
.	1037	1038		|O
This	1039	1043		|O
has	1044	1047		|O
never	1048	1053		|O
been	1054	1058		|O
seen	1059	1063		|O
for	1064	1067		|O
(	1068	1069	(S)-(-)-3-PPP	|B-IUPAC
S	1069	1070		|I-IUPAC
)	1070	1071		|I-IUPAC
-	1071	1072		|I-IUPAC
(	1072	1073		|I-IUPAC
-	1073	1074		|I-IUPAC
)	1074	1075		|I-IUPAC
-	1075	1076		|I-IUPAC
3	1076	1077		|I-IUPAC
-	1077	1078		|I-IUPAC
PPP	1078	1081		|I-IUPAC
without	1082	1089		|O
tropolone	1090	1099	tropolone	|B-TRIVIAL
pretreatment	1100	1112		|O
and	1113	1116		|O
might	1117	1122		|O
indicate	1123	1131		|O
that	1132	1136		|O
,	1136	1137		|O
in	1138	1140		|O
this	1141	1145		|O
special	1146	1153		|O
case	1154	1158		|O
,	1158	1159		|O
the	1160	1163		|O
catecholic	1164	1174		|O
metabolite	1175	1185		|O
affects	1186	1193		|O
the	1194	1197		|O
in	1198	1200		|O
vivo	1201	1205		|O
pharmacological	1206	1221		|O
profile	1222	1229		|O
of	1230	1232		|O
(	1233	1234	(S)-(-)-3-PPP	|B-IUPAC
S	1234	1235		|I-IUPAC
)	1235	1236		|I-IUPAC
-	1236	1237		|I-IUPAC
(	1237	1238		|I-IUPAC
-	1238	1239		|I-IUPAC
)	1239	1240		|I-IUPAC
-	1240	1241		|I-IUPAC
3	1241	1242		|I-IUPAC
-	1242	1243		|I-IUPAC
PPP	1243	1246		|I-IUPAC
.	1246	1247		|O

### 1512594
1512594	0	7		|O
Genetic	9	16		|O
absence	17	24		|O
epilepsy	25	33		|O
in	34	36		|O
rats	37	41		|O
from	42	46		|O
Strasbourg	47	57		|O
-	57	58		|O
-	58	59		|O
a	59	60		|O
review	61	67		|O
.	67	68		|O
We	70	72		|O
have	73	77		|O
selected	78	86		|O
a	87	88		|O
strain	89	95		|O
of	96	98		|O
rats	99	103		|O
and	104	107		|O
designated	108	118		|O
it	119	121		|O
the	122	125		|O
Genetic	126	133		|O
Absence	134	141		|O
Epilepsy	142	150		|O
Rat	151	154		|O
from	155	159		|O
Strasbourg	160	170		|O
(	171	172		|O
GAERS	172	177		|O
)	177	178		|O
.	178	179		|O
In	180	182		|O
this	183	187		|O
strain	188	194		|O
,	194	195		|O
of	201	203		|O
the	204	207		|O
animals	208	215		|O
present	216	223		|O
recurrent	224	233		|O
generalized	234	245		|O
non	246	249		|O
-	249	250		|O
convulsive	250	260		|O
seizures	261	269		|O
characterized	270	283		|O
by	284	286		|O
bilateral	287	296		|O
and	297	300		|O
synchronous	301	312		|O
spike	313	318		|O
-	318	319		|O
and	319	322		|O
-	322	323		|O
wave	323	327		|O
discharges	328	338		|O
accompanied	339	350		|O
with	351	355		|O
behavioural	356	367		|O
arrest	368	374		|O
,	374	375		|O
staring	376	383		|O
and	384	387		|O
sometimes	388	397		|O
twitching	398	407		|O
of	408	410		|O
the	411	414		|O
vibrissae	415	424		|O
.	424	425		|O
Spontaneous	426	437		|O
SWD	438	441		|O
(	442	443		|O
7-11	443	447		|O
cps	448	451		|O
,	451	452		|O
microV	463	469		|O
,	469	470		|O
0.5-75	471	477		|O
sec	478	481		|O
)	481	482		|O
start	483	488		|O
and	489	492		|O
end	493	496		|O
abruptly	497	505		|O
on	506	508		|O
a	509	510		|O
normal	511	517		|O
background	518	528		|O
EEG	529	532		|O
.	532	533		|O
They	534	538		|O
usually	539	546		|O
occur	547	552		|O
at	553	555		|O
a	556	557		|O
mean	558	562		|O
frequency	563	572		|O
of	573	575		|O
1.5	576	579		|O
per	580	583		|O
min	584	587		|O
when	588	592		|O
the	593	596		|O
animals	597	604		|O
are	605	608		|O
in	609	611		|O
a	612	613		|O
state	614	619		|O
of	620	622		|O
quiet	623	628		|O
wakefulness	629	640		|O
.	640	641		|O
Drugs	642	647		|O
effective	648	657		|O
against	658	665		|O
absence	666	673		|O
seizures	674	682		|O
in	683	685		|O
humans	686	692		|O
(	693	694		|O
ethosuccimide	694	707	ethosuccimide	|B-TRIVIAL
,	707	708		|O
trimethadione	709	722	trimethadione	|B-TRIVIAL
,	722	723		|O
valproate	724	733	valproate	|B-TRIVIAL
,	733	734		|O
benzodiazepines	735	750	benzodiazepines	|B-TRIVIAL
)	750	751		|O
suppress	752	760		|O
the	761	764		|O
SWD	765	768		|O
dose	769	773		|O
-	773	774		|O
dependently	774	785		|O
,	785	786		|O
whereas	787	794		|O
drugs	795	800		|O
specific	801	809		|O
for	810	813		|O
convulsive	814	824		|O
or	825	827		|O
focal	828	833		|O
seizures	834	842		|O
(	843	844		|O
carbamazepine	844	857	carbamazepine	|B-TRIVIAL
,	857	858		|O
phenytoin	859	868	phenytoin	|B-TRIVIAL
)	868	869		|O
are	870	873		|O
ineffective	874	885		|O
.	885	886		|O
SWD	887	890		|O
are	891	894		|O
increased	895	904		|O
by	905	907		|O
epileptogenic	908	921		|O
drugs	922	927		|O
inducing	928	936		|O
petit	937	942		|O
mal	943	946		|O
-	946	947		|O
like	947	951		|O
seizures	952	960		|O
,	960	961		|O
such	962	966		|O
as	967	969		|O
pentylenetetrazol	970	987	pentylenetetrazol	|B-TRIVIAL
,	987	988		|O
gamma	989	994	gamma-hydroxybutyrate	|B-IUPAC
-	994	995		|I-IUPAC
hydroxybutyrate	995	1010		|I-IUPAC
,	1010	1011		|O
THIP	1012	1016	THIP	|B-ABBREVIATION
and	1017	1020		|O
penicillin	1021	1031	penicillin	|B-TRIVIAL
.	1031	1032		|O
Depth	1033	1038		|O
EEG	1039	1042		|O
recordings	1043	1053		|O
and	1054	1057		|O
lesion	1058	1064		|O
experiments	1065	1076		|O
show	1077	1081		|O
that	1082	1086		|O
SWD	1087	1090		|O
in	1091	1093		|O
GAERs	1094	1099		|O
depend	1100	1106		|O
on	1107	1109		|O
cortical	1110	1118		|O
and	1119	1122		|O
thalamic	1123	1131		|O
structures	1132	1142		|O
with	1143	1147		|O
a	1148	1149		|O
possible	1150	1158		|O
rhythmic	1159	1167		|O
triggering	1168	1178		|O
by	1179	1181		|O
the	1182	1185		|O
lateral	1186	1193		|O
thalamus	1194	1202		|O
.	1202	1203		|O
Most	1204	1208		|O
neurotransmitters	1209	1226		|O
are	1227	1230		|O
involved	1231	1239		|O
in	1240	1242		|O
the	1243	1246		|O
control	1247	1254		|O
of	1255	1257		|O
SWD	1258	1261		|O
(	1262	1263		|O
dopamine	1263	1271	dopamine	|B-TRIVIAL
,	1271	1272		|O
noradrenaline	1273	1286	noradrenaline	|B-TRIVIAL
,	1286	1287		|O
NMDA	1288	1292	NMDA	|B-ABBREVIATION
,	1292	1293		|O
acetylcholine	1294	1307	acetylcholine	|B-TRIVIAL
)	1307	1308		|O
,	1308	1309		|O
but	1310	1313		|O
GABA	1314	1318	GABA 	|B-ABBREVIATION
and	1319	1322		|O
gamma	1323	1328	gamma-hydroxybutyrate	|B-IUPAC
-	1328	1329		|I-IUPAC
hydroxybutyrate	1329	1344		|I-IUPAC
(	1345	1346		|O
GHB	1346	1349	GHB	|B-ABBREVIATION
)	1349	1350		|O
seem	1351	1355		|O
to	1356	1358		|O
play	1359	1363		|O
a	1364	1365		|O
critical	1366	1374		|O
role	1375	1379		|O
.	1379	1380		|O
SWD	1381	1384		|O
are	1385	1388		|O
genetically	1389	1400		|O
determined	1401	1411		|O
with	1412	1416		|O
an	1417	1419		|O
autosomal	1420	1429		|O
dominant	1430	1438		|O
inheritance	1439	1450		|O
.	1450	1451		|O
The	1452	1455		|O
variable	1456	1464		|O
expression	1465	1475		|O
of	1476	1478		|O
SWD	1479	1482		|O
in	1483	1485		|O
offsprings	1486	1496		|O
from	1497	1501		|O
GAERS	1502	1507		|O
x	1508	1509		|O
control	1510	1517		|O
reciprocal	1518	1528		|O
crosses	1529	1536		|O
may	1537	1540		|O
be	1541	1543		|O
due	1544	1547		|O
to	1548	1550		|O
the	1551	1554		|O
existence	1555	1564		|O
of	1565	1567		|O
multiple	1568	1576		|O
genes	1577	1582		|O
.	1582	1583		|O
Neurophysiological	1584	1602		|O
,	1602	1603		|O
behavioural	1604	1615		|O
,	1615	1616		|O
pharmacological	1617	1632		|O
and	1633	1636		|O
genetic	1637	1644		|O
studies	1645	1652		|O
demonstrate	1653	1664		|O
that	1665	1669		|O
spontaneous	1670	1681		|O
SWD	1682	1685		|O
in	1686	1688		|O
GAERS	1689	1694		|O
fulfill	1695	1702		|O
all	1703	1706		|O
the	1707	1710		|O
requirements	1711	1723		|O
for	1724	1727		|O
an	1728	1730		|O
experimental	1731	1743		|O
model	1744	1749		|O
of	1750	1752		|O
absence	1753	1760		|O
epilepsy	1761	1769		|O
.	1769	1770		|O
As	1771	1773		|O
the	1774	1777		|O
mechanisms	1778	1788		|O
underlying	1789	1799		|O
absence	1800	1807		|O
epilepsy	1808	1816		|O
in	1817	1819		|O
humans	1820	1826		|O
are	1827	1830		|O
still	1831	1836		|O
unknown	1837	1844		|O
,	1844	1845		|O
the	1846	1849		|O
analysis	1850	1858		|O
of	1859	1861		|O
the	1862	1865		|O
genetic	1866	1873		|O
thalamocortical	1874	1889		|O
dysfunction	1890	1901		|O
in	1902	1904		|O
GAERS	1905	1910		|O
may	1911	1914		|O
be	1915	1917		|O
fruitful	1918	1926		|O
in	1927	1929		|O
investigations	1930	1944		|O
of	1945	1947		|O
the	1948	1951		|O
pathogenesis	1952	1964		|O
of	1965	1967		|O
generalized	1968	1979		|O
non	1980	1983		|O
-	1983	1984		|O
convulsive	1984	1994		|O
seizures	1995	2003		|O
.	2003	2004		|O

### 11879044
Diphenol	10	18	Diphenol	|B-FAMILY
activation	19	29		|O
of	30	32		|O
the	33	36		|O
monophenolase	37	50		|O
and	51	54		|O
diphenolase	55	66		|O
activities	67	77		|O
of	78	80		|O
field	81	86		|O
bean	87	91		|O
(	92	93		|O
Dolichos	93	101		|O
lablab	102	108		|O
)	108	109		|O
polyphenol	110	120		|O
oxidase	121	128		|O
.	128	129		|O
This	131	135		|O
paper	136	141		|O
reports	142	149		|O
a	150	151		|O
study	152	157		|O
on	158	160		|O
the	161	164		|O
hydroxylation	165	178		|O
of	179	181		|O
ferulic	182	189	ferulic acid	|B-IUPAC
acid	190	194		|I-IUPAC
and	195	198		|O
tyrosine	199	207	tyrosine	|B-TRIVIAL
by	208	210		|O
field	211	216		|O
bean	217	221		|O
(	222	223		|O
Dolichos	223	231		|O
lablab	232	238		|O
)	238	239		|O
polyphenol	240	250		|O
oxidase	251	258		|O
,	258	259		|O
a	260	261		|O
reaction	262	270		|O
that	271	275		|O
does	276	280		|O
not	281	284		|O
take	285	289		|O
place	290	295		|O
without	296	303		|O
the	304	307		|O
addition	308	316		|O
of	317	319		|O
catechol	320	328	catechol	|B-TRIVIAL
.	328	329		|O
A	330	331		|O
lag	332	335		|O
period	336	342		|O
similar	343	350		|O
to	351	353		|O
the	354	357		|O
characteristic	358	372		|O
lag	373	376		|O
of	377	379		|O
tyrosinase	380	390		|O
activity	391	399		|O
was	400	403		|O
observed	404	412		|O
,	412	413		|O
the	414	417		|O
length	418	424		|O
of	425	427		|O
which	428	433		|O
decreased	434	443		|O
with	444	448		|O
increasing	449	459		|O
catechol	460	468	catechol	|B-TRIVIAL
concentration	469	482		|O
and	483	486		|O
increased	487	496		|O
with	497	501		|O
increasing	502	512		|O
ferulic	513	520	ferulic acid	|B-IUPAC
acid	521	525		|I-IUPAC
concentration	526	539		|O
.	539	540		|O
The	541	544		|O
activation	545	555		|O
constant	556	564		|O
K	565	566		|O
(	566	567		|O
a	567	568		|O
)	568	569		|O
of	570	572		|O
catechol	573	581	catechol	|B-TRIVIAL
for	582	585		|O
ferulic	586	593	ferulic acid	|B-IUPAC
acid	594	598		|I-IUPAC
hydroxylation	599	612		|O
reaction	613	621		|O
was	622	625		|O
5	626	627		|O
mM	628	630		|O
.	630	631		|O
The	632	635		|O
kinetic	636	643		|O
parameters	644	654		|O
of	655	657		|O
field	658	663		|O
bean	664	668		|O
polyphenol	669	679		|O
oxidase	680	687		|O
toward	688	694		|O
ferulic	695	702	ferulic acid	|B-IUPAC
acid	703	707		|I-IUPAC
and	708	711		|O
tyrosine	712	720	tyrosine	|B-TRIVIAL
were	721	725		|O
evaluated	726	735		|O
in	736	738		|O
the	739	742		|O
presence	743	751		|O
of	752	754		|O
catechol	755	763	catechol	|B-TRIVIAL
.	763	764		|O
4	765	766	4-Methyl catechol	|B-IUPAC
-	766	767		|I-IUPAC
Methyl	767	773		|I-IUPAC
catechol	774	782		|I-IUPAC
,	782	783		|O
L	784	785	L-dihydroxyphenylalanine	|B-IUPAC
-	785	786		|I-IUPAC
dihydroxyphenylalanine	786	808		|I-IUPAC
,	808	809		|O
pyrogallol	810	820	pyrogallol	|B-TRIVIAL
,	820	821		|O
and	822	825		|O
2,3,4	826	831	2,3,4-trihydroxybenzoic acid	|B-IUPAC
-	831	832		|I-IUPAC
trihydroxybenzoic	832	849		|I-IUPAC
acid	850	854		|I-IUPAC
,	854	855		|O
substrates	856	866		|O
with	867	871		|O
high	872	876		|O
binding	877	884		|O
affinity	885	893		|O
to	894	896		|O
field	897	902		|O
bean	903	907		|O
polyphenol	908	918		|O
oxidase	919	926		|O
,	926	927		|O
could	928	933		|O
stimulate	934	943		|O
this	944	948		|O
hydroxylation	949	962		|O
reaction	963	971		|O
.	971	972		|O
In	973	975		|O
contrast	976	984		|O
,	984	985		|O
diphenols	986	995	diphenols	|B-FAMILY
such	996	1000		|O
as	1001	1003		|O
protocatechuic	1004	1018	protocatechuic acid	|B-IUPAC
acid	1019	1023		|I-IUPAC
,	1023	1024		|O
gallic	1025	1031	gallic acid	|B-IUPAC
acid	1032	1036		|I-IUPAC
,	1036	1037		|O
chlorogenic	1038	1049	chlorogenic acid	|B-IUPAC
acid	1050	1054		|I-IUPAC
,	1054	1055		|O
and	1056	1059		|O
caffeic	1060	1067	caffeic acid	|B-IUPAC
acid	1068	1072		|I-IUPAC
,	1072	1073		|O
which	1074	1079		|O
were	1080	1084		|O
not	1085	1088		|O
substrates	1089	1099		|O
for	1100	1103		|O
the	1104	1107		|O
oxidation	1108	1117		|O
reaction	1118	1126		|O
,	1126	1127		|O
were	1128	1132		|O
unable	1133	1139		|O
to	1140	1142		|O
bring	1143	1148		|O
about	1149	1154		|O
this	1155	1159		|O
activation	1160	1170		|O
.	1170	1171		|O
It	1172	1174		|O
is	1175	1177		|O
most	1178	1182		|O
likely	1183	1189		|O
that	1190	1194		|O
only	1195	1199		|O
o	1200	1201	o-diphenols	|B-FAMILY
-	1201	1202		|I-FAMILY
diphenols	1202	1211		|I-FAMILY
that	1212	1216		|O
are	1217	1220		|O
substrates	1221	1231		|O
for	1232	1235		|O
the	1236	1239		|O
diphenolase	1240	1251		|O
serve	1252	1257		|O
as	1258	1260		|O
cosubstrates	1261	1273		|O
by	1274	1276		|O
donating	1277	1285		|O
electrons	1286	1295		|O
at	1296	1298		|O
the	1299	1302		|O
active	1303	1309		|O
site	1310	1314		|O
for	1315	1318		|O
the	1319	1322		|O
monophenolase	1323	1336		|O
activity	1337	1345		|O
.	1345	1346		|O
The	1347	1350		|O
reaction	1351	1359		|O
mechanism	1360	1369		|O
for	1370	1373		|O
this	1374	1378		|O
activation	1379	1389		|O
is	1390	1392		|O
consistent	1393	1403		|O
with	1404	1408		|O
that	1409	1413		|O
proposed	1414	1422		|O
for	1423	1426		|O
tyrosinase	1427	1437		|O
(	1438	1439		|O
Sanchez	1439	1446		|O
-	1446	1447		|O
Ferrer	1447	1453		|O
,	1453	1454		|O
A	1455	1456		|O
.	1456	1457		|O
;	1457	1458		|O
Rodriguez	1459	1468		|O
-	1468	1469		|O
Lopez	1469	1474		|O
,	1474	1475		|O
J	1476	1477		|O
.	1477	1478		|O
N	1479	1480		|O
.	1480	1481		|O
;	1481	1482		|O
Garcia	1483	1489		|O
-	1489	1490		|O
Canovas	1490	1497		|O
,	1497	1498		|O
F	1499	1500		|O
.	1500	1501		|O
;	1501	1502		|O
Garcia	1503	1509		|O
-	1509	1510		|O
Carmona	1510	1517		|O
,	1517	1518		|O
F	1519	1520		|O
.	1520	1521		|O
Biochim	1522	1529		|O
.	1529	1530		|O
Biophys	1531	1538		|O
.	1538	1539		|O
Acta	1540	1544		|O
1995	1545	1549		|O
,	1549	1550		|O
1247	1551	1555		|O
,	1555	1556		|O
1-11	1557	1561		|O
)	1561	1562		|O
.	1562	1563		|O
The	1564	1567		|O
presence	1568	1576		|O
of	1577	1579		|O
o	1580	1581	o-diphenols	|B-FAMILY
-	1581	1582		|I-FAMILY
diphenols	1582	1591		|I-FAMILY
,	1591	1592		|O
viz	1593	1596		|O
.	1596	1597		|O
catechol	1598	1606	catechol	|B-TRIVIAL
,	1606	1607		|O
L	1608	1609	L-dihydroxyphenylalanine	|B-IUPAC
-	1609	1610		|I-IUPAC
dihydroxyphenylalanine	1610	1632		|I-IUPAC
,	1632	1633		|O
and	1634	1637		|O
4	1638	1639	4-methyl catechol	|B-IUPAC
-	1639	1640		|I-IUPAC
methyl	1640	1646		|I-IUPAC
catechol	1647	1655		|I-IUPAC
,	1655	1656		|O
is	1657	1659		|O
also	1660	1664		|O
necessary	1665	1674		|O
for	1675	1678		|O
the	1679	1682		|O
oxidation	1683	1692		|O
of	1693	1695		|O
the	1696	1699		|O
diphenols	1700	1709	diphenols	|B-FAMILY
,	1709	1710		|O
caffeic	1711	1718	caffeic acid	|B-TRIVIAL
acid	1719	1723		|I-TRIVIAL
,	1723	1724		|O
and	1725	1728		|O
catechin	1729	1737	catechin	|B-TRIVIAL
to	1738	1740		|O
their	1741	1746		|O
quinones	1747	1755	quinones	|B-FAMILY
by	1756	1758		|O
the	1759	1762		|O
field	1763	1768		|O
bean	1769	1773		|O
polyphenol	1774	1784		|O
oxidase	1785	1792		|O
.	1792	1793		|O
This	1794	1798		|O
oxidation	1799	1808		|O
reaction	1809	1817		|O
occurs	1818	1824		|O
immediately	1825	1836		|O
with	1837	1841		|O
no	1842	1844		|O
lag	1845	1848		|O
period	1849	1855		|O
and	1856	1859		|O
does	1860	1864		|O
not	1865	1868		|O
occur	1869	1874		|O
without	1875	1882		|O
the	1883	1886		|O
addition	1887	1895		|O
of	1896	1898		|O
diphenol	1899	1907	diphenol	|B-FAMILY
.	1907	1908		|O
The	1909	1912		|O
kinetic	1913	1920		|O
parameters	1921	1931		|O
for	1932	1935		|O
caffeic	1936	1943	caffeic acid	|B-TRIVIAL
acid	1944	1948		|I-TRIVIAL
(	1949	1950		|O
K	1950	1951		|O
(	1951	1952		|O
m	1952	1953		|O
)	1953	1954		|O
=	1955	1956		|O
0.08	1957	1961		|O
mM	1962	1964		|O
,	1964	1965		|O
V	1966	1967		|O
(	1967	1968		|O
max	1968	1971		|O
)	1971	1972		|O
=	1973	1974		|O
u	1981	1982		|O
/	1982	1983		|O
mg	1983	1985		|O
)	1985	1986		|O
in	1987	1989		|O
the	1990	1993		|O
presence	1994	2002		|O
of	2003	2005		|O
catechol	2006	2014	catechol	|B-TRIVIAL
and	2015	2018		|O
the	2019	2022		|O
activation	2023	2033		|O
constant	2034	2042		|O
K	2043	2044		|O
(	2044	2045		|O
a	2045	2046		|O
)	2046	2047		|O
of	2048	2050		|O
catechol	2051	2059	catechol	|B-TRIVIAL
(	2060	2061		|O
4.6	2061	2064		|O
mM	2065	2067		|O
)	2067	2068		|O
for	2069	2072		|O
this	2073	2077		|O
reaction	2078	2086		|O
were	2087	2091		|O
enumerated	2092	2102		|O
.	2102	2103		|O
The	2104	2107		|O
absence	2108	2115		|O
of	2116	2118		|O
a	2119	2120		|O
lag	2121	2124		|O
period	2125	2131		|O
for	2132	2135		|O
this	2136	2140		|O
reaction	2141	2149		|O
indicates	2150	2159		|O
that	2160	2164		|O
the	2165	2168		|O
diphenol	2169	2177	diphenol	|B-FAMILY
mechanism	2178	2187		|O
of	2188	2190		|O
diphenolase	2191	2202		|O
activation	2203	2213		|O
differs	2214	2221		|O
from	2222	2226		|O
the	2227	2230		|O
way	2231	2234		|O
in	2235	2237		|O
which	2238	2243		|O
the	2244	2247		|O
same	2248	2252		|O
o	2253	2254	o-diphenols	|B-FAMILY
-	2254	2255		|I-FAMILY
diphenols	2255	2264		|I-FAMILY
activate	2264	2272		|O
the	2274	2277		|O
monophenolase	2278	2291		|O
activity	2292	2300		|O
.	2300	2301		|O

### 8960550
In	0	2		|O
the	3	6		|O
present	7	14		|O
investigation	15	28		|O
,	28	29		|O
the	30	33		|O
last	34	38		|O
two	39	42		|O
possible	43	51		|O
modes	52	57		|O
of	58	60		|O
generating	61	71		|O
conformationally	72	88		|O
semirigid	89	98		|O
diacylglycerol	99	113	diacylglycerol	|B-TRIVIAL
(	114	115		|O
DAG	115	118	DAG	|B-ABBREVIATION
)	118	119		|O
analogues	120	129	analogues	|B-MODIFIER
embedded	130	138		|O
into	139	143		|O
five	144	148		|O
-	148	149		|O
membered	149	157		|O
ring	158	162		|O
lactones	163	171	lactones	|B-FAMILY
as	172	174		|O
templates	175	184		|O
III	185	188		|O
and	189	192		|O
IV	193	195		|O
are	196	199		|O
investigated	200	212		|O
.	212	213		|O
The	214	217		|O
first	218	223		|O
two	224	227		|O
templates	228	237		|O
studied	238	245		|O
in	246	248		|O
previous	249	257		|O
investigations	258	272		|O
corresponded	273	285		|O
to	286	288		|O
2	289	290	2-deoxyribonolactone	|B-IUPAC
-	290	291		|I-IUPAC
deoxyribonolactone	291	309		|I-IUPAC
(	310	311		|O
template	311	319		|O
I	320	321		|O
)	321	322		|O
and	323	326		|O
4,4	327	330	4,4-disubstituted gamma-butyrolactone	|B-IUPAC
-	330	331		|I-IUPAC
disubstituted	331	344		|I-IUPAC
gamma	345	350		|I-IUPAC
-	350	351		|I-IUPAC
butyrolactone	351	364		|I-IUPAC
(	365	366		|O
template	366	374		|O
II	375	377		|O
)	377	378		|O
,	378	379		|O
with	380	384		|O
the	385	388		|O
latter	389	395		|O
producing	396	405		|O
potent	406	412		|O
protein	413	420		|O
kinase	421	427		|O
C	428	429		|O
(	430	431		|O
PK	431	433		|O
-	433	434		|O
C	434	435		|O
)	435	436		|O
ligands	437	444		|O
with	445	449		|O
low	450	453		|O
nanomolar	454	463		|O
binding	464	471		|O
affinities	472	482		|O
.	482	483		|O
The	484	487		|O
templates	488	497		|O
reported	498	506		|O
in	507	509		|O
this	510	514		|O
work	515	519		|O
correspond	520	530		|O
to	531	533		|O
2,3	534	537	2,3-dideoxy-L-erythro-	|B-PARTIUPAC
-	537	538		|I-PARTIUPAC
dideoxy	538	545		|I-PARTIUPAC
-	545	546		|I-PARTIUPAC
L	546	547		|I-PARTIUPAC
-	547	548		|I-PARTIUPAC
erythro	548	555		|I-PARTIUPAC
-	555	556		|I-PARTIUPAC
or	557	559		|O
-	560	561	-threo-hexono-1,4-lactone	|B-IUPAC
threo	561	566		|I-IUPAC
-	566	567		|I-IUPAC
hexono	567	573		|I-IUPAC
-	573	574		|I-IUPAC
1,4	574	577		|I-IUPAC
-	577	578		|I-IUPAC
lactone	578	585		|I-IUPAC
(	586	587		|O
template	587	595		|O
III	596	599		|O
)	599	600		|O
and	601	604		|O
2	605	606	2-deoxyapiolactone	|B-IUPAC
-	606	607		|I-IUPAC
deoxyapiolactone	607	623		|I-IUPAC
(	624	625		|O
template	625	633		|O
IV	634	636		|O
)	636	637		|O
.	637	638		|O
Compounds	639	648		|O
constructed	649	660		|O
with	661	665		|O
the	666	669		|O
dideoxy	670	677	dideoxy-L-erythro-	|B-PARTIUPAC
-	677	678		|I-PARTIUPAC
L	678	679		|I-PARTIUPAC
-	679	680		|I-PARTIUPAC
erythro	680	687		|I-PARTIUPAC
-	687	688		|I-PARTIUPAC
or	689	691		|O
-	692	693	-threo-hexono-1,4-lactone	|B-IUPAC
threo	693	698		|I-IUPAC
-	698	699		|I-IUPAC
hexono	699	705		|I-IUPAC
-	705	706		|I-IUPAC
1,4	706	709		|I-IUPAC
-	709	710		|I-IUPAC
lactone	710	717		|I-IUPAC
template	718	726		|O
were	727	731		|O
synthesized	732	743		|O
stereospecifically	744	762		|O
from	763	767		|O
tri	768	771	tri-O-acetyl-L-glucal	|B-IUPAC
-	771	772		|I-IUPAC
O	772	773		|I-IUPAC
-	773	774		|I-IUPAC
acetyl	774	780		|I-IUPAC
-	780	781		|I-IUPAC
L	781	782		|I-IUPAC
-	782	783		|I-IUPAC
glucal	783	789		|I-IUPAC
and	790	793		|O
L	794	795	L-galactono-1,4-lactone	|B-IUPAC
-	795	796		|I-IUPAC
galactono	796	805		|I-IUPAC
-	805	806		|I-IUPAC
1,4	806	809		|I-IUPAC
-	809	810		|I-IUPAC
lactone	810	817		|I-IUPAC
,	817	818		|O
respectively	819	831		|O
.	831	832		|O
Compounds	833	842		|O
constructed	843	854		|O
with	855	859		|O
the	860	863		|O
2	864	865	2-deoxyapiolactone	|B-IUPAC
-	865	866		|I-IUPAC
deoxyapiolactone	866	882		|I-IUPAC
template	883	891		|O
were	892	896		|O
synthesized	897	908		|O
stereoselectively	909	926		|O
from	927	931		|O
di	932	934	di-O-isopropylidene-alpha-D-apiose	|B-IUPAC
-	934	935		|I-IUPAC
O	935	936		|I-IUPAC
-	936	937		|I-IUPAC
isopropylidene	937	951		|I-IUPAC
-	951	952		|I-IUPAC
alpha	952	957		|I-IUPAC
-	957	958		|I-IUPAC
D	958	959		|I-IUPAC
-	959	960		|I-IUPAC
apiose	960	966		|I-IUPAC
.	966	967		|O
Inhibition	968	978		|O
of	979	981		|O
the	982	985		|O
binding	986	993		|O
of	994	996		|O
[	997	998	[3H]phorbol-12,13-dibutyrate	|B-IUPAC
3H	998	1000		|I-IUPAC
]	1000	1001		|I-IUPAC
phorbol	1001	1008		|I-IUPAC
-	1008	1009		|I-IUPAC
12,13	1009	1014		|I-IUPAC
-	1014	1015		|I-IUPAC
dibutyrate	1015	1025		|I-IUPAC
to	1026	1028		|O
PK	1029	1031		|O
-	1031	1032		|O
C	1032	1033		|O
alpha	1034	1039		|O
showed	1040	1046		|O
that	1047	1051		|O
only	1052	1056		|O
the	1057	1060		|O
threo	1061	1066	threo-isomer	|B-FAMILY
-	1066	1067		|I-FAMILY
isomer	1067	1073		|I-FAMILY
,	1073	1074		|O
5	1075	1076	5-O-tetradecanoyl-2,3-dideoxy-L-threo-hexono-1,4-lactone	|B-IUPAC
-	1076	1077		|I-IUPAC
O	1077	1078		|I-IUPAC
-	1078	1079		|I-IUPAC
tetradecanoyl	1079	1092		|I-IUPAC
-	1092	1093		|I-IUPAC
2,3	1093	1096		|I-IUPAC
-	1096	1097		|I-IUPAC
dideoxy	1097	1104		|I-IUPAC
-	1104	1105		|I-IUPAC
L	1105	1106		|I-IUPAC
-	1106	1107		|I-IUPAC
threo	1107	1112		|I-IUPAC
-	1112	1113		|I-IUPAC
hexono	1113	1119		|I-IUPAC
-	1119	1120		|I-IUPAC
1,4	1120	1123		|I-IUPAC
-	1123	1124		|I-IUPAC
lactone	1124	1131		|I-IUPAC
(	1132	1133		|O
2	1133	1134		|O
)	1134	1135		|O
was	1136	1139		|O
a	1140	1141		|O
good	1142	1146		|O
PK	1147	1149		|O
-	1149	1150		|O
C	1150	1151		|O
ligand	1152	1158		|O
(	1159	1160		|O
Ki	1160	1162		|O
=	1163	1164		|O
1	1165	1166		|O
microM	1167	1173		|O
)	1173	1174		|O
.	1174	1175		|O
The	1176	1179		|O
rest	1180	1184		|O
of	1185	1187		|O
the	1188	1191		|O
ligands	1192	1199		|O
had	1200	1203		|O
poorer	1204	1210		|O
affinities	1211	1221		|O
with	1222	1226		|O
Ki	1227	1229		|O
values	1230	1236		|O
between	1237	1244		|O
and	1248	1251		|O
28	1252	1254		|O
microM	1255	1261		|O
.	1261	1262		|O
With	1263	1267		|O
these	1268	1273		|O
results	1274	1281		|O
,	1281	1282		|O
the	1283	1286		|O
order	1287	1292		|O
of	1293	1295		|O
importance	1296	1306		|O
of	1307	1309		|O
five	1310	1314		|O
-	1314	1315		|O
membered	1315	1323		|O
ring	1324	1328		|O
lactones	1329	1337	lactones	|B-FAMILY
as	1338	1340		|O
competent	1341	1350		|O
templates	1351	1360		|O
for	1361	1364		|O
the	1365	1368		|O
construction	1369	1381		|O
of	1382	1384		|O
semirigid	1385	1394		|O
DAG	1395	1398	DAG	|B-ABBREVIATION
surrogates	1398	1408		|O
with	1410	1414		|O
effective	1415	1424		|O
PK	1425	1427		|O
-	1427	1428		|O
C	1428	1429		|O
binding	1430	1437		|O
affinity	1438	1446		|O
can	1447	1450		|O
be	1451	1453		|O
established	1454	1465		|O
as	1466	1468		|O
II	1469	1471		|O
&	1472	1473		|O
gt	1473	1475		|O
;	1475	1476		|O
&	1476	1477		|O
gt	1477	1479		|O
;	1479	1480		|O
I	1481	1482		|O
approximately	1483	1496		|O
III	1497	1500		|O
&	1501	1502		|O
gt	1502	1504		|O
;	1504	1505		|O
IV	1506	1508		|O
.	1508	1509		|O

### 7473576
Hypoxic	0	7		|O
cells	8	13		|O
are	14	17		|O
an	18	20		|O
important	21	30		|O
target	31	37		|O
for	38	41		|O
antitumor	42	51		|O
therapy	52	59		|O
because	60	67		|O
tumors	68	74		|O
are	75	78		|O
typically	79	88		|O
characterized	89	102		|O
by	103	105		|O
such	106	110		|O
cells	111	116		|O
.	116	117		|O
Virtually	118	127		|O
all	128	131		|O
tumors	132	138		|O
which	139	144		|O
are	145	148		|O
present	149	156		|O
as	157	159		|O
solid	160	165		|O
masses	166	172		|O
contain	173	180		|O
hypoxic	181	188		|O
cells	189	194		|O
,	194	195		|O
while	196	201		|O
normal	202	208		|O
cells	209	214		|O
generally	215	224		|O
have	225	229		|O
an	230	232		|O
adequate	233	241		|O
supply	242	248		|O
of	249	251		|O
oxygen	252	258		|O
.	258	259		|O
Accordingly	260	271		|O
,	271	272		|O
antitumor	273	282		|O
agents	283	289		|O
can	290	293		|O
be	294	296		|O
made	297	301		|O
selective	302	311		|O
for	312	315		|O
tumors	316	322		|O
by	323	325		|O
virtue	326	332		|O
of	333	335		|O
high	336	340		|O
activity	341	349		|O
under	350	355		|O
hypoxic	356	363		|O
conditions	364	374		|O
.	374	375		|O
The	376	379		|O
initial	380	387		|O
purpose	388	395		|O
of	396	398		|O
this	399	403		|O
work	404	408		|O
was	409	412		|O
to	413	415		|O
determine	416	425		|O
the	426	429		|O
influence	430	439		|O
of	440	442		|O
different	443	452		|O
groups	453	459		|O
in	460	462		|O
position	463	471		|O
3	472	473		|O
.	473	474		|O
Thus	475	479		|O
,	479	480		|O
the	481	484		|O
synthesis	485	494		|O
of	495	497		|O
some	498	502		|O
3	503	504	3-NH-substituted	|B-PARTIUPAC
-	504	505		|I-PARTIUPAC
NH	505	507		|I-PARTIUPAC
-	507	508		|I-PARTIUPAC
substituted	508	519		|I-PARTIUPAC
derivatives	520	531	derivatives	|B-MODIFIER
(	532	533		|O
2a	533	535		|O
,	535	536		|O
3a	537	539		|O
,	539	540		|O
4a	541	543		|O
)	543	544		|O
starting	545	553		|O
from	554	558		|O
3	559	560	3-amino-2-quinoxalinecarbonitrile 1,4-di-N-oxide	|B-IUPAC
-	560	561		|I-IUPAC
amino	561	566		|I-IUPAC
-	566	567		|I-IUPAC
2	567	568		|I-IUPAC
-	568	569		|I-IUPAC
quinoxalinecarbonitrile	569	592		|I-IUPAC
1,4	593	596		|I-IUPAC
-	596	597		|I-IUPAC
di	597	599		|I-IUPAC
-	599	600		|I-IUPAC
N	600	601		|I-IUPAC
-	601	602		|I-IUPAC
oxide	602	607		|I-IUPAC
(	608	609		|O
1a	609	611		|O
)	611	612		|O
is	613	615		|O
described	616	625		|O
.	625	626		|O
Reductive	627	636		|O
deamination	637	648		|O
of	649	651		|O
compounds	652	661		|O
1a	662	664		|O
-	664	665		|O
k	665	666		|O
provides	667	675		|O
the	676	679		|O
2	680	681	2-quinoxalinecarbonitriles	|B-IUPAC
-	681	682		|I-IUPAC
quinoxalinecarbonitriles	682	706		|I-IUPAC
5a	707	709		|O
-	709	710		|O
k	710	711		|O
,	711	712		|O
which	713	718		|O
are	719	722		|O
more	723	727		|O
potent	728	734		|O
,	734	735		|O
while	736	741		|O
selectivity	742	753		|O
is	754	756		|O
maintained	757	767		|O
or	768	770		|O
increased	771	780		|O
in	781	783		|O
some	784	788		|O
derivatives	789	800		|O
.	800	801		|O
The	802	805		|O
compound	806	814		|O
7	815	816	7-(4-nitrophenyl)-2-quinoxalinecarbonitrile 1,4-di-N-oxide	|B-IUPAC
-	816	817		|I-IUPAC
(	817	818		|I-IUPAC
4	818	819		|I-IUPAC
-	819	820		|I-IUPAC
nitrophenyl	820	831		|I-IUPAC
)	831	832		|I-IUPAC
-	832	833		|I-IUPAC
2	833	834		|I-IUPAC
-	834	835		|I-IUPAC
quinoxalinecarbonitrile	835	858		|I-IUPAC
1,4	859	862		|I-IUPAC
-	862	863		|I-IUPAC
di	863	865		|I-IUPAC
-	865	866		|I-IUPAC
N	866	867		|I-IUPAC
-	867	868		|I-IUPAC
oxide	868	873		|I-IUPAC
(	874	875		|O
5k	875	877		|O
)	877	878		|O
is	879	881		|O
-	885	886		|O
fold	886	890		|O
more	891	895		|O
potent	896	902		|O
than	903	907		|O
tirapazamine	908	920	tirapazamine	|B-TRIVIAL
(	921	922		|O
3	922	923	3-amino-1,2,4- benzotriazine 1,4-di-N-oxide	|B-IUPAC
-	923	924		|I-IUPAC
amino	924	929		|I-IUPAC
-	929	930		|I-IUPAC
1,2,4	930	935		|I-IUPAC
-	935	936		|I-IUPAC
benzotriazine	937	950		|I-IUPAC
1,4	951	954		|I-IUPAC
-	954	955		|I-IUPAC
di	955	957		|I-IUPAC
-	957	958		|I-IUPAC
N	958	959		|I-IUPAC
-	959	960		|I-IUPAC
oxide	960	965		|I-IUPAC
)	965	966		|O
,	966	967		|O
which	968	973		|O
has	974	977		|O
been	978	982		|O
used	983	987		|O
as	988	990		|O
a	991	992		|O
standard	993	1001		|O
.	1001	1002		|O
Three	1003	1008		|O
derivatives	1009	1020		|O
(	1021	1022		|O
5g	1022	1024		|O
,	1024	1025		|O
i	1025	1026		|O
,	1026	1027		|O
k	1027	1028		|O
)	1028	1029		|O
show	1030	1034		|O
a	1035	1036		|O
hypoxic	1037	1044		|O
cytotoxicity	1045	1057		|O
ratio	1058	1063		|O
(	1064	1065		|O
HCR	1065	1068		|O
)	1068	1069		|O
&	1070	1071		|O
gt	1071	1073		|O
;	1073	1074		|O
or	1075	1077		|O
=	1078	1079		|O
,	1083	1084		|O
better	1085	1091		|O
than	1092	1096		|O
that	1097	1101		|O
of	1102	1104		|O
tirapazamine	1105	1117	tirapazamine	|B-TRIVIAL
(	1118	1119		|O
HCR	1119	1122		|O
=	1123	1124		|O
75	1125	1127		|O
)	1127	1128		|O
in	1129	1131		|O
V79	1132	1135		|O
cells	1136	1141		|O
.	1141	1142		|O
Replacement	1143	1154		|O
of	1155	1157		|O
the	1158	1161		|O
3	1162	1163	3-amino	|B-PARTIUPAC
-	1163	1164		|I-PARTIUPAC
amino	1164	1169		|I-PARTIUPAC
group	1170	1175	group	|B-MODIFIER
by	1176	1178		|O
chlorine	1179	1187	chlorine	|B-TRIVIAL
affords	1188	1195		|O
the	1196	1199		|O
potent	1200	1206		|O
but	1207	1210		|O
nonselective	1211	1223		|O
3	1224	1225	3-chloro	|B-PARTIUPAC
-	1225	1226		|I-PARTIUPAC
chloro	1226	1232		|I-PARTIUPAC
derivatives	1233	1244	derivatives	|B-MODIFIER
6a	1245	1247		|O
-	1247	1248		|O
k	1248	1249		|O
showing	1250	1257		|O
similar	1258	1265		|O
toxicities	1266	1276		|O
under	1277	1282		|O
both	1283	1287		|O
aerobic	1288	1295		|O
and	1296	1299		|O
hypoxic	1300	1307		|O
conditions	1308	1318		|O
.	1318	1319		|O
These	1320	1325		|O
compounds	1326	1335		|O
were	1336	1340		|O
used	1341	1345		|O
as	1346	1348		|O
intermediates	1349	1362		|O
for	1363	1366		|O
the	1367	1370		|O
synthesis	1371	1380		|O
of	1381	1383		|O
a	1384	1385		|O
new	1386	1389		|O
series	1390	1396		|O
of	1397	1399		|O
water	1400	1405		|O
-	1405	1406		|O
soluble	1406	1413		|O
compounds	1414	1423		|O
derived	1424	1431		|O
from	1432	1436		|O
3	1437	1438	3-[[(N,N- dialkylamino)alkyl[amino]-2-quinoxalinecarbonitrile 1,4-di-N-oxides	|B-IUPAC
-	1438	1439		|I-IUPAC
[	1439	1440		|I-IUPAC
[	1440	1441		|I-IUPAC
(	1441	1442		|I-IUPAC
N	1442	1443		|I-IUPAC
,	1443	1444		|I-IUPAC
N	1444	1445		|I-IUPAC
-	1445	1446		|I-IUPAC
dialkylamino	1447	1459		|I-IUPAC
)	1459	1460		|I-IUPAC
alkyl	1460	1465		|I-IUPAC
[	1465	1466		|I-IUPAC
amino	1466	1471		|I-IUPAC
]	1471	1472		|I-IUPAC
-	1472	1473		|I-IUPAC
2	1473	1474		|I-IUPAC
-	1474	1475		|I-IUPAC
quinoxalinecarbonitrile	1475	1498		|I-IUPAC
1,4	1499	1502		|I-IUPAC
-	1502	1503		|I-IUPAC
di	1503	1505		|I-IUPAC
-	1505	1506		|I-IUPAC
N	1506	1507		|I-IUPAC
-	1507	1508		|I-IUPAC
oxides	1508	1514		|I-IUPAC
-	1518	1519		|O
i	1519	1520		|O
and	1521	1524		|O
11a	1525	1528		|O
-	1528	1529		|O
i	1529	1530		|O
.	1530	1531		|O
The	1532	1535		|O
7	1536	1537	7-chloro	|B-PARTIUPAC
-	1537	1538		|I-PARTIUPAC
chloro	1538	1544		|I-PARTIUPAC
and	1545	1548		|O
the	1549	1552		|O
7	1553	1554	7-trifluoromethyl	|B-PARTIUPAC
-	1554	1555		|I-PARTIUPAC
trifluoromethyl	1555	1570		|I-PARTIUPAC
derivatives	1571	1582	derivatives	|B-MODIFIER
,	1586	1587		|O
f	1587	1588		|O
have	1589	1593		|O
demonstrated	1594	1606		|O
high	1607	1611		|O
potency	1612	1619		|O
(	1620	1621		|O
0.4	1621	1624		|O
and	1625	1628		|O
0.3	1629	1632		|O
microM	1633	1639		|O
)	1639	1640		|O
and	1641	1644		|O
excellent	1645	1654		|O
selectivity	1655	1666		|O
(	1667	1668		|O
HCR	1668	1671		|O
=	1672	1673		|O
and	1678	1681		|O
)	1685	1686		|O
.	1686	1687		|O
Several	1688	1695		|O
7	1696	1697	7-chloro	|B-PARTIUPAC
-	1697	1698		|I-PARTIUPAC
chloro	1698	1704		|I-PARTIUPAC
analogues	1705	1714	analogues	|B-MODIFIER
,	1714	1715		|O
12b	1716	1719		|O
,	1719	1720		|O
13b	1721	1724		|O
.1	1724	1726		|O
,	1726	1727		|O
b	1727	1728		|O
.2	1728	1730		|O
,	1730	1731		|O
and	1732	1735		|O
14b	1736	1739		|O
,	1739	1740		|O
and	1741	1744		|O
the	1745	1748		|O
dimer	1749	1754		|O
16b	1755	1758		|O
have	1759	1763		|O
been	1764	1768		|O
prepared	1769	1777		|O
and	1778	1781		|O
evaluated	1782	1791		|O
in	1792	1794		|O
order	1795	1800		|O
to	1801	1803		|O
determine	1804	1813		|O
the	1814	1817		|O
optimum	1818	1825		|O
lateral	1826	1833		|O
chain	1834	1839		|O
in	1840	1842		|O
position	1843	1851		|O
3	1852	1853		|O
,	1853	1854		|O
which	1855	1860		|O
appears	1861	1868		|O
to	1869	1871		|O
be	1872	1874		|O
the	1875	1878		|O
[	1879	1880		|O
(	1880	1881	(N,N-dimethylamino)propyl]amino	|B-PARTIUPAC
N	1881	1882		|I-PARTIUPAC
,	1882	1883		|I-PARTIUPAC
N	1883	1884		|I-PARTIUPAC
-	1884	1885		|I-PARTIUPAC
dimethylamino	1885	1898		|I-PARTIUPAC
)	1898	1899		|I-PARTIUPAC
propyl	1899	1905		|I-PARTIUPAC
]	1905	1906		|I-PARTIUPAC
amino	1906	1911		|I-PARTIUPAC
moiety	1912	1918	moiety	|B-MODIFIER
.	1918	1919		|O

### 8654448
8654448	0	7		|O
Activity	9	17		|O
of	18	20		|O
beta	21	25		|O
-	25	26		|O
lactamase	26	35		|O
inhibitor	36	45		|O
combinations	46	58		|O
on	59	61		|O
Escherichia	62	73		|O
coli	74	78		|O
isolates	79	87		|O
exhibiting	88	98		|O
various	99	106		|O
patterns	107	115		|O
of	116	118		|O
resistance	119	129		|O
to	130	132		|O
beta	133	137	beta-lactam	|B-FAMILY
-	137	138		|I-FAMILY
lactam	138	144		|I-FAMILY
agents	145	151		|O
.	151	152		|O
The	154	157		|O
efficacy	158	166		|O
of	167	169		|O
the	170	173		|O
clinically	174	184		|O
available	185	194		|O
beta	195	199		|O
-	199	200		|O
lactam	200	206		|O
/	206	207		|O
beta	207	211		|O
-	211	212		|O
lactamase	212	221		|O
inhibitor	222	231		|O
combinations	232	244		|O
(	245	246		|O
amoxicillin	246	257	amoxicillin	|B-TRIVIAL
/	257	258		|O
clavulanic	258	268	clavulanic acid	|B-TRIVIAL
acid	269	273		|I-TRIVIAL
(	274	275		|O
CA	275	277	CA	|B-ABBREVIATION
)	277	278		|O
,	278	279		|O
ticarcillin	280	291	ticarcillin	|B-TRIVIAL
/	291	292		|O
CA	292	294	CA	|B-ABBREVIATION
,	294	295		|O
amoxicillin	296	307	amoxicillin	|B-TRIVIAL
/	307	308		|O
sulbactam	308	317	sulbactam	|B-TRIVIAL
,	317	318		|O
and	319	322		|O
piperacillin	323	335	piperacillin	|B-TRIVIAL
/	335	336		|O
tazobactam	336	346	tazobactam	|B-TRIVIAL
)	346	347		|O
was	348	351		|O
evaluated	352	361		|O
on	362	364		|O
amoxicillin	369	380	amoxicillin	|B-TRIVIAL
-	380	381		|O
resistant	381	390		|O
Escherichia	391	402		|O
coli	403	407		|O
isolates	408	416		|O
having	417	423		|O
the	424	427		|O
main	428	432		|O
patterns	433	441		|O
of	442	444		|O
beta	445	449	beta-lactam	|B-FAMILY
-	449	450		|I-FAMILY
lactam	450	456		|I-FAMILY
resistance	457	467		|O
.	467	468		|O
The	469	472		|O
patterns	473	481		|O
,	481	482		|O
which	483	488		|O
reflect	489	496		|O
the	497	500		|O
production	501	511		|O
of	512	514		|O
various	515	522		|O
beta	523	527		|O
-	527	528		|O
lactamase	528	537		|O
enzymes	538	545		|O
,	545	546		|O
were	547	551		|O
analyzed	552	560		|O
by	561	563		|O
a	564	565		|O
principal	566	575		|O
component	576	585		|O
analysis	586	594		|O
of	595	597		|O
susceptibility	598	612		|O
to	613	615		|O
11	616	618		|O
beta	619	623	beta-lactam	|B-FAMILY
-	623	624		|I-FAMILY
lactam	624	630		|I-FAMILY
antibiotics	631	642		|O
or	643	645		|O
beta	646	650	beta-lactam	|B-FAMILY
-	650	651		|I-FAMILY
lactam	651	657		|I-FAMILY
/	657	658		|O
beta	658	662		|O
-	662	663		|O
lactamase	663	672		|O
inhibitor	673	682		|O
combinations	683	695		|O
.	695	696		|O
Sixty	697	702		|O
-	702	703		|O
two	703	706		|O
percent	707	714		|O
of	715	717		|O
strains	718	725		|O
were	726	730		|O
not	731	734		|O
very	735	739		|O
susceptible	740	751		|O
to	752	754		|O
penicillins	755	766	penicillins	|B-TRIVIAL
,	766	767		|O
cephalothin	768	779	cephalothin	|B-TRIVIAL
,	779	780		|O
or	781	783		|O
any	784	787		|O
beta	788	792	beta-lactam	|B-FAMILY
-	792	793		|I-FAMILY
lactam	793	799		|I-FAMILY
/	799	800		|O
beta	800	804		|O
-	804	805		|O
lactamase	805	814		|O
inhibitor	815	824		|O
combinations	825	837		|O
except	838	844		|O
for	845	848		|O
piperacillin	849	861	piperacillin	|B-TRIVIAL
/	861	862		|O
tazobactam	862	872	tazobactam	|B-TRIVIAL
;	872	873		|O
these	874	879		|O
strains	880	887		|O
may	888	891		|O
represent	892	901		|O
high	902	906		|O
-	906	907		|O
level	907	912		|O
broad	913	918		|O
-	918	919		|O
spectrum	919	927		|O
beta	928	932		|O
-	932	933		|O
lactamase	933	942		|O
(	943	944		|O
so	944	946		|O
-	946	947		|O
called	947	953		|O
penicillinase	954	967		|O
)	967	968		|O
production	969	979		|O
phenotype	980	989		|O
or	990	992		|O
inhibitor	993	1002		|O
-	1002	1003		|O
resistant	1003	1012		|O
TEM	1013	1016		|O
-	1016	1017		|O
like	1017	1021		|O
enzyme	1022	1028		|O
production	1029	1039		|O
phenotype	1040	1049		|O
.	1049	1050		|O
Of	1051	1053		|O
the	1054	1057		|O
strains	1058	1065		|O
,	1065	1066		|O
14.7%	1067	1072		|O
were	1073	1077		|O
resistant	1078	1087		|O
to	1088	1090		|O
amoxicillin	1091	1102	amoxicillin	|B-TRIVIAL
and	1103	1106		|O
ticarcillin	1106	1117	 ticarcillin	|B-TRIVIAL
compatible	1119	1129		|O
with	1130	1134		|O
low	1135	1138		|O
-	1138	1139		|O
level	1139	1144		|O
broad	1145	1150		|O
-	1150	1151		|O
spectrum	1151	1159		|O
beta	1160	1164		|O
-	1164	1165		|O
lactamase	1165	1174		|O
production	1175	1185		|O
phenotype	1186	1195		|O
;	1195	1196		|O
5.7%	1197	1201		|O
were	1202	1206		|O
cefoxitin	1207	1216	cefoxitin	|B-TRIVIAL
resistant	1217	1226		|O
and	1227	1230		|O
were	1231	1235		|O
postulated	1236	1246		|O
to	1247	1249		|O
present	1250	1257		|O
a	1258	1259		|O
high	1260	1264		|O
-	1264	1265		|O
level	1265	1270		|O
cephalosporinase	1271	1287		|O
production	1288	1298		|O
phenotype	1299	1308		|O
;	1308	1309		|O
and	1310	1313		|O
2.6%	1314	1318		|O
were	1319	1323		|O
resistant	1324	1333		|O
to	1334	1336		|O
cephalothin	1337	1348	cephalothin	|B-TRIVIAL
only	1349	1353		|O
,	1353	1354		|O
attributable	1355	1367		|O
to	1368	1370		|O
a	1371	1372		|O
low	1373	1376		|O
-	1376	1377		|O
level	1377	1382		|O
cephalosporinase	1383	1399		|O
production	1400	1410		|O
phenotype	1411	1420		|O
.	1420	1421		|O
Three	1422	1427		|O
percent	1428	1435		|O
of	1436	1438		|O
strains	1439	1446		|O
were	1447	1451		|O
intermediate	1452	1464		|O
or	1465	1467		|O
resistant	1468	1477		|O
to	1478	1480		|O
cefotaxime	1481	1491	cefotaxime	|B-TRIVIAL
and	1492	1495		|O
may	1496	1499		|O
produce	1500	1507		|O
an	1508	1510		|O
extended	1511	1519		|O
-	1519	1520		|O
spectrum	1520	1528		|O
beta	1529	1533		|O
-	1533	1534		|O
lactamase	1534	1543		|O
,	1543	1544		|O
and	1545	1548		|O
the	1549	1552		|O
remaining	1553	1562		|O
strains	1563	1570		|O
(	1571	1572		|O
12	1572	1574		|O
%	1575	1576		|O
)	1576	1577		|O
,	1577	1578		|O
resistant	1579	1588		|O
to	1589	1591		|O
all	1592	1595		|O
tested	1596	1602		|O
antibiotics	1603	1614		|O
except	1615	1621		|O
for	1622	1625		|O
cefotaxime	1626	1636	cefotaxime	|B-TRIVIAL
and	1637	1640		|O
piperacillin	1641	1653	piperacillin	|B-TRIVIAL
/	1653	1654		|O
tazobactam	1654	1664	tazobactam	|B-TRIVIAL
,	1664	1665		|O
were	1666	1670		|O
hypothesized	1671	1683		|O
to	1684	1686		|O
produce	1687	1694		|O
both	1695	1699		|O
broad	1700	1705		|O
-	1705	1706		|O
spectrum	1706	1714		|O
beta	1715	1719		|O
-	1719	1720		|O
lactamase	1720	1729		|O
plus	1730	1734		|O
cephalosporinase	1735	1751		|O
.	1751	1752		|O
The	1753	1756		|O
minimal	1757	1764		|O
inhibitory	1765	1775		|O
concentration	1776	1789		|O
(	1790	1791		|O
MIC	1791	1794		|O
)	1794	1795		|O
for	1796	1799		|O
these	1800	1805		|O
phenotype	1806	1815		|O
patterns	1816	1824		|O
indicated	1825	1834		|O
that	1835	1839		|O
combinations	1840	1852		|O
of	1853	1855		|O
CA	1856	1858	CA	|B-ABBREVIATION
plus	1859	1863		|O
amoxicillin	1864	1875	amoxicillin	|B-TRIVIAL
or	1876	1878		|O
ticarcillin	1879	1890	ticarcillin	|B-TRIVIAL
,	1890	1891		|O
or	1892	1894		|O
sulbactam	1895	1904	sulbactam	|B-TRIVIAL
plus	1905	1909		|O
amoxicillin	1910	1921	amoxicillin	|B-TRIVIAL
,	1921	1922		|O
restored	1923	1931		|O
the	1932	1935		|O
activity	1936	1944		|O
of	1945	1947		|O
penicillins	1948	1959	penicillins	|B-TRIVIAL
against	1960	1967		|O
phenotype	1968	1977		|O
1	1978	1979		|O
strains	1980	1987		|O
,	1987	1988		|O
whereas	1989	1996		|O
these	1997	2002		|O
combinations	2003	2015		|O
remained	2016	2024		|O
inactive	2025	2033		|O
against	2034	2041		|O
the	2042	2045		|O
other	2046	2051		|O
phenotype	2052	2061		|O
strains	2062	2069		|O
.	2069	2070		|O
Piperacillin	2071	2083	Piperacillin	|B-TRIVIAL
plus	2084	2088		|O
tazobactam	2089	2099	tazobactam	|B-TRIVIAL
showed	2099	2105		|O
the	2107	2110		|O
best	2111	2115		|O
in	2116	2118		|O
vitro	2119	2124		|O
effect	2125	2131		|O
against	2132	2139		|O
the	2140	2143		|O
strains	2144	2151		|O
of	2152	2154		|O
all	2155	2158		|O
resistance	2159	2169		|O
phenotypes	2170	2180		|O
.	2180	2181		|O

### 4032426
The	0	3		|O
syntheses	4	13		|O
and	14	17		|O
anthelmintic	18	30		|O
activities	31	41		|O
of	42	44		|O
31	45	47		|O
3	48	49	3-	|B-PARTIUPAC
-	49	50		|I-PARTIUPAC
and	51	54		|O
5	55	56	5-(isothiocyanatophenyl)-1,2,4-oxadiazoles	|B-IUPAC
-	56	57		|I-IUPAC
(	57	58		|I-IUPAC
isothiocyanatophenyl	58	78		|I-IUPAC
)	78	79		|I-IUPAC
-	79	80		|I-IUPAC
1,2,4	80	85		|I-IUPAC
-	85	86		|I-IUPAC
oxadiazoles	86	97		|I-IUPAC
are	98	101		|O
reported	102	110		|O
.	110	111		|O
In	112	114		|O
the	115	118		|O
primary	119	126		|O
anthelmintic	127	139		|O
screen	140	146		|O
,	146	147		|O
3	148	149	3-(4-isothiocyanatophenyl)-1,2,4-oxadiazole	|B-IUPAC
-	149	150		|I-IUPAC
(	150	151		|I-IUPAC
4	151	152		|I-IUPAC
-	152	153		|I-IUPAC
isothiocyanatophenyl	153	173		|I-IUPAC
)	173	174		|I-IUPAC
-	174	175		|I-IUPAC
1,2,4	175	180		|I-IUPAC
-	180	181		|I-IUPAC
oxadiazole	181	191		|I-IUPAC
(	192	193		|O
39	193	195		|O
)	195	196		|O
showed	197	203		|O
nematocidal	209	220		|O
activity	221	229		|O
and	230	233		|O
3	234	235	3-(2-furanyl)-5-(4-isothiocyanatophenyl)-1,2,4-oxadiazole	|B-IUPAC
-	235	236		|I-IUPAC
(	236	237		|I-IUPAC
2	237	238		|I-IUPAC
-	238	239		|I-IUPAC
furanyl	239	246		|I-IUPAC
)	246	247		|I-IUPAC
-	247	248		|I-IUPAC
5	248	249		|I-IUPAC
-	249	250		|I-IUPAC
(	250	251		|I-IUPAC
4	251	252		|I-IUPAC
-	252	253		|I-IUPAC
isothiocyanatophenyl	253	273		|I-IUPAC
)	273	274		|I-IUPAC
-	274	275		|I-IUPAC
1,2,4	275	280		|I-IUPAC
-	280	281		|I-IUPAC
oxadiazole	281	291		|I-IUPAC
(	292	293		|O
63	293	295		|O
)	295	296		|O
,	296	297		|O
3	298	299	3-(2-furanyl)-5-(2-chloro-4-isothiocyanatophenyl)-1,2,4-oxadiazole	|B-IUPAC
-	299	300		|I-IUPAC
(	300	301		|I-IUPAC
2	301	302		|I-IUPAC
-	302	303		|I-IUPAC
furanyl	303	310		|I-IUPAC
)	310	311		|I-IUPAC
-	311	312		|I-IUPAC
5	312	313		|I-IUPAC
-	313	314		|I-IUPAC
(	314	315		|I-IUPAC
2	315	316		|I-IUPAC
-	316	317		|I-IUPAC
chloro	317	323		|I-IUPAC
-	323	324		|I-IUPAC
4	324	325		|I-IUPAC
-	325	326		|I-IUPAC
isothiocyanatophenyl	326	346		|I-IUPAC
)	346	347		|I-IUPAC
-	347	348		|I-IUPAC
1,2,4	348	353		|I-IUPAC
-	353	354		|I-IUPAC
oxadiazole	354	364		|I-IUPAC
(	365	366		|O
64	366	368		|O
)	368	369		|O
,	369	370		|O
and	371	374		|O
3	375	376	3-(2-furanyl)-5-(4-chloro-3-isothiocyanatophenyl)-1,2,4-oxadiazole	|B-IUPAC
-	376	377		|I-IUPAC
(	377	378		|I-IUPAC
2	378	379		|I-IUPAC
-	379	380		|I-IUPAC
furanyl	380	387		|I-IUPAC
)	387	388		|I-IUPAC
-	388	389		|I-IUPAC
5	389	390		|I-IUPAC
-	390	391		|I-IUPAC
(	391	392		|I-IUPAC
4	392	393		|I-IUPAC
-	393	394		|I-IUPAC
chloro	394	400		|I-IUPAC
-	400	401		|I-IUPAC
3	401	402		|I-IUPAC
-	402	403		|I-IUPAC
isothiocyanatophenyl	403	423		|I-IUPAC
)	423	424		|I-IUPAC
-	424	425		|I-IUPAC
1,2,4	425	430		|I-IUPAC
-	430	431		|I-IUPAC
oxadiazole	431	441		|I-IUPAC
(	441	442		|O
66	443	445		|O
)	445	446		|O
showed	447	453		|O
taeniacidal	459	470		|O
activity	471	479		|O
when	480	484		|O
administered	485	497		|O
orally	498	504		|O
to	505	507		|O
mice	508	512		|O
.	512	513		|O
The	514	517		|O
two	518	521		|O
most	522	526		|O
active	527	533		|O
members	534	541		|O
of	542	544		|O
this	545	549		|O
series	550	556		|O
,	556	557		|O
39	558	560		|O
and	561	564		|O
63	565	567		|O
,	567	568		|O
were	569	573		|O
active	574	580		|O
against	581	588		|O
the	589	592		|O
gastrointestinal	593	609		|O
nematodes	610	619		|O
of	620	622		|O
sheep	623	628		|O
at	629	631		|O
mg	636	638		|O
/	638	639		|O
kg	639	641		|O
.	641	642		|O
In	643	645		|O
addition	646	654		|O
,	654	655		|O
39	656	658		|O
was	659	662		|O
also	663	667		|O
found	668	673		|O
to	674	676		|O
be	677	679		|O
active	680	686		|O
against	687	694		|O
hookworms	695	704		|O
in	705	707		|O
dogs	708	712		|O
at	713	715		|O
a	716	717		|O
single	718	724		|O
,	724	725		|O
oral	726	730		|O
dose	731	735		|O
of	736	738		|O
mg	743	745		|O
/	745	746		|O
kg	746	748		|O
.	748	749		|O

### 10823345
Allopurinol	10	21	Allopurinol	|B-TRIVIAL
induces	22	29		|O
renal	30	35		|O
toxicity	36	44		|O
by	45	47		|O
impairing	48	57		|O
pyrimidine	58	68	pyrimidine	|B-FAMILY
metabolism	69	79		|O
in	80	82		|O
mice	83	87		|O
.	87	88		|O
We	90	92		|O
investigated	93	105		|O
the	106	109		|O
relationship	110	122		|O
between	123	130		|O
the	131	134		|O
toxic	135	140		|O
effect	141	147		|O
of	148	150		|O
allopurinol	151	162	allopurinol	|B-TRIVIAL
and	163	166		|O
pyrimidine	167	177	pyrimidine	|B-FAMILY
metabolism	178	188		|O
in	189	191		|O
mice	192	196		|O
.	196	197		|O
Allopurinol	198	209	Allopurinol	|B-TRIVIAL
-	209	210		|O
induced	210	217		|O
increases	218	227		|O
in	228	230		|O
plasma	231	237		|O
transaminase	238	250		|O
levels	251	257		|O
in	258	260		|O
dinitrofluorobenzene	261	281	dinitrofluorobenzene	|B-TRIVIAL
(	282	283		|O
DNFB	283	287	DNFB	|B-ABBREVIATION
)	287	288		|O
-	288	289		|O
sensitized	289	299		|O
mice	300	304		|O
were	305	309		|O
not	310	313		|O
affected	314	322		|O
by	323	325		|O
uridine	326	333	uridine	|B-TRIVIAL
.	333	334		|O
In	335	337		|O
contrast	338	346		|O
,	346	347		|O
plasma	348	354		|O
creatinine	355	365	creatinine	|B-TRIVIAL
and	366	369		|O
BUN	370	373		|O
tended	374	380		|O
to	381	383		|O
decrease	384	392		|O
18	393	395		|O
hr	396	398		|O
after	399	404		|O
the	405	408		|O
last	409	413		|O
injection	414	423		|O
of	424	426		|O
uridine	427	434	uridine	|B-TRIVIAL
.	434	435		|O
Both	436	440		|O
plasma	441	447		|O
and	448	451		|O
urinary	452	459		|O
orotidine	460	469	orotidine	|B-TRIVIAL
(	470	471		|O
OD	471	473	OD	|B-ABBREVIATION
)	473	474		|O
were	475	479		|O
detected	480	488		|O
in	489	491		|O
DNFB	492	496		|O
-	496	497		|O
sensitized	497	507		|O
mice	508	512		|O
after	513	518		|O
administration	519	533		|O
of	534	536		|O
a	537	538		|O
single	539	545		|O
dose	546	550		|O
of	551	553		|O
allopurinol	554	565	allopurinol	|B-TRIVIAL
.	565	566		|O
In	567	569		|O
contrast	570	578		|O
,	578	579		|O
TEI	580	583	TEI-6720	|B-TRIVIALVAR
-	583	584		|I-TRIVIALVAR
,	588	589		|O
a	590	591		|O
newly	592	597		|O
synthesized	598	609		|O
xanthine	610	618		|O
oxidase	619	626		|O
/	626	627		|O
xanthine	627	635		|O
dehydrogenase	636	649		|O
inhibitor	650	659		|O
,	659	660		|O
caused	661	667		|O
neither	668	675		|O
pyrimidine	676	686	pyrimidine	|B-FAMILY
metabolism	687	697		|O
abnormality	698	709		|O
nor	710	713		|O
renal	714	719		|O
impairment	720	730		|O
in	731	733		|O
DNFB	734	738	DNFB	|B-ABBREVIATION
-	738	739		|O
sensitized	739	749		|O
mice	750	754		|O
.	754	755		|O
Also	756	760		|O
,	760	761		|O
normal	762	768		|O
mice	769	773		|O
administered	774	786		|O
high	787	791		|O
doses	792	797		|O
of	798	800		|O
allopurinol	801	812	allopurinol	|B-TRIVIAL
showed	813	819		|O
abnormal	820	828		|O
pyrimidine	829	839	pyrimidine	|B-FAMILY
metabolism	840	850		|O
together	851	859		|O
with	860	864		|O
renal	865	870		|O
toxicity	871	879		|O
which	880	885		|O
could	886	891		|O
be	892	894		|O
ameliorated	895	906		|O
by	907	909		|O
uridine	910	917	uridine	|B-TRIVIAL
,	917	918		|O
indicating	919	929		|O
that	930	934		|O
allopurinol	935	946	allopurinol	|B-TRIVIAL
essentially	947	958		|O
causes	959	965		|O
pyrimidine	966	976	pyrimidine	|B-FAMILY
metabolism	977	987		|O
abnormality	988	999		|O
leading	1000	1007		|O
to	1008	1010		|O
renal	1011	1016		|O
impairment	1017	1027		|O
.	1027	1028		|O
In	1029	1031		|O
DNFB	1032	1036		|O
-	1036	1037		|O
sensitized	1037	1047		|O
mice	1048	1052		|O
,	1052	1053		|O
allopurinol	1054	1065	allopurinol	|B-TRIVIAL
increased	1066	1075		|O
urinary	1076	1083		|O
OD	1084	1086	OD	|B-ABBREVIATION
excretion	1087	1096		|O
to	1097	1099		|O
an	1100	1102		|O
extent	1103	1109		|O
similar	1110	1117		|O
to	1118	1120		|O
that	1121	1125		|O
in	1126	1128		|O
normal	1129	1135		|O
mice	1136	1140		|O
administered	1141	1153		|O
the	1154	1157		|O
same	1158	1162		|O
dose	1163	1167		|O
of	1168	1170		|O
allopurinol	1171	1182	allopurinol	|B-TRIVIAL
.	1182	1183		|O
However	1184	1191		|O
,	1191	1192		|O
renal	1193	1198		|O
impairment	1199	1209		|O
by	1210	1212		|O
allopurinol	1213	1224	allopurinol	|B-TRIVIAL
was	1225	1228		|O
more	1229	1233		|O
striking	1234	1242		|O
in	1243	1245		|O
DNFB	1246	1250		|O
-	1250	1251		|O
sensitized	1251	1261		|O
mice	1262	1266		|O
than	1267	1271		|O
in	1272	1274		|O
normal	1275	1281		|O
mice	1282	1286		|O
.	1286	1287		|O
Histopathological	1288	1305		|O
observations	1306	1318		|O
showed	1319	1325		|O
that	1326	1330		|O
allopurinol	1331	1342	allopurinol	|B-TRIVIAL
induced	1343	1350		|O
calculus	1351	1359		|O
formation	1360	1369		|O
in	1370	1372		|O
the	1373	1376		|O
collecting	1377	1387		|O
tubules	1388	1395		|O
and	1396	1399		|O
papillary	1400	1409		|O
duct	1410	1414		|O
.	1414	1415		|O
Calculus	1416	1424		|O
formation	1425	1434		|O
was	1435	1438		|O
increased	1439	1448		|O
by	1449	1451		|O
DNFB	1452	1456	DNFB	|B-ABBREVIATION
and	1457	1460		|O
decreased	1461	1470		|O
by	1471	1473		|O
uridine	1474	1481	uridine	|B-TRIVIAL
.	1481	1482		|O
These	1483	1488		|O
observations	1489	1501		|O
indicate	1502	1510		|O
that	1511	1515		|O
the	1516	1519		|O
enhancement	1520	1531		|O
of	1532	1534		|O
the	1535	1538		|O
renal	1539	1544		|O
toxicity	1545	1553		|O
of	1554	1556		|O
allopurinol	1557	1568	allopurinol	|B-TRIVIAL
by	1569	1571		|O
DNFB	1572	1576		|O
-	1576	1577		|O
sensitization	1577	1590		|O
may	1591	1594		|O
be	1595	1597		|O
due	1598	1601		|O
to	1602	1604		|O
some	1605	1609		|O
biological	1610	1620		|O
interactions	1621	1633		|O
between	1634	1641		|O
DNFB	1642	1646	DNFB	|B-ABBREVIATION
and	1647	1650		|O
allopurinol	1651	1662	allopurinol	|B-TRIVIAL
.	1662	1663		|O
In	1664	1666		|O
humans	1667	1673		|O
,	1673	1674		|O
it	1675	1677		|O
is	1678	1680		|O
possible	1681	1689		|O
that	1690	1694		|O
there	1695	1700		|O
are	1701	1704		|O
some	1705	1709		|O
biological	1710	1720		|O
interactions	1721	1733		|O
which	1734	1739		|O
serve	1740	1745		|O
to	1746	1748		|O
enhance	1749	1756		|O
the	1757	1760		|O
toxicity	1761	1769		|O
of	1770	1772		|O
allopurinol	1773	1784	allopurinol	|B-TRIVIAL
,	1784	1785		|O
resulting	1786	1795		|O
in	1796	1798		|O
the	1799	1802		|O
development	1803	1814		|O
of	1815	1817		|O
allopurinol	1818	1829	allopurinol	|B-TRIVIAL
hypersensitivity	1830	1846		|O
syndrome	1847	1855		|O
(	1856	1857		|O
AHS	1857	1860		|O
)	1860	1861		|O
.	1861	1862		|O
In	1863	1865		|O
contrast	1866	1874		|O
,	1874	1875		|O
TEI	1876	1879	TEI-6720	|B-TRIVIALVAR
-	1879	1880		|I-TRIVIALVAR
,	1884	1885		|O
had	1886	1889		|O
no	1890	1892		|O
effect	1893	1899		|O
on	1900	1902		|O
pyrimidine	1903	1913	pyrimidine	|B-FAMILY
metabolism	1913	1923		|O
and	1925	1928		|O
showed	1929	1935		|O
no	1936	1938		|O
toxic	1939	1944		|O
effect	1945	1951		|O
.	1951	1952		|O

### 7490727
The	0	3		|O
determination	4	17		|O
of	18	20		|O
the	21	24		|O
structure	25	34		|O
and	35	38		|O
function	39	47		|O
of	48	50		|O
the	51	54		|O
sigma	55	60		|O
receptor	61	69		|O
subtypes	70	78		|O
and	79	82		|O
their	83	88		|O
physiological	89	102		|O
role	103	107		|O
(	107	108		|O
s	108	109		|O
)	109	110		|O
has	111	114		|O
been	115	119		|O
impeded	120	127		|O
by	128	130		|O
the	131	134		|O
unavailability	135	149		|O
of	150	152		|O
selective	153	162		|O
ligands	163	170		|O
.	170	171		|O
We	172	174		|O
have	175	179		|O
developed	180	189		|O
a	190	191		|O
new	192	195		|O
class	196	201		|O
of	202	204		|O
sigma	205	210		|O
subtype	211	218		|O
selective	219	228		|O
receptor	229	237		|O
ligands	238	245		|O
that	246	250		|O
are	251	254		|O
(	255	256	(E)-8-benzylidene	|B-IUPAC
E	256	257		|I-IUPAC
)	257	258		|I-IUPAC
-	258	259		|I-IUPAC
8	259	260		|I-IUPAC
-	260	261		|I-IUPAC
benzylidene	261	272		|I-IUPAC
derivatives	273	284	derivatives	|B-MODIFIER
of	285	287		|O
the	288	291		|O
synthetic	292	301		|O
opioid	302	308		|O
(	309	310	(+/-)-	|B-PARTIUPAC
+	310	311		|I-PARTIUPAC
/	311	312		|I-PARTIUPAC
-	312	313		|I-PARTIUPAC
)	313	314		|I-PARTIUPAC
-	314	315		|I-PARTIUPAC
,	315	316		|O
(	317	318	(+)-	|B-PARTIUPAC
+	318	319		|I-PARTIUPAC
)	319	320		|I-PARTIUPAC
-	320	321		|I-PARTIUPAC
,	321	322		|O
and	323	326		|O
(	327	328	(-)-2-methyl-5-(3-hydroxyphenyl)morphan-7-one	|B-IUPAC
-	328	329		|I-IUPAC
)	329	330		|I-IUPAC
-	330	331		|I-IUPAC
2	331	332		|I-IUPAC
-	332	333		|I-IUPAC
methyl	333	339		|I-IUPAC
-	339	340		|I-IUPAC
5	340	341		|I-IUPAC
-	341	342		|I-IUPAC
(	342	343		|I-IUPAC
3	343	344		|I-IUPAC
-	344	345		|I-IUPAC
hydroxyphenyl	345	358		|I-IUPAC
)	358	359		|I-IUPAC
morphan	359	366		|I-IUPAC
-	366	367		|I-IUPAC
7	367	368		|I-IUPAC
-	368	369		|I-IUPAC
one	369	372		|I-IUPAC
(	373	374		|O
1	374	375		|O
)	375	376		|O
.	376	377		|O
The	378	381		|O
derivatives	382	393		|O
can	394	397		|O
be	398	400		|O
prepared	401	409		|O
by	410	412		|O
reaction	413	421		|O
of	422	424		|O
1	425	426		|O
,	426	427		|O
(	428	429		|O
+	429	430		|O
)	430	431		|O
-	431	432		|O
1	432	433		|O
,	433	434		|O
and	435	438		|O
(	439	440		|O
-	440	441		|O
)	441	442		|O
-	442	443		|O
1	443	444		|O
with	445	449		|O
the	450	453		|O
appropriate	454	465		|O
benzaldehyde	466	478	benzaldehyde	|B-TRIVIAL
under	479	484		|O
Claisen	485	492		|O
-	492	493		|O
Schmidt	493	500		|O
conditions	501	511		|O
.	511	512		|O
Incorporation	513	526		|O
of	527	529		|O
substituted	530	541		|O
(	542	543	(E)-8-benzylidene	|B-IUPAC
E	543	544		|I-IUPAC
)	544	545		|I-IUPAC
-	545	546		|I-IUPAC
8	546	547		|I-IUPAC
-	547	548		|I-IUPAC
benzylidene	548	559		|I-IUPAC
moieties	560	568	moieties	|B-MODIFIER
onto	569	573		|O
the	574	577		|O
7	578	579		|O
-	579	580		|O
keto	580	584		|O
precursor	585	594		|O
of	595	597		|O
(	598	599	(+)-2-methyl-5-(3-hydroxyphenyl)morphan	|B-IUPAC
+	599	600		|I-IUPAC
)	600	601		|I-IUPAC
-	601	602		|I-IUPAC
2	602	603		|I-IUPAC
-	603	604		|I-IUPAC
methyl	604	610		|I-IUPAC
-	610	611		|I-IUPAC
5	611	612		|I-IUPAC
-	612	613		|I-IUPAC
(	613	614		|I-IUPAC
3	614	615		|I-IUPAC
-	615	616		|I-IUPAC
hydroxyphenyl	616	629		|I-IUPAC
)	629	630		|I-IUPAC
morphan	630	637		|I-IUPAC
,	637	638		|O
(	639	640		|O
+	640	641		|O
)	641	642		|O
-	642	643		|O
1	643	644		|O
,	644	645		|O
produces	646	654		|O
compounds	655	664		|O
(	665	666		|O
-	666	667		|O
)	667	668		|O
-	668	669		|O
2	669	670		|O
through	671	678		|O
(	679	680		|O
-	680	681		|O
)	681	682		|O
-	682	683		|O
7	683	684		|O
(	685	686		|O
5.8-32.0	686	694		|O
nM	695	697		|O
,	697	698		|O
sigma	699	704		|O
1	705	706		|O
)	706	707		|O
,	707	708		|O
which	709	714		|O
have	715	719		|O
between	720	727		|O
a	728	729		|O
25	730	732		|O
-	732	733		|O
and	734	737		|O
131	738	741		|O
-	741	742		|O
fold	742	746		|O
increase	747	755		|O
in	756	758		|O
affinity	759	767		|O
for	768	771		|O
the	772	775		|O
sigma	776	781		|O
1	782	783		|O
receptor	784	792		|O
subtype	793	800		|O
relative	801	809		|O
to	810	812		|O
the	813	816		|O
keto	817	821		|O
precursor	822	831		|O
(	832	833		|O
+	833	834		|O
)	834	835		|O
-	835	836		|O
1	836	837		|O
(	838	839		|O
Ki	839	841		|O
=	842	843		|O
762	844	847		|O
nM	848	850		|O
,	850	851		|O
sigma	852	857		|O
1	858	859		|O
)	859	860		|O
.	860	861		|O
Compound	862	870		|O
(	871	872		|O
-	872	873		|O
)	873	874		|O
-	874	875		|O
2	875	876		|O
is	877	879		|O
the	880	883		|O
most	884	888		|O
selective	889	898		|O
of	899	901		|O
this	902	906		|O
group	907	912		|O
(	913	914		|O
16	914	916		|O
-	916	917		|O
fold	917	921		|O
)	921	922		|O
for	923	926		|O
the	927	930		|O
sigma	931	936		|O
1	937	938		|O
subtype	939	946		|O
versus	947	953		|O
sigma	954	959		|O
2	960	961		|O
.	961	962		|O
Substitution	963	975		|O
of	976	978		|O
an	979	981		|O
(	982	983	(E)-8-benzylidene	|B-IUPAC
E	983	984		|I-IUPAC
)	984	985		|I-IUPAC
-	985	986		|I-IUPAC
8	986	987		|I-IUPAC
-	987	988		|I-IUPAC
benzylidene	988	999		|I-IUPAC
moiety	999	1005		|O
onto	1007	1011		|O
the	1012	1015		|O
7	1016	1017		|O
-	1017	1018		|O
keto	1018	1022		|O
precursor	1023	1032		|O
of	1033	1035		|O
(	1036	1037		|O
-	1037	1038		|O
)	1038	1039		|O
-	1039	1040		|O
2	1040	1041		|O
-	1041	1042		|O
methyl	1042	1048		|O
-	1048	1049		|O
5	1049	1050		|O
-	1050	1051		|O
(	1051	1052		|O
3	1052	1053		|O
-	1053	1054		|O
hydroxyphenyl	1054	1067		|O
)	1067	1068		|O
morphan	1068	1075		|O
,	1075	1076		|O
(	1077	1078		|O
-	1078	1079		|O
)	1079	1080		|O
-	1080	1081		|O
1	1081	1082		|O
,	1082	1083		|O
produces	1084	1092		|O
compounds	1093	1102		|O
(	1103	1104		|O
+	1104	1105		|O
)	1105	1106		|O
-	1106	1107		|O
2	1107	1108		|O
-	1108	1109		|O
(	1109	1110		|O
+	1110	1111		|O
)	1111	1112		|O
-	1112	1113		|O
9	1113	1114		|O
(	1115	1116		|O
6.4-52.6	1116	1124		|O
nM	1125	1127		|O
,	1127	1128		|O
sigma	1129	1134		|O
2	1135	1136		|O
)	1136	1137		|O
,	1137	1138		|O
which	1139	1144		|O
have	1145	1149		|O
at	1150	1152		|O
least	1153	1158		|O
a	1159	1160		|O
475-3906	1161	1169		|O
-	1169	1170		|O
fold	1170	1174		|O
increase	1175	1183		|O
in	1184	1186		|O
affinity	1187	1195		|O
for	1196	1199		|O
the	1200	1203		|O
sigma	1204	1209		|O
2	1210	1211		|O
receptor	1212	1220		|O
subtype	1221	1228		|O
relative	1229	1237		|O
to	1238	1240		|O
the	1241	1244		|O
keto	1245	1249		|O
precursor	1250	1259		|O
(	1260	1261		|O
-	1261	1262		|O
)	1262	1263		|O
-	1263	1264		|O
1	1264	1265		|O
(	1266	1267		|O
Ki	1267	1269		|O
=	1270	1271		|O
25	1272	1274		|O
x	1275	1276		|O
(	1279	1280		|O
3	1280	1281		|O
)	1281	1282		|O
nM	1283	1285		|O
)	1285	1286		|O
.	1286	1287		|O
This	1288	1292		|O
enhancement	1293	1304		|O
of	1305	1307		|O
sigma	1308	1313		|O
2	1314	1315		|O
receptor	1316	1324		|O
affinity	1325	1333		|O
is	1334	1336		|O
accompanied	1337	1348		|O
by	1349	1351		|O
substantial	1352	1363		|O
selectivity	1364	1375		|O
of	1376	1378		|O
all	1379	1382		|O
of	1383	1385		|O
these	1386	1391		|O
dextrorotatory	1392	1406		|O
products	1407	1415		|O
for	1416	1419		|O
the	1420	1423		|O
sigma	1424	1429		|O
2	1430	1431		|O
relative	1432	1440		|O
to	1441	1443		|O
the	1444	1447		|O
sigma	1448	1453		|O
1	1454	1455		|O
subtype	1456	1463		|O
(	1464	1465		|O
32-238	1465	1471		|O
-	1471	1472		|O
fold	1472	1476		|O
)	1476	1477		|O
,	1477	1478		|O
and	1479	1482		|O
thus	1483	1487		|O
,	1487	1488		|O
they	1489	1493		|O
are	1494	1497		|O
among	1498	1503		|O
the	1504	1507		|O
most	1508	1512		|O
sigma	1513	1518		|O
2	1519	1520		|O
selective	1521	1530		|O
compounds	1531	1540		|O
currently	1541	1550		|O
known	1551	1556		|O
.	1556	1557		|O
Furthermore	1558	1569		|O
,	1569	1570		|O
the	1571	1574		|O
sigma	1575	1580		|O
1	1581	1582		|O
subtype	1583	1590		|O
is	1591	1593		|O
highly	1594	1600		|O
enantioselective	1601	1617		|O
for	1618	1621		|O
the	1622	1625		|O
levorotatory	1626	1638		|O
isomers	1639	1646		|O
,	1646	1647		|O
(	1648	1649		|O
-	1649	1650		|O
)	1650	1651		|O
-	1651	1652		|O
2	1652	1653		|O
-	1653	1654		|O
(	1654	1655		|O
-	1655	1656		|O
)	1656	1657		|O
-	1657	1658		|O
7	1658	1659		|O
(	1660	1661		|O
41-1034	1661	1668		|O
-	1668	1669		|O
fold	1669	1673		|O
)	1673	1674		|O
,	1674	1675		|O
whereas	1676	1683		|O
the	1684	1687		|O
sigma	1688	1693		|O
2	1694	1695		|O
subtype	1696	1703		|O
is	1704	1706		|O
only	1707	1711		|O
somewhat	1712	1720		|O
enantioselective	1721	1737		|O
for	1738	1741		|O
the	1742	1745		|O
dextrorotatory	1746	1760		|O
isomers	1761	1768		|O
,	1768	1769		|O
(	1770	1771		|O
+	1771	1772		|O
)	1772	1773		|O
-	1773	1774		|O
2	1774	1775		|O
-	1775	1776		|O
(	1776	1777		|O
+	1777	1778		|O
)	1778	1779		|O
-	1779	1780		|O
7	1780	1781		|O
(	1782	1783		|O
2.6-9.3	1783	1790		|O
-	1790	1791		|O
fold	1791	1795		|O
)	1795	1796		|O
.	1796	1797		|O
All	1798	1801		|O
of	1802	1804		|O
these	1805	1810		|O
derivatives	1811	1822		|O
retain	1823	1829		|O
substantial	1830	1841		|O
affinity	1842	1850		|O
for	1851	1854		|O
the	1855	1858		|O
mu	1859	1861		|O
opioid	1862	1868		|O
receptor	1869	1877		|O
.	1877	1878		|O
Despite	1879	1886		|O
the	1887	1890		|O
high	1891	1895		|O
affinity	1896	1904		|O
of	1905	1907		|O
the	1908	1911		|O
dextrorotatory	1912	1926		|O
derivatives	1927	1938		|O
for	1939	1942		|O
the	1943	1946		|O
mu	1947	1949		|O
opioid	1950	1956		|O
receptor	1957	1965		|O
,	1965	1966		|O
the	1967	1970		|O
high	1971	1975		|O
affinity	1976	1984		|O
and	1985	1988		|O
selectivity	1989	2000		|O
for	2001	2004		|O
sigma	2005	2010		|O
2	2011	2012		|O
over	2013	2017		|O
sigma	2018	2023		|O
1	2024	2025		|O
sites	2026	2031		|O
will	2032	2036		|O
surely	2037	2043		|O
prove	2044	2049		|O
beneficial	2050	2060		|O
as	2061	2063		|O
tools	2064	2069		|O
for	2070	2073		|O
the	2074	2077		|O
delineation	2078	2089		|O
of	2090	2092		|O
the	2093	2096		|O
function	2097	2105		|O
and	2106	2109		|O
physiological	2110	2123		|O
role	2124	2128		|O
of	2129	2131		|O
sigma	2132	2137		|O
2	2138	2139		|O
receptors	2140	2149		|O
.	2149	2150		|O

### 1573637
The	0	3		|O
design	4	10		|O
,	10	11		|O
synthesis	12	21		|O
,	21	22		|O
and	23	26		|O
biological	27	37		|O
evaluation	38	48		|O
of	49	51		|O
several	52	59		|O
unsaturated	60	71	unsaturated acyclonucleosides	|B-FAMILY
acyclonucleosides	72	89		|I-FAMILY
related	90	97		|O
to	98	100		|O
augustmycin	101	112	augustmycin A	|B-TRIVIAL
A	113	114		|I-TRIVIAL
are	115	118		|O
described	119	128		|O
.	128	129		|O
The	130	133		|O
(	134	135	(propargyloxy)methyl acyclonucleoside	|B-IUPAC
propargyloxy	135	147		|I-IUPAC
)	147	148		|I-IUPAC
methyl	148	154		|I-IUPAC
acyclonucleoside	155	171		|I-IUPAC
analogues	172	181	analogues	|B-MODIFIER
of	182	184		|O
6	185	186	6-chloropurine	|B-IUPAC
-	186	187		|I-IUPAC
chloropurine	187	199		|I-IUPAC
,	199	200		|O
adenine	201	208	adenine	|B-TRIVIAL
,	208	209		|O
6	210	211	6-methoxypurine	|B-IUPAC
-	211	212		|I-IUPAC
methoxypurine	212	225		|I-IUPAC
,	225	226		|O
hypoxanthine	227	239	hypoxanthine	|B-TRIVIAL
,	239	240		|O
6	241	242	6-mercaptopurine	|B-IUPAC
-	242	243		|I-IUPAC
mercaptopurine	243	257		|I-IUPAC
,	257	258		|O
and	259	262		|O
azathioprine	263	275	azathioprine	|B-TRIVIAL
have	276	280		|O
been	281	285		|O
prepared	286	294		|O
.	294	295		|O
The	296	299		|O
9	300	301	9-[(propargyloxy)methyl]adenine	|B-IUPAC
-	301	302		|I-IUPAC
[	302	303		|I-IUPAC
(	303	304		|I-IUPAC
propargyloxy	304	316		|I-IUPAC
)	316	317		|I-IUPAC
methyl	317	323		|I-IUPAC
]	323	324		|I-IUPAC
adenine	324	331		|I-IUPAC
(	332	333		|O
5	333	334		|O
)	334	335		|O
and	336	339		|O
9	340	341	9-[(propargyloxy)methyl]hypoxanthine	|B-IUPAC
-	341	342		|I-IUPAC
[	342	343		|I-IUPAC
(	343	344		|I-IUPAC
propargyloxy	344	356		|I-IUPAC
)	356	357		|I-IUPAC
methyl	357	363		|I-IUPAC
]	363	364		|I-IUPAC
hypoxanthine	364	376		|I-IUPAC
(	377	378		|O
12	378	380		|O
)	380	381		|O
analogues	382	391	analogues	|B-MODIFIER
were	392	396		|O
converted	397	406		|O
to	407	409		|O
the	410	413		|O
corresponding	414	427		|O
5'	428	430	5'-tributylstannyl	|B-PARTIUPAC
-	430	431		|I-PARTIUPAC
tributylstannyl	431	446		|I-PARTIUPAC
intermediates	447	460	intermediates	|B-MODIFIER
(	461	462		|O
9	462	463		|O
and	464	467		|O
13	468	470		|O
)	470	471		|O
,	471	472		|O
respectively	473	485		|O
,	485	486		|O
which	487	492		|O
gave	493	497		|O
9	498	499	9-[[[(Z)-5-iodo-5-propenyl]oxy]methyl]adenine	|B-IUPAC
-	499	500		|I-IUPAC
[	500	501		|I-IUPAC
[	501	502		|I-IUPAC
[	502	503		|I-IUPAC
(	503	504		|I-IUPAC
Z	504	505		|I-IUPAC
)	505	506		|I-IUPAC
-	506	507		|I-IUPAC
5	507	508		|I-IUPAC
-	508	509		|I-IUPAC
iodo	509	513		|I-IUPAC
-	513	514		|I-IUPAC
5	514	515		|I-IUPAC
-	515	516		|I-IUPAC
propenyl	516	524		|I-IUPAC
]	524	525		|I-IUPAC
oxy	525	528		|I-IUPAC
]	528	529		|I-IUPAC
methyl	529	535		|I-IUPAC
]	535	536		|I-IUPAC
adenine	536	543		|I-IUPAC
(	544	545		|O
)	547	548		|O
and	549	552		|O
9	553	554	9-[[[(Z)-5-iodo-5-propenyl]oxy]methyl]hypoxanthine	|B-IUPAC
-	554	555		|I-IUPAC
[	555	556		|I-IUPAC
[	556	557		|I-IUPAC
[	557	558		|I-IUPAC
(	558	559		|I-IUPAC
Z	559	560		|I-IUPAC
)	560	561		|I-IUPAC
-	561	562		|I-IUPAC
5	562	563		|I-IUPAC
-	563	564		|I-IUPAC
iodo	564	568		|I-IUPAC
-	568	569		|I-IUPAC
5	569	570		|I-IUPAC
-	570	571		|I-IUPAC
propenyl	571	579		|I-IUPAC
]	579	580		|I-IUPAC
oxy	580	583		|I-IUPAC
]	583	584		|I-IUPAC
methyl	584	590		|I-IUPAC
]	590	591		|I-IUPAC
hypoxanthine	591	603		|I-IUPAC
(	604	605		|O
14	605	607		|O
)	607	608		|O
,	608	609		|O
respectively	610	622		|O
,	622	623		|O
after	624	629		|O
iododestannylation	630	648		|O
.	648	649		|O
The	650	653		|O
[	654	655		|O
125I	655	659		|O
]	659	660		|O
-	660	661		|O
radiolabeled	661	673		|O
congeners	674	683		|O
of	684	686		|O
and	690	693		|O
14	694	696		|O
were	697	701		|O
prepared	702	710		|O
as	711	713		|O
potential	714	723		|O
metabolic	724	733		|O
markers	734	741		|O
.	741	742		|O
Among	743	748		|O
the	749	752		|O
unsaturated	753	764	unsaturated acyclonucleosides	|B-FAMILY
acyclonucleosides	765	782		|I-FAMILY
tested	783	789		|O
,	789	790		|O
9	791	792	9-[(propargyloxy)methyl]-6-chloropurine	|B-IUPAC
-	792	793		|I-IUPAC
[	793	794		|I-IUPAC
(	794	795		|I-IUPAC
propargyloxy	795	807		|I-IUPAC
)	807	808		|I-IUPAC
methyl	808	814		|I-IUPAC
]	814	815		|I-IUPAC
-	815	816		|I-IUPAC
6	816	817		|I-IUPAC
-	817	818		|I-IUPAC
chloropurine	818	830		|I-IUPAC
(	831	832		|O
3	832	833		|O
)	833	834		|O
,	834	835		|O
9	836	837	9-[(propargyloxy)methyl]-6-mercaptopurine	|B-IUPAC
-	837	838		|I-IUPAC
[	838	839		|I-IUPAC
(	839	840		|I-IUPAC
propargyloxy	840	852		|I-IUPAC
)	852	853		|I-IUPAC
methyl	853	859		|I-IUPAC
]	859	860		|I-IUPAC
-	860	861		|I-IUPAC
6	861	862		|I-IUPAC
-	862	863		|I-IUPAC
mercaptopurine	863	877		|I-IUPAC
(	878	879		|O
15	879	881		|O
)	881	882		|O
,	882	883		|O
9	884	885	9-[(propargyloxy)methyl]azathioprine	|B-IUPAC
-	885	886		|I-IUPAC
[	886	887		|I-IUPAC
(	887	888		|I-IUPAC
propargyloxy	888	900		|I-IUPAC
)	900	901		|I-IUPAC
methyl	901	907		|I-IUPAC
]	907	908		|I-IUPAC
azathioprine	908	920		|I-IUPAC
(	921	922		|O
17	922	924		|O
)	924	925		|O
,	925	926		|O
and	927	930		|O
angustmycin	931	942	angustmycin A	|B-TRIVIAL
A	943	944		|I-TRIVIAL
analogue	944	952		|O
showed	957	963		|O
inhibition	964	974		|O
of	975	977		|O
cancer	978	984		|O
cell	985	989		|O
growth	990	996		|O
,	996	997		|O
but	998	1001		|O
only	1002	1006		|O
at	1007	1009		|O
a	1010	1011		|O
minimal	1012	1019		|O
level	1020	1025		|O
,	1025	1026		|O
and	1027	1030		|O
17	1031	1033		|O
also	1034	1038		|O
showed	1039	1045		|O
14%	1046	1049		|O
cancer	1050	1056		|O
cell	1057	1061		|O
death	1062	1067		|O
in	1068	1070		|O
vitro	1071	1076		|O
.	1076	1077		|O
Compound	1078	1086		|O
provided	1090	1098		|O
approximately	1099	1112		|O
protection	1117	1127		|O
against	1128	1135		|O
HIV	1136	1139		|O
at	1140	1142		|O
(	1145	1146		|O
-	1146	1147		|O
4	1147	1148		|O
)	1148	1149		|O
M	1150	1151		|O
concentrations	1152	1166		|O
.	1166	1167		|O
Biodistribution	1168	1183		|O
results	1184	1191		|O
of	1192	1194		|O
[	1195	1196		|O
125I	1196	1200		|O
]	1200	1201		|O
-	1201	1202		|O
in	1205	1207		|O
mice	1208	1212		|O
indicate	1213	1221		|O
that	1222	1226		|O
compound	1227	1235		|O
is	1239	1241		|O
readily	1242	1249		|O
metabolized	1250	1261		|O
via	1262	1265		|O
deiodination	1266	1278		|O
in	1279	1281		|O
vivo	1282	1286		|O
,	1286	1287		|O
possibly	1288	1296		|O
by	1297	1299		|O
serving	1300	1307		|O
as	1308	1310		|O
a	1311	1312		|O
substrate	1313	1322		|O
for	1323	1326		|O
the	1327	1330		|O
enzyme	1331	1337		|O
S	1338	1339		|O
-	1339	1340		|O
adenosyl	1340	1348		|O
-	1348	1349		|O
L	1349	1350		|O
-	1350	1351		|O
homocysteine	1351	1363		|O
hydrolase	1364	1373		|O
.	1373	1374		|O

### 1177256
In	0	2		|O
an	3	5		|O
attempt	6	13		|O
to	14	16		|O
increase	17	25		|O
the	26	29		|O
combined	30	38		|O
toxicity	39	47		|O
of	48	50		|O
the	51	54		|O
metabolic	55	64		|O
end	65	68		|O
-	68	69		|O
products	69	77		|O
[	78	79		|O
acrolein	79	87	acrolein	|B-TRIVIAL
(	88	89		|O
4	89	90		|O
)	90	91		|O
and	92	95		|O
phosphoramide	96	109		|O
mustard	110	117		|O
(	118	119		|O
3	119	120		|O
)	120	121		|O
]	121	122		|O
from	123	127		|O
cyclophosphamide	128	144	cyclophosphamide	|B-TRIVIAL
(	145	146		|O
1	146	147		|O
)	147	148		|O
,	148	149		|O
the	150	153		|O
analog	154	160	analog	|B-MODIFIER
2	161	162	2-[bis(2-chloroethyl)amino]tetrahydro-6-trifluoromethyl-2H-1,3,2-oxazaphosphorine 2-oxide	|B-IUPAC
-	162	163		|I-IUPAC
[	163	164		|I-IUPAC
bis	164	167		|I-IUPAC
(	167	168		|I-IUPAC
2	168	169		|I-IUPAC
-	169	170		|I-IUPAC
chloroethyl	170	181		|I-IUPAC
)	181	182		|I-IUPAC
amino	182	187		|I-IUPAC
]	187	188		|I-IUPAC
tetrahydro	188	198		|I-IUPAC
-	198	199		|I-IUPAC
6	199	200		|I-IUPAC
-	200	201		|I-IUPAC
trifluoromethyl	201	216		|I-IUPAC
-	216	217		|I-IUPAC
2H	217	219		|I-IUPAC
-	219	220		|I-IUPAC
1,3,2	220	225		|I-IUPAC
-	225	226		|I-IUPAC
oxazaphosphorine	226	242		|I-IUPAC
2	243	244		|I-IUPAC
-	244	245		|I-IUPAC
oxide	245	250		|I-IUPAC
(	251	252		|O
2	252	253	2, 6-trifluoromethylcyclophosphamide	|B-IUPAC
,	253	254		|I-IUPAC
6	255	256		|I-IUPAC
-	256	257		|I-IUPAC
trifluoromethylcyclophosphamide	257	288		|I-IUPAC
)	288	289		|O
was	290	293		|O
synthesized	294	305		|O
and	306	309		|O
its	310	313		|O
metabolism	314	324		|O
and	325	328		|O
antitumor	329	338		|O
activity	339	347		|O
studied	348	355		|O
.	355	356		|O
Following	357	366		|O
metabolism	367	377		|O
of	378	380		|O
2	381	382		|O
by	383	385		|O
rat	386	389		|O
liver	390	395		|O
microsomes	396	406		|O
the	407	410		|O
predicted	411	420		|O
formation	421	430		|O
of	431	433		|O
4,4,4	434	439	4,4,4-trifluorocrotonaldehyde	|B-IUPAC
-	439	440		|I-IUPAC
trifluorocrotonaldehyde	440	463		|I-IUPAC
(	464	465		|O
5	465	466		|O
)	466	467		|O
was	468	471		|O
confirmed	472	481		|O
by	482	484		|O
isolation	485	494		|O
and	495	498		|O
identification	499	513		|O
,	513	514		|O
by	515	517		|O
mass	518	522		|O
spectrometry	523	535		|O
,	535	536		|O
of	537	539		|O
its	540	543		|O
dinitrophenylhydrazone	544	566	dinitrophenylhydrazone	|B-TRIVIAL
.	566	567		|O
The	568	571		|O
therapeutic	572	583		|O
indices	584	591		|O
(	592	593		|O
LD50	593	597		|O
-	597	598		|O
/	598	599		|O
ID90	599	603		|O
)	603	604		|O
for	605	608		|O
2	609	610		|O
against	611	618		|O
the	619	622		|O
ADJ	623	626		|O
/	626	627		|O
PC6	627	630		|O
mouse	631	636		|O
tumor	637	642		|O
and	643	646		|O
the	647	650		|O
Walker	651	657		|O
256	658	661		|O
tumor	662	667		|O
in	668	670		|O
the	671	674		|O
rat	675	678		|O
were	679	683		|O
28.6	684	688		|O
and	689	692		|O
7.7	693	696		|O
,	696	697		|O
respectively	698	710		|O
,	710	711		|O
and	712	715		|O
were	716	720		|O
lower	721	726		|O
than	727	731		|O
the	732	735		|O
corresponding	736	749		|O
values	750	756		|O
for	757	760		|O
1	761	762		|O
(	763	764		|O
91.8	764	768		|O
and	769	772		|O
33.2	773	777		|O
,	777	778		|O
respectively	779	791		|O
)	791	792		|O
although	793	801		|O
the	802	805		|O
toxicities	806	816		|O
toward	817	823		|O
Walker	824	830		|O
cells	831	836		|O
in	837	839		|O
a	840	841		|O
bioassay	842	850		|O
system	851	857		|O
of	858	860		|O
1	861	862		|O
and	863	866		|O
2	867	868		|O
following	869	878		|O
microsomal	879	889		|O
metabolism	890	900		|O
were	901	905		|O
similar	906	913		|O
.	913	914		|O
In	915	917		|O
order	918	923		|O
to	924	926		|O
study	927	932		|O
the	933	936		|O
toxicities	937	947		|O
of	948	950		|O
4	951	952		|O
and	953	956		|O
5	957	958		|O
released	959	967		|O
under	968	973		|O
drug	974	978		|O
metabolizing	979	991		|O
conditions	992	1002		|O
independently	1003	1016		|O
of	1017	1019		|O
the	1020	1023		|O
production	1024	1034		|O
of	1035	1037		|O
a	1038	1039		|O
toxic	1040	1045		|O
mustard	1046	1053	mustard	|B-FAMILY
the	1054	1057		|O
analogs	1058	1065	analogs	|B-MODIFIER
18	1066	1068		|O
[	1069	1070		|O
2	1070	1071	2-(diethylamino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide	|B-IUPAC
-	1071	1072		|I-IUPAC
(	1072	1073		|I-IUPAC
diethylamino	1073	1085		|I-IUPAC
)	1085	1086		|I-IUPAC
tetrahydro	1086	1096		|I-IUPAC
-	1096	1097		|I-IUPAC
2H	1097	1099		|I-IUPAC
-	1099	1100		|I-IUPAC
1,3,2	1100	1105		|I-IUPAC
-	1105	1106		|I-IUPAC
oxazaphosphorine	1106	1122		|I-IUPAC
2	1123	1124		|I-IUPAC
-	1124	1125		|I-IUPAC
oxide	1125	1130		|I-IUPAC
]	1130	1131		|O
and	1132	1135		|O
6	1136	1137		|O
[	1138	1139		|O
2	1139	1140	2-(diethylamino)tetrahydro-6-trifluoromethyl-2H-1,3,2-oxazaphosphorine 2-oxide	|B-IUPAC
-	1140	1141		|I-IUPAC
(	1141	1142		|I-IUPAC
diethylamino	1142	1154		|I-IUPAC
)	1154	1155		|I-IUPAC
tetrahydro	1155	1165		|I-IUPAC
-	1165	1166		|I-IUPAC
6	1166	1167		|I-IUPAC
-	1167	1168		|I-IUPAC
trifluoromethyl	1168	1183		|I-IUPAC
-	1183	1184		|I-IUPAC
2H	1184	1186		|I-IUPAC
-	1186	1187		|I-IUPAC
1,3,2	1187	1192		|I-IUPAC
-	1192	1193		|I-IUPAC
oxazaphosphorine	1193	1209		|I-IUPAC
2	1210	1211		|I-IUPAC
-	1211	1212		|I-IUPAC
oxide	1212	1217		|I-IUPAC
]	1217	1218		|O
were	1219	1223		|O
also	1224	1228		|O
synthesized	1229	1240		|O
.	1240	1241		|O
The	1242	1245		|O
release	1246	1253		|O
of	1254	1256		|O
5	1257	1258		|O
from	1259	1263		|O
6	1264	1265		|O
following	1266	1275		|O
metabolism	1276	1286		|O
was	1287	1290		|O
confirmed	1291	1300		|O
and	1301	1304		|O
shown	1305	1310		|O
by	1311	1313		|O
use	1314	1317		|O
of	1318	1320		|O
the	1321	1324		|O
bioassay	1325	1333		|O
system	1334	1340		|O
to	1341	1343		|O
be	1344	1346		|O
an	1347	1349		|O
event	1350	1355		|O
of	1356	1358		|O
similar	1359	1366		|O
toxicity	1367	1375		|O
to	1376	1378		|O
release	1379	1386		|O
of	1387	1389		|O
4	1390	1391		|O
from	1392	1396		|O
18	1397	1399		|O
;	1399	1400		|O
in	1401	1403		|O
vivo	1404	1408		|O
,	1408	1409		|O
however	1410	1417		|O
,	1417	1418		|O
6	1419	1420		|O
(	1421	1422		|O
LD50	1422	1426		|O
mg	1431	1433		|O
/	1433	1434		|O
kg	1434	1436		|O
)	1436	1437		|O
was	1438	1441		|O
more	1442	1446		|O
toxic	1447	1452		|O
to	1453	1455		|O
mice	1456	1460		|O
than	1461	1465		|O
18	1466	1468		|O
(	1469	1470		|O
LD50	1470	1474		|O
greater	1475	1482		|O
than	1483	1487		|O
mg	1492	1494		|O
/	1494	1495		|O
kg	1495	1497		|O
)	1497	1498		|O
.	1498	1499		|O

### 2578190
There	0	5		|O
is	6	8		|O
reported	9	17		|O
the	18	21		|O
first	22	27		|O
four	28	32		|O
members	33	40		|O
of	41	43		|O
heteroarotinoids	44	60	heteroarotinoids	|B-FAMILY
,	60	61		|O
the	62	65		|O
names	66	71		|O
of	72	74		|O
which	75	80		|O
are	81	84		|O
ethyl	85	90	ethyl (E)-p-[2-(4,4-dimethylthiochroman-6-yl)propenyl]benzoate	|B-IUPAC
(	91	92		|I-IUPAC
E	92	93		|I-IUPAC
)	93	94		|I-IUPAC
-	94	95		|I-IUPAC
p	95	96		|I-IUPAC
-	96	97		|I-IUPAC
[	97	98		|I-IUPAC
2	98	99		|I-IUPAC
-	99	100		|I-IUPAC
(	100	101		|I-IUPAC
4,4	101	104		|I-IUPAC
-	104	105		|I-IUPAC
dimethylthiochroman	105	124		|I-IUPAC
-	124	125		|I-IUPAC
6	125	126		|I-IUPAC
-	126	127		|I-IUPAC
yl	127	129		|I-IUPAC
)	129	130		|I-IUPAC
propenyl	130	138		|I-IUPAC
]	138	139		|I-IUPAC
benzoate	139	147		|I-IUPAC
(	148	149		|O
1b	149	151		|O
)	151	152		|O
,	152	153		|O
ethyl	154	159	ethyl (E)-p-[2-(4,4-dimethylchroman-6-yl)propenyl]benzoate	|B-IUPAC
(	160	161		|I-IUPAC
E	161	162		|I-IUPAC
)	162	163		|I-IUPAC
-	163	164		|I-IUPAC
p	164	165		|I-IUPAC
-	165	166		|I-IUPAC
[	166	167		|I-IUPAC
2	167	168		|I-IUPAC
-	168	169		|I-IUPAC
(	169	170		|I-IUPAC
4,4	170	173		|I-IUPAC
-	173	174		|I-IUPAC
dimethylchroman	174	189		|I-IUPAC
-	189	190		|I-IUPAC
6	190	191		|I-IUPAC
-	191	192		|I-IUPAC
yl	192	194		|I-IUPAC
)	194	195		|I-IUPAC
propenyl	195	203		|I-IUPAC
]	203	204		|I-IUPAC
benzoate	204	212		|I-IUPAC
(	213	214		|O
1c	214	216		|O
)	216	217		|O
,	217	218		|O
ethyl	219	224	ethyl (E)-p-[2-(4,4-dimethyl-1-oxothiochroman-6-yl)propenyl]benzoate	|B-IUPAC
(	225	226		|I-IUPAC
E	226	227		|I-IUPAC
)	227	228		|I-IUPAC
-	228	229		|I-IUPAC
p	229	230		|I-IUPAC
-	230	231		|I-IUPAC
[	231	232		|I-IUPAC
2	232	233		|I-IUPAC
-	233	234		|I-IUPAC
(	234	235		|I-IUPAC
4,4	235	238		|I-IUPAC
-	238	239		|I-IUPAC
dimethyl	239	247		|I-IUPAC
-	247	248		|I-IUPAC
1	248	249		|I-IUPAC
-	249	250		|I-IUPAC
oxothiochroman	250	264		|I-IUPAC
-	264	265		|I-IUPAC
6	265	266		|I-IUPAC
-	266	267		|I-IUPAC
yl	267	269		|I-IUPAC
)	269	270		|I-IUPAC
propenyl	270	278		|I-IUPAC
]	278	279		|I-IUPAC
benzoate	279	287		|I-IUPAC
(	288	289		|O
1d	289	291		|O
)	291	292		|O
,	292	293		|O
and	294	297		|O
(	298	299	(E)-p-[2-(4,4-dimethylchroman-6-yl)propenyl]benzoic acid	|B-IUPAC
E	299	300		|I-IUPAC
)	300	301		|I-IUPAC
-	301	302		|I-IUPAC
p	302	303		|I-IUPAC
-	303	304		|I-IUPAC
[	304	305		|I-IUPAC
2	305	306		|I-IUPAC
-	306	307		|I-IUPAC
(	307	308		|I-IUPAC
4,4	308	311		|I-IUPAC
-	311	312		|I-IUPAC
dimethylchroman	312	327		|I-IUPAC
-	327	328		|I-IUPAC
6	328	329		|I-IUPAC
-	329	330		|I-IUPAC
yl	330	332		|I-IUPAC
)	332	333		|I-IUPAC
propenyl	333	341		|I-IUPAC
]	341	342		|I-IUPAC
benzoic	342	349		|I-IUPAC
acid	350	354		|I-IUPAC
(	355	356		|O
1e	356	358		|O
)	358	359		|O
.	359	360		|O
IR	361	363		|O
,	363	364		|O
1H	365	367		|O
NMR	368	371		|O
and	372	375		|O
13C	376	379		|O
NMR	380	383		|O
data	384	388		|O
have	389	393		|O
been	394	398		|O
recorded	399	407		|O
for	408	411		|O
each	412	416		|O
compound	417	425		|O
and	426	429		|O
support	430	437		|O
the	438	441		|O
structural	442	452		|O
assignments	453	464		|O
.	464	465		|O
To	466	468		|O
provide	469	476		|O
a	477	478		|O
firm	479	483		|O
basis	484	489		|O
for	490	493		|O
comparison	494	504		|O
purposes	505	513		|O
of	514	516		|O
future	517	523		|O
analogues	524	533		|O
,	533	534		|O
an	535	537		|O
X	538	539		|O
-	539	540		|O
ray	540	543		|O
analysis	544	552		|O
was	553	556		|O
performed	557	566		|O
on	567	569		|O
a	570	571		|O
single	572	578		|O
crystal	579	586		|O
of	587	589		|O
ethyl	590	595	ethyl (E)-p-[2-(4,4-dimethylthiochroman-6-yl)propenyl]benzoate	|B-IUPAC
(	596	597		|I-IUPAC
E	597	598		|I-IUPAC
)	598	599		|I-IUPAC
-	599	600		|I-IUPAC
p	600	601		|I-IUPAC
-	601	602		|I-IUPAC
[	602	603		|I-IUPAC
2	603	604		|I-IUPAC
-	604	605		|I-IUPAC
(	605	606		|I-IUPAC
4,4	606	609		|I-IUPAC
-	609	610		|I-IUPAC
dimethylthiochroman	610	629		|I-IUPAC
-	629	630		|I-IUPAC
6	630	631		|I-IUPAC
-	631	632		|I-IUPAC
yl	632	634		|I-IUPAC
)	634	635		|I-IUPAC
propenyl	635	643		|I-IUPAC
]	643	644		|I-IUPAC
benzoate	644	652		|I-IUPAC
(	653	654		|O
1b	654	656		|O
)	656	657		|O
and	658	661		|O
a	662	663		|O
precursor	664	673		|O
4,4	674	677	4,4-dimethylthiochroman-6-yl methyl ketone 1,1-dioxide	|B-IUPAC
-	677	678		|I-IUPAC
dimethylthiochroman	678	697		|I-IUPAC
-	697	698		|I-IUPAC
6	698	699		|I-IUPAC
-	699	700		|I-IUPAC
yl	700	702		|I-IUPAC
methyl	703	709		|I-IUPAC
ketone	710	716		|I-IUPAC
1,1	717	720		|I-IUPAC
-	720	721		|I-IUPAC
dioxide	721	728		|I-IUPAC
(	729	730		|O
18	730	732		|O
)	732	733		|O
.	733	734		|O
These	735	740		|O
data	741	745		|O
for	746	749		|O
the	750	753		|O
heteroarotinoid	754	769	heteroarotinoid	|B-FAMILY
1b	770	772		|O
revealed	773	781		|O
that	782	786		|O
the	787	790		|O
two	791	794		|O
aryl	795	799		|O
ring	800	804		|O
systems	805	812		|O
were	813	817		|O
nearly	818	824		|O
perpendicular	825	838		|O
in	839	841		|O
each	842	846		|O
of	847	849		|O
the	850	853		|O
two	854	857		|O
molecules	858	867		|O
present	868	875		|O
in	876	878		|O
the	879	882		|O
unit	883	887		|O
cell	888	892		|O
(	893	894		|O
86.37	894	899		|O
degrees	900	907		|O
and	908	911		|O
84.17	912	917		|O
degrees	918	925		|O
,	925	926		|O
respectively	927	939		|O
)	939	940		|O
.	940	941		|O
The	942	945		|O
space	946	951		|O
group	952	957		|O
for	958	961		|O
both	962	966		|O
molecules	967	976		|O
was	977	980		|O
P1	981	983		|O
in	984	986		|O
triclinic	987	996		|O
systems	997	1004		|O
.	1004	1005		|O
Unit	1006	1010		|O
cell	1011	1015		|O
dimensions	1016	1026		|O
(	1027	1028		|O
at	1028	1030		|O
15	1031	1033		|O
degrees	1034	1041		|O
C	1042	1043		|O
)	1043	1044		|O
are	1045	1048		|O
as	1049	1051		|O
follows	1052	1059		|O
:	1059	1060		|O
for	1061	1064		|O
1b	1065	1067		|O
,	1067	1068		|O
a	1069	1070		|O
=	1071	1072		|O
(	1080	1081		|O
6	1081	1082		|O
)	1082	1083		|O
A	1084	1085		|O
,	1085	1086		|O
b	1087	1088		|O
=	1089	1090		|O
14.760	1091	1097		|O
(	1098	1099		|O
3	1099	1100		|O
)	1100	1101		|O
A	1102	1103		|O
,	1103	1104		|O
c	1105	1106		|O
=	1107	1108		|O
7.679	1109	1114		|O
(	1115	1116		|O
2	1116	1117		|O
)	1117	1118		|O
A	1119	1120		|O
,	1120	1121		|O
alpha	1122	1127		|O
=	1128	1129		|O
113.33	1130	1136		|O
(	1137	1138		|O
2	1138	1139		|O
)	1139	1140		|O
degrees	1141	1148		|O
,	1148	1149		|O
beta	1150	1154		|O
=	1155	1156		|O
79.45	1157	1162		|O
(	1163	1164		|O
2	1164	1165		|O
)	1165	1166		|O
degrees	1167	1174		|O
,	1174	1175		|O
gamma	1176	1181		|O
=	1182	1183		|O
79.98	1184	1189		|O
(	1190	1191		|O
2	1191	1192		|O
)	1192	1193		|O
degrees	1194	1201		|O
,	1201	1202		|O
Z	1203	1204		|O
=	1205	1206		|O
4	1207	1208		|O
;	1208	1209		|O
for	1210	1213		|O
18	1214	1216		|O
,	1216	1217		|O
a	1218	1219		|O
=	1220	1221		|O
9.292	1222	1227		|O
(	1228	1229		|O
5	1229	1230		|O
)	1230	1231		|O
A	1232	1233		|O
,	1233	1234		|O
b	1235	1236		|O
=	1237	1238		|O
9.291	1239	1244		|O
(	1245	1246		|O
5	1246	1247		|O
)	1247	1248		|O
A	1249	1250		|O
,	1250	1251		|O
c	1252	1253		|O
=	1254	1255		|O
7.951	1256	1261		|O
(	1262	1263		|O
3	1263	1264		|O
)	1264	1265		|O
A	1266	1267		|O
,	1267	1268		|O
alpha	1269	1274		|O
=	1275	1276		|O
(	1284	1285		|O
3	1285	1286		|O
)	1286	1287		|O
degrees	1288	1295		|O
,	1295	1296		|O
beta	1297	1301		|O
=	1302	1303		|O
77.49	1304	1309		|O
(	1310	1311		|O
3	1311	1312		|O
)	1312	1313		|O
degrees	1314	1321		|O
,	1321	1322		|O
gamma	1323	1328		|O
=	1329	1330		|O
79.60	1331	1336		|O
(	1337	1338		|O
4	1338	1339		|O
)	1339	1340		|O
degrees	1341	1348		|O
,	1348	1349		|O
Z	1350	1351		|O
=	1352	1353		|O
2	1354	1355		|O
.	1355	1356		|O
The	1357	1360		|O
sulfur	1361	1367	sulfur	|B-TRIVIAL
-	1367	1368		|O
containing	1368	1378		|O
ring	1379	1383		|O
is	1384	1386		|O
in	1387	1389		|O
a	1390	1391		|O
distorted	1392	1401		|O
half	1402	1406		|O
-	1406	1407		|O
chair	1407	1412		|O
in	1413	1415		|O
1b	1416	1418		|O
and	1419	1422		|O
the	1423	1426		|O
methyl	1427	1433	methyl	|B-PARTIUPAC
carbon	1434	1440	carbon	|B-TRIVIAL
C	1441	1442		|O
(	1442	1443		|O
12	1443	1445		|O
)	1445	1446		|O
is	1447	1449		|O
shown	1450	1455		|O
to	1456	1458		|O
be	1459	1461		|O
trans	1462	1467		|O
to	1468	1470		|O
H	1471	1472		|O
(	1472	1473		|O
13	1473	1475		|O
)	1475	1476		|O
at	1477	1479		|O
the	1480	1483		|O
C	1484	1485		|O
(	1485	1486		|O
11	1486	1488		|O
)	1488	1489		|O
-	1489	1490		|O
C	1490	1491		|O
(	1491	1492		|O
13	1492	1494		|O
)	1494	1495		|O
bond	1496	1500		|O
.	1500	1501		|O
The	1502	1505		|O
biological	1506	1516		|O
activity	1517	1525		|O
of	1526	1528		|O
these	1529	1534		|O
arotinoids	1535	1545	arotinoids	|B-FAMILY
was	1546	1549		|O
determined	1550	1560		|O
in	1561	1563		|O
the	1564	1567		|O
tracheal	1568	1576		|O
organ	1577	1582		|O
culture	1583	1590		|O
assay	1591	1596		|O
and	1597	1600		|O
compared	1601	1609		|O
with	1610	1614		|O
trans	1615	1620	trans-retinoic acid	|B-TRIVIAL
-	1620	1621		|I-TRIVIAL
retinoic	1621	1629		|I-TRIVIAL
acid	1630	1634		|I-TRIVIAL
for	1635	1638		|O
ability	1639	1646		|O
to	1647	1649		|O
reverse	1650	1657		|O
keratinization	1658	1672		|O
in	1673	1675		|O
vitamin	1676	1683	vitamin A	|B-TRIVIAL
A	1684	1685		|I-TRIVIAL
deficient	1686	1695		|O
hamsters	1696	1704		|O
.	1704	1705		|O
The	1706	1709		|O
ester	1710	1715		|O
1b	1716	1718		|O
displayed	1719	1728		|O
activity	1729	1737		|O
about	1738	1743		|O
one	1744	1747		|O
-	1747	1748		|O
half	1748	1752		|O
log	1753	1756		|O
unit	1757	1761		|O
less	1762	1766		|O
than	1767	1771		|O
that	1772	1776		|O
of	1777	1779		|O
the	1780	1783		|O
reference	1784	1793		|O
while	1794	1799		|O
1c	1800	1802		|O
and	1803	1806		|O
1e	1807	1809		|O
had	1810	1813		|O
activity	1814	1822		|O
nearly	1823	1829		|O
one	1830	1833		|O
log	1834	1837		|O
until	1838	1843		|O
less	1844	1848		|O
than	1849	1853		|O
trans	1854	1859	trans-retinoic acid	|B-TRIVIAL
-	1859	1860		|I-TRIVIAL
retinoic	1860	1868		|I-TRIVIAL
acid	1869	1873		|I-TRIVIAL
.	1873	1874		|O
The	1875	1878		|O
sulfoxide	1879	1888	sulfoxide	|B-FAMILY
was	1889	1892		|O
the	1893	1896		|O
least	1897	1902		|O
active	1903	1909		|O
of	1910	1912		|O
the	1913	1916		|O
heteroretinoids	1917	1932	heteroretinoids	|B-FAMILY
.	1932	1933		|O

### 15652357
15652357	0	8		|O
Identification	10	24		|O
of	25	27		|O
MAGI	28	32		|O
-	32	33		|O
3	33	34		|O
as	35	37		|O
a	38	39		|O
transforming	40	52		|O
growth	53	59		|O
factor	60	66		|O
-	66	67		|O
alpha	67	72		|O
tail	73	77		|O
binding	78	85		|O
protein	86	93		|O
.	93	94		|O
The	96	99		|O
cytoplasmic	100	111		|O
domain	112	118		|O
of	119	121		|O
the	122	125		|O
transforming	126	138		|O
growth	139	145		|O
factor	146	152		|O
-	152	153		|O
alpha	153	158		|O
precursor	159	168		|O
(	169	170		|O
proTGFalpha	170	181		|O
)	181	182		|O
contains	183	191		|O
a	192	193		|O
C	194	195		|O
-	195	196		|O
terminal	196	204		|O
PSD	205	208		|O
-	208	209		|O
95	209	211		|O
/	211	212		|O
SAP90	212	217		|O
,	217	218		|O
Discs	219	224		|O
Large	225	230		|O
,	230	231		|O
and	232	235		|O
Zona	236	240		|O
Occludens	241	250		|O
-	250	251		|O
1	251	252		|O
(	253	254		|O
PDZ	254	257		|O
)	257	258		|O
recognition	259	270		|O
motif	271	276		|O
(	277	278		|O
TVV	278	281		|O
)	281	282		|O
.	282	283		|O
By	284	286		|O
yeast	287	292		|O
two	293	296		|O
-	296	297		|O
hybrid	297	303		|O
screening	304	313		|O
of	314	316		|O
a	317	318		|O
mouse	319	324		|O
embryo	325	331		|O
library	332	339		|O
,	339	340		|O
we	341	343		|O
have	344	348		|O
found	349	354		|O
that	355	359		|O
a	360	361		|O
third	362	367		|O
member	368	374		|O
of	375	377		|O
a	378	379		|O
family	380	386		|O
of	387	389		|O
PDZ	390	393		|O
-	393	394		|O
containing	394	404		|O
proteins	405	413		|O
,	413	414		|O
membrane	415	423		|O
associated	424	434		|O
guanylate	435	444		|O
kinase	445	451		|O
inverted	452	460		|O
-	460	461		|O
3	461	462		|O
(	463	464		|O
MAGI	464	468		|O
-	468	469		|O
3	469	470		|O
)	470	471		|O
,	471	472		|O
binds	473	478		|O
to	479	481		|O
TGFalpha	482	490		|O
's	490	492		|O
TVV	493	496		|O
.	496	497		|O
MAGI	498	502		|O
-	502	503		|O
3	503	504		|O
is	505	507		|O
widely	508	514		|O
expressed	515	524		|O
in	525	527		|O
multiple	528	536		|O
mouse	537	542		|O
tissues	543	550		|O
,	550	551		|O
including	552	561		|O
brain	562	567		|O
.	567	568		|O
Immunolocalization	569	587		|O
showed	588	594		|O
that	595	599		|O
MAGI	600	604		|O
-	604	605		|O
3	605	606		|O
and	607	610		|O
TGFalpha	611	619		|O
were	620	624		|O
colocalized	625	636		|O
in	637	639		|O
neurons	640	647		|O
in	648	650		|O
the	651	654		|O
cortex	655	661		|O
and	662	665		|O
dentate	666	673		|O
gyrus	674	679		|O
,	679	680		|O
as	681	683		|O
well	684	688		|O
as	689	691		|O
in	692	694		|O
ependymal	695	704		|O
cells	705	710		|O
and	711	714		|O
some	715	719		|O
astrocytes	720	730		|O
.	730	731		|O
In	732	734		|O
vitro	735	740		|O
,	740	741		|O
proTGFalpha	742	753		|O
bound	754	759		|O
the	760	763		|O
PDZ	764	767		|O
-	767	768		|O
1	768	769		|O
domain	770	776		|O
of	777	779		|O
MAGI	780	784		|O
-	784	785		|O
3	785	786		|O
and	787	790		|O
MAGI	791	795		|O
-	795	796		|O
2	796	797		|O
,	797	798		|O
but	799	802		|O
not	803	806		|O
MAGI	807	811		|O
-	811	812		|O
1	812	813		|O
.	813	814		|O
MAGI	815	819		|O
-	819	820		|O
3	820	821		|O
and	822	825		|O
the	826	829		|O
17	830	832		|O
-	832	833		|O
kDa	833	836		|O
cell	837	841		|O
surface	842	849		|O
form	850	854		|O
of	855	857		|O
proTGFalpha	858	869		|O
interact	870	878		|O
transiently	879	890		|O
in	891	893		|O
MDCK	894	898		|O
cells	899	904		|O
stably	905	911		|O
transfected	912	923		|O
with	924	928		|O
both	929	933		|O
MAGI	934	938		|O
-	938	939		|O
3	939	940		|O
and	941	944		|O
human	945	950		|O
proTGFalpha	951	962		|O
cDNAs	963	968		|O
.	968	969		|O
MAGI	970	974		|O
-	974	975		|O
3	975	976		|O
and	977	980		|O
wild	981	985		|O
-	985	986		|O
type	986	990		|O
proTGFalpha	991	1002		|O
colocalize	1003	1013		|O
at	1014	1016		|O
the	1017	1020		|O
cell	1021	1025		|O
surface	1026	1033		|O
.	1033	1034		|O
In	1035	1037		|O
contrast	1038	1046		|O
,	1046	1047		|O
MAGI	1048	1052		|O
-	1052	1053		|O
3	1053	1054		|O
forms	1055	1060		|O
a	1061	1062		|O
stable	1063	1069		|O
complex	1070	1077		|O
with	1078	1082		|O
membrane	1083	1091		|O
-	1091	1092		|O
fixed	1092	1097		|O
TGFalpha	1098	1106		|O
early	1107	1112		|O
in	1113	1115		|O
the	1116	1119		|O
secretory	1120	1129		|O
pathway	1130	1137		|O
and	1138	1141		|O
interacts	1142	1151		|O
with	1152	1156		|O
immature	1157	1165		|O
and	1166	1169		|O
cell	1170	1174		|O
surface	1175	1182		|O
forms	1183	1188		|O
of	1189	1191		|O
membrane	1192	1200		|O
-	1200	1201		|O
fixed	1201	1206		|O
TGFalpha	1207	1215		|O
.	1215	1216		|O
Overexpression	1217	1231		|O
of	1232	1234		|O
MAGI	1235	1239		|O
-	1239	1240		|O
3	1240	1241		|O
resulted	1242	1250		|O
in	1251	1253		|O
increased	1254	1263		|O
levels	1264	1270		|O
of	1271	1273		|O
TGFalpha	1274	1282		|O
in	1283	1285		|O
the	1286	1289		|O
basolateral	1290	1301		|O
medium	1302	1308		|O
of	1309	1311		|O
polarized	1312	1321		|O
MDCK	1322	1326		|O
cells	1327	1332		|O
,	1332	1333		|O
suggesting	1334	1344		|O
that	1345	1349		|O
MAGI	1350	1354		|O
-	1354	1355		|O
3	1355	1356		|O
has	1357	1360		|O
a	1361	1362		|O
role	1363	1367		|O
in	1368	1370		|O
efficient	1371	1380		|O
trafficking	1381	1392		|O
of	1393	1395		|O
TGFalpha	1396	1404		|O
to	1405	1407		|O
the	1408	1411		|O
cell	1412	1416		|O
surface	1417	1424		|O
in	1425	1427		|O
polarized	1428	1437		|O
epithelial	1438	1448		|O
cells	1449	1454		|O
.	1454	1455		|O

### 3968683
A	0	1		|O
series	2	8		|O
of	9	11		|O
22	12	14	22-hydroxycholesterol	|B-IUPAC
-	14	15		|I-IUPAC
hydroxycholesterol	15	33		|I-IUPAC
derivatives	34	45	derivatives	|B-MODIFIER
with	46	50		|O
a	51	52		|O
modified	53	61		|O
side	62	66		|O
chain	67	72		|O
terminus	73	81		|O
was	82	85		|O
prepared	86	94		|O
.	94	95		|O
These	96	101		|O
agents	102	108		|O
were	109	113		|O
evaluated	114	123		|O
in	124	126		|O
vitro	127	132		|O
and	133	136		|O
in	137	139		|O
vivo	140	144		|O
for	145	148		|O
their	149	154		|O
ability	155	162		|O
to	163	165		|O
suppress	166	174		|O
HMG	175	178		|O
CoA	179	182		|O
reductase	183	192		|O
,	192	193		|O
the	194	197		|O
rate	198	202		|O
-	202	203		|O
limiting	203	211		|O
enzyme	212	218		|O
of	219	221		|O
cholesterol	222	233	cholesterol	|B-TRIVIAL
biosynthesis	234	246		|O
.	246	247		|O
In	248	250		|O
tissue	251	257		|O
culture	258	265		|O
assays	266	272		|O
,	272	273		|O
22	274	276	22-hydroxycholesterol	|B-IUPAC
-	276	277		|I-IUPAC
hydroxycholesterol	277	295		|I-IUPAC
as	296	298		|O
well	299	303		|O
as	304	306		|O
the	307	310		|O
side	311	315		|O
chain	316	321		|O
modified	322	330		|O
analogues	331	340		|O
were	341	345		|O
potent	346	352		|O
inhibitors	353	363		|O
of	364	366		|O
HMG	367	370		|O
CoA	371	374		|O
reductase	375	384		|O
.	384	385		|O
However	386	393		|O
,	393	394		|O
only	395	399		|O
those	400	405		|O
sterols	406	413		|O
with	414	418		|O
a	419	420		|O
modified	421	429		|O
side	430	434		|O
chain	435	440		|O
terminus	441	449		|O
were	450	454		|O
effective	455	464		|O
suppressors	465	476		|O
of	477	479		|O
liver	480	485		|O
reductase	486	495		|O
when	496	500		|O
administered	501	513		|O
ig	514	516		|O
to	517	519		|O
rats	520	524		|O
.	524	525		|O
22	526	528	22-Hydroxy-25-methylcholesterol	|B-IUPAC
-	528	529		|I-IUPAC
Hydroxy	529	536		|I-IUPAC
-	536	537		|I-IUPAC
25	537	539		|I-IUPAC
-	539	540		|I-IUPAC
methylcholesterol	540	557		|I-IUPAC
(	558	559		|O
4a	559	561		|O
)	561	562		|O
and	563	566		|O
25	567	569	25-fluoro-22-hydroxycholesterol	|B-IUPAC
-	569	570		|I-IUPAC
fluoro	570	576		|I-IUPAC
-	576	577		|I-IUPAC
22	577	579		|I-IUPAC
-	579	580		|I-IUPAC
hydroxycholesterol	580	598		|I-IUPAC
(	599	600		|O
15a	600	603		|O
)	603	604		|O
significantly	605	618		|O
lowered	619	626		|O
serum	627	632		|O
cholesterol	633	644		|O
levels	645	651		|O
when	652	656		|O
administered	657	669		|O
ig	670	672		|O
to	673	675		|O
primates	676	684		|O
;	684	685		|O
25	686	688	25-chloro-22-hydroxycholesterol	|B-IUPAC
-	688	689		|I-IUPAC
chloro	689	695		|I-IUPAC
-	695	696		|I-IUPAC
22	696	698		|I-IUPAC
-	698	699		|I-IUPAC
hydroxycholesterol	699	717		|I-IUPAC
(	718	719		|O
15b	719	722		|O
)	722	723		|O
and	724	727		|O
the	728	731		|O
analogue	732	740		|O
with	741	745		|O
a	746	747		|O
cyclopropyl	748	759	cyclopropyl	|B-TRIVIAL
terminus	760	768		|O
,	768	769		|O
,	773	774		|O
were	775	779		|O
ineffective	780	791		|O
.	791	792		|O
The	793	796		|O
cholesterol	797	808	cholesterol	|B-TRIVIAL
-	808	809		|O
lowering	809	817		|O
sterols	818	825	sterols	|B-FAMILY
did	825	828		|O
not	830	833		|O
significantly	834	847		|O
alter	848	853		|O
lipoprotein	854	865		|O
levels	866	872		|O
;	872	873		|O
however	874	881		|O
,	881	882		|O
the	883	886		|O
two	887	890		|O
compounds	891	900		|O
have	901	905		|O
been	906	910		|O
shown	911	916		|O
to	917	919		|O
inhibit	920	927		|O
acyl	928	932		|O
-	932	933		|O
coenzyme	933	941		|O
A	942	943		|O
:	943	944		|O
cholesterol	944	955		|O
acyl	956	960		|O
-	960	961		|O
transferase	961	972		|O
(	973	974		|O
ACAT	974	978		|O
)	978	979		|O
in	980	982		|O
tissue	983	989		|O
culture	990	997		|O
studies	998	1005		|O
.	1005	1006		|O

### 11597479
11597479	0	8		|O
Synthesis	10	19		|O
of	20	22		|O
pyridino	23	31	pyridino[2,3-f]indole-4,9-dione	|B-IUPAC
[	31	32		|I-IUPAC
2,3	32	35		|I-IUPAC
-	35	36		|I-IUPAC
f	36	37		|I-IUPAC
]	37	38		|I-IUPAC
indole	38	44		|I-IUPAC
-	44	45		|I-IUPAC
4,9	45	48		|I-IUPAC
-	48	49		|I-IUPAC
dione	49	54		|I-IUPAC
and	55	58		|O
6,7	59	62	6,7-disubstituted quinoline-5,8-dione	|B-IUPAC
-	62	63		|I-IUPAC
disubstituted	63	76		|I-IUPAC
quinoline	77	86		|I-IUPAC
-	86	87		|I-IUPAC
5,8	87	90		|I-IUPAC
-	90	91		|I-IUPAC
dione	91	96		|I-IUPAC
derivatives	97	108	derivatives	|B-MODIFIER
and	109	112		|O
evaluation	113	123		|O
on	124	126		|O
their	127	132		|O
cytotoxic	133	142		|O
activity	143	151		|O
.	151	152		|O
We	154	156		|O
report	157	163		|O
upon	164	168		|O
the	169	172		|O
synthesis	173	182		|O
of	183	185		|O
the	186	189		|O
following	190	199		|O
derivatives	200	211		|O
:	211	212		|O
N	213	214	N-substituted-pyridino[2,3-f]indole-4,9-dione	|B-IUPAC
-	214	215		|I-IUPAC
substituted	215	226		|I-IUPAC
-	226	227		|I-IUPAC
pyridino	227	235		|I-IUPAC
[	235	236		|I-IUPAC
2,3	236	239		|I-IUPAC
-	239	240		|I-IUPAC
f	240	241		|I-IUPAC
]	241	242		|I-IUPAC
indole	242	248		|I-IUPAC
-	248	249		|I-IUPAC
4,9	249	252		|I-IUPAC
-	252	253		|I-IUPAC
dione	253	258		|I-IUPAC
,	258	259		|O
and	260	263		|O
6	264	265	6-(alpha-diethoxycarbonyl-methyl)-7-substituted-amino-quinoline-5,8-dione	|B-IUPAC
-	265	266		|I-IUPAC
(	266	267		|I-IUPAC
alpha	267	272		|I-IUPAC
-	272	273		|I-IUPAC
diethoxycarbonyl	273	289		|I-IUPAC
-	289	290		|I-IUPAC
methyl	290	296		|I-IUPAC
)	296	297		|I-IUPAC
-	297	298		|I-IUPAC
7	298	299		|I-IUPAC
-	299	300		|I-IUPAC
substituted	300	311		|I-IUPAC
-	311	312		|I-IUPAC
amino	312	317		|I-IUPAC
-	317	318		|I-IUPAC
quinoline	318	327		|I-IUPAC
-	327	328		|I-IUPAC
5,8	328	331		|I-IUPAC
-	331	332		|I-IUPAC
dione	332	337		|I-IUPAC
,	337	338		|O
which	339	344		|O
contain	345	352		|O
the	353	356		|O
active	357	363		|O
quinoline	364	373	quinoline-5,8-dione	|B-IUPAC
-	373	374		|I-IUPAC
5,8	374	377		|I-IUPAC
-	377	378		|I-IUPAC
dione	378	383		|I-IUPAC
(	384	385		|O
VII	385	388		|O
)	388	389		|O
moiety	390	396	moiety	|B-MODIFIER
.	396	397		|O
The	398	401		|O
cytotoxic	402	411		|O
activities	412	422		|O
of	423	425		|O
these	426	431		|O
compounds	432	441		|O
have	442	446		|O
been	447	451		|O
tested	452	458		|O
in	459	461		|O
SRB	462	465		|O
(	466	467		|O
SulfoRhodamine	467	481		|O
B	482	483		|O
)	483	484		|O
assays	485	491		|O
against	492	499		|O
the	500	503		|O
cancer	504	510		|O
cell	511	515		|O
lines	516	521		|O
of	522	524		|O
A	525	526		|O
-	526	527		|O
549	527	530		|O
(	531	532		|O
human	532	537		|O
lung	538	542		|O
cancer	543	549		|O
)	549	550		|O
,	550	551		|O
SK	552	554		|O
-	554	555		|O
MEL	555	558		|O
-	558	559		|O
2	559	560		|O
(	561	562		|O
human	562	567		|O
melanoma	568	576		|O
cancer	577	583		|O
)	583	584		|O
,	584	585		|O
SK	586	588		|O
-	588	589		|O
OV	589	591		|O
-	591	592		|O
3	592	593		|O
(	594	595		|O
human	595	600		|O
ovarian	601	608		|O
cancer	609	615		|O
)	615	616		|O
,	616	617		|O
XF	618	620		|O
-	620	621		|O
498	621	624		|O
(	625	626		|O
human	626	631		|O
brain	632	637		|O
cancer	638	644		|O
)	644	645		|O
and	646	649		|O
HCT	650	653		|O
15	654	656		|O
(	657	658		|O
human	658	663		|O
colon	664	669		|O
cancer	670	676		|O
)	676	677		|O
.	677	678		|O
The	679	682		|O
compound	683	691		|O
,	691	692		|O
N	693	694	N-benzyl-3-ethoxycarbonyl-2-hydroxy-pyridino[2,3-f]indole-4,9-dione	|B-IUPAC
-	694	695		|I-IUPAC
benzyl	695	701		|I-IUPAC
-	701	702		|I-IUPAC
3	702	703		|I-IUPAC
-	703	704		|I-IUPAC
ethoxycarbonyl	704	718		|I-IUPAC
-	718	719		|I-IUPAC
2	719	720		|I-IUPAC
-	720	721		|I-IUPAC
hydroxy	721	728		|I-IUPAC
-	728	729		|I-IUPAC
pyridino	729	737		|I-IUPAC
[	737	738		|I-IUPAC
2,3	738	741		|I-IUPAC
-	741	742		|I-IUPAC
f	742	743		|I-IUPAC
]	743	744		|I-IUPAC
indole	744	750		|I-IUPAC
-	750	751		|I-IUPAC
4,9	751	754		|I-IUPAC
-	754	755		|I-IUPAC
dione	755	760		|I-IUPAC
(	761	762		|O
A	762	763		|O
-	763	764		|O
9	764	765		|O
)	765	766		|O
,	766	767		|O
also	768	772		|O
showed	773	779		|O
higher	780	786		|O
activity	787	795		|O
than	796	800		|O
cis	801	804	cis-platin	|B-TRIVIAL
-	804	805		|I-TRIVIAL
platin	805	811		|I-TRIVIAL
.	811	812		|O
The	813	816		|O
highest	817	824		|O
level	825	830		|O
of	831	833		|O
cytotoxic	834	843		|O
activity	844	852		|O
in	853	855		|O
these	856	861		|O
human	862	867		|O
tumor	868	873		|O
cell	874	878		|O
lines	879	884		|O
was	885	888		|O
observed	889	897		|O
in	898	900		|O
the	901	904		|O
compound	905	913		|O
6	914	915	6-(alpha-diethoxycarbonyl-methyl)-7-(2-methyl-phenylamino)-quinoline-5,8-dione	|B-IUPAC
-	915	916		|I-IUPAC
(	916	917		|I-IUPAC
alpha	917	922		|I-IUPAC
-	922	923		|I-IUPAC
diethoxycarbonyl	923	939		|I-IUPAC
-	939	940		|I-IUPAC
methyl	940	946		|I-IUPAC
)	946	947		|I-IUPAC
-	947	948		|I-IUPAC
7	948	949		|I-IUPAC
-	949	950		|I-IUPAC
(	950	951		|I-IUPAC
2	951	952		|I-IUPAC
-	952	953		|I-IUPAC
methyl	953	959		|I-IUPAC
-	959	960		|I-IUPAC
phenylamino	960	971		|I-IUPAC
)	971	972		|I-IUPAC
-	972	973		|I-IUPAC
quinoline	973	982		|I-IUPAC
-	982	983		|I-IUPAC
5,8	983	986		|I-IUPAC
-	986	987		|I-IUPAC
dione	987	992		|I-IUPAC
(	992	993		|O
B	994	995		|O
-	995	996		|O
3	996	997		|O
)	997	998		|O
.	998	999		|O

### 1992127
Two	0	3		|O
2,3	4	7	2,3-dihydrobenzofuran	|B-IUPAC
-	7	8		|I-IUPAC
dihydrobenzofuran	8	25		|I-IUPAC
analogues	26	35	analogues	|B-MODIFIER
of	36	38		|O
hallucinogenic	39	53		|O
amphetamines	54	66	amphetamines	|B-FAMILY
were	67	71		|O
prepared	72	80		|O
and	81	84		|O
evaluated	85	94		|O
for	95	98		|O
activity	99	107		|O
in	108	110		|O
the	111	114		|O
two	115	118		|O
-	118	119		|O
lever	119	124		|O
drug	125	129		|O
-	129	130		|O
discrimination	130	144		|O
paradigm	145	153		|O
in	154	156		|O
rats	157	161		|O
trained	162	169		|O
to	170	172		|O
discriminate	173	185		|O
saline	186	192		|O
from	193	197		|O
LSD	198	201	LSD tartrate	|B-IUPAC
tartrate	202	210		|I-IUPAC
(	211	212		|O
0.08	212	216		|O
mg	217	219		|O
/	219	220		|O
kg	220	222		|O
)	222	223		|O
and	224	227		|O
for	228	231		|O
the	232	235		|O
ability	236	243		|O
to	244	246		|O
displace	247	255		|O
[	256	257	[125I]-(R)-DOI	|B-IUPAC
125I	257	261		|I-IUPAC
]	261	262		|I-IUPAC
-	262	263		|I-IUPAC
(	263	264		|I-IUPAC
R	264	265		|I-IUPAC
)	265	266		|I-IUPAC
-	266	267		|I-IUPAC
DOI	267	270		|I-IUPAC
[	271	272		|O
(	272	273	( 125I]-(R)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane)	|B-IUPAC
125I	274	278		|I-IUPAC
]	278	279		|I-IUPAC
-	279	280		|I-IUPAC
(	280	281		|I-IUPAC
R	281	282		|I-IUPAC
)	282	283		|I-IUPAC
-	283	284		|I-IUPAC
1	284	285		|I-IUPAC
-	285	286		|I-IUPAC
(	286	287		|I-IUPAC
2,5	287	290		|I-IUPAC
-	290	291		|I-IUPAC
dimethoxy	291	300		|I-IUPAC
-	300	301		|I-IUPAC
4	301	302		|I-IUPAC
-	302	303		|I-IUPAC
iodophenyl	303	313		|I-IUPAC
)	313	314		|I-IUPAC
-	314	315		|I-IUPAC
2	315	316		|I-IUPAC
-	316	317		|I-IUPAC
aminopropane	317	329		|I-IUPAC
)	329	330		|I-IUPAC
from	331	335		|O
rat	336	339		|O
cortical	340	348		|O
homogenate	349	359		|O
5	360	361		|O
-	361	362		|O
HT2	362	365		|O
receptors	366	375		|O
.	375	376		|O
The	377	380		|O
compounds	381	390		|O
,	390	391		|O
1	392	393	1-(5-methoxy-2,3-dihydrobenzofuran-4-yl)-2-aminopropane	|B-IUPAC
-	393	394		|I-IUPAC
(	394	395		|I-IUPAC
5	395	396		|I-IUPAC
-	396	397		|I-IUPAC
methoxy	397	404		|I-IUPAC
-	404	405		|I-IUPAC
2,3	405	408		|I-IUPAC
-	408	409		|I-IUPAC
dihydrobenzofuran	409	426		|I-IUPAC
-	426	427		|I-IUPAC
4	427	428		|I-IUPAC
-	428	429		|I-IUPAC
yl	429	431		|I-IUPAC
)	431	432		|I-IUPAC
-	432	433		|I-IUPAC
2	433	434		|I-IUPAC
-	434	435		|I-IUPAC
aminopropane	435	447		|I-IUPAC
(	448	449		|O
6a	449	451		|O
)	451	452		|O
and	453	456		|O
its	457	460		|O
7	461	462	7-brominated	|B-PARTIUPAC
-	462	463		|I-PARTIUPAC
brominated	463	473		|I-PARTIUPAC
analogue	474	482	analogue	|B-MODIFIER
6b	483	485		|O
,	485	486		|O
possessed	487	496		|O
activity	497	505		|O
comparable	506	516		|O
to	517	519		|O
their	520	525		|O
conformationally	526	542		|O
flexible	543	551		|O
counterparts	552	564		|O
1	565	566	1-(2,5-dimethoxyphenyl)-2-aminopropane	|B-IUPAC
-	566	567		|I-IUPAC
(	567	568		|I-IUPAC
2,5	568	571		|I-IUPAC
-	571	572		|I-IUPAC
dimethoxyphenyl	572	587		|I-IUPAC
)	587	588		|I-IUPAC
-	588	589		|I-IUPAC
2	589	590		|I-IUPAC
-	590	591		|I-IUPAC
aminopropane	591	603		|I-IUPAC
(	604	605		|O
3	605	606		|O
)	606	607		|O
and	608	611		|O
its	612	615		|O
4	616	617	4-bromo	|B-PARTIUPAC
-	617	618		|I-PARTIUPAC
bromo	618	623		|I-PARTIUPAC
derivative	624	634	derivative	|B-MODIFIER
DOB	635	638	DOB	|B-ABBREVIATION
(	639	640		|O
5	640	641		|O
)	641	642		|O
,	642	643		|O
respectively	644	656		|O
.	656	657		|O
The	658	661		|O
results	662	669		|O
suggest	670	677		|O
that	678	682		|O
the	683	686		|O
dihydrofuran	687	699	dihydrofuran	|B-TRIVIAL
ring	700	704		|O
in	705	707		|O
6a	708	710		|O
and	711	714		|O
6b	715	717		|O
models	718	724		|O
the	725	728		|O
active	729	735		|O
conformation	736	748		|O
of	749	751		|O
the	752	755		|O
5	756	757	5-methoxy	|B-PARTIUPAC
-	757	758		|I-PARTIUPAC
methoxy	758	765		|I-PARTIUPAC
groups	766	772	groups	|B-MODIFIER
in	773	775		|O
3	776	777		|O
and	778	781		|O
5	782	783		|O
.	783	784		|O
Free	785	789		|O
energy	790	796		|O
of	797	799		|O
binding	800	807		|O
,	807	808		|O
derived	809	816		|O
from	817	821		|O
radioligand	822	833		|O
displacement	834	846		|O
KA	847	849		|O
values	850	856		|O
,	856	857		|O
indicated	858	867		|O
that	868	872		|O
addition	873	881		|O
of	882	884		|O
the	885	888		|O
bromine	889	896	bromine	|B-TRIVIAL
in	897	899		|O
either	900	906		|O
series	907	913		|O
contributes	914	925		|O
2.4-3.2	926	933		|O
kcal	934	938		|O
/	938	939		|O
mol	939	942		|O
of	943	945		|O
binding	946	953		|O
energy	954	960		|O
.	960	961		|O
On	962	964		|O
the	965	968		|O
basis	969	974		|O
of	975	977		|O
surface	978	985		|O
area	986	990		|O
of	991	993		|O
the	994	997		|O
bromine	998	1005	bromine	|B-TRIVIAL
atom	1006	1010	atom	|B-MODIFIER
,	1010	1011		|O
this	1012	1016		|O
value	1017	1022		|O
is	1023	1025		|O
2-3	1026	1029		|O
times	1030	1035		|O
higher	1036	1042		|O
than	1043	1047		|O
would	1048	1053		|O
be	1054	1056		|O
expected	1057	1065		|O
on	1066	1068		|O
the	1069	1072		|O
basis	1073	1078		|O
of	1079	1081		|O
hydrophobic	1082	1093		|O
binding	1094	1101		|O
.	1101	1102		|O
Thus	1103	1107		|O
,	1107	1108		|O
hydrophobicity	1109	1123		|O
of	1124	1126		|O
the	1127	1130		|O
para	1131	1135		|O
substituent	1136	1147		|O
alone	1148	1153		|O
cannot	1154	1160		|O
account	1161	1168		|O
for	1169	1172		|O
the	1173	1176		|O
dramatic	1177	1185		|O
enhancement	1186	1197		|O
of	1198	1200		|O
hallucinogenic	1201	1215		|O
activity	1216	1224		|O
.	1224	1225		|O
Although	1226	1234		|O
this	1235	1239		|O
substituent	1240	1251		|O
may	1252	1255		|O
play	1256	1260		|O
a	1261	1262		|O
minor	1263	1268		|O
role	1269	1273		|O
in	1274	1276		|O
orienting	1277	1286		|O
the	1287	1290		|O
conformation	1291	1303		|O
of	1304	1306		|O
the	1307	1310		|O
5	1311	1312	5-methoxy	|B-PARTIUPAC
-	1312	1313		|I-PARTIUPAC
methoxy	1313	1320		|I-PARTIUPAC
group	1321	1326	group	|B-MODIFIER
in	1326	1328		|O
derivatives	1330	1341		|O
such	1342	1346		|O
as	1347	1349		|O
4	1350	1351		|O
and	1352	1355		|O
5	1356	1357		|O
,	1357	1358		|O
there	1359	1364		|O
appears	1365	1372		|O
to	1373	1375		|O
be	1376	1378		|O
some	1379	1383		|O
other	1384	1389		|O
,	1389	1390		|O
as	1391	1393		|O
yet	1394	1397		|O
unknown	1398	1405		|O
,	1405	1406		|O
critical	1407	1415		|O
receptor	1416	1424		|O
interaction	1425	1436		|O
.	1436	1437		|O

### 16134936
Sulfur	0	6		|O
-	6	7		|O
bridged	7	14		|O
pregnanes	15	24		|O
6,19	25	29	6,19-epithioprogesterone	|B-IUPAC
-	29	30		|I-IUPAC
epithioprogesterone	30	49		|I-IUPAC
,	49	50		|O
21	51	53	21-hydroxy-6,19-epithioprogesterone	|B-IUPAC
-	53	54		|I-IUPAC
hydroxy	54	61		|I-IUPAC
-	61	62		|I-IUPAC
6,19	62	66		|I-IUPAC
-	66	67		|I-IUPAC
epithioprogesterone	67	86		|I-IUPAC
,	86	87		|O
and	88	91		|O
the	92	95		|O
corresponding	96	109		|O
sulfoxides	110	120	sulfoxides	|B-FAMILY
and	121	124		|O
sulfones	125	133	sulfones	|B-FAMILY
were	134	138		|O
synthesized	139	150		|O
and	151	154		|O
tested	155	161		|O
as	162	164		|O
blockers	165	173		|O
of	174	176		|O
the	177	180		|O
immunosuppresive	181	197		|O
activity	198	206		|O
of	207	209		|O
dexamethasone	210	223	dexamethasone	|B-TRIVIAL
in	224	226		|O
rat	227	230		|O
thymocytes	231	241		|O
.	241	242		|O
A	243	244		|O
new	245	248		|O
one	249	252		|O
-	252	253		|O
pot	253	256		|O
procedure	257	266		|O
is	267	269		|O
described	270	279		|O
for	280	283		|O
the	284	287		|O
preparation	288	299		|O
of	300	302		|O
6,19	303	307	6,19-epithioprogesterone	|B-IUPAC
-	307	308		|I-IUPAC
epithioprogesterone	308	327		|I-IUPAC
and	328	331		|O
related	332	339		|O
compounds	340	349		|O
by	350	352		|O
iodocyclization	353	368		|O
of	369	371		|O
a	372	373		|O
19	374	376	19-sulfanylpregn-5-ene	|B-IUPAC
-	376	377		|I-IUPAC
sulfanylpregn	377	390		|I-IUPAC
-	390	391		|I-IUPAC
5	391	392		|I-IUPAC
-	392	393		|I-IUPAC
ene	393	396		|I-IUPAC
.	396	397		|O
Antiimmunosuppresive	398	418		|O
activity	419	427		|O
was	428	431		|O
evaluated	432	441		|O
by	442	444		|O
the	445	448		|O
ability	449	456		|O
of	457	459		|O
the	460	463		|O
different	464	473		|O
steroids	474	482		|O
to	483	485		|O
block	486	491		|O
dexamethasone	492	505	dexamethasone	|B-TRIVIAL
-	505	506		|O
mediated	506	514		|O
apoptosis	515	524		|O
in	525	527		|O
thymocytes	528	538		|O
and	539	542		|O
dexamethasone	543	556	dexamethasone	|B-TRIVIAL
-	556	557		|O
mediated	557	565		|O
inhibition	566	576		|O
of	577	579		|O
the	580	583		|O
NFkappa	584	591		|O
-	591	592		|O
B	592	593		|O
transcription	594	607		|O
factor	608	614		|O
activity	615	623		|O
.	623	624		|O
DNA	625	628		|O
fragmentation	629	642		|O
and	643	646		|O
annexin	647	654		|O
V	655	656		|O
-	656	657		|O
FITC	657	661		|O
positive	662	670		|O
cells	671	676		|O
were	677	681		|O
taken	682	687		|O
as	688	690		|O
parameters	691	701		|O
of	702	704		|O
apoptosis	705	714		|O
whereas	715	722		|O
NFkappa	723	730		|O
-	730	731		|O
B	731	732		|O
activity	733	741		|O
was	742	745		|O
tested	746	752		|O
by	753	755		|O
the	756	759		|O
expression	760	770		|O
of	771	773		|O
the	774	777		|O
reporter	778	786		|O
vector	787	793		|O
kappaB	794	800		|O
-	800	801		|O
luciferase	801	811		|O
by	812	814		|O
TNF	815	818		|O
-	818	819		|O
alpha	819	824		|O
in	825	827		|O
Hela	828	832		|O
cells	833	838		|O
.	838	839		|O
21	840	842	21-Hydroxy-6,19-epithioprogesterone S,S-dioxide	|B-IUPAC
-	842	843		|I-IUPAC
Hydroxy	843	850		|I-IUPAC
-	850	851		|I-IUPAC
6,19	851	855		|I-IUPAC
-	855	856		|I-IUPAC
epithioprogesterone	856	875		|I-IUPAC
S	876	877		|I-IUPAC
,	877	878		|I-IUPAC
S	878	879		|I-IUPAC
-	879	880		|I-IUPAC
dioxide	880	887		|I-IUPAC
had	888	891		|O
improved	892	900		|O
activity	901	909		|O
in	910	912		|O
both	913	917		|O
parameters	918	928		|O
,	928	929		|O
while	930	935		|O
21	936	938	21-hydroxy-6,19-epithioprogesterone	|B-IUPAC
-	938	939		|I-IUPAC
hydroxy	939	946		|I-IUPAC
-	946	947		|I-IUPAC
6,19	947	951		|I-IUPAC
-	951	952		|I-IUPAC
epithioprogesterone	952	971		|I-IUPAC
had	972	975		|O
improved	976	984		|O
activity	985	993		|O
only	994	998		|O
in	999	1001		|O
blocking	1002	1010		|O
dexamethasone	1011	1024	dexamethasone	|B-TRIVIAL
-	1024	1025		|O
induced	1025	1032		|O
programmed	1033	1043		|O
cell	1044	1048		|O
death	1049	1054		|O
.	1054	1055		|O

### 11754577
A	0	1		|O
number	2	8		|O
of	9	11		|O
derivatives	12	23		|O
structurally	24	36		|O
related	37	44		|O
to	45	47		|O
cirazoline	48	58	cirazoline	|B-TRIVIAL
(	59	60		|O
1	60	61		|O
)	61	62		|O
were	63	67		|O
synthesized	68	79		|O
and	80	83		|O
studied	84	91		|O
with	92	96		|O
the	97	100		|O
purpose	101	108		|O
of	109	111		|O
modulating	112	122		|O
alpha2	123	129		|O
-	129	130		|O
adrenoreceptors	130	145		|O
selectivity	146	157		|O
versus	158	164		|O
both	165	169		|O
alpha1	170	176		|O
-	176	177		|O
adrenoreceptors	177	192		|O
and	193	196		|O
I2	197	199		|O
imidazoline	200	211	imidazoline	|B-TRIVIAL
binding	212	219		|O
sites	220	225		|O
.	225	226		|O
The	227	230		|O
most	231	235		|O
potent	236	242		|O
alpha2	243	249		|O
-	249	250		|O
agonist	250	257		|O
was	258	261		|O
2	262	263	2-[1-(biphenyl-2-yloxy)ethyl]-4,5-dihydro-1H-imidazole	|B-IUPAC
-	263	264		|I-IUPAC
[	264	265		|I-IUPAC
1	265	266		|I-IUPAC
-	266	267		|I-IUPAC
(	267	268		|I-IUPAC
biphenyl	268	276		|I-IUPAC
-	276	277		|I-IUPAC
2	277	278		|I-IUPAC
-	278	279		|I-IUPAC
yloxy	279	284		|I-IUPAC
)	284	285		|I-IUPAC
ethyl	285	290		|I-IUPAC
]	290	291		|I-IUPAC
-	291	292		|I-IUPAC
4,5	292	295		|I-IUPAC
-	295	296		|I-IUPAC
dihydro	296	303		|I-IUPAC
-	303	304		|I-IUPAC
1H	304	306		|I-IUPAC
-	306	307		|I-IUPAC
imidazole	307	316		|I-IUPAC
(	317	318		|O
7	318	319		|O
)	319	320		|O
,	320	321		|O
whose	322	327		|O
key	328	331		|O
pharmacophoric	332	346		|O
features	347	355		|O
closely	356	363		|O
matched	364	371		|O
those	372	377		|O
found	378	383		|O
in	384	386		|O
the	387	390		|O
alpha2	391	397		|O
-	397	398		|O
agonist	398	405		|O
2	406	407	2-(3-exo-(3-phenylprop-1-yl)-2-exo-norbornyl)amino-2-oxazoline	|B-IUPAC
-	407	408		|I-IUPAC
(	408	409		|I-IUPAC
3	409	410		|I-IUPAC
-	410	411		|I-IUPAC
exo	411	414		|I-IUPAC
-	414	415		|I-IUPAC
(	415	416		|I-IUPAC
3	416	417		|I-IUPAC
-	417	418		|I-IUPAC
phenylprop	418	428		|I-IUPAC
-	428	429		|I-IUPAC
1	429	430		|I-IUPAC
-	430	431		|I-IUPAC
yl	431	433		|I-IUPAC
)	433	434		|I-IUPAC
-	434	435		|I-IUPAC
2	435	436		|I-IUPAC
-	436	437		|I-IUPAC
exo	437	440		|I-IUPAC
-	440	441		|I-IUPAC
norbornyl	441	450		|I-IUPAC
)	450	451		|I-IUPAC
amino	451	456		|I-IUPAC
-	456	457		|I-IUPAC
2	457	458		|I-IUPAC
-	458	459		|I-IUPAC
oxazoline	459	468		|I-IUPAC
(	469	470		|O
15	470	472		|O
)	472	473		|O
.	473	474		|O
(	475	476	(S)-(-)-7	|O
S	476	477		|O
)	477	478		|O
-	478	479		|O
(	479	480		|O
-	480	481		|O
)	481	482		|O
-	482	483		|O
7	483	484		|O
was	485	488		|O
the	489	492		|O
most	493	497		|O
potent	498	504		|O
of	505	507		|O
the	508	511		|O
two	512	515		|O
enantiomers	516	527		|O
,	527	528		|O
confirming	529	539		|O
the	540	543		|O
stereospecificity	544	561		|O
of	562	564		|O
the	565	568		|O
interaction	569	580		|O
with	581	585		|O
alpha2	586	592		|O
-	592	593		|O
adrenoreceptors	593	608		|O
.	608	609		|O
This	610	614		|O
eutomer	615	622		|O
was	623	626		|O
tested	627	633		|O
on	634	636		|O
two	637	640		|O
algesiometric	641	654		|O
paradigms	655	664		|O
and	665	668		|O
,	668	669		|O
because	670	677		|O
of	678	680		|O
the	681	684		|O
interaction	685	696		|O
with	697	701		|O
alpha2	702	708		|O
-	708	709		|O
adrenoreceptors	709	724		|O
,	724	725		|O
showed	726	732		|O
a	733	734		|O
potent	735	741		|O
and	742	745		|O
long	746	750		|O
-	750	751		|O
lasting	751	758		|O
antinociceptive	759	774		|O
activity	775	783		|O
,	783	784		|O
since	785	790		|O
it	791	793		|O
was	794	797		|O
abolished	798	807		|O
by	808	810		|O
the	811	814		|O
selective	815	824		|O
alpha2	825	831		|O
-	831	832		|O
antagonist	832	842		|O
RX821002	843	851	RX821002	|B-TRIVIALVAR
.	851	852		|O

### 17368496
17368496	0	8		|O
Tissue	10	16		|O
and	17	20		|O
serum	21	26		|O
levels	27	33		|O
of	34	36		|O
principal	37	46		|O
androgens	47	56	androgens	|B-FAMILY
in	57	59		|O
benign	60	66		|O
prostatic	67	76		|O
hyperplasia	77	88		|O
and	89	92		|O
prostate	93	101		|O
cancer	102	108		|O
.	108	109		|O
Androgens	111	120	Androgens	|B-FAMILY
are	121	124		|O
considered	125	135		|O
to	136	138		|O
play	139	143		|O
a	144	145		|O
substantial	146	157		|O
role	158	162		|O
in	163	165		|O
pathogenesis	166	178		|O
of	179	181		|O
both	182	186		|O
benign	187	193		|O
prostatic	194	203		|O
hyperplasia	204	215		|O
(	216	217		|O
BPH	217	220		|O
)	220	221		|O
and	222	225		|O
prostate	226	234		|O
cancer	235	241		|O
.	241	242		|O
The	243	246		|O
importance	247	257		|O
of	258	260		|O
determination	261	274		|O
of	275	277		|O
androgen	278	286	androgen	|B-FAMILY
levels	287	293		|O
in	294	296		|O
tissue	297	303		|O
and	304	307		|O
serum	308	313		|O
for	314	317		|O
cancer	318	324		|O
progression	325	336		|O
and	337	340		|O
prognosis	341	350		|O
has	351	354		|O
been	355	359		|O
poorly	360	366		|O
understood	367	377		|O
.	377	378		|O
The	379	382		|O
aim	383	386		|O
of	387	389		|O
study	390	395		|O
was	396	399		|O
to	400	402		|O
find	403	407		|O
out	408	411		|O
hormonal	412	420		|O
differences	421	432		|O
in	433	435		|O
both	436	440		|O
diseases	441	449		|O
,	449	450		|O
their	451	456		|O
correlations	457	469		|O
between	470	477		|O
intraprostatic	478	492		|O
and	493	496		|O
serum	497	502		|O
levels	503	509		|O
and	510	513		|O
predicted	514	523		|O
value	524	529		|O
of	530	532		|O
their	533	538		|O
investigation	539	552		|O
.	552	553		|O
Testosterone	554	566	Testosterone	|B-TRIVIAL
,	566	567		|O
dihydrotestosterone	568	587	dihydrotestosterone	|B-TRIVIAL
,	587	588		|O
androstenedione	589	604	androstenedione	|B-TRIVIAL
and	605	608		|O
also	609	613		|O
epitestosterone	614	629	epitestosterone	|B-TRIVIAL
were	630	634		|O
determined	635	645		|O
in	646	648		|O
prostate	649	657		|O
tissue	658	664		|O
from	665	669		|O
57	670	672		|O
patients	673	681		|O
who	682	685		|O
underwent	686	695		|O
transvesical	696	708		|O
prostatectomy	709	722		|O
for	723	726		|O
BPH	727	730		|O
and	731	734		|O
121	735	738		|O
patients	739	747		|O
after	748	753		|O
radical	754	761		|O
prostatectomy	762	775		|O
for	776	779		|O
prostate	780	788		|O
cancer	789	795		|O
.	795	796		|O
In	797	799		|O
75	800	802		|O
subjects	803	811		|O
with	812	816		|O
cancer	817	823		|O
and	824	827		|O
51	828	830		|O
with	831	835		|O
BPH	836	839		|O
the	840	843		|O
serum	844	849		|O
samples	850	857		|O
were	858	862		|O
analyzed	863	871		|O
for	872	875		|O
testosterone	876	888	testosterone	|B-TRIVIAL
,	888	889		|O
dihydrotestosterone	890	909	dihydrotestosterone	|B-TRIVIAL
and	910	913		|O
SHBG	914	918		|O
.	918	919		|O
Significantly	920	933		|O
higher	934	940		|O
intraprostatic	941	955		|O
androgen	956	964	androgen	|B-TRIVIAL
concentrations	965	979		|O
,	979	980		|O
i.e.	981	985		|O
8.85	986	990		|O
+	990	991		|O
/	991	992		|O
-	992	993		|O
6.77	993	997		|O
versus	998	1004		|O
6.44	1005	1009		|O
+	1009	1010		|O
/	1010	1011		|O
-	1011	1012		|O
6.43	1012	1016		|O
pmol	1017	1021		|O
/	1021	1022		|O
g	1022	1023		|O
,	1023	1024		|O
p	1025	1026		|O
<	1026	1027		|O
0.01	1027	1031		|O
for	1032	1035		|O
dihydrotestosterone	1036	1055	dihydrotestosterone	|B-TRIVIAL
,	1055	1056		|O
and	1057	1060		|O
4.61	1061	1065		|O
+	1065	1066		|O
/	1066	1067		|O
-	1067	1068		|O
7.02	1068	1072		|O
versus	1073	1079		|O
3.44	1080	1084		|O
+	1084	1085		|O
/	1085	1086		|O
-	1086	1087		|O
4.53	1087	1091		|O
pmol	1092	1096		|O
/	1096	1097		|O
g	1097	1098		|O
,	1098	1099		|O
p	1100	1101		|O
<	1101	1102		|O
0.05	1102	1106		|O
for	1107	1110		|O
testosterone	1111	1123	testosterone	|B-TRIVIAL
,	1123	1124		|O
respectively	1125	1137		|O
,	1137	1138		|O
were	1139	1143		|O
found	1144	1149		|O
in	1150	1152		|O
patients	1153	1161		|O
with	1162	1166		|O
prostate	1167	1175		|O
cancer	1176	1182		|O
than	1183	1187		|O
in	1188	1190		|O
BPH	1191	1194		|O
.	1194	1195		|O
Higher	1196	1202		|O
levels	1203	1209		|O
in	1210	1212		|O
cancer	1213	1219		|O
tissue	1220	1226		|O
were	1227	1231		|O
found	1232	1237		|O
also	1238	1242		|O
for	1243	1246		|O
epitestosterone	1247	1262	epitestosterone	|B-TRIVIAL
.	1262	1263		|O
However	1264	1271		|O
,	1271	1272		|O
no	1273	1275		|O
differences	1276	1287		|O
were	1288	1292		|O
found	1293	1298		|O
in	1299	1301		|O
serum	1302	1307		|O
levels	1308	1314		|O
.	1314	1315		|O
Highly	1316	1322		|O
significant	1323	1334		|O
correlations	1335	1347		|O
occurred	1348	1356		|O
between	1357	1364		|O
all	1365	1368		|O
pairs	1369	1374		|O
of	1375	1377		|O
intraprostatic	1378	1392		|O
androgens	1393	1402	androgens	|B-FAMILY
and	1403	1406		|O
also	1407	1411		|O
epitestosterone	1412	1427	epitestosterone	|B-TRIVIAL
as	1428	1430		|O
well	1431	1435		|O
as	1436	1438		|O
between	1439	1446		|O
serum	1447	1452		|O
testosterone	1453	1465	testosterone	|B-TRIVIAL
and	1466	1469		|O
dihydrotestosterone	1470	1489	dihydrotestosterone	|B-TRIVIAL
(	1490	1491		|O
p	1491	1492		|O
<	1492	1493		|O
0.001	1493	1498		|O
)	1498	1499		|O
in	1500	1502		|O
both	1503	1507		|O
BPH	1508	1511		|O
and	1512	1515		|O
cancer	1516	1522		|O
groups	1523	1529		|O
.	1529	1530		|O
Correlation	1531	1542		|O
was	1543	1546		|O
not	1547	1550		|O
found	1551	1556		|O
between	1557	1564		|O
corresponding	1565	1578		|O
tissue	1579	1585		|O
and	1586	1589		|O
serum	1590	1595		|O
testosterone	1596	1608	testosterone	|B-TRIVIAL
and	1609	1612		|O
dihydrotestosterone	1613	1632	dihydrotestosterone	|B-TRIVIAL
,	1632	1633		|O
either	1634	1640		|O
in	1641	1643		|O
benign	1644	1650		|O
or	1651	1653		|O
cancer	1654	1660		|O
samples	1661	1668		|O
.	1668	1669		|O
The	1670	1673		|O
results	1674	1681		|O
point	1682	1687		|O
to	1688	1690		|O
importance	1691	1701		|O
of	1702	1704		|O
intraprostatic	1705	1719		|O
hormone	1720	1727		|O
levels	1728	1734		|O
for	1735	1738		|O
evaluation	1739	1749		|O
of	1750	1752		|O
androgen	1753	1761		|O
status	1762	1768		|O
of	1769	1771		|O
patients	1772	1780		|O
,	1780	1781		|O
contrasting	1782	1793		|O
to	1794	1796		|O
a	1797	1798		|O
low	1799	1802		|O
value	1803	1808		|O
of	1809	1811		|O
serum	1812	1817		|O
hormone	1818	1825		|O
measurement	1826	1837		|O
.	1837	1838		|O

### 9079034
XBMP	9	13		|O
-	13	14		|O
1B	14	16		|O
(	17	18		|O
Xtld	18	22		|O
)	22	23		|O
,	23	24		|O
a	25	26		|O
Xenopus	27	34		|O
homolog	35	42		|O
of	43	45		|O
dorso	46	51		|O
-	51	52		|O
ventral	52	59		|O
polarity	60	68		|O
gene	69	73		|O
in	74	76		|O
Drosophila	77	87		|O
,	87	88		|O
modifies	89	97		|O
tissue	98	104		|O
phenotypes	105	115		|O
of	116	118		|O
ventral	119	126		|O
explants	127	135		|O
.	135	136		|O
Previously	138	148		|O
we	149	151		|O
have	152	156		|O
isolated	157	165		|O
a	166	167		|O
Xenopus	168	175		|O
cDNA	176	180		|O
homolog	181	188		|O
of	189	191		|O
bone	192	196		|O
morphogenetic	197	210		|O
protein	211	218		|O
-	218	219		|O
1	219	220		|O
(	221	222		|O
XBMP	222	226		|O
-	226	227		|O
1A	227	229		|O
)	229	230		|O
.	230	231		|O
In	232	234		|O
the	235	238		|O
present	239	246		|O
report	247	253		|O
we	254	256		|O
describe	257	265		|O
a	266	267		|O
new	268	271		|O
cDNA	272	276		|O
clone	277	282		|O
called	283	289		|O
XBMP	290	294		|O
-	294	295		|O
1B	295	297		|O
(	298	299		|O
or	299	301		|O
Xtld	302	306		|O
)	306	307		|O
from	308	312		|O
a	313	314		|O
Xenopus	315	322		|O
embryonic	323	332		|O
library	333	340		|O
.	340	341		|O
Sequence	342	350		|O
analysis	351	359		|O
indicates	360	369		|O
that	370	374		|O
these	375	380		|O
two	381	384		|O
clones	385	391		|O
share	392	397		|O
an	398	400		|O
indentical	401	411		|O
N	412	413		|O
-	413	414		|O
terminal	414	422		|O
sequence	423	431		|O
,	431	432		|O
including	433	442		|O
a	443	444		|O
region	445	451		|O
of	452	454		|O
metalloprotease	455	470		|O
domain	471	477		|O
,	477	478		|O
three	479	484		|O
copies	485	491		|O
of	492	494		|O
a	495	496		|O
repeat	497	503		|O
first	504	509		|O
found	510	515		|O
in	516	518		|O
complement	519	529		|O
proteins	530	538		|O
C1r	539	542		|O
/	542	543		|O
s	543	544		|O
and	545	548		|O
an	549	551		|O
epidermal	552	561		|O
growth	562	568		|O
factor	569	575		|O
(	576	577		|O
EGF	577	580		|O
)	580	581		|O
-	581	582		|O
like	582	586		|O
sequence	587	595		|O
.	595	596		|O
XBMP	597	601		|O
-	601	602		|O
1B	602	604		|O
protein	605	612		|O
has	613	616		|O
an	617	619		|O
additional	620	630		|O
copy	631	635		|O
of	636	638		|O
an	639	641		|O
EGF	642	645		|O
-	645	646		|O
like	646	650		|O
sequence	651	659		|O
followed	660	668		|O
by	669	671		|O
two	672	675		|O
copies	676	682		|O
of	683	685		|O
complement	686	696		|O
1	697	698		|O
r	699	700		|O
/	700	701		|O
s	701	702		|O
repeat	703	709		|O
in	710	712		|O
the	713	716		|O
C	717	718		|O
-	718	719		|O
terminus	719	727		|O
.	727	728		|O
The	729	732		|O
overall	733	740		|O
protein	741	748		|O
structure	749	758		|O
predicted	759	768		|O
from	769	773		|O
the	774	777		|O
XBMP	778	782		|O
-	782	783		|O
1B	783	785		|O
sequence	786	794		|O
reveals	795	802		|O
that	803	807		|O
it	808	810		|O
encodes	811	818		|O
a	819	820		|O
protein	821	828		|O
homologous	829	839		|O
to	840	842		|O
Drosophila	843	853		|O
tolloid	854	861		|O
.	861	862		|O
Three	863	868		|O
XBMP	869	873		|O
-	873	874		|O
1	874	875		|O
transcripts	876	887		|O
(	888	889		|O
2.9	889	892		|O
,	892	893		|O
5.2	894	897		|O
and	898	901		|O
6.6	902	905		|O
kb	906	908		|O
)	908	909		|O
were	910	914		|O
detected	915	923		|O
by	924	926		|O
northern	927	935		|O
blot	936	940		|O
analysis	941	949		|O
.	949	950		|O
However	951	958		|O
,	958	959		|O
the	960	963		|O
2.9	964	967		|O
kb	968	970		|O
transcript	971	981		|O
hybridized	982	992		|O
specifically	993	1005		|O
with	1006	1010		|O
XBMP	1011	1015		|O
-	1015	1016		|O
1A	1016	1018		|O
and	1019	1022		|O
the	1023	1026		|O
5.2	1027	1030		|O
and	1031	1034		|O
6.6	1035	1038		|O
kb	1039	1041		|O
transcripts	1042	1053		|O
hybridized	1054	1064		|O
with	1065	1069		|O
XBMP	1070	1074		|O
-	1074	1075		|O
1B	1075	1077		|O
.	1077	1078		|O
In	1079	1081		|O
Drosophila	1082	1092		|O
,	1092	1093		|O
a	1094	1095		|O
major	1096	1101		|O
function	1102	1110		|O
of	1111	1113		|O
tolloid	1114	1121		|O
is	1122	1124		|O
to	1125	1127		|O
augment	1128	1135		|O
the	1136	1139		|O
activity	1140	1148		|O
of	1149	1151		|O
the	1152	1155		|O
decapentaplegic	1156	1171		|O
gene	1172	1176		|O
product	1177	1184		|O
,	1184	1185		|O
a	1186	1187		|O
close	1188	1193		|O
relative	1194	1202		|O
of	1203	1205		|O
tumor	1206	1211		|O
growth	1212	1218		|O
factor	1219	1225		|O
(	1226	1227		|O
TGF	1227	1230		|O
)	1230	1231		|O
-	1231	1232		|O
beta	1232	1236		|O
superfamily	1237	1248		|O
members	1249	1256		|O
,	1256	1257		|O
BMP	1258	1261		|O
-	1261	1262		|O
2/4	1262	1265		|O
.	1265	1266		|O
Although	1267	1275		|O
XBMP	1276	1280		|O
-	1280	1281		|O
1	1281	1282		|O
and	1283	1286		|O
XBMP	1287	1291		|O
-	1291	1292		|O
4	1292	1293		|O
are	1294	1297		|O
detected	1298	1306		|O
in	1307	1309		|O
various	1310	1317		|O
adult	1318	1323		|O
tissues	1324	1331		|O
of	1332	1334		|O
Xenopus	1335	1342		|O
,	1342	1343		|O
the	1344	1347		|O
expression	1348	1358		|O
pattern	1359	1366		|O
of	1367	1369		|O
these	1370	1375		|O
two	1376	1379		|O
genes	1380	1385		|O
was	1386	1389		|O
not	1390	1393		|O
tightly	1394	1401		|O
correlated	1402	1412		|O
.	1412	1413		|O
In	1414	1416		|O
the	1417	1420		|O
embryo	1421	1427		|O
,	1427	1428		|O
the	1429	1432		|O
expression	1433	1443		|O
of	1444	1446		|O
XBMP	1447	1451		|O
-	1451	1452		|O
1	1452	1453		|O
increased	1454	1463		|O
gradually	1464	1473		|O
from	1474	1478		|O
the	1479	1482		|O
morula	1483	1489		|O
to	1490	1492		|O
the	1493	1496		|O
swimming	1497	1505		|O
tadpole	1506	1513		|O
stages	1514	1520		|O
.	1520	1521		|O
Injection	1522	1531		|O
of	1532	1534		|O
XBMP	1535	1539		|O
-	1539	1540		|O
1B	1540	1542		|O
RNA	1543	1546		|O
into	1547	1551		|O
the	1552	1555		|O
ventral	1556	1563		|O
blastomeres	1564	1575		|O
at	1576	1578		|O
the	1579	1582		|O
4	1583	1584		|O
-	1584	1585		|O
cell	1585	1589		|O
stage	1590	1595		|O
caused	1596	1602		|O
an	1603	1605		|O
elongation	1606	1616		|O
of	1617	1619		|O
the	1620	1623		|O
ventral	1624	1631		|O
marginal	1632	1640		|O
zone	1641	1645		|O
explants	1646	1654		|O
and	1655	1658		|O
converted	1659	1668		|O
globin	1669	1675		|O
-	1675	1676		|O
positive	1676	1684		|O
blood	1685	1690		|O
cells	1691	1696		|O
to	1697	1699		|O
mesenchymal	1700	1711		|O
and	1712	1715		|O
muscle	1716	1722		|O
tissues	1723	1730		|O
at	1731	1733		|O
later	1734	1739		|O
stages	1740	1746		|O
.	1746	1747		|O
It	1748	1750		|O
was	1751	1754		|O
shown	1755	1760		|O
that	1761	1765		|O
XBMP	1766	1770		|O
-	1770	1771		|O
1A	1771	1773		|O
was	1774	1777		|O
less	1778	1782		|O
active	1783	1789		|O
and	1790	1793		|O
a	1794	1795		|O
1A	1796	1798		|O
mutant	1799	1805		|O
lacking	1806	1813		|O
the	1814	1817		|O
signal	1818	1824		|O
sequence	1825	1833		|O
was	1834	1837		|O
inactive	1838	1846		|O
.	1846	1847		|O
Further	1848	1855		|O
studies	1856	1863		|O
revealed	1864	1872		|O
that	1873	1877		|O
injection	1878	1887		|O
of	1888	1890		|O
XBMP	1891	1895		|O
-	1895	1896		|O
1B	1896	1898		|O
RNA	1899	1902		|O
into	1903	1907		|O
the	1908	1911		|O
ventral	1912	1919		|O
marginal	1920	1928		|O
zone	1929	1933		|O
induced	1934	1941		|O
up	1942	1944		|O
-	1944	1945		|O
regulation	1945	1955		|O
of	1956	1958		|O
dorsal	1959	1965		|O
marginal	1966	1974		|O
zone	1975	1979		|O
markers	1980	1987		|O
,	1987	1988		|O
such	1989	1993		|O
as	1994	1996		|O
goosecoid	1997	2006		|O
and	2007	2010		|O
chordin	2011	2018		|O
,	2018	2019		|O
at	2020	2022		|O
the	2023	2026		|O
gastrulation	2027	2039		|O
stage	2040	2045		|O
.	2045	2046		|O
These	2047	2052		|O
data	2053	2057		|O
indicate	2058	2066		|O
that	2067	2071		|O
XBMP	2072	2076		|O
-	2076	2077		|O
1	2077	2078		|O
may	2079	2082		|O
have	2083	2087		|O
a	2088	2089		|O
role	2090	2094		|O
in	2095	2097		|O
determining	2098	2109		|O
dorso	2110	2115		|O
-	2115	2116		|O
ventral	2116	2123		|O
patterning	2124	2134		|O
in	2135	2137		|O
Xenopus	2138	2145		|O
,	2145	2146		|O
but	2147	2150		|O
in	2151	2153		|O
a	2154	2155		|O
different	2156	2165		|O
way	2166	2169		|O
from	2170	2174		|O
the	2175	2178		|O
dpp	2179	2182		|O
/	2182	2183		|O
tolloid	2183	2190		|O
system	2191	2197		|O
demonstrated	2198	2210		|O
in	2211	2213		|O
Drosophila	2214	2224		|O
.	2224	2225		|O

### 7783132
Spiro	0	5		|O
[	5	6		|O
isobenzofuran	6	19		|O
-	19	20		|O
1	20	21		|O
(	21	22		|O
3H	22	24		|O
)	24	25		|O
,	25	26		|O
4'	26	28		|O
-	28	29		|O
piperidines	29	40		|O
]	40	41		|O
and	42	45		|O
the	46	49		|O
corresponding	50	63		|O
benzofuran	64	74	benzofuran	|B-TRIVIAL
and	75	78		|O
benzopyran	79	89	benzopyran	|B-TRIVIAL
derivatives	90	101	derivatives	|B-MODIFIER
have	102	106		|O
been	107	111		|O
synthesized	112	123		|O
and	124	127		|O
evaluated	128	137		|O
as	138	140		|O
sigma	141	146		|O
ligands	147	154		|O
.	154	155		|O
The	156	159		|O
compounds	160	169		|O
are	170	173		|O
related	174	181		|O
to	182	184		|O
Lu	185	187	Lu 28-179	|B-TRIVIALVAR
28-179	188	194		|I-TRIVIALVAR
(	195	196		|O
1'	196	198	1'-[4-[1-(4-fluorophenyl)-1H-indol-3-yl]-1- butyl]spiro[isobenzofuran-1(3H),4'-piperidine]	|B-IUPAC
-	198	199		|I-IUPAC
[	199	200		|I-IUPAC
4	200	201		|I-IUPAC
-	201	202		|I-IUPAC
[	202	203		|I-IUPAC
1	203	204		|I-IUPAC
-	204	205		|I-IUPAC
(	205	206		|I-IUPAC
4	206	207		|I-IUPAC
-	207	208		|I-IUPAC
fluorophenyl	208	220		|I-IUPAC
)	220	221		|I-IUPAC
-	221	222		|I-IUPAC
1H	222	224		|I-IUPAC
-	224	225		|I-IUPAC
indol	225	230		|I-IUPAC
-	230	231		|I-IUPAC
3	231	232		|I-IUPAC
-	232	233		|I-IUPAC
yl	233	235		|I-IUPAC
]	235	236		|I-IUPAC
-	236	237		|I-IUPAC
1	237	238		|I-IUPAC
-	238	239		|I-IUPAC
butyl	240	245		|I-IUPAC
]	245	246		|I-IUPAC
spiro	246	251		|I-IUPAC
[	251	252		|I-IUPAC
isobenzofuran	252	265		|I-IUPAC
-	265	266		|I-IUPAC
1	266	267		|I-IUPAC
(	267	268		|I-IUPAC
3H	268	270		|I-IUPAC
)	270	271		|I-IUPAC
,	271	272		|I-IUPAC
4'	272	274		|I-IUPAC
-	274	275		|I-IUPAC
piperidine	275	285		|I-IUPAC
]	285	286		|I-IUPAC
)	286	287		|O
that	288	292		|O
has	293	296		|O
been	297	301		|O
demonstrated	302	314		|O
to	315	317		|O
be	318	320		|O
a	321	322		|O
selective	323	332		|O
sigma	333	338		|O
2	339	340		|O
ligand	341	347		|O
with	348	352		|O
affinity	353	361		|O
in	362	364		|O
the	365	368		|O
subnanomolar	369	381		|O
range	382	387		|O
.	387	388		|O
The	389	392		|O
object	393	399		|O
of	400	402		|O
the	403	406		|O
study	407	412		|O
was	413	416		|O
to	417	419		|O
determine	420	429		|O
the	430	433		|O
structural	434	444		|O
factors	445	452		|O
governing	453	462		|O
sigma	463	468		|O
1	469	470		|O
/	470	471		|O
sigma	471	476		|O
2	477	478		|O
affinity	479	487		|O
and	488	491		|O
selectivity	492	503		|O
within	504	510		|O
this	511	515		|O
class	516	521		|O
of	522	524		|O
compounds	525	534		|O
.	534	535		|O
The	536	539		|O
N	539	540	 N-substituent	|B-PARTIUPAC
-	541	542		|I-PARTIUPAC
substituent	542	553		|I-PARTIUPAC
in	554	556		|O
spiro	557	562	spiro[isobenzofuran-1(3H),4'-piperidines]	|B-IUPAC
[	562	563		|I-IUPAC
isobenzofuran	563	576		|I-IUPAC
-	576	577		|I-IUPAC
1	577	578		|I-IUPAC
(	578	579		|I-IUPAC
3H	579	581		|I-IUPAC
)	581	582		|I-IUPAC
,	582	583		|I-IUPAC
4'	583	585		|I-IUPAC
-	585	586		|I-IUPAC
piperidines	586	597		|I-IUPAC
]	597	598		|I-IUPAC
is	599	601		|O
highly	602	608		|O
important	609	618		|O
,	618	619		|O
both	620	624		|O
for	625	628		|O
affinity	629	637		|O
and	638	641		|O
selectivity	642	653		|O
.	653	654		|O
Spiropiperidines	655	671	Spiropiperidines	|B-TRIVIAL
with	672	676		|O
no	677	679		|O
or	680	682		|O
small	683	688		|O
N	689	690	N-substituents	|B-PARTIUPAC
-	690	691		|I-PARTIUPAC
substituents	691	703		|I-PARTIUPAC
(	704	705		|O
H	705	706	H	|B-SUM
,	706	707		|O
Me	708	710	Me	|B-ABBREVIATION
,	710	711		|O
Et	712	714	Et	|B-ABBREVIATION
)	714	715		|O
exert	716	721		|O
very	722	726		|O
low	727	730		|O
affinity	731	739		|O
for	740	743		|O
both	744	748		|O
sigma	749	754		|O
1	755	756		|O
and	757	760		|O
sigma	761	766		|O
2	767	768		|O
binding	769	776		|O
sites	777	782		|O
(	783	784		|O
IC50	784	788		|O
(	788	789		|O
sigma	789	794		|O
1	795	796		|O
,	796	797		|O
sigma	798	803		|O
2	804	805		|O
)	805	806		|O
&	807	808		|O
gt	808	810		|O
;	810	811		|O
nM	816	818		|O
)	818	819		|O
,	819	820		|O
whereas	821	828		|O
medium	829	835		|O
-	835	836		|O
sized	836	841		|O
substituents	842	854		|O
(	855	856		|O
e.g.	856	860		|O
,	860	861		|O
Pr	862	864	Pr	|B-ABBREVIATION
,	864	865		|O
Bu	866	868	Bu	|B-ABBREVIATION
,	868	869		|O
Ph	870	872	Ph(CH2)2	|B-SUM
(	872	873		|I-SUM
CH2	873	876		|I-SUM
)	876	877		|I-SUM
2	877	878		|I-SUM
)	878	879		|O
result	880	886		|O
in	887	889		|O
potent	890	896		|O
,	896	897		|O
but	898	901		|O
unselective	902	913		|O
compounds	914	923		|O
(	924	925		|O
IC50	925	929		|O
(	929	930		|O
sigma	930	935		|O
1	936	937		|O
,	937	938		|O
sigma	939	944		|O
2	945	946		|O
)	946	947		|O
=	948	949		|O
2-5	950	953		|O
nM	954	956		|O
)	956	957		|O
.	957	958		|O
Increasing	959	969		|O
the	970	973		|O
chain	974	979		|O
length	980	986		|O
and	987	990		|O
the	991	994		|O
lipophilicity	995	1008		|O
of	1009	1011		|O
the	1012	1015		|O
N	1016	1017	N-substituent	|B-PARTIUPAC
-	1017	1018		|I-PARTIUPAC
substituent	1018	1029		|I-PARTIUPAC
result	1030	1036		|O
in	1037	1039		|O
compounds	1040	1049		|O
in	1050	1052		|O
which	1053	1058		|O
high	1059	1063		|O
affinity	1064	1072		|O
for	1073	1076		|O
sigma	1077	1082		|O
2	1083	1084		|O
binding	1085	1092		|O
sites	1093	1098		|O
is	1099	1101		|O
retained	1102	1110		|O
and	1111	1114		|O
with	1115	1119		|O
selectivity	1120	1131		|O
for	1132	1135		|O
sigma	1136	1141		|O
2	1142	1143		|O
vs	1144	1146		|O
sigma	1147	1152		|O
1	1153	1154		|O
binding	1155	1162		|O
sites	1163	1168		|O
(	1169	1170		|O
e.g.	1170	1174		|O
,	1174	1175		|O
4	1176	1177	4-cyclohexyl-1-butyl	|B-IUPAC
-	1177	1178		|I-IUPAC
cyclohexyl	1178	1188		|I-IUPAC
-	1188	1189		|I-IUPAC
1	1189	1190		|I-IUPAC
-	1190	1191		|I-IUPAC
butyl	1191	1196		|I-IUPAC
:	1196	1197		|O
IC50	1198	1202		|O
-	1202	1203		|O
(	1203	1204		|O
sigma	1204	1209		|O
1	1210	1211		|O
)	1211	1212		|O
=	1213	1214		|O
1.5	1215	1218		|O
nM	1219	1221		|O
,	1221	1222		|O
IC50	1223	1227		|O
(	1227	1228		|O
sigma	1228	1233		|O
2	1234	1235		|O
)	1235	1236		|O
=	1237	1238		|O
0.07	1239	1243		|O
nM	1244	1246		|O
)	1246	1247		|O
.	1247	1248		|O
Introduction	1249	1261		|O
of	1262	1264		|O
substituents	1265	1277		|O
in	1278	1280		|O
the	1281	1284		|O
benzene	1285	1292	benzene	|B-TRIVIAL
ring	1293	1297		|O
of	1298	1300		|O
the	1301	1304		|O
spiro	1305	1310	spiro[isobenzofuran-1(3H),4'-piperidine]	|B-IUPAC
[	1310	1311		|I-IUPAC
isobenzofuran	1311	1324		|I-IUPAC
-	1324	1325		|I-IUPAC
1	1325	1326		|I-IUPAC
(	1326	1327		|I-IUPAC
3H	1327	1329		|I-IUPAC
)	1329	1330		|I-IUPAC
,	1330	1331		|I-IUPAC
4'	1331	1333		|I-IUPAC
-	1333	1334		|I-IUPAC
piperidine	1334	1344		|I-IUPAC
]	1344	1345		|I-IUPAC
ring	1346	1350		|O
system	1351	1357		|O
of	1358	1360		|O
Lu	1361	1363	Lu 28-179	|B-TRIVIAL
28-179	1364	1370		|I-TRIVIAL
mainly	1371	1377		|O
affects	1378	1385		|O
affinity	1386	1394		|O
for	1395	1398		|O
sigma	1399	1404		|O
1	1405	1406		|O
binding	1407	1414		|O
sites	1415	1420		|O
.	1420	1421		|O
Compounds	1422	1431		|O
with	1432	1436		|O
substituents	1437	1449		|O
(	1450	1451		|O
F	1451	1452	F	|B-SUM
,	1452	1453		|O
CF3	1454	1457	CF3	|B-SUM
)	1457	1458		|O
in	1459	1461		|O
the	1462	1465		|O
4	1466	1467		|O
-	1467	1468		|O
or	1469	1471		|O
7	1472	1473		|O
-	1473	1474		|O
position	1474	1482		|O
of	1483	1485		|O
the	1486	1489		|O
isobenzofuran	1490	1503	isobenzofuran	|B-TRIVIAL
display	1504	1511		|O
high	1512	1516		|O
affinity	1517	1525		|O
for	1526	1529		|O
sigma	1530	1535		|O
2	1536	1537		|O
binding	1538	1545		|O
sites	1546	1551		|O
(	1552	1553		|O
IC50	1553	1557		|O
(	1557	1558		|O
sigma	1558	1563		|O
2	1564	1565		|O
)	1565	1566		|O
=	1567	1568		|O
0.5-2	1569	1574		|O
nM	1575	1577		|O
)	1577	1578		|O
and	1579	1582		|O
very	1583	1587		|O
low	1588	1591		|O
affinity	1592	1600		|O
for	1601	1604		|O
sigma	1605	1610		|O
1	1611	1612		|O
binding	1613	1620		|O
sites	1621	1626		|O
(	1627	1628		|O
IC50	1628	1632		|O
(	1632	1633		|O
sigma	1633	1638		|O
1	1639	1640		|O
)	1640	1641		|O
&	1642	1643		|O
gt	1643	1645		|O
;	1645	1646		|O
nM	1651	1653		|O
)	1653	1654		|O
.	1654	1655		|O
Compounds	1656	1665		|O
with	1666	1670		|O
substituents	1671	1683		|O
(	1684	1685		|O
F	1685	1686	F	|B-ABBREVIATION
,	1686	1687		|O
CF3	1688	1691	CF3	|B-ABBREVIATION
,	1691	1692		|O
Me	1693	1695	Me	|B-ABBREVIATION
)	1695	1696		|O
in	1697	1699		|O
the	1700	1703		|O
5	1704	1705		|O
-	1705	1706		|O
or	1707	1709		|O
6	1710	1711		|O
-	1711	1712		|O
position	1712	1720		|O
of	1721	1723		|O
the	1724	1727		|O
isobenzofuran	1728	1741	isobenzofuran	|B-TRIVIAL
exert	1742	1747		|O
increased	1748	1757		|O
affinity	1758	1766		|O
for	1767	1770		|O
sigma	1771	1776		|O
1	1777	1778		|O
binding	1779	1786		|O
sites	1787	1792		|O
(	1793	1794		|O
IC50	1794	1798		|O
(	1798	1799		|O
sigma	1799	1804		|O
1	1805	1806		|O
)	1806	1807		|O
=	1808	1809		|O
5-30	1810	1814		|O
nM	1815	1817		|O
,	1817	1818		|O
IC50	1819	1823		|O
(	1823	1824		|O
sigma	1824	1829		|O
2	1830	1831		|O
)	1831	1832		|O
=	1833	1834		|O
0.3-7	1835	1840		|O
nM	1841	1843		|O
)	1843	1844		|O
,	1844	1845		|O
thus	1846	1850		|O
rendering	1851	1860		|O
unselective	1861	1872		|O
compounds	1873	1882		|O
.	1882	1883		|O
Exchanging	1884	1894		|O
the	1895	1898		|O
isobenzofuran	1899	1912	isobenzofuran	|B-TRIVIAL
moiety	1913	1919		|O
of	1920	1922		|O
Lu	1923	1925	Lu 28-179	|B-TRIVIALVAR
28-179	1926	1932		|I-TRIVIALVAR
with	1933	1937		|O
thioisobenzofuran	1938	1955	thioisobenzofuran	|B-TRIVIAL
,	1955	1956		|O
benzofuran	1957	1967	benzofuran	|B-IUPAC
,	1967	1968		|O
or	1969	1971		|O
benzopyran	1972	1982	benzopyran	|B-TRIVIAL
also	1983	1987		|O
has	1988	1991		|O
a	1992	1993		|O
pronounced	1994	2004		|O
effect	2005	2011		|O
on	2012	2014		|O
both	2015	2019		|O
affinity	2020	2028		|O
and	2029	2032		|O
selectivity	2033	2044		|O
for	2045	2048		|O
sigma	2049	2054		|O
binding	2055	2062		|O
sites	2063	2068		|O
.	2068	2069		|O
The	2070	2073		|O
position	2074	2082		|O
of	2083	2085		|O
the	2086	2089		|O
oxygen	2090	2096		|O
atom	2097	2101		|O
and	2102	2105		|O
the	2106	2109		|O
position	2110	2118		|O
of	2119	2121		|O
the	2122	2125		|O
spiroconnection	2126	2141		|O
with	2142	2146		|O
the	2147	2150		|O
4	2151	2152		|O
-	2152	2153		|O
position	2153	2161		|O
of	2162	2164		|O
the	2165	2168		|O
piperidine	2169	2179	piperidine	|B-TRIVIAL
ring	2180	2184		|O
were	2185	2189		|O
varied	2190	2196		|O
,	2196	2197		|O
and	2198	2201		|O
only	2202	2206		|O
compounds	2207	2216		|O
in	2217	2219		|O
which	2220	2225		|O
both	2226	2230		|O
the	2231	2234		|O
benzene	2235	2242	benzene	|B-TRIVIAL
ring	2243	2247		|O
and	2248	2251		|O
the	2252	2255		|O
heteroatom	2256	2266		|O
are	2267	2270		|O
attached	2271	2279		|O
directly	2280	2288		|O
to	2289	2291		|O
the	2292	2295		|O
piperidine	2296	2306	piperidine	|B-TRIVIAL
ring	2307	2311		|O
retain	2312	2318		|O
high	2319	2323		|O
affinity	2324	2332		|O
and	2333	2336		|O
selectivity	2337	2348		|O
for	2349	2352		|O
sigma	2353	2358		|O
2	2359	2360		|O
binding	2361	2368		|O
sites	2369	2374		|O
(	2375	2376		|O
e.g.	2376	2380		|O
,	2380	2381		|O
3,4	2382	2385	3,4-dihydro-1'-[4-[1-(4-fluorophenyl)-1H-indol-3-yl]-1- butyl]spiro[1H-2-benzopyran-1,4'-piperidine]	|B-IUPAC
-	2385	2386		|I-IUPAC
dihydro	2386	2393		|I-IUPAC
-	2393	2394		|I-IUPAC
1'	2394	2396		|I-IUPAC
-	2396	2397		|I-IUPAC
[	2397	2398		|I-IUPAC
4	2398	2399		|I-IUPAC
-	2399	2400		|I-IUPAC
[	2400	2401		|I-IUPAC
1	2401	2402		|I-IUPAC
-	2402	2403		|I-IUPAC
(	2403	2404		|I-IUPAC
4	2404	2405		|I-IUPAC
-	2405	2406		|I-IUPAC
fluorophenyl	2406	2418		|I-IUPAC
)	2418	2419		|I-IUPAC
-	2419	2420		|I-IUPAC
1H	2420	2422		|I-IUPAC
-	2422	2423		|I-IUPAC
indol	2423	2428		|I-IUPAC
-	2428	2429		|I-IUPAC
3	2429	2430		|I-IUPAC
-	2430	2431		|I-IUPAC
yl	2431	2433		|I-IUPAC
]	2433	2434		|I-IUPAC
-	2434	2435		|I-IUPAC
1	2435	2436		|I-IUPAC
-	2436	2437		|I-IUPAC
butyl	2438	2443		|I-IUPAC
]	2443	2444		|I-IUPAC
spiro	2444	2449		|I-IUPAC
[	2449	2450		|I-IUPAC
1H	2450	2452		|I-IUPAC
-	2452	2453		|I-IUPAC
2	2453	2454		|I-IUPAC
-	2454	2455		|I-IUPAC
benzopyran	2455	2465		|I-IUPAC
-	2465	2466		|I-IUPAC
1,4	2466	2469		|I-IUPAC
'	2469	2470		|I-IUPAC
-	2470	2471		|I-IUPAC
piperidine	2471	2481		|I-IUPAC
]	2481	2482		|I-IUPAC
:	2482	2483		|O
IC50	2484	2488		|O
(	2488	2489		|O
sigma	2489	2494		|O
1	2495	2496		|O
)	2496	2497		|O
=	2498	2499		|O
53	2500	2502		|O
nM	2503	2505		|O
,	2505	2506		|O
IC50	2507	2511		|O
(	2511	2512		|O
sigma	2512	2517		|O
2	2518	2519		|O
)	2519	2520		|O
=	2521	2522		|O
0.9	2523	2526		|O
nM	2527	2529		|O
)	2529	2530		|O
.	2530	2531		|O
(	2531	2532		|O
ABSTRACT	2532	2540		|O
TRUNCATED	2541	2550		|O
AT	2551	2553		|O
WORDS	2558	2563		|O
)	2563	2564		|O

### 11602181
Maitotoxin	10	20	Maitotoxin	|B-TRIVIAL
-	20	21		|O
induced	21	28		|O
calcium	29	36		|O
entry	37	42		|O
in	43	45		|O
human	46	51		|O
lymphocytes	52	63		|O
:	63	64		|O
modulation	65	75		|O
by	76	78		|O
yessotoxin	79	89	yessotoxin	|B-TRIVIAL
,	89	90		|O
Ca	91	93	Ca(2+)	|B-SUM
(	93	94		|I-SUM
2+	94	96		|I-SUM
)	96	97		|I-SUM
channel	98	105		|O
blockers	106	114		|O
and	115	118		|O
kinases	119	126		|O
.	126	127		|O
We	129	131		|O
have	132	136		|O
studied	137	144		|O
the	145	148		|O
effect	149	155		|O
of	156	158		|O
the	159	162		|O
ciguatera	163	172		|O
-	172	173		|O
related	173	180		|O
toxin	181	186		|O
maitotoxin	187	197	maitotoxin	|B-TRIVIAL
(	198	199		|O
MTX	199	202	MTX	|B-ABBREVIATION
)	202	203		|O
on	204	206		|O
the	207	210		|O
cytosolic	211	220		|O
free	221	225		|O
calcium	226	233	calcium	|B-TRIVIAL
concentration	234	247		|O
(	248	249		|O
[	249	250		|O
Ca	250	252	Ca(2+)	|B-SUM
(	252	253		|I-SUM
2+	253	255		|I-SUM
)	255	256		|I-SUM
]	256	257		|O
i	257	258		|O
)	258	259		|O
of	260	262		|O
human	263	268		|O
peripheral	269	279		|O
blood	280	285		|O
lymphocytes	286	297		|O
loaded	298	304		|O
with	305	309		|O
the	310	313		|O
fluorescent	314	325		|O
probe	326	331		|O
Fura2	332	337		|O
and	338	341		|O
the	342	345		|O
regulation	346	356		|O
of	357	359		|O
MTX	360	363	MTX	|B-ABBREVIATION
action	364	370		|O
by	371	373		|O
different	374	383		|O
drugs	384	389		|O
known	390	395		|O
to	396	398		|O
interfere	399	408		|O
in	409	411		|O
cellular	412	420		|O
Ca	421	423	Ca(2+)	|B-SUM
(	423	424		|I-SUM
2+	424	426		|I-SUM
)	426	427		|I-SUM
signalling	428	438		|O
mechanisms	439	449		|O
and	450	453		|O
by	454	456		|O
the	457	460		|O
marine	461	467		|O
phycotoxin	468	478		|O
yessotoxin	479	489	yessotoxin	|B-TRIVIAL
(	490	491		|O
YTX	491	494	YTX	|B-ABBREVIATION
)	494	495		|O
.	495	496		|O
MTX	497	500	MTX	|B-ABBREVIATION
produced	501	509		|O
a	510	511		|O
concentration	512	525		|O
-	525	526		|O
dependent	526	535		|O
elevation	536	545		|O
of	546	548		|O
[	549	550		|O
Ca	550	552	Ca(2+)	|B-SUM
(	552	553		|I-SUM
2+	553	555		|I-SUM
)	555	556		|I-SUM
]	556	557		|O
i	557	558		|O
in	559	561		|O
a	562	563		|O
Ca	564	566	Ca(2+)	|B-SUM
(	566	567		|I-SUM
2+	567	569		|I-SUM
)	569	570		|I-SUM
-	570	571		|O
containing	571	581		|O
medium	582	588		|O
.	588	589		|O
This	590	594		|O
effect	595	601		|O
was	602	605		|O
stimulated	606	616		|O
by	617	619		|O
pretreatment	620	632		|O
with	633	637		|O
YTX	638	641	YTX	|B-ABBREVIATION
1	642	643		|O
microM	644	650		|O
and	651	654		|O
NiCl	655	659	NiCl(2)	|B-SUM
(	659	660		|I-SUM
2	660	661		|I-SUM
)	661	662		|I-SUM
15	663	665		|O
microM	666	672		|O
.	672	673		|O
The	674	677		|O
voltage	678	685		|O
-	685	686		|O
independent	686	697		|O
Ca	698	700	Ca(2+)	|B-SUM
(	700	701		|I-SUM
2+	701	703		|I-SUM
)	703	704		|I-SUM
channel	705	712		|O
antagonist	713	723		|O
1	724	725	1-[beta-[3-(4-methoxyphenyl)propoxyl]-4-methoxyphenyl]-1H-imidazole hydrochloride	|B-IUPAC
-	725	726		|I-IUPAC
[	726	727		|I-IUPAC
beta	727	731		|I-IUPAC
-	731	732		|I-IUPAC
[	732	733		|I-IUPAC
3	733	734		|I-IUPAC
-	734	735		|I-IUPAC
(	735	736		|I-IUPAC
4	736	737		|I-IUPAC
-	737	738		|I-IUPAC
methoxyphenyl	738	751		|I-IUPAC
)	751	752		|I-IUPAC
propoxyl	752	760		|I-IUPAC
]	760	761		|I-IUPAC
-	761	762		|I-IUPAC
4	762	763		|I-IUPAC
-	763	764		|I-IUPAC
methoxyphenyl	764	777		|I-IUPAC
]	777	778		|I-IUPAC
-	778	779		|I-IUPAC
1H	779	781		|I-IUPAC
-	781	782		|I-IUPAC
imidazole	782	791		|I-IUPAC
hydrochloride	792	805		|I-IUPAC
(	806	807		|O
SKF96365	807	815	SKF96365	|B-TRIVIALVAR
)	815	816		|O
blocked	817	824		|O
the	825	828		|O
MTX	829	832	MTX	|B-ABBREVIATION
-	832	833		|O
induced	833	840		|O
[	841	842		|O
Ca	842	844	Ca(2+)	|B-SUM
(	844	845		|I-SUM
2+	845	847		|I-SUM
)	847	848		|I-SUM
]	848	849		|O
i	849	850		|O
elevation	851	860		|O
,	860	861		|O
while	862	867		|O
the	868	871		|O
L	872	873		|O
-	873	874		|O
type	874	878		|O
channel	879	886		|O
blocker	887	894		|O
nifedipine	895	905	nifedipine	|B-TRIVIAL
had	906	909		|O
no	910	912		|O
effect	913	919		|O
.	919	920		|O
Pretreatment	921	933		|O
with	934	938		|O
NiCl	939	943	NiCl(2)	|B-SUM
(	943	944		|I-SUM
2	944	945		|I-SUM
)	945	946		|I-SUM
or	947	949		|O
nifedipine	950	960	nifedipine	|B-TRIVIAL
did	961	964		|O
not	965	968		|O
modify	969	975		|O
YTX	976	979	YTX	|B-ABBREVIATION
-	979	980		|O
induced	980	987		|O
potentiation	988	1000		|O
of	1001	1003		|O
MTX	1004	1007	MTX	|B-ABBREVIATION
effect	1008	1014		|O
,	1014	1015		|O
and	1016	1019		|O
SKF96365	1020	1028	SKF96365	|B-TRIVIAL
-	1028	1029		|O
induced	1029	1036		|O
inhibition	1037	1047		|O
was	1048	1051		|O
reduced	1052	1059		|O
in	1060	1062		|O
the	1063	1066		|O
presence	1067	1075		|O
of	1076	1078		|O
YTX	1079	1082	YTX	|B-ABBREVIATION
,	1082	1083		|O
which	1084	1089		|O
suggest	1090	1097		|O
different	1098	1107		|O
pathways	1108	1116		|O
to	1117	1119		|O
act	1120	1123		|O
on	1124	1126		|O
[	1127	1128		|O
Ca	1128	1130	Ca(2+)	|B-SUM
(	1130	1131		|I-SUM
2+	1131	1133		|I-SUM
)	1133	1134		|I-SUM
]	1134	1135		|O
i	1135	1136		|O
.	1136	1137		|O
Preincubation	1138	1151		|O
with	1152	1156		|O
N	1157	1158	N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide	|B-IUPAC
-	1158	1159		|I-IUPAC
[	1159	1160		|I-IUPAC
2	1160	1161		|I-IUPAC
-	1161	1162		|I-IUPAC
(	1162	1163		|I-IUPAC
p	1163	1164		|I-IUPAC
-	1164	1165		|I-IUPAC
bromocinnamylamino	1165	1183		|I-IUPAC
)	1183	1184		|I-IUPAC
ethyl	1184	1189		|I-IUPAC
]	1189	1190		|I-IUPAC
-	1190	1191		|I-IUPAC
5	1191	1192		|I-IUPAC
-	1192	1193		|I-IUPAC
isoquinolinesulfonamide	1193	1216		|I-IUPAC
.	1216	1217		|O
2HCl	1217	1221	2HCl	|B-SUM
(	1222	1223		|O
H	1223	1224	H-89	|B-TRIVIALVAR
-	1224	1225		|I-TRIVIALVAR
89	1225	1227		|I-TRIVIALVAR
)	1227	1228		|O
or	1229	1231		|O
genistein	1232	1241	genistein	|B-TRIVIAL
(	1242	1243		|O
microM	1246	1252		|O
)	1252	1253		|O
also	1254	1258		|O
had	1259	1262		|O
no	1263	1265		|O
effect	1266	1272		|O
on	1273	1275		|O
the	1276	1279		|O
MTX	1280	1283	MTX	|B-ABBREVIATION
-	1283	1284		|O
induced	1284	1291		|O
[	1292	1293		|O
Ca	1293	1295	Ca(2+)	|B-SUM
(	1295	1296		|I-SUM
2+	1296	1298		|I-SUM
)	1298	1299		|I-SUM
]	1299	1300		|O
i	1300	1301		|O
increment	1302	1311		|O
.	1311	1312		|O
In	1313	1315		|O
contrast	1316	1324		|O
,	1324	1325		|O
the	1326	1329		|O
PKC	1330	1333		|O
inhibitor	1334	1343		|O
bisindolilmaleimide	1344	1363	bisindolilmaleimide I	|B-TRIVIAL
I	1364	1365		|I-TRIVIAL
(	1366	1367		|O
GF109203X	1367	1376	GF109203X	|B-TRIVIALVAR
1	1377	1378		|O
microM	1379	1385		|O
)	1385	1386		|O
potentiated	1387	1398		|O
the	1399	1402		|O
MTX	1403	1406	MTX	|B-ABBREVIATION
effect	1407	1413		|O
,	1413	1414		|O
whereas	1415	1422		|O
phosphatidylinositol	1423	1443		|O
(	1444	1445		|O
PI	1445	1447		|O
)	1447	1448		|O
3	1449	1450		|O
-	1450	1451		|O
kinase	1451	1457		|O
inhibition	1458	1468		|O
with	1469	1473		|O
wortmannin	1474	1484	wortmannin	|B-TRIVIAL
(	1485	1486		|O
nM	1489	1491		|O
)	1491	1492		|O
reduced	1493	1500		|O
the	1501	1504		|O
MTX	1505	1508	MTX	|B-ABBREVIATION
-	1508	1509		|O
elicited	1509	1517		|O
Ca	1518	1520	Ca(2+)	|B-SUM
(	1520	1521		|I-SUM
2+	1521	1523		|I-SUM
)	1523	1524		|I-SUM
entry	1525	1530		|O
.	1530	1531		|O
In	1532	1534		|O
summary	1535	1542		|O
,	1542	1543		|O
MTX	1544	1547	MTX	|B-ABBREVIATION
produced	1548	1556		|O
Ca	1557	1559	Ca(2+)	|B-ABBREVIATION
(	1559	1560		|I-ABBREVIATION
2+	1560	1562		|I-ABBREVIATION
)	1562	1563		|I-ABBREVIATION
influx	1564	1570		|O
into	1571	1575		|O
human	1576	1581		|O
lymphocytes	1582	1593		|O
through	1594	1601		|O
a	1602	1603		|O
SKF96365	1604	1612	SKF96365	|B-TRIVIALVAR
-	1612	1613		|O
sensitive	1613	1622		|O
,	1622	1623		|O
nifedipine	1624	1634	nifedipine	|B-TRIVIAL
-	1634	1635		|O
insensitive	1635	1646		|O
pathway	1647	1654		|O
.	1654	1655		|O
The	1656	1659		|O
MTX	1660	1663	MTX	|B-ABBREVIATION
-	1663	1664		|O
induced	1664	1671		|O
[	1672	1673		|O
Ca	1673	1675	Ca(2+)	|B-SUM
(	1675	1676		|I-SUM
2+	1676	1678		|I-SUM
)	1678	1679		|I-SUM
]	1679	1680		|O
i	1680	1681		|O
elevation	1682	1691		|O
was	1692	1695		|O
stimulated	1696	1706		|O
by	1707	1709		|O
the	1710	1713		|O
marine	1714	1720		|O
toxin	1721	1726		|O
YTX	1727	1730	YTX	|B-ABBREVIATION
through	1731	1738		|O
a	1739	1740		|O
mechanism	1741	1750		|O
insensitive	1751	1762		|O
to	1763	1765		|O
SKF96365	1766	1774	SKF96365	|B-TRIVIALVAR
,	1774	1775		|O
nifedipine	1776	1786	nifedipine	|B-TRIVIAL
or	1787	1789		|O
NiCl	1790	1794	NiCl(2)	|B-SUM
(	1794	1795		|I-SUM
2	1795	1796		|I-SUM
)	1796	1797		|I-SUM
.	1797	1798		|O
It	1799	1801		|O
was	1802	1805		|O
also	1806	1810		|O
stimulated	1811	1821		|O
by	1822	1824		|O
the	1825	1828		|O
divalent	1829	1837		|O
cation	1838	1844		|O
Ni	1845	1847	Ni(2+)	|B-SUM
(	1847	1848		|I-SUM
2+	1848	1850		|I-SUM
)	1850	1851		|I-SUM
and	1851	1854		|O
PKC	1856	1859		|O
inhibition	1860	1870		|O
and	1871	1874		|O
was	1875	1878		|O
partially	1879	1888		|O
inhibited	1889	1898		|O
by	1899	1901		|O
PI	1902	1904		|O
3	1905	1906		|O
-	1906	1907		|O
kinase	1907	1913		|O
inhibition	1914	1924		|O
.	1924	1925		|O

### 1766004
Selective	0	9		|O
protection	10	20		|O
of	21	23		|O
(	24	25	(9R)-9-amino-9-deoxoerythromycin A	|B-IUPAC
9R	25	27		|I-IUPAC
)	27	28		|I-IUPAC
-	28	29		|I-IUPAC
9	29	30		|I-IUPAC
-	30	31		|I-IUPAC
amino	31	36		|I-IUPAC
-	36	37		|I-IUPAC
9	37	38		|I-IUPAC
-	38	39		|I-IUPAC
deoxoerythromycin	39	56		|I-IUPAC
A	57	58		|I-IUPAC
allowed	59	66		|O
for	67	70		|O
elimination	71	82		|O
of	83	85		|O
the	86	89		|O
12	90	92	12-hydroxyl	|B-PARTIUPAC
-	92	93		|I-PARTIUPAC
hydroxyl	93	101		|I-PARTIUPAC
group	102	107	group	|B-MODIFIER
to	108	110		|O
afford	111	117		|O
a	118	119		|O
versatile	120	129		|O
12,21	130	135	12,21-olefin	|B-IUPAC
-	135	136		|I-IUPAC
olefin	136	142		|I-IUPAC
intermediate	143	155	intermediate	|B-MODIFIER
.	155	156		|O
Further	157	164		|O
modifications	165	178		|O
of	179	181		|O
the	182	185		|O
intermediate	186	198		|O
led	199	202		|O
to	203	205		|O
the	206	209		|O
syntheses	210	219		|O
of	220	222		|O
(	223	224	(9R)-9-deoxo-9-(N,N-dimethylamino)-12,21-epoxyerythromycin B	|B-IUPAC
9R	224	226		|I-IUPAC
)	226	227		|I-IUPAC
-	227	228		|I-IUPAC
9	228	229		|I-IUPAC
-	229	230		|I-IUPAC
deoxo	230	235		|I-IUPAC
-	235	236		|I-IUPAC
9	236	237		|I-IUPAC
-	237	238		|I-IUPAC
(	238	239		|I-IUPAC
N	239	240		|I-IUPAC
,	240	241		|I-IUPAC
N	241	242		|I-IUPAC
-	242	243		|I-IUPAC
dimethylamino	243	256		|I-IUPAC
)	256	257		|I-IUPAC
-	257	258		|I-IUPAC
12,21	258	263		|I-IUPAC
-	263	264		|I-IUPAC
epoxyerythromycin	264	281		|I-IUPAC
B	282	283		|I-IUPAC
,	283	284		|O
(	285	286	(9R)-9-deoxo-9-(N,N-dimethylamino)-21-hydroxyerythromycin A	|B-IUPAC
9R	286	288		|I-IUPAC
)	288	289		|I-IUPAC
-	289	290		|I-IUPAC
9	290	291		|I-IUPAC
-	291	292		|I-IUPAC
deoxo	292	297		|I-IUPAC
-	297	298		|I-IUPAC
9	298	299		|I-IUPAC
-	299	300		|I-IUPAC
(	300	301		|I-IUPAC
N	301	302		|I-IUPAC
,	302	303		|I-IUPAC
N	303	304		|I-IUPAC
-	304	305		|I-IUPAC
dimethylamino	305	318		|I-IUPAC
)	318	319		|I-IUPAC
-	319	320		|I-IUPAC
21	320	322		|I-IUPAC
-	322	323		|I-IUPAC
hydroxyerythromycin	323	342		|I-IUPAC
A	343	344		|I-IUPAC
,	344	345		|O
and	346	349		|O
(	350	351	(9R)-9-deoxo-9-(N,N-dimethylamino)-21-hydroxyerythromycin B	|B-IUPAC
9R	351	353		|I-IUPAC
)	353	354		|I-IUPAC
-	354	355		|I-IUPAC
9	355	356		|I-IUPAC
-	356	357		|I-IUPAC
deoxo	357	362		|I-IUPAC
-	362	363		|I-IUPAC
9	363	364		|I-IUPAC
-	364	365		|I-IUPAC
(	365	366		|I-IUPAC
N	366	367		|I-IUPAC
,	367	368		|I-IUPAC
N	368	369		|I-IUPAC
-	369	370		|I-IUPAC
dimethylamino	370	383		|I-IUPAC
)	383	384		|I-IUPAC
-	384	385		|I-IUPAC
21	385	387		|I-IUPAC
-	387	388		|I-IUPAC
hydroxyerythromycin	388	407		|I-IUPAC
B	408	409		|I-IUPAC
.	409	410		|O
All	411	414		|O
three	415	420		|O
compounds	421	430		|O
retained	431	439		|O
antibacterial	440	453		|O
activity	454	462		|O
against	463	470		|O
several	471	478		|O
organisms	479	488		|O
normally	489	497		|O
susceptible	498	509		|O
to	510	512		|O
(	513	514	(9R)-9-deoxo-9-(N,N-dimethylamino)erythromycin A	|B-IUPAC
9R	514	516		|I-IUPAC
)	516	517		|I-IUPAC
-	517	518		|I-IUPAC
9	518	519		|I-IUPAC
-	519	520		|I-IUPAC
deoxo	520	525		|I-IUPAC
-	525	526		|I-IUPAC
9	526	527		|I-IUPAC
-	527	528		|I-IUPAC
(	528	529		|I-IUPAC
N	529	530		|I-IUPAC
,	530	531		|I-IUPAC
N	531	532		|I-IUPAC
-	532	533		|I-IUPAC
dimethylamino	533	546		|I-IUPAC
)	546	547		|I-IUPAC
erythromycin	547	559		|I-IUPAC
A	560	561		|I-IUPAC
.	561	562		|O
However	563	570		|O
,	570	571		|O
the	572	575		|O
21	576	578	21-hydroxylated erythromycin A	|B-IUPAC
-	578	579		|I-IUPAC
hydroxylated	579	591		|I-IUPAC
erythromycin	592	604		|I-IUPAC
A	605	606		|I-IUPAC
analogue	607	615	analogue	|B-MODIFIER
was	616	619		|O
weaker	620	626		|O
in	627	629		|O
potency	630	637		|O
than	638	642		|O
the	643	646		|O
corresponding	647	660		|O
erythromycin	661	673	erythromycin B congener	|B-TRIVIAL
B	674	675		|I-TRIVIAL
congener	676	684		|I-TRIVIAL
and	685	688		|O
much	689	693		|O
weaker	694	700		|O
than	701	705		|O
the	706	709		|O
epoxy	710	715	epoxy	|B-TRIVIAL
derivative	716	726	derivative	|B-MODIFIER
.	726	727		|O
This	728	732		|O
suggests	733	741		|O
that	742	746		|O
while	747	752		|O
substitution	753	765		|O
of	766	768		|O
a	769	770		|O
polar	771	776		|O
functionality	777	790		|O
at	791	793		|O
C	794	795		|O
-	795	796		|O
21	796	798		|O
does	799	803		|O
not	804	807		|O
abolish	808	815		|O
antibacterial	816	829		|O
activity	830	838		|O
,	838	839		|O
introduction	840	852		|O
of	853	855		|O
vicinal	856	863		|O
polar	864	869		|O
groups	870	876		|O
at	877	879		|O
both	880	884		|O
C	885	886		|O
-	886	887		|O
12	887	889		|O
and	890	893		|O
C	894	895		|O
-	895	896		|O
21	896	898		|O
may	899	902		|O
lead	903	907		|O
to	908	910		|O
reduction	911	920		|O
in	921	923		|O
potency	924	931		|O
.	931	932		|O
Nevertheless	933	945		|O
,	945	946		|O
these	947	952		|O
21	953	955		|O
-	955	956		|O
functionalized	956	970		|O
derivatives	971	982		|O
of	983	985		|O
(	986	987	(9R)-erythromycylamine	|B-IUPAC
9R	987	989		|I-IUPAC
)	989	990		|I-IUPAC
-	990	991		|I-IUPAC
erythromycylamine	991	1008		|I-IUPAC
provide	1009	1016		|O
an	1017	1019		|O
entry	1020	1025		|O
into	1026	1030		|O
novel	1031	1036		|O
analogues	1037	1046		|O
of	1047	1049		|O
the	1050	1053		|O
important	1054	1063		|O
macrolide	1064	1073		|O
antibiotic	1074	1084		|O
erythromycin	1085	1097	erythromycin	|B-TRIVIAL
.	1097	1098		|O

### 10849585
Serum	10	15		|O
lipid	16	21	lipid	|B-FAMILY
and	22	25		|O
leptin	26	32		|O
concentrations	33	47		|O
in	48	50		|O
hypopituitary	51	64		|O
patients	65	73		|O
with	74	78		|O
growth	79	85		|O
hormone	86	93		|O
deficiency	94	104		|O
.	104	105		|O
OBJECTIVE	107	116		|O
:	116	117		|O
To	118	120		|O
investigate	121	132		|O
the	133	136		|O
effects	137	144		|O
of	145	147		|O
growth	148	154		|O
hormone	155	162		|O
(	163	164		|O
GH	164	166		|O
)	166	167		|O
deficiency	168	178		|O
on	179	181		|O
serum	182	187		|O
lipid	188	193	lipid	|B-FAMILY
and	194	197		|O
leptin	198	204		|O
concentrations	205	219		|O
in	220	222		|O
hypopituitary	223	236		|O
patients	237	245		|O
taking	246	252		|O
conventional	253	265		|O
replacement	266	277		|O
therapy	278	285		|O
and	286	289		|O
to	290	292		|O
determine	293	302		|O
the	303	306		|O
relations	307	316		|O
between	317	324		|O
leptin	325	331		|O
and	332	335		|O
gender	336	342		|O
and	343	346		|O
anthropometric	347	361		|O
and	362	365		|O
metabolic	366	375		|O
variables	376	385		|O
.	385	386		|O
SUBJECTS	387	395		|O
:	395	396		|O
Twenty	397	403		|O
-	403	404		|O
one	404	407		|O
GH	408	410		|O
deficient	411	420		|O
adult	421	426		|O
hypopituitary	427	440		|O
patients	441	449		|O
(	450	451		|O
15	451	453		|O
women	454	459		|O
,	459	460		|O
six	461	464		|O
men	465	468		|O
)	468	469		|O
and	470	473		|O
21	474	476		|O
(	477	478		|O
14	478	480		|O
women	481	486		|O
,	486	487		|O
seven	488	493		|O
men	494	497		|O
)	497	498		|O
age	499	502		|O
,	502	503		|O
sex	504	507		|O
and	508	511		|O
body	512	516		|O
mass	517	521		|O
index	522	527		|O
(	528	529		|O
BMI	529	532		|O
)	532	533		|O
matched	534	541		|O
healthy	542	549		|O
controls	550	558		|O
.	558	559		|O
MEASUREMENTS	560	572		|O
:	572	573		|O
After	574	579		|O
an	580	582		|O
overnight	583	592		|O
fast	593	597		|O
,	597	598		|O
anthropometric	599	613		|O
parameters	614	624		|O
were	625	629		|O
measured	630	638		|O
and	639	642		|O
body	643	647		|O
composition	648	659		|O
was	660	663		|O
determined	664	674		|O
by	675	677		|O
a	678	679		|O
bioelectrical	680	693		|O
impedance	694	703		|O
analyser	704	712		|O
.	712	713		|O
Venous	714	720		|O
blood	721	726		|O
samples	727	734		|O
were	735	739		|O
obtained	740	748		|O
for	749	752		|O
the	753	756		|O
measurements	757	769		|O
of	770	772		|O
glucose	773	780	glucose	|B-TRIVIAL
,	780	781		|O
total	782	787		|O
cholesterol	788	799	cholesterol	|B-TRIVIAL
,	799	800		|O
high	801	805		|O
density	806	813		|O
lipoprotein	814	825		|O
(	826	827		|O
HDL	827	830		|O
)	830	831		|O
cholesterol	832	843	cholesterol	|B-TRIVIAL
,	843	844		|O
triglyceride	845	857	triglyceride	|B-FAMILY
,	857	858		|O
intact	859	865		|O
insulin	866	873		|O
,	873	874		|O
insulin	875	882		|O
-	882	883		|O
like	883	887		|O
growth	888	894		|O
factor	895	901		|O
1	902	903		|O
(	904	905		|O
IGF	905	908		|O
-	908	909		|O
1	909	910		|O
)	910	911		|O
and	912	915		|O
leptin	916	922		|O
concentrations	923	937		|O
.	937	938		|O
Serum	939	944		|O
leptin	945	951		|O
and	952	955		|O
hormones	956	964		|O
were	965	969		|O
analysed	970	978		|O
by	979	981		|O
radioimmunoassay	982	998		|O
.	998	999		|O
RESULTS	1000	1007		|O
:	1007	1008		|O
Hypopituitary	1009	1022		|O
patients	1023	1031		|O
with	1032	1036		|O
GH	1037	1039		|O
deficiency	1040	1050		|O
showed	1051	1057		|O
significantly	1058	1071		|O
higher	1072	1078		|O
triglyceride	1079	1091	triglyceride	|B-FAMILY
,	1091	1092		|O
total	1093	1098		|O
and	1099	1102		|O
low	1103	1106		|O
density	1107	1114		|O
lipoprotein	1115	1126		|O
(	1127	1128		|O
LDL	1128	1131		|O
)	1131	1132		|O
cholesterol	1133	1144	cholesterol	|B-TRIVIAL
and	1145	1148		|O
lower	1149	1154		|O
HDL	1155	1158		|O
cholesterol	1159	1170	cholesterol	|B-TRIVIAL
concentrations	1171	1185		|O
on	1186	1188		|O
conventional	1189	1201		|O
replacement	1202	1213		|O
therapy	1214	1221		|O
.	1221	1222		|O
The	1223	1226		|O
unfavourable	1227	1239		|O
lipid	1240	1245	lipid	|B-FAMILY
profile	1246	1253		|O
was	1254	1257		|O
particularly	1258	1270		|O
evident	1271	1278		|O
in	1279	1281		|O
women	1282	1287		|O
.	1287	1288		|O
Significantly	1289	1302		|O
higher	1303	1309		|O
leptin	1310	1316		|O
concentrations	1317	1331		|O
were	1332	1336		|O
found	1337	1342		|O
in	1343	1345		|O
patients	1346	1354		|O
compared	1355	1363		|O
with	1364	1368		|O
healthy	1369	1376		|O
controls	1377	1385		|O
with	1386	1390		|O
similar	1391	1398		|O
body	1399	1403		|O
fat	1404	1407		|O
content	1408	1415		|O
(	1416	1417		|O
23	1417	1419		|O
.	1419	1420		|O
5+	1421	1423		|O
/	1423	1424		|O
-	1424	1425		|O
11.8	1425	1429		|O
ng	1430	1432		|O
/	1432	1433		|O
ml	1433	1435		|O
vs	1436	1438		|O
11.7	1439	1443		|O
+	1443	1444		|O
/	1444	1445		|O
-	1445	1446		|O
6.9	1446	1449		|O
ng	1450	1452		|O
/	1452	1453		|O
ml	1453	1455		|O
,	1455	1456		|O
P	1457	1458		|O
=	1458	1459		|O
0.01	1459	1463		|O
)	1463	1464		|O
.	1464	1465		|O
This	1466	1470		|O
difference	1471	1481		|O
remained	1482	1490		|O
significant	1491	1502		|O
even	1503	1507		|O
when	1508	1512		|O
leptin	1513	1519		|O
values	1520	1526		|O
were	1527	1531		|O
expressed	1532	1541		|O
in	1542	1544		|O
relation	1545	1553		|O
to	1554	1556		|O
fat	1557	1560		|O
mass	1561	1565		|O
percentage	1566	1576		|O
(	1577	1578		|O
0.79	1578	1582		|O
+	1582	1583		|O
/	1583	1584		|O
-	1584	1585		|O
0.40	1585	1589		|O
vs.	1590	1593		|O
0.42	1594	1598		|O
+	1598	1599		|O
/	1599	1600		|O
-	1600	1601		|O
0.17	1601	1605		|O
ng	1606	1608		|O
/	1608	1609		|O
ml	1609	1611		|O
%	1611	1612		|O
,	1612	1613		|O
P	1614	1615		|O
<	1615	1616		|O
0.05	1616	1620		|O
)	1620	1621		|O
and	1622	1625		|O
fat	1626	1629		|O
mass	1630	1634		|O
kg	1635	1637		|O
(	1638	1639		|O
1.32	1639	1643		|O
+	1643	1644		|O
/	1644	1645		|O
-	1645	1646		|O
0.81	1646	1650		|O
vs	1651	1653		|O
0.66	1654	1658		|O
+	1658	1659		|O
/	1659	1660		|O
-	1660	1661		|O
0.30	1661	1665		|O
ng	1666	1668		|O
/	1668	1669		|O
ml	1669	1671		|O
kg	1672	1674		|O
,	1674	1675		|O
P	1676	1677		|O
<	1677	1678		|O
0	1678	1679		|O
.	1679	1680		|O
05	1681	1683		|O
)	1683	1684		|O
.	1684	1685		|O
Significant	1686	1697		|O
positive	1698	1706		|O
correlations	1707	1719		|O
were	1720	1724		|O
observed	1725	1733		|O
between	1734	1741		|O
leptin	1742	1748		|O
concentrations	1749	1763		|O
and	1764	1767		|O
body	1768	1772		|O
fat	1773	1776		|O
percentage	1777	1787		|O
and	1788	1791		|O
age	1792	1795		|O
in	1796	1798		|O
the	1799	1802		|O
control	1803	1810		|O
group	1811	1816		|O
.	1816	1817		|O
In	1818	1820		|O
patients	1821	1829		|O
the	1830	1833		|O
sole	1834	1838		|O
significant	1839	1850		|O
relation	1851	1859		|O
between	1860	1867		|O
leptin	1868	1874		|O
and	1875	1878		|O
study	1879	1884		|O
parameters	1885	1895		|O
was	1896	1899		|O
the	1900	1903		|O
positive	1904	1912		|O
correlation	1913	1924		|O
observed	1925	1933		|O
between	1934	1941		|O
leptin	1942	1948		|O
and	1949	1952		|O
total	1953	1958		|O
cholesterol	1959	1970	cholesterol	|B-TRIVIAL
concentrations	1971	1985		|O
.	1985	1986		|O
Serum	1987	1992		|O
leptin	1993	1999		|O
concentrations	2000	2014		|O
were	2015	2019		|O
significantly	2020	2033		|O
higher	2034	2040		|O
in	2041	2043		|O
women	2044	2049		|O
than	2050	2054		|O
men	2055	2058		|O
in	2059	2061		|O
the	2062	2065		|O
control	2066	2073		|O
group	2074	2079		|O
,	2079	2080		|O
but	2081	2084		|O
not	2085	2088		|O
in	2089	2091		|O
the	2092	2095		|O
patients	2096	2104		|O
.	2104	2105		|O
No	2106	2108		|O
significant	2109	2120		|O
gender	2121	2127		|O
difference	2128	2138		|O
was	2139	2142		|O
observed	2143	2151		|O
when	2152	2156		|O
leptin	2157	2163		|O
concentrations	2164	2178		|O
were	2179	2183		|O
expressed	2184	2193		|O
in	2194	2196		|O
relation	2197	2205		|O
to	2206	2208		|O
fat	2209	2212		|O
mass	2213	2217		|O
(	2218	2219		|O
percentage	2219	2229		|O
and	2230	2233		|O
kg	2234	2236		|O
)	2236	2237		|O
.	2237	2238		|O
CONCLUSION	2239	2249		|O
:	2249	2250		|O
Growth	2251	2257		|O
hormone	2258	2265		|O
deficient	2266	2275		|O
hypopituitary	2276	2289		|O
patients	2290	2298		|O
(	2299	2300		|O
particularly	2300	2312		|O
women	2313	2318		|O
)	2318	2319		|O
on	2320	2322		|O
conventional	2323	2335		|O
replacement	2336	2347		|O
therapy	2348	2355		|O
have	2356	2360		|O
a	2361	2362		|O
more	2363	2367		|O
atherogenic	2368	2379		|O
lipid	2380	2385	lipid	|B-FAMILY
profile	2385	2392		|O
.	2393	2394		|O
Leptin	2395	2401		|O
concentrations	2402	2416		|O
are	2417	2420		|O
increased	2421	2430		|O
in	2431	2433		|O
GH	2434	2436		|O
deficient	2437	2446		|O
adults	2447	2453		|O
even	2454	2458		|O
after	2459	2464		|O
adjustment	2465	2475		|O
for	2476	2479		|O
percentage	2480	2490		|O
body	2491	2495		|O
fat	2496	2499		|O
and	2500	2503		|O
body	2504	2508		|O
fat	2509	2512		|O
mass	2513	2517		|O
(	2518	2519		|O
kg	2519	2521		|O
)	2521	2522		|O
.	2522	2523		|O
Although	2524	2532		|O
the	2533	2536		|O
nature	2537	2543		|O
of	2544	2546		|O
our	2547	2550		|O
data	2551	2555		|O
does	2556	2560		|O
not	2561	2564		|O
allow	2565	2570		|O
us	2571	2573		|O
to	2574	2576		|O
draw	2577	2581		|O
any	2582	2585		|O
conclusions	2586	2597		|O
on	2598	2600		|O
the	2601	2604		|O
mechanism	2605	2614		|O
(	2614	2615		|O
s	2615	2616		|O
)	2616	2617		|O
of	2618	2620		|O
increased	2621	2630		|O
leptin	2631	2637		|O
concentrations	2638	2652		|O
in	2653	2655		|O
GH	2656	2658		|O
deficiency	2659	2669		|O
,	2669	2670		|O
decreased	2671	2680		|O
central	2681	2688		|O
sensitivity	2689	2700		|O
to	2701	2703		|O
leptin	2704	2710		|O
and	2711	2714		|O
increased	2715	2724		|O
leptin	2725	2731		|O
production	2732	2742		|O
from	2743	2747		|O
per	2748	2751		|O
unit	2752	2756		|O
fat	2757	2760		|O
mass	2761	2765		|O
,	2765	2766		|O
or	2767	2769		|O
alterations	2770	2781		|O
in	2782	2784		|O
leptin	2785	2791		|O
clearance	2792	2801		|O
,	2801	2802		|O
might	2803	2808		|O
be	2809	2811		|O
operative	2812	2821		|O
.	2821	2822		|O

### 2999399
Conversion	0	10		|O
of	11	13		|O
the	14	17		|O
8	18	19	8-phenolic 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines	|B-IUPAC
-	19	20		|I-IUPAC
phenolic	20	28		|I-IUPAC
1,2,3,4,5,6	29	40		|I-IUPAC
-	40	41		|I-IUPAC
hexahydro	41	50		|I-IUPAC
-	50	51		|I-IUPAC
2,6	51	54		|I-IUPAC
-	54	55		|I-IUPAC
methano	55	62		|I-IUPAC
-	62	63		|I-IUPAC
3	63	64		|I-IUPAC
-	64	65		|I-IUPAC
benzazocines	65	77		|I-IUPAC
to	78	80		|O
the	81	84		|O
corresponding	85	98		|O
8	99	100	8-thiophenolic	|B-PARTIUPAC
-	100	101		|I-PARTIUPAC
thiophenolic	101	113		|I-PARTIUPAC
analogues	114	123	analogues	|B-MODIFIER
was	124	127		|O
achieved	128	136		|O
by	137	139		|O
three	140	145		|O
different	146	155		|O
routes	156	162		|O
.	162	163		|O
Diazotization	164	177		|O
of	178	180		|O
8	181	182	8-amino-2,6-methano-3-benzazocine	|B-IUPAC
-	182	183		|I-IUPAC
amino	183	188		|I-IUPAC
-	188	189		|I-IUPAC
2,6	189	192		|I-IUPAC
-	192	193		|I-IUPAC
methano	193	200		|I-IUPAC
-	200	201		|I-IUPAC
3	201	202		|I-IUPAC
-	202	203		|I-IUPAC
benzazocine	203	214		|I-IUPAC
(	215	216		|O
2	216	217		|O
)	217	218		|O
followed	219	227		|O
by	228	230		|O
the	231	234		|O
reaction	235	243		|O
with	244	248		|O
CH3SNa	249	255	CH3SNa	|B-SUM
afforded	256	264		|O
8	265	266	8-(methylthio)-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocine	|B-IUPAC
-	266	267		|I-IUPAC
(	267	268		|I-IUPAC
methylthio	268	278		|I-IUPAC
)	278	279		|I-IUPAC
-	279	280		|I-IUPAC
1,2,3,4,5,6	280	291		|I-IUPAC
-	291	292		|I-IUPAC
hexahydro	292	301		|I-IUPAC
-	301	302		|I-IUPAC
2,6	302	305		|I-IUPAC
-	305	306		|I-IUPAC
methano	306	313		|I-IUPAC
-	313	314		|I-IUPAC
3	314	315		|I-IUPAC
-	315	316		|I-IUPAC
benzazocine	316	327		|I-IUPAC
(	328	329		|O
3	329	330		|O
)	330	331		|O
.	331	332		|O
Another	333	340		|O
route	341	346		|O
using	347	352		|O
Grewe	353	358		|O
cyclization	359	370		|O
was	371	374		|O
also	375	379		|O
examined	380	388		|O
for	389	392		|O
the	393	396		|O
synthesis	397	406		|O
of	407	409		|O
3	410	411		|O
.	411	412		|O
As	413	415		|O
the	416	419		|O
most	420	424		|O
effective	425	434		|O
route	435	440		|O
,	440	441		|O
Newman	442	448		|O
-	448	449		|O
Kwart	449	454		|O
rearrangement	455	468		|O
of	469	471		|O
benzazocines	472	484		|O
was	485	488		|O
selected	489	497		|O
and	498	501		|O
closely	502	509		|O
investigated	510	522		|O
.	522	523		|O
8	524	525	8-(N,N-Dimethylthiocarbamoyl)oxy	|B-PARTIUPAC
-	525	526		|I-PARTIUPAC
(	526	527		|I-PARTIUPAC
N	527	528		|I-PARTIUPAC
,	528	529		|I-PARTIUPAC
N	529	530		|I-PARTIUPAC
-	530	531		|I-PARTIUPAC
Dimethylthiocarbamoyl	531	552		|I-PARTIUPAC
)	552	553		|I-PARTIUPAC
oxy	553	556		|I-PARTIUPAC
derivatives	557	568	derivatives	|B-MODIFIER
(	569	570		|O
6a	570	572		|O
-	572	573		|O
e	573	574		|O
)	574	575		|O
rearranged	576	586		|O
to	587	589		|O
8	590	591	8-(N,N-dimethylcarbamoyl)thio	|B-PARTIUPAC
-	591	592		|I-PARTIUPAC
(	592	593		|I-PARTIUPAC
N	593	594		|I-PARTIUPAC
,	594	595		|I-PARTIUPAC
N	595	596		|I-PARTIUPAC
-	596	597		|I-PARTIUPAC
dimethylcarbamoyl	597	614		|I-PARTIUPAC
)	614	615		|I-PARTIUPAC
thio	615	619		|I-PARTIUPAC
derivatives	620	631	derivatives	|B-MODIFIER
(	632	633		|O
7a	633	635		|O
-	635	636		|O
e	636	637		|O
)	637	638		|O
in	639	641		|O
good	642	646		|O
yields	647	653		|O
.	653	654		|O
Reductive	655	664		|O
cleavage	665	673		|O
of	674	676		|O
7a	677	679		|O
-	679	680		|O
e	680	681		|O
and	682	685		|O
subsequent	686	696		|O
methylation	697	708		|O
or	709	711		|O
acylations	712	722		|O
gave	723	727		|O
the	728	731		|O
title	732	737		|O
compounds	738	747		|O
(	748	749		|O
3	749	750		|O
,	750	751		|O
8-24	752	756		|O
)	756	757		|O
.	757	758		|O
Although	759	767		|O
analgesic	768	777		|O
activities	778	788		|O
of	789	791		|O
sulfur	792	798		|O
-	798	799		|O
containing	799	809		|O
benzazocines	810	822	benzazocines	|B-FAMILY
decreased	823	832		|O
compared	833	841		|O
to	842	844		|O
the	845	848		|O
corresponding	849	862		|O
hydroxy	863	870	hydroxy	|B-PARTIUPAC
compounds	871	880	compounds	|B-MODIFIER
,	880	881		|O
the	882	885		|O
N	886	887	N-methyl	|B-PARTIUPAC
-	887	888		|I-PARTIUPAC
methyl	888	894		|I-PARTIUPAC
derivative	895	905	derivative	|B-MODIFIER
(	906	907		|O
S	907	908	S-metazocine	|B-IUPAC
-	908	909		|I-IUPAC
metazocine	909	919		|I-IUPAC
,	919	920		|O
8	921	922		|O
)	922	923		|O
showed	924	930		|O
potent	931	937		|O
analgesic	938	947		|O
activity	948	956		|O
.	956	957		|O

### 7783119
N	0	1		|O
,	1	2		|O
O	2	3		|O
-	3	4		|O
Dicarbethoxy	4	16		|O
-	16	17		|O
4	17	18		|O
-	18	19		|O
chlorobenzenesulfohydroxamate	19	48		|O
(	49	50		|O
1c	50	52		|O
)	52	53		|O
and	54	57		|O
O	58	59	O-carbethoxy-N-hydroxysaccharin	|B-IUPAC
-	59	60		|I-IUPAC
carbethoxy	60	70		|I-IUPAC
-	70	71		|I-IUPAC
N	71	72		|I-IUPAC
-	72	73		|I-IUPAC
hydroxysaccharin	73	89		|I-IUPAC
(	90	91		|O
6	91	92		|O
)	92	93		|O
,	93	94		|O
both	95	99		|O
potential	100	109		|O
carbethoxylating	110	126		|O
agents	127	133		|O
,	133	134		|O
inhibited	135	144		|O
yeast	145	150		|O
aldehyde	151	159		|O
dehydrogenase	160	173		|O
(	174	175		|O
AlDH	175	179		|O
)	179	180		|O
with	181	185		|O
IC50	186	190		|O
's	190	192		|O
of	193	195		|O
24	196	198		|O
and	199	202		|O
56	203	205		|O
microM	206	212		|O
,	212	213		|O
respectively	214	226		|O
.	226	227		|O
The	228	231		|O
esterase	232	240		|O
activity	241	249		|O
of	250	252		|O
the	253	256		|O
enzyme	257	263		|O
was	264	267		|O
commensurably	268	281		|O
inhibited	282	291		|O
.	291	292		|O
AlDH	293	297		|O
activity	298	306		|O
was	307	310		|O
only	311	315		|O
partially	316	325		|O
restored	326	334		|O
on	335	337		|O
incubation	338	348		|O
with	349	353		|O
mercaptoethanol	354	369	mercaptoethanol	|B-TRIVIAL
(	370	371		|O
mM	374	376		|O
)	376	377		|O
for	378	381		|O
1	382	383		|O
h	384	385		|O
.	385	386		|O
On	387	389		|O
incubation	390	400		|O
with	401	405		|O
rat	406	409		|O
plasma	410	416		|O
,	416	417		|O
1c	418	420		|O
liberated	421	430		|O
nitroxyl	431	439	nitroxyl	|B-TRIVIAL
,	439	440		|O
a	441	442		|O
potent	443	449		|O
inhibitor	450	459		|O
of	460	462		|O
AlDH	463	467		|O
.	467	468		|O
Under	469	474		|O
the	475	478		|O
same	479	483		|O
conditions	484	494		|O
,	494	495		|O
nitroxyl	496	504	nitroxyl	|B-TRIVIAL
generation	505	515		|O
from	516	520		|O
6	521	522		|O
was	523	526		|O
minimal	527	534		|O
,	534	535		|O
a	536	537		|O
result	538	544		|O
compatible	545	555		|O
with	556	560		|O
a	561	562		|O
previous	563	571		|O
observation	572	583		|O
that	584	588		|O
nitroxyl	589	597	nitroxyl	|B-TRIVIAL
generation	598	608		|O
from	609	613		|O
N	614	615	N-hydroxysaccharin	|B-IUPAC
-	615	616		|I-IUPAC
hydroxysaccharin	616	632		|I-IUPAC
(	633	634		|O
7	634	635		|O
)	635	636		|O
,	636	637		|O
the	638	641		|O
product	642	649		|O
of	650	652		|O
the	653	656		|O
hydrolysis	657	667		|O
of	668	670		|O
the	671	674		|O
carbethoxy	675	685	carbethoxy	|B-PARTIUPAC
group	686	691	group	|B-MODIFIER
of	692	694		|O
6	695	696		|O
,	696	697		|O
was	698	701		|O
minimal	702	709		|O
at	710	712		|O
physiological	713	726		|O
pH	727	729		|O
.	729	730		|O
Since	731	736		|O
chemical	737	745		|O
carbethoxylating	746	762		|O
agents	763	769		|O
represented	770	781		|O
by	782	784		|O
the	785	788		|O
O	789	790	O-carbethoxylated N-hydroxyphthalimide	|B-IUPAC
-	790	791		|I-IUPAC
carbethoxylated	791	806		|I-IUPAC
N	807	808		|I-IUPAC
-	808	809		|I-IUPAC
hydroxyphthalimide	809	827		|I-IUPAC
,	827	828		|O
1	829	830	1-hydroxybenzotriazole	|B-IUPAC
-	830	831		|I-IUPAC
hydroxybenzotriazole	831	851		|I-IUPAC
,	851	852		|O
and	853	856		|O
N	857	858	N-hydroxysuccinimide	|B-IUPAC
-	858	859		|I-IUPAC
hydroxysuccinimide	859	877		|I-IUPAC
(	877	878		|O
8	879	880		|O
,	880	881		|O
9	882	883		|O
,	883	884		|O
and	885	888		|O
,	891	892		|O
respectively	893	905		|O
)	905	906		|O
likewise	907	915		|O
inhibited	916	925		|O
yeast	926	931		|O
AlDH	932	936		|O
,	936	937		|O
albeit	938	944		|O
with	945	949		|O
IC50	950	954		|O
's	954	956		|O
1	957	958		|O
order	959	964		|O
of	965	967		|O
magnitude	968	977		|O
higher	978	984		|O
,	984	985		|O
we	986	988		|O
postulate	989	998		|O
that	999	1003		|O
1c	1004	1006		|O
and	1007	1010		|O
6	1011	1012		|O
act	1013	1016		|O
as	1017	1019		|O
irreversible	1020	1032		|O
inhibitors	1033	1043		|O
of	1044	1046		|O
AlDH	1047	1051		|O
by	1052	1054		|O
carbethoxylating	1055	1071		|O
the	1072	1075		|O
active	1076	1082		|O
site	1083	1087		|O
of	1088	1090		|O
the	1091	1094		|O
enzyme	1095	1101		|O
.	1101	1102		|O

### 1361579
At	0	2		|O
physiological	3	16		|O
pH	17	19		|O
,	19	20		|O
the	21	24		|O
spatial	25	32		|O
arrangement	33	44		|O
of	45	47		|O
the	48	51		|O
three	52	57		|O
charges	58	65		|O
of	66	68		|O
DL	69	71	DL-tetrazol-5-ylglycine	|B-IUPAC
-	71	72		|I-IUPAC
tetrazol	72	80		|I-IUPAC
-	80	81		|I-IUPAC
5	81	82		|I-IUPAC
-	82	83		|I-IUPAC
ylglycine	83	92		|I-IUPAC
(	93	94		|O
5	94	95		|O
)	95	96		|O
could	97	102		|O
be	103	105		|O
viewed	106	112		|O
as	113	115		|O
similar	116	123		|O
to	124	126		|O
those	127	132		|O
found	133	138		|O
in	139	141		|O
certain	142	149		|O
conformations	150	163		|O
of	164	166		|O
the	167	170		|O
two	171	174		|O
excitatory	175	185		|O
amino	186	191		|O
acids	192	197		|O
(	198	199		|O
EAAs	199	203		|O
)	203	204		|O
-	204	205		|O
-	205	206		|O
aspartic	206	214	aspartic	|B-PARTIUPAC
and	215	218		|O
glutamic	219	227	glutamic acids	|B-IUPAC
acids	228	233		|I-IUPAC
.	233	234		|O
Given	235	240		|O
significant	241	252		|O
binding	253	260		|O
to	261	263		|O
one	264	267		|O
or	268	270		|O
more	271	275		|O
EAA	276	279		|O
receptors	280	289		|O
,	289	290		|O
5	291	292		|O
would	293	298		|O
offer	299	304		|O
unique	305	311		|O
modeling	312	320		|O
and	321	324		|O
perhaps	325	332		|O
biological	333	343		|O
opportunities	344	357		|O
.	357	358		|O
We	359	361		|O
have	362	366		|O
previously	367	377		|O
shown	378	383		|O
it	384	386		|O
to	387	389		|O
be	390	392		|O
the	393	396		|O
most	397	401		|O
potent	402	408		|O
NMDA	409	413	NMDA	|B-ABBREVIATION
agonist	414	421		|O
known	422	427		|O
,	427	428		|O
with	429	433		|O
a	434	435		|O
unique	436	442		|O
and	443	446		|O
marked	447	453		|O
in	454	456		|O
vitro	457	462		|O
neutrotoxicity	463	477		|O
at	478	480		|O
depolarizing	481	493		|O
concentrations	494	508		|O
.	508	509		|O
Now	510	513		|O
we	514	516		|O
report	517	523		|O
the	524	527		|O
details	528	535		|O
required	536	544		|O
for	545	548		|O
its	549	552		|O
synthesis	553	562		|O
,	562	563		|O
together	564	572		|O
with	573	577		|O
its	578	581		|O
potency	582	589		|O
and	590	593		|O
efficacy	594	602		|O
in	603	605		|O
two	606	609		|O
assays	610	616		|O
of	617	619		|O
functional	620	630		|O
activation	631	641		|O
of	642	644		|O
the	645	648		|O
NMDA	649	653		|O
receptor	654	662		|O
,	662	663		|O
namely	664	670		|O
agonist	671	678		|O
-	678	679		|O
influenced	679	689		|O
[	690	691	[3H]MK801	|B-IUPAC
3H	691	693		|I-IUPAC
]	693	694		|I-IUPAC
MK801	694	699		|I-IUPAC
binding	700	707		|O
and	708	711		|O
agonist	712	719		|O
-	719	720		|O
induced	720	727		|O
release	728	735		|O
of	736	738		|O
the	739	742		|O
neurotransmitter	743	759		|O
[	760	761	[3H]-norepinephrine	|B-IUPAC
3H	761	763		|I-IUPAC
]	763	764		|I-IUPAC
-	764	765		|I-IUPAC
norepinephrine	765	779		|I-IUPAC
from	780	784		|O
brain	785	790		|O
slices	791	797		|O
.	797	798		|O
In	799	801		|O
both	802	806		|O
these	807	812		|O
assays	813	819		|O
DL	820	822	DL-tetrazol-5-ylglycine	|B-IUPAC
-	822	823		|I-IUPAC
tetrazol	823	831		|I-IUPAC
-	831	832		|I-IUPAC
5	832	833		|I-IUPAC
-	833	834		|I-IUPAC
ylglycine	834	843		|I-IUPAC
proved	844	850		|O
to	851	853		|O
be	854	856		|O
more	857	861		|O
potent	862	868		|O
and	869	872		|O
efficacious	873	884		|O
than	885	889		|O
NMDA	890	894	NMDA	|B-ABBREVIATION
and	895	898		|O
cis	899	902	cis-methanoglutamate	|B-IUPAC
-	902	903		|I-IUPAC
methanoglutamate	903	919		|I-IUPAC
.	919	920		|O
It	921	923		|O
was	924	927		|O
more	928	932		|O
potent	933	939		|O
than	940	944		|O
,	944	945		|O
and	946	949		|O
equally	950	957		|O
efficacious	958	969		|O
to	970	972		|O
,	972	973		|O
L	974	975	L-glutamate	|B-IUPAC
-	975	976		|I-IUPAC
glutamate	976	985		|I-IUPAC
in	986	988		|O
[	989	990	[3H]MK801	|B-IUPAC
3H	990	992		|I-IUPAC
]	992	993		|I-IUPAC
MK801	993	998		|I-IUPAC
binding	999	1006		|O
.	1006	1007		|O
The	1008	1011		|O
structural	1012	1022		|O
features	1023	1031		|O
of	1032	1034		|O
5	1035	1036		|O
may	1037	1040		|O
well	1041	1045		|O
reflect	1046	1053		|O
optimal	1054	1061		|O
agonist	1062	1069		|O
interaction	1070	1081		|O
at	1082	1084		|O
the	1085	1088		|O
NMDA	1089	1093		|O
receptor	1094	1102		|O
site	1103	1107		|O
.	1107	1108		|O
(	1109	1110		|O
We	1110	1112		|O
considered	1113	1123		|O
the	1124	1127		|O
possibility	1128	1139		|O
that	1140	1144		|O
some	1145	1149		|O
decarboxylation	1150	1165		|O
of	1166	1168		|O
DL	1169	1171	DL-tetrazol-5-ylglycine	|B-IUPAC
-	1171	1172		|I-IUPAC
tetrazol	1172	1180		|I-IUPAC
-	1180	1181		|I-IUPAC
5	1181	1182		|I-IUPAC
-	1182	1183		|I-IUPAC
ylglycine	1183	1192		|I-IUPAC
may	1193	1196		|O
have	1197	1201		|O
occurred	1202	1210		|O
during	1211	1217		|O
testing	1218	1225		|O
.	1225	1226		|O
This	1227	1231		|O
would	1232	1237		|O
give	1238	1242		|O
5	1243	1244	5-(aminomethyl)tetrazole	|B-IUPAC
-	1244	1245		|I-IUPAC
(	1245	1246		|I-IUPAC
aminomethyl	1246	1257		|I-IUPAC
)	1257	1258		|I-IUPAC
tetrazole	1258	1267		|I-IUPAC
(	1268	1269		|O
13	1269	1271		|O
)	1271	1272		|O
,	1272	1273		|O
the	1274	1277		|O
tetrazole	1278	1287	tetrazole acid	|B-IUPAC
acid	1288	1292		|I-IUPAC
analog	1293	1299	analog	|B-MODIFIER
of	1300	1302		|O
glycine	1303	1310	glycine	|B-TRIVIAL
;	1310	1311		|O
and	1312	1315		|O
glycine	1316	1323	glycine	|B-TRIVIAL
is	1324	1326		|O
involved	1327	1335		|O
in	1336	1338		|O
NMDA	1339	1343		|O
receptor	1344	1352		|O
activation	1353	1363		|O
.	1363	1364		|O
Compound	1365	1373		|O
13	1374	1376		|O
does	1377	1381		|O
not	1382	1385		|O
affect	1386	1392		|O
[	1393	1394	[3H]glycine	|B-IUPAC
3H	1394	1396		|I-IUPAC
]	1396	1397		|I-IUPAC
glycine	1397	1404		|I-IUPAC
binding	1405	1412		|O
at	1413	1415		|O
the	1416	1419		|O
strychnine	1420	1430	strychnine	|B-TRIVIAL
-	1430	1431		|O
insensitive	1431	1442		|O
glycine	1443	1450	glycine	|B-TRIVIAL
binding	1451	1458		|O
site	1459	1463		|O
,	1463	1464		|O
and	1465	1468		|O
[	1469	1470	[3H]MK801	|B-IUPAC
3H	1470	1472		|I-IUPAC
]	1472	1473		|I-IUPAC
MK801	1473	1478		|I-IUPAC
binding	1479	1486		|O
studies	1487	1494		|O
showed	1495	1501		|O
that	1502	1506		|O
the	1507	1510		|O
(	1511	1512	(aminomethyl)-tetrazole	|B-IUPAC
aminomethyl	1512	1523		|I-IUPAC
)	1523	1524		|I-IUPAC
-	1524	1525		|I-IUPAC
tetrazole	1525	1534		|I-IUPAC
,	1534	1535		|O
even	1536	1540		|O
if	1541	1543		|O
is	1544	1546		|O
formed	1547	1553		|O
,	1553	1554		|O
would	1555	1560		|O
probably	1561	1569		|O
have	1570	1574		|O
no	1575	1577		|O
effect	1578	1584		|O
on	1585	1587		|O
the	1588	1591		|O
activity	1592	1600		|O
of	1601	1603		|O
tetrazol	1604	1612	tetrazol-5-ylglycine	|B-IUPAC
-	1612	1613		|I-IUPAC
5	1613	1614		|I-IUPAC
-	1614	1615		|I-IUPAC
ylglycine	1615	1624		|I-IUPAC
at	1624	1626		|O
the	1628	1631		|O
NMDA	1632	1636		|O
receptor	1637	1645		|O
.	1645	1646		|O

### 18419918
Oribatid	10	18		|O
Mite	19	23		|O
Communities	24	35		|O
in	36	38		|O
the	39	42		|O
Canopy	43	49		|O
of	50	52		|O
Montane	53	60		|O
Abies	61	66		|O
amabilis	67	75		|O
and	76	79		|O
Tsuga	80	85		|O
heterophylla	86	98		|O
Trees	99	104		|O
on	105	107		|O
Vancouver	108	117		|O
Island	118	124		|O
,	124	125		|O
British	126	133		|O
Columbia	134	142		|O
.	142	143		|O
To	145	147		|O
study	148	153		|O
the	154	157		|O
oribatid	158	166		|O
mite	167	171		|O
community	172	181		|O
inhabiting	182	192		|O
microhabitats	193	206		|O
in	207	209		|O
the	210	213		|O
canopy	214	220		|O
of	221	223		|O
montane	224	231		|O
Abies	232	237		|O
amabilis	238	246		|O
[	247	248		|O
(	248	249		|O
Douglas	249	256		|O
ex	257	259		|O
D	260	261		|O
.	261	262		|O
Don	263	266		|O
)	266	267		|O
Lindl	268	273		|O
.	273	274		|O
]	274	275		|O
and	276	279		|O
Tsuga	280	285		|O
heterophylla	286	298		|O
[	299	300		|O
(	300	301		|O
Raf	301	304		|O
.	304	305		|O
)	305	306		|O
Sarg	307	311		|O
]	311	312		|O
tree	313	317		|O
species	318	325		|O
across	326	332		|O
five	333	337		|O
elevational	338	349		|O
sites	350	355		|O
,	355	356		|O
we	357	359		|O
collected	360	369		|O
branch	374	380		|O
tips	381	385		|O
and	386	389		|O
foliose	394	401		|O
/	401	402		|O
crustose	402	410		|O
lichen	411	417		|O
samples	418	425		|O
over	426	430		|O
three	431	436		|O
time	437	441		|O
periods	442	449		|O
.	449	450		|O
Thirty	451	457		|O
-	457	458		|O
three	458	463		|O
species	464	471		|O
of	472	474		|O
oribatid	475	483		|O
mites	484	489		|O
were	490	494		|O
identified	495	505		|O
from	506	510		|O
the	511	514		|O
study	515	520		|O
area	521	525		|O
.	525	526		|O
Mite	527	531		|O
species	532	539		|O
richness	540	548		|O
and	549	552		|O
abundance	553	562		|O
was	563	566		|O
significantly	567	580		|O
affected	581	589		|O
by	590	592		|O
microhabitat	593	605		|O
,	605	606		|O
and	607	610		|O
this	611	615		|O
association	616	627		|O
was	628	631		|O
independent	632	643		|O
of	644	646		|O
sampling	647	655		|O
time	656	660		|O
.	660	661		|O
At	662	664		|O
the	665	668		|O
microhabitat	669	681		|O
scale	682	687		|O
,	687	688		|O
distinct	689	697		|O
species	698	705		|O
assemblages	706	717		|O
were	718	722		|O
associated	723	733		|O
with	734	738		|O
lichen	739	745		|O
and	746	749		|O
branch	750	756		|O
tip	757	760		|O
habitats	761	769		|O
,	769	770		|O
and	771	774		|O
to	775	777		|O
a	778	779		|O
lesser	780	786		|O
degree	787	793		|O
,	793	794		|O
tree	795	799		|O
species	800	807		|O
.	807	808		|O
Conifer	809	816		|O
specificity	817	828		|O
was	829	832		|O
most	833	837		|O
apparent	838	846		|O
in	847	849		|O
the	850	853		|O
closely	854	861		|O
related	862	869		|O
species	870	877		|O
of	878	880		|O
Jugatala	881	889		|O
,	889	890		|O
where	891	896		|O
Jugatala	897	905		|O
tuberosa	906	914		|O
Ewing	915	920		|O
was	921	924		|O
only	925	929		|O
found	930	935		|O
on	936	938		|O
branch	939	945		|O
tips	946	950		|O
from	951	955		|O
A	956	957		|O
.	957	958		|O
amabilis	959	967		|O
and	968	971		|O
Jugatala	972	980		|O
sp	981	983		|O
.	983	984		|O
was	985	988		|O
primarily	989	998		|O
found	999	1004		|O
on	1005	1007		|O
branch	1008	1014		|O
tips	1015	1019		|O
from	1020	1024		|O
T	1025	1026		|O
.	1026	1027		|O
heterophylla	1028	1040		|O
.	1040	1041		|O
Microhabitat	1042	1054		|O
specificity	1055	1066		|O
was	1067	1070		|O
most	1071	1075		|O
pronounced	1076	1086		|O
in	1087	1089		|O
Dendrozetes	1090	1101		|O
sp	1102	1104		|O
.	1104	1105		|O
where	1106	1111		|O
most	1112	1116		|O
individuals	1117	1128		|O
were	1129	1133		|O
found	1134	1139		|O
on	1140	1142		|O
branch	1143	1149		|O
tips	1150	1154		|O
and	1155	1158		|O
Anachiperia	1159	1170		|O
geminus	1171	1178		|O
Lindo	1179	1184		|O
et	1185	1187		|O
al.	1188	1191		|O
that	1192	1196		|O
occurred	1197	1205		|O
primarily	1206	1215		|O
on	1216	1218		|O
lichens	1219	1226		|O
.	1226	1227		|O
Principal	1228	1237		|O
components	1238	1248		|O
analysis	1249	1257		|O
of	1258	1260		|O
oribatid	1261	1269		|O
mite	1270	1274		|O
community	1275	1284		|O
composition	1285	1296		|O
further	1297	1304		|O
showed	1305	1311		|O
a	1312	1313		|O
high	1314	1318		|O
degree	1319	1325		|O
of	1326	1328		|O
association	1329	1340		|O
with	1341	1345		|O
microhabitat	1346	1358		|O
and	1359	1362		|O
tree	1363	1367		|O
species	1368	1375		|O
.	1375	1376		|O
Habitat	1377	1384		|O
profiles	1385	1393		|O
are	1394	1397		|O
difficult	1398	1407		|O
to	1408	1410		|O
discern	1411	1418		|O
for	1419	1422		|O
many	1423	1427		|O
species	1428	1435		|O
because	1436	1443		|O
tree	1444	1448		|O
,	1448	1449		|O
microhabitat	1450	1462		|O
,	1462	1463		|O
and	1464	1467		|O
elevation	1468	1477		|O
preferences	1478	1489		|O
confound	1490	1498		|O
distribution	1499	1511		|O
patterns	1512	1520		|O
.	1520	1521		|O
Given	1522	1527		|O
the	1528	1531		|O
significant	1532	1543		|O
tree	1544	1548		|O
-	1548	1549		|O
microhabitat	1549	1561		|O
associations	1562	1574		|O
in	1575	1577		|O
species	1578	1585		|O
composition	1586	1597		|O
in	1598	1600		|O
this	1601	1605		|O
montane	1606	1613		|O
canopy	1614	1620		|O
study	1621	1626		|O
,	1626	1627		|O
we	1628	1630		|O
suggest	1631	1638		|O
that	1639	1643		|O
sampling	1644	1652		|O
multiple	1653	1661		|O
microhabitats	1662	1675		|O
across	1676	1682		|O
elevations	1683	1693		|O
to	1694	1696		|O
look	1697	1701		|O
for	1702	1705		|O
patterns	1706	1714		|O
in	1715	1717		|O
community	1718	1727		|O
structure	1728	1737		|O
offers	1738	1744		|O
opportunities	1745	1758		|O
to	1759	1761		|O
explicitly	1762	1772		|O
test	1773	1777		|O
organizing	1778	1788		|O
principles	1789	1799		|O
in	1800	1802		|O
community	1803	1812		|O
ecology	1813	1820		|O
.	1820	1821		|O

### 18421606
Tinnitus	10	18		|O
and	19	22		|O
brain	23	28		|O
MRI	29	32		|O
findings	33	41		|O
in	42	44		|O
Japanese	45	53		|O
elderly	54	61		|O
.	61	62		|O
Conclusion	64	74		|O
.	74	75		|O
There	76	81		|O
is	82	84		|O
evidence	85	93		|O
of	94	96		|O
an	97	99		|O
inverse	100	107		|O
association	108	119		|O
between	120	127		|O
cerebral	128	136		|O
infarction	137	147		|O
and	148	151		|O
tinnitus	152	160		|O
in	161	163		|O
this	164	168		|O
study	169	174		|O
.	174	175		|O
The	176	179		|O
effects	180	187		|O
of	188	190		|O
cerebral	191	199		|O
infarction	200	210		|O
on	211	213		|O
tinnitus	214	222		|O
could	223	228		|O
be	229	231		|O
explained	232	241		|O
by	242	244		|O
a	245	246		|O
neurophysiological	247	265		|O
model	266	271		|O
of	272	274		|O
tinnitus	275	283		|O
.	283	284		|O
Objectives	285	295		|O
.	295	296		|O
We	297	299		|O
examined	300	308		|O
the	309	312		|O
relationship	313	325		|O
between	326	333		|O
tinnitus	334	342		|O
and	343	346		|O
brain	347	352		|O
MRI	353	356		|O
findings	357	365		|O
including	366	375		|O
cerebral	376	384		|O
infarction	385	395		|O
,	395	396		|O
brain	397	402		|O
atrophy	403	410		|O
,	410	411		|O
ventricular	412	423		|O
dilatation	424	434		|O
,	434	435		|O
and	436	439		|O
white	440	445		|O
matter	446	452		|O
lesions	453	460		|O
.	460	461		|O
Subjects	462	470		|O
and	471	474		|O
methods	475	482		|O
.	482	483		|O
This	484	488		|O
was	489	492		|O
a	493	494		|O
cross	495	500		|O
-	500	501		|O
sectional	501	510		|O
population	511	521		|O
-	521	522		|O
based	522	527		|O
study	528	533		|O
of	534	536		|O
2193	537	541		|O
subjects	542	550		|O
aged	551	555		|O
41-82	556	561		|O
years	562	567		|O
living	568	574		|O
in	575	577		|O
Aichi	578	583		|O
prefecture	584	594		|O
,	594	595		|O
Japan	596	601		|O
.	601	602		|O
Detailed	603	611		|O
questionnaires	612	626		|O
,	626	627		|O
pure	628	632		|O
tone	633	637		|O
audiometry	638	648		|O
,	648	649		|O
and	650	653		|O
brain	654	659		|O
MRI	660	663		|O
were	664	668		|O
performed	669	678		|O
.	678	679		|O
Results	680	687		|O
.	687	688		|O
After	689	694		|O
adjusting	695	704		|O
for	705	708		|O
potential	709	718		|O
confounders	719	730		|O
in	731	733		|O
a	734	735		|O
multiple	736	744		|O
logistic	745	753		|O
analysis	754	762		|O
,	762	763		|O
cerebral	764	772		|O
infarction	773	783		|O
was	784	787		|O
inversely	788	797		|O
associated	798	808		|O
with	809	813		|O
tinnitus	814	822		|O
(	823	824		|O
odds	824	828		|O
ratio	829	834		|O
(	835	836		|O
OR	836	838		|O
)	838	839		|O
=	839	840		|O
0.649	840	845		|O
,	845	846		|O
95%	847	850		|O
confidence	851	861		|O
interval	862	870		|O
(	871	872		|O
CI	872	874		|O
)	874	875		|O
=	875	876		|O
0.477-0.884	876	887		|O
)	887	888		|O
.	888	889		|O
Cerebral	890	898		|O
infarctions	899	910		|O
of	911	913		|O
the	914	917		|O
basal	918	923		|O
ganglia	924	931		|O
(	932	933		|O
OR	933	935		|O
=	935	936		|O
0.542	936	941		|O
)	941	942		|O
,	942	943		|O
thalamus	944	952		|O
(	953	954		|O
OR	954	956		|O
=	956	957		|O
0.441	957	962		|O
)	962	963		|O
,	963	964		|O
and	965	968		|O
pons	969	973		|O
(	974	975		|O
OR	975	977		|O
=	977	978		|O
0.319	978	983		|O
)	983	984		|O
were	985	989		|O
especially	990	1000		|O
associated	1001	1011		|O
with	1012	1016		|O
tinnitus	1017	1025		|O
.	1025	1026		|O
Brain	1027	1032		|O
atrophy	1033	1040		|O
,	1040	1041		|O
ventricular	1042	1053		|O
dilatation	1054	1064		|O
,	1064	1065		|O
and	1066	1069		|O
white	1070	1075		|O
matter	1076	1082		|O
lesions	1083	1090		|O
had	1091	1094		|O
no	1095	1097		|O
significant	1098	1109		|O
effects	1110	1117		|O
on	1118	1120		|O
the	1121	1124		|O
prevalence	1125	1135		|O
of	1136	1138		|O
tinnitus	1139	1147		|O
.	1147	1148		|O

### 18419664
A	10	11		|O
neural	12	18		|O
network	19	26		|O
-	26	27		|O
based	27	32		|O
method	33	39		|O
for	40	43		|O
risk	44	48		|O
factor	49	55		|O
analysis	56	64		|O
of	65	67		|O
West	68	72		|O
Nile	73	77		|O
virus	78	83		|O
.	83	84		|O
There	86	91		|O
is	92	94		|O
a	95	96		|O
lack	97	101		|O
of	102	104		|O
knowledge	105	114		|O
about	115	120		|O
which	121	126		|O
risk	127	131		|O
factors	132	139		|O
are	140	143		|O
more	144	148		|O
important	149	158		|O
in	159	161		|O
West	162	166		|O
Nile	167	171		|O
virus	172	177		|O
(	178	179		|O
WNV	179	182		|O
)	182	183		|O
transmission	184	196		|O
and	197	200		|O
risk	201	205		|O
magnitude	206	215		|O
.	215	216		|O
A	217	218		|O
better	219	225		|O
understanding	226	239		|O
of	240	242		|O
the	243	246		|O
risk	247	251		|O
factors	252	259		|O
is	260	262		|O
of	263	265		|O
great	266	271		|O
help	272	276		|O
in	277	279		|O
developing	280	290		|O
effective	291	300		|O
new	301	304		|O
technologies	305	317		|O
and	318	321		|O
appropriate	322	333		|O
prevention	334	344		|O
strategies	345	355		|O
for	356	359		|O
WNV	360	363		|O
infection	364	373		|O
.	373	374		|O
A	375	376		|O
contribution	377	389		|O
analysis	390	398		|O
of	399	401		|O
all	402	405		|O
risk	406	410		|O
factors	411	418		|O
in	419	421		|O
WNV	422	425		|O
infection	426	435		|O
would	436	441		|O
identify	442	450		|O
those	451	456		|O
major	457	462		|O
risk	463	467		|O
factors	468	475		|O
.	475	476		|O
Based	477	482		|O
on	483	485		|O
the	486	489		|O
identified	490	500		|O
major	501	506		|O
risk	507	511		|O
factors	512	519		|O
,	519	520		|O
measures	521	529		|O
to	530	532		|O
control	533	540		|O
WNV	541	544		|O
proliferation	545	558		|O
could	559	564		|O
be	565	567		|O
directed	568	576		|O
toward	577	583		|O
those	584	589		|O
significant	590	601		|O
risk	602	606		|O
factors	607	614		|O
,	614	615		|O
thus	616	620		|O
improving	621	630		|O
the	631	634		|O
effectiveness	635	648		|O
and	649	652		|O
efficiency	653	663		|O
in	664	666		|O
developing	667	677		|O
WNV	678	681		|O
control	682	689		|O
and	690	693		|O
prevention	694	704		|O
strategies	705	715		|O
.	715	716		|O
Neural	717	723		|O
networks	724	732		|O
have	733	737		|O
many	738	742		|O
generally	743	752		|O
accepted	753	761		|O
advantages	762	772		|O
over	773	777		|O
conventional	778	790		|O
analytical	791	801		|O
techniques	802	812		|O
,	812	813		|O
for	814	817		|O
instance	818	826		|O
,	826	827		|O
ability	828	835		|O
to	836	838		|O
automatically	839	852		|O
learn	853	858		|O
the	859	862		|O
relationship	863	875		|O
between	876	883		|O
the	884	887		|O
inputs	888	894		|O
and	895	898		|O
outputs	899	906		|O
from	907	911		|O
training	912	920		|O
data	921	925		|O
,	925	926		|O
powerful	927	935		|O
generalization	936	950		|O
ability	951	958		|O
,	958	959		|O
and	960	963		|O
capability	964	974		|O
of	975	977		|O
handling	978	986		|O
nonlinear	987	996		|O
interactions	997	1009		|O
.	1009	1010		|O
In	1011	1013		|O
this	1014	1018		|O
article	1019	1026		|O
,	1026	1027		|O
a	1028	1029		|O
neural	1030	1036		|O
network	1037	1044		|O
model	1045	1050		|O
was	1051	1054		|O
developed	1055	1064		|O
for	1065	1068		|O
analysis	1069	1077		|O
of	1078	1080		|O
risk	1081	1085		|O
factors	1086	1093		|O
in	1094	1096		|O
WNV	1097	1100		|O
infection	1101	1110		|O
.	1110	1111		|O
To	1112	1114		|O
reveal	1115	1121		|O
the	1122	1125		|O
relative	1126	1134		|O
contribution	1135	1147		|O
of	1148	1150		|O
the	1151	1154		|O
input	1155	1160		|O
variables	1161	1170		|O
,	1170	1171		|O
the	1172	1175		|O
neural	1176	1182		|O
network	1183	1190		|O
was	1191	1194		|O
trained	1195	1202		|O
using	1203	1208		|O
an	1209	1211		|O
algorithm	1212	1221		|O
called	1222	1228		|O
structural	1229	1239		|O
learning	1240	1248		|O
with	1249	1253		|O
forgetting	1254	1264		|O
.	1264	1265		|O
During	1266	1272		|O
the	1273	1276		|O
learning	1277	1285		|O
,	1285	1286		|O
weak	1287	1291		|O
neural	1292	1298		|O
connections	1299	1310		|O
are	1311	1314		|O
forced	1315	1321		|O
to	1322	1324		|O
fade	1325	1329		|O
away	1330	1334		|O
while	1335	1340		|O
a	1341	1342		|O
skeletal	1343	1351		|O
network	1352	1359		|O
with	1360	1364		|O
strong	1365	1371		|O
connections	1372	1383		|O
emerges	1384	1391		|O
.	1391	1392		|O
The	1393	1396		|O
significant	1397	1408		|O
risk	1409	1413		|O
factors	1414	1421		|O
can	1422	1425		|O
be	1426	1428		|O
identified	1429	1439		|O
by	1440	1442		|O
analyzing	1443	1452		|O
this	1453	1457		|O
skeletal	1458	1466		|O
network	1467	1474		|O
.	1474	1475		|O
The	1476	1479		|O
proposed	1480	1488		|O
approach	1489	1497		|O
is	1498	1500		|O
tested	1501	1507		|O
with	1508	1512		|O
the	1513	1516		|O
dead	1517	1521		|O
bird	1522	1526		|O
surveillance	1527	1539		|O
data	1540	1544		|O
in	1545	1547		|O
Ontario	1548	1555		|O
,	1555	1556		|O
Canada	1557	1563		|O
.	1563	1564		|O
The	1565	1568		|O
results	1569	1576		|O
demonstrate	1577	1588		|O
the	1589	1592		|O
effectiveness	1593	1606		|O
of	1607	1609		|O
the	1610	1613		|O
proposed	1614	1622		|O
approach	1623	1631		|O
.	1631	1632		|O

### 18421604
Involvement	10	21		|O
of	22	24		|O
the	25	28		|O
incudostapedial	29	44		|O
joint	45	50		|O
anomaly	51	58		|O
in	59	61		|O
conductive	62	72		|O
deafness	73	81		|O
.	81	82		|O
Conclusion	84	94		|O
.	94	95		|O
The	96	99		|O
outcome	100	107		|O
of	108	110		|O
surgery	111	118		|O
depends	119	126		|O
on	127	129		|O
complexities	130	142		|O
of	143	145		|O
middle	146	152		|O
ear	153	156		|O
anomalies	157	166		|O
and	167	170		|O
definite	171	179		|O
diagnosis	180	189		|O
can	190	193		|O
only	194	198		|O
be	199	201		|O
achieved	202	210		|O
during	211	217		|O
exploratory	218	229		|O
tympanotomy	230	241		|O
.	241	242		|O
We	243	245		|O
must	246	250		|O
be	251	253		|O
aware	254	259		|O
that	260	264		|O
the	265	268		|O
pathology	269	278		|O
of	279	281		|O
the	282	285		|O
congenital	286	296		|O
ossicular	297	306		|O
anomalies	307	316		|O
is	317	319		|O
variable	320	328		|O
and	329	332		|O
careful	333	340		|O
surgery	341	348		|O
is	349	351		|O
needed	352	358		|O
for	359	362		|O
hearing	363	370		|O
improvement	371	382		|O
.	382	383		|O
Objective	384	393		|O
.	393	394		|O
This	395	399		|O
study	400	405		|O
aimed	406	411		|O
to	412	414		|O
investigate	415	426		|O
congenital	427	437		|O
ossicular	438	447		|O
malformation	448	460		|O
.	460	461		|O
Subjects	462	470		|O
and	471	474		|O
methods	475	482		|O
.	482	483		|O
Fifteen	484	491		|O
cases	492	497		|O
of	498	500		|O
ossicular	501	510		|O
anomalies	511	520		|O
without	521	528		|O
external	529	537		|O
ear	538	541		|O
malformation	542	554		|O
were	555	559		|O
studied	560	567		|O
.	567	568		|O
The	569	572		|O
anomaly	573	580		|O
of	581	583		|O
the	584	587		|O
incus	588	593		|O
-	593	594		|O
stapes	594	600		|O
complex	601	608		|O
was	609	612		|O
the	613	616		|O
most	617	621		|O
frequent	622	630		|O
.	630	631		|O
There	632	637		|O
were	638	642		|O
two	643	646		|O
cases	647	652		|O
of	653	655		|O
fused	656	661		|O
incudostapedial	662	677		|O
(	678	679		|O
IS	679	681		|O
)	681	682		|O
joint	683	688		|O
,	688	689		|O
which	690	695		|O
is	696	698		|O
an	699	701		|O
extremely	702	711		|O
rare	712	716		|O
occurrence	717	727		|O
.	727	728		|O
Case	729	733		|O
1	734	735		|O
was	736	739		|O
a	740	741		|O
33	742	744		|O
-	744	745		|O
year	745	749		|O
-	749	750		|O
old	750	753		|O
man	754	757		|O
,	757	758		|O
in	759	761		|O
whom	762	766		|O
otosclerosis	767	779		|O
was	780	783		|O
suspected	784	793		|O
and	794	797		|O
exploratory	798	809		|O
tympanotomy	810	821		|O
was	822	825		|O
performed	826	835		|O
.	835	836		|O
The	837	840		|O
IS	841	843		|O
joint	844	849		|O
was	850	853		|O
fused	854	859		|O
,	859	860		|O
and	861	864		|O
the	865	868		|O
stapes	869	875		|O
was	876	879		|O
immobile	880	888		|O
.	888	889		|O
Small	890	895		|O
fenestra	896	904		|O
stapedectomy	905	917		|O
was	918	921		|O
performed	922	931		|O
.	931	932		|O
In	933	935		|O
case	936	940		|O
2	941	942		|O
,	942	943		|O
a	944	945		|O
52	946	948		|O
-	948	949		|O
year	949	953		|O
-	953	954		|O
old	954	957		|O
woman	958	963		|O
,	963	964		|O
otosclerosis	965	977		|O
was	978	981		|O
also	982	986		|O
suspected	987	996		|O
and	997	1000		|O
exploratory	1001	1012		|O
tympanotomy	1013	1024		|O
was	1025	1028		|O
performed	1029	1038		|O
.	1038	1039		|O
The	1040	1043		|O
IS	1044	1046		|O
joint	1047	1052		|O
was	1053	1056		|O
fused	1057	1062		|O
and	1063	1066		|O
the	1067	1070		|O
incus	1071	1076		|O
was	1077	1080		|O
fixed	1081	1086		|O
.	1086	1087		|O
After	1088	1093		|O
the	1094	1097		|O
long	1098	1102		|O
process	1103	1110		|O
of	1111	1113		|O
the	1114	1117		|O
incus	1118	1123		|O
was	1124	1127		|O
cut	1128	1131		|O
,	1131	1132		|O
the	1133	1136		|O
stapes	1137	1143		|O
became	1144	1150		|O
mobile	1151	1157		|O
.	1157	1158		|O
However	1159	1166		|O
,	1166	1167		|O
since	1168	1173		|O
the	1174	1177		|O
incus	1178	1183		|O
remained	1184	1192		|O
immobile	1193	1201		|O
,	1201	1202		|O
it	1203	1205		|O
was	1206	1209		|O
removed	1210	1217		|O
and	1218	1221		|O
was	1222	1225		|O
placed	1226	1232		|O
on	1233	1235		|O
the	1236	1239		|O
stapes	1240	1246		|O
.	1246	1247		|O
In	1248	1250		|O
both	1251	1255		|O
cases	1256	1261		|O
,	1261	1262		|O
the	1263	1266		|O
hearing	1267	1274		|O
improved	1275	1283		|O
after	1284	1289		|O
surgery	1290	1297		|O
.	1297	1298		|O
The	1299	1302		|O
averaged	1303	1311		|O
hearing	1312	1319		|O
gain	1320	1324		|O
of	1325	1327		|O
15	1328	1330		|O
cases	1331	1336		|O
was	1337	1340		|O
28.8	1341	1345		|O
dB	1346	1348		|O
.	1348	1349		|O

### 18421613
Combination	10	21		|O
of	22	24		|O
Bernouilli	25	35		|O
effect	36	42		|O
producing	43	52		|O
maneuver	53	61		|O
-	61	62		|O
induced	62	69		|O
pharyngeal	70	80		|O
narrowing	81	90		|O
rate	91	95		|O
with	96	100		|O
body	101	105		|O
mass	106	110		|O
index	111	116		|O
as	117	119		|O
predictive	120	130		|O
tool	131	135		|O
for	136	139		|O
obstructive	140	151		|O
sleep	152	157		|O
apnea	158	163		|O
syndrome	164	172		|O
.	172	173		|O
Conclusions	175	186		|O
.	186	187		|O
It	188	190		|O
is	191	193		|O
suggested	194	203		|O
that	204	208		|O
the	209	212		|O
combination	213	224		|O
of	225	227		|O
the	228	231		|O
pharyngeal	232	242		|O
narrowing	243	252		|O
rate	253	257		|O
during	258	264		|O
the	265	268		|O
Bernouilli	269	279		|O
effect	280	286		|O
producing	287	296		|O
maneuver	297	305		|O
(	306	307		|O
BEPM	307	311		|O
)	311	312		|O
with	313	317		|O
the	318	321		|O
body	322	326		|O
mass	327	331		|O
index	332	337		|O
(	338	339		|O
BMI	339	342		|O
)	342	343		|O
might	344	349		|O
be	350	352		|O
a	353	354		|O
promising	355	364		|O
predictive	365	375		|O
method	376	382		|O
for	383	386		|O
obstructive	387	398		|O
sleep	399	404		|O
apnea	405	410		|O
syndrome	411	419		|O
(	420	421		|O
OSAS	421	425		|O
)	425	426		|O
.	426	427		|O
Objectives	428	438		|O
.	438	439		|O
An	440	442		|O
attempt	443	450		|O
was	451	454		|O
made	455	459		|O
to	460	462		|O
clarify	463	470		|O
the	471	474		|O
possibility	475	486		|O
that	487	491		|O
the	492	495		|O
dynamic	496	503		|O
narrowing	504	513		|O
of	514	516		|O
the	517	520		|O
pharynx	521	528		|O
evaluated	529	538		|O
by	539	541		|O
nasopharyngoscopy	542	559		|O
with	560	564		|O
BEPM	565	569		|O
,	569	570		|O
a	571	572		|O
forced	573	579		|O
inspiration	580	591		|O
through	592	599		|O
the	600	603		|O
nose	604	608		|O
with	609	613		|O
the	614	617		|O
mouth	618	623		|O
closed	624	630		|O
,	630	631		|O
might	632	637		|O
be	638	640		|O
a	641	642		|O
reliable	643	651		|O
clinical	652	660		|O
daytime	661	668		|O
predictor	669	678		|O
for	679	682		|O
identifying	683	694		|O
patients	695	703		|O
at	704	706		|O
risk	707	711		|O
of	712	714		|O
developing	715	725		|O
OSAS	726	730		|O
.	730	731		|O
Subjects	732	740		|O
and	741	744		|O
methods	745	752		|O
.	752	753		|O
Subjects	754	762		|O
were	763	767		|O
57	768	770		|O
patients	771	779		|O
complaining	780	791		|O
of	792	794		|O
snoring	795	802		|O
and	803	806		|O
sleepiness	807	817		|O
during	818	824		|O
daytime	825	832		|O
.	832	833		|O
Endoscopic	834	844		|O
images	845	851		|O
of	852	854		|O
the	855	858		|O
retropalatal	859	871		|O
pharynx	872	879		|O
were	880	884		|O
obtained	885	893		|O
and	894	897		|O
their	898	903		|O
area	904	908		|O
was	909	912		|O
measured	913	921		|O
by	922	924		|O
NIH	925	928		|O
imaging	929	936		|O
.	936	937		|O
The	938	941		|O
pharyngeal	942	952		|O
narrowing	953	962		|O
rate	963	967		|O
during	968	974		|O
quiet	975	980		|O
nasal	981	986		|O
breathing	987	996		|O
and	997	1000		|O
that	1001	1005		|O
during	1006	1012		|O
BEPM	1013	1017		|O
were	1018	1022		|O
compared	1023	1031		|O
to	1032	1034		|O
assess	1035	1041		|O
pharyngeal	1042	1052		|O
dynamics	1053	1061		|O
.	1061	1062		|O
To	1063	1065		|O
increase	1066	1074		|O
the	1075	1078		|O
sensitivity	1079	1090		|O
of	1091	1093		|O
this	1094	1098		|O
method	1099	1105		|O
,	1105	1106		|O
BMI	1107	1110		|O
was	1111	1114		|O
added	1115	1120		|O
to	1121	1123		|O
the	1124	1127		|O
pharyngeal	1128	1138		|O
narrowing	1139	1148		|O
rate	1149	1153		|O
during	1154	1160		|O
BEPM	1161	1165		|O
.	1165	1166		|O
Results	1167	1174		|O
.	1174	1175		|O
The	1176	1179		|O
criterion	1180	1189		|O
of	1190	1192		|O
BEPM	1193	1197		|O
at	1198	1200		|O
a	1201	1202		|O
cut	1203	1206		|O
-	1206	1207		|O
off	1207	1210		|O
value	1211	1216		|O
of	1217	1219		|O
with	1224	1228		|O
BMI	1229	1232		|O
at	1233	1235		|O
a	1236	1237		|O
cut	1238	1241		|O
-	1241	1242		|O
off	1242	1245		|O
value	1246	1251		|O
of	1252	1254		|O
25	1255	1257		|O
kg	1258	1260		|O
/	1260	1261		|O
m	1261	1262		|O
(	1262	1263		|O
2	1263	1264		|O
)	1264	1265		|O
achieved	1266	1274		|O
a	1275	1276		|O
sensitivity	1277	1288		|O
of	1289	1291		|O
93%	1292	1295		|O
,	1295	1296		|O
while	1297	1302		|O
the	1303	1306		|O
specificity	1307	1318		|O
was	1319	1322		|O
67%	1323	1326		|O
in	1327	1329		|O
differentiating	1330	1345		|O
simple	1346	1352		|O
snorers	1353	1360		|O
from	1361	1365		|O
OSAS	1366	1370		|O
patients	1371	1379		|O
(	1380	1381		|O
apnea	1381	1386		|O
index	1387	1392		|O
>	1393	1394		|O
5	1394	1395		|O
)	1395	1396		|O
.	1396	1397		|O
In	1398	1400		|O
addition	1401	1409		|O
,	1409	1410		|O
the	1411	1414		|O
likelihood	1415	1425		|O
ratio	1426	1431		|O
of	1432	1434		|O
the	1435	1438		|O
method	1439	1445		|O
was	1446	1449		|O
found	1450	1455		|O
to	1456	1458		|O
be	1459	1461		|O
2.81	1462	1466		|O
.	1466	1467		|O

### 18419842
Frequency	10	19		|O
and	20	23		|O
bases	24	29		|O
of	30	32		|O
abnormal	33	41		|O
performance	42	53		|O
by	54	56		|O
healthy	57	64		|O
adults	65	71		|O
on	72	74		|O
neuropsychological	75	93		|O
testing	94	101		|O
.	101	102		|O
The	104	107		|O
frequency	108	117		|O
and	118	121		|O
determinants	122	134		|O
of	135	137		|O
abnormal	138	146		|O
test	147	151		|O
performance	152	163		|O
by	164	166		|O
normal	167	173		|O
individuals	174	185		|O
are	186	189		|O
critically	190	200		|O
important	201	210		|O
to	211	213		|O
clinical	214	222		|O
inference	223	232		|O
.	232	233		|O
Here	234	238		|O
we	239	241		|O
compare	242	249		|O
two	250	253		|O
approaches	254	264		|O
to	265	267		|O
predicting	268	278		|O
rates	279	284		|O
of	285	287		|O
abnormal	288	296		|O
test	297	301		|O
performance	302	313		|O
among	314	319		|O
healthy	320	327		|O
individuals	328	339		|O
with	340	344		|O
the	345	348		|O
rates	349	354		|O
actually	355	363		|O
shown	364	369		|O
by	370	372		|O
327	373	376		|O
neurologically	377	391		|O
normal	392	398		|O
adults	399	405		|O
aged	406	410		|O
18-92	411	416		|O
years	417	422		|O
.	422	423		|O
We	424	426		|O
counted	427	434		|O
how	435	438		|O
many	439	443		|O
participants	444	456		|O
produced	457	465		|O
abnormal	466	474		|O
scores	475	481		|O
,	481	482		|O
defined	483	490		|O
by	491	493		|O
three	494	499		|O
different	500	509		|O
cutoffs	510	517		|O
with	518	522		|O
test	523	527		|O
batteries	528	537		|O
of	538	540		|O
varied	541	547		|O
length	548	554		|O
,	554	555		|O
and	556	559		|O
the	560	563		|O
number	564	570		|O
of	571	573		|O
abnormal	574	582		|O
scores	583	589		|O
they	590	594		|O
produced	595	603		|O
.	603	604		|O
Observed	605	613		|O
rates	614	619		|O
generally	620	629		|O
were	630	634		|O
closer	635	641		|O
to	642	644		|O
predictions	645	656		|O
based	657	662		|O
on	663	665		|O
a	666	667		|O
series	668	674		|O
of	675	677		|O
Monte	678	683		|O
Carlo	684	689		|O
simulations	690	701		|O
than	702	706		|O
on	707	709		|O
the	710	713		|O
binomial	714	722		|O
model	723	728		|O
.	728	729		|O
They	730	734		|O
increased	735	744		|O
with	745	749		|O
the	750	753		|O
number	754	760		|O
of	761	763		|O
tests	764	769		|O
administered	770	782		|O
,	782	783		|O
decreased	784	793		|O
as	794	796		|O
more	797	801		|O
stringent	802	811		|O
cutoffs	812	819		|O
were	820	824		|O
used	825	829		|O
to	830	832		|O
identify	833	841		|O
abnormality	842	853		|O
,	853	854		|O
varied	855	861		|O
with	862	866		|O
the	867	870		|O
degree	871	877		|O
of	878	880		|O
correlation	881	892		|O
among	893	898		|O
test	899	903		|O
scores	904	910		|O
,	910	911		|O
and	912	915		|O
depended	916	924		|O
on	925	927		|O
individual	928	938		|O
differences	939	950		|O
in	951	953		|O
age	954	957		|O
,	957	958		|O
education	959	968		|O
,	968	969		|O
race	970	974		|O
,	974	975		|O
sex	976	979		|O
,	979	980		|O
and	981	984		|O
estimated	985	994		|O
premorbid	995	1004		|O
IQ	1005	1007		|O
.	1007	1008		|O
Adjusting	1009	1018		|O
scores	1019	1025		|O
for	1026	1029		|O
demographic	1030	1041		|O
variables	1042	1051		|O
and	1052	1055		|O
premorbid	1056	1065		|O
IQ	1066	1068		|O
did	1069	1072		|O
not	1073	1076		|O
reduce	1077	1083		|O
rates	1084	1089		|O
of	1090	1092		|O
abnormal	1093	1101		|O
performance	1102	1113		|O
.	1113	1114		|O
However	1115	1122		|O
,	1122	1123		|O
it	1124	1126		|O
eliminated	1127	1137		|O
the	1138	1141		|O
contribution	1142	1154		|O
of	1155	1157		|O
these	1158	1163		|O
variables	1164	1173		|O
to	1174	1176		|O
rates	1177	1182		|O
of	1183	1185		|O
abnormal	1186	1194		|O
test	1195	1199		|O
performance	1200	1211		|O
.	1211	1212		|O
These	1213	1218		|O
findings	1219	1227		|O
raise	1228	1233		|O
fundamental	1234	1245		|O
questions	1246	1255		|O
about	1256	1261		|O
the	1262	1265		|O
nature	1266	1272		|O
and	1273	1276		|O
interpretation	1277	1291		|O
of	1292	1294		|O
abnormal	1295	1303		|O
test	1304	1308		|O
performance	1309	1320		|O
by	1321	1323		|O
normal	1324	1330		|O
,	1330	1331		|O
healthy	1332	1339		|O
adults	1340	1346		|O
.	1346	1347		|O

### 18419992
Is	10	12		|O
laparoscopy	13	24		|O
dying	25	30		|O
for	31	34		|O
radical	35	42		|O
prostatectomy	43	56		|O
?	56	57		|O
Training	59	67		|O
in	68	70		|O
laparoscopic	71	83		|O
urology	84	91		|O
,	91	92		|O
extensive	93	102		|O
experimental	103	115		|O
work	116	120		|O
,	120	121		|O
and	122	125		|O
dedicated	126	135		|O
surgical	136	144		|O
performance	145	156		|O
constitute	157	167		|O
the	168	171		|O
foundation	172	182		|O
of	183	185		|O
advanced	186	194		|O
laparoscopic	195	207		|O
urology	208	215		|O
,	215	216		|O
which	217	222		|O
is	223	225		|O
currently	226	235		|O
a	236	237		|O
reasonable	238	248		|O
surgical	249	257		|O
option	258	264		|O
in	265	267		|O
pediatrics	268	278		|O
,	278	279		|O
reconstructive	280	294		|O
surgery	295	302		|O
,	302	303		|O
and	304	307		|O
oncology	308	316		|O
.	316	317		|O
This	318	322		|O
article	323	330		|O
discusses	331	340		|O
topics	341	347		|O
related	348	355		|O
to	356	358		|O
laparoscopic	359	371		|O
approaches	372	382		|O
for	383	386		|O
radical	387	394		|O
prostatectomy	395	408		|O
,	408	409		|O
focusing	410	418		|O
on	419	421		|O
their	422	427		|O
introduction	428	440		|O
,	440	441		|O
development	442	453		|O
,	453	454		|O
accomplishments	455	470		|O
,	470	471		|O
and	472	475		|O
current	476	483		|O
standards	484	493		|O
and	494	497		|O
future	498	504		|O
goals	505	510		|O
for	511	514		|O
the	515	518		|O
minimally	519	528		|O
invasive	529	537		|O
treatment	538	547		|O
of	548	550		|O
urologic	551	559		|O
diseases	560	568		|O
.	568	569		|O
We	570	572		|O
highlight	573	582		|O
the	583	586		|O
dynamic	587	594		|O
status	595	601		|O
of	602	604		|O
the	605	608		|O
laparoscopic	609	621		|O
approach	622	630		|O
for	631	634		|O
radical	635	642		|O
prostatectomy	643	656		|O
(	657	658		|O
pure	658	662		|O
or	663	665		|O
robotic	666	673		|O
-	673	674		|O
assisted	674	682		|O
)	682	683		|O
that	684	688		|O
constitutes	689	700		|O
one	701	704		|O
of	705	707		|O
the	708	711		|O
most	712	716		|O
rapidly	717	724		|O
evolving	725	733		|O
fields	734	740		|O
in	741	743		|O
urology	744	751		|O
.	751	752		|O

### 18419839
Quantitative	10	22		|O
magnetic	23	31		|O
resonance	32	41		|O
image	42	47		|O
analysis	48	56		|O
of	57	59		|O
the	60	63		|O
cerebellum	64	74		|O
in	75	77		|O
macrocephalic	78	91		|O
and	92	95		|O
normocephalic	96	109		|O
children	110	118		|O
and	119	122		|O
adults	123	129		|O
with	130	134		|O
autism	135	141		|O
.	141	142		|O
A	144	145		|O
detailed	146	154		|O
morphometric	155	167		|O
analysis	168	176		|O
of	177	179		|O
the	180	183		|O
cerebellum	184	194		|O
in	195	197		|O
autism	198	204		|O
with	205	209		|O
and	210	213		|O
without	214	221		|O
macrocephaly	222	234		|O
.	234	235		|O
Four	236	240		|O
subject	241	248		|O
groups	249	255		|O
(	256	257		|O
N	257	258		|O
=	259	260		|O
65	261	263		|O
;	263	264		|O
male	265	269		|O
;	269	270		|O
IQs	271	274		|O
>	275	276		|O
or	277	279		|O
=	280	281		|O
65	282	284		|O
;	284	285		|O
age	286	289		|O
7	290	291		|O
to	292	294		|O
26	295	297		|O
years	298	303		|O
)	303	304		|O
were	305	309		|O
studied	310	317		|O
with	318	322		|O
quantitative	323	335		|O
MRI	336	339		|O
;	339	340		|O
normocephalic	341	354		|O
and	355	358		|O
macrocephalic	359	372		|O
individuals	373	384		|O
with	385	389		|O
autism	390	396		|O
without	397	404		|O
mental	405	411		|O
retardation	412	423		|O
were	424	428		|O
compared	429	437		|O
to	438	440		|O
normocephalic	441	454		|O
and	455	458		|O
benign	459	465		|O
macrocephalic	466	479		|O
typically	480	489		|O
developing	490	500		|O
individuals	501	512		|O
.	512	513		|O
Total	514	519		|O
cerebellum	520	530		|O
volumes	531	538		|O
and	539	542		|O
surface	543	550		|O
areas	551	556		|O
of	557	559		|O
four	560	564		|O
lobular	565	572		|O
midsagittal	573	584		|O
groups	585	591		|O
were	592	596		|O
measured	597	605		|O
.	605	606		|O
Independent	607	618		|O
t	619	620		|O
-	620	621		|O
tests	621	626		|O
between	627	634		|O
autism	635	641		|O
and	642	645		|O
control	646	653		|O
subjects	654	662		|O
matched	663	670		|O
for	671	674		|O
head	675	679		|O
size	680	684		|O
revealed	685	693		|O
no	694	696		|O
significant	697	708		|O
differences	709	720		|O
.	720	721		|O
Multivariate	722	734		|O
analyses	735	743		|O
of	744	746		|O
variance	747	755		|O
were	756	760		|O
also	761	765		|O
performed	766	775		|O
,	775	776		|O
using	777	782		|O
the	783	786		|O
diagnostic	787	797		|O
group	798	803		|O
as	804	806		|O
the	807	810		|O
fixed	811	816		|O
factor	817	823		|O
,	823	824		|O
cerebellar	825	835		|O
measures	836	844		|O
as	845	847		|O
the	848	851		|O
dependent	852	861		|O
variables	862	871		|O
and	872	875		|O
total	876	881		|O
intracranial	882	894		|O
volume	895	901		|O
,	901	902		|O
total	903	908		|O
brain	909	914		|O
volume	915	921		|O
,	921	922		|O
age	923	926		|O
,	926	927		|O
verbal	928	934		|O
IQ	935	937		|O
,	937	938		|O
and	939	942		|O
performance	943	954		|O
IQ	955	957		|O
as	958	960		|O
covariates	961	971		|O
.	971	972		|O
No	973	975		|O
significant	976	987		|O
differences	988	999		|O
were	1000	1004		|O
found	1005	1010		|O
;	1010	1011		|O
however	1012	1019		|O
,	1019	1020		|O
a	1021	1022		|O
trend	1023	1028		|O
was	1029	1032		|O
noted	1033	1038		|O
in	1039	1041		|O
which	1042	1047		|O
macrocephalic	1048	1061		|O
individuals	1062	1073		|O
with	1074	1078		|O
autism	1079	1085		|O
consistently	1086	1098		|O
exhibited	1099	1108		|O
slightly	1109	1117		|O
smaller	1118	1125		|O
cerebellar	1126	1136		|O
volume	1137	1143		|O
or	1144	1146		|O
surface	1147	1154		|O
area	1155	1159		|O
when	1160	1164		|O
compared	1165	1173		|O
to	1174	1176		|O
individuals	1177	1188		|O
with	1189	1193		|O
benign	1194	1200		|O
macrocephaly	1201	1213		|O
.	1213	1214		|O
In	1215	1217		|O
autism	1218	1224		|O
,	1224	1225		|O
with	1226	1230		|O
and	1231	1234		|O
without	1235	1242		|O
macrocephaly	1243	1255		|O
,	1255	1256		|O
cerebellar	1257	1267		|O
structures	1268	1278		|O
were	1279	1283		|O
found	1284	1289		|O
to	1290	1292		|O
be	1293	1295		|O
proportional	1296	1308		|O
to	1309	1311		|O
head	1312	1316		|O
size	1317	1321		|O
and	1322	1325		|O
did	1326	1329		|O
not	1330	1333		|O
differ	1334	1340		|O
from	1341	1345		|O
typically	1346	1355		|O
developing	1356	1366		|O
subjects	1367	1375		|O
.	1375	1376		|O

### 18419912
Worker	10	16		|O
size	17	21		|O
in	22	24		|O
the	25	28		|O
formosan	29	37		|O
subterranean	38	50		|O
termite	51	58		|O
in	59	61		|O
relation	62	70		|O
to	71	73		|O
colony	74	80		|O
breeding	81	89		|O
structure	90	99		|O
as	100	102		|O
inferred	103	111		|O
from	112	116		|O
molecular	117	126		|O
markers	127	134		|O
.	134	135		|O
The	137	140		|O
Formosan	141	149		|O
subterranean	150	162		|O
termite	163	170		|O
,	170	171		|O
Coptotermes	172	183		|O
formosanus	184	194		|O
Shiraki	195	202		|O
,	202	203		|O
is	204	206		|O
an	207	209		|O
invasive	210	218		|O
species	219	226		|O
that	227	231		|O
originated	232	242		|O
in	243	245		|O
China	246	251		|O
and	252	255		|O
has	256	259		|O
been	260	264		|O
introduced	265	275		|O
to	276	278		|O
Hawaii	279	285		|O
and	286	289		|O
the	290	293		|O
U	294	295		|O
.	295	296		|O
S	296	297		|O
.	297	298		|O
mainland	299	307		|O
.	307	308		|O
Colonies	309	317		|O
are	318	321		|O
headed	322	328		|O
either	329	335		|O
by	336	338		|O
a	339	340		|O
pair	341	345		|O
of	346	348		|O
reproductives	349	362		|O
(	363	364		|O
simple	364	370		|O
families	371	379		|O
)	379	380		|O
or	381	383		|O
by	384	386		|O
varying	387	394		|O
numbers	395	402		|O
of	403	405		|O
inbreeding	406	416		|O
reproductives	417	430		|O
(	431	432		|O
extended	432	440		|O
families	441	449		|O
)	449	450		|O
,	450	451		|O
and	452	455		|O
therefore	456	465		|O
have	466	470		|O
variable	471	479		|O
degrees	480	487		|O
of	488	490		|O
inbreeding	491	501		|O
.	501	502		|O
Worker	503	509		|O
size	510	514		|O
also	515	519		|O
varies	520	526		|O
among	527	532		|O
colonies	533	541		|O
of	542	544		|O
Formosan	545	553		|O
termites	554	562		|O
.	562	563		|O
We	564	566		|O
tested	567	573		|O
whether	574	581		|O
variation	582	591		|O
in	592	594		|O
worker	595	601		|O
size	602	606		|O
can	607	610		|O
be	611	613		|O
explained	614	623		|O
by	624	626		|O
the	627	630		|O
breeding	631	639		|O
system	640	646		|O
.	646	647		|O
Workers	648	655		|O
were	656	660		|O
collected	661	670		|O
from	671	675		|O
colonies	676	684		|O
from	685	689		|O
three	690	695		|O
geographically	696	710		|O
separated	711	720		|O
populations	721	732		|O
(	733	734		|O
China	734	739		|O
,	739	740		|O
Hawaii	741	747		|O
,	747	748		|O
and	749	752		|O
Louisiana	753	762		|O
)	762	763		|O
,	763	764		|O
and	765	768		|O
body	769	773		|O
weight	774	780		|O
and	781	784		|O
head	785	789		|O
size	790	794		|O
were	795	799		|O
measured	800	808		|O
.	808	809		|O
Microsatellite	810	824		|O
genotyping	825	835		|O
was	836	839		|O
used	840	844		|O
to	845	847		|O
establish	848	857		|O
whether	858	865		|O
colonies	866	874		|O
were	875	879		|O
simple	880	886		|O
or	887	889		|O
extended	890	898		|O
families	899	907		|O
and	908	911		|O
to	912	914		|O
determine	915	924		|O
the	925	928		|O
heterozygosity	929	943		|O
of	944	946		|O
workers	947	954		|O
and	955	958		|O
their	959	964		|O
degree	965	971		|O
of	972	974		|O
inbreeding	975	985		|O
relative	986	994		|O
to	995	997		|O
their	998	1003		|O
colony	1004	1010		|O
(	1011	1012		|O
F	1012	1013		|O
(	1014	1015		|O
IC	1015	1017		|O
)	1017	1018		|O
,	1018	1019		|O
sensitive	1020	1029		|O
to	1030	1032		|O
the	1033	1036		|O
number	1037	1043		|O
of	1044	1046		|O
reproductives	1047	1060		|O
)	1060	1061		|O
.	1061	1062		|O
All	1063	1066		|O
Chinese	1067	1074		|O
colonies	1075	1083		|O
contained	1084	1093		|O
multiple	1094	1102		|O
inbreeding	1103	1113		|O
neotenics	1114	1123		|O
.	1123	1124		|O
In	1125	1127		|O
Hawaii	1128	1134		|O
,	1134	1135		|O
37%	1136	1139		|O
of	1140	1142		|O
the	1143	1146		|O
colonies	1147	1155		|O
were	1156	1160		|O
simple	1161	1167		|O
families	1168	1176		|O
and	1177	1180		|O
63%	1181	1184		|O
were	1185	1189		|O
extended	1190	1198		|O
families	1199	1207		|O
,	1207	1208		|O
both	1209	1213		|O
having	1214	1220		|O
considerable	1221	1233		|O
degrees	1234	1241		|O
of	1242	1244		|O
inbreeding	1245	1255		|O
.	1255	1256		|O
In	1257	1259		|O
Louisiana	1260	1269		|O
,	1269	1270		|O
57%	1271	1274		|O
of	1275	1277		|O
the	1278	1281		|O
colonies	1282	1290		|O
were	1291	1295		|O
simple	1296	1302		|O
families	1303	1311		|O
,	1311	1312		|O
which	1313	1318		|O
were	1319	1323		|O
mostly	1324	1330		|O
headed	1331	1337		|O
by	1338	1340		|O
unrelated	1341	1350		|O
pairs	1351	1356		|O
,	1356	1357		|O
and	1358	1361		|O
43%	1362	1365		|O
were	1366	1370		|O
extended	1371	1379		|O
families	1380	1388		|O
.	1388	1389		|O
In	1390	1392		|O
simple	1393	1399		|O
families	1400	1408		|O
,	1408	1409		|O
size	1410	1414		|O
and	1415	1418		|O
body	1419	1423		|O
weight	1424	1430		|O
of	1431	1433		|O
workers	1434	1441		|O
were	1442	1446		|O
not	1447	1450		|O
associated	1451	1461		|O
with	1462	1466		|O
F	1467	1468		|O
(	1469	1470		|O
IC	1470	1472		|O
)	1472	1473		|O
or	1474	1476		|O
heterozygosity	1477	1491		|O
.	1491	1492		|O
In	1493	1495		|O
extended	1496	1504		|O
families	1505	1513		|O
of	1514	1516		|O
two	1517	1520		|O
populations	1521	1532		|O
,	1532	1533		|O
both	1534	1538		|O
size	1539	1543		|O
parameters	1544	1554		|O
were	1555	1559		|O
negatively	1560	1570		|O
correlated	1571	1581		|O
with	1582	1586		|O
F	1587	1588		|O
(	1589	1590		|O
IC	1590	1592		|O
)	1592	1593		|O
;	1593	1594		|O
however	1595	1602		|O
,	1602	1603		|O
heterozygosity	1604	1618		|O
was	1619	1622		|O
not	1623	1626		|O
associated	1627	1637		|O
with	1638	1642		|O
worker	1643	1649		|O
size	1650	1654		|O
in	1655	1657		|O
any	1658	1661		|O
of	1662	1664		|O
the	1665	1668		|O
populations	1669	1680		|O
.	1680	1681		|O
This	1682	1686		|O
suggests	1687	1695		|O
that	1696	1700		|O
the	1701	1704		|O
number	1705	1711		|O
of	1712	1714		|O
reproductives	1715	1728		|O
within	1729	1735		|O
colonies	1736	1744		|O
has	1745	1748		|O
a	1749	1750		|O
stronger	1751	1759		|O
influence	1760	1769		|O
on	1770	1772		|O
worker	1773	1779		|O
size	1780	1784		|O
than	1785	1789		|O
the	1790	1793		|O
individuals	1794	1805		|O
'	1805	1806		|O
genetic	1807	1814		|O
diversity	1815	1824		|O
in	1825	1827		|O
Formosan	1828	1836		|O
subterranean	1837	1849		|O
termite	1850	1857		|O
colonies	1858	1866		|O
.	1866	1867		|O

### 18421600
Protease	10	18		|O
production	19	29		|O
by	30	32		|O
different	33	42		|O
thermophilic	43	55		|O
fungi	56	61		|O
.	61	62		|O
A	64	65		|O
comparative	66	77		|O
study	78	83		|O
was	84	87		|O
carried	88	95		|O
out	96	99		|O
to	100	102		|O
evaluate	103	111		|O
protease	112	120		|O
production	121	131		|O
in	132	134		|O
solid	135	140		|O
-	140	141		|O
state	141	146		|O
fermentation	147	159		|O
(	160	161		|O
SSF	161	164		|O
)	164	165		|O
and	166	169		|O
submerged	170	179		|O
fermentation	180	192		|O
(	193	194		|O
SmF	194	197		|O
)	197	198		|O
by	199	201		|O
nine	202	206		|O
different	207	216		|O
thermophilic	217	229		|O
fungi	230	235		|O
-	236	237		|O
Thermoascus	238	249		|O
aurantiacus	250	261		|O
Miehe	262	267		|O
,	267	268		|O
Thermomyces	269	280		|O
lanuginosus	281	292		|O
,	292	293		|O
T	294	295		|O
.	295	296		|O
lanuginosus	297	308		|O
TO	309	311		|O
.03	311	314		|O
,	314	315		|O
Aspergillus	316	327		|O
flavus	328	334		|O
1.2	335	338		|O
,	338	339		|O
Aspergillus	340	351		|O
sp	352	354		|O
.	354	355		|O
13.33	356	361		|O
,	361	362		|O
Aspergillus	363	374		|O
sp	375	377		|O
.	377	378		|O
13.34	379	384		|O
,	384	385		|O
Aspergillus	386	397		|O
sp	398	400		|O
.	400	401		|O
13.35	402	407		|O
,	407	408		|O
Rhizomucor	409	419		|O
pusillus	420	428		|O
13.36	429	434		|O
and	435	438		|O
Rhizomucor	439	449		|O
sp	450	452		|O
.	452	453		|O
13.37	454	459		|O
-	460	461		|O
using	462	467		|O
substrates	468	478		|O
containing	479	489		|O
proteins	490	498		|O
to	499	501		|O
induce	502	508		|O
enzyme	509	515		|O
secretion	516	525		|O
.	525	526		|O
Soybean	527	534		|O
extract	535	542		|O
(	543	544		|O
soybean	544	551		|O
milk	552	556		|O
)	556	557		|O
,	557	558		|O
soybean	559	566		|O
flour	567	572		|O
,	572	573		|O
milk	574	578		|O
powder	579	585		|O
,	585	586		|O
rice	587	591		|O
,	591	592		|O
and	593	596		|O
wheat	597	602		|O
bran	603	607		|O
were	608	612		|O
tested	613	619		|O
.	619	620		|O
The	621	624		|O
most	625	629		|O
satisfactory	630	642		|O
results	643	650		|O
were	651	655		|O
obtained	656	664		|O
when	665	669		|O
using	670	675		|O
wheat	676	681		|O
bran	682	686		|O
in	687	689		|O
SSF	690	693		|O
.	693	694		|O
The	695	698		|O
fungi	699	704		|O
that	705	709		|O
stood	710	715		|O
out	716	719		|O
in	720	722		|O
SSF	723	726		|O
were	727	731		|O
T	732	733		|O
.	733	734		|O
lanuginosus	735	746		|O
,	746	747		|O
T	748	749		|O
.	749	750		|O
lanuginosus	751	762		|O
TO	763	765		|O
.03	765	768		|O
,	768	769		|O
Aspergillus	770	781		|O
sp	782	784		|O
.	784	785		|O
13.34	786	791		|O
,	791	792		|O
Aspergillus	793	804		|O
sp	805	807		|O
.	807	808		|O
13.35	809	814		|O
,	814	815		|O
and	816	819		|O
Rhizomucor	820	830		|O
sp	831	833		|O
.	833	834		|O
13.37	835	840		|O
,	840	841		|O
and	842	845		|O
those	846	851		|O
in	852	854		|O
SmF	855	858		|O
were	859	863		|O
T	864	865		|O
.	865	866		|O
aurantiacus	867	878		|O
,	878	879		|O
T	880	881		|O
.	881	882		|O
lanuginosus	883	894		|O
TO	895	897		|O
.03	897	900		|O
,	900	901		|O
and	902	905		|O
13.37	906	911		|O
.	911	912		|O
In	913	915		|O
both	916	920		|O
fermentation	921	933		|O
systems	934	941		|O
,	941	942		|O
A	943	944		|O
.	944	945		|O
flavus	946	952		|O
1.2	953	956		|O
and	957	960		|O
R	961	962		|O
.	962	963		|O
pusillus	964	972		|O
13.36	973	978		|O
presented	979	988		|O
the	989	992		|O
lowest	993	999		|O
levels	1000	1006		|O
of	1007	1009		|O
proteolytic	1010	1021		|O
activity	1022	1030		|O
.	1030	1031		|O

### 18421171
Inhomogeneity	10	23		|O
of	24	26		|O
Fecal	27	32		|O
Flora	33	38		|O
in	39	41		|O
Separately	42	52		|O
Reared	53	59		|O
Laboratory	60	70		|O
Mice	71	75		|O
,	75	76		|O
as	77	79		|O
Detected	80	88		|O
by	89	91		|O
Denaturing	92	102		|O
Gradient	103	111		|O
Gel	112	115		|O
Electrophoresis	116	131		|O
(	132	133		|O
DGGE	133	137		|O
)	137	138		|O
.	138	139		|O
Laboratory	141	151		|O
mice	152	156		|O
were	157	161		|O
divided	162	169		|O
into	170	174		|O
2	175	176		|O
groups	177	183		|O
and	184	187		|O
introduced	188	198		|O
to	199	201		|O
different	202	211		|O
rooms	212	217		|O
immediately	218	229		|O
after	230	235		|O
being	236	241		|O
transferred	242	253		|O
from	254	258		|O
a	259	260		|O
mouse	261	266		|O
farm	267	271		|O
.	271	272		|O
Polymerase	273	283		|O
chain	284	289		|O
reaction	290	298		|O
followed	299	307		|O
by	308	310		|O
denaturing	311	321		|O
gradient	322	330		|O
gel	331	334		|O
electrophoresis	335	350		|O
were	351	355		|O
performed	356	365		|O
on	366	368		|O
the	369	372		|O
V6	373	375		|O
-	375	376		|O
V8	376	378		|O
regions	379	386		|O
of	387	389		|O
bacterial	390	399		|O
16S	400	403		|O
rDNA	404	408		|O
obtained	409	417		|O
from	418	422		|O
fecal	423	428		|O
samples	429	436		|O
at	437	439		|O
0	440	441		|O
,	441	442		|O
1	443	444		|O
,	444	445		|O
2	446	447		|O
,	447	448		|O
3	449	450		|O
,	450	451		|O
4	452	453		|O
and	454	457		|O
8	458	459		|O
weeks	460	465		|O
after	466	471		|O
the	472	475		|O
introduction	476	488		|O
.	488	489		|O
Binary	490	496		|O
data	497	501		|O
were	502	506		|O
obtained	507	515		|O
from	516	520		|O
banding	521	528		|O
patterns	529	537		|O
,	537	538		|O
and	539	542		|O
Euclidean	543	552		|O
distances	553	562		|O
for	563	566		|O
each	567	571		|O
week	572	576		|O
were	577	581		|O
calculated	582	592		|O
and	593	596		|O
analyzed	597	605		|O
by	606	608		|O
cluster	609	616		|O
analysis	617	625		|O
and	626	629		|O
non	630	633		|O
-	633	634		|O
metric	634	640		|O
multidimensional	641	657		|O
scaling	658	665		|O
.	665	666		|O
Euclidean	667	676		|O
distances	677	686		|O
were	687	691		|O
significantly	692	705		|O
higher	706	712		|O
at	713	715		|O
weeks	716	721		|O
1	722	723		|O
and	724	727		|O
2	728	729		|O
than	730	734		|O
at	735	737		|O
week	738	742		|O
0	743	744		|O
in	745	747		|O
both	748	752		|O
groups	753	759		|O
,	759	760		|O
although	761	769		|O
the	770	773		|O
distances	774	783		|O
between	784	791		|O
the	792	795		|O
2	796	797		|O
groups	798	804		|O
were	805	809		|O
significantly	810	823		|O
higher	824	830		|O
after	831	836		|O
week	837	841		|O
1	842	843		|O
than	844	848		|O
week	849	853		|O
0	854	855		|O
.	855	856		|O
The	857	860		|O
distances	861	870		|O
between	871	878		|O
the	879	882		|O
2	883	884		|O
groups	885	891		|O
were	892	896		|O
significantly	897	910		|O
higher	911	917		|O
than	918	922		|O
those	923	928		|O
within	929	935		|O
each	936	940		|O
group	941	946		|O
at	947	949		|O
weeks	950	955		|O
4	956	957		|O
and	958	961		|O
8	962	963		|O
.	963	964		|O
Mice	965	969		|O
in	970	972		|O
the	973	976		|O
2	977	978		|O
groups	979	985		|O
formed	986	992		|O
clusters	993	1001		|O
at	1002	1004		|O
weeks	1005	1010		|O
2	1011	1012		|O
and	1013	1016		|O
3	1017	1018		|O
respectively	1019	1031		|O
,	1031	1032		|O
and	1033	1036		|O
mice	1037	1041		|O
were	1042	1046		|O
divided	1047	1054		|O
into	1055	1059		|O
2	1060	1061		|O
clusters	1062	1070		|O
by	1071	1073		|O
their	1074	1079		|O
respective	1080	1090		|O
groups	1091	1097		|O
at	1098	1100		|O
weeks	1101	1106		|O
4	1107	1108		|O
and	1109	1112		|O
8	1113	1114		|O
.	1114	1115		|O
Mice	1116	1120		|O
in	1121	1123		|O
the	1124	1127		|O
2	1128	1129		|O
groups	1130	1136		|O
were	1137	1141		|O
distributed	1142	1153		|O
on	1154	1156		|O
opposite	1157	1165		|O
sides	1166	1171		|O
of	1172	1174		|O
the	1175	1178		|O
origin	1179	1185		|O
on	1186	1188		|O
the	1189	1192		|O
2	1193	1194		|O
-	1194	1195		|O
dimensional	1195	1206		|O
plane	1207	1212		|O
after	1213	1218		|O
week	1219	1223		|O
2	1224	1225		|O
.	1225	1226		|O
These	1227	1232		|O
results	1233	1240		|O
suggest	1241	1248		|O
that	1249	1253		|O
mouse	1254	1259		|O
fecal	1260	1265		|O
flora	1266	1271		|O
changed	1272	1279		|O
characteristically	1280	1298		|O
,	1298	1299		|O
according	1300	1309		|O
to	1310	1312		|O
the	1313	1316		|O
local	1317	1322		|O
environment	1323	1334		|O
after	1335	1340		|O
introduction	1341	1353		|O
.	1353	1354		|O

### 18421161
Mail	10	14		|O
-	14	15		|O
in	15	17		|O
data	18	22		|O
collection	23	33		|O
at	34	36		|O
SPring	37	43		|O
-	43	44		|O
8	44	45		|O
protein	46	53		|O
crystallography	54	69		|O
beamlines	70	79		|O
.	79	80		|O
A	82	83		|O
mail	84	88		|O
-	88	89		|O
in	89	91		|O
data	92	96		|O
collection	97	107		|O
system	108	114		|O
makes	115	120		|O
it	121	123		|O
possible	124	132		|O
for	133	136		|O
beamline	137	145		|O
users	146	151		|O
to	152	154		|O
collect	155	162		|O
diffraction	163	174		|O
data	175	179		|O
without	180	187		|O
visiting	188	196		|O
a	197	198		|O
synchrotron	199	210		|O
facility	211	219		|O
.	219	220		|O
In	221	223		|O
the	224	227		|O
mail	228	232		|O
-	232	233		|O
in	233	235		|O
data	236	240		|O
collection	241	251		|O
system	252	258		|O
at	259	261		|O
SPring	262	268		|O
-	268	269		|O
8	269	270		|O
,	270	271		|O
users	272	277		|O
pack	278	282		|O
crystals	283	291		|O
into	292	296		|O
sample	297	303		|O
trays	304	309		|O
and	310	313		|O
send	314	318		|O
the	319	322		|O
trays	323	328		|O
to	329	331		|O
SPring	332	338		|O
-	338	339		|O
8	339	340		|O
via	341	344		|O
a	345	346		|O
courier	347	354		|O
service	355	362		|O
as	363	365		|O
the	366	369		|O
first	370	375		|O
step	376	380		|O
.	380	381		|O
Next	382	386		|O
,	386	387		|O
the	388	391		|O
user	392	396		|O
specifies	397	406		|O
measurement	407	418		|O
conditions	419	429		|O
and	430	433		|O
checks	434	440		|O
the	441	444		|O
diffraction	445	456		|O
images	457	463		|O
via	464	467		|O
the	468	471		|O
Internet	472	480		|O
.	480	481		|O
The	482	485		|O
user	486	490		|O
can	491	494		|O
also	495	499		|O
collect	500	507		|O
diffraction	508	519		|O
data	520	524		|O
using	525	530		|O
an	531	533		|O
automated	534	543		|O
sample	544	550		|O
changer	551	558		|O
robot	559	564		|O
and	565	568		|O
beamline	569	577		|O
control	578	585		|O
software	586	594		|O
.	594	595		|O
For	596	599		|O
distant	600	607		|O
users	608	613		|O
there	614	619		|O
is	620	622		|O
a	623	624		|O
newly	625	630		|O
developed	631	640		|O
data	641	645		|O
management	646	656		|O
system	657	663		|O
,	663	664		|O
D	665	666		|O
-	666	667		|O
Cha	667	670		|O
.	670	671		|O
D	672	673		|O
-	673	674		|O
Cha	674	677		|O
provides	678	686		|O
a	687	688		|O
graphical	689	698		|O
user	699	703		|O
interface	704	713		|O
that	714	718		|O
enables	719	726		|O
the	727	730		|O
user	731	735		|O
to	736	738		|O
specify	739	746		|O
the	747	750		|O
experimental	751	763		|O
conditions	764	774		|O
for	775	778		|O
samples	779	786		|O
and	787	790		|O
to	791	793		|O
check	794	799		|O
and	800	803		|O
download	804	812		|O
the	813	816		|O
diffraction	817	828		|O
images	829	835		|O
using	836	841		|O
a	842	843		|O
web	844	847		|O
browser	848	855		|O
.	855	856		|O
This	857	861		|O
system	862	868		|O
is	869	871		|O
now	872	875		|O
in	876	878		|O
routine	879	886		|O
operation	887	896		|O
and	897	900		|O
is	901	903		|O
contributing	904	916		|O
to	917	919		|O
high	920	924		|O
-	924	925		|O
throughput	925	935		|O
beamline	936	944		|O
operation	945	954		|O
.	954	955		|O

### 18419667
Implied	10	17		|O
preference	18	28		|O
for	29	32		|O
seismic	33	40		|O
design	41	47		|O
level	48	53		|O
and	54	57		|O
earthquake	58	68		|O
insurance	69	78		|O
.	78	79		|O
Seismic	81	88		|O
risk	89	93		|O
can	94	97		|O
be	98	100		|O
reduced	101	108		|O
by	109	111		|O
implementing	112	124		|O
newly	125	130		|O
developed	131	140		|O
seismic	141	148		|O
provisions	149	159		|O
in	160	162		|O
design	163	169		|O
codes	170	175		|O
.	175	176		|O
Furthermore	177	188		|O
,	188	189		|O
financial	190	199		|O
protection	200	210		|O
or	211	213		|O
enhanced	214	222		|O
utility	223	230		|O
and	231	234		|O
happiness	235	244		|O
for	245	248		|O
stakeholders	249	261		|O
could	262	267		|O
be	268	270		|O
gained	271	277		|O
through	278	285		|O
the	286	289		|O
purchase	290	298		|O
of	299	301		|O
earthquake	302	312		|O
insurance	313	322		|O
.	322	323		|O
If	324	326		|O
this	327	331		|O
is	332	334		|O
not	335	338		|O
so	339	341		|O
,	341	342		|O
there	343	348		|O
would	349	354		|O
be	355	357		|O
no	358	360		|O
market	361	367		|O
for	368	371		|O
such	372	376		|O
insurance	377	386		|O
.	386	387		|O
However	388	395		|O
,	395	396		|O
perceived	397	406		|O
benefit	407	414		|O
associated	415	425		|O
with	426	430		|O
insurance	431	440		|O
is	441	443		|O
not	444	447		|O
universally	448	459		|O
shared	460	466		|O
by	467	469		|O
stakeholders	470	482		|O
partly	483	489		|O
due	490	493		|O
to	494	496		|O
their	497	502		|O
diverse	503	510		|O
risk	511	515		|O
attitudes	516	525		|O
.	525	526		|O
This	527	531		|O
study	532	537		|O
investigates	538	550		|O
the	551	554		|O
implied	555	562		|O
seismic	563	570		|O
design	571	577		|O
preference	578	588		|O
with	589	593		|O
insurance	594	603		|O
options	604	611		|O
for	612	615		|O
decisionmakers	616	630		|O
of	631	633		|O
bounded	634	641		|O
rationality	642	653		|O
whose	654	659		|O
preferences	660	671		|O
could	672	677		|O
be	678	680		|O
adequately	681	691		|O
represented	692	703		|O
by	704	706		|O
the	707	710		|O
cumulative	711	721		|O
prospect	722	730		|O
theory	731	737		|O
(	738	739		|O
CPT	739	742		|O
)	742	743		|O
.	743	744		|O
The	745	748		|O
investigation	749	762		|O
is	763	765		|O
focused	766	773		|O
on	774	776		|O
assessing	777	786		|O
the	787	790		|O
sensitivity	791	802		|O
of	803	805		|O
the	806	809		|O
implied	810	817		|O
seismic	818	825		|O
design	826	832		|O
preference	833	843		|O
with	844	848		|O
insurance	849	858		|O
options	859	866		|O
to	867	869		|O
model	870	875		|O
parameters	876	886		|O
of	887	889		|O
the	890	893		|O
CPT	894	897		|O
and	898	901		|O
to	902	904		|O
fair	905	909		|O
and	910	913		|O
unfair	914	920		|O
insurance	921	930		|O
arrangements	931	943		|O
.	943	944		|O
Numerical	945	954		|O
results	955	962		|O
suggest	963	970		|O
that	971	975		|O
human	976	981		|O
cognitive	982	991		|O
limitation	992	1002		|O
and	1003	1006		|O
risk	1007	1011		|O
perception	1012	1022		|O
can	1023	1026		|O
affect	1027	1033		|O
the	1034	1037		|O
implied	1038	1045		|O
seismic	1046	1053		|O
design	1054	1060		|O
preference	1061	1071		|O
by	1072	1074		|O
the	1075	1078		|O
CPT	1079	1082		|O
significantly	1083	1096		|O
.	1096	1097		|O
The	1098	1101		|O
mandatory	1102	1111		|O
purchase	1112	1120		|O
of	1121	1123		|O
fair	1124	1128		|O
insurance	1129	1138		|O
will	1139	1143		|O
lead	1144	1148		|O
the	1149	1152		|O
implied	1153	1160		|O
seismic	1161	1168		|O
design	1169	1175		|O
preference	1176	1186		|O
to	1187	1189		|O
the	1190	1193		|O
optimum	1194	1201		|O
design	1202	1208		|O
level	1209	1214		|O
that	1215	1219		|O
is	1220	1222		|O
dictated	1223	1231		|O
by	1232	1234		|O
the	1235	1238		|O
minimum	1239	1246		|O
expected	1247	1255		|O
lifecycle	1256	1265		|O
cost	1266	1270		|O
rule	1271	1275		|O
.	1275	1276		|O
Unfair	1277	1283		|O
insurance	1284	1293		|O
decreases	1294	1303		|O
the	1304	1307		|O
expected	1308	1316		|O
gain	1317	1321		|O
as	1322	1324		|O
well	1325	1329		|O
as	1330	1332		|O
its	1333	1336		|O
associated	1337	1347		|O
variability	1348	1359		|O
,	1359	1360		|O
which	1361	1366		|O
is	1367	1369		|O
preferred	1370	1379		|O
by	1380	1382		|O
risk	1383	1387		|O
-	1387	1388		|O
averse	1388	1394		|O
decisionmakers	1395	1409		|O
.	1409	1410		|O
The	1411	1414		|O
obtained	1415	1423		|O
results	1424	1431		|O
of	1432	1434		|O
the	1435	1438		|O
implied	1439	1446		|O
preference	1447	1457		|O
for	1458	1461		|O
the	1462	1465		|O
combination	1466	1477		|O
of	1478	1480		|O
the	1481	1484		|O
seismic	1485	1492		|O
design	1493	1499		|O
level	1500	1505		|O
and	1506	1509		|O
insurance	1510	1519		|O
option	1520	1526		|O
suggest	1527	1534		|O
that	1535	1539		|O
property	1540	1548		|O
owners	1549	1555		|O
,	1555	1556		|O
financial	1557	1566		|O
institutions	1567	1579		|O
,	1579	1580		|O
and	1581	1584		|O
municipalities	1585	1599		|O
can	1600	1603		|O
take	1604	1608		|O
advantage	1609	1618		|O
of	1619	1621		|O
affordable	1622	1632		|O
insurance	1633	1642		|O
to	1643	1645		|O
establish	1646	1655		|O
successful	1656	1666		|O
seismic	1667	1674		|O
risk	1675	1679		|O
management	1680	1690		|O
strategies	1691	1701		|O
.	1701	1702		|O

### 18421162
X	10	11		|O
-	11	12		|O
ray	12	15		|O
beam	16	20		|O
stabilization	21	34		|O
at	35	37		|O
BL	38	40		|O
-	40	41		|O
17A	41	44		|O
,	44	45		|O
the	46	49		|O
protein	50	57		|O
microcrystallography	58	78		|O
beamline	79	87		|O
of	88	90		|O
the	91	94		|O
Photon	95	101		|O
Factory	102	109		|O
.	109	110		|O
BL	112	114		|O
-	114	115		|O
17A	115	118		|O
is	119	121		|O
a	122	123		|O
new	124	127		|O
structural	128	138		|O
biology	139	146		|O
beamline	147	155		|O
at	156	158		|O
the	159	162		|O
Photon	163	169		|O
Factory	170	177		|O
,	177	178		|O
Japan	179	184		|O
.	184	185		|O
The	186	189		|O
high	190	194		|O
-	194	195		|O
brilliance	195	205		|O
beam	206	210		|O
,	210	211		|O
derived	212	219		|O
from	220	224		|O
the	225	228		|O
new	229	232		|O
short	233	238		|O
-	238	239		|O
gap	239	242		|O
undulator	243	252		|O
(	253	254		|O
SGU	254	257		|O
#	257	258		|O
17	258	260		|O
)	260	261		|O
,	261	262		|O
allows	263	269		|O
for	270	273		|O
unique	274	280		|O
protein	281	288		|O
crystallographic	289	305		|O
experiments	306	317		|O
such	318	322		|O
as	323	325		|O
data	326	330		|O
collection	331	341		|O
from	342	346		|O
microcrystals	347	360		|O
and	361	364		|O
structural	365	375		|O
determination	376	389		|O
using	390	395		|O
softer	396	402		|O
X	403	404		|O
-	404	405		|O
rays	405	409		|O
.	409	410		|O
However	411	418		|O
,	418	419		|O
microcrystal	420	432		|O
experiments	433	444		|O
require	445	452		|O
robust	453	459		|O
beam	460	464		|O
stability	465	474		|O
during	475	481		|O
data	482	486		|O
collection	487	497		|O
and	498	501		|O
minor	502	507		|O
fluctuations	508	520		|O
could	521	526		|O
not	527	530		|O
be	531	533		|O
ignored	534	541		|O
.	541	542		|O
Initially	543	552		|O
,	552	553		|O
significant	554	565		|O
beam	566	570		|O
instability	571	582		|O
was	583	586		|O
observed	587	595		|O
at	596	598		|O
BL	599	601		|O
-	601	602		|O
17A	602	605		|O
.	605	606		|O
The	607	610		|O
causes	611	617		|O
of	618	620		|O
the	621	624		|O
beam	625	629		|O
instability	630	641		|O
were	642	646		|O
investigated	647	659		|O
and	660	663		|O
its	664	667		|O
various	668	675		|O
sources	676	683		|O
identified	684	694		|O
.	694	695		|O
Subsequently	696	708		|O
,	708	709		|O
several	710	717		|O
effective	718	727		|O
countermeasures	728	743		|O
have	744	748		|O
been	749	753		|O
implemented	754	765		|O
,	765	766		|O
and	767	770		|O
the	771	774		|O
fluctuation	775	786		|O
of	787	789		|O
the	790	793		|O
beam	794	798		|O
intensity	799	808		|O
successfully	809	821		|O
suppressed	822	832		|O
to	833	835		|O
within	836	842		|O
1%	843	845		|O
.	845	846		|O
Here	847	851		|O
the	852	855		|O
instability	856	867		|O
reduction	868	877		|O
techniques	878	888		|O
used	889	893		|O
at	894	896		|O
BL	897	899		|O
-	899	900		|O
17A	900	903		|O
are	904	907		|O
presented	908	917		|O
.	917	918		|O

### 18419895
Neonatal	10	18		|O
pulmonary	19	28		|O
tuberculosis	29	41		|O
evolving	42	50		|O
to	51	53		|O
a	54	55		|O
destroyed	56	65		|O
lung	66	70		|O
.	70	71		|O
Tuberculosis	73	85		|O
(	86	87		|O
TB	87	89		|O
)	89	90		|O
in	91	93		|O
the	94	97		|O
newborn	98	105		|O
is	106	108		|O
infrequent	109	119		|O
,	119	120		|O
difficult	121	130		|O
to	131	133		|O
diagnose	134	142		|O
and	143	146		|O
often	147	152		|O
devastating	153	164		|O
.	164	165		|O
Congenital	166	176		|O
TB	177	179		|O
is	180	182		|O
rare	183	187		|O
,	187	188		|O
with	189	193		|O
most	194	198		|O
neonates	199	207		|O
and	208	211		|O
young	212	217		|O
infants	218	225		|O
becoming	226	234		|O
infected	235	243		|O
after	244	249		|O
birth	250	255		|O
.	255	256		|O
The	257	260		|O
incidence	261	270		|O
of	271	273		|O
neonatal	274	282		|O
TB	283	285		|O
might	286	291		|O
increase	292	300		|O
in	301	303		|O
industrialised	304	318		|O
countries	319	328		|O
as	329	331		|O
a	332	333		|O
result	334	340		|O
of	341	343		|O
immigration	344	355		|O
from	356	360		|O
countries	361	370		|O
with	371	375		|O
higher	376	382		|O
TB	383	385		|O
incidence	386	395		|O
among	396	401		|O
women	402	407		|O
of	408	410		|O
childbearing	411	423		|O
age	424	427		|O
.	427	428		|O
We	429	431		|O
report	432	438		|O
two	439	442		|O
cases	443	448		|O
of	449	451		|O
post	452	456		|O
-	456	457		|O
natally	457	464		|O
acquired	465	473		|O
pulmonary	474	483		|O
TB	484	486		|O
in	487	489		|O
newborns	490	498		|O
who	499	502		|O
developed	503	512		|O
marked	513	519		|O
lung	520	524		|O
destruction	525	536		|O
,	536	537		|O
a	538	539		|O
complication	540	552		|O
of	553	555		|O
TB	556	558		|O
which	559	564		|O
has	565	568		|O
seldom	569	575		|O
been	576	580		|O
described	581	590		|O
in	591	593		|O
the	594	597		|O
first	598	603		|O
month	604	609		|O
of	610	612		|O
life	613	617		|O
.	617	618		|O
A	619	620		|O
high	621	625		|O
index	626	631		|O
of	632	634		|O
clinical	635	643		|O
suspicion	644	653		|O
is	654	656		|O
required	657	665		|O
when	666	670		|O
evaluating	671	681		|O
pregnant	682	690		|O
women	691	696		|O
at	697	699		|O
risk	700	704		|O
for	705	708		|O
TB	709	711		|O
and	712	715		|O
their	716	721		|O
ill	722	725		|O
children	726	734		|O
,	734	735		|O
as	736	738		|O
early	739	744		|O
identification	745	759		|O
and	760	763		|O
treatment	764	773		|O
can	774	777		|O
prevent	778	785		|O
the	786	789		|O
devastating	790	801		|O
consequences	802	814		|O
of	815	817		|O
TB	818	820		|O
.	820	821		|O

### 18419843
Visual	10	16		|O
perception	17	27		|O
in	28	30		|O
prediagnostic	31	44		|O
and	45	48		|O
early	49	54		|O
stage	55	60		|O
Huntington	61	71		|O
's	71	73		|O
disease	74	81		|O
.	81	82		|O
Disturbances	84	96		|O
of	97	99		|O
visual	100	106		|O
perception	107	117		|O
frequently	118	128		|O
accompany	129	138		|O
neurodegenerative	139	156		|O
disorders	157	166		|O
but	167	170		|O
have	171	175		|O
been	176	180		|O
little	181	187		|O
studied	188	195		|O
in	196	198		|O
Huntington	199	209		|O
's	209	211		|O
disease	212	219		|O
(	220	221		|O
HD	221	223		|O
)	223	224		|O
gene	225	229		|O
carriers	230	238		|O
.	238	239		|O
We	240	242		|O
used	243	247		|O
psychophysical	248	262		|O
tests	263	268		|O
to	269	271		|O
assess	272	278		|O
visual	279	285		|O
perception	286	296		|O
among	297	302		|O
individuals	303	314		|O
in	315	317		|O
the	318	321		|O
prediagnostic	322	335		|O
and	336	339		|O
early	340	345		|O
stages	346	352		|O
of	353	355		|O
HD	356	358		|O
.	358	359		|O
The	360	363		|O
sample	364	370		|O
comprised	371	380		|O
four	381	385		|O
groups	386	392		|O
,	392	393		|O
which	394	399		|O
included	400	408		|O
nongene	413	420		|O
carriers	421	429		|O
(	430	431		|O
NG	431	433		|O
)	433	434		|O
,	434	435		|O
32	436	438		|O
prediagnostic	439	452		|O
gene	453	457		|O
carriers	458	466		|O
with	467	471		|O
minimal	472	479		|O
neurological	480	492		|O
abnormalities	493	506		|O
(	507	508		|O
PD1	508	511		|O
)	511	512		|O
;	512	513		|O
prediagnostic	517	530		|O
gene	531	535		|O
carriers	536	544		|O
with	545	549		|O
moderate	550	558		|O
neurological	559	571		|O
abnormalities	572	585		|O
(	586	587		|O
PD2	587	590		|O
)	590	591		|O
,	591	592		|O
and	593	596		|O
36	597	599		|O
gene	600	604		|O
carriers	605	613		|O
with	614	618		|O
diagnosed	619	628		|O
HD	629	631		|O
.	631	632		|O
Contrast	633	641		|O
sensitivity	642	653		|O
for	654	657		|O
stationary	658	668		|O
and	669	672		|O
moving	673	679		|O
sinusoidal	680	690		|O
gratings	691	699		|O
,	699	700		|O
and	701	704		|O
tests	705	710		|O
of	711	713		|O
form	714	718		|O
and	719	722		|O
motion	723	729		|O
discrimination	730	744		|O
,	744	745		|O
were	746	750		|O
used	751	755		|O
to	756	758		|O
probe	759	764		|O
different	765	774		|O
visual	775	781		|O
pathways	782	790		|O
.	790	791		|O
Patients	792	800		|O
with	801	805		|O
HD	806	808		|O
showed	809	815		|O
impaired	816	824		|O
contrast	825	833		|O
sensitivity	834	845		|O
for	846	849		|O
moving	850	856		|O
gratings	857	865		|O
.	865	866		|O
For	867	870		|O
one	871	874		|O
of	875	877		|O
the	878	881		|O
three	882	887		|O
contrast	888	896		|O
sensitivity	897	908		|O
tests	909	914		|O
,	914	915		|O
the	916	919		|O
prediagnostic	920	933		|O
gene	934	938		|O
carriers	939	947		|O
with	948	952		|O
greater	953	960		|O
neurological	961	973		|O
abnormality	974	985		|O
(	986	987		|O
PD2	987	990		|O
)	990	991		|O
also	992	996		|O
had	997	1000		|O
impaired	1001	1009		|O
performance	1010	1021		|O
as	1022	1024		|O
compared	1025	1033		|O
with	1034	1038		|O
NG	1039	1041		|O
.	1041	1042		|O
These	1043	1048		|O
findings	1049	1057		|O
suggest	1058	1065		|O
that	1066	1070		|O
early	1071	1076		|O
stage	1077	1082		|O
HD	1083	1085		|O
disrupts	1086	1094		|O
visual	1095	1101		|O
functions	1102	1111		|O
associated	1112	1122		|O
with	1123	1127		|O
the	1128	1131		|O
magnocellular	1132	1145		|O
pathway	1146	1153		|O
.	1153	1154		|O
However	1155	1162		|O
,	1162	1163		|O
these	1164	1169		|O
changes	1170	1177		|O
are	1178	1181		|O
only	1182	1186		|O
observed	1187	1195		|O
in	1196	1198		|O
individuals	1199	1210		|O
diagnosed	1211	1220		|O
with	1221	1225		|O
HD	1226	1228		|O
or	1229	1231		|O
who	1232	1235		|O
are	1236	1239		|O
in	1240	1242		|O
the	1243	1246		|O
more	1247	1251		|O
symptomatic	1252	1263		|O
stages	1264	1270		|O
of	1271	1273		|O
prediagnostic	1274	1287		|O
HD	1288	1290		|O
.	1290	1291		|O

### 18419676
Prospects	10	19		|O
for	20	23		|O
the	24	27		|O
use	28	31		|O
of	32	34		|O
differentiation	35	50		|O
-	50	51		|O
modulating	51	61		|O
agents	62	68		|O
as	69	71		|O
adjuvant	72	80		|O
of	81	83		|O
photodynamic	84	96		|O
therapy	97	104		|O
for	105	108		|O
proliferative	109	122		|O
dermatoses	123	133		|O
.	133	134		|O
Current	136	143		|O
interest	144	152		|O
in	153	155		|O
photodynamic	156	168		|O
therapy	169	176		|O
(	177	178		|O
PDT	178	181		|O
)	181	182		|O
in	183	185		|O
dermatology	186	197		|O
stems	198	203		|O
from	204	208		|O
its	209	212		|O
recognized	213	223		|O
success	224	231		|O
in	232	234		|O
dermatological	235	249		|O
oncology	250	258		|O
,	258	259		|O
straightforward	260	275		|O
approach	276	284		|O
,	284	285		|O
easy	286	290		|O
accessibility	291	304		|O
and	305	308		|O
low	309	312		|O
cost	313	317		|O
.	317	318		|O
PDT	319	322		|O
is	323	325		|O
a	326	327		|O
photochemistry	328	342		|O
-	342	343		|O
based	343	348		|O
modality	349	357		|O
in	358	360		|O
which	361	366		|O
a	367	368		|O
light	369	374		|O
-	374	375		|O
activated	375	384		|O
photosensitizer	385	400		|O
(	401	402		|O
PS	402	404		|O
)	404	405		|O
destroys	406	414		|O
tissue	415	421		|O
through	422	429		|O
oxygen	430	436		|O
-	436	437		|O
dependent	437	446		|O
and	447	450		|O
-	451	452		|O
independent	452	463		|O
mechanisms	464	474		|O
.	474	475		|O
Although	476	484		|O
PDT	485	488		|O
has	489	492		|O
been	493	497		|O
used	498	502		|O
in	503	505		|O
dermatology	506	517		|O
for	518	521		|O
several	522	529		|O
decades	530	537		|O
,	537	538		|O
its	539	542		|O
application	543	554		|O
has	555	558		|O
still	559	564		|O
not	565	568		|O
extended	569	577		|O
significantly	578	591		|O
into	592	596		|O
the	597	600		|O
routine	601	608		|O
management	609	619		|O
of	620	622		|O
neoplastic	623	633		|O
and	634	637		|O
proliferative	638	651		|O
dermatoses	652	662		|O
because	663	670		|O
of	671	673		|O
continuing	674	684		|O
issues	685	691		|O
with	692	696		|O
the	697	700		|O
selectivity	701	712		|O
of	713	715		|O
the	716	719		|O
PS	720	722		|O
for	723	726		|O
affected	727	735		|O
tissues	736	743		|O
.	743	744		|O
This	745	749		|O
review	750	756		|O
analyzes	757	765		|O
prospects	766	775		|O
for	776	779		|O
optimization	780	792		|O
of	793	795		|O
PDT	796	799		|O
for	800	803		|O
the	804	807		|O
management	808	818		|O
of	819	821		|O
dermatoses	822	832		|O
with	833	837		|O
defects	838	845		|O
in	846	848		|O
keratinocyte	849	861		|O
proliferation	862	875		|O
/	875	876		|O
differentiation	876	891		|O
,	891	892		|O
and	893	896		|O
discusses	897	906		|O
the	907	910		|O
use	911	914		|O
of	915	917		|O
differentiating	918	933		|O
agents	934	940		|O
that	941	945		|O
redirect	946	954		|O
metabolic	955	964		|O
utilization	965	976		|O
within	977	983		|O
cells	984	989		|O
and	990	993		|O
lead	994	998		|O
to	999	1001		|O
high	1002	1006		|O
levels	1007	1013		|O
of	1014	1016		|O
PS	1017	1019		|O
accumulation	1020	1032		|O
.	1032	1033		|O

### 18419993
Photodynamic	10	22		|O
diagnostics	23	34		|O
of	35	37		|O
bladder	38	45		|O
tumors	46	52		|O
.	52	53		|O
Approximately	55	68		|O
18,000	69	75		|O
new	76	79		|O
cases	80	85		|O
of	86	88		|O
urothelial	89	99		|O
cancer	100	106		|O
of	107	109		|O
the	110	113		|O
bladder	114	121		|O
occur	122	127		|O
annually	128	136		|O
,	136	137		|O
making	138	144		|O
it	145	147		|O
the	148	151		|O
most	152	156		|O
frequent	157	165		|O
urogenital	166	176		|O
neoplasia	177	186		|O
representing	187	199		|O
nearly	200	206		|O
4%	207	209		|O
of	210	212		|O
all	213	216		|O
malignomas	217	227		|O
.	227	228		|O
Tumor	229	234		|O
stage	235	240		|O
defines	241	248		|O
two	249	252		|O
subgroups	253	262		|O
requiring	263	272		|O
specific	273	281		|O
therapeutic	282	293		|O
approaches	294	304		|O
and	305	308		|O
implying	309	317		|O
distinct	318	326		|O
prognoses	327	336		|O
.	336	337		|O
Non	338	341		|O
-	341	342		|O
muscle	342	348		|O
-	348	349		|O
invasive	349	357		|O
urothelial	358	368		|O
cancer	369	375		|O
recurs	376	382		|O
frequently	383	393		|O
and	394	397		|O
occasionally	398	410		|O
progresses	411	421		|O
to	422	424		|O
muscle	425	431		|O
-	431	432		|O
invasive	432	440		|O
stages	441	447		|O
.	447	448		|O
Remnant	449	456		|O
tumor	457	462		|O
after	463	468		|O
initial	469	476		|O
resection	477	486		|O
is	487	489		|O
seen	490	494		|O
as	495	497		|O
one	498	501		|O
major	502	507		|O
factor	508	514		|O
in	515	517		|O
high	518	522		|O
recurrence	523	533		|O
rates	534	539		|O
.	539	540		|O
Although	541	549		|O
photodynamic	550	562		|O
diagnostics	563	574		|O
improving	575	584		|O
detection	585	594		|O
and	595	598		|O
increasing	599	609		|O
recurrence	610	620		|O
-	620	621		|O
free	621	625		|O
survival	626	634		|O
has	635	638		|O
been	639	643		|O
introduced	644	654		|O
to	655	657		|O
broad	658	663		|O
application	664	675		|O
,	675	676		|O
it	677	679		|O
has	680	683		|O
yet	684	687		|O
not	688	691		|O
been	692	696		|O
established	697	708		|O
as	709	711		|O
standard	712	720		|O
procedure	721	730		|O
.	730	731		|O
This	732	736		|O
article	737	744		|O
reviews	745	752		|O
the	753	756		|O
current	757	764		|O
literature	765	775		|O
and	776	779		|O
discusses	780	789		|O
controversial	790	803		|O
aspects	804	811		|O
.	811	812		|O

### 18419837
Thalamic	10	18		|O
atrophy	19	26		|O
and	27	30		|O
cognition	31	40		|O
in	41	43		|O
unilateral	44	54		|O
temporal	55	63		|O
lobe	64	68		|O
epilepsy	69	77		|O
.	77	78		|O
This	80	84		|O
study	85	90		|O
examined	91	99		|O
quantitative	100	112		|O
magnetic	113	121		|O
resonance	122	131		|O
volumes	132	139		|O
of	140	142		|O
the	143	146		|O
thalamus	147	155		|O
and	156	159		|O
hippocampus	160	171		|O
and	172	175		|O
determined	176	186		|O
their	187	192		|O
relationship	193	205		|O
with	206	210		|O
cognitive	211	220		|O
function	221	229		|O
and	230	233		|O
clinical	234	242		|O
seizure	243	250		|O
characteristics	251	266		|O
in	267	269		|O
a	270	271		|O
sample	272	278		|O
of	279	281		|O
46	282	284		|O
unilateral	285	295		|O
temporal	296	304		|O
lobe	305	309		|O
epilepsy	310	318		|O
(	319	320		|O
TLE	320	323		|O
)	323	324		|O
subjects	325	333		|O
(	334	335		|O
left	338	342		|O
and	343	346		|O
26	347	349		|O
right	350	355		|O
)	355	356		|O
and	357	360		|O
29	361	363		|O
controls	364	372		|O
.	372	373		|O
The	374	377		|O
hippocampus	378	389		|O
and	390	393		|O
thalamus	394	402		|O
exhibited	403	412		|O
different	413	422		|O
patterns	423	431		|O
of	432	434		|O
volume	435	441		|O
abnormality	442	453		|O
,	453	454		|O
different	455	464		|O
associations	465	477		|O
with	478	482		|O
clinical	483	491		|O
seizure	492	499		|O
characteristics	500	515		|O
,	515	516		|O
and	517	520		|O
different	521	530		|O
patterns	531	539		|O
of	540	542		|O
relationship	543	555		|O
with	556	560		|O
cognitive	561	570		|O
measures	571	579		|O
.	579	580		|O
Hippocampal	581	592		|O
volume	593	599		|O
reduction	600	609		|O
was	610	613		|O
primarily	614	623		|O
ipsilateral	624	635		|O
to	636	638		|O
the	639	642		|O
seizure	643	650		|O
focus	651	656		|O
,	656	657		|O
and	658	661		|O
thalamic	662	670		|O
volume	671	677		|O
reduction	678	687		|O
was	688	691		|O
bilateral	692	701		|O
.	701	702		|O
Ipsilateral	703	714		|O
hippocampal	715	726		|O
volume	727	733		|O
was	734	737		|O
significantly	738	751		|O
correlated	752	762		|O
with	763	767		|O
both	768	772		|O
early	773	778		|O
neurodevelopmental	779	797		|O
features	798	806		|O
(	807	808		|O
age	808	811		|O
of	812	814		|O
seizure	815	822		|O
onset	823	828		|O
)	828	829		|O
and	830	833		|O
disease	834	841		|O
characteristics	842	857		|O
(	858	859		|O
duration	859	867		|O
of	868	870		|O
epilepsy	871	879		|O
)	879	880		|O
,	880	881		|O
whereas	882	889		|O
thalamus	890	898		|O
integrity	899	908		|O
was	909	912		|O
related	913	920		|O
only	921	925		|O
to	926	928		|O
disease	929	936		|O
variables	937	946		|O
.	946	947		|O
Hippocampal	948	959		|O
volume	960	966		|O
showed	967	973		|O
a	974	975		|O
selective	976	985		|O
association	986	997		|O
with	998	1002		|O
verbal	1003	1009		|O
memory	1010	1016		|O
performance	1017	1028		|O
.	1028	1029		|O
In	1030	1032		|O
contrast	1033	1041		|O
,	1041	1042		|O
both	1043	1047		|O
left	1048	1052		|O
and	1053	1056		|O
right	1057	1062		|O
thalamic	1063	1071		|O
volumes	1072	1079		|O
were	1080	1084		|O
significantly	1085	1098		|O
correlated	1099	1109		|O
with	1110	1114		|O
performance	1115	1126		|O
on	1127	1129		|O
both	1130	1134		|O
memory	1135	1141		|O
and	1142	1145		|O
nonmemory	1146	1155		|O
cognitive	1156	1165		|O
domains	1166	1173		|O
.	1173	1174		|O
These	1175	1180		|O
findings	1181	1189		|O
underscore	1190	1200		|O
the	1201	1204		|O
importance	1205	1215		|O
of	1216	1218		|O
thalamic	1219	1227		|O
atrophy	1228	1235		|O
in	1236	1238		|O
chronic	1239	1246		|O
TLE	1247	1250		|O
and	1251	1254		|O
its	1255	1258		|O
potential	1259	1268		|O
implications	1269	1281		|O
for	1282	1285		|O
cognition	1286	1295		|O
.	1295	1296		|O

### 18421201
Unilateral	10	20		|O
hearing	21	28		|O
disturbance	29	40		|O
could	41	46		|O
be	47	49		|O
an	50	52		|O
isolated	53	61		|O
manifestation	62	75		|O
prior	76	81		|O
to	82	84		|O
ipsilateral	85	96		|O
anterior	97	105		|O
inferior	106	114		|O
cerebellar	115	125		|O
artery	126	132		|O
infarction	133	143		|O
.	143	144		|O
A	146	147		|O
-	150	151		|O
year	151	155		|O
-	155	156		|O
old	156	159		|O
man	160	163		|O
presented	164	173		|O
with	174	178		|O
a	179	180		|O
sudden	181	187		|O
onset	188	193		|O
of	194	196		|O
right	197	202		|O
-	202	203		|O
sided	203	208		|O
hearing	209	216		|O
disturbance	217	228		|O
.	228	229		|O
His	230	233		|O
hearing	234	241		|O
disturbance	242	253		|O
improved	254	262		|O
gradually	263	272		|O
,	272	273		|O
however	274	281		|O
,	281	282		|O
dysarthria	283	293		|O
,	293	294		|O
right	295	300		|O
-	300	301		|O
sided	301	306		|O
facial	307	313		|O
weakness	314	322		|O
and	323	326		|O
dysesthesia	327	338		|O
,	338	339		|O
and	340	343		|O
gait	344	348		|O
disturbance	349	360		|O
was	361	364		|O
developed	365	374		|O
11	375	377		|O
days	378	382		|O
after	383	388		|O
the	389	392		|O
onset	393	398		|O
of	399	401		|O
hearing	402	409		|O
disturbance	410	421		|O
.	421	422		|O
MR	423	425		|O
imaging	426	433		|O
revealed	434	442		|O
fresh	443	448		|O
infarctions	449	460		|O
of	461	463		|O
the	464	467		|O
right	468	473		|O
dorsolateral	474	486		|O
pons	487	491		|O
and	492	495		|O
middle	496	502		|O
cerebellar	503	513		|O
peduncle	514	522		|O
localized	523	532		|O
in	533	535		|O
the	536	539		|O
territory	540	549		|O
of	550	552		|O
anterior	553	561		|O
inferior	562	570		|O
cerebellar	571	581		|O
artery	582	588		|O
.	588	589		|O
Unilateral	590	600		|O
hearing	601	608		|O
disturbance	609	620		|O
could	621	626		|O
be	627	629		|O
an	630	632		|O
isolated	633	641		|O
manifestation	642	655		|O
prior	656	661		|O
to	662	664		|O
ipsilateral	665	676		|O
anterior	677	685		|O
inferior	686	694		|O
cerebellar	695	705		|O
artery	706	712		|O
infarction	713	723		|O
.	723	724		|O

### 18421176
An	10	12		|O
OLETF	13	18		|O
Allele	19	25		|O
of	26	28		|O
Hyperglycemic	29	42		|O
QTL	43	46		|O
Nidd3	47	52		|O
/	52	53		|O
of	53	55		|O
Is	56	58		|O
Dominant	59	67		|O
.	67	68		|O
The	70	73		|O
OLETF	74	79		|O
rat	80	83		|O
is	84	86		|O
a	87	88		|O
well	89	93		|O
-	93	94		|O
established	94	105		|O
model	106	111		|O
for	112	115		|O
the	116	119		|O
study	120	125		|O
of	126	128		|O
type	129	133		|O
2	134	135		|O
diabetes	136	144		|O
associated	145	155		|O
with	156	160		|O
obesity	161	168		|O
and	169	172		|O
has	173	176		|O
been	177	181		|O
shown	182	187		|O
to	188	190		|O
possess	191	198		|O
multiple	199	207		|O
hyperglycemic	208	221		|O
alleles	222	229		|O
in	230	232		|O
its	233	236		|O
genome	237	243		|O
.	243	244		|O
Here	245	249		|O
we	250	252		|O
focused	253	260		|O
on	261	263		|O
and	264	267		|O
carefully	268	277		|O
characterized	278	291		|O
one	292	295		|O
of	296	298		|O
the	299	302		|O
previously	303	313		|O
reported	314	322		|O
congenic	323	331		|O
strains	332	339		|O
,	339	340		|O
F	341	342		|O
.	342	343		|O
O	343	344		|O
-	344	345		|O
Nidd3	345	350		|O
/	350	351		|O
of	351	353		|O
that	354	358		|O
carries	359	366		|O
the	367	370		|O
OLETF	371	376		|O
allele	377	383		|O
of	384	386		|O
the	387	390		|O
Nidd3	391	396		|O
/	396	397		|O
of	397	399		|O
locus	400	405		|O
(	406	407		|O
also	407	411		|O
known	412	417		|O
as	418	420		|O
Niddm21	421	428		|O
in	429	431		|O
the	432	435		|O
Rat	436	439		|O
Genome	440	446		|O
Database	447	455		|O
)	455	456		|O
in	457	459		|O
the	460	463		|O
normoglycemic	464	477		|O
F344	478	482		|O
genetic	483	490		|O
background	491	501		|O
.	501	502		|O
A	503	504		|O
prominent	505	514		|O
finding	515	522		|O
was	523	526		|O
that	527	531		|O
the	532	535		|O
F1	536	538		|O
progeny	539	546		|O
between	547	554		|O
the	555	558		|O
congenic	559	567		|O
and	568	571		|O
the	572	575		|O
F344	576	580		|O
stain	581	586		|O
,	586	587		|O
whose	588	593		|O
genotype	594	602		|O
is	603	605		|O
heterozygote	606	618		|O
at	619	621		|O
the	622	625		|O
Nidd3	626	631		|O
/	631	632		|O
of	632	634		|O
locus	635	640		|O
,	640	641		|O
showed	642	648		|O
mild	649	653		|O
hyperglycemia	654	667		|O
equal	668	673		|O
to	674	676		|O
the	677	680		|O
parental	681	689		|O
congenic	690	698		|O
rat	699	702		|O
,	702	703		|O
suggesting	704	714		|O
that	715	719		|O
the	720	723		|O
OLETF	724	729		|O
allele	730	736		|O
is	737	739		|O
dominant	740	748		|O
.	748	749		|O
To	750	752		|O
our	753	756		|O
knowledge	757	766		|O
,	766	767		|O
this	768	772		|O
is	773	775		|O
the	776	779		|O
first	780	785		|O
study	786	791		|O
in	792	794		|O
which	795	800		|O
a	801	802		|O
diabetic	803	811		|O
QTL	812	815		|O
has	816	819		|O
been	820	824		|O
directly	825	833		|O
demonstrated	834	846		|O
to	847	849		|O
be	850	852		|O
dominant	853	861		|O
by	862	864		|O
using	865	870		|O
congenic	871	879		|O
strains	880	887		|O
.	887	888		|O

### 18421163
Implementation	10	24		|O
of	25	27		|O
remote	28	34		|O
monitoring	35	45		|O
and	46	49		|O
diffraction	50	61		|O
evaluation	62	72		|O
systems	73	80		|O
at	81	83		|O
the	84	87		|O
Photon	88	94		|O
Factory	95	102		|O
macromolecular	103	117		|O
crystallography	118	133		|O
beamlines	134	143		|O
.	143	144		|O
Owing	146	151		|O
to	152	154		|O
recent	155	161		|O
advances	162	170		|O
in	171	173		|O
high	174	178		|O
-	178	179		|O
throughput	179	189		|O
technology	190	200		|O
in	201	203		|O
macromolecular	204	218		|O
crystallography	219	234		|O
beamlines	235	244		|O
,	244	245		|O
such	246	250		|O
as	251	253		|O
high	254	258		|O
-	258	259		|O
brilliant	259	268		|O
X	269	270		|O
-	270	271		|O
ray	271	274		|O
sources	275	282		|O
,	282	283		|O
high	284	288		|O
-	288	289		|O
speed	289	294		|O
readout	295	302		|O
detectors	303	312		|O
and	313	316		|O
robotics	317	325		|O
,	325	326		|O
the	327	330		|O
number	331	337		|O
of	338	340		|O
samples	341	348		|O
that	349	353		|O
can	354	357		|O
be	358	360		|O
examined	361	369		|O
in	370	372		|O
a	373	374		|O
single	375	381		|O
visit	382	387		|O
to	388	390		|O
the	391	394		|O
beamline	395	403		|O
has	404	407		|O
increased	408	417		|O
dramatically	418	430		|O
.	430	431		|O
In	432	434		|O
order	435	440		|O
to	441	443		|O
make	444	448		|O
these	449	454		|O
experiments	455	466		|O
more	467	471		|O
efficient	472	481		|O
,	481	482		|O
two	483	486		|O
functions	487	496		|O
,	496	497		|O
remote	498	504		|O
monitoring	505	515		|O
and	516	519		|O
diffraction	520	531		|O
image	532	537		|O
evaluation	538	548		|O
,	548	549		|O
have	550	554		|O
been	555	559		|O
implemented	560	571		|O
in	572	574		|O
the	575	578		|O
macromolecular	579	593		|O
crystallography	594	609		|O
beamlines	610	619		|O
at	620	622		|O
the	623	626		|O
Photon	627	633		|O
Factory	634	641		|O
(	642	643		|O
PF	643	645		|O
)	645	646		|O
.	646	647		|O
Remote	648	654		|O
monitoring	655	665		|O
allows	666	672		|O
scientists	673	683		|O
to	684	686		|O
participate	687	698		|O
in	699	701		|O
the	702	705		|O
experiment	706	716		|O
by	717	719		|O
watching	720	728		|O
from	729	733		|O
their	734	739		|O
laboratories	740	752		|O
,	752	753		|O
without	754	761		|O
having	762	768		|O
to	769	771		|O
come	772	776		|O
to	777	779		|O
the	780	783		|O
beamline	784	792		|O
.	792	793		|O
Diffraction	794	805		|O
image	806	811		|O
evaluation	812	822		|O
makes	823	828		|O
experiments	829	840		|O
easier	841	847		|O
,	847	848		|O
especially	849	859		|O
when	860	864		|O
using	865	870		|O
the	871	874		|O
sample	875	881		|O
exchange	882	890		|O
robot	891	896		|O
.	896	897		|O
To	898	900		|O
implement	901	910		|O
these	911	916		|O
two	917	920		|O
functions	921	930		|O
,	930	931		|O
two	932	935		|O
independent	936	947		|O
clients	948	955		|O
have	956	960		|O
been	961	965		|O
developed	966	975		|O
that	976	980		|O
work	981	985		|O
specifically	986	998		|O
for	999	1002		|O
remote	1003	1009		|O
monitoring	1010	1020		|O
and	1021	1024		|O
diffraction	1025	1036		|O
image	1037	1042		|O
evaluation	1043	1053		|O
.	1053	1054		|O
In	1055	1057		|O
the	1058	1061		|O
macromolecular	1062	1076		|O
crystallography	1077	1092		|O
beamlines	1093	1102		|O
at	1103	1105		|O
PF	1106	1108		|O
,	1108	1109		|O
beamline	1110	1118		|O
control	1119	1126		|O
is	1127	1129		|O
performed	1130	1139		|O
using	1140	1145		|O
STARS	1146	1151		|O
(	1152	1153		|O
simple	1153	1159		|O
transmission	1160	1172		|O
and	1173	1176		|O
retrieval	1177	1186		|O
system	1187	1193		|O
)	1193	1194		|O
.	1194	1195		|O
The	1196	1199		|O
system	1200	1206		|O
adopts	1207	1213		|O
a	1214	1215		|O
client	1216	1222		|O
-	1222	1223		|O
server	1223	1229		|O
style	1230	1235		|O
in	1236	1238		|O
which	1239	1244		|O
client	1245	1251		|O
programs	1252	1260		|O
communicate	1261	1272		|O
with	1273	1277		|O
each	1278	1282		|O
other	1283	1288		|O
through	1289	1296		|O
a	1297	1298		|O
server	1299	1305		|O
process	1306	1313		|O
using	1314	1319		|O
the	1320	1323		|O
STARS	1324	1329		|O
protocol	1330	1338		|O
.	1338	1339		|O
This	1340	1344		|O
is	1345	1347		|O
an	1348	1350		|O
advantage	1351	1360		|O
of	1361	1363		|O
the	1364	1367		|O
extension	1368	1377		|O
of	1378	1380		|O
the	1381	1384		|O
system	1385	1391		|O
;	1391	1392		|O
implementation	1393	1407		|O
of	1408	1410		|O
these	1411	1416		|O
new	1417	1420		|O
functions	1421	1430		|O
required	1431	1439		|O
few	1440	1443		|O
modifications	1444	1457		|O
of	1458	1460		|O
the	1461	1464		|O
existing	1465	1473		|O
system	1474	1480		|O
.	1480	1481		|O

### 18421178
Direct	10	16		|O
Comparison	17	27		|O
between	28	35		|O
ICSI	36	40		|O
-	40	41		|O
Mediated	41	49		|O
DNA	50	53		|O
Transfer	54	62		|O
and	63	66		|O
Pronuclear	67	77		|O
DNA	78	81		|O
Microinjection	82	96		|O
for	97	100		|O
Producing	101	110		|O
Transgenic	111	121		|O
Rats	122	126		|O
.	126	127		|O
Production	129	139		|O
efficiency	140	150		|O
of	151	153		|O
transgenic	154	164		|O
rats	165	169		|O
was	170	173		|O
compared	174	182		|O
directly	183	191		|O
between	192	199		|O
the	200	203		|O
routine	204	211		|O
pronuclear	212	222		|O
microinjection	223	237		|O
of	238	240		|O
exogenous	241	250		|O
DNA	251	254		|O
solution	255	263		|O
(	264	265		|O
PNMI	265	269		|O
-	269	270		|O
Tg	270	272		|O
method	273	279		|O
)	279	280		|O
and	281	284		|O
the	285	288		|O
ooplasmic	289	298		|O
injection	299	308		|O
of	309	311		|O
sperm	312	317		|O
cells	318	323		|O
exposed	324	331		|O
to	332	334		|O
exogenous	335	344		|O
DNA	345	348		|O
solution	349	357		|O
(	358	359		|O
ICSI	359	363		|O
-	363	364		|O
Tg	364	366		|O
method	367	373		|O
)	373	374		|O
using	375	380		|O
six	381	384		|O
DNA	385	388		|O
constructs	389	399		|O
.	399	400		|O
The	401	404		|O
overall	405	412		|O
production	413	423		|O
efficiency	424	434		|O
per	435	438		|O
treated	439	446		|O
oocyte	447	453		|O
in	454	456		|O
the	457	460		|O
ICSI	461	465		|O
-	465	466		|O
Tg	466	468		|O
method	469	475		|O
(	476	477		|O
mean	477	481		|O
1.1%	482	486		|O
,	486	487		|O
range	488	493		|O
0.2	494	497		|O
to	498	500		|O
3.1%	501	505		|O
)	505	506		|O
was	507	510		|O
similar	511	518		|O
to	519	521		|O
that	522	526		|O
in	527	529		|O
the	530	533		|O
PNMI	534	538		|O
-	538	539		|O
Tg	539	541		|O
method	542	548		|O
(	549	550		|O
mean	550	554		|O
1.1%	555	559		|O
,	559	560		|O
range	561	566		|O
0	567	568		|O
to	569	571		|O
2.4%	572	576		|O
)	576	577		|O
.	577	578		|O
An	579	581		|O
advantage	582	591		|O
of	592	594		|O
the	595	598		|O
ICSI	599	603		|O
-	603	604		|O
Tg	604	606		|O
method	607	613		|O
in	614	616		|O
the	617	620		|O
production	621	631		|O
of	632	634		|O
transgenic	635	645		|O
rats	646	650		|O
is	651	653		|O
noted	654	659		|O
in	660	662		|O
cases	663	668		|O
in	669	671		|O
which	672	677		|O
a	678	679		|O
low	680	683		|O
yield	684	689		|O
of	690	692		|O
pronuclear	693	703		|O
zygotes	704	711		|O
is	712	714		|O
an	715	717		|O
inevitable	718	728		|O
fate	729	733		|O
of	734	736		|O
the	737	740		|O
rat	741	744		|O
strain	745	751		|O
.	751	752		|O

### 18421840
EEG	10	13		|O
observations	14	26		|O
in	27	29		|O
a	30	31		|O
case	32	36		|O
with	37	41		|O
thalamic	42	50		|O
syndrome	51	59		|O
.	59	60		|O
A	62	63		|O
case	64	68		|O
of	69	71		|O
thalamic	72	80		|O
syndrome	81	89		|O
of	90	92		|O
the	93	96		|O
D	97	98		|O
	98	99		|O
	99	100		|O
jerine	100	106		|O
-	106	107		|O
Roussy	107	113		|O
type	114	118		|O
is	119	121		|O
presented	122	131		|O
.	131	132		|O
EEG	133	136		|O
studies	137	144		|O
reveal	145	151		|O
that	152	156		|O
although	157	165		|O
bilaterally	166	177		|O
symmetrical	178	189		|O
rhythmic	190	198		|O
activity	199	207		|O
may	208	211		|O
be	212	214		|O
present	215	222		|O
when	223	227		|O
the	228	231		|O
patient	232	239		|O
is	240	242		|O
awake	243	248		|O
,	248	249		|O
during	250	256		|O
drowsiness	257	267		|O
and	268	271		|O
deeper	272	278		|O
sleep	279	284		|O
a	285	286		|O
marked	287	293		|O
asymmetry	294	303		|O
often	304	309		|O
appears	310	317		|O
with	318	322		|O
early	323	328		|O
disappearance	329	342		|O
of	343	345		|O
alpha	346	351		|O
activity	352	360		|O
and	361	364		|O
reduction	365	374		|O
or	375	377		|O
abolition	378	387		|O
of	388	390		|O
spindles	391	399		|O
on	400	402		|O
the	403	406		|O
side	407	411		|O
involved	412	420		|O
.	420	421		|O
Thalamic	422	430		|O
integration	431	442		|O
in	443	445		|O
the	446	449		|O
sleep	450	455		|O
mechanism	456	465		|O
is	466	468		|O
briefly	469	476		|O
discussed	477	486		|O
.	486	487		|O

### 18419836
Distinct	10	18		|O
cognitive	19	28		|O
profiles	29	37		|O
and	38	41		|O
rates	42	47		|O
of	48	50		|O
decline	51	58		|O
on	59	61		|O
the	62	65		|O
Mattis	66	72		|O
Dementia	73	81		|O
Rating	82	88		|O
Scale	89	94		|O
in	95	97		|O
autopsy	98	105		|O
-	105	106		|O
confirmed	106	115		|O
frontotemporal	116	130		|O
dementia	131	139		|O
and	140	143		|O
Alzheimer	144	153		|O
's	153	155		|O
disease	156	163		|O
.	163	164		|O
Neuropsychological	166	184		|O
studies	185	192		|O
have	193	197		|O
shown	198	203		|O
that	204	208		|O
patients	209	217		|O
with	218	222		|O
Frontotemporal	223	237		|O
dementia	238	246		|O
(	247	248		|O
FTD	248	251		|O
)	251	252		|O
perform	253	260		|O
worse	261	266		|O
than	267	271		|O
patients	272	280		|O
with	281	285		|O
Alzheimer	286	295		|O
's	295	297		|O
disease	298	305		|O
(	306	307		|O
AD	307	309		|O
)	309	310		|O
on	311	313		|O
tests	314	319		|O
of	320	322		|O
conceptualization	323	340		|O
and	341	344		|O
verbal	345	351		|O
fluency	352	359		|O
,	359	360		|O
but	361	364		|O
better	365	371		|O
on	372	374		|O
tests	375	380		|O
of	381	383		|O
memory	384	390		|O
and	391	394		|O
visuospatial	395	407		|O
functions	408	417		|O
.	417	418		|O
However	419	426		|O
,	426	427		|O
it	428	430		|O
is	431	433		|O
not	434	437		|O
known	438	443		|O
if	444	446		|O
these	447	452		|O
distinct	453	461		|O
cognitive	462	471		|O
profiles	472	480		|O
are	481	484		|O
robust	485	491		|O
enough	492	498		|O
to	499	501		|O
be	502	504		|O
detected	505	513		|O
using	514	519		|O
a	520	521		|O
relatively	522	532		|O
brief	533	538		|O
dementia	539	547		|O
screening	548	557		|O
instrument	558	568		|O
such	569	573		|O
as	574	576		|O
the	577	580		|O
Mattis	581	587		|O
Dementia	588	596		|O
Rating	597	603		|O
Scale	604	609		|O
(	610	611		|O
MDRS	611	615		|O
)	615	616		|O
.	616	617		|O
To	618	620		|O
address	621	628		|O
this	629	633		|O
issue	634	639		|O
,	639	640		|O
the	641	644		|O
MDRS	645	649		|O
subscale	650	658		|O
profiles	659	667		|O
of	668	670		|O
patients	671	679		|O
with	680	684		|O
autopsy	685	692		|O
-	692	693		|O
confirmed	693	702		|O
FTD	703	706		|O
(	707	708		|O
n	708	709		|O
=	710	711		|O
17	712	714		|O
)	714	715		|O
or	716	718		|O
AD	719	721		|O
(	722	723		|O
n	723	724		|O
=	725	726		|O
34	727	729		|O
)	729	730		|O
were	731	735		|O
compared	736	744		|O
.	744	745		|O
Results	746	753		|O
showed	754	760		|O
distinct	761	769		|O
cognitive	770	779		|O
profiles	780	788		|O
in	789	791		|O
which	792	797		|O
FTD	798	801		|O
patients	802	810		|O
performed	811	820		|O
worse	821	826		|O
than	827	831		|O
AD	832	834		|O
patients	835	843		|O
on	844	846		|O
the	847	850		|O
Initiation	851	861		|O
/	861	862		|O
Perseveration	862	875		|O
and	876	879		|O
Conceptualization	880	897		|O
subscales	898	907		|O
while	908	913		|O
performing	914	924		|O
better	925	931		|O
on	932	934		|O
the	935	938		|O
Memory	939	945		|O
and	946	949		|O
Construction	950	962		|O
subscales	963	972		|O
.	972	973		|O
The	974	977		|O
distinct	978	986		|O
subscale	987	995		|O
profiles	996	1004		|O
correctly	1005	1014		|O
classified	1015	1025		|O
85%	1026	1029		|O
of	1030	1032		|O
AD	1033	1035		|O
patients	1036	1044		|O
and	1045	1048		|O
76%	1049	1052		|O
of	1053	1055		|O
FTD	1056	1059		|O
patients	1060	1068		|O
.	1068	1069		|O
Profiles	1070	1078		|O
were	1079	1083		|O
maintained	1084	1094		|O
in	1095	1097		|O
a	1098	1099		|O
subset	1100	1106		|O
of	1107	1109		|O
mildly	1110	1116		|O
-	1116	1117		|O
to	1117	1119		|O
-	1119	1120		|O
moderately	1120	1130		|O
demented	1131	1139		|O
patients	1140	1148		|O
(	1149	1150		|O
MDRS	1150	1154		|O
>	1155	1156		|O
or	1157	1159		|O
=	1160	1161		|O
)	1165	1166		|O
and	1167	1170		|O
correctly	1171	1180		|O
classified	1181	1191		|O
89%	1192	1195		|O
of	1196	1198		|O
these	1199	1204		|O
patients	1205	1213		|O
.	1213	1214		|O
In	1215	1217		|O
addition	1218	1226		|O
,	1226	1227		|O
FTD	1228	1231		|O
patients	1232	1240		|O
(	1241	1242		|O
mean	1242	1246		|O
=	1247	1248		|O
points	1254	1260		|O
/	1260	1261		|O
year	1261	1265		|O
)	1265	1266		|O
declined	1267	1275		|O
faster	1276	1282		|O
than	1283	1287		|O
AD	1288	1290		|O
patients	1291	1299		|O
(	1300	1301		|O
mean	1301	1305		|O
=	1306	1307		|O
14.8	1308	1312		|O
points	1313	1319		|O
/	1319	1320		|O
year	1320	1324		|O
)	1324	1325		|O
on	1326	1328		|O
MDRS	1329	1333		|O
total	1334	1339		|O
and	1340	1343		|O
specific	1344	1352		|O
subscale	1353	1361		|O
scores	1362	1368		|O
.	1368	1369		|O
These	1370	1375		|O
results	1376	1383		|O
suggest	1384	1391		|O
that	1392	1396		|O
the	1397	1400		|O
MDRS	1401	1405		|O
may	1406	1409		|O
be	1410	1412		|O
a	1413	1414		|O
useful	1415	1421		|O
adjunct	1422	1429		|O
to	1430	1432		|O
other	1433	1438		|O
clinical	1439	1447		|O
measures	1448	1456		|O
for	1457	1460		|O
distinguishing	1461	1475		|O
FTD	1476	1479		|O
from	1480	1484		|O
AD	1485	1487		|O
and	1488	1491		|O
tracking	1492	1500		|O
the	1501	1504		|O
progression	1505	1516		|O
of	1517	1519		|O
the	1520	1523		|O
disorder	1524	1532		|O
.	1532	1533		|O

### 18419668
Households	10	20		|O
'	20	21		|O
perceived	22	31		|O
personal	32	40		|O
risk	41	45		|O
and	46	49		|O
responses	50	59		|O
in	60	62		|O
a	63	64		|O
multihazard	65	76		|O
environment	77	88		|O
.	88	89		|O
This	91	95		|O
study	96	101		|O
proposed	102	110		|O
and	111	114		|O
tested	115	121		|O
a	122	123		|O
multistage	124	134		|O
model	135	140		|O
of	141	143		|O
household	144	153		|O
response	154	162		|O
to	163	165		|O
three	166	171		|O
hazards	172	179		|O
-	179	180		|O
flood	180	185		|O
,	185	186		|O
hurricane	187	196		|O
,	196	197		|O
and	198	201		|O
toxic	202	207		|O
chemical	208	216		|O
release	217	224		|O
-	224	225		|O
in	225	227		|O
Harris	228	234		|O
County	235	241		|O
Texas	242	247		|O
.	247	248		|O
The	249	252		|O
model	253	258		|O
,	258	259		|O
which	260	265		|O
extends	266	273		|O
Lindell	274	281		|O
and	282	285		|O
Perry	286	291		|O
's	291	293		|O
(	294	295		|O
1992	295	299		|O
,	299	300		|O
)	305	306		|O
Protective	307	317		|O
Action	318	324		|O
Decision	325	333		|O
Model	334	339		|O
,	339	340		|O
proposed	341	349		|O
a	350	351		|O
basic	352	357		|O
causal	358	364		|O
chain	365	370		|O
from	371	375		|O
hazard	376	382		|O
proximity	383	392		|O
through	393	400		|O
hazard	401	407		|O
experience	408	418		|O
and	419	422		|O
perceived	423	432		|O
personal	433	441		|O
risk	442	446		|O
to	447	449		|O
expectations	450	462		|O
of	463	465		|O
continued	466	475		|O
residence	476	485		|O
in	486	488		|O
the	489	492		|O
home	493	497		|O
and	498	501		|O
adoption	502	510		|O
of	511	513		|O
household	514	523		|O
hazard	524	530		|O
adjustments	531	542		|O
.	542	543		|O
Data	544	548		|O
from	549	553		|O
321	554	557		|O
households	558	568		|O
generally	569	578		|O
supported	579	588		|O
the	589	592		|O
model	593	598		|O
,	598	599		|O
but	600	603		|O
the	604	607		|O
mediating	608	617		|O
effects	618	625		|O
of	626	628		|O
hazard	629	635		|O
experience	636	646		|O
and	647	650		|O
perceived	651	660		|O
personal	661	669		|O
risk	670	674		|O
were	675	679		|O
partial	680	687		|O
rather	688	694		|O
than	695	699		|O
complete	700	708		|O
.	708	709		|O
In	710	712		|O
addition	713	721		|O
,	721	722		|O
the	723	726		|O
data	727	731		|O
suggested	732	741		|O
that	742	746		|O
four	747	751		|O
demographic	752	763		|O
variables	764	773		|O
-	773	774		|O
gender	774	780		|O
,	780	781		|O
age	782	785		|O
,	785	786		|O
income	787	793		|O
,	793	794		|O
and	795	798		|O
ethnicity	799	808		|O
-	808	809		|O
affect	809	815		|O
the	816	819		|O
basic	820	825		|O
causal	826	832		|O
chain	833	838		|O
at	839	841		|O
different	842	851		|O
points	852	858		|O
.	858	859		|O

### 18420559
An	10	12		|O
exploratory	13	24		|O
evaluation	25	35		|O
of	36	38		|O
the	39	42		|O
contribution	43	55		|O
of	56	58		|O
personality	59	70		|O
and	71	74		|O
childhood	75	84		|O
sexual	85	91		|O
victimization	92	105		|O
to	106	108		|O
the	109	112		|O
development	113	124		|O
of	125	127		|O
sexually	128	136		|O
abusive	137	144		|O
behavior	145	153		|O
.	153	154		|O
Scores	156	162		|O
on	163	165		|O
the	166	169		|O
Millon	170	176		|O
Adolescent	177	187		|O
Clinical	188	196		|O
Inventory	197	206		|O
(	207	208		|O
MACI	208	212		|O
)	212	213		|O
and	214	217		|O
the	218	221		|O
Childhood	222	231		|O
Trauma	232	238		|O
Questionnaire	239	252		|O
(	253	254		|O
CTQ	254	257		|O
)	257	258		|O
were	259	263		|O
collected	264	273		|O
from	274	278		|O
two	279	282		|O
samples	283	290		|O
of	291	293		|O
incarcerated	294	306		|O
delinquent	307	317		|O
males	318	323		|O
:	323	324		|O
74	325	327		|O
adjudicated	328	339		|O
sexual	340	346		|O
abusers	347	354		|O
and	355	358		|O
53	359	361		|O
nonsexual	362	371		|O
abusers	372	379		|O
.	379	380		|O
In	381	383		|O
comparison	384	394		|O
to	395	397		|O
non	398	401		|O
-	401	402		|O
sexually	402	410		|O
abusive	411	418		|O
youths	419	425		|O
,	425	426		|O
a	427	428		|O
larger	429	435		|O
percentage	436	446		|O
of	447	449		|O
the	450	453		|O
sexually	454	462		|O
abusive	463	470		|O
youths	471	477		|O
indicated	478	487		|O
a	488	489		|O
history	490	497		|O
of	498	500		|O
childhood	501	510		|O
sexual	511	517		|O
victimization	518	531		|O
.	531	532		|O
The	533	536		|O
scores	537	543		|O
were	544	548		|O
then	549	553		|O
entered	554	561		|O
into	562	566		|O
a	567	568		|O
logistic	569	577		|O
regression	578	588		|O
to	589	591		|O
assess	592	598		|O
the	599	602		|O
contribution	603	615		|O
of	616	618		|O
personality	619	630		|O
characteristics	631	646		|O
to	647	649		|O
a	650	651		|O
social	652	658		|O
learning	659	667		|O
"	668	669		|O
victim	669	675		|O
-	675	676		|O
to	676	678		|O
-	678	679		|O
victimizer	679	689		|O
"	689	690		|O
etiological	691	702		|O
model	703	708		|O
.	708	709		|O
After	710	715		|O
controlling	716	727		|O
for	728	731		|O
time	732	736		|O
in	737	739		|O
treatment	740	749		|O
,	749	750		|O
the	751	754		|O
model	755	760		|O
correctly	761	770		|O
classified	771	781		|O
76.6%	782	787		|O
of	788	790		|O
the	791	794		|O
youths	795	801		|O
.	801	802		|O
The	803	806		|O
variables	807	816		|O
that	817	821		|O
contributed	822	833		|O
significantly	834	847		|O
to	848	850		|O
the	851	854		|O
social	855	861		|O
learning	862	870		|O
model	871	876		|O
were	877	881		|O
the	882	885		|O
CTQ	886	889		|O
Sexual	890	896		|O
Abuse	897	902		|O
and	903	906		|O
Physical	907	915		|O
Neglect	916	923		|O
scales	924	930		|O
and	931	934		|O
the	935	938		|O
Submissive	939	949		|O
and	950	953		|O
Forceful	954	962		|O
scales	963	969		|O
on	970	972		|O
the	973	976		|O
MACI	977	981		|O
.	981	982		|O
Research	983	991		|O
and	992	995		|O
treatment	996	1005		|O
implications	1006	1018		|O
of	1019	1021		|O
these	1022	1027		|O
findings	1028	1036		|O
are	1037	1040		|O
discussed	1041	1050		|O
.	1050	1051		|O

